<SEC-DOCUMENT>0001628280-25-023234.txt : 20250507
<SEC-HEADER>0001628280-25-023234.hdr.sgml : 20250507
<ACCEPTANCE-DATETIME>20250507164532
ACCESSION NUMBER:		0001628280-25-023234
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250507
DATE AS OF CHANGE:		20250507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CROSS COUNTRY HEALTHCARE INC
		CENTRAL INDEX KEY:			0001141103
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HELP SUPPLY SERVICES [7363]
		ORGANIZATION NAME:           	07 Trade & Services
		EIN:				134066229
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-33169
		FILM NUMBER:		25922185

	BUSINESS ADDRESS:	
		STREET 1:		6551 PARK OF COMMERCE BOULEVARD, N.W.
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		8003472264

	MAIL ADDRESS:	
		STREET 1:		6551 PARK OF COMMERCE BOULEVARD, N.W.
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROSS COUNTRY INC
		DATE OF NAME CHANGE:	20010521
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ccrn-20250331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:dd6031fa-8918-4f16-99cd-07b7064df9d2,g:a332f0b9-5dad-4d87-8e39-4baf62f16fbe,d:e094c362a2b8472c8b046d777cad339c-->
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ccrn="http://www.crosscountryhealthcare.com/20250331" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ccrn-20250331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001141103</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-29">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-102">http://fasb.org/us-gaap/2024#ServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-103">http://fasb.org/us-gaap/2024#ServiceMember</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ccrn-20250331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ccrn:segment</xbrli:measure></xbrli:unit><xbrli:unit id="state"><xbrli:measure>ccrn:state</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:AyaHoldingsIIInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ccrn:ExitCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ccrn:ExitCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ccrn:ExitCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:HireUpLeadershipIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-13</xbrli:startDate><xbrli:endDate>2022-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:HireUpLeadershipIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:HireUpLeadershipIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-03</xbrli:startDate><xbrli:endDate>2022-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DatabasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DatabasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-25</xbrli:startDate><xbrli:endDate>2019-10-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ccrn:LineOfCreditSublimitAxis">ccrn:SwingLoansSublimitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ccrn:LineOfCreditSublimitAxis">ccrn:StandbyLettersOfCreditSublimitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-21</xbrli:startDate><xbrli:endDate>2022-03-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-21</xbrli:startDate><xbrli:endDate>2022-03-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ccrn:RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ccrn:RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ccrn:RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ccrn:RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ccrn:OmnibusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ccrn:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ccrn:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ccrn:ServicesProvidedEntitiesAffiliatedWithBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ccrn:ServicesProvidedEntitiesAffiliatedWithBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie094c362a2b8472c8b046d777cad339c_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Quarterly Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the Quarterly Period Ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2025</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Or</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the Transition Period From</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> _________ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> _________</span></div><div style="text-align:center"><img src="ccrn-20250331_g1.jpg" alt="cchfinallogorbga01.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:249px" id="i-1"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-5">CROSS COUNTRY HEALTHCARE, INC</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.064%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.892%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-6">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-7">0-33169</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">13-4066229</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>Incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Commission<br/>file number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">6551 Park of Commerce Boulevard, N.W.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Boca Raton</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">Florida</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">33487</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices)(Zip Code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">561</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">998-2232</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:33.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">CCRN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files).&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;No</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Large accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated&#160;filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744; </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller reporting company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The registrant had outstandin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">g </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">32,783,168</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">shares of common stock, par value $0.0001 per share, as of April&#160;18, 2025.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to historical information, this Quarterly Report on Form&#160;10-Q contains statements relating to our future results (including certain projections and business trends) that are &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, Section&#160;21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), and the Private Securities Litigation Reform Act of 1995, and are subject to the &#8220;safe harbor&#8221; created by those sections. Statements regarding the proposed Aya Merger (as defined below); the expected timing and closing of the proposed Aya Merger; the Company&#8217;s ability to consummate the proposed Aya Merger; the expected benefits of the proposed Aya Merger and other considerations taken into account by the Company&#8217;s Board of Directors in approving the proposed Aya Merger; the amounts to be received by stockholders in connection with the proposed Aya Merger; and expectations for the Company prior to and following the closing of the proposed Aya Merger, may be deemed to be forward-looking statements. Forward-looking statements consist of statements that are predictive in nature, depend upon or refer to future events. Words such as &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;intends&#8221;, &#8220;plans&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;suggests&#8221;, &#8220;appears&#8221;, &#8220;seeks&#8221;, &#8220;will&#8221;, &#8220;could&#8221;, and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include, but are not limited to, the following: the timing to consummate the proposed Aya Merger, the risk that a condition of closing of the proposed Aya Merger may not be satisfied or that the closing of the proposed Aya Merger might otherwise not occur, the risk that a regulatory approval that may be required for the proposed Aya Merger is not obtained or is obtained subject to conditions that are not anticipated, the diversion of management time on transaction-related issues, risks related to disruption of management time from ongoing business operations due to the proposed Aya Merger, the risk that any announcements relating to the proposed Aya Merger could have adverse effects on the market price of the common stock of the Company, the risk that the proposed Aya Merger and its announcement could have an adverse effect on the ability of the Company to retain customers and retain and hire key personnel and maintain relationships with its suppliers and customers, the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement, including in circumstances requiring the Company to pay a termination fee, the risk that competing offers will be made, unexpected costs, charges or expenses resulting from the Aya Merger, potential litigation relating to the Aya Merger that could be instituted against the parties to the Merger Agreement or their respective directors, managers or officers, including the effects of any outcomes related thereto, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the overall macroeconomic environment, including increased inflation and interest rates, dema</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nd for the healthcare services that we provide, both nationally and in the regions in which we operate, our ability to attract and retain qualified nurses, physicians and other healthcare personnel, costs and availability of short-term housing for our travel healthcare professionals, the functioning of our information systems, the effect of cyber security risks and cyber incidents on our business, the effect of existing or future government regulation and federal and state legislative and enforcement initiatives on our business, including data privacy and protection laws, social, ethical, and security issues relating to the use of artificial intelligence, our customers&#8217; ability to pay us for our services, our ability to successfully implement our acquisition and development strategies, including our ability to successfully integrate acquired businesses and realize synergies from such acquisitions, the effect of liabilities and other claims asserted against us, the effect of competition in the markets we serve, our ability to successfully defend the Company, its subsidiaries, and its officers and directors on the merits of any lawsuit or determine its potential liability, if any, and other factors, including, without limitation, the risk factors set forth in Item 1A. &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2024, as amended by Amendment No. 1 on Form 10-K/A (2024 Form 10-K), as filed and updated in our subsequent Quarterly Reports on Form&#160;10-Q and other filings with the Securities and Exchange Commission (SEC).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management&#8217;s opinions only as of the date of this filing. There can be no assurance that (i)&#160;we have correctly measured or identified all of the factors affecting our business or the extent of these factors&#8217; likely impact, (ii)&#160;the available information with respect to these factors on which such analysis is based is complete or accurate, (iii)&#160;such analysis is correct or (iv)&#160;our strategy, which is based in part on this analysis, will be successful. Except as may be required by law, the Company undertakes no obligation to update or revise forward-looking statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references to &#8220;the Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or &#8220;Cross Country&#8221; in this Quarterly Report on Form&#160;10-Q mean Cross Country Healthcare, Inc. and its consolidated subsidiaries.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CROSS COUNTRY HEALTHCARE, INC.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAGE</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_13">PART I. &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_13">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_16">Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_16">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_19">Condensed Consolidated Balance Sheets (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_19">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_22">Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_22">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_28">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_28">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_31">Condensed Consolidated Statements of Cash Flows (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_31">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_34">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_34">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_88">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_88">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_88">22</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_130">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_130">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_130">31</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_133">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_133">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_133">31</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_136">PART II. &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_136">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_139">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_139">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_139">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_142">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_142">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_142">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_148">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_148">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_148">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Item 6.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_151">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_151">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_154">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie094c362a2b8472c8b046d777cad339c_154">34</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I.&#160;FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CROSS COUNTRY HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, amounts in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:73.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.343%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">80,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">81,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-32">9,792</ix:nonFraction> in 2025 and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">9,301</ix:nonFraction> in 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">219,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">223,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-36">5,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-37">10,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">8,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">7,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance recovery receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InsuranceSettlementsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">9,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InsuranceSettlementsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">9,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">2,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">325,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">335,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-46">21,837</ix:nonFraction> in 2025 and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-47">19,285</ix:nonFraction> in 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-48">28,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-49">28,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-50">2,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-51">2,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-52">135,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-53">135,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-54">39,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-55">42,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-56">8,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-57">8,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance recovery receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InsuranceSettlementsReceivableNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">20,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InsuranceSettlementsReceivableNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">20,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cloud computing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ccrn:CloudComputingNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">11,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ccrn:CloudComputingNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">10,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">5,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">5,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-64">576,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-65">589,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">56,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">64,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">50,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">47,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">2,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnout liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">4,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-74">980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">109,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">120,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">1,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">1,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-80">33,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-81">34,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-82">10,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">10,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">3,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">3,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-86">158,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-87">170,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-88"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-89"></ix:nonFraction></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-90">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-91">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-92">202,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-93">202,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-94">1,436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-95">1,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-96">217,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-97">218,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-98">418,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-99">418,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-100">576,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-101">589,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                     </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CROSS COUNTRY HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, amounts in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.771%"><tr><td style="width:1.0%"/><td style="width:74.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-102"><span style="-sec-ix-hidden:f-103">Revenue from services</span></span> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-104">293,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-105">379,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DirectOperatingCosts" format="ixt:num-dot-decimal" scale="3" id="f-106">234,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DirectOperatingCosts" format="ixt:num-dot-decimal" scale="3" id="f-107">301,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-108">52,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-109">63,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-110">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-111">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-112">4,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-113">4,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ccrn:AcquisitionAndIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-114">2,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ccrn:AcquisitionAndIntegrationRelatedCosts" format="ixt:fixed-zero" scale="3" id="f-115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-116">301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-117">938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and other losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ccrn:LegalAndOtherLosses" format="ixt:fixed-zero" scale="3" id="f-118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ccrn:LegalAndOtherLosses" format="ixt:num-dot-decimal" scale="3" id="f-119">3,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-120">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="f-121">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-122">294,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-123">376,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-124">977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-125">2,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses (income):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-126">543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-127">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-128">681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-129">173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-130">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-131">1,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="f-132">899</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-133">3,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-134">409</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-135">997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-136">490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-137">2,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign currency translation gain (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-138">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-139">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="f-140">485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-141">2,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share attributable to common stockholders - Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-142">0.02</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-143">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share attributable to common stockholders - Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-144">0.02</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-145">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-146">32,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-147">34,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-148">32,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-149">34,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CROSS COUNTRY HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2025 and 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, amounts in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:36.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.901%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-In Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Accumulated Other <br/>Comprehensive Loss, net</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-150">32,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-151">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-152">202,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-153">1,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-154">218,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-155">418,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Vesting of restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-156">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-157">1,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-158">1,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-159">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-160">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign currency translation adjustment, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-161">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-162">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-163">490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-164">490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances at March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-165">32,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-166">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-167">202,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-168">1,436</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-169">217,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-170">418,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-In Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Accumulated Other <br/>Comprehensive Loss, net</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Accumulated Deficit) Retained Earnings</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances at December&#160;31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-171">34,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-172">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">236,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-174">1,385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-175">232,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-176">467,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Vesting of restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-177">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-178">2,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-179">2,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-180">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-181">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock repurchase and retirement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="3" id="f-182">310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-183">6,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-184">6,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock repurchase excise tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="ccrn:StockRepurchasedDuringPeriodExciseTax" scale="3" id="f-185">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ccrn:StockRepurchasedDuringPeriodExciseTax" scale="3" id="f-186">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign currency translation adjustment, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-187">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-188">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-189">2,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-190">2,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances at March 31, 2024</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-191">34,326</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-192">4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">228,525</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">1,388</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-195">235,307</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-196">462,448</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CROSS COUNTRY HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, amounts in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-197">490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-198">2,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-199">4,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-200">4,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ccrn:ProvisionForDoubtfulAccountsAndOtherAllowances" scale="3" id="f-201">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ccrn:ProvisionForDoubtfulAccountsAndOtherAllowances" format="ixt:num-dot-decimal" scale="3" id="f-202">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-203">680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-204">809</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ccrn:OperatingLeaseExpenseNonCash" scale="3" id="f-205">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ccrn:OperatingLeaseExpenseNonCash" scale="3" id="f-206">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-207">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="f-208">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-209">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-210">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-211">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-212">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-213">3,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-214">13,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-215">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-216">1,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-217">4,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-218">1,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-219">9,173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-220">15,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ccrn:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-221">562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="ccrn:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-222">785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-223">1,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-224">1,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-225">5,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-226">6,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-227">1,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-228">2,210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-229">1,886</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-230">2,210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings under Senior Secured Asset-Based revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="3" id="f-231">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-232">14,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments on Senior Secured Asset-Based revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="3" id="f-233">373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-234">14,166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-236">2,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock repurchase and retirement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="f-237">314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-238">6,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-239">4,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-240">6,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-241">4,725</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-242">15,653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-243">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="f-245">936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-246">11,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-247">81,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-248">17,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-249">80,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-250">5,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                      </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CROSS COUNTRY HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_37"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-251" continuedAt="f-251-1" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-251-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-252" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. All such adjustments consisted of all normal recurring items, including the elimination of all intercompany transactions and balances.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-253" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form&#160;10-Q and Article 10 of Regulation&#160;S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2024 included in the 2024 Form 10-K. The December&#160;31, 2024 condensed consolidated balance sheet included herein was derived from the December&#160;31, 2024 audited consolidated balance sheet included in the 2024 Form&#160;10-K.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the current year presentation. See the condensed consolidated statements of operations and comprehensive (loss) income.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aya Healthcare</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2024, the Company entered into an Agreement and Plan of Merger (Merger Agreement) with Aya Holdings II Inc., a Delaware corporation (Parent), Spark Merger Sub One Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), and, solely for purposes of Section 11.14 thereto, Aya Healthcare, Inc. (Aya Healthcare), pursuant to which Merger Sub will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (Aya Merger). On February 20, 2025, the Company and Aya Healthcare each received a request for additional information (Second Request) from the U.S. Federal Trade Commission (FTC) in connection with the FTC&#8217;s review of the transactions contemplated by the Merger Agreement. Issuance of the Second Request extends the waiting period under the Hart-Scott- Rodino Antitrust Improvements Act of 1976 until 30 days after both the Company and Aya Healthcare substantially comply with the Second Request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. The Company expects that the Aya Merger will close in the second half of 2025, subject to the satisfaction or waiver of the other customary closing conditions specified in the Merger Agreement. The Aya Merger was approved by the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s stockholders at a special meeting held on February 28, 2025. Upon completion of the transaction, it is expected that the Company will become a private company and its common stock will no longer trade on Nasdaq. During the first quarter of 2025, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="f-254">2.0</ix:nonFraction>&#160;million in fees associated with the pending Aya Merger, which is included in acquisition and integration-related costs in the condensed consolidated statement of operations and comprehensive (loss) income.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_40"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-255" continuedAt="f-255-1" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-255-1" continuedAt="f-255-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-256" continuedAt="f-256-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div></ix:nonNumeric><div><span><br/></span></div><div><ix:continuation id="f-256-1" continuedAt="f-256-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, using information that is reasonably available to the Company at the time. Significant estimates and assumptions are used for, but not limited to: (i) the valuation of accounts receivable; (ii) goodwill, trade names, and other intangible assets; (iii) other long-lived assets; (iv) revenue recognition; (v) accruals for health, workers&#8217; compensation, and professional liability claims; (vi) valuation of deferred tax assets; (vii) legal contingencies; and (viii) income taxes. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. As additional information becomes available to the Company, its future assessment of these estimates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-256-2">could materially and adversely impact the Company&#8217;s consolidated financial statements in future reporting periods. Actual results could differ from those estimates.</ix:continuation>  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="f-255-2" continuedAt="f-255-3"><ix:nonNumeric contextRef="c-1" name="ccrn:RisksAndUncertaintiesPolicyTextBlock" id="f-257" escape="true"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments from customers and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers. See associated risk factors in Item 1A. Risk Factors in the 2024 Form 10-K.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-258" continuedAt="f-258-1" escape="true"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Accounts Receivable, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers, which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for credit losses and sales allowances. Estimated revenue for the Company employees&#8217;, subcontracted employees&#8217;, and independent contractors&#8217; time worked but not yet billed at March 31, 2025 and December 31, 2024 totaled $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:UnbilledContractsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-259">61.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnbilledContractsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-260">60.4</ix:nonFraction>&#160;million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for credit losses is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for credit losses when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of its accounts receivable based on a combination of factors. The Company bases its allowance for credit loss estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered expectations of future economic condition</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when estimating its allowance for credit losses.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="f-261" escape="true"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening balance of the allowance for credit losses is reconciled to the closing balance for expected credit losses as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-262">8,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-263">19,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Loss Expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-264">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-265">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-Offs, net of Recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ccrn:AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery" scale="3" id="f-266">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ccrn:AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery" format="ixt:num-dot-decimal" scale="3" id="f-267">1,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-268">9,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-269">19,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:continuation id="f-258-1" continuedAt="f-258-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the allowance for credit losses, the Company maintains a sales allowance for billing-related adjustments that may arise in the ordinary course of business and adjustments to the reserve are recorded as contra-revenue. The sales allowance balance as of March 31, 2025 and December 31, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ccrn:SalesAllowanceBillingRelatedAdjustments" format="ixt:num-dot-decimal" scale="6" id="f-270">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ccrn:SalesAllowanceBillingRelatedAdjustments" format="ixt:num-dot-decimal" scale="6" id="f-271">0.5</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-258-2">The Company&#8217;s contract terms typically require payment between <ix:nonNumeric contextRef="c-33" name="ccrn:ThresholdPeriodPastDueForPaymentOfServicesProvided" format="ixt-sec:durday" id="f-272">30</ix:nonNumeric> to <ix:nonNumeric contextRef="c-34" name="ccrn:ThresholdPeriodPastDueForPaymentOfServicesProvided" format="ixt-sec:durday" id="f-273">60</ix:nonNumeric> days from the date of invoice and are considered past due based on the particular negotiated contract terms. The majority of the Company&#8217;s customers are healthcare systems with a significant percentage in acute-care facilities.</ix:continuation> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No single customer accounted for more than 10% of the Company&#8217;s revenue for the three months ended March 31, 2025 and 2024, or the Company&#8217;s accounts receivable balance as of March 31, 2025 and December 31, 2024.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="f-274" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions, and are primarily included in the accounts payable and accrued expenses on the condensed consolidated balance sheets. Restructuring costs on the condensed consolidated statements of operations and comprehensive (loss) income primarily include employee termination costs and lease-related exit costs.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-255-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-275" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliations of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:50.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Termination Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease-Related Exit Costs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-276">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-277">788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to restructuring</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-278">152</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="f-279">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="f-280">137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="f-281">184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2025</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-282">115</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-283">604</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-284" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 27, 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses, enhances interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and requires certain disclosures related to the chief operating decision maker. The Company adopted this standard for its fiscal year ended December 31, 2024, and its interim periods beginning in the first quarter of 2025, and applied the guidance retrospectively to all prior periods presented in the financial statements. This standard only expanded the Company&#8217;s disclosures with no impact to results of operations, cash flows, and financial condition. See Note 12 - Segment Data.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve decision usefulness of business entities&#8217; income statements through the disaggregation of certain expense captions, such as employee compensation, depreciation, and intangible asset amortization, with required disclosure in a single note to the financial statements. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments in this update should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this update, or (2) retrospectively to any or all prior periods presented in the financial statements. The Company expects to adopt this standard for its annual report for the fiscal year ending December 31, 2027. The Company expects this ASU to only impact its disclosures with no impacts to results of operations, cash flows, and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that public business entities, on an annual basis, (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The amendments also require that all entities disclose, on an annual basis, disaggregated information regarding income taxes paid and income tax expense. This guidance is effective for annual periods beginning after December 15, 2024. The amendments should be applied prospectively, but retrospective application is permitted. The Company plans to adopt this standard for its annual report for the fiscal year ended December 31, 2025. The Company expects this ASU to only impact its disclosures with no impacts to results of operations, cash flows, and financial condition.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-285" continuedAt="f-285-1" escape="true">REVENUE RECOGNITION</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-285-1" continuedAt="f-285-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-286" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s revenues from customer contracts are generated from temporary staffing services and other services. Revenue is disaggregated by segment in the following table. Sales and usage-based taxes are excluded from revenue.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse<br/>And Allied<br/>Staffing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician<br/>Staffing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary Staffing Services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-287">236,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-288">48,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-289">284,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-290">6,134</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-291">2,417</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-292">8,551</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-293">242,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-294">51,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-295">293,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse<br/>And Allied<br/>Staffing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician<br/>Staffing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary Staffing Services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-296">324,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-297">44,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-298">369,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-299">7,212</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-300">2,499</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-301">9,711</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-302">332,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-303">46,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-304">379,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-285-2">See Note 12 - Segment Data.</ix:continuation>                                                                                                </span></div><div><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_46"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-305" continuedAt="f-305-1" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-305-1" continuedAt="f-305-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HireUp</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 13, 2022, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of HireUp Leadership Inc. (HireUp) for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-306">6.0</ix:nonFraction>&#160;million in cash, subject to adjustment, and $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="f-307">0.8</ix:nonFraction>&#160;million in shares (or <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-308">29,811</ix:nonFraction> shares) of the Company&#8217;s common stock. The transaction was treated as a purchase of assets for income tax purposes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The sellers were eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-309">8.0</ix:nonFraction>&#160;million in earnout cash consideration based on HireUp&#8217;s revenues and Adjusted EBITDA for each of the twelve-month periods ending on the first and second anniversaries of the first day after the closing date. Quarterly throughout 2023, and during the first quarter of 2024, the Company performed analyses using multiple updated forecasted scenarios and determined that the earnout would only be partially achieved. As a result, the Company recognized a decrease in the fair value of the related liabilities in the second and third quarters of 2023 and the first quarter of 2024. The Company paid the remaining earnout liability of $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-310">1.7</ix:nonFraction>&#160;million in the first quarter of 2024. See Note 10 - Fair Value Measurements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mint</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 3, 2022, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of Mint Medical Physician Staffing, LP and Lotus Medical Staffing LLC (collectively, Mint) for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-311">27.0</ix:nonFraction>&#160;million in cash, subject to adjustment, and $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="f-312">3.6</ix:nonFraction>&#160;million in shares (or <ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-313">114,278</ix:nonFraction> shares) of the Company&#8217;s common stock. The transaction was treated as a purchase of assets for income tax purposes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The sellers were eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-314">10.0</ix:nonFraction>&#160;million in earnout cash consideration based on Mint&#8217;s revenues and gross profit for each of the twelve-month periods ending on the first and second anniversaries of the first day of the calendar month following the closing date. In the fourth quarter of 2023, the Company performed a calculation for the first measurement period, resulting in the achievement of a $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-315">4.9</ix:nonFraction>&#160;million earnout, which was paid in the first quarter of 2024. During </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-305-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the fourth quarter of 2024, the Company performed a calculation for the second measurement period, resulting in the achievement of a $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-316">4.4</ix:nonFraction>&#160;million earnout, which was paid in the first quarter of 2025. See Note 10 - Fair Value Measurements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other than the fees associated with the pending Aya Merger as discussed on Note 1 - Organization and Basis of Presentation, the Company did not record any acquisition-related costs associated with the Company&#8217;s acquisitions for the three months ended March 31, 2025, and recorded an immaterial credit for the three months ended March 31, 2024.</span></div></ix:continuation><div><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_49"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="f-317" continuedAt="f-317-1" escape="true">COMPREHENSIVE (LOSS) INCOME</ix:nonNumeric></span></div><ix:continuation id="f-317-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total comprehensive (loss) income includes net income or loss and foreign currency translation adjustments, net of any related deferred taxes, and is included within the accompanying condensed consolidated statements of operations and comprehensive (loss) income. Certain of the Company&#8217;s foreign subsidiaries use their respective local currency as their functional currency. Assets and liabilities of these operations are translated at the exchange rates in effect on the balance sheet date. Income statement items are translated at the average exchange rates for the period. The cumulative impact of currency fluctuations related to the balance sheet translation is included in accumulated other comprehensive loss in the accompanying condensed consolidated balance sheets and was an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-318"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-319">1.5</ix:nonFraction></ix:nonFraction>&#160;million as of March 31, 2025 and December&#160;31, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax impact related to components of other comprehensive income (loss) for the three months ended March 31, 2025 and 2024 is included in unrealized foreign currency translation gain (loss), net of tax in the condensed consolidated statements of operations and comprehensive (loss) income.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-320" continuedAt="f-320-1" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><ix:continuation id="f-320-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-321" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(amounts in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common stockholders - Basic and Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="f-322"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="f-323">490</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-324"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-325">2,692</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares - Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-326">32,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-327">34,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of diluted shares:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Share-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-329">381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares - Diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">a</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-330">32,282</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-331">34,597</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share attributable to common stockholders - Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-332">0.02</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-333">0.08</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share attributable to common stockholders - Diluted</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-334">0.02</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-335">0.08</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)  For the three months ended March 31, 2025, the effect of diluted shares was not included in the weighted average share calculation due to the Company&#8217;s net operating loss position.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-336" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the share-based awards that could potentially dilute net (loss) income per share attributable to common stockholders in the future that were not included in the computation of diluted net (loss) income per share attributable to common stockholders because to do so would have been anti-dilutive for the periods presented.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based awards</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-337">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-338">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-339" continuedAt="f-339-1" escape="true">GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-339-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="f-340" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following acquired intangible assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Databases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-341">36,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-342">23,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-343">13,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-344">36,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-345">21,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-346">14,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-347">52,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-348">31,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-349">20,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-350">52,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-351">30,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-352">21,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-353">89,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-354">55,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-355">34,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-356">89,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-357">52,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-358">36,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets not subject to amortization:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names, indefinite-lived</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:IndefiniteLivedTradeNames" format="ixt:num-dot-decimal" scale="3" id="f-359">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IndefiniteLivedTradeNames" format="ixt:num-dot-decimal" scale="3" id="f-360">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-361" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, estimated future annual amortization expense was as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:80.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-362">6,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-363">7,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-364">6,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-365">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-366">4,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ccrn:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-367">5,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-368">34,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Goodwill, Trade Names, and Other Intangible Assets Impairment </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests reporting units&#8217; goodwill and intangible assets with indefinite lives for impairment annually during the fourth quarter and more frequently if impairment indicators exist. The Company performs quarterly qualitative assessments of significant events and circumstances, such as reporting units&#8217; historical and current results, assumptions regarding future performance, strategic initiatives and overall economic factors,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and macro-economic developments, to determine the existence of potential indicators of impairment and assess if it is more likely than not that the fair value of reporting units or intangible assets is less than their carrying value. If indicators of impairments are identified a quantitative impairment test is performed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company performed a qualitative assessment of each of its reporting units and determined that it was not more likely than not that the fair value of its reporting units dropped below their carrying value. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lthough management believes that the Company&#8217;s current estimates and assumptions utilized in its qualitative testing are reasonable and supportable, there can be no assurance that the estimates and assumptions management used for purposes of its assessment as of March 31, 2025 will prove to be accurate predictions of future performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, goodwill by reporting segment was: $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-369">112.2</ix:nonFraction>&#160;million for Nurse and Allied Staffing and $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-370">22.9</ix:nonFraction>&#160;million for Physician Staffing, for a total of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-371">135.1</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-lived assets and definite-lived intangible assets, the Company reviews for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of March 31, 2025 and 2024, the Company performed a qualitative assessment of its trade names and other intangible assets and determined it was not more likely than not that their carrying value may not be recoverable.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-372" continuedAt="f-372-1" escape="true">DEBT</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-372-1" continuedAt="f-372-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-373" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s debt consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Secured Asset-Based Loan, interest of <ix:nonFraction unitRef="number" contextRef="c-72" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-374">6.21</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-73" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-375">6.31</ix:nonFraction>% at March 31, 2025 and December 31, 2024, respectively</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-377">1,606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-379">1,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-381">1,606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-383">1,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025 and December 31, 2024, there was <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt-sec:numwordsen" scale="0" id="f-384"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt-sec:numwordsen" scale="0" id="f-385">no</ix:nonFraction></ix:nonFraction> debt outstanding on the condensed consolidated balance sheets. The Company has elected to present the debt issuance costs associated with its senior secured asset-based credit facility as an asset, included in other assets on the condensed consolidated balance sheets.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Asset-Based Loan Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October 25, 2019, the Company terminated its prior senior credit facility and entered into an asset-based loan agreement, by and among the Company and certain of its domestic subsidiaries, as borrowers or guarantors, Wells Fargo Bank, N.A., and PNC Bank N.A., as well as other Lenders (as defined therein) from time to time parties thereto (Loan Agreement). The Loan Agreement provided for a <ix:nonNumeric contextRef="c-74" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="f-386">five-year</ix:nonNumeric> revolving senior secured asset-based credit facility (ABL) in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-387">120.0</ix:nonFraction>&#160;million, including a sublimit for swing loans up to $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-388">15.0</ix:nonFraction>&#160;million and a $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-389">35.0</ix:nonFraction>&#160;million sublimit for standby letters of credit.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2020, the Company amended the Loan Agreement (First Amendment), which increased the current aggregate committed size of the ABL from $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-390">120.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-391">130.0</ix:nonFraction>&#160;million. All other terms, conditions, covenants, and pricing of the Loan Agreement remained the same. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2021, the Company amended the Loan Agreement (Second Amendment), which increased the current aggregate committed size of the ABL from $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-392">130.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-393">150.0</ix:nonFraction>&#160;million, increased certain borrowing base sub-limits, and decreased both the cash dominion event and financial reporting triggers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company amended the Loan Agreement (Third Amendment), which permitted the incurrence of indebtedness and grant of security as set forth in the Loan Agreement and in accordance with the Intercreditor Agreement (as defined in the Loan Agreement), and provides mechanics relating to a transition away from the London Interbank Offered Rate (LIBOR) as a benchmark interest rate to a replacement alternative benchmark rate or mechanism for loans made in U.S. dollars.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2021, the Company amended the Loan Agreement (Fourth Amendment), whereby the permitted indebtedness (as defined in the Loan Agreement), was increased to $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="INF" name="ccrn:LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" scale="6" id="f-394">175.0</ix:nonFraction> million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2022, the Company amended the Loan Agreement (Fifth Amendment), which increased the current aggregate committed size of the ABL from $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-395">150.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-396">300.0</ix:nonFraction> million, extended the term of the credit facility for an additional <ix:nonNumeric contextRef="c-82" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="f-397">five years</ix:nonNumeric>, through March 21, 2027, and increased certain borrowing base sub-limits. In addition, the agreement provides the option for all or a portion of the borrowings to bear interest at a rate based on the Secured Overnight Financing Rate (SOFR) or the Base Rate (as defined in the Loan Agreement), at the election of the borrowers, plus an applicable margin. The applicable margin increased <ix:nonFraction unitRef="number" contextRef="c-83" decimals="INF" name="ccrn:DebtInstrumentBasisSpreadOnVariableRateAdjustment" scale="-4" id="f-398">10</ix:nonFraction> basis points due to the credit spread associated with the transition to SOFR.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 29, 2023, the Company amended the Loan Agreement (Sixth Amendment), which changed the minimum fixed charge coverage ratio from a maintenance covenant to a springing covenant based on excess availability, which provides for compliance with the covenant only during a compliance period (any time that excess availability falls below a certain threshold), and in such case, the financial covenant shall be tested during this period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2024, the Company amended the Loan Agreement (Seventh Amendment), which allows for all share repurchases paid in cash prior to June 30, 2024 and thereafter to be excluded as restricted payments in the fixed charge coverage ratio calculation, if as of the date of the share repurchase, there is <ix:nonFraction unitRef="usd" contextRef="c-84" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="f-399">no</ix:nonFraction> revolving ABL balance (except for interest and fees payable in accordance with the terms of the Loan Agreement).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amendments were treated as modifications of debt and, as a result, the associated fees and costs were included in debt issuance costs and are amortized ratably over the remaining term of the Loan Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ABL availability is subject to a borrowing base of up to <ix:nonFraction unitRef="number" contextRef="c-75" decimals="INF" name="ccrn:LineOfCreditBorrowingBasePercentageOfAccountsReceivable" scale="-2" id="f-400">85</ix:nonFraction>% of secured eligible accounts receivable, subject to adjustment at certain quality levels, minus customary reserves and subject to customary adjustments. Revolving loans and letters of credit </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-372-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued under the Loan Agreement reduce availability under the ABL on a dollar-for-dollar basis. At March 31, 2025, there were <ix:nonFraction unitRef="usd" contextRef="c-85" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="f-401">no</ix:nonFraction> borrowings drawn under the ABL, and borrowing base availability under the ABL was $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="ccrn:LineOfCreditFacilityBorrowingBaseAvailability" format="ixt:num-dot-decimal" scale="6" id="f-402">148.4</ix:nonFraction>&#160;million, with $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-403">133.5</ix:nonFraction>&#160;million of availability net of $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="f-404">14.9</ix:nonFraction>&#160;million of letters of credit outstanding related to workers&#8217; compensation and professional liability policies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the interest rate spreads and fees under the ABL were based on SOFR plus <ix:nonFraction unitRef="number" contextRef="c-86" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-405">1.85</ix:nonFraction>% for the revolving portion of the borrowing base. The Base Rate margin would have been <ix:nonFraction unitRef="number" contextRef="c-87" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-406">0.75</ix:nonFraction>% for the revolving portion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The SOFR and Base Rate margins are subject to monthly adjustments, pursuant to a pricing matrix based on the Company&#8217;s excess availability under the revolving credit facility. In addition, the facility is subject to an unused line fee, letter of credit fees, and an administrative fee. The unused line fee is <ix:nonFraction unitRef="number" contextRef="c-88" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="f-407">0.375</ix:nonFraction>% of the average daily unused portion of the revolving credit facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains various restrictions applicable to the Company and its subsidiaries. For the three months ended March 31, 2025, the excess availability did not fall below the stated threshold and, as a result, there was no covenant compliance period. Obligations under the ABL are secured by substantially all of the assets of the borrowers and guarantors, subject to customary exceptions.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-408" continuedAt="f-408-1" escape="true">LEASES</ix:nonNumeric></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><ix:continuation id="f-408-1" continuedAt="f-408-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease population of its right-of-use assets and lease liabilities is substantially related to the rental of office space. The Company enters into lease agreements as a lessee that may include options to extend or terminate early. Some of these real estate leases require variable payments of property taxes, insurance, and common area maintenance, in addition to base rent. Certain of the leases have provisions for free rent during the lease term and/or escalating rent payments and, particularly for the Company&#8217;s longer-term leases for its corporate offices, it has received incentives to enter into the leases, such as receiving up to a specified dollar amount to construct tenant improvements. These leases do not include residual value guarantees, covenants, or other restrictions.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ccrn:AssetsAndLiabilitiesLeasesTableTextBlock" id="f-409" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification on Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-410">2,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-411">2,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-412">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-413">2,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-414">1,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-415">1,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-416">2.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-417">2.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-418">7.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-419">7.05</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-420" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the undiscounted cash flows for each of, and total of, the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of March 31, 2025:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:75.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-421">1,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-422">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-423">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-424">523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-425">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ccrn:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:fixed-zero" scale="3" id="f-426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-427">3,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-428">342</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-429">3,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: operating lease liabilities - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-430">1,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-431">1,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-408-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Information</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-432" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding supplemental cash flows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="f-433">625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="f-434">863</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets acquired under operating lease</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-436">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Included in Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-437">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-438">322</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-439">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-440">597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable and other lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-441">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-442">628</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense, short-term lease expense, and variable and other lease costs are included in selling, general and administrative expenses, direct operating expenses, and restructuring costs in the condensed consolidated statements of operations and comprehensive (loss) income, depending on the nature of the leased asset. Operating lease expense is reported net of sublease income, which is not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company did not have any material operating leases that had not yet commenced, and does not have any finance lease contracts.</span></div></ix:continuation><div><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_64"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-443" continuedAt="f-443-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="f-443-1" continuedAt="f-443-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy was established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Measured at Fair Value on a Recurring Basis:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial assets/liabilities required to be measured on a recurring basis were primarily its: (i) deferred compensation asset included in other assets; and (ii) deferred compensation liability included in other liabilities on its condensed consolidated balance sheets.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-443-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company utilizes Level 1 inputs to value its deferred compensation assets and liabilities. The Company&#8217;s deferred compensation assets and liabilities are measured using publicly available indices, as per the plan documents.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-444" continuedAt="f-444-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s financial assets and liabilities measured on a recurring basis is as follows:&#160;</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:center"><ix:continuation id="f-444-1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:58.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-445">2,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-446">2,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations" format="ixt:num-dot-decimal" scale="3" id="f-447">2,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations" format="ixt:num-dot-decimal" scale="3" id="f-448">2,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Measured at Fair Value on a Non-Recurring Basis:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s non-financial assets, such as goodwill, trade names, other intangible assets, right-of-use assets, and property and equipment, are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record any material impairment charges during the three months ended March 31, 2025 and 2024.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments not measured or recorded at fair value in the condensed consolidated balance sheets consist of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses. The estimated fair value of accounts receivable and accounts payable and&#160;accrued expenses approximate their carrying amount due to the short-term nature of these instruments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial instruments not measured or recorded at fair value include earnout liabilities related to the (i) Mint and (ii) HireUp acquisitions, as discussed below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i) Potential earnout payments related to the Mint acquisition were contingent upon meeting certain performance requirements based on 2022 through 2024 performance. On a quarterly basis, the Company performed an analysis using multiple forecasted scenarios to determine the fair value of the earnout liability. In the fourth quarter of 2023, the Company performed the earnout calculation for the first measurement period, resulting in an earnout of $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-449">4.9</ix:nonFraction>&#160;million, which was paid in the first quarter of 2024. During the fourth quarter of 2024, the Company performed a calculation for the second measurement period, resulting in the achievement of a $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-450">4.4</ix:nonFraction>&#160;million earnout, which was paid in the first quarter of 2025. See Note 4 - Acquisitions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii) Potential earnout payments related to the HireUp acquisition were contingent upon meeting certain performance requirements based on 2022 through 2024 performance. Quarterly throughout 2023 and in the first quarter of 2024, the Company performed analyses using multiple updated forecasted scenarios and determined that the earnout would only be partially achieved. As a result, the Company recognized a decrease in the fair value of the related liabilities in the second and third quarters of 2023 and the first quarter of 2024. The remaining liability of $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-451">1.7</ix:nonFraction>&#160;million was paid in the first quarter of 2024. See Note 4 - Acquisitions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk:</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See discussion of credit losses and allowance for credit losses in Note 2 - Summary of Significant Accounting Policies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, based on the large number of customers in differing geographic areas, primarily throughout the United States and its territories, the Company believes that the concentration of credit risk is limited.</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="f-452" continuedAt="f-452-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STOCKHOLDERS&#8217; EQUITY</span></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-452-1" continuedAt="f-452-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 1, 2023, the Company&#8217;s Board of Directors authorized approximately $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="ccrn:StockRepurchaseProgramAdditionalAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-453">59.0</ix:nonFraction>&#160;million in additional share repurchases, such that, effective for trades made after May 3, 2023, the aggregate amount available for stock repurchases was set at $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="f-454">100.0</ix:nonFraction>&#160;million (the Repurchase Program). The shares can be repurchased from time-to-time in the open market or in privately negotiated transactions. The Repurchase Program does not obligate the Company to repurchase any particular number of shares of common stock and may be discontinued by the Board of Directors at any time. Decisions regarding the amount and the timing of repurchases under the Repurchase Program will be subject to the Company&#8217;s available liquidity and cash on hand, applicable legal requirements, the terms of the Company&#8217;s Loan Agreement, general market conditions, and other factors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the third quarter of 2023, the Company entered into a Rule 10b5-1 Repurchase Plan to allow for share repurchases during the Company&#8217;s blackout periods, beginning on January 2, 2024 and effective through November 7, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, the Company repurchased a total of <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-455">310,235</ix:nonFraction> shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-456">6.4</ix:nonFraction>&#160;million, at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-94" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-457">20.51</ix:nonFraction> per share. During the three months ended March 31, 2025, the Company did <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="f-458">no</ix:nonFraction>t repurchase any shares of its common stock, but did pay $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="ccrn:StockRepurchasedDuringPeriodExciseTax" format="ixt:num-dot-decimal" scale="6" id="f-459">0.3</ix:nonFraction>&#160;million in excise tax related to previous share repurchases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2025, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="f-460">40.5</ix:nonFraction>&#160;million remaining for share repurchase under the Repurchase Program, subject to certain conditions in the Company&#8217;s Loan Agreement. As of March 31, 2025, the Company had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-461">32,476,983</ix:nonFraction> unrestricted shares of common stock outstanding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 14, 2024, the Company&#8217;s stockholders approved the Cross Country Healthcare, Inc. 2024 Omnibus Incentive Plan (2024 Plan). Pursuant to the 2024 Plan, awards may be granted to employees, non-employee directors, consultants, and key advisors of the Company and its subsidiaries, including stock options (including incentive stock options and nonqualified stock options), stock appreciation rights, stock awards, stock units, other stock-based awards, and cash awards. The 2024 Plan was adopted principally to serve as a successor plan to the Cross Country Healthcare, Inc. 2020 Omnibus Incentive Plan (2020 Plan) and to increase the number of shares of Company common stock reserved for equity-based awards to <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-462">2,400,000</ix:nonFraction> shares (in addition to the share reserve amount that remained available under the 2020 Plan immediately prior to the adoption of the 2024 Plan and other eligible returning shares). No awards may be granted under the 2024 Plan after May 13, 2034.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-463" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock awards and performance stock awards activity issued under the 2020 Plan and the 2024 Plan (Plans) for the three months ended March&#160;31, 2025:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.741%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Stock Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Target <br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock awards, January&#160;1, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-464">538,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-98" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-465">19.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-466">409,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-99" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-467">20.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-472">220,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-473">20.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-474">85,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-475">21.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-476">9,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-477">20.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-478">27,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-479">21.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock awards, March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-480">308,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-481">18.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-482">297,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-483">20.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards granted under the Company&#8217;s Plans entitle the holder to receive, at the end of a vesting period, a specified number of shares of the Company&#8217;s common stock. Share-based compensation expense is measured by the market value of the Company&#8217;s stock on the date of grant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards granted to non-employee directors under the Plans will vest on the first anniversary of such grant date, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or earlier subject to retirement eligibility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, effective for the three months ended June 30, 2020, the Company implemented modified guidelines that provide for accelerated vesting of restricted stock grants on the last date of service when a retirement-eligible director retires.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-452-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Plans, the number of target shares that are issued for performance-based stock awards are determined based on the level of attainment of the targets. During the first quarter of 2025, the Company&#8217;s Compensation Committee of the Board of Directors approved a <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" scale="-2" id="f-484">75.5</ix:nonFraction>% level of attainment for the 2022 performance-based share awards, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-485">85,001</ix:nonFraction> performance shares that vested on March 31, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March 31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-486">1.3</ix:nonFraction> million was included in selling, general and administrative expenses related to share-based payments, and a net of <ix:nonFraction unitRef="shares" contextRef="c-105" decimals="INF" name="ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" format="ixt:num-dot-decimal" scale="0" id="f-487">199,588</ix:nonFraction> shares of common stock were issued upon the vesting of restricted and performance stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-488">1.2</ix:nonFraction> million was included in selling, general and administrative expenses related to share-based payments, and a net of <ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" format="ixt:num-dot-decimal" scale="0" id="f-489">251,024</ix:nonFraction> shares of common stock were issued upon the vesting of restricted and performance stock.</span></div></ix:continuation><div><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_70"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-490" continuedAt="f-490-1" escape="true">SEGMENT DATA</ix:nonNumeric></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><ix:continuation id="f-490-1" continuedAt="f-490-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-491"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-492">two</ix:nonFraction></ix:nonFraction> operating and reportable segments, Nurse and Allied Staffing and Physician Staffing, which align with its management structure and reflect how the operating results are regularly reviewed by the Chief Executive Officer, who the Company has determined to be its Chief Operating Decision Maker (CODM). The Company&#8217;s segments offer services to its customers as described below:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9679;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Nurse and Allied Staffing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211; Nurse and Allied Staffing provides traditional staffing, recruiting, and value-added total talent solutions including: temporary and permanent placement of travel nurse and allied professionals, per diem, and healthcare leaders within nursing, allied, human resources, and finance, managed service programs services, education healthcare services, in-home care services, and outsourcing services. In addition, Nurse and Allied Staffing provides executive search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services, and offers the Company&#8217;s SaaS-based, proprietary, vendor management technology, Intellify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to facilities to manage all or a portion of their agency services. Its customers include: public and private acute care hospitals, non-acute care hospitals, government facilities, local healthcare plans, national healthcare plans, managed care providers, public schools, charter schools, academic medical centers, Programs of All-Inclusive Care for the Elderly (PACE) programs, outpatient clinics, ambulatory care facilities, physician practice groups, and many other healthcare providers throughout the United States.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9679;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Physician Staffing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Physician Staffing provides physicians in many specialties, as well as certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments throughout the United States at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, and the profit and loss measure of contribution income, are reported to the CODM by each of the operating segments to assess performance. Contribution income is the profit and loss measure used by the CODM to allocate operating and capital resources to each segment. The Company defines contribution income as income (loss) from operations before depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, impairment charges, and corporate overhead. Management believes that its measure of contribution income is most consistent with that used to measure the corresponding amounts on its consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in the following tables is derived from the segments&#8217; internal financial information as used for corporate management purposes. Certain corporate expenses are not allocated to and/or among the operating segments. Those include corporate overhead and the remaining line items below contribution income in the consolidated column in the tables below, and are presented to the CODM on a consolidated basis only.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-493" continuedAt="f-493-1" escape="true"><ix:continuation id="f-490-2" continuedAt="f-490-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on reportable segments and a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reconciliation to loss before income taxes for the period indicated are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:40.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse and Allied Staffing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician Staffing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-494">242,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-495">51,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-496">293,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:DirectOperatingCosts" format="ixt:num-dot-decimal" scale="3" id="f-497">194,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:DirectOperatingCosts" format="ixt:num-dot-decimal" scale="3" id="f-498">40,717</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="ccrn:LaborAndRelatedExpenseExcludingBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-499">21,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="ccrn:LaborAndRelatedExpenseExcludingBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-500">5,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="ccrn:BenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-501">2,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="ccrn:BenefitsExpense" scale="3" id="f-502">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:MarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-503">1,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:MarketingExpense" scale="3" id="f-504">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss (income) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-505">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-506">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divisional corporate G&amp;A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-507">3,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="f-508">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-509">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="f-510">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard" format="ixt:num-dot-decimal" scale="3" id="f-511">17,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard" format="ixt:num-dot-decimal" scale="3" id="f-512">4,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard" format="ixt:num-dot-decimal" scale="3" id="f-513">21,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of profit or loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate overhead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="ccrn:SegmentReportingUnallocatedCorporateExpenses" format="ixt:num-dot-decimal" scale="3" id="f-514">15,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-515">4,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration-related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ccrn:AcquisitionAndIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-516">2,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-517">301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-518">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-519">681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-520">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="f-521">899</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) For each reportable segment, the other segment items category includes the following expenses: rent, insurance, maintenance, utilities, professional services, office, software and hardware, taxes, and miscellaneous employee expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).</span></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-490-3"><ix:continuation id="f-493-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on reportable segments and a reconciliation to income before income taxes for the period indicated are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:40.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse and Allied Staffing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician Staffing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-522">332,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-523">46,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-524">379,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:DirectOperatingCosts" format="ixt:num-dot-decimal" scale="3" id="f-525">264,880</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:DirectOperatingCosts" format="ixt:num-dot-decimal" scale="3" id="f-526">36,997</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="ccrn:LaborAndRelatedExpenseExcludingBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-527">28,365</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="ccrn:LaborAndRelatedExpenseExcludingBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-528">5,430</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="ccrn:BenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-529">2,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="ccrn:BenefitsExpense" scale="3" id="f-530">507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:MarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-531">2,209</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:MarketingExpense" scale="3" id="f-532">232</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-533">990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-534">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divisional corporate G&amp;A</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-535">4,337</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="f-536">121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-537">1,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="f-538">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution Income</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard" format="ixt:num-dot-decimal" scale="3" id="f-539">27,183</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard" format="ixt:num-dot-decimal" scale="3" id="f-540">3,138</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard" format="ixt:num-dot-decimal" scale="3" id="f-541">30,321</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of profit or loss:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate overhead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="ccrn:SegmentReportingUnallocatedCorporateExpenses" format="ixt:num-dot-decimal" scale="3" id="f-542">17,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-543">4,642</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-544">938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and other losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ccrn:LegalAndOtherLosses" format="ixt:num-dot-decimal" scale="3" id="f-545">3,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="f-546">604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-547">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-548">173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-549">1,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-550">3,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) For each reportable segment, the other segment items category includes the following expenses: rent, insurance, maintenance, utilities, professional services, office, software and hardware, taxes, and miscellaneous employee expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is based on services provided. During the three months ended March 31, 2025 and 2024, all revenue was generated in the U.S., and all of the Company&#8217;s long-lived assets were located in the U.S. and India. The Company provides its staffing services and workforce solutions in all <ix:nonFraction unitRef="state" contextRef="c-3" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="f-551">50</ix:nonFraction> states. The India location is a cost center with <ix:nonFraction unitRef="usd" contextRef="c-116" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-552"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-553">no</ix:nonFraction></ix:nonFraction> revenues and an immaterial amount of long-lived assets. The Company had <ix:nonFraction unitRef="usd" contextRef="c-118" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-554"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-555">no</ix:nonFraction></ix:nonFraction> intersegment revenues between reportable segments for the three months ended March 31, 2025 and 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not evaluate, manage, or measure performance of segments using asset information; accordingly, total asset information by segment is not prepared or disclosed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the segments are the same as those described in Note 2 &#8211; Summary of Significant Accounting Policies, which also provides information about major customers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the tables in Note 3 - Revenue Recognition, which present segment revenues by services.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-556" continuedAt="f-556-1" escape="true"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTINGENCIES</span></ix:nonNumeric></div><div><span><br/></span></div><ix:continuation id="f-556-1" continuedAt="f-556-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various litigation, claims, investigations, and other proceedings that arise in the ordinary course of its business. These proceedings primarily relate to employee-related matters that include individual and collective claims, professional liability, tax, and payroll practices. The Company establishes reserves when available information indicates that a loss is probable and an amount or range of loss can be reasonably estimated. These assessments are performed at least quarterly and are based on the information available to management at the time and involve significant management judgment to determine the probability and estimated amount of potential losses, if any. Based on the available information considered in its reviews, the Company adjusts its loss contingency accruals and its disclosures as may be required. Actual outcomes or losses may differ materially from those estimated by the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s current assessments, including available insurance recoveries, which would impact the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s profitability. Adverse developments in existing litigation claims or legal proceedings involving the Company or new claims could require management to establish or increase litigation reserves or enter into unfavorable settlements or satisfy judgments for monetary damages for amounts in excess of current reserves, which could adversely affect the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s financial results. The Company believes that the outcome of any outstanding loss contingencies as of March 31, 2025 will not have a material adverse effect on its business, financial condition, results of operations, or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Other State Non-Income Tax Liabilities </span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-556-2">The Company&#8217;s sales and other state non-income tax filings are subject to routine audits by authorities in the jurisdictions where it conducts business in the United States which may result in assessments of additional taxes. The Company accrues sales and other non-income tax liabilities based on the Company&#8217;s best estimate of its probable liability utilizing currently available information and interpretation of relevant tax regulations. Given the nature of the Company&#8217;s business, significant subjectivity exists as to both whether sales and other state non-income taxes can be assessed on its activity and how the sales tax will ultimately be measured by the relevant jurisdictions. The Company makes a determination for each reporting period whether the estimates for sales and other non-income taxes in certain states should be revised. The expense is included in selling, general and administrative expenses in the Company&#8217;s condensed consolidated statements of operations and comprehensive (loss) income and the liability is reflected in sales tax payable within other current liabilities in its condensed consolidated balance sheets.</ix:continuation> </span></div><div><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_76"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-557" continuedAt="f-557-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-557-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three-month periods ended March 31, 2025 and 2024, the Company calculated its effective tax rate estimating its annual effective tax rate. The Company&#8217;s effective tax rate for the three months ended March 31, 2025 and 2024 was <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-558">45.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-559">27.0</ix:nonFraction>%, respectively, including the impact of discrete items. Excluding discrete items, the Company&#8217;s effective tax rate for the three months ended March 31, 2025 and 2024 was <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ccrn:EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent" scale="-2" id="f-560">56.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="ccrn:EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent" scale="-2" id="f-561">37.0</ix:nonFraction>%, respectively. The effective tax rates for the first quarters of 2025 and 2024 were primarily impacted by federal and state taxes. The increase in the effective tax rate was primarily related to a decrease in book income relative to nondeductible items.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-562">10.2</ix:nonFraction>&#160;million of unrecognized tax benefits included in other non-current liabilities, $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-563">11.1</ix:nonFraction>&#160;million, net of deferred taxes, which would impact the effective tax rate if recognized. During the three months ended March 31, 2025, the Company had net increases of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="f-564">0.3</ix:nonFraction>&#160;million to its current year unrecognized tax benefits related to federal and state tax provisions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2024, many international jurisdictions implemented the Pillar Two rules issued by the Organization for Economic Co-operation and Development. In general, large multinational entity groups with consolidated revenue in excess of 750 million Euros in at least two of the preceding four years could be subject to the new rules in jurisdictions with an effective tax rate below fifteen percent. The Company currently operates in one country that has adopted the Pillar Two rules, but should meet the safe harbor rules. The Company does not expect the adoption of the Pillar Two rules by any jurisdiction in which it currently operates to have a material impact on its financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax years 2012 through 2024 remain open to examination by certain taxing jurisdictions to which the Company is subject to tax, other than certain states in which the statute of limitations has been extended.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-565" continuedAt="f-565-1" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-565-1"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an arrangement for digital marketing services provided by a firm that is related to a certain member of the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Board of Directors, who is a minority shareholder in the firm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s parent company and is a member of the parent company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Board of Directors. Management believes that the terms of the arrangement are equivalent to those prevailing in an arm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s-length transaction and have been approved by the Audit Committee of the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Board of Directors through the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s related party transaction approval process. The digital marketing firm manages a limited number of digital publishers covering various Company brands for a monthly management fee. During the three months ended March 31, 2025 and 2024, the Company incurred an immaterial amount in expenses and had an immaterial payable balance at March 31, 2025 and December 31, 2024.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides services to entities that are affiliated with certain members of the Company&#8217;s Board of Directors. Management believes that the services were conducted on terms equivalent to those prevailing in an arm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s-length transaction. Revenue related to these transactions was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-566">2.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2025 and an <ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-567">immaterial</ix:nonFraction> amount for the three months ended March 31, 2024. Accounts receivable due from these entities was an immaterial amount at March 31, 2025 and December 31, 2024.</span></div></ix:continuation><div><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_88"></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the following Management&#8217;s Discussion and Analysis (MD&amp;A) is to help facilitate the understanding of significant factors influencing the quarterly operating results, financial condition, and cash flows of the Company. Additionally, MD&amp;A also conveys our current expectations of the potential impact of known trends, events, or uncertainties that may impact future results. MD&amp;A is provided as a supplement to, and should be read in conjunction with, our Annual Report on Form&#160;10-K for the year ended December 31, 2024, as amended by Amendment No. 1 on Form 10-K/A (2024 Form 10-K) (including Part I, Item 1A. &#8220;Risk Factors&#8221;), our financial statements and the accompanying notes to our financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie094c362a2b8472c8b046d777cad339c_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide total talent management services, including strategic workforce solutions, contingent staffing, permanent placement, and consultative services for healthcare customers across the continuum of care, by recruiting and placing highly qualified healthcare professionals in virtually every specialty and area of expertise. In addition to clinical roles such as school nurses, speech language, and behavioral therapists, we place non-clinical professionals such as teachers, substitute teachers, and other education specialties at educational facilities across the nation. Our diverse customer base includes both public and private acute care and non-acute care hospitals, outpatient clinics, ambulatory care facilities, single- and multi-specialty physician practices, rehabilitation facilities, Program of All-Inclusive Care for the Elderly (PACE) programs, urgent care centers, local and national healthcare systems, managed care providers, public and charter schools, correctional facilities, government facilities, pharmacies, and many other healthcare providers. Through our national staffing teams, we offer our workforce solutions and place clinicians on travel and per diem assignments, local short-term contracts, and permanent positions. In addition, we continually evaluate opportunities to acquire companies that would complement or enhance our business, like Workforce Solutions Group, Inc. (WSG) and Mint Medical Physician Staffing, LP and Lotus Medical Staffing LLC (collectively, Mint).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our workforce solutions include managed service programs (MSPs), vendor management systems (VMS), in-home care services, education health services, recruitment process outsourcing (RPO), project management, and other outsourcing and consultative services as described in Item 1. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2024 Form 10-K. By utilizing the solutions that we offer, customers are able to better plan their personnel needs, optimize their talent acquisition and management processes, strategically flex and balance their workforce, have access to quality healthcare personnel, and provide continuity of care for improved patient outcomes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s two reportable segments offer services to its customers as described below:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9679;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nurse and Allied Staffing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Nurse and Allied Staffing represented approximately 83% of total revenue in the first quarter of 2025. The Nurse and Allied Staffing segment provides workforce solutions and traditional staffing, including temporary and permanent placement of travel nurses and allied professionals, as well as per diem and contract nurses and allied personnel. We also provide clinical and non-clinical professionals on short-term and long-term assignments to customers such as local and national healthcare plans, managed care providers, public and charter schools, correctional facilities, skilled nursing facilities, and other non-acute settings. In addition, Nurse and Allied Staffing provides executive search services for healthcare professionals, as well as contingent search. We provide </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">flexible workforce solutions to our healthcare customers through diversified offerings designed to meet their unique needs, including MSP, RPO, and consulting services. We also offer our SaaS-based, proprietary, vendor management technology, Intellify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to facilities to manage all or a portion of their agency services.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9679;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Physician Staffing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Physician Staffing represented approximately 17% of total revenue in the first quarter of 2025. Physician Staffing provides physicians in many specialties, as well as certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments throughout the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarter ended March 31, 2025, consolidated revenue declined 22.6% year-over-year to $293.4 million, as travel nurse and allied, and per diem, has seen a decline in both volume and average bill rates. The declines were partly offset by continued growth in Homecare Staffing, which was up 29.5% over the prior year, as well as growth in our Physician Staffing segment, which was up 8.8% over the prior year. Net loss attributable to common stockholders in the first quarter of 2025 was $0.5 million, as compared to net income of $2.7 million for the same period in the prior year. Exiting the first quarter and into the second quarter of 2025, Nurse and Allied Staffing margins showed continued improvement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025, cash and cash equivalents totaled $80.7 million. Cash flow provided by operating activities for the three months ended March 31, 2025 was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.7 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million. As of March 31, 2025, there were no borrowings drawn under the revolving senior-secured asset-based credit facility (ABL), and borrowing base availability under the ABL was $148.4 million, with $133.5 million of availability net of $14.9 million of letters of credit. See Note 8 - Debt to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2024, Cross Country entered into an Agreement and Plan of Merger (Merger Agreement) with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aya Holdings II Inc., a Delaware corporation (Parent), Spark Merger Sub One Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), and, solely for purposes of Section 11.14 thereto, Aya Healthcare, Inc. (Aya Healthcare), pursuant to which Merger Sub will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (Aya Merger)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On February 20, 2025, the Company and Aya Healthcare each received a request for additional information from the U.S. Federal Trade Commission in connection with their review of the transactions contemplated by the Merger Agreement. The Company expects that the Aya Merger will close in the second half of 2025, subject to the satisfaction of other customary closing conditions, including regulatory approvals. The Aya Merger was approved by the Company&#8217;s stockholders at a special meeting held on February 28, 2025. Upon completion of the Aya Merger, it is expected that Cross Country will become a private company and its common stock will no longer trade on Nasdaq. See Note 1 - Organization and Basis of Presentation to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Results of Operations, Segment Results, and Liquidity and Capital Resources sections that follow for further information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Metrics</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our financial condition by tracking operating metrics and financial results specific to each of our segments. Key operating metrics include hours worked, days filled, number of contract personnel on a full-time equivalent (FTE) basis, revenue per FTE, and revenue per day filled. Other operating metrics include number of open orders, candidate applications, contract bookings, length of assignment, bill and pay rates, renewal and fill rates, number of active searches, and number of placements. These operating metrics are representative of trends that assist management in evaluating business performance. Due to the timing of our business process and other factors, certain of these operating metrics may not necessarily correlate to the reported U.S. GAAP results for the periods presented. Some of the segment financial results analyzed include revenue, operating expenses, and contribution income. In addition, we monitor cash flow, as well as operating and leverage ratios, to help us assess our liquidity needs.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:53.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business Segment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business Measurement</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse and Allied Staffing </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FTEs represent the average number of Nurse and Allied Staffing contract personnel on a full-time equivalent basis.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average revenue per FTE per day is calculated by dividing the Nurse and Allied Staffing revenue, excluding permanent placement, per FTE by the number of days worked in the respective periods.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician Staffing</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days filled is calculated by dividing the total hours invoiced during the period, including an estimate for the impact of accrued revenue,  by eight hours.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per day filled is calculated by dividing revenue as reported by days filled for the period presented.</span></td></tr></table></div><div><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, for the periods indicated, selected condensed consolidated statements of operations and comprehensive (loss) income data expressed as a&#160;percentage of revenue. Our historical results of operations are not necessarily indicative of future operating results.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.282%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and other losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common stockholders</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Comparison of Results for the Three Months Ended March 31, 2025 and the Three Months Ended March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,877&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,127)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,255)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and other losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(977)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,921&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,898)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,057)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(899)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,689&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,588)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common stockholders</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(490)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,692&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,182)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from services</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenue from services decreased 22.6% to $293.4 million for the three months ended March&#160;31, 2025, as compared to $379.2 million for the three months ended March&#160;31, 2024, due to volume and bill rate declines in the Nurse and Allied Staffing segment partially offset by higher average bill rates in the Physician Staffing segment. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">See further discussion in Segment Results. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Direct operating expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct operating expenses consist primarily of field employee compensation and independent contractor expenses, housing expenses, travel expenses, and related insurance expenses. Direct operating expenses decreased $67.1 million, or 22.2%, to $234.8 million for the three months ended March&#160;31, 2025, as compared to $301.9 million for the three months ended March&#160;31, 2024, as a result of revenue decreases and the tightening of the bill/pay spreads. As a percentage of total revenue, direct operating expenses increased to 80.0%, as compared to 79.6% in the prior year period.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses decreased 17.0% to $52.5 million for the three months ended March&#160;31, 2025, as compared to $63.3 million for the three months ended March&#160;31, 2024,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily due to decreases in compensation and benefit expense through proactive cost management. As a&#160;percentage of total revenue, selling, general and administrative expenses increased to 17.9% for the three months ended March&#160;31, 2025, as compared to 16.7% for the three months ended March&#160;31, 2024.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit loss expense</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit loss expense for the three months ended March 31, 2025 was immaterial, as compared to $1.3 million for the three months ended March 31, 2024. As a percentage of revenue, credit loss expense was 0.0% for the three months ended March 31, 2025 and 0.3% for the three months ended March 31, 2024.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and amortization expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense&#160;for the three months ended March&#160;31, 2025 was $4.8 million, as compared to $4.6 million for the three months ended March 31, 2024. As a percentage of revenue, depreciation and amortization expense was 1.6% for the three months ended March&#160;31, 2025 and 1.2% for the three months ended March&#160;31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition and integration-related costs </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition and integration-related costs relate primarily to fees associated with the pending Aya Merger. See Note 1 - Organization and Basis of Presentation to our condensed consolidated financial statements. There were no such costs for the three months ended March 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs for the three months ended March 31, 2025 were primarily comprised of employee terminations costs, and were primarily comprised of ongoing lease exit costs for the three months ended March 31, 2024. See Note 2 - Summary of Significant Accounting Policies to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal and other losses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2024, the Company recorded legal and other losses of $3.7 million representing an offer to settle a lawsuit, as well as estimated costs related to an unrecoverable asset. There were no such losses for the three months ended March 31, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment charges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash impairment charges totaled $0.6 million for the three months ended March 31, 2024 and related to real estate restructuring activities. There were no such charges for the three months ended March 31, 2025.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest income</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income of $0.7 million for the three months ended March&#160;31, 2025 related to higher average cash on hand with higher available interest rates during the quarter. Interest income was immaterial for the three months ended March 31, 2024.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other expense (income), net</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, other expense (income), net included a $0.9 million decrease of the remaining earnout liability related to the Mint acquisition. There were no such adjustments for the three months ended March 31, 2025.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax (benefit) expense</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit totaled $0.4 million for the three months ended March&#160;31, 2025, as compared to income tax expense of $1.0 million for the three months ended March&#160;31, 2024. The income tax benefit for the first quarter of 2025 and the income tax expense for the first quarter of 2024 were primarily driven by federal and state taxes. The decrease in income tax expense was primarily related to a decrease in book income. See Note 14 - Income Taxes to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Segment Results</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on operating segments and a reconciliation to (loss) income from operations for the periods indicated are as follows:  </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nurse and Allied Staffing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physician Staffing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,408&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nurse and Allied Staffing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physician Staffing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate overhead</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and other losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(977)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12 - Segment Data to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statistical data for our business segments for the periods indicated are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:44.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.686%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Nurse and Allied Staffing statistical data:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FTEs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,713)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average Nurse and Allied Staffing revenue per FTE per day </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Physician Staffing statistical data:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Days filled </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,692&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,785&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,093)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue per day filled </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See definition of Business Measurements under the Operating Metrics section of the MD&amp;A.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Segment Comparison - Three Months Ended March 31, 2025 and Three Months Ended March 31, 2024</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Nurse and Allied Staffing</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue decreased $89.9 million, or 27.1%, to $242.3 million for the three months ended March&#160;31, 2025, as compared to $332.2 million for the three months ended March&#160;31, 2024, driven primarily by an 18.8% decline in professionals on assignment and, to a lesser extent, a 9.3% normalization in bill rates. The decline in professionals on assignment is largely the result of lower demand, as many customers reduced their spend on contingent labor. Also within the segment, Homecare Staffing experienced year-over-year revenue growth of 29.5% and sequential revenue growth of 10.3%, and Cross Country Education experienced sequential revenue growth of 11.5%, in the first quarter of 2025.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contribution income decreased $10.0 million, or 36.6%, to $17.2 million for the three months ended March&#160;31, 2025, as compared to $27.2 million for the three months ended March&#160;31, 2024. As a&#160;percentage of segment revenue, contribution income margin decreased to 7.1% for the three months ended March&#160;31, 2025, as compared to 8.2% for the three months ended March&#160;31, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average number of FTEs on contract during the three months ended March&#160;31, 2025 decreased 18.8% from the three months ended March&#160;31, 2024, primarily due to headcount decline in travel nurse and allied, per diem, and education. The average revenue per FTE per day decreased 9.3%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Staffing</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased $4.1 million, or 8.8%, to $51.1 million for the three months ended March&#160;31, 2025, as compared to $47.0 million for the three months ended March&#160;31, 2024, primarily due to the impact from higher rates and favorable specialty mix.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contribution income increased $0.9 million, or 28.4%, to $4.0 million for the three months ended March&#160;31, 2025, as compared to $3.1 million for the three months ended March&#160;31, 2024. As a&#160;percentage of segment revenue, contribution income was 7.9% for the three months ended March&#160;31, 2025, as compared to 6.7% for the three months ended March&#160;31, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total days filled for the three months ended March&#160;31, 2025 decreased 4.6% to 22,692, as compared to 23,785 in the prior year. Revenue per day filled was $2,253, as compared with $1,976 in the prior year, due to price increases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Overhead</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs, such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects. Corporate overhead decreased to $15.1 million for the three months ended March&#160;31, 2025, from $17.6 million for the three months ended March 31, 2024, primarily due to de</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">creases in compensation and benefit expense, and software and hardware expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a percentage of consolidated revenue, corporate overhead was 5.2% for the three months ended March&#160;31, 2025 and 4.6% for the three months ended March&#160;31, 2024.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2025, we reported $80.7 million in cash and cash equivalents, with no borrowings drawn under the ABL. Working capital increased by $1.6 million to $216.2 million as of March&#160;31, 2025, as compared to $214.6 million as of December&#160;31, 2024, primarily due to a decrease in net receivables and the timing of disbursements. As of March 31, 2025, our days</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales outstanding, net of amounts owed to subcontractors, was 57 days, down 15 days year-ov</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">er-year and up 2 days sequentially. As of March 31, 2025, we did not have any off-balance sheet arrangements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow constitutes our primary source of liquidity and, historically, has been sufficient to fund working capital, capital expenditures, internal business expansion, and debt service. This includes commitments, both short-term and long-term, of interest expense on our debt and operating lease commitments, and future principal payments on the ABL.&#160;We expect to meet our future cash needs from a combination of cash on hand, operating cash flows, and funds available through the ABL. See debt discussion which follows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2023, the Company&#8217;s Board of Directors authorized approximately $59.0&#160;million in additional share repurchases, such that, effective for trades made after May 3, 2023, the aggregate amount available for stock repurchases was set at $100.0&#160;million (the Repurchase Program). In the third quarter of 2023, we entered into a Rule 10b5-1 Repurchase Plan to allow for share repurchases during the Company&#8217;s blackout periods, beginning on January 2, 2024 and effective through November 7, 2024. During the three months ended March 31, 2024, we repurchased and retired a total of 310,235 shares of common stock for $6.4&#160;million, at an average price of $20.51 per share. During the three months ended March 31, 2025, we did not repurchase any shares of our common stock, but did pay $0.3&#160;million in excise tax related to previous share repurchases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, we had $40.5 million remaining for share repurchase under the Repurchase Program, subject to certain conditions in the Loan Agreement (as defined below).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities decreased $0.3 million to $5.7 million for the three months ended March&#160;31, 2025, as compared to $6.0 million for the three months ended March&#160;31, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $1.9 million for the three months ended March&#160;31, 2025, as compared to $2.2 million for the three months ended March&#160;31, 2024, for capital expenditures in both years.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities during the three months ended March&#160;31, 2025 was $4.7 million, as compared to $15.7 million during the three months ended March&#160;31, 2024. During the three months ended March 31, 2025, we used cash to pay  $0.3 million for excise tax related to previous share repurchases and $4.4 million for contingent consideration. During the three months ended March 31, 2024, we used cash to pay $2.7 million for income taxes on share-based compensation, $6.4 million for share repurchases, and $6.6 million for contingent consideration.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie094c362a2b8472c8b046d777cad339c_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Debt</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Asset-Based Loan Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October 25, 2019, the prior senior credit facility entered into in August 2017 was replaced by a $120.0&#160;million asset-based loan agreement (Loan Agreement), which provided for a five-year senior secured revolving credit facility. On June 30, 2020, we amended the Loan Agreement (First Amendment), which increased the current aggregate committed size of the ABL from $120.0&#160;million to $130.0&#160;million. All other terms, conditions, covenants, and pricing of the Loan Agreement remained the same. On March 8, 2021, we amended the Loan Agreement (Second Amendment), which increased the current aggregate committed size of the ABL from $130.0&#160;million to $150.0&#160;million, increased certain borrowing base sub-limits, and decreased both the cash dominion event and financial reporting triggers. On June 8, 2021, we amended the Loan Agreement (Third Amendment), which permitted the incurrence of indebtedness and grant of security as set forth in the Loan Agreement and in accordance with the Intercreditor Agreement, and provides mechanics relating to a transition away from LIBOR as a benchmark interest rate to a replacement alternative benchmark rate or mechanism for loans made in U.S. dollars. On November 18, 2021, we amended the Loan Agreement (Fourth Amendment), whereby the permitted indebtedness (as defined in the Loan Agreement) was increased to $175.0 million. On March 21, 2022, we amended the Loan Agreement (Fifth Amendment), which increased the current aggregate committed size of the ABL from $150.0 million to $300.0 million, extended the credit facility for an additional five years, increased certain borrowing base sub-limits, and provided the option for all or a portion of the borrowings to bear interest at a rate based on the Secured Overnight Financing Rate (SOFR) or Base Rate (as defined in the Loan Agreement), at the election of the borrowers, plus an applicable margin. On September 29, 2023, we amended the Loan Agreement (Sixth Amendment), which changed the minimum fixed charge coverage ratio from a maintenance covenant to a springing covenant based on excess availability. On July 29, 2024, we amended the Loan Agreement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Seventh Amendment), which allows for all share repurchases paid in cash prior to June 30, 2024 and thereafter to be excluded as restricted payments in the fixed charge coverage ratio calculation if there is no revolving ABL balance. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the interest rate spreads and fees under the ABL were based on SOFR plus 1.85% for the revolving portion of the borrowing base. The Base Rate margin would have been 0.75%  for the revolving portion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The SOFR and Base Rate margins are subject to monthly adjustments, pursuant to a pricing matrix based on our excess availability under the revolving credit facility. In addition, the facility is subject to an unused line fee, letter of credit fees, and an administrative fee. Borrowing base availability under the ABL was $148.4&#160;million as of March 31, 2025, with no borrowings drawn and $133.5 million of availability net of $14.9&#160;million of letters of credit. For the three months ended March 31, 2025, the excess availability did not fall below the stated threshold and, as a result, there was no covenant compliance period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 - Debt to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Critical Accounting Policies and Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies and estimates remain consistent with those reported in our 2024 Form 10-K.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to variable interest rate risk associated with our Loan Agreement entered into on October 25, 2019. This agreement charges interest at a rate based on either SOFR or Base Rate (as defined in the Loan Agreement) plus an applicable margin.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A 1.0% change in interest rates would have resulted in interest expense fluctuating an </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immaterial a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mount for the three months ended March 31, 2025 and 2024, respectively. See Note 8 - Debt to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our other exposures as disclosed in our 2024 Form&#160;10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_133"></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our &#8220;disclosure controls and procedures&#8221; (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of the end of the period covered by this report. Based upon the evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this quarterly report. Disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, communicated to management, including the Chief Executive Officer and the Chief Financial Officer, and reported within the time periods specified in the SEC&#8217;s rules and forms. The disclosure controls and procedures are designed to ensure that information required to be disclosed by us in reports required under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, in order to allow timely decisions regarding any required disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting as defined in Exchange Act Rules&#160;13a-15(f) that occurred during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. &#8211; OTHER INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie094c362a2b8472c8b046d777cad339c_139"></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to certain legal proceedings is included in Part I, Item 1, Note 13 - Contingencies - </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Quarterly Report on Form 10-Q, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_142"></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are no material changes to our Risk Factors as previously disclosed in our 2024 Form 10-K.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ie094c362a2b8472c8b046d777cad339c_148"></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.       OTHER INFORMATION</span></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(c) Trading Plans</span></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) of the Company may execute purchases and sales of the Company&#8217;s common stock through Rule 10b5-1 and non-Rule 10b5-1 equity trading plans. Pursuant to Item 408(a) of Regulation S-K, we are required to disclose whether any director or officer adopted or terminated a Rule 10b5-1 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trading arrangement or non-Rule 10b5-1 trading arrangement (as that term is defined in Item 408(c) of Regulation S-K) during the most recently completed quarter.</span></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, neither the Company nor any of its Section 16 officers or directors <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-568"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-569">adopted</ix:nonNumeric></ix:nonNumeric>, modified, or <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-570"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-571">terminated</ix:nonNumeric></ix:nonNumeric> any contract, instruction, or written plan for the purchase or sale of the Company&#8217;s securities, under either a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (in each case, as defined in Item 408(a) of Regulation S-K).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.265%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20250331-10qex31x1.htm">Certification pursuant to Rule&#160;13a-14(a) and Rule&#160;15d-14(a) and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by John A. Martins,&#160;President, Chief Executive Officer, Director (Principal Executive Officer)</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20250331-10qex31x2.htm">Certification pursuant to Rule 13a-14(a) and Rule 15d-14(a) and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by William J. Burns, Executive Vice President, Chief Financial Officer (Principal Financial Officer)</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20250331-10qex32x1.htm">Certification pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by John A. Martins,&#160;President, Chief Executive Officer, Director (Principal Executive Officer)</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**32.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20250331-10qex32x2.htm">Certification pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by William J. Burns, Executive Vice President, Chief Financial Officer (Principal Financial Officer)</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Represents a management contract or compensatory plan or arrangement</span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="ie094c362a2b8472c8b046d777cad339c_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.930%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CROSS&#160;COUNTRY&#160;HEALTHCARE,&#160;INC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May&#160;7, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ William J. Burns</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William J. Burns <br/>Executive Vice President &amp; Chief Financial Officer<br/>(Principal Financial Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ccrn20250331-10qex31x1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i71200cdb575f4c5983b40aaa347bb7ee_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John A. Martins, certify that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q of Cross Country Healthcare, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 7, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John A. Martins</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John A. Martins<br>President &#38; Chief&#160;Executive Officer<br>(Principal&#160;Executive&#160;Officer)</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ccrn20250331-10qex31x2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i3abf3a3bcc7a481193dda57641605007_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, William J. Burns, certify that&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q of Cross Country Healthcare, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 7, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William J. Burns</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William J. Burns<br>Executive Vice President &#38; Chief&#160;Financial&#160;Officer                                                                                    (Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ccrn20250331-10qex32x1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ic05f23d8872b4eeca4e86b85974d9d32_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the accompanying Quarterly Report on Form&#160;10-Q of Cross Country Healthcare, Inc. (the Company) for the quarterly period ended March&#160;31, 2025, (the &#34;Periodic Report&#34;), I, John A. Martins, President and Chief Executive Officer of the Company, hereby certify pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Periodic Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 7, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John A. Martins</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John A. Martins<br>President &#38; Chief&#160;Executive Officer<br>(Principal&#160;Executive&#160;Officer)</font></td></tr></table></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to Cross Country Healthcare, Inc. and will be retained by Cross Country Healthcare, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is provided solely for purposes of complying with the provisions of Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ccrn20250331-10qex32x2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9084bbf6799748dba772a55aa5dfdef4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the accompanying Quarterly Report on Form&#160;10-Q of Cross Country Healthcare, Inc. (the &#34;Company&#34;) for the quarterly period ended March&#160;31, 2025, (the &#34;Periodic Report&#34;), I, William J. Burns, Executive Vice President and Chief Financial Officer of the Company, hereby certify pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Periodic Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 7, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William J. Burns</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William J. Burns<br>Executive Vice President &#38; Chief&#160;Financial&#160;Officer                                                                                    (Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to Cross Country Healthcare, Inc. and will be retained by Cross Country Healthcare, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is provided solely for purposes of complying with the provisions of Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ccrn-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:dd6031fa-8918-4f16-99cd-07b7064df9d2,g:a332f0b9-5dad-4d87-8e39-4baf62f16fbe-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ccrn="http://www.crosscountryhealthcare.com/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.crosscountryhealthcare.com/20250331">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ccrn-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ccrn-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ccrn-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ccrn-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.crosscountryhealthcare.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME" roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME">
        <link:definition>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDBASISOFPRESENTATION" roleURI="http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATION">
        <link:definition>9952156 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952157 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITION" roleURI="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITION">
        <link:definition>9952158 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONS" roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONS">
        <link:definition>9952159 - Disclosure - ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMPREHENSIVELOSSINCOME" roleURI="http://www.crosscountryhealthcare.com/role/COMPREHENSIVELOSSINCOME">
        <link:definition>9952160 - Disclosure - COMPREHENSIVE (LOSS) INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHARE" roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARE">
        <link:definition>9952161 - Disclosure - EARNINGS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS" roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS">
        <link:definition>9952162 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://www.crosscountryhealthcare.com/role/DEBT">
        <link:definition>9952163 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.crosscountryhealthcare.com/role/LEASES">
        <link:definition>9952164 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>9952165 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITY">
        <link:definition>9952166 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTDATA" roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATA">
        <link:definition>9952167 - Disclosure - SEGMENT DATA</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONTINGENCIES" roleURI="http://www.crosscountryhealthcare.com/role/CONTINGENCIES">
        <link:definition>9952168 - Disclosure - CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.crosscountryhealthcare.com/role/INCOMETAXES">
        <link:definition>9952169 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>9952170 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONTables" roleURI="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONTables">
        <link:definition>9955513 - Disclosure - REVENUE RECOGNITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHARETables" roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARETables">
        <link:definition>9955514 - Disclosure - EARNINGS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables" roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables">
        <link:definition>9955515 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://www.crosscountryhealthcare.com/role/DEBTTables">
        <link:definition>9955516 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.crosscountryhealthcare.com/role/LEASESTables">
        <link:definition>9955517 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>9955518 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9955519 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTDATATables" roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATATables">
        <link:definition>9955520 - Disclosure - SEGMENT DATA (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails" roleURI="http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails">
        <link:definition>9955521 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
        <link:definition>9955522 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails" roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails">
        <link:definition>9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails" roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails">
        <link:definition>9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring (Benefits) Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONDetails" roleURI="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails">
        <link:definition>9955525 - Disclosure - REVENUE RECOGNITION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSDetails" roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails">
        <link:definition>9955526 - Disclosure - ACQUISITIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMPREHENSIVELOSSINCOMEDetails" roleURI="http://www.crosscountryhealthcare.com/role/COMPREHENSIVELOSSINCOMEDetails">
        <link:definition>9955527 - Disclosure - COMPREHENSIVE (LOSS) INCOME (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails" roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails">
        <link:definition>9955528 - Disclosure - EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHAREAntidilutiveSecuritiesDetails" roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesDetails">
        <link:definition>9955529 - Disclosure - EARNINGS PER SHARE - Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails" roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails">
        <link:definition>9955530 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails" roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails">
        <link:definition>9955531 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Estimated Annual Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails" roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails">
        <link:definition>9955532 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTLongtermDebtDetails" roleURI="http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails">
        <link:definition>9955533 - Disclosure - DEBT - Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTNarrativeDetails" roleURI="http://www.crosscountryhealthcare.com/role/DEBTNarrativeDetails">
        <link:definition>9955534 - Disclosure - DEBT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT2019AssetBasedLoanAgreementDetails" roleURI="http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails">
        <link:definition>9955535 - Disclosure - DEBT - 2019 Asset-Based Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSupplementalBalanceSheetInformationDetails" roleURI="http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails">
        <link:definition>9955536 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESOperatingLeaseMaturityDetails" roleURI="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails">
        <link:definition>9955537 - Disclosure - LEASES - Operating Lease Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESOperatingLeaseMaturityDetails_1" roleURI="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1">
        <link:definition>9955537 - Disclosure - LEASES - Operating Lease Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseCostsDetails" roleURI="http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails">
        <link:definition>9955538 - Disclosure - LEASES - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>9955539 - Disclosure - FAIR VALUE MEASUREMENTS - Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAdditionalInformationDetails" roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails">
        <link:definition>9955540 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYAdditionalInformationDetails" roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails">
        <link:definition>9955541 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYRestrictedStockActivityDetails" roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails">
        <link:definition>9955542 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTDATAAdditionalInformationDetails" roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails">
        <link:definition>9955543 - Disclosure - SEGMENT DATA - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTDATAOperatingSegmentsDetails" roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails">
        <link:definition>9955544 - Disclosure - SEGMENT DATA - Operating Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDetails" roleURI="http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails">
        <link:definition>9955545 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>9955546 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ccrn_CloudComputingNoncurrent" abstract="false" name="CloudComputingNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_AcquisitionAndIntegrationRelatedCosts" abstract="false" name="AcquisitionAndIntegrationRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_LegalAndOtherLosses" abstract="false" name="LegalAndOtherLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_StockRepurchasedDuringPeriodExciseTax" abstract="false" name="StockRepurchasedDuringPeriodExciseTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances" abstract="false" name="ProvisionForDoubtfulAccountsAndOtherAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_OperatingLeaseExpenseNonCash" abstract="false" name="OperatingLeaseExpenseNonCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_RisksAndUncertaintiesPolicyTextBlock" abstract="false" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ccrn_AssetsAndLiabilitiesLeasesTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ccrn_AyaHoldingsIIInc.Member" abstract="true" name="AyaHoldingsIIInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_SalesAllowanceBillingRelatedAdjustments" abstract="false" name="SalesAllowanceBillingRelatedAdjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided" abstract="false" name="ThresholdPeriodPastDueForPaymentOfServicesProvided" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery" abstract="false" name="AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_ExitCostsMember" abstract="true" name="ExitCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ccrn_NurseAndAlliedStaffingMember" abstract="true" name="NurseAndAlliedStaffingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ccrn_PhysicianStaffingMember" abstract="true" name="PhysicianStaffingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ccrn_TemporaryStaffingServicesMember" abstract="true" name="TemporaryStaffingServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ccrn_OtherServicesMember" abstract="true" name="OtherServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ccrn_HireUpLeadershipIncMember" abstract="true" name="HireUpLeadershipIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember" abstract="true" name="MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" abstract="false" name="AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" abstract="true" name="ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_SeniorSecuredAssetBasedLoanMember" abstract="true" name="SeniorSecuredAssetBasedLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ccrn_LineOfCreditSublimitAxis" abstract="true" name="LineOfCreditSublimitAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ccrn_LineOfCreditSublimitDomain" abstract="true" name="LineOfCreditSublimitDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ccrn_SwingLoansSublimitMember" abstract="true" name="SwingLoansSublimitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ccrn_StandbyLettersOfCreditSublimitMember" abstract="true" name="StandbyLettersOfCreditSublimitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" abstract="false" name="LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment" abstract="false" name="DebtInstrumentBasisSpreadOnVariableRateAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable" abstract="false" name="LineOfCreditBorrowingBasePercentageOfAccountsReceivable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ccrn_LineOfCreditFacilityBorrowingBaseAvailability" abstract="false" name="LineOfCreditFacilityBorrowingBaseAvailability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_DeferredCompensationMember" abstract="true" name="DeferredCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ccrn_FairValueMeasurementTable" abstract="true" name="FairValueMeasurementTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ccrn_FairValueMeasurementLineItems" abstract="true" name="FairValueMeasurementLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ccrn_RepurchaseProgramMember" abstract="true" name="RepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_RestrictedStockAndPerformanceSharesMember" abstract="true" name="RestrictedStockAndPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ccrn_OmnibusPlanMember" abstract="true" name="OmnibusPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount" abstract="false" name="StockRepurchaseProgramAdditionalAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense" abstract="false" name="LaborAndRelatedExpenseExcludingBenefitsExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_BenefitsExpense" abstract="false" name="BenefitsExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard" abstract="false" name="OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_SegmentReportingUnallocatedCorporateExpenses" abstract="false" name="SegmentReportingUnallocatedCorporateExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember" abstract="true" name="ServicesProvidedEntitiesAffiliatedWithBoardMembersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ccrn-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:dd6031fa-8918-4f16-99cd-07b7064df9d2,g:a332f0b9-5dad-4d87-8e39-4baf62f16fbe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ccrn-20250331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e437c435-1934-48e9-8f69-98c74275aa62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ac4fe4a5-ae11-470f-9127-857d849bfc56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e437c435-1934-48e9-8f69-98c74275aa62" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ac4fe4a5-ae11-470f-9127-857d849bfc56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a6cc395e-0568-4dca-aab7-e804da002e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e437c435-1934-48e9-8f69-98c74275aa62" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a6cc395e-0568-4dca-aab7-e804da002e78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_108d9f05-ced5-40f2-a387-418b03593646" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e437c435-1934-48e9-8f69-98c74275aa62" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_108d9f05-ced5-40f2-a387-418b03593646" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5e444cba-7095-422c-a909-326a820b7477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e437c435-1934-48e9-8f69-98c74275aa62" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5e444cba-7095-422c-a909-326a820b7477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_39f6fa12-53fb-4e47-bb57-e13806665224" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e437c435-1934-48e9-8f69-98c74275aa62" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_39f6fa12-53fb-4e47-bb57-e13806665224" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fed8b291-c197-4594-ac87-b110e27d5700" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5f65086d-e32f-48a1-8d8c-a431ab8ef169" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fed8b291-c197-4594-ac87-b110e27d5700" xlink:to="loc_us-gaap_StockholdersEquity_5f65086d-e32f-48a1-8d8c-a431ab8ef169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_981893f9-1a01-455f-acd1-c5f0bb36e51e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fed8b291-c197-4594-ac87-b110e27d5700" xlink:to="loc_us-gaap_Liabilities_981893f9-1a01-455f-acd1-c5f0bb36e51e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7c72b74e-6417-44cd-8a0d-c6108c90443e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fed8b291-c197-4594-ac87-b110e27d5700" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7c72b74e-6417-44cd-8a0d-c6108c90443e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0a9d26d2-58f8-4455-be30-422fc531c4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_142ddfe9-63cd-4a56-8746-b821fcede7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a9d26d2-58f8-4455-be30-422fc531c4f0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_142ddfe9-63cd-4a56-8746-b821fcede7e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_aede003b-00db-47b7-b96e-7b52b33e81f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a9d26d2-58f8-4455-be30-422fc531c4f0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_aede003b-00db-47b7-b96e-7b52b33e81f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_87b1010c-93e0-47c9-9085-cca5227eac70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a9d26d2-58f8-4455-be30-422fc531c4f0" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableCurrent_87b1010c-93e0-47c9-9085-cca5227eac70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5d1ec3b-c594-4f98-b6eb-abe5d8d8bb72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a9d26d2-58f8-4455-be30-422fc531c4f0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5d1ec3b-c594-4f98-b6eb-abe5d8d8bb72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_4ea89b02-fc51-4489-96c2-68bd1178eda2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a9d26d2-58f8-4455-be30-422fc531c4f0" xlink:to="loc_us-gaap_IncomeTaxesReceivable_4ea89b02-fc51-4489-96c2-68bd1178eda2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9d13c7b3-c2f3-4817-84e0-a4f9ba815bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a9d26d2-58f8-4455-be30-422fc531c4f0" xlink:to="loc_us-gaap_OtherAssetsCurrent_9d13c7b3-c2f3-4817-84e0-a4f9ba815bd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_49529cd5-cffa-44fe-9977-5b6862f90497" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_999b13f5-b7cf-4a68-b3c9-5869c2fbd79c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_49529cd5-cffa-44fe-9977-5b6862f90497" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_999b13f5-b7cf-4a68-b3c9-5869c2fbd79c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f8d2f88e-aaff-421f-a447-4b1a04e3ba05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_49529cd5-cffa-44fe-9977-5b6862f90497" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f8d2f88e-aaff-421f-a447-4b1a04e3ba05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a6876385-9534-40f3-abca-e5767ef094ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_49529cd5-cffa-44fe-9977-5b6862f90497" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a6876385-9534-40f3-abca-e5767ef094ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c72de652-face-45bb-979c-2da423fb673a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_49529cd5-cffa-44fe-9977-5b6862f90497" xlink:to="loc_us-gaap_LiabilitiesCurrent_c72de652-face-45bb-979c-2da423fb673a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2b55bc81-5268-4d9d-8a84-1d87f32c5ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_49529cd5-cffa-44fe-9977-5b6862f90497" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2b55bc81-5268-4d9d-8a84-1d87f32c5ac1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c1ec3d9c-8c28-48ff-bbf4-3edb5bad30a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4639c6b5-7748-4fbe-bdde-4ce0bc3af837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1ec3d9c-8c28-48ff-bbf4-3edb5bad30a2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4639c6b5-7748-4fbe-bdde-4ce0bc3af837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9cbe09ec-2278-41db-96ce-6e7c04649f04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1ec3d9c-8c28-48ff-bbf4-3edb5bad30a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9cbe09ec-2278-41db-96ce-6e7c04649f04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9489daf5-4995-4783-a699-111b97e0d0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1ec3d9c-8c28-48ff-bbf4-3edb5bad30a2" xlink:to="loc_us-gaap_AssetsCurrent_9489daf5-4995-4783-a699-111b97e0d0f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_61b6a7fc-9796-4075-be63-6a88260cf77b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1ec3d9c-8c28-48ff-bbf4-3edb5bad30a2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_61b6a7fc-9796-4075-be63-6a88260cf77b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableNoncurrent_192a2a94-1333-4984-84ec-073ecf25bb03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1ec3d9c-8c28-48ff-bbf4-3edb5bad30a2" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableNoncurrent_192a2a94-1333-4984-84ec-073ecf25bb03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2d9a5394-977f-493a-b557-3ffac5d0cc48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1ec3d9c-8c28-48ff-bbf4-3edb5bad30a2" xlink:to="loc_us-gaap_Goodwill_2d9a5394-977f-493a-b557-3ffac5d0cc48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_26244a01-ce50-487f-b755-345e0f8b29f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1ec3d9c-8c28-48ff-bbf4-3edb5bad30a2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_26244a01-ce50-487f-b755-345e0f8b29f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_da929858-f8d8-4171-811e-5eb184ea1e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1ec3d9c-8c28-48ff-bbf4-3edb5bad30a2" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_da929858-f8d8-4171-811e-5eb184ea1e2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_CloudComputingNoncurrent_1d4045b5-e434-48bc-8776-6a1082b82212" xlink:href="ccrn-20250331.xsd#ccrn_CloudComputingNoncurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1ec3d9c-8c28-48ff-bbf4-3edb5bad30a2" xlink:to="loc_ccrn_CloudComputingNoncurrent_1d4045b5-e434-48bc-8776-6a1082b82212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5a1fe2e4-f0ae-4b28-9be3-c13e04d3bf96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c2ba841d-516d-465a-a4ca-16ff3d2a96c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5a1fe2e4-f0ae-4b28-9be3-c13e04d3bf96" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c2ba841d-516d-465a-a4ca-16ff3d2a96c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7c91ef5a-5d0a-4436-96c7-cb57939c02d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5a1fe2e4-f0ae-4b28-9be3-c13e04d3bf96" xlink:to="loc_us-gaap_CommonStockValue_7c91ef5a-5d0a-4436-96c7-cb57939c02d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c7ead237-d931-42b1-bcc7-a7484ad03f78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5a1fe2e4-f0ae-4b28-9be3-c13e04d3bf96" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c7ead237-d931-42b1-bcc7-a7484ad03f78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_09ce7465-a54f-4337-ab42-55758a3d66ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5a1fe2e4-f0ae-4b28-9be3-c13e04d3bf96" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_09ce7465-a54f-4337-ab42-55758a3d66ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="ccrn-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ccc2147b-52b3-464d-87a0-843031b10be4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_47d5f01a-5ed7-4038-910b-0d69999cb983" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ccc2147b-52b3-464d-87a0-843031b10be4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_47d5f01a-5ed7-4038-910b-0d69999cb983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4ff8c597-6fc4-4648-baae-c60389b189f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ccc2147b-52b3-464d-87a0-843031b10be4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4ff8c597-6fc4-4648-baae-c60389b189f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_39af6c6e-42fb-4f7e-9745-70ff7b662fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d0fc4f56-2300-46db-8223-02704c0300aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_39af6c6e-42fb-4f7e-9745-70ff7b662fb0" xlink:to="loc_us-gaap_CostsAndExpenses_d0fc4f56-2300-46db-8223-02704c0300aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb36fc1b-f481-4bdd-82a8-5935b78f2459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_39af6c6e-42fb-4f7e-9745-70ff7b662fb0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb36fc1b-f481-4bdd-82a8-5935b78f2459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0f186e9-7e94-4dad-bfe9-5026008706b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_929460ec-81f7-45d8-9935-99945af634e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0f186e9-7e94-4dad-bfe9-5026008706b0" xlink:to="loc_us-gaap_InterestExpenseNonoperating_929460ec-81f7-45d8-9935-99945af634e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c89d980a-dccd-4d47-a1ac-b65ca683b940" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0f186e9-7e94-4dad-bfe9-5026008706b0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c89d980a-dccd-4d47-a1ac-b65ca683b940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6cbbf46c-1954-4dcd-b80f-f0d7e106792f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0f186e9-7e94-4dad-bfe9-5026008706b0" xlink:to="loc_us-gaap_OperatingIncomeLoss_6cbbf46c-1954-4dcd-b80f-f0d7e106792f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d1a401d2-4a9a-427a-a0cd-039a03fbde32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0f186e9-7e94-4dad-bfe9-5026008706b0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d1a401d2-4a9a-427a-a0cd-039a03fbde32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_91c877d9-c86e-48fa-90aa-9769251c75e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3cf5031e-a9a3-43b4-b056-38f227d18e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_91c877d9-c86e-48fa-90aa-9769251c75e1" xlink:to="loc_us-gaap_NetIncomeLoss_3cf5031e-a9a3-43b4-b056-38f227d18e56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2032f748-6403-4b0e-b768-d9949b68d192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_91c877d9-c86e-48fa-90aa-9769251c75e1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2032f748-6403-4b0e-b768-d9949b68d192" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b559c725-8ba7-4bae-b541-c97fc2d4dc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ac2af652-bd83-4300-bef2-61a85de7fbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b559c725-8ba7-4bae-b541-c97fc2d4dc0e" xlink:to="loc_us-gaap_RestructuringCharges_ac2af652-bd83-4300-bef2-61a85de7fbf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectOperatingCosts_b2e3b172-c05d-4d40-9038-9cb7af2dcbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b559c725-8ba7-4bae-b541-c97fc2d4dc0e" xlink:to="loc_us-gaap_DirectOperatingCosts_b2e3b172-c05d-4d40-9038-9cb7af2dcbd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_62cd35ef-92f9-4693-82ab-f8955f23d4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b559c725-8ba7-4bae-b541-c97fc2d4dc0e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_62cd35ef-92f9-4693-82ab-f8955f23d4d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_5dd42983-212b-4133-9f5b-3ac1f75a61ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b559c725-8ba7-4bae-b541-c97fc2d4dc0e" xlink:to="loc_us-gaap_AssetImpairmentCharges_5dd42983-212b-4133-9f5b-3ac1f75a61ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_ced697da-c0c7-493f-8981-b01d3cc5b63b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b559c725-8ba7-4bae-b541-c97fc2d4dc0e" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_ced697da-c0c7-493f-8981-b01d3cc5b63b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_da09c89a-e351-4bc4-8337-0760eca33138" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b559c725-8ba7-4bae-b541-c97fc2d4dc0e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_da09c89a-e351-4bc4-8337-0760eca33138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LegalAndOtherLosses_56ff2ad0-9bdc-4ba7-a1e7-f120d2c55328" xlink:href="ccrn-20250331.xsd#ccrn_LegalAndOtherLosses"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b559c725-8ba7-4bae-b541-c97fc2d4dc0e" xlink:to="loc_ccrn_LegalAndOtherLosses_56ff2ad0-9bdc-4ba7-a1e7-f120d2c55328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_c9ba5a6d-0927-457d-839b-ad9e8739431b" xlink:href="ccrn-20250331.xsd#ccrn_AcquisitionAndIntegrationRelatedCosts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b559c725-8ba7-4bae-b541-c97fc2d4dc0e" xlink:to="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_c9ba5a6d-0927-457d-839b-ad9e8739431b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ccrn-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_91fd02bd-d0cb-433e-a976-dc74afff564a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_775602b1-3102-4ad2-9aff-dbb681f21837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_91fd02bd-d0cb-433e-a976-dc74afff564a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_775602b1-3102-4ad2-9aff-dbb681f21837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c75618ce-3bd4-47d5-b769-62d020ce66e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_91fd02bd-d0cb-433e-a976-dc74afff564a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c75618ce-3bd4-47d5-b769-62d020ce66e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2355f2b-69e8-4795-b696-15a6c0a12090" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_91fd02bd-d0cb-433e-a976-dc74afff564a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2355f2b-69e8-4795-b696-15a6c0a12090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee512dd1-67b6-45cb-9153-858954cc1d75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_91fd02bd-d0cb-433e-a976-dc74afff564a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee512dd1-67b6-45cb-9153-858954cc1d75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c856675a-f1b4-42ef-ae6b-6ff9d66eeb33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c856675a-f1b4-42ef-ae6b-6ff9d66eeb33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_fc2993f5-f151-470a-94a5-6825f744218a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_fc2993f5-f151-470a-94a5-6825f744218a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_13ba063e-71c6-4e4c-98a6-d821c2f993ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_13ba063e-71c6-4e4c-98a6-d821c2f993ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b5ce3993-4b6e-4bb1-ba29-75d4e2318e18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b5ce3993-4b6e-4bb1-ba29-75d4e2318e18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities_813c03f1-b701-4c16-945e-5c9856f0da66" xlink:href="ccrn-20250331.xsd#ccrn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:to="loc_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities_813c03f1-b701-4c16-945e-5c9856f0da66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_0a080fa4-462b-46c0-b95a-281d85c0281d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_0a080fa4-462b-46c0-b95a-281d85c0281d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_791df226-b107-4db1-90c4-5810209003c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_791df226-b107-4db1-90c4-5810209003c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_97ea39a6-7246-4345-9221-9dd9d0f61908" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:to="loc_us-gaap_NetIncomeLoss_97ea39a6-7246-4345-9221-9dd9d0f61908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances_00727840-0242-4852-bd24-d1bf9a5e9d75" xlink:href="ccrn-20250331.xsd#ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:to="loc_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances_00727840-0242-4852-bd24-d1bf9a5e9d75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_de502ead-b541-403e-a681-b4e3212f3e21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_de502ead-b541-403e-a681-b4e3212f3e21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a6a382bf-b056-4a87-a369-47422eb047bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:to="loc_us-gaap_ShareBasedCompensation_a6a382bf-b056-4a87-a369-47422eb047bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OperatingLeaseExpenseNonCash_7da84220-731e-4b43-8c67-0d8202b37902" xlink:href="ccrn-20250331.xsd#ccrn_OperatingLeaseExpenseNonCash"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:to="loc_ccrn_OperatingLeaseExpenseNonCash_7da84220-731e-4b43-8c67-0d8202b37902" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_123183b8-9a4b-43b8-9ca8-fe23034245fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_123183b8-9a4b-43b8-9ca8-fe23034245fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_659d65b1-22fb-4a17-9d4e-ce071661d6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ea915d9-78b3-4165-86a1-f79d4308cf0c" xlink:to="loc_us-gaap_AssetImpairmentCharges_659d65b1-22fb-4a17-9d4e-ce071661d6e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c696dfe8-42cd-48c7-bc9c-2a71ca123a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_842c0129-9fa5-4c97-b569-d39b38955a74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c696dfe8-42cd-48c7-bc9c-2a71ca123a2e" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_842c0129-9fa5-4c97-b569-d39b38955a74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_52a90509-a5c1-4f11-a36d-c160132168cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c696dfe8-42cd-48c7-bc9c-2a71ca123a2e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_52a90509-a5c1-4f11-a36d-c160132168cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5dd0f47b-fe59-48bf-8980-cfa3354fecc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c696dfe8-42cd-48c7-bc9c-2a71ca123a2e" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5dd0f47b-fe59-48bf-8980-cfa3354fecc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_6ae92f05-e8af-4d9f-9925-d47c3f63fd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c696dfe8-42cd-48c7-bc9c-2a71ca123a2e" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_6ae92f05-e8af-4d9f-9925-d47c3f63fd3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_6f59de12-bc96-48fd-854e-28a9797621bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c696dfe8-42cd-48c7-bc9c-2a71ca123a2e" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_6f59de12-bc96-48fd-854e-28a9797621bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_386d48e6-d0de-4b33-89bd-b2d01d95a16d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_48b2a2c2-4c16-4532-93d8-a70aa5879026" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_386d48e6-d0de-4b33-89bd-b2d01d95a16d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_48b2a2c2-4c16-4532-93d8-a70aa5879026" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e5e27909-e40d-41a6-8ad8-7bf1b4dfb831" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b20f29f1-63b9-4089-8013-05e20b16c76c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e5e27909-e40d-41a6-8ad8-7bf1b4dfb831" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b20f29f1-63b9-4089-8013-05e20b16c76c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_70abd504-83fc-4686-877e-b7a6d003561c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e5e27909-e40d-41a6-8ad8-7bf1b4dfb831" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_70abd504-83fc-4686-877e-b7a6d003561c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_27d7c66c-38ae-40a7-9cc0-a04ad61f9c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_88c55e61-5652-447c-a7a8-7685d0b4e22b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_27d7c66c-38ae-40a7-9cc0-a04ad61f9c6b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_88c55e61-5652-447c-a7a8-7685d0b4e22b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fe6b1696-3c80-449c-b2e6-abbd48f18433" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_27d7c66c-38ae-40a7-9cc0-a04ad61f9c6b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fe6b1696-3c80-449c-b2e6-abbd48f18433" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce3e8fdd-9e20-41f6-ac3f-4a3b57471f81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_4f7ff753-3648-43f2-bcbc-82ee97188bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce3e8fdd-9e20-41f6-ac3f-4a3b57471f81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_4f7ff753-3648-43f2-bcbc-82ee97188bbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_14992fdd-9288-4f7f-93f8-ceffceece788" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce3e8fdd-9e20-41f6-ac3f-4a3b57471f81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_14992fdd-9288-4f7f-93f8-ceffceece788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8223243d-ec5c-48ad-b0fb-58caf066be2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce3e8fdd-9e20-41f6-ac3f-4a3b57471f81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8223243d-ec5c-48ad-b0fb-58caf066be2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9da634d6-59c6-46e6-b851-9aad5aeae2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce3e8fdd-9e20-41f6-ac3f-4a3b57471f81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9da634d6-59c6-46e6-b851-9aad5aeae2d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_7c864971-ec46-40e5-9e75-dc652d93075b" xlink:href="ccrn-20250331.xsd#ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce3e8fdd-9e20-41f6-ac3f-4a3b57471f81" xlink:to="loc_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_7c864971-ec46-40e5-9e75-dc652d93075b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d02af05c-6bdf-4a1a-87f4-ca9e034790f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce3e8fdd-9e20-41f6-ac3f-4a3b57471f81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d02af05c-6bdf-4a1a-87f4-ca9e034790f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#LEASESOperatingLeaseMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_641b8d09-b732-4c50-80e9-44df5c50457a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_657aa0e6-ac09-4ef0-86c2-9b608e051ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_641b8d09-b732-4c50-80e9-44df5c50457a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_657aa0e6-ac09-4ef0-86c2-9b608e051ef0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b9488acf-508a-4f82-ba2a-8697c83bdc31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_641b8d09-b732-4c50-80e9-44df5c50457a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b9488acf-508a-4f82-ba2a-8697c83bdc31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8e5d6722-61d4-4858-8637-fbdcd323fc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_641b8d09-b732-4c50-80e9-44df5c50457a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8e5d6722-61d4-4858-8637-fbdcd323fc4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8bcde7d0-57d8-41fe-86ad-f46ff02a8b43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_641b8d09-b732-4c50-80e9-44df5c50457a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8bcde7d0-57d8-41fe-86ad-f46ff02a8b43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_594f96d2-c936-417f-9aa6-a2cc981b35cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_641b8d09-b732-4c50-80e9-44df5c50457a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_594f96d2-c936-417f-9aa6-a2cc981b35cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_3c883f0c-d273-477c-aeef-df802fbf45e9" xlink:href="ccrn-20250331.xsd#ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_641b8d09-b732-4c50-80e9-44df5c50457a" xlink:to="loc_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_3c883f0c-d273-477c-aeef-df802fbf45e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8477a263-7e0f-4082-bcb7-ec5724be7482" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_29f3fe98-8c0a-4aca-ac8f-1adc04b75e57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8477a263-7e0f-4082-bcb7-ec5724be7482" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_29f3fe98-8c0a-4aca-ac8f-1adc04b75e57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_db885764-7bfa-4c87-8da2-bd432d920a02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8477a263-7e0f-4082-bcb7-ec5724be7482" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_db885764-7bfa-4c87-8da2-bd432d920a02" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1" xlink:type="simple" xlink:href="ccrn-20250331.xsd#LEASESOperatingLeaseMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e4212fe-12ef-4044-b71b-a2772fd1d5df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_257e9524-2779-4e31-b44e-5f6135afe26a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e4212fe-12ef-4044-b71b-a2772fd1d5df" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_257e9524-2779-4e31-b44e-5f6135afe26a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_17ab2461-4c4d-45eb-861a-bf9003e9bf67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e4212fe-12ef-4044-b71b-a2772fd1d5df" xlink:to="loc_us-gaap_OperatingLeaseLiability_17ab2461-4c4d-45eb-861a-bf9003e9bf67" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SEGMENTDATAOperatingSegmentsDetails"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_39fadf9c-0aeb-4d5d-ace9-9b42980ed855" xlink:href="ccrn-20250331.xsd#ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectOperatingCosts_9b1d9e9f-59ca-4e71-b314-55e0f21148d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_39fadf9c-0aeb-4d5d-ace9-9b42980ed855" xlink:to="loc_us-gaap_DirectOperatingCosts_9b1d9e9f-59ca-4e71-b314-55e0f21148d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_ed60537c-03d6-4936-be1c-b5d64690ac6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_39fadf9c-0aeb-4d5d-ace9-9b42980ed855" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_ed60537c-03d6-4936-be1c-b5d64690ac6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingExpense_a6abc3e1-e1ba-421d-bb61-f03c3f11d9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_39fadf9c-0aeb-4d5d-ace9-9b42980ed855" xlink:to="loc_us-gaap_MarketingExpense_a6abc3e1-e1ba-421d-bb61-f03c3f11d9d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense_cb684230-776b-4f1d-bc1a-3dd39dee88a0" xlink:href="ccrn-20250331.xsd#ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_39fadf9c-0aeb-4d5d-ace9-9b42980ed855" xlink:to="loc_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense_cb684230-776b-4f1d-bc1a-3dd39dee88a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_e18d054f-6f0a-420d-a9ab-2fc2f2dc061a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_39fadf9c-0aeb-4d5d-ace9-9b42980ed855" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_e18d054f-6f0a-420d-a9ab-2fc2f2dc061a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f24ad2a2-b187-45a6-8673-967e7e2c02ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_39fadf9c-0aeb-4d5d-ace9-9b42980ed855" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f24ad2a2-b187-45a6-8673-967e7e2c02ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0e700d88-eda5-4f43-adb4-3e8335a735d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_39fadf9c-0aeb-4d5d-ace9-9b42980ed855" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0e700d88-eda5-4f43-adb4-3e8335a735d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BenefitsExpense_d45215ef-65d5-4a44-8f66-b75ca84e2b32" xlink:href="ccrn-20250331.xsd#ccrn_BenefitsExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_39fadf9c-0aeb-4d5d-ace9-9b42980ed855" xlink:to="loc_ccrn_BenefitsExpense_d45215ef-65d5-4a44-8f66-b75ca84e2b32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7704e7e-3400-4a2d-9baf-a6d008647ced" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SegmentReportingUnallocatedCorporateExpenses_21dfeba7-8dcf-4a66-9a4c-f7d0805083ac" xlink:href="ccrn-20250331.xsd#ccrn_SegmentReportingUnallocatedCorporateExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7704e7e-3400-4a2d-9baf-a6d008647ced" xlink:to="loc_ccrn_SegmentReportingUnallocatedCorporateExpenses_21dfeba7-8dcf-4a66-9a4c-f7d0805083ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e6ec5d73-e662-477a-bb7c-280633a18915" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7704e7e-3400-4a2d-9baf-a6d008647ced" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e6ec5d73-e662-477a-bb7c-280633a18915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_7c149943-2335-4a22-a233-4437c4cd8d3f" xlink:href="ccrn-20250331.xsd#ccrn_AcquisitionAndIntegrationRelatedCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7704e7e-3400-4a2d-9baf-a6d008647ced" xlink:to="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_7c149943-2335-4a22-a233-4437c4cd8d3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LegalAndOtherLosses_aa73b5c8-eebb-4f5d-891a-31b0c66b665e" xlink:href="ccrn-20250331.xsd#ccrn_LegalAndOtherLosses"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7704e7e-3400-4a2d-9baf-a6d008647ced" xlink:to="loc_ccrn_LegalAndOtherLosses_aa73b5c8-eebb-4f5d-891a-31b0c66b665e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_aad106a5-ec97-47fa-b34f-886e63f80dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7704e7e-3400-4a2d-9baf-a6d008647ced" xlink:to="loc_us-gaap_InterestExpenseNonoperating_aad106a5-ec97-47fa-b34f-886e63f80dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c81c93cf-5346-45db-ad5e-f6c85bef2537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7704e7e-3400-4a2d-9baf-a6d008647ced" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c81c93cf-5346-45db-ad5e-f6c85bef2537" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9aff67d5-04a6-41c8-bf1e-d386b82cb615" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7704e7e-3400-4a2d-9baf-a6d008647ced" xlink:to="loc_us-gaap_RestructuringCharges_9aff67d5-04a6-41c8-bf1e-d386b82cb615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ad58192f-771e-4253-b7b7-8accc08841f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7704e7e-3400-4a2d-9baf-a6d008647ced" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ad58192f-771e-4253-b7b7-8accc08841f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_ba6d0766-cfff-4ded-9e19-1109eb580d0a" xlink:href="ccrn-20250331.xsd#ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7704e7e-3400-4a2d-9baf-a6d008647ced" xlink:to="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_ba6d0766-cfff-4ded-9e19-1109eb580d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_1e4ddd12-ecc3-4e98-b78a-19f80f75f855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7704e7e-3400-4a2d-9baf-a6d008647ced" xlink:to="loc_us-gaap_AssetImpairmentCharges_1e4ddd12-ecc3-4e98-b78a-19f80f75f855" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ccrn-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:dd6031fa-8918-4f16-99cd-07b7064df9d2,g:a332f0b9-5dad-4d87-8e39-4baf62f16fbe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ccrn-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5475d333-7011-47e2-b5c6-7212d842dcbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_30499616-2a2d-47c9-9b95-4820452c3943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5475d333-7011-47e2-b5c6-7212d842dcbf" xlink:to="loc_us-gaap_StatementTable_30499616-2a2d-47c9-9b95-4820452c3943" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_87566685-47e5-4554-8271-eeb71da7fd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_30499616-2a2d-47c9-9b95-4820452c3943" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_87566685-47e5-4554-8271-eeb71da7fd8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87566685-47e5-4554-8271-eeb71da7fd8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_87566685-47e5-4554-8271-eeb71da7fd8e" xlink:to="loc_us-gaap_EquityComponentDomain_87566685-47e5-4554-8271-eeb71da7fd8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_23a871e5-dd37-4239-a885-c9d0fbe48e22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_87566685-47e5-4554-8271-eeb71da7fd8e" xlink:to="loc_us-gaap_EquityComponentDomain_23a871e5-dd37-4239-a885-c9d0fbe48e22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9bd89a88-e849-4f9e-a492-85b814152c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_23a871e5-dd37-4239-a885-c9d0fbe48e22" xlink:to="loc_us-gaap_CommonStockMember_9bd89a88-e849-4f9e-a492-85b814152c8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_858585ca-0ce1-4f9d-9e00-a9c81681e13b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_23a871e5-dd37-4239-a885-c9d0fbe48e22" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_858585ca-0ce1-4f9d-9e00-a9c81681e13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2878e1e3-be5b-4cc7-b8b6-6362cc3a4fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_23a871e5-dd37-4239-a885-c9d0fbe48e22" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2878e1e3-be5b-4cc7-b8b6-6362cc3a4fbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d687318a-6c15-4cae-bec2-241c9aaaf1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_23a871e5-dd37-4239-a885-c9d0fbe48e22" xlink:to="loc_us-gaap_RetainedEarningsMember_d687318a-6c15-4cae-bec2-241c9aaaf1f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5475d333-7011-47e2-b5c6-7212d842dcbf" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ae73a8f8-1621-4f44-a8df-8ac42ef18670" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ae73a8f8-1621-4f44-a8df-8ac42ef18670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fbc7f7c5-41ce-4776-b059-2eab3a3ea166" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_StockholdersEquity_fbc7f7c5-41ce-4776-b059-2eab3a3ea166" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c0a2900f-a423-4142-ae06-a73affd576dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c0a2900f-a423-4142-ae06-a73affd576dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ad7de9d7-b27d-44b9-af35-54c5fa90e30e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ad7de9d7-b27d-44b9-af35-54c5fa90e30e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4750a720-4723-4b87-9194-9a3ad3caca12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4750a720-4723-4b87-9194-9a3ad3caca12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5052dbbd-6442-4483-ba0d-0008084ce56a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5052dbbd-6442-4483-ba0d-0008084ce56a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_53b589db-5bbc-443d-8202-f8e496fdb213" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_53b589db-5bbc-443d-8202-f8e496fdb213" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_StockRepurchasedDuringPeriodExciseTax_a4c667e1-793f-4e76-960a-2f8b10cd0f16" xlink:href="ccrn-20250331.xsd#ccrn_StockRepurchasedDuringPeriodExciseTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_ccrn_StockRepurchasedDuringPeriodExciseTax_a4c667e1-793f-4e76-960a-2f8b10cd0f16" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f38db7dd-d53f-4e36-a2e4-ebc3a38060f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f38db7dd-d53f-4e36-a2e4-ebc3a38060f5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f9427db-e8a2-4fc4-9086-53d310b351e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_NetIncomeLoss_2f9427db-e8a2-4fc4-9086-53d310b351e3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_76ef8775-3c04-45a5-ba00-6002ab6f0fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b853a781-0d61-4fce-9a43-c0253c5204fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_35b5619f-aa96-47a5-8575-ddff4dbd6fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_87bcc945-e7a5-4106-8acf-6a3db064405e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_35b5619f-aa96-47a5-8575-ddff4dbd6fa9" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_87bcc945-e7a5-4106-8acf-6a3db064405e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_48ec80c3-9881-4c7c-acbb-c93fe3622f92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_87bcc945-e7a5-4106-8acf-6a3db064405e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_48ec80c3-9881-4c7c-acbb-c93fe3622f92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48ec80c3-9881-4c7c-acbb-c93fe3622f92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_48ec80c3-9881-4c7c-acbb-c93fe3622f92" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48ec80c3-9881-4c7c-acbb-c93fe3622f92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3576a10-50cb-4cf9-a2f4-262079bf49cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_48ec80c3-9881-4c7c-acbb-c93fe3622f92" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3576a10-50cb-4cf9-a2f4-262079bf49cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AyaHoldingsIIInc.Member_9bc85817-91bf-4711-b988-9fcc5d46e0c4" xlink:href="ccrn-20250331.xsd#ccrn_AyaHoldingsIIInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3576a10-50cb-4cf9-a2f4-262079bf49cb" xlink:to="loc_ccrn_AyaHoldingsIIInc.Member_9bc85817-91bf-4711-b988-9fcc5d46e0c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_93d417c7-33cb-46ea-8e9f-1186bc29b9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_35b5619f-aa96-47a5-8575-ddff4dbd6fa9" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_93d417c7-33cb-46ea-8e9f-1186bc29b9a3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e1318bbb-d299-400a-a240-ddd5a2cac3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d111facf-b463-4e27-bbd7-ab4054b3f140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e1318bbb-d299-400a-a240-ddd5a2cac3f2" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d111facf-b463-4e27-bbd7-ab4054b3f140" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3cc6aa36-0f79-4177-8baf-5aadc37f9fd2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d111facf-b463-4e27-bbd7-ab4054b3f140" xlink:to="loc_srt_RangeAxis_3cc6aa36-0f79-4177-8baf-5aadc37f9fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3cc6aa36-0f79-4177-8baf-5aadc37f9fd2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3cc6aa36-0f79-4177-8baf-5aadc37f9fd2" xlink:to="loc_srt_RangeMember_3cc6aa36-0f79-4177-8baf-5aadc37f9fd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5281f673-27ac-4d28-8fe8-fcd61b8fc604" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3cc6aa36-0f79-4177-8baf-5aadc37f9fd2" xlink:to="loc_srt_RangeMember_5281f673-27ac-4d28-8fe8-fcd61b8fc604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0e7a3d07-db63-46fe-8adf-8afd4b77fd33" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5281f673-27ac-4d28-8fe8-fcd61b8fc604" xlink:to="loc_srt_MinimumMember_0e7a3d07-db63-46fe-8adf-8afd4b77fd33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6f41dbbf-3b17-4271-a046-0873f9bdede2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5281f673-27ac-4d28-8fe8-fcd61b8fc604" xlink:to="loc_srt_MaximumMember_6f41dbbf-3b17-4271-a046-0873f9bdede2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_1e2039c6-df0a-47f4-88a7-e15846986136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e1318bbb-d299-400a-a240-ddd5a2cac3f2" xlink:to="loc_us-gaap_UnbilledContractsReceivable_1e2039c6-df0a-47f4-88a7-e15846986136" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SalesAllowanceBillingRelatedAdjustments_85f26afe-1094-424d-b9a6-8ba68d7233af" xlink:href="ccrn-20250331.xsd#ccrn_SalesAllowanceBillingRelatedAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e1318bbb-d299-400a-a240-ddd5a2cac3f2" xlink:to="loc_ccrn_SalesAllowanceBillingRelatedAdjustments_85f26afe-1094-424d-b9a6-8ba68d7233af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided_1406fd48-5cbd-4764-aa03-9ff5cd3f3296" xlink:href="ccrn-20250331.xsd#ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e1318bbb-d299-400a-a240-ddd5a2cac3f2" xlink:to="loc_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided_1406fd48-5cbd-4764-aa03-9ff5cd3f3296" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_01a2bdcd-fad5-4187-81e4-39eb7161ca15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8b4d40ac-dab8-434b-9e42-8461823e0aca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_01a2bdcd-fad5-4187-81e4-39eb7161ca15" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8b4d40ac-dab8-434b-9e42-8461823e0aca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2f5a160d-394c-4a68-a6c5-635b50bb8b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8b4d40ac-dab8-434b-9e42-8461823e0aca" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2f5a160d-394c-4a68-a6c5-635b50bb8b3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2f5a160d-394c-4a68-a6c5-635b50bb8b3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2f5a160d-394c-4a68-a6c5-635b50bb8b3c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2f5a160d-394c-4a68-a6c5-635b50bb8b3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_da8cf77b-fdf5-4c95-82be-a8a6c348045d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2f5a160d-394c-4a68-a6c5-635b50bb8b3c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_da8cf77b-fdf5-4c95-82be-a8a6c348045d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_4b977b2a-5af8-42ac-82d8-60755ee8006d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_da8cf77b-fdf5-4c95-82be-a8a6c348045d" xlink:to="loc_us-gaap_EmployeeSeveranceMember_4b977b2a-5af8-42ac-82d8-60755ee8006d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ExitCostsMember_467771b8-ac15-4c8e-a12d-ee05b90ac5cf" xlink:href="ccrn-20250331.xsd#ccrn_ExitCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_da8cf77b-fdf5-4c95-82be-a8a6c348045d" xlink:to="loc_ccrn_ExitCostsMember_467771b8-ac15-4c8e-a12d-ee05b90ac5cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_d9bc0f3e-81d2-424c-8a0f-543547c1f425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_01a2bdcd-fad5-4187-81e4-39eb7161ca15" xlink:to="loc_us-gaap_RestructuringReserveRollForward_d9bc0f3e-81d2-424c-8a0f-543547c1f425" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_efc5c9d3-cc58-45dd-98c5-62a184387e95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d9bc0f3e-81d2-424c-8a0f-543547c1f425" xlink:to="loc_us-gaap_RestructuringReserve_efc5c9d3-cc58-45dd-98c5-62a184387e95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_751ad015-193d-4f27-aa59-328fd2a60997" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d9bc0f3e-81d2-424c-8a0f-543547c1f425" xlink:to="loc_us-gaap_RestructuringCharges_751ad015-193d-4f27-aa59-328fd2a60997" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_352a47cc-06a9-4ccb-837b-8b4ce80171ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d9bc0f3e-81d2-424c-8a0f-543547c1f425" xlink:to="loc_us-gaap_PaymentsForRestructuring_352a47cc-06a9-4ccb-837b-8b4ce80171ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_7db180aa-e8d1-4ce0-b499-7f7ac9cbcece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#REVENUERECOGNITIONDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e82b5596-62c5-45cb-b3c6-69ecf1a8f315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_27a7bdec-99d1-446e-ae6c-899d4c20b704" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e82b5596-62c5-45cb-b3c6-69ecf1a8f315" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_27a7bdec-99d1-446e-ae6c-899d4c20b704" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ee38076b-0000-46e8-81c6-e9a362efafa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_27a7bdec-99d1-446e-ae6c-899d4c20b704" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ee38076b-0000-46e8-81c6-e9a362efafa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ee38076b-0000-46e8-81c6-e9a362efafa3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ee38076b-0000-46e8-81c6-e9a362efafa3" xlink:to="loc_us-gaap_SegmentDomain_ee38076b-0000-46e8-81c6-e9a362efafa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fd8a417c-f2e1-476c-be2d-4dbb8d36848d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ee38076b-0000-46e8-81c6-e9a362efafa3" xlink:to="loc_us-gaap_SegmentDomain_fd8a417c-f2e1-476c-be2d-4dbb8d36848d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NurseAndAlliedStaffingMember_65ffa1de-6099-450a-b47e-b4679cd9223a" xlink:href="ccrn-20250331.xsd#ccrn_NurseAndAlliedStaffingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fd8a417c-f2e1-476c-be2d-4dbb8d36848d" xlink:to="loc_ccrn_NurseAndAlliedStaffingMember_65ffa1de-6099-450a-b47e-b4679cd9223a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PhysicianStaffingMember_c66fd75f-f6da-4fe7-8586-65aeaeb0f06a" xlink:href="ccrn-20250331.xsd#ccrn_PhysicianStaffingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fd8a417c-f2e1-476c-be2d-4dbb8d36848d" xlink:to="loc_ccrn_PhysicianStaffingMember_c66fd75f-f6da-4fe7-8586-65aeaeb0f06a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ebadce31-c1cd-431e-89f8-3132cecbc224" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_27a7bdec-99d1-446e-ae6c-899d4c20b704" xlink:to="loc_srt_ProductOrServiceAxis_ebadce31-c1cd-431e-89f8-3132cecbc224" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ebadce31-c1cd-431e-89f8-3132cecbc224_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ebadce31-c1cd-431e-89f8-3132cecbc224" xlink:to="loc_srt_ProductsAndServicesDomain_ebadce31-c1cd-431e-89f8-3132cecbc224_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_415369d5-7d95-4764-ad87-a0a88afb9ea2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ebadce31-c1cd-431e-89f8-3132cecbc224" xlink:to="loc_srt_ProductsAndServicesDomain_415369d5-7d95-4764-ad87-a0a88afb9ea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_TemporaryStaffingServicesMember_85ca2194-037d-49b6-b4bd-60c452adc141" xlink:href="ccrn-20250331.xsd#ccrn_TemporaryStaffingServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_415369d5-7d95-4764-ad87-a0a88afb9ea2" xlink:to="loc_ccrn_TemporaryStaffingServicesMember_85ca2194-037d-49b6-b4bd-60c452adc141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OtherServicesMember_42cb2b84-250b-4b7a-9cf2-365004567ee1" xlink:href="ccrn-20250331.xsd#ccrn_OtherServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_415369d5-7d95-4764-ad87-a0a88afb9ea2" xlink:to="loc_ccrn_OtherServicesMember_42cb2b84-250b-4b7a-9cf2-365004567ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_649318a8-f2e7-4b60-a477-6e9d607c6138" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e82b5596-62c5-45cb-b3c6-69ecf1a8f315" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_649318a8-f2e7-4b60-a477-6e9d607c6138" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#ACQUISITIONSDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_df3e1376-7ca4-4955-81bc-e490392c88d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960c55f3-f73a-4b65-a227-eca0dd1fbd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_df3e1376-7ca4-4955-81bc-e490392c88d3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960c55f3-f73a-4b65-a227-eca0dd1fbd7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_40e98ac2-67fd-4d3e-b994-83a1b0fe421b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960c55f3-f73a-4b65-a227-eca0dd1fbd7c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_40e98ac2-67fd-4d3e-b994-83a1b0fe421b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_40e98ac2-67fd-4d3e-b994-83a1b0fe421b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_40e98ac2-67fd-4d3e-b994-83a1b0fe421b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_40e98ac2-67fd-4d3e-b994-83a1b0fe421b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5a7c4e-9590-44f3-b97f-2d404e8da0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_40e98ac2-67fd-4d3e-b994-83a1b0fe421b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5a7c4e-9590-44f3-b97f-2d404e8da0a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_HireUpLeadershipIncMember_d276201d-d860-4f68-888d-3cf58a14e43c" xlink:href="ccrn-20250331.xsd#ccrn_HireUpLeadershipIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5a7c4e-9590-44f3-b97f-2d404e8da0a3" xlink:to="loc_ccrn_HireUpLeadershipIncMember_d276201d-d860-4f68-888d-3cf58a14e43c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember_bd1a0dc2-b54b-46f8-80f4-df6899f73d69" xlink:href="ccrn-20250331.xsd#ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5a7c4e-9590-44f3-b97f-2d404e8da0a3" xlink:to="loc_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember_bd1a0dc2-b54b-46f8-80f4-df6899f73d69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b64c2ac5-2b44-4ee3-8a67-895f9287cad5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_df3e1376-7ca4-4955-81bc-e490392c88d3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b64c2ac5-2b44-4ee3-8a67-895f9287cad5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e6b73006-2a09-45f6-ae9d-0922541d6971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_df3e1376-7ca4-4955-81bc-e490392c88d3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e6b73006-2a09-45f6-ae9d-0922541d6971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_ba056c9f-9a02-45f5-ac63-289095583585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_df3e1376-7ca4-4955-81bc-e490392c88d3" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_ba056c9f-9a02-45f5-ac63-289095583585" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8c3dd8e8-e974-44d8-8c84-da0ee0e7c36c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_df3e1376-7ca4-4955-81bc-e490392c88d3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8c3dd8e8-e974-44d8-8c84-da0ee0e7c36c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a828a2c0-95e1-417b-a751-df542299c272" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_df3e1376-7ca4-4955-81bc-e490392c88d3" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a828a2c0-95e1-417b-a751-df542299c272" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#EARNINGSPERSHAREAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5c38763c-1289-41c6-b8a6-27e846de7a83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e7a40f70-bd4f-49dc-a6fa-c3518d408b70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5c38763c-1289-41c6-b8a6-27e846de7a83" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e7a40f70-bd4f-49dc-a6fa-c3518d408b70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1b8c8b6c-221b-4756-af16-a4057587f9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e7a40f70-bd4f-49dc-a6fa-c3518d408b70" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1b8c8b6c-221b-4756-af16-a4057587f9b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1b8c8b6c-221b-4756-af16-a4057587f9b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1b8c8b6c-221b-4756-af16-a4057587f9b2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1b8c8b6c-221b-4756-af16-a4057587f9b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_99513b0d-d2eb-4435-9843-436bc414ec84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1b8c8b6c-221b-4756-af16-a4057587f9b2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_99513b0d-d2eb-4435-9843-436bc414ec84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_f93b9cbc-eaf0-44ca-831e-bcfa0719e2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_99513b0d-d2eb-4435-9843-436bc414ec84" xlink:to="loc_us-gaap_StockCompensationPlanMember_f93b9cbc-eaf0-44ca-831e-bcfa0719e2fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5287f786-770d-46f2-9b3b-0a74d15de27f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5c38763c-1289-41c6-b8a6-27e846de7a83" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5287f786-770d-46f2-9b3b-0a74d15de27f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_244863d9-820b-4d91-bb48-1331d2a64f4e" xlink:href="ccrn-20250331.xsd#ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_52fcf4d4-90b5-43db-aa1c-7d345b2c78fe" xlink:href="ccrn-20250331.xsd#ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_244863d9-820b-4d91-bb48-1331d2a64f4e" xlink:to="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_52fcf4d4-90b5-43db-aa1c-7d345b2c78fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07d1008e-56be-48b5-bc9e-674be178a34b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_52fcf4d4-90b5-43db-aa1c-7d345b2c78fe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07d1008e-56be-48b5-bc9e-674be178a34b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_07d1008e-56be-48b5-bc9e-674be178a34b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07d1008e-56be-48b5-bc9e-674be178a34b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_07d1008e-56be-48b5-bc9e-674be178a34b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e62d040-2c4f-483c-8ca4-ccbcf4d4ea6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07d1008e-56be-48b5-bc9e-674be178a34b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e62d040-2c4f-483c-8ca4-ccbcf4d4ea6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DatabasesMember_19072a49-034b-4916-90c9-691bae3e0448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DatabasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e62d040-2c4f-483c-8ca4-ccbcf4d4ea6b" xlink:to="loc_us-gaap_DatabasesMember_19072a49-034b-4916-90c9-691bae3e0448" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_f611d7e7-1d17-45ee-9002-a79b72091861" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e62d040-2c4f-483c-8ca4-ccbcf4d4ea6b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_f611d7e7-1d17-45ee-9002-a79b72091861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a64b4d0c-5b93-4920-ad78-e59fac0b7412" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_244863d9-820b-4d91-bb48-1331d2a64f4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a64b4d0c-5b93-4920-ad78-e59fac0b7412" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7422f26c-ece3-4f1a-87ac-bb6619b6af32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a64b4d0c-5b93-4920-ad78-e59fac0b7412" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7422f26c-ece3-4f1a-87ac-bb6619b6af32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c07e9004-0035-454c-bac0-801657671de3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a64b4d0c-5b93-4920-ad78-e59fac0b7412" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c07e9004-0035-454c-bac0-801657671de3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b556f163-98d2-4295-a33f-ff07a92b1033" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a64b4d0c-5b93-4920-ad78-e59fac0b7412" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b556f163-98d2-4295-a33f-ff07a92b1033" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_37399942-0643-4254-acaf-eec35fa51f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_244863d9-820b-4d91-bb48-1331d2a64f4e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_37399942-0643-4254-acaf-eec35fa51f6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedTradeNames_c91734a6-d96b-448e-834c-327dd86579c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedTradeNames"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_37399942-0643-4254-acaf-eec35fa51f6c" xlink:to="loc_us-gaap_IndefiniteLivedTradeNames_c91734a6-d96b-448e-834c-327dd86579c7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_cd34134a-2f4d-4a56-9e87-45bd256bd706" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_7e0bc485-d3a9-4d4e-a4c8-1ba4499dc0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_cd34134a-2f4d-4a56-9e87-45bd256bd706" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_7e0bc485-d3a9-4d4e-a4c8-1ba4499dc0eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5a55b2cc-169e-4fd3-a3a8-21c7c52d6813" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7e0bc485-d3a9-4d4e-a4c8-1ba4499dc0eb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5a55b2cc-169e-4fd3-a3a8-21c7c52d6813" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5a55b2cc-169e-4fd3-a3a8-21c7c52d6813_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5a55b2cc-169e-4fd3-a3a8-21c7c52d6813" xlink:to="loc_us-gaap_SegmentDomain_5a55b2cc-169e-4fd3-a3a8-21c7c52d6813_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8158487a-be0f-48b6-b8a8-feb21d688c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5a55b2cc-169e-4fd3-a3a8-21c7c52d6813" xlink:to="loc_us-gaap_SegmentDomain_8158487a-be0f-48b6-b8a8-feb21d688c1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NurseAndAlliedStaffingMember_696fff47-6da1-494b-b4f8-a3ff2d85475b" xlink:href="ccrn-20250331.xsd#ccrn_NurseAndAlliedStaffingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8158487a-be0f-48b6-b8a8-feb21d688c1e" xlink:to="loc_ccrn_NurseAndAlliedStaffingMember_696fff47-6da1-494b-b4f8-a3ff2d85475b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PhysicianStaffingMember_fd3cfe28-bbdf-4649-9079-615affbf6140" xlink:href="ccrn-20250331.xsd#ccrn_PhysicianStaffingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8158487a-be0f-48b6-b8a8-feb21d688c1e" xlink:to="loc_ccrn_PhysicianStaffingMember_fd3cfe28-bbdf-4649-9079-615affbf6140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_48fe2f89-2391-4b9e-9821-8aedcbcd44c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_cd34134a-2f4d-4a56-9e87-45bd256bd706" xlink:to="loc_us-gaap_Goodwill_48fe2f89-2391-4b9e-9821-8aedcbcd44c4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#DEBTLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9ee42316-e799-4b83-b0f9-02a7cd912d40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c0cb3650-114b-45f5-ad8b-558b60bcaa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ee42316-e799-4b83-b0f9-02a7cd912d40" xlink:to="loc_us-gaap_DebtInstrumentTable_c0cb3650-114b-45f5-ad8b-558b60bcaa0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_06c1632f-c935-4f99-b6c1-d20cf6933a12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c0cb3650-114b-45f5-ad8b-558b60bcaa0a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_06c1632f-c935-4f99-b6c1-d20cf6933a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_06c1632f-c935-4f99-b6c1-d20cf6933a12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_06c1632f-c935-4f99-b6c1-d20cf6933a12" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_06c1632f-c935-4f99-b6c1-d20cf6933a12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c47a1cd3-e5d3-41a0-8430-e14db4de0078" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_06c1632f-c935-4f99-b6c1-d20cf6933a12" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c47a1cd3-e5d3-41a0-8430-e14db4de0078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2304523f-b37d-40b0-a599-d70525ee2e15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c47a1cd3-e5d3-41a0-8430-e14db4de0078" xlink:to="loc_us-gaap_LineOfCreditMember_2304523f-b37d-40b0-a599-d70525ee2e15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ddb812ae-e378-43eb-a7ea-bc508c629348" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c0cb3650-114b-45f5-ad8b-558b60bcaa0a" xlink:to="loc_us-gaap_CreditFacilityAxis_ddb812ae-e378-43eb-a7ea-bc508c629348" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ddb812ae-e378-43eb-a7ea-bc508c629348_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_ddb812ae-e378-43eb-a7ea-bc508c629348" xlink:to="loc_us-gaap_CreditFacilityDomain_ddb812ae-e378-43eb-a7ea-bc508c629348_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_eb639981-9b7a-4b93-bcbc-a24c51bc3f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_ddb812ae-e378-43eb-a7ea-bc508c629348" xlink:to="loc_us-gaap_CreditFacilityDomain_eb639981-9b7a-4b93-bcbc-a24c51bc3f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SeniorSecuredAssetBasedLoanMember_e2fe5ae8-48c2-4312-8436-cf7b2d41e12d" xlink:href="ccrn-20250331.xsd#ccrn_SeniorSecuredAssetBasedLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_eb639981-9b7a-4b93-bcbc-a24c51bc3f1a" xlink:to="loc_ccrn_SeniorSecuredAssetBasedLoanMember_e2fe5ae8-48c2-4312-8436-cf7b2d41e12d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b0ce1fd0-0227-47d3-9175-96d39efb3f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ee42316-e799-4b83-b0f9-02a7cd912d40" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b0ce1fd0-0227-47d3-9175-96d39efb3f9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_70a439f9-78f0-4296-a80e-d133d595c8de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ee42316-e799-4b83-b0f9-02a7cd912d40" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_70a439f9-78f0-4296-a80e-d133d595c8de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_41f88b9a-62ae-48f6-86f8-e5d60061bdec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ee42316-e799-4b83-b0f9-02a7cd912d40" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_41f88b9a-62ae-48f6-86f8-e5d60061bdec" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#DEBT2019AssetBasedLoanAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_d241951c-0711-4b66-879f-76a8d58f6888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_d241951c-0711-4b66-879f-76a8d58f6888" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_866a2367-6b2e-45f4-aa3a-5904702fcbab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d241951c-0711-4b66-879f-76a8d58f6888" xlink:to="loc_us-gaap_CreditFacilityAxis_866a2367-6b2e-45f4-aa3a-5904702fcbab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_866a2367-6b2e-45f4-aa3a-5904702fcbab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_866a2367-6b2e-45f4-aa3a-5904702fcbab" xlink:to="loc_us-gaap_CreditFacilityDomain_866a2367-6b2e-45f4-aa3a-5904702fcbab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0ef97bdf-2d3c-4ae8-bf22-68c15578f523" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_866a2367-6b2e-45f4-aa3a-5904702fcbab" xlink:to="loc_us-gaap_CreditFacilityDomain_0ef97bdf-2d3c-4ae8-bf22-68c15578f523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SeniorSecuredAssetBasedLoanMember_f67aff30-ec55-44bb-a18d-441ab9b22524" xlink:href="ccrn-20250331.xsd#ccrn_SeniorSecuredAssetBasedLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0ef97bdf-2d3c-4ae8-bf22-68c15578f523" xlink:to="loc_ccrn_SeniorSecuredAssetBasedLoanMember_f67aff30-ec55-44bb-a18d-441ab9b22524" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditSublimitAxis_f3abaaff-c783-4f2e-910f-074de2358aac" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditSublimitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d241951c-0711-4b66-879f-76a8d58f6888" xlink:to="loc_ccrn_LineOfCreditSublimitAxis_f3abaaff-c783-4f2e-910f-074de2358aac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditSublimitDomain_f3abaaff-c783-4f2e-910f-074de2358aac_default" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditSublimitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ccrn_LineOfCreditSublimitAxis_f3abaaff-c783-4f2e-910f-074de2358aac" xlink:to="loc_ccrn_LineOfCreditSublimitDomain_f3abaaff-c783-4f2e-910f-074de2358aac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditSublimitDomain_7c3c4239-3a06-4686-935c-fd9697a19109" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditSublimitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ccrn_LineOfCreditSublimitAxis_f3abaaff-c783-4f2e-910f-074de2358aac" xlink:to="loc_ccrn_LineOfCreditSublimitDomain_7c3c4239-3a06-4686-935c-fd9697a19109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SwingLoansSublimitMember_b9a1081a-42e3-4380-8c47-a0a9de085d65" xlink:href="ccrn-20250331.xsd#ccrn_SwingLoansSublimitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ccrn_LineOfCreditSublimitDomain_7c3c4239-3a06-4686-935c-fd9697a19109" xlink:to="loc_ccrn_SwingLoansSublimitMember_b9a1081a-42e3-4380-8c47-a0a9de085d65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_StandbyLettersOfCreditSublimitMember_81f05011-ca1d-47a8-a4d7-aee100c81f4e" xlink:href="ccrn-20250331.xsd#ccrn_StandbyLettersOfCreditSublimitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ccrn_LineOfCreditSublimitDomain_7c3c4239-3a06-4686-935c-fd9697a19109" xlink:to="loc_ccrn_StandbyLettersOfCreditSublimitMember_81f05011-ca1d-47a8-a4d7-aee100c81f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_af4bdb9b-5425-4cda-9b18-dcbd10e3a46d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d241951c-0711-4b66-879f-76a8d58f6888" xlink:to="loc_us-gaap_VariableRateAxis_af4bdb9b-5425-4cda-9b18-dcbd10e3a46d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_af4bdb9b-5425-4cda-9b18-dcbd10e3a46d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_af4bdb9b-5425-4cda-9b18-dcbd10e3a46d" xlink:to="loc_us-gaap_VariableRateDomain_af4bdb9b-5425-4cda-9b18-dcbd10e3a46d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8969140b-f30c-4853-9dc4-8d67f96a25e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_af4bdb9b-5425-4cda-9b18-dcbd10e3a46d" xlink:to="loc_us-gaap_VariableRateDomain_8969140b-f30c-4853-9dc4-8d67f96a25e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_674a5e48-9f1c-4f5a-ac48-c4a79d556479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_8969140b-f30c-4853-9dc4-8d67f96a25e0" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_674a5e48-9f1c-4f5a-ac48-c4a79d556479" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_6b7cf422-9643-4996-92c9-a366d0169d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_8969140b-f30c-4853-9dc4-8d67f96a25e0" xlink:to="loc_us-gaap_BaseRateMember_6b7cf422-9643-4996-92c9-a366d0169d73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_3ff432ee-7265-4d11-b56d-a4e5bb0010c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_3ff432ee-7265-4d11-b56d-a4e5bb0010c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ae284d48-2b57-45d6-9bf9-2bff75643211" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ae284d48-2b57-45d6-9bf9-2bff75643211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources_1857a413-a358-42f9-a867-3e48f7b49843" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources_1857a413-a358-42f9-a867-3e48f7b49843" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment_b88c13b9-a5e8-4185-968c-de7bab98295f" xlink:href="ccrn-20250331.xsd#ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment_b88c13b9-a5e8-4185-968c-de7bab98295f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_30b49bc4-9245-4c1e-ad54-ba1abf8fe55a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_LineOfCredit_30b49bc4-9245-4c1e-ad54-ba1abf8fe55a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable_e381a6bd-fcc9-4eca-bbfb-f3a767adc4aa" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable_e381a6bd-fcc9-4eca-bbfb-f3a767adc4aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditFacilityBorrowingBaseAvailability_abd625db-0f4b-4dcf-93cb-66619632f253" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditFacilityBorrowingBaseAvailability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_ccrn_LineOfCreditFacilityBorrowingBaseAvailability_abd625db-0f4b-4dcf-93cb-66619632f253" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_0c8d1f20-d516-4451-be99-9565d7183841" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_0c8d1f20-d516-4451-be99-9565d7183841" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_76f8814d-ee0f-4b25-9b61-004fb0953b45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_76f8814d-ee0f-4b25-9b61-004fb0953b45" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_08143988-5cb6-4a82-85c8-e4a44437c738" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_08143988-5cb6-4a82-85c8-e4a44437c738" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_24e08aef-c0fc-4d6b-8e05-ce02c4a2d579" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_24e08aef-c0fc-4d6b-8e05-ce02c4a2d579" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41050186-10a6-488a-9a79-547268c6da06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e8228dd-0b38-4097-8ff7-4690895dfb26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41050186-10a6-488a-9a79-547268c6da06" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e8228dd-0b38-4097-8ff7-4690895dfb26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b2971630-1ed3-4e52-8a43-2f48e8c1f7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e8228dd-0b38-4097-8ff7-4690895dfb26" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b2971630-1ed3-4e52-8a43-2f48e8c1f7b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b2971630-1ed3-4e52-8a43-2f48e8c1f7b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b2971630-1ed3-4e52-8a43-2f48e8c1f7b9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b2971630-1ed3-4e52-8a43-2f48e8c1f7b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b94d0099-20d1-4143-a09e-d467e8655b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b2971630-1ed3-4e52-8a43-2f48e8c1f7b9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b94d0099-20d1-4143-a09e-d467e8655b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DeferredCompensationMember_f697662c-453f-4d83-8e06-d7c96a5f95e7" xlink:href="ccrn-20250331.xsd#ccrn_DeferredCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b94d0099-20d1-4143-a09e-d467e8655b5b" xlink:to="loc_ccrn_DeferredCompensationMember_f697662c-453f-4d83-8e06-d7c96a5f95e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_28dad11c-53de-4d75-9e03-033c09cc29ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e8228dd-0b38-4097-8ff7-4690895dfb26" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_28dad11c-53de-4d75-9e03-033c09cc29ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_28dad11c-53de-4d75-9e03-033c09cc29ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_28dad11c-53de-4d75-9e03-033c09cc29ef" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_28dad11c-53de-4d75-9e03-033c09cc29ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8df1603b-86b9-4735-bc82-66ea98a66df6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_28dad11c-53de-4d75-9e03-033c09cc29ef" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8df1603b-86b9-4735-bc82-66ea98a66df6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DeferredCompensationMember_d9736bd4-93d1-475b-9bbc-e43cec477b6e" xlink:href="ccrn-20250331.xsd#ccrn_DeferredCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8df1603b-86b9-4735-bc82-66ea98a66df6" xlink:to="loc_ccrn_DeferredCompensationMember_d9736bd4-93d1-475b-9bbc-e43cec477b6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_25292f99-39fa-4ada-b686-fac1efd573f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e8228dd-0b38-4097-8ff7-4690895dfb26" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_25292f99-39fa-4ada-b686-fac1efd573f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_25292f99-39fa-4ada-b686-fac1efd573f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_25292f99-39fa-4ada-b686-fac1efd573f8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_25292f99-39fa-4ada-b686-fac1efd573f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bb69ccf4-04a3-470b-987d-8998bfaecc92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_25292f99-39fa-4ada-b686-fac1efd573f8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bb69ccf4-04a3-470b-987d-8998bfaecc92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3ed8ec8e-d62f-4a58-b905-d5b6855745e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bb69ccf4-04a3-470b-987d-8998bfaecc92" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3ed8ec8e-d62f-4a58-b905-d5b6855745e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1d407393-b67c-461d-b5ae-219dda283a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41050186-10a6-488a-9a79-547268c6da06" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1d407393-b67c-461d-b5ae-219dda283a1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_1b2bd66c-3265-4cad-90e7-93517e960f83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41050186-10a6-488a-9a79-547268c6da06" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_1b2bd66c-3265-4cad-90e7-93517e960f83" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#FAIRVALUEMEASUREMENTSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FairValueMeasurementLineItems_13e483f8-66c9-4a4f-ba2c-c8b94bb99870" xlink:href="ccrn-20250331.xsd#ccrn_FairValueMeasurementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FairValueMeasurementTable_7f334793-82d3-41c8-a44e-a7d2b33e81e3" xlink:href="ccrn-20250331.xsd#ccrn_FairValueMeasurementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ccrn_FairValueMeasurementLineItems_13e483f8-66c9-4a4f-ba2c-c8b94bb99870" xlink:to="loc_ccrn_FairValueMeasurementTable_7f334793-82d3-41c8-a44e-a7d2b33e81e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d68cfdd3-b123-4eb5-97e3-1bd76dd4ef34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ccrn_FairValueMeasurementTable_7f334793-82d3-41c8-a44e-a7d2b33e81e3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d68cfdd3-b123-4eb5-97e3-1bd76dd4ef34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d68cfdd3-b123-4eb5-97e3-1bd76dd4ef34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d68cfdd3-b123-4eb5-97e3-1bd76dd4ef34" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d68cfdd3-b123-4eb5-97e3-1bd76dd4ef34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_801cf86f-1134-4fd3-89f9-51a44ef860e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d68cfdd3-b123-4eb5-97e3-1bd76dd4ef34" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_801cf86f-1134-4fd3-89f9-51a44ef860e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember_e98bf187-d82d-469c-84bb-063b09e049bb" xlink:href="ccrn-20250331.xsd#ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_801cf86f-1134-4fd3-89f9-51a44ef860e9" xlink:to="loc_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember_e98bf187-d82d-469c-84bb-063b09e049bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_HireUpLeadershipIncMember_9a7fc134-ccfc-48fb-94fc-6198198283fb" xlink:href="ccrn-20250331.xsd#ccrn_HireUpLeadershipIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_801cf86f-1134-4fd3-89f9-51a44ef860e9" xlink:to="loc_ccrn_HireUpLeadershipIncMember_9a7fc134-ccfc-48fb-94fc-6198198283fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_69ff1c48-5f1e-426e-8a5c-812c2b733679" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ccrn_FairValueMeasurementLineItems_13e483f8-66c9-4a4f-ba2c-c8b94bb99870" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_69ff1c48-5f1e-426e-8a5c-812c2b733679" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c68bd9e-1bd7-44da-88cf-4697c3caa584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c68bd9e-1bd7-44da-88cf-4697c3caa584" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_1866a7ce-d696-4c29-a09b-142a2b54bb4d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c68bd9e-1bd7-44da-88cf-4697c3caa584" xlink:to="loc_srt_ShareRepurchaseProgramAxis_1866a7ce-d696-4c29-a09b-142a2b54bb4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_1866a7ce-d696-4c29-a09b-142a2b54bb4d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ShareRepurchaseProgramAxis_1866a7ce-d696-4c29-a09b-142a2b54bb4d" xlink:to="loc_srt_ShareRepurchaseProgramDomain_1866a7ce-d696-4c29-a09b-142a2b54bb4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_6cc89c96-576c-44b7-b556-87a833e30961" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ShareRepurchaseProgramAxis_1866a7ce-d696-4c29-a09b-142a2b54bb4d" xlink:to="loc_srt_ShareRepurchaseProgramDomain_6cc89c96-576c-44b7-b556-87a833e30961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_RepurchaseProgramMember_62c257fc-5c50-4fa7-8854-53b12e3bd662" xlink:href="ccrn-20250331.xsd#ccrn_RepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_6cc89c96-576c-44b7-b556-87a833e30961" xlink:to="loc_ccrn_RepurchaseProgramMember_62c257fc-5c50-4fa7-8854-53b12e3bd662" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fd84908b-63d5-42cc-b1a0-71f2afa5126e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c68bd9e-1bd7-44da-88cf-4697c3caa584" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fd84908b-63d5-42cc-b1a0-71f2afa5126e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fd84908b-63d5-42cc-b1a0-71f2afa5126e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fd84908b-63d5-42cc-b1a0-71f2afa5126e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fd84908b-63d5-42cc-b1a0-71f2afa5126e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2c8203b4-899b-4b99-9e0e-5a0493b7f91f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fd84908b-63d5-42cc-b1a0-71f2afa5126e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2c8203b4-899b-4b99-9e0e-5a0493b7f91f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9f67cf89-5fa9-49ff-ac6e-ec57c0d69db4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2c8203b4-899b-4b99-9e0e-5a0493b7f91f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9f67cf89-5fa9-49ff-ac6e-ec57c0d69db4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9b234eb6-d696-4f52-9fb9-c7fee6038df5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c68bd9e-1bd7-44da-88cf-4697c3caa584" xlink:to="loc_us-gaap_AwardTypeAxis_9b234eb6-d696-4f52-9fb9-c7fee6038df5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b234eb6-d696-4f52-9fb9-c7fee6038df5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9b234eb6-d696-4f52-9fb9-c7fee6038df5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b234eb6-d696-4f52-9fb9-c7fee6038df5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a738dee0-88c9-44f2-b8a4-eb468c65f222" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9b234eb6-d696-4f52-9fb9-c7fee6038df5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a738dee0-88c9-44f2-b8a4-eb468c65f222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_RestrictedStockAndPerformanceSharesMember_2466d8b4-16d1-49e0-a955-1eaab368d1ad" xlink:href="ccrn-20250331.xsd#ccrn_RestrictedStockAndPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a738dee0-88c9-44f2-b8a4-eb468c65f222" xlink:to="loc_ccrn_RestrictedStockAndPerformanceSharesMember_2466d8b4-16d1-49e0-a955-1eaab368d1ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4a700c70-5685-4d48-bb61-27d5df189c12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ccrn_RestrictedStockAndPerformanceSharesMember_2466d8b4-16d1-49e0-a955-1eaab368d1ad" xlink:to="loc_us-gaap_PerformanceSharesMember_4a700c70-5685-4d48-bb61-27d5df189c12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f289fd7e-b2f6-48be-88a7-6a106aff878f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c68bd9e-1bd7-44da-88cf-4697c3caa584" xlink:to="loc_us-gaap_PlanNameAxis_f289fd7e-b2f6-48be-88a7-6a106aff878f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f289fd7e-b2f6-48be-88a7-6a106aff878f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f289fd7e-b2f6-48be-88a7-6a106aff878f" xlink:to="loc_us-gaap_PlanNameDomain_f289fd7e-b2f6-48be-88a7-6a106aff878f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_39225b34-b5d1-4710-8090-90eea3ebe074" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f289fd7e-b2f6-48be-88a7-6a106aff878f" xlink:to="loc_us-gaap_PlanNameDomain_39225b34-b5d1-4710-8090-90eea3ebe074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OmnibusPlanMember_c8c7c0bd-8da9-48a5-a17c-15747341bfca" xlink:href="ccrn-20250331.xsd#ccrn_OmnibusPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_39225b34-b5d1-4710-8090-90eea3ebe074" xlink:to="loc_ccrn_OmnibusPlanMember_c8c7c0bd-8da9-48a5-a17c-15747341bfca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount_a132e8f9-0582-4050-b0e8-68ff461532d6" xlink:href="ccrn-20250331.xsd#ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount_a132e8f9-0582-4050-b0e8-68ff461532d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_32867c2f-53b9-4562-a281-85c8ea40e87e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_32867c2f-53b9-4562-a281-85c8ea40e87e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_3a867e7b-2ff7-43a7-83b0-01a857fc6b50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_3a867e7b-2ff7-43a7-83b0-01a857fc6b50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_ca68e81c-d6a2-46dd-a836-850054fff94d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_ca68e81c-d6a2-46dd-a836-850054fff94d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_ed2b43e7-9a13-4531-8684-4888de91a717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_ed2b43e7-9a13-4531-8684-4888de91a717" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_StockRepurchasedDuringPeriodExciseTax_a76846d4-dd9a-4260-ba7f-ba19418eebe8" xlink:href="ccrn-20250331.xsd#ccrn_StockRepurchasedDuringPeriodExciseTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_ccrn_StockRepurchasedDuringPeriodExciseTax_a76846d4-dd9a-4260-ba7f-ba19418eebe8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8022b0d7-6fb5-48e7-8064-676496dba298" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8022b0d7-6fb5-48e7-8064-676496dba298" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3a7e8fe9-9000-42f4-b7b9-82c9e839e08c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3a7e8fe9-9000-42f4-b7b9-82c9e839e08c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage_16c0e0bc-22dc-4d91-a146-d2f1d795208b" xlink:href="ccrn-20250331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage_16c0e0bc-22dc-4d91-a146-d2f1d795208b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_150d9eff-0db6-42ee-84c7-9ea456cb0c82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_150d9eff-0db6-42ee-84c7-9ea456cb0c82" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_61ec624f-c1b9-4d54-9d88-e0b7d3bb7852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_61ec624f-c1b9-4d54-9d88-e0b7d3bb7852" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet_a0ebb90b-0ae8-445e-b0ec-0040c6e622a6" xlink:href="ccrn-20250331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet_a0ebb90b-0ae8-445e-b0ec-0040c6e622a6" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#STOCKHOLDERSEQUITYRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47b179bf-3886-40ca-b908-e6c205b5aed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88566985-58d2-4ca5-8716-67673d39a109" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47b179bf-3886-40ca-b908-e6c205b5aed3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88566985-58d2-4ca5-8716-67673d39a109" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_de5e4ea7-3628-4e26-9423-6320a1c76c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88566985-58d2-4ca5-8716-67673d39a109" xlink:to="loc_us-gaap_AwardTypeAxis_de5e4ea7-3628-4e26-9423-6320a1c76c1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_de5e4ea7-3628-4e26-9423-6320a1c76c1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_de5e4ea7-3628-4e26-9423-6320a1c76c1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_de5e4ea7-3628-4e26-9423-6320a1c76c1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6eb776ec-3ebd-46b7-b59e-564ff58ee0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_de5e4ea7-3628-4e26-9423-6320a1c76c1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6eb776ec-3ebd-46b7-b59e-564ff58ee0c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_82bbaf1f-48e5-4b2a-8ab5-e0e6f8c9b4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6eb776ec-3ebd-46b7-b59e-564ff58ee0c1" xlink:to="loc_us-gaap_RestrictedStockMember_82bbaf1f-48e5-4b2a-8ab5-e0e6f8c9b4bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_cfb9f40c-159b-4cac-a5e8-0f767569a1db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6eb776ec-3ebd-46b7-b59e-564ff58ee0c1" xlink:to="loc_us-gaap_PerformanceSharesMember_cfb9f40c-159b-4cac-a5e8-0f767569a1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97728236-c97a-4ea6-ac91-8c314bd6e286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47b179bf-3886-40ca-b908-e6c205b5aed3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97728236-c97a-4ea6-ac91-8c314bd6e286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ca8317f4-2e45-42c7-adf4-a3ba74aa696c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97728236-c97a-4ea6-ac91-8c314bd6e286" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ca8317f4-2e45-42c7-adf4-a3ba74aa696c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d7a33d2-0a72-4270-b624-6f4fba7ca94e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97728236-c97a-4ea6-ac91-8c314bd6e286" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d7a33d2-0a72-4270-b624-6f4fba7ca94e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a2b2ab9f-8c1b-4ccc-8cdb-d693768a7827" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97728236-c97a-4ea6-ac91-8c314bd6e286" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a2b2ab9f-8c1b-4ccc-8cdb-d693768a7827" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9896eaaf-f717-42f9-bfc8-cb81c50b9ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97728236-c97a-4ea6-ac91-8c314bd6e286" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9896eaaf-f717-42f9-bfc8-cb81c50b9ae8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2c038d93-70cf-4b70-bad2-298df0350904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0af8afd9-b88c-49cf-b531-93e4cc25c5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47b179bf-3886-40ca-b908-e6c205b5aed3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0af8afd9-b88c-49cf-b531-93e4cc25c5cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_727f683b-c04d-472e-b1f8-31c4b22da0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0af8afd9-b88c-49cf-b531-93e4cc25c5cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_727f683b-c04d-472e-b1f8-31c4b22da0f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4792c9b1-17bb-4efc-a4e8-01efbdb6fa86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0af8afd9-b88c-49cf-b531-93e4cc25c5cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4792c9b1-17bb-4efc-a4e8-01efbdb6fa86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f4643c76-2d62-4bac-a04e-a936f582307a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0af8afd9-b88c-49cf-b531-93e4cc25c5cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f4643c76-2d62-4bac-a04e-a936f582307a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_04edd97e-4f2b-4a58-b068-46c6cf69323d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0af8afd9-b88c-49cf-b531-93e4cc25c5cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_04edd97e-4f2b-4a58-b068-46c6cf69323d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_748b03ac-b6af-4cff-b4fe-e2e70ef77403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SEGMENTDATAAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_c24b5480-9427-419a-b798-adcb2b756da0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_eedbfe22-f482-4ccf-98e2-79b4ea89d63d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_c24b5480-9427-419a-b798-adcb2b756da0" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_eedbfe22-f482-4ccf-98e2-79b4ea89d63d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_eb77d046-4697-4e33-9ef9-61aed018972a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_eedbfe22-f482-4ccf-98e2-79b4ea89d63d" xlink:to="loc_srt_StatementGeographicalAxis_eb77d046-4697-4e33-9ef9-61aed018972a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_eb77d046-4697-4e33-9ef9-61aed018972a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_eb77d046-4697-4e33-9ef9-61aed018972a" xlink:to="loc_srt_SegmentGeographicalDomain_eb77d046-4697-4e33-9ef9-61aed018972a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4da75908-8315-42cf-aee2-af8dac27d682" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_eb77d046-4697-4e33-9ef9-61aed018972a" xlink:to="loc_srt_SegmentGeographicalDomain_4da75908-8315-42cf-aee2-af8dac27d682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_a7814192-6c8e-43ff-969e-686dec2dc494" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4da75908-8315-42cf-aee2-af8dac27d682" xlink:to="loc_country_IN_a7814192-6c8e-43ff-969e-686dec2dc494" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_784b659f-8e0e-4680-b17c-90839faa9606" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_eedbfe22-f482-4ccf-98e2-79b4ea89d63d" xlink:to="loc_srt_ConsolidationItemsAxis_784b659f-8e0e-4680-b17c-90839faa9606" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_784b659f-8e0e-4680-b17c-90839faa9606_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_784b659f-8e0e-4680-b17c-90839faa9606" xlink:to="loc_srt_ConsolidationItemsDomain_784b659f-8e0e-4680-b17c-90839faa9606_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_5e78fce1-fb1f-480c-a151-f3fb01684034" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_784b659f-8e0e-4680-b17c-90839faa9606" xlink:to="loc_srt_ConsolidationItemsDomain_5e78fce1-fb1f-480c-a151-f3fb01684034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_385edf4e-17e6-410c-8ee5-21fca4f52718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_5e78fce1-fb1f-480c-a151-f3fb01684034" xlink:to="loc_us-gaap_IntersegmentEliminationMember_385edf4e-17e6-410c-8ee5-21fca4f52718" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f5d980c1-354c-4c5a-a883-b0c3a1242aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_c24b5480-9427-419a-b798-adcb2b756da0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f5d980c1-354c-4c5a-a883-b0c3a1242aa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_2fcede98-2509-4ab5-87da-310dc4941b68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_c24b5480-9427-419a-b798-adcb2b756da0" xlink:to="loc_us-gaap_NumberOfReportableSegments_2fcede98-2509-4ab5-87da-310dc4941b68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_534af47a-33e7-40ca-b8a7-dd44f6f401d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_c24b5480-9427-419a-b798-adcb2b756da0" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_534af47a-33e7-40ca-b8a7-dd44f6f401d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6ad041d3-ddf1-4cf2-af45-a08dca79eef5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_c24b5480-9427-419a-b798-adcb2b756da0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6ad041d3-ddf1-4cf2-af45-a08dca79eef5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SEGMENTDATAOperatingSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_06fe532f-fe99-4204-9008-b4a0d09d43c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_06fe532f-fe99-4204-9008-b4a0d09d43c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a4d51b10-f698-4eab-a455-d06d452ec33f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_06fe532f-fe99-4204-9008-b4a0d09d43c5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a4d51b10-f698-4eab-a455-d06d452ec33f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a4d51b10-f698-4eab-a455-d06d452ec33f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a4d51b10-f698-4eab-a455-d06d452ec33f" xlink:to="loc_us-gaap_SegmentDomain_a4d51b10-f698-4eab-a455-d06d452ec33f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5e1691e3-63e6-4edc-b7ef-3b1ca05669a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a4d51b10-f698-4eab-a455-d06d452ec33f" xlink:to="loc_us-gaap_SegmentDomain_5e1691e3-63e6-4edc-b7ef-3b1ca05669a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NurseAndAlliedStaffingMember_40f93de8-f847-44ae-9382-2606ad057e63" xlink:href="ccrn-20250331.xsd#ccrn_NurseAndAlliedStaffingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5e1691e3-63e6-4edc-b7ef-3b1ca05669a2" xlink:to="loc_ccrn_NurseAndAlliedStaffingMember_40f93de8-f847-44ae-9382-2606ad057e63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PhysicianStaffingMember_2e01c101-2d87-4d06-973e-7ebe38fb62c4" xlink:href="ccrn-20250331.xsd#ccrn_PhysicianStaffingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5e1691e3-63e6-4edc-b7ef-3b1ca05669a2" xlink:to="loc_ccrn_PhysicianStaffingMember_2e01c101-2d87-4d06-973e-7ebe38fb62c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_cb40c9d4-85ff-4850-914d-20d2742e9248" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_06fe532f-fe99-4204-9008-b4a0d09d43c5" xlink:to="loc_srt_ConsolidationItemsAxis_cb40c9d4-85ff-4850-914d-20d2742e9248" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cb40c9d4-85ff-4850-914d-20d2742e9248_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_cb40c9d4-85ff-4850-914d-20d2742e9248" xlink:to="loc_srt_ConsolidationItemsDomain_cb40c9d4-85ff-4850-914d-20d2742e9248_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a70ca814-1601-4ed1-9757-c8c55c8f96cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_cb40c9d4-85ff-4850-914d-20d2742e9248" xlink:to="loc_srt_ConsolidationItemsDomain_a70ca814-1601-4ed1-9757-c8c55c8f96cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_a9575aae-9ab2-416e-9bf5-d63d03260c05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a70ca814-1601-4ed1-9757-c8c55c8f96cd" xlink:to="loc_us-gaap_OperatingSegmentsMember_a9575aae-9ab2-416e-9bf5-d63d03260c05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_3dc6598b-8366-466d-b7ea-69b8f5eaf96a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a70ca814-1601-4ed1-9757-c8c55c8f96cd" xlink:to="loc_us-gaap_CorporateNonSegmentMember_3dc6598b-8366-466d-b7ea-69b8f5eaf96a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0c8f15bc-5535-42d3-96a2-3a531fed5678" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0c8f15bc-5535-42d3-96a2-3a531fed5678" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectOperatingCosts_59d11bff-1b09-49fc-87ee-5b7ca59a4853" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_DirectOperatingCosts_59d11bff-1b09-49fc-87ee-5b7ca59a4853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense_036a9f32-866f-456b-b3fd-239414a33539" xlink:href="ccrn-20250331.xsd#ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense_036a9f32-866f-456b-b3fd-239414a33539" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BenefitsExpense_c501a2c0-a371-401d-bfab-3d17cb911c7c" xlink:href="ccrn-20250331.xsd#ccrn_BenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_ccrn_BenefitsExpense_c501a2c0-a371-401d-bfab-3d17cb911c7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingExpense_f2332958-1b70-4e6b-b3fe-60f3979f4cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_MarketingExpense_f2332958-1b70-4e6b-b3fe-60f3979f4cca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_1ca55e1f-721c-41e1-a59c-991aabd1c988" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_1ca55e1f-721c-41e1-a59c-991aabd1c988" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_715fe3f9-f298-4741-94dd-9381ce0be82c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_715fe3f9-f298-4741-94dd-9381ce0be82c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_d0bd244e-ad74-40fd-b84c-41a0dd5379d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_d0bd244e-ad74-40fd-b84c-41a0dd5379d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_7a8d68ee-3ade-4366-9d4d-8ce52c0cd1fb" xlink:href="ccrn-20250331.xsd#ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_7a8d68ee-3ade-4366-9d4d-8ce52c0cd1fb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SegmentReportingUnallocatedCorporateExpenses_b62a596e-be26-482c-ab37-d661c7f6a05b" xlink:href="ccrn-20250331.xsd#ccrn_SegmentReportingUnallocatedCorporateExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_ccrn_SegmentReportingUnallocatedCorporateExpenses_b62a596e-be26-482c-ab37-d661c7f6a05b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_60b058e2-e6fe-4e16-b45f-9602890417ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_60b058e2-e6fe-4e16-b45f-9602890417ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_934dd11f-b4a6-4731-b474-d9f4e5529d3b" xlink:href="ccrn-20250331.xsd#ccrn_AcquisitionAndIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_934dd11f-b4a6-4731-b474-d9f4e5529d3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_438d7e3a-47e8-4323-9e02-f40a0de77b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_us-gaap_RestructuringCharges_438d7e3a-47e8-4323-9e02-f40a0de77b7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LegalAndOtherLosses_5cd5b68e-23f1-4b6d-8074-7d52a6fe33c3" xlink:href="ccrn-20250331.xsd#ccrn_LegalAndOtherLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_ccrn_LegalAndOtherLosses_5cd5b68e-23f1-4b6d-8074-7d52a6fe33c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a8b4cc35-81d3-4515-9a55-37849f93c911" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_us-gaap_AssetImpairmentCharges_a8b4cc35-81d3-4515-9a55-37849f93c911" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_f25a59f2-8615-40ab-84f9-0f7178c4b6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_us-gaap_InterestExpenseNonoperating_f25a59f2-8615-40ab-84f9-0f7178c4b6bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_765c9a5b-f0d9-4d55-bdba-250e567b3030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_us-gaap_InvestmentIncomeInterest_765c9a5b-f0d9-4d55-bdba-250e567b3030" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2f2a8a22-c633-47c5-a921-74556f9dbcea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2f2a8a22-c633-47c5-a921-74556f9dbcea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6fe78f0-036a-4f85-8155-9e2c22e0c291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6fe78f0-036a-4f85-8155-9e2c22e0c291" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_00937b88-b4b7-4877-aa7f-713259a98904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_37e12906-4987-43df-afea-6bcff23080fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00937b88-b4b7-4877-aa7f-713259a98904" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_37e12906-4987-43df-afea-6bcff23080fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e0c35f5f-51e3-45f4-8a0b-1ec628680fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_37e12906-4987-43df-afea-6bcff23080fb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e0c35f5f-51e3-45f4-8a0b-1ec628680fa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e0c35f5f-51e3-45f4-8a0b-1ec628680fa9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e0c35f5f-51e3-45f4-8a0b-1ec628680fa9" xlink:to="loc_us-gaap_RelatedPartyDomain_e0c35f5f-51e3-45f4-8a0b-1ec628680fa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_06cce916-7f27-4d33-9550-0fa234993a84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e0c35f5f-51e3-45f4-8a0b-1ec628680fa9" xlink:to="loc_us-gaap_RelatedPartyDomain_06cce916-7f27-4d33-9550-0fa234993a84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_b6943eeb-8896-4245-ae43-cfc3855ba18c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_06cce916-7f27-4d33-9550-0fa234993a84" xlink:to="loc_us-gaap_RelatedPartyMember_b6943eeb-8896-4245-ae43-cfc3855ba18c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_712ca2a6-8b8f-43d6-8129-a017456f069c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_37e12906-4987-43df-afea-6bcff23080fb" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_712ca2a6-8b8f-43d6-8129-a017456f069c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_712ca2a6-8b8f-43d6-8129-a017456f069c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_712ca2a6-8b8f-43d6-8129-a017456f069c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_712ca2a6-8b8f-43d6-8129-a017456f069c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e4138970-f334-4533-b5ad-fc631f388da4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_712ca2a6-8b8f-43d6-8129-a017456f069c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e4138970-f334-4533-b5ad-fc631f388da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember_27131005-e1fe-4d42-9da0-57a2d4af675b" xlink:href="ccrn-20250331.xsd#ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e4138970-f334-4533-b5ad-fc631f388da4" xlink:to="loc_ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember_27131005-e1fe-4d42-9da0-57a2d4af675b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_03b595af-91cf-4b78-a93a-4053d6e61424" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00937b88-b4b7-4877-aa7f-713259a98904" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_03b595af-91cf-4b78-a93a-4053d6e61424" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ccrn-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:dd6031fa-8918-4f16-99cd-07b7064df9d2,g:a332f0b9-5dad-4d87-8e39-4baf62f16fbe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_23145b55-9b09-44af-bbb2-fcf7ec6498d4_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Borrowings under Senior Secured Asset-Based revolving credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_BenefitsExpense_d0da1bac-bfc2-4f0a-a440-eb01b6728b3f_terseLabel_en-US" xlink:label="lab_ccrn_BenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefits</link:label>
    <link:label id="lab_ccrn_BenefitsExpense_label_en-US" xlink:label="lab_ccrn_BenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benefits Expense</link:label>
    <link:label id="lab_ccrn_BenefitsExpense_documentation_en-US" xlink:label="lab_ccrn_BenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Benefits Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BenefitsExpense" xlink:href="ccrn-20250331.xsd#ccrn_BenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_BenefitsExpense" xlink:to="lab_ccrn_BenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0983a6e4-7eca-450c-94b1-ab00252c9c9b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0c087010-f787-474c-bba4-731b22029772_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5d444669-1237-4c90-92d5-4916cff80423_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_509bb122-1154-457d-9cbc-7a0bbc29e38c_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares amount left remaining to repurchase under the plan (up to)</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Remaining Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_fc8a46a7-1460-4d09-8310-8e7576ba4f15_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_758814b5-896d-49ca-b75f-be92ba8de6c8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_17b0aed4-b6ad-4887-b34f-5036fcd6710e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Lease Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_866fc2b8-adca-47ac-91ba-e11773b87c51_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_db07490a-d83a-403a-9b22-9b56f33bf91b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b5ab9a7a-d26a-4f3f-a385-8518d2156015_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_DeferredCompensationMember_c01b910b-ed81-4cdc-b0e6-80d502d182b5_terseLabel_en-US" xlink:label="lab_ccrn_DeferredCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation</link:label>
    <link:label id="lab_ccrn_DeferredCompensationMember_label_en-US" xlink:label="lab_ccrn_DeferredCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation [Member]</link:label>
    <link:label id="lab_ccrn_DeferredCompensationMember_documentation_en-US" xlink:label="lab_ccrn_DeferredCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DeferredCompensationMember" xlink:href="ccrn-20250331.xsd#ccrn_DeferredCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_DeferredCompensationMember" xlink:to="lab_ccrn_DeferredCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_240febaa-dfe9-48d6-ae2a-b122fa2ab782_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_fdb3fa87-0237-41a7-808a-a15aeedf39b1_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_533efc7d-ec97-482e-a730-1da0d2539fc5_terseLabel_en-US" xlink:label="lab_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite Lived And Indefinite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="ccrn-20250331.xsd#ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_48c3b610-3b20-4efc-88b7-925de274dd92_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_09a8651b-660b-4031-8fb3-032e6ab17094_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_84d4b26c-dfcb-4ff8-9f76-86ee9d08fce4_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_c5342555-1c1d-40a5-ab3c-ada141c4947f_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f4b6af90-353b-4dfd-bb57-7de4bdd3fc8e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_SwingLoansSublimitMember_56f74b24-0981-4992-b4f0-85145f65aca6_terseLabel_en-US" xlink:label="lab_ccrn_SwingLoansSublimitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swingline Sublimit</link:label>
    <link:label id="lab_ccrn_SwingLoansSublimitMember_label_en-US" xlink:label="lab_ccrn_SwingLoansSublimitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Swing Loans Sublimit [Member]</link:label>
    <link:label id="lab_ccrn_SwingLoansSublimitMember_documentation_en-US" xlink:label="lab_ccrn_SwingLoansSublimitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Swing Loans Sublimit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SwingLoansSublimitMember" xlink:href="ccrn-20250331.xsd#ccrn_SwingLoansSublimitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_SwingLoansSublimitMember" xlink:to="lab_ccrn_SwingLoansSublimitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_018b0964-1f7a-47f8-8611-e91dc4fa70ab_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_c9126c20-5b70-4817-98fb-c04a0cebb1af_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_b629708f-81ea-419d-9432-4b17e494ee2d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_76eebb5a-ff06-4bef-a47a-f31fd8c6c06f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6092ab90-3223-4ade-90c0-ff375001a980_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_fbe28177-9283-493b-aa50-30696f73340c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrestricted shares of common stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_2acc1d8c-6a48-47bb-91ee-0046c0ae857f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4a8c9121-b4c2-445c-b207-76bc32d70151_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ce152083-ce55-4295-b369-f39068e429ad_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities - non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_202ec62e-1669-483d-b876-cf757b4612b3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_d720e27b-052b-408e-a627-670afbc0713d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_33a87f8e-172f-4418-8aef-d16bd970ce5b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8412ab3e-d669-4b80-b47a-d344cc09ca06_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_c277342f-4ebd-419d-a03c-9581c6893758_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_2389d0fd-cc04-4eac-a6c7-1e800ea0df86_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_d0d4b6fa-9ac4-476f-98cb-91485c3c9019_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1e959c01-1205-4544-89b8-5107c19af900_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_64167d2f-e30c-4b89-adb8-e44f895cf919_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f6ef1c6e-0c0e-42b3-99bb-58967cb1a835_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_05e603e6-92aa-4ab0-8493-45c12adc70de_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dee52149-bed6-43f1-ab49-6367f8ac040c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_a11367d7-ddd4-426a-bf2e-f8bd5bc215b2_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intersegment Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c0c1c708-6c72-46a3-8c57-a53d6a45293b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_a4bf65dc-eba4-4e9d-853a-156f557bb1fc_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6cf3f63e-498b-4470-9caa-7b94c4e828bb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_84f14dd3-fa3e-4e91-8a83-a104539191d6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_126a35d3-48f6-4093-ad34-bab2469e65ff_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_e7481404-b7f9-445b-8127-1da51ca17909_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, net</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivableCurrent_3cdb7c02-7dcf-4d18-bc3e-3214cad1e73a_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance recovery receivable</link:label>
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Settlements Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:to="lab_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d622fbb5-adbd-4a32-844d-c3ec40d47849_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_SegmentReportingUnallocatedCorporateExpenses_102f4996-2210-48b5-8e02-6323c60335ce_terseLabel_en-US" xlink:label="lab_ccrn_SegmentReportingUnallocatedCorporateExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate overhead</link:label>
    <link:label id="lab_ccrn_SegmentReportingUnallocatedCorporateExpenses_label_en-US" xlink:label="lab_ccrn_SegmentReportingUnallocatedCorporateExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Unallocated Corporate Expenses</link:label>
    <link:label id="lab_ccrn_SegmentReportingUnallocatedCorporateExpenses_documentation_en-US" xlink:label="lab_ccrn_SegmentReportingUnallocatedCorporateExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment Reporting Unallocated Corporate Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SegmentReportingUnallocatedCorporateExpenses" xlink:href="ccrn-20250331.xsd#ccrn_SegmentReportingUnallocatedCorporateExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_SegmentReportingUnallocatedCorporateExpenses" xlink:to="lab_ccrn_SegmentReportingUnallocatedCorporateExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1e6c5ad4-977c-4b7c-a0f6-1d8a200330c1_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_a269ebd2-a7b1-4f25-a120-62a6e8edb60a_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4921f71b-f3a1-470a-98a4-bab52bfb8de5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_07ec3a5b-ab71-44d1-9cca-c0a66d0b5bfb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity consideration for acquisition, value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_99a90a5c-c02b-4466-82d7-ba6bf12ae59d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f36fea37-5f86-4f40-9881-b967ef90e3e6_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of profit or loss:</link:label>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_e6773ee6-65d4-4fa6-a006-57a778e2a7a1_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of states in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ff11aaf0-4d07-4674-9989-0878348b09b0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_73ddfa9b-baa2-4afd-a405-b444b2976749_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_9d13bac1-c5c0-4a58-a6da-cb80a28849e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Termination Costs and Lease-Related Exit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d7fa3a6-4ab1-4e03-80eb-fc5c46099d34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4db1a41b-bf8f-4594-900d-03a40e1b19c6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnout liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_acc9b3d5-e4e9-4f13-bf0c-1ba7308be383_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_441c1f75-ecf9-4017-97d1-f1e9ba553482_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based awards (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_9161fb8f-3a1e-4faf-af27-42fe3e83aa07_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_91a6f435-a318-4fbd-bb71-6215a00c9185_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f06d9e9a-25d3-43ea-87e2-58b518464c7e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_19e289f9-df36-4ec4-906a-848ba9932cfb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_80e967ca-511a-4c1e-83c0-05dcf0db191c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts and Financing Receivables [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d3378110-1eda-4246-a43a-1c900562e2b6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4724264c-d1f9-4c62-ad74-8e9570853302_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_73a0bbe4-5991-494c-8373-103cf241d92c_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_fb59eba4-9c4b-49a4-a55a-77de5a81996c_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_b94c2a0d-3c21-4b9f-a2c5-af348801ab5c_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_e7d119bd-f776-4fd2-b6d4-b856b1ba4ff0_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9c0fede7-a42b-47ce-92dc-b29d1b50c3dd_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_876c8151-14c7-4d0c-ad4b-50f15bab84e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7e380008-3897-438a-995a-a8dc93b0a7e0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_a0af10e3-1381-4a83-a445-89b358fe89e4_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_2dbaab30-fbc3-4a90-83cc-2170027db283_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease expense</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1298f1af-f18a-47e7-a1f0-57e2730451b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_cfe9820b-8ffe-4801-8e54-b72236a185d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7a0ab4b4-87d8-4c6f-adba-83e887687878_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock_c7636ec9-289d-40e8-b43a-a43be50def39_terseLabel_en-US" xlink:label="lab_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock_label_en-US" xlink:label="lab_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Leases [Table Text Block]</link:label>
    <link:label id="lab_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock_documentation_en-US" xlink:label="lab_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock" xlink:href="ccrn-20250331.xsd#ccrn_AssetsAndLiabilitiesLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock" xlink:to="lab_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f5ece831-a6b9-4dfd-897f-c3f175a0c7a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f03f290f-a096-4158-85e2-33783c7b3b19_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet_ab614a04-e47b-48b4-8e5f-91d077ebb2a7_terseLabel_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested in period, net (shares)</link:label>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet_label_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other than Options, Vested In Period, Net</link:label>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet_documentation_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other than Options, Vested In Period, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" xlink:href="ccrn-20250331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" xlink:to="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_RepurchaseProgramMember_1af6afb1-9f51-4a24-b509-aa344c54844d_terseLabel_en-US" xlink:label="lab_ccrn_RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase Program</link:label>
    <link:label id="lab_ccrn_RepurchaseProgramMember_label_en-US" xlink:label="lab_ccrn_RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Program [Member]</link:label>
    <link:label id="lab_ccrn_RepurchaseProgramMember_documentation_en-US" xlink:label="lab_ccrn_RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_RepurchaseProgramMember" xlink:href="ccrn-20250331.xsd#ccrn_RepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_RepurchaseProgramMember" xlink:to="lab_ccrn_RepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8fd27706-cb2a-4ba8-8976-bf1999d82505_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f5f452a6-189a-4631-b267-2c816fc1418f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest margin percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5fa8a5f7-01a5-4e26-ad2f-17dec67a8f5c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_9fd74302-da36-4c0d-9feb-8907f38c7646_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0dc6199b-3fe6-4376-85e8-f1df70f22fa5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_812eb680-59bd-4cdf-850c-9f60b8e70b2a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $21,837 in 2025 and $19,285 in 2024</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_59157fd0-13e2-4406-8e45-3b508b6a4861_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4813796f-4095-4523-b98c-c3c8dabbccab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_36ab0bf0-f2c7-4b58-bace-b2790b2faee1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4aad584c-308b-48b7-9804-735703047f58_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d21966b1-cd4b-4f2f-8af1-a98ffd96db9c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a343b03e-9cf0-4725-a672-5fc69b03c5a3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_06410b1a-bf42-4fb8-8b87-21bb5319e86f_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: operating lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_06a7f1c4-7097-41ec-8eaa-b47b0ad926a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f76b0c2a-ddb1-45c6-a5cb-d4022904934e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment_afc8a914-39d6-439b-9864-7def9d610d9d_terseLabel_en-US" xlink:label="lab_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate, additional credit spread associated with SOFR</link:label>
    <link:label id="lab_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment_label_en-US" xlink:label="lab_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread On Variable Rate, Adjustment</link:label>
    <link:label id="lab_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment_documentation_en-US" xlink:label="lab_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread On Variable Rate, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment" xlink:href="ccrn-20250331.xsd#ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment" xlink:to="lab_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8c97aae2-06d4-4f56-9dad-bdd99631417e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_c907c572-8dbc-4f50-8d64-cc4f571670f7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_ffee44e6-86c4-4028-a1cb-faf81ad56c65_terseLabel_en-US" xlink:label="lab_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Indefinite Lived And Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Indefinite Lived And Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_documentation_en-US" xlink:label="lab_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Indefinite Lived And Finite Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" xlink:href="ccrn-20250331.xsd#ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" xlink:to="lab_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_16c2b38b-e274-4336-a831-5d43f43f65b9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Accounting</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46cb7479-cf80-436a-973c-96a999727530_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c3519421-e1f4-483a-a248-088362d8aa5b_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares - Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b516d8c8-49a9-46d9-b5b0-183b8e228e4f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_94ce1ff8-ccb2-44af-9f86-9f004c41708f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_fe22b92b-75e0-4f99-a2f9-e89d85d9594b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_84d0b3a1-3181-455c-a5eb-6d068b45705a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4b12a518-a981-44c3-8ce2-355d56db2eeb_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LineOfCreditSublimitAxis_550bc731-8fa7-42aa-bb48-78c67ddb527c_terseLabel_en-US" xlink:label="lab_ccrn_LineOfCreditSublimitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line Of Credit Sublimit [Axis]</link:label>
    <link:label id="lab_ccrn_LineOfCreditSublimitAxis_label_en-US" xlink:label="lab_ccrn_LineOfCreditSublimitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Sublimit [Axis]</link:label>
    <link:label id="lab_ccrn_LineOfCreditSublimitAxis_documentation_en-US" xlink:label="lab_ccrn_LineOfCreditSublimitAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line Of Credit Sublimit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditSublimitAxis" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditSublimitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LineOfCreditSublimitAxis" xlink:to="lab_ccrn_LineOfCreditSublimitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_b928eb48-78ae-48f9-bd0b-1115088a158a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_f5f14749-f414-4886-9a1b-f3d8a904a8ee_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_210983cf-f231-4b36-b84c-a34d8f62d6ed_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_62be361f-554f-4fed-839d-76d6e52660e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_0f2e6204-9402-4b69-acc6-428b52304a0e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_ee28a6c5-1da3-48aa-8a61-8ad05a330d73_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letters of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_af77f8f4-b190-49fc-97a3-5c5a14cf4577_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a9f9825b-83e2-43f3-bb20-29097ddb20aa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of allowances of $9,792 in 2025 and $9,301 in 2024</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e74260a-f838-44f8-91f7-952b0e5776ff_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d31777bc-d9ab-44cb-9e00-f168983c11a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_6a02fa24-7186-439e-adab-32f69bf1e969_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_ab4be44d-dcb1-4768-8461-d537b963d5bd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_1edf7640-270f-4e62-b1e2-3050fdd84fcd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_336b6d3d-28e6-4682-a074-acc8cd10eee5_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based awards (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d743bf1e-ef7c-4d3b-af0c-d861c01a9343_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_PhysicianStaffingMember_0e5642bc-6ec3-480f-8d53-c1b4f9c583e8_terseLabel_en-US" xlink:label="lab_ccrn_PhysicianStaffingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Physician Staffing</link:label>
    <link:label id="lab_ccrn_PhysicianStaffingMember_label_en-US" xlink:label="lab_ccrn_PhysicianStaffingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Physician Staffing [Member]</link:label>
    <link:label id="lab_ccrn_PhysicianStaffingMember_documentation_en-US" xlink:label="lab_ccrn_PhysicianStaffingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Physician staffing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PhysicianStaffingMember" xlink:href="ccrn-20250331.xsd#ccrn_PhysicianStaffingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_PhysicianStaffingMember" xlink:to="lab_ccrn_PhysicianStaffingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0571662b-7949-4650-bd19-17fa9dfd60b4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_63a05e96-4be2-44c1-a8b3-9c1e66e91039_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_98ce8234-80a6-4f69-9a95-ca1391f1009f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_981e556c-c72d-472d-b3f6-74f53fa3202a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7267359b-d823-4844-9c6f-024d9e4fe4cf_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average market price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4ac5e4aa-badb-4dbd-8ae7-de4e848906f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2c6b2727-0e47-4183-a22f-ae2da07e8fba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_e58ae0c8-60b4-4e57-afbf-2fa11eded413_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Annual Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_18701323-72ba-4e48-9995-b65604ad5d45_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_3f7e2164-7b13-4786-b8ff-1e7408f448d5_totalLabel_en-US" xlink:label="lab_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Contribution Income</link:label>
    <link:label id="lab_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_label_en-US" xlink:label="lab_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income Loss Before D And A Acquisition And Integration Restructuring Legal Impairment And Corporate Overheard</link:label>
    <link:label id="lab_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_documentation_en-US" xlink:label="lab_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Income Loss Before D And A Acquisition And Integration Restructuring Legal Impairment And Corporate Overheard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard" xlink:href="ccrn-20250331.xsd#ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard" xlink:to="lab_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_79cdc0c8-f55a-4c06-b7e8-65ad1286c5af_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a7f7745a-926e-4849-a7e8-488ccd45e5b4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_62872a26-cc73-498a-896c-7c505fe61781_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_3de30ca5-fdc0-481c-88da-775be68d9cdc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_93aaee95-c3dd-4124-996d-433993674241_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7ec1af0e-8e3d-43a2-92b3-6a452e79b257_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: amount of lease payments representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3619a705-da9a-4b02-9463-f10c4065987b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_d8bb2b85-b901-4f28-b469-e5b006223a43_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of diluted shares:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9d6837ca-7e18-42b1-9227-151fd14d106b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6574c4be-c8aa-4074-8a85-b088bfa24379_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db10e4c-344d-42bd-8c8e-329843cce68f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount_05037cc6-e8f3-4617-8f4b-c107f4bcb0d1_terseLabel_en-US" xlink:label="lab_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional authorized amount</link:label>
    <link:label id="lab_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount_label_en-US" xlink:label="lab_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Additional Authorized Amount</link:label>
    <link:label id="lab_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount_documentation_en-US" xlink:label="lab_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Additional Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount" xlink:href="ccrn-20250331.xsd#ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount" xlink:to="lab_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_4593eb34-f04d-4ad9-b068-7ac6f3cfb619_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c8d19115-e8ca-42ef-93de-d76537b7d2d0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_f61f9f55-c8b3-4040-a3c8-373ea2f39761_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable and other lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_209258fe-7ae2-4a99-a43f-21497d30be88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_cd9a8edb-df05-421a-8e8f-f898d032c3e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_c2359753-2d4e-43b9-9a49-feca4eaf934c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8110b150-1afa-40cd-91b9-bedeb4991187_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax_81b30b2f-3199-49a2-8ea3-7a3119cb8356_negatedTerseLabel_en-US" xlink:label="lab_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on currency fluctuations</link:label>
    <link:label id="lab_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax_label_en-US" xlink:label="lab_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Before Tax</link:label>
    <link:label id="lab_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax_documentation_en-US" xlink:label="lab_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" xlink:href="ccrn-20250331.xsd#ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" xlink:to="lab_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_79ae831e-1423-4f08-bdec-7a1bd48fdb7a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit term</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_46279a34-d104-46e7-bd74-55b75c220bd1_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_db7fa128-ee80-4d31-acbe-59d80987169f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0020341c-6f76-4eab-827d-a2177700e833_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per share attributable to common stockholders - Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4c472f5d-eb8d-490b-a217-5fac1023b5ef_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per share attributable to common stockholders - Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bc7a0fbe-2805-4b2f-bc5a-0fce31aa520e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f9b233ab-fba6-4590-8bc3-433a548343fb_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_251c11a1-635c-4f5d-99aa-347c34f28782_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_TemporaryStaffingServicesMember_ec9cf14f-f07c-480a-ac62-d7ea318cba17_terseLabel_en-US" xlink:label="lab_ccrn_TemporaryStaffingServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Staffing Services</link:label>
    <link:label id="lab_ccrn_TemporaryStaffingServicesMember_label_en-US" xlink:label="lab_ccrn_TemporaryStaffingServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Staffing Services [Member]</link:label>
    <link:label id="lab_ccrn_TemporaryStaffingServicesMember_documentation_en-US" xlink:label="lab_ccrn_TemporaryStaffingServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Staffing Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_TemporaryStaffingServicesMember" xlink:href="ccrn-20250331.xsd#ccrn_TemporaryStaffingServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_TemporaryStaffingServicesMember" xlink:to="lab_ccrn_TemporaryStaffingServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_df6fa58e-4b5f-40ff-a18e-257c71fbc121_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f4d587e3-ae3f-4f16-92a2-319839e90d74_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5fe4aee2-4374-45f0-9e4e-918b49507ab9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_cdd0f7eb-fed9-46f0-9b4f-b0dc3e11120e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_f69d1e89-f450-452b-94a5-a88058ccd5f0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Termination Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b566ba3a-5726-4ea6-bff6-02019001f294_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e21090a5-c545-460d-abfe-6ff661fdc9f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9ea487d4-533b-40ba-bfbb-88c20515ac56_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_58ecaf05-a1f9-41ed-a038-c3235551bb47_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expenses (income):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_20006f51-876e-4f1d-806e-e7380b7a9fff_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Corporate Nonsegment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_6bf3d918-f5dc-40c1-9424-eb364e134729_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_72d4cf5f-a376-46b3-ab7c-356637f59b9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9a1bf6a0-bed6-48bd-97a1-5ba4dee9571f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income attributable to common stockholders - Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities_66d4f646-4bf2-44fc-8cb0-d5efda6548b9_terseLabel_en-US" xlink:label="lab_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="ccrn-20250331.xsd#ccrn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_258e7571-5eec-4299-a0dd-1b78cb7c587a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from services</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7833e3d5-3bf9-40ff-bbcf-71cbfe663b71_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from services</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7c5b1906-056c-40f3-993a-2831160fda29_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_16085c03-2175-4e78-8004-0a77f200f5ac_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_49883f9b-9c6a-49a6-9579-4154832a10f0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_6a1dfa4e-da35-4297-af93-eda35296d22c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_1a2ee93f-c3f2-4fcc-9ca8-3bba1d2f76ff_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_5327658d-f254-42af-bd51-7fae7ab6bf16_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8a669785-5bed-4858-8593-666c05bca3c4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_40bd13b0-b15c-4efe-af72-e7b31668f0ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_de36fb3d-ba64-4c1c-866d-182b58f452dd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_212e057d-1466-4241-b50a-2343932b94d8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_22a1e113-8c8f-4c89-857c-b23c29239f1e_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Charged to restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8d37805b-012c-4430-ada8-0fcf8a66c285_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_ae86288b-6fe6-4446-a973-97b11dab9dbf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4a7bcf8-3b7b-4587-a50d-c6f24c8f452a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_6eedb71c-dfb0-484e-8f87-233a1d761259_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_CloudComputingNoncurrent_d2643caa-5cdf-417f-a872-5ac0af3d47d5_terseLabel_en-US" xlink:label="lab_ccrn_CloudComputingNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cloud computing</link:label>
    <link:label id="lab_ccrn_CloudComputingNoncurrent_label_en-US" xlink:label="lab_ccrn_CloudComputingNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cloud Computing, Noncurrent</link:label>
    <link:label id="lab_ccrn_CloudComputingNoncurrent_documentation_en-US" xlink:label="lab_ccrn_CloudComputingNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cloud Computing, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_CloudComputingNoncurrent" xlink:href="ccrn-20250331.xsd#ccrn_CloudComputingNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_CloudComputingNoncurrent" xlink:to="lab_ccrn_CloudComputingNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a62f6c7f-bd05-4857-a98f-4f5e465ce35e_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets acquired under operating lease</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable_9f55539e-8390-41d4-92aa-4f9fb79aed3f_terseLabel_en-US" xlink:label="lab_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing base, percentage of accounts receivable</link:label>
    <link:label id="lab_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable_label_en-US" xlink:label="lab_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit, Borrowing Base, Percentage Of Accounts Receivable</link:label>
    <link:label id="lab_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable_documentation_en-US" xlink:label="lab_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line Of Credit, Borrowing Base, Percentage Of Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable" xlink:to="lab_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_2ba7d947-95d8-4d19-9593-66a663ee025a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e73e8d47-2ed1-45b1-a7a9-53dc0bd49f59_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_206f9a27-4fa6-44db-be3d-7e0b9038768b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_4b0427f1-cc08-452c-829a-e0df22c61733_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1a33c2f7-e482-460b-93bf-49627b47ede3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6750a10b-decc-4f20-8569-0013dc19e2da_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_6d021323-cd52-4eae-980e-a836f720afa8_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Information on Operating Segments and Reconciliation to (Loss) Income from Operations</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_57026ab8-b85c-4d85-80a5-556f93bf60d9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_f78106ce-482c-4507-b253-7666d17803c9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_870b921c-7ade-400d-b91b-7947393c63af_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock awards, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d65a1c39-f46d-4717-888d-0eee2cc295c5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock awards, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LineOfCreditFacilityBorrowingBaseAvailability_f521b582-9fc1-47ae-a647-0f67d92fd0ec_terseLabel_en-US" xlink:label="lab_ccrn_LineOfCreditFacilityBorrowingBaseAvailability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing base availability</link:label>
    <link:label id="lab_ccrn_LineOfCreditFacilityBorrowingBaseAvailability_label_en-US" xlink:label="lab_ccrn_LineOfCreditFacilityBorrowingBaseAvailability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Borrowing Base Availability</link:label>
    <link:label id="lab_ccrn_LineOfCreditFacilityBorrowingBaseAvailability_documentation_en-US" xlink:label="lab_ccrn_LineOfCreditFacilityBorrowingBaseAvailability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Borrowing Base Availability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditFacilityBorrowingBaseAvailability" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditFacilityBorrowingBaseAvailability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LineOfCreditFacilityBorrowingBaseAvailability" xlink:to="lab_ccrn_LineOfCreditFacilityBorrowingBaseAvailability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfdb8261-f27b-4370-97a2-b1f01cf8e24d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LineOfCreditSublimitDomain_c1bec57d-7190-4267-8a64-cc2a5617fc28_terseLabel_en-US" xlink:label="lab_ccrn_LineOfCreditSublimitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line Of Credit Sublimit [Domain]</link:label>
    <link:label id="lab_ccrn_LineOfCreditSublimitDomain_label_en-US" xlink:label="lab_ccrn_LineOfCreditSublimitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Sublimit [Domain]</link:label>
    <link:label id="lab_ccrn_LineOfCreditSublimitDomain_documentation_en-US" xlink:label="lab_ccrn_LineOfCreditSublimitDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Line Of Credit Sublimit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditSublimitDomain" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditSublimitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LineOfCreditSublimitDomain" xlink:to="lab_ccrn_LineOfCreditSublimitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ce54012a-3ea2-439c-875f-87cbe5e5712e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_cdd96551-4959-42d9-a683-43052c82bea4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_OperatingLeaseExpenseNonCash_435536f8-ee22-483c-99e4-da9dda7df32d_terseLabel_en-US" xlink:label="lab_ccrn_OperatingLeaseExpenseNonCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_ccrn_OperatingLeaseExpenseNonCash_label_en-US" xlink:label="lab_ccrn_OperatingLeaseExpenseNonCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Expense, Non-Cash</link:label>
    <link:label id="lab_ccrn_OperatingLeaseExpenseNonCash_documentation_en-US" xlink:label="lab_ccrn_OperatingLeaseExpenseNonCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Expense, Non-Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OperatingLeaseExpenseNonCash" xlink:href="ccrn-20250331.xsd#ccrn_OperatingLeaseExpenseNonCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_OperatingLeaseExpenseNonCash" xlink:to="lab_ccrn_OperatingLeaseExpenseNonCash" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_RestrictedStockAndPerformanceSharesMember_f0665f58-6120-4c16-9147-64ed1f9e3f24_terseLabel_en-US" xlink:label="lab_ccrn_RestrictedStockAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock And Performance Shares</link:label>
    <link:label id="lab_ccrn_RestrictedStockAndPerformanceSharesMember_label_en-US" xlink:label="lab_ccrn_RestrictedStockAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock And Performance Shares [Member]</link:label>
    <link:label id="lab_ccrn_RestrictedStockAndPerformanceSharesMember_documentation_en-US" xlink:label="lab_ccrn_RestrictedStockAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock And Performance Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_RestrictedStockAndPerformanceSharesMember" xlink:href="ccrn-20250331.xsd#ccrn_RestrictedStockAndPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_RestrictedStockAndPerformanceSharesMember" xlink:to="lab_ccrn_RestrictedStockAndPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_eaee1d86-7741-461d-82c3-8ec37980eb9f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_61d6e355-f9cf-411b-96c9-528b6244a3b2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_411c1b8d-c6a6-4dcd-894e-1e3a756e8b14_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit loss expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_c1bdc426-acbb-4300-b94f-61dde13fc5c0_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Credit loss (income) expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_0ddb4682-61c3-41bf-ac4d-a540a2f91b6d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_FairValueMeasurementTable_5f3e7a38-12f8-4f5d-87cb-fd80a472b27e_terseLabel_en-US" xlink:label="lab_ccrn_FairValueMeasurementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Table]</link:label>
    <link:label id="lab_ccrn_FairValueMeasurementTable_label_en-US" xlink:label="lab_ccrn_FairValueMeasurementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Table]</link:label>
    <link:label id="lab_ccrn_FairValueMeasurementTable_documentation_en-US" xlink:label="lab_ccrn_FairValueMeasurementTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FairValueMeasurementTable" xlink:href="ccrn-20250331.xsd#ccrn_FairValueMeasurementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_FairValueMeasurementTable" xlink:to="lab_ccrn_FairValueMeasurementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_9be4d84c-fef6-440b-8315-ad56cbad25b1_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_021735af-2c29-4e55-8e2b-45d7c05006e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Obligations, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_424ce6b5-0788-437d-8bfd-05bd73f4e0e2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_564d3af3-f0d2-4dec-9097-6948f8060679_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4c3b5fec-db7c-421f-bbb9-67898cda44a8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b8c5f7d0-09b6-40e8-b591-2c13955194f0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a9954dda-df39-4607-866a-49006d49f58c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery_e4798c26-11e8-48ea-a12f-dee1cef9f308_negatedLabel_en-US" xlink:label="lab_ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Write-Offs, net of Recoveries</link:label>
    <link:label id="lab_ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery_label_en-US" xlink:label="lab_ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance For Credit Loss, Writeoff, After Recovery</link:label>
    <link:label id="lab_ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery_documentation_en-US" xlink:label="lab_ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance For Credit Loss, Writeoff, After Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery" xlink:href="ccrn-20250331.xsd#ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery" xlink:to="lab_ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage_5e85b902-944b-4ebc-abb1-5ec64256b1b5_terseLabel_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance attainment percentage</link:label>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage_label_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Attainment Percentage</link:label>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage_documentation_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Target Attainment Level, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" xlink:href="ccrn-20250331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" xlink:to="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances_22be8caa-f309-4bc8-98ad-0fcac84cdeaf_verboseLabel_en-US" xlink:label="lab_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Provision for allowances</link:label>
    <link:label id="lab_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances_label_en-US" xlink:label="lab_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision For Doubtful Accounts And Other Allowances</link:label>
    <link:label id="lab_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances_documentation_en-US" xlink:label="lab_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provision For Doubtful Accounts And Other Allowances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances" xlink:href="ccrn-20250331.xsd#ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances" xlink:to="lab_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_5774e418-bc5e-4acc-9451-449c6e87b24e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_18fe3a1a-10f1-4791-aaf0-404e50397940_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_317d9d5f-327e-4048-a441-12db461dc856_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_35105be6-bf17-40ff-885f-635c7c3dab12_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_a04fbc42-17bb-4aad-bc33-77b7d99827b8_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6756c399-a9d5-4215-adb3-baa59fc09668_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_044ceb1e-a8bd-4656-b6f0-aed5429a2858_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_992260c6-1a81-44c7-b7dd-d94ae273f56a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent_9c7573e4-1a28-47ae-8d2c-c08dd11a63e8_terseLabel_en-US" xlink:label="lab_ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate, excluding discrete items</link:label>
    <link:label id="lab_ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent_label_en-US" xlink:label="lab_ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Excluding Discrete Items, Percent</link:label>
    <link:label id="lab_ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent_documentation_en-US" xlink:label="lab_ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Excluding Discrete Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent" xlink:href="ccrn-20250331.xsd#ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent" xlink:to="lab_ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_8ba8ac99-3843-4e58-9c0c-e3f6cb1d74ec_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly commitment fee on the average daily unused portion percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_33d1b03c-ad8f-42f2-a481-96b675de1a12_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_SeniorSecuredAssetBasedLoanMember_8376662a-cc50-4aff-b906-8ad6a5ce7757_terseLabel_en-US" xlink:label="lab_ccrn_SeniorSecuredAssetBasedLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Secured Asset-Based Loan</link:label>
    <link:label id="lab_ccrn_SeniorSecuredAssetBasedLoanMember_label_en-US" xlink:label="lab_ccrn_SeniorSecuredAssetBasedLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Secured Asset-Based Loan [Member]</link:label>
    <link:label id="lab_ccrn_SeniorSecuredAssetBasedLoanMember_documentation_en-US" xlink:label="lab_ccrn_SeniorSecuredAssetBasedLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Secured Asset-Based Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SeniorSecuredAssetBasedLoanMember" xlink:href="ccrn-20250331.xsd#ccrn_SeniorSecuredAssetBasedLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_SeniorSecuredAssetBasedLoanMember" xlink:to="lab_ccrn_SeniorSecuredAssetBasedLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11bd1f99-724b-423e-89e7-5580884124f1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for share-based payments (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_85cdc1c1-2d9d-42b6-aa2d-b306805a85cb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_5d0e06f0-e910-4721-b31c-cf8faddd2c36_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_381768b3-3de5-4d3d-8e44-f52c4dab6c19_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_ac787b10-862c-452d-902c-8d826e866c59_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_SalesAllowanceBillingRelatedAdjustments_fbae039b-879a-4fe1-a81c-12e405e02e62_terseLabel_en-US" xlink:label="lab_ccrn_SalesAllowanceBillingRelatedAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales allowance, billing-related adjustments</link:label>
    <link:label id="lab_ccrn_SalesAllowanceBillingRelatedAdjustments_label_en-US" xlink:label="lab_ccrn_SalesAllowanceBillingRelatedAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Allowance, Billing-Related Adjustments</link:label>
    <link:label id="lab_ccrn_SalesAllowanceBillingRelatedAdjustments_documentation_en-US" xlink:label="lab_ccrn_SalesAllowanceBillingRelatedAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Allowance, Billing-Related Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SalesAllowanceBillingRelatedAdjustments" xlink:href="ccrn-20250331.xsd#ccrn_SalesAllowanceBillingRelatedAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_SalesAllowanceBillingRelatedAdjustments" xlink:to="lab_ccrn_SalesAllowanceBillingRelatedAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8f2ecff3-075c-4f5d-aeca-f5aa1e6558f4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84ee2208-03d8-4aea-91a5-4d74fb227d86_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_4ba54170-24d0-4b6a-81e9-477be43b158e_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_11814ea5-d7d0-4e4f-ba71-e9485a822b5d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity consideration for acquisition (shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_AyaHoldingsIIInc.Member_852c7dc6-73a3-4de1-aad1-254e20bec819_terseLabel_en-US" xlink:label="lab_ccrn_AyaHoldingsIIInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aya Holdings II Inc.</link:label>
    <link:label id="lab_ccrn_AyaHoldingsIIInc.Member_label_en-US" xlink:label="lab_ccrn_AyaHoldingsIIInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aya Holdings II Inc. [Member]</link:label>
    <link:label id="lab_ccrn_AyaHoldingsIIInc.Member_documentation_en-US" xlink:label="lab_ccrn_AyaHoldingsIIInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aya Holdings II Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AyaHoldingsIIInc.Member" xlink:href="ccrn-20250331.xsd#ccrn_AyaHoldingsIIInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_AyaHoldingsIIInc.Member" xlink:to="lab_ccrn_AyaHoldingsIIInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b068eb88-18a8-4556-b13c-89be237904a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_29553fb7-c2ab-476d-9f82-df68dfebd6c3_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramDomain" xlink:to="lab_srt_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9b147307-8c6b-4fd3-b4bb-5e827dea8ddd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_910cf744-30a8-4109-9c06-71866650f8bc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_a989d464-b7b6-426f-83d0-e22e4969c377_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_412a151e-a106-4b41-858d-a0f842d3cd97_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_78d1e1ae-a510-4b14-a518-540c3770cf8c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross increase to current year unrecognized tax benefits related to federal and state tax issues</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_647b3e67-d7c6-4a27-b2f1-2333c5e3e5e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fa83a7de-8041-4167-acdf-e7a3f0048b2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_c2dccabe-2e62-4035-ab2a-65993c87380f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_90684c61-69ed-407c-8e84-2ed765b9a02b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_a9bbf099-facd-41cf-ad39-7f4b21166c6a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d5e02fad-e9d8-49bd-895b-20a5b1acdbfa_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_1b8c3f35-df57-44bf-826f-d628e63503d7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment items</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided_592c9069-b28c-4716-8f22-4b2c1a803cb7_terseLabel_en-US" xlink:label="lab_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold period, past due for payment of services provided</link:label>
    <link:label id="lab_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided_label_en-US" xlink:label="lab_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Period, Past Due For Payment Of Services Provided</link:label>
    <link:label id="lab_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided_documentation_en-US" xlink:label="lab_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold Period, Past Due For Payment Of Services Provided</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided" xlink:href="ccrn-20250331.xsd#ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided" xlink:to="lab_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1edaac56-3443-48b8-9857-21039e28f408_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d272e572-7165-4639-bfac-bcb29992881b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_922ce124-b295-48b3-a587-e1d25fbded57_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEGMENT DATA</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c559d131-5bcc-4635-8d31-1a0a63a59e12_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_03ce9d53-8dec-4f2f-87a0-33c53513e9d5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a3459023-1377-4060-9d23-416d944c3fbe_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2088d7ba-42ef-48de-813f-867ee74233d9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_RisksAndUncertaintiesPolicyTextBlock_9e924ce7-c792-4759-bbd1-0e157dcf72c4_terseLabel_en-US" xlink:label="lab_ccrn_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_ccrn_RisksAndUncertaintiesPolicyTextBlock_label_en-US" xlink:label="lab_ccrn_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks And Uncertainties [Policy Text Block]</link:label>
    <link:label id="lab_ccrn_RisksAndUncertaintiesPolicyTextBlock_documentation_en-US" xlink:label="lab_ccrn_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risks And Uncertainties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_RisksAndUncertaintiesPolicyTextBlock" xlink:href="ccrn-20250331.xsd#ccrn_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_RisksAndUncertaintiesPolicyTextBlock" xlink:to="lab_ccrn_RisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_15d426c9-5316-4586-9029-cd53b7633ee9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember_8af376b4-c041-4a55-8d3d-180bec8a5776_terseLabel_en-US" xlink:label="lab_ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Services Provided Entities Affiliated With Board Members</link:label>
    <link:label id="lab_ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember_label_en-US" xlink:label="lab_ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Services Provided Entities Affiliated With Board Members [Member]</link:label>
    <link:label id="lab_ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember_documentation_en-US" xlink:label="lab_ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Services Provided Entities Affiliated With Board Members</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember" xlink:href="ccrn-20250331.xsd#ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember" xlink:to="lab_ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_73addc96-c242-443a-8cc2-21ae7e7ddbd6_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_c61c2004-55e9-416c-9c13-e12aaf9c7b36_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_79d3c3f5-6a62-423d-aa4c-437575f9bd23_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_11c0f2b4-3d7e-4295-9bce-b6dd172cecc7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_90afaafe-61cf-49c6-82f4-e2fc2fc762a6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_10617bfa-921c-4d14-a6ef-3e94ce76cc3e_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IN_5416cf15-6aae-4630-ad75-38127317a8b3_terseLabel_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INDIA</link:label>
    <link:label id="lab_country_IN_label_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INDIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IN" xlink:to="lab_country_IN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_b96926d5-70b4-42d5-be61-ff0b4d89bed7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnout liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a4b33c85-460d-4734-b6a1-91cc684b103c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_HireUpLeadershipIncMember_94d5b9fd-77fc-4439-81f6-c033bb486fcb_terseLabel_en-US" xlink:label="lab_ccrn_HireUpLeadershipIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HireUp</link:label>
    <link:label id="lab_ccrn_HireUpLeadershipIncMember_label_en-US" xlink:label="lab_ccrn_HireUpLeadershipIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HireUp Leadership Inc [Member]</link:label>
    <link:label id="lab_ccrn_HireUpLeadershipIncMember_documentation_en-US" xlink:label="lab_ccrn_HireUpLeadershipIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">HireUp Leadership Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_HireUpLeadershipIncMember" xlink:href="ccrn-20250331.xsd#ccrn_HireUpLeadershipIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_HireUpLeadershipIncMember" xlink:to="lab_ccrn_HireUpLeadershipIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3cf22537-f41f-46de-9e46-a5cae59254f3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_1a793395-bf1a-4235-8a0a-c9d11898c750_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_8ea9d00e-fd53-47b4-82f7-6e5f63925ca3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_90a2363f-d66c-4a86-ad52-4e461e979973_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase and retirement</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_4fe7cbb5-35d9-4de5-8218-0d7963e9a528_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_96c3df73-0344-43d5-8eda-8d4ac3c35783_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_72a22e8d-566c-4843-936b-8650b741f0e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_3fb309c4-192e-469a-b003-8e368f953786_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase and retirement</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_3bdb168c-f2f6-4f63-8ece-9eaf3a3392b4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase and retirement</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3c9700f3-efd2-436a-96f7-62c7ae6a2f9d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2abd2179-0dc8-439f-8fef-8005689e2e12_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_c82b26ab-562c-41fb-b704-47bd9ee5df96_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_8d33b64c-6055-4341-842e-e3c8b22451d2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7a66bf1b-956e-4e52-9bd7-155c21b22483_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_573539bc-4e40-4db3-83f9-969e2f98180c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase and retirement (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_fe4cabb0-29e8-4803-8c5e-b07484b7121d_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased and retired (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_a64030de-bb00-4867-9d8e-aea42bd5f6e0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_a407eca7-f3eb-4de2-be67-8e3939fac2d2_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayments on Senior Secured Asset-Based revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8cb4ba45-1de8-4efb-8441-acfd4e397ee5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divisional corporate G&amp;A</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6728c2ad-fc92-489f-b82a-bed99db86dd0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_938fbdeb-4fe9-47a5-adf9-2c08ab17046e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_6b6fd1e9-6d65-46fa-a1ca-b55d888ddc52_terseLabel_en-US" xlink:label="lab_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="ccrn-20250331.xsd#ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f56f9d31-6eee-42ae-b836-04b58a57c461_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Present value of future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_fd16b0eb-86bf-487b-8627-60653b2f315c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_1f27d05c-6856-418f-b246-3905d7288ceb_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Stock Awards</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_NurseAndAlliedStaffingMember_1c19358d-0652-490a-9af7-14f5546bcb0d_verboseLabel_en-US" xlink:label="lab_ccrn_NurseAndAlliedStaffingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Nurse And Allied Staffing</link:label>
    <link:label id="lab_ccrn_NurseAndAlliedStaffingMember_label_en-US" xlink:label="lab_ccrn_NurseAndAlliedStaffingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nurse And Allied Staffing [Member]</link:label>
    <link:label id="lab_ccrn_NurseAndAlliedStaffingMember_documentation_en-US" xlink:label="lab_ccrn_NurseAndAlliedStaffingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nurse and allied staffing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NurseAndAlliedStaffingMember" xlink:href="ccrn-20250331.xsd#ccrn_NurseAndAlliedStaffingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_NurseAndAlliedStaffingMember" xlink:to="lab_ccrn_NurseAndAlliedStaffingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_b517f610-73d4-463f-909f-b4609af489eb_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DirectOperatingCosts_43a18ac4-c240-401f-b2e4-396e4b896572_terseLabel_en-US" xlink:label="lab_us-gaap_DirectOperatingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Direct operating expenses</link:label>
    <link:label id="lab_us-gaap_DirectOperatingCosts_label_en-US" xlink:label="lab_us-gaap_DirectOperatingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Operating Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectOperatingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectOperatingCosts" xlink:to="lab_us-gaap_DirectOperatingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4f709a7d-ff6e-49b4-be00-b27fcf7fc68e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_999a6894-dc50-4106-b99d-06ce6ee5084d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_ee870910-952a-4cc8-9049-5e8736878133_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash consideration, gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_39c53606-c4c9-4ce9-8d45-0f6a93898570_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_868a44ae-c54a-4b3a-ae7e-8b4760992eab_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_209f0f47-82c1-457f-bfb5-b03a59067ebb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign currency translation gain (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_b4d99645-48e7-4e43-9ef1-c2c08fb9818a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment, net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_40788769-8082-4ac8-891c-b4600b7e935f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible List]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_f110ab6e-9b58-4cfe-8c2f-615985333294_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_dd9439fc-65fb-4f46-bc9e-44755e630795_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7a9e3de-f290-4b7a-a178-8fc93f8024b7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_FairValueMeasurementLineItems_51e3cbc7-f87d-49da-a785-84a7f946ec60_terseLabel_en-US" xlink:label="lab_ccrn_FairValueMeasurementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Line Items]</link:label>
    <link:label id="lab_ccrn_FairValueMeasurementLineItems_label_en-US" xlink:label="lab_ccrn_FairValueMeasurementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Line Items]</link:label>
    <link:label id="lab_ccrn_FairValueMeasurementLineItems_documentation_en-US" xlink:label="lab_ccrn_FairValueMeasurementLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FairValueMeasurementLineItems" xlink:href="ccrn-20250331.xsd#ccrn_FairValueMeasurementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_FairValueMeasurementLineItems" xlink:to="lab_ccrn_FairValueMeasurementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_6c0c74a6-d4c8-4028-9673-3ae554991824_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_cf00e280-d223-4d7e-af6f-fb5f1cc5fda1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_17edc200-224c-4e03-ac58-735186544bd1_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled contracts receivable</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_64db6009-dfd7-4785-964f-f24204820b7a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_c1cb3abb-077c-439e-937a-671d3fda1cb3_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_170d5b9f-0999-47ac-aaa1-f061269e085c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2cc793c9-ebc9-45d6-b57c-44aa28dc764d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0e5def2a-f2f8-42e4-860c-d6c1b79c136b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivableNoncurrent_794888e3-76a2-4142-8292-d3363e8168ec_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance recovery receivable</link:label>
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivableNoncurrent_label_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Settlements Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceSettlementsReceivableNoncurrent" xlink:to="lab_us-gaap_InsuranceSettlementsReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_StandbyLettersOfCreditSublimitMember_59062615-d626-4fa6-bb90-a4ca9452df6f_terseLabel_en-US" xlink:label="lab_ccrn_StandbyLettersOfCreditSublimitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standby Letters Of Credit Sublimit</link:label>
    <link:label id="lab_ccrn_StandbyLettersOfCreditSublimitMember_label_en-US" xlink:label="lab_ccrn_StandbyLettersOfCreditSublimitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standby Letters Of Credit Sublimit [Member]</link:label>
    <link:label id="lab_ccrn_StandbyLettersOfCreditSublimitMember_documentation_en-US" xlink:label="lab_ccrn_StandbyLettersOfCreditSublimitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Standby Letters Of Credit Sublimit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_StandbyLettersOfCreditSublimitMember" xlink:href="ccrn-20250331.xsd#ccrn_StandbyLettersOfCreditSublimitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_StandbyLettersOfCreditSublimitMember" xlink:to="lab_ccrn_StandbyLettersOfCreditSublimitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3af4366-4d70-4999-97d1-2c5a8f9d7e6a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4faeb900-47fb-4e98-ab94-32ebb3bc56de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cbf1e549-9203-4742-9304-0f047a480b45_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0ca184a-c3f0-4b94-b284-3239d6e0f869_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources_c890380e-a440-4dda-ab15-aa87494e8953_terseLabel_en-US" xlink:label="lab_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of indebtedness permitted from other sources</link:label>
    <link:label id="lab_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources_label_en-US" xlink:label="lab_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit, Amount Of Indebtedness Permitted By Senior Secured Asset Based Loan To Be Borrowed From Other Sources</link:label>
    <link:label id="lab_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources_documentation_en-US" xlink:label="lab_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line Of Credit, Amount Of Indebtedness Permitted By Senior Secured Asset Based Loan To Be Borrowed From Other Sources</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" xlink:to="lab_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_0861a8f1-89e2-421a-ad2c-3b4ee4a6d8b9_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ExitCostsMember_3ea6e470-834c-4772-a915-98c25e6e57e2_terseLabel_en-US" xlink:label="lab_ccrn_ExitCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease-Related Exit Costs</link:label>
    <link:label id="lab_ccrn_ExitCostsMember_label_en-US" xlink:label="lab_ccrn_ExitCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exit Costs [Member]</link:label>
    <link:label id="lab_ccrn_ExitCostsMember_documentation_en-US" xlink:label="lab_ccrn_ExitCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exit Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ExitCostsMember" xlink:href="ccrn-20250331.xsd#ccrn_ExitCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ExitCostsMember" xlink:to="lab_ccrn_ExitCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_dcdca34a-2253-4139-a35d-517e646a1c7a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per share attributable to common stockholders - Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_10ac92a7-aae2-413f-bea8-82bd774bfa94_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per share attributable to common stockholders - Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_332d723d-d6b5-4ab7-a60d-735429e7d093_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_OtherServicesMember_44c55749-eaf8-4e5c-bb8b-f0d611024ff2_terseLabel_en-US" xlink:label="lab_ccrn_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Services</link:label>
    <link:label id="lab_ccrn_OtherServicesMember_label_en-US" xlink:label="lab_ccrn_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Services [Member]</link:label>
    <link:label id="lab_ccrn_OtherServicesMember_documentation_en-US" xlink:label="lab_ccrn_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OtherServicesMember" xlink:href="ccrn-20250331.xsd#ccrn_OtherServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_OtherServicesMember" xlink:to="lab_ccrn_OtherServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_79c0127e-ef75-4dad-96cd-4e0aab53836a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5a555893-d818-4e4c-969c-799b64bb230e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1389a1ba-3c91-4b23-b4ea-ba09dc4866ce_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income attributable to common stockholders - Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedTradeNames_74726c99-89ef-4a87-b979-a74e6ac8e985_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedTradeNames" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade names, indefinite-lived</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedTradeNames_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedTradeNames" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Trade Names</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedTradeNames" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedTradeNames"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedTradeNames" xlink:to="lab_us-gaap_IndefiniteLivedTradeNames" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c5b0d8f4-2198-419b-a04b-702dc4c74dfa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets subject to amortization:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6ab950a7-1466-4ada-b322-d709ff112bba_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7dc5487a-974b-4dee-9334-8da8310a9d44_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_f696fca0-8aab-4271-bb18-d6919c5a0ccb_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramAxis" xlink:to="lab_srt_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9831c69d-174d-46db-bc3b-4c95ab5d59ab_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e3e97ca5-7873-4cc1-a6af-4c7ca84cf62b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_5a149ec8-85e9-4a46-8631-b7d29e4c5ea7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_88576350-99c2-4e0f-8bd4-317eda85cf8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_57d561fa-40b2-41e8-942c-63062bbfe1b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7a7e2091-663c-465a-b67c-4911f1efa795_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_312b78cb-feb7-4053-a115-faea85feedc4_terseLabel_en-US" xlink:label="lab_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ccrn-20250331.xsd#ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a0019c27-f732-4115-b28e-963c91bd6532_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DatabasesMember_7b1986ed-58eb-4d19-86f6-2fb4d25f05fa_terseLabel_en-US" xlink:label="lab_us-gaap_DatabasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Databases</link:label>
    <link:label id="lab_us-gaap_DatabasesMember_label_en-US" xlink:label="lab_us-gaap_DatabasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Database Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DatabasesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DatabasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DatabasesMember" xlink:to="lab_us-gaap_DatabasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_10c19671-5be7-414b-95a9-c18573c57bfa_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketingExpense_4dc360ef-d4ce-4ad7-842e-e7605183ed5b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketing</link:label>
    <link:label id="lab_us-gaap_MarketingExpense_label_en-US" xlink:label="lab_us-gaap_MarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketingExpense" xlink:to="lab_us-gaap_MarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_OmnibusPlanMember_229eb8fc-a2a7-4137-9609-c22793617b3b_terseLabel_en-US" xlink:label="lab_ccrn_OmnibusPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Omnibus Plan</link:label>
    <link:label id="lab_ccrn_OmnibusPlanMember_label_en-US" xlink:label="lab_ccrn_OmnibusPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Omnibus Plan [Member]</link:label>
    <link:label id="lab_ccrn_OmnibusPlanMember_documentation_en-US" xlink:label="lab_ccrn_OmnibusPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Omnibus Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OmnibusPlanMember" xlink:href="ccrn-20250331.xsd#ccrn_OmnibusPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_OmnibusPlanMember" xlink:to="lab_ccrn_OmnibusPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4513fbed-10b6-4975-b9b1-cbc3898f6088_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e95eb27c-a1b1-4089-b73e-2e774b810748_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d18a4814-b43d-4e8a-af3f-e8edb9aea913_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5239d997-0ff4-4593-9475-1d98b685b759_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0ba6e567-fe76-4ed0-9242-a962719d0472_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ef87e31b-c048-4d6f-b90d-416f52e5e127_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bc961a10-4ab0-4e8e-8a92-83e6016d51b4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d24506b1-439a-4aaf-90f6-b6df2f6bebfa_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Consolidated net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_e82f1055-945a-4737-83f0-2ae9759e033f_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMPREHENSIVE (LOSS) INCOME</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_AcquisitionAndIntegrationRelatedCosts_c8a142cc-5f5b-45a2-b5b3-ee9eeaac2b9e_terseLabel_en-US" xlink:label="lab_ccrn_AcquisitionAndIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition and integration-related costs</link:label>
    <link:label id="lab_ccrn_AcquisitionAndIntegrationRelatedCosts_label_en-US" xlink:label="lab_ccrn_AcquisitionAndIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition And Integration-Related Costs</link:label>
    <link:label id="lab_ccrn_AcquisitionAndIntegrationRelatedCosts_documentation_en-US" xlink:label="lab_ccrn_AcquisitionAndIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquisition and integration-related costs include costs for prior acquisitions, costs incurred for potential transactions, and accretion and valuation adjustments on contingent consideration liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AcquisitionAndIntegrationRelatedCosts" xlink:href="ccrn-20250331.xsd#ccrn_AcquisitionAndIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_AcquisitionAndIntegrationRelatedCosts" xlink:to="lab_ccrn_AcquisitionAndIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_52df81cb-3952-4a50-96a0-1b27617dca5c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_0647ea09-7a02-4a90-9021-af4494284011_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7f2e9160-24a4-42cf-920f-5b2b8be54837_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_e95a20f0-b4ea-469a-8abb-613ffca11cb6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUE RECOGNITION</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0bc4d580-e001-4df6-a101-928104101302_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4a154e9d-dc2b-4ac5-b2f0-5a5201e92ce2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_208a0795-19c4-4325-9394-65d8386de55e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c87875a9-14ee-4fb3-8a3b-149cbe2c7c31_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_eda3d9cb-d9fd-4400-bb32-3c21584f6f75_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets not subject to amortization:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3f159438-88ed-4e7a-83dc-46e8f87bdce2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_074656e9-cc7a-4bcb-a6ef-ac79f94b25c6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation asset</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_95b97b35-43ee-4a33-97bb-762ea6aa1534_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b0cfb78d-bbcd-4a49-bec4-0081324772c9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c2716470-2d72-4841-879a-ba4a28ee377e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_1e316b57-9ed8-4b99-be74-ca7fc2bb9037_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other non-cash costs</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_54b5d36c-a33c-429f-bed0-9c94c2fb343c_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_72ac340e-73f4-48cf-a632-c798fe5b14db_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_59541f1d-3f80-4496-a15f-fdaf36ac4216_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock awards, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bdb16bbf-d188-4b55-9f16-249a7394957c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock awards, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_a4c916f7-6b88-40c4-bfbc-ac9c294ad28c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_22a16203-0a5c-45c7-bdd3-c8bf3ae3c970_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_15aedc30-d1a6-4e8f-a63c-239c72dff441_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense_91b34b2e-7f9f-4690-a7fb-806bf6c33ff3_terseLabel_en-US" xlink:label="lab_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense_label_en-US" xlink:label="lab_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Labor and Related Expense, Excluding Benefits Expense</link:label>
    <link:label id="lab_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense_documentation_en-US" xlink:label="lab_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Labor and Related Expense, Excluding Benefits Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense" xlink:href="ccrn-20250331.xsd#ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense" xlink:to="lab_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b1070cbd-1a53-40b3-bec8-3db44d8f5284_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_5649dbd7-539a-483a-98b2-4ff7fa968e25_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_78b2f379-1a44-4c8b-a38b-d05c3e67b8e8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d02b6bc9-97ae-4134-8aea-31ccec6a0fe1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5e29fd1b-7bfc-4c76-a297-3f1d5882a284_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_fb2cd40b-813e-4090-b164-7c1ec6634c2a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_100d368f-dad6-4c64-9a46-1f4eb91bcd7c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_776a77fb-fd5b-4f62-97b7-9ed0e80b0cb2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2e210f86-c675-47c0-8e7c-47e3909d5ce4_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares - Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember_868a47f4-7adc-483d-8f8c-be50b25575e5_terseLabel_en-US" xlink:label="lab_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mint</link:label>
    <link:label id="lab_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember_label_en-US" xlink:label="lab_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mint Medical Physician Staffing, LP And Lotus Medical Staffing LLC [Member]</link:label>
    <link:label id="lab_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember_documentation_en-US" xlink:label="lab_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mint Medical Physician Staffing, LP And Lotus Medical Staffing LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember" xlink:href="ccrn-20250331.xsd#ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember" xlink:to="lab_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25c0a8b0-6b97-4185-ada9-4030b7c7aabc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_StockRepurchasedDuringPeriodExciseTax_fcf27cab-0f0b-46a9-8bf3-6d2add4493c3_negatedTerseLabel_en-US" xlink:label="lab_ccrn_StockRepurchasedDuringPeriodExciseTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase excise tax</link:label>
    <link:label id="lab_ccrn_StockRepurchasedDuringPeriodExciseTax_3e86c11a-f60b-47dc-a350-75218511b051_terseLabel_en-US" xlink:label="lab_ccrn_StockRepurchasedDuringPeriodExciseTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase excise tax</link:label>
    <link:label id="lab_ccrn_StockRepurchasedDuringPeriodExciseTax_label_en-US" xlink:label="lab_ccrn_StockRepurchasedDuringPeriodExciseTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Excise Tax</link:label>
    <link:label id="lab_ccrn_StockRepurchasedDuringPeriodExciseTax_documentation_en-US" xlink:label="lab_ccrn_StockRepurchasedDuringPeriodExciseTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Excise Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_StockRepurchasedDuringPeriodExciseTax" xlink:href="ccrn-20250331.xsd#ccrn_StockRepurchasedDuringPeriodExciseTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_StockRepurchasedDuringPeriodExciseTax" xlink:to="lab_ccrn_StockRepurchasedDuringPeriodExciseTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_a098e859-8aa1-49a9-8dee-6e40e7b74cea_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_ac6a13c1-9718-4163-b59f-94a0706e3e57_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_0cf455e0-58e7-4148-b7eb-f2e8e9f34d92_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a2a06fed-33f3-4252-9718-3ed03c4168a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LegalAndOtherLosses_f8eb95cf-4e96-4227-b742-60c7bfa7af64_terseLabel_en-US" xlink:label="lab_ccrn_LegalAndOtherLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal and other losses</link:label>
    <link:label id="lab_ccrn_LegalAndOtherLosses_label_en-US" xlink:label="lab_ccrn_LegalAndOtherLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal And Other Losses</link:label>
    <link:label id="lab_ccrn_LegalAndOtherLosses_documentation_en-US" xlink:label="lab_ccrn_LegalAndOtherLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal And Other Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LegalAndOtherLosses" xlink:href="ccrn-20250331.xsd#ccrn_LegalAndOtherLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LegalAndOtherLosses" xlink:to="lab_ccrn_LegalAndOtherLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ccrn-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:dd6031fa-8918-4f16-99cd-07b7064df9d2,g:a332f0b9-5dad-4d87-8e39-4baf62f16fbe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/Cover" xlink:type="simple" xlink:href="ccrn-20250331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5aba7ae4-6820-4615-b881-6935fe19bade" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_DocumentType_5aba7ae4-6820-4615-b881-6935fe19bade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_1f10abe8-e841-46b8-b96c-7392a6a369af" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_DocumentQuarterlyReport_1f10abe8-e841-46b8-b96c-7392a6a369af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_abaf7eeb-84ce-497d-82b2-ba61696100d3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_DocumentPeriodEndDate_abaf7eeb-84ce-497d-82b2-ba61696100d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a0a8afba-87b1-47cf-ad6c-a10028e896b8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_DocumentTransitionReport_a0a8afba-87b1-47cf-ad6c-a10028e896b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b430fa18-7634-4ecd-ba56-bf9aeeaa9e49" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityRegistrantName_b430fa18-7634-4ecd-ba56-bf9aeeaa9e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d0adc101-9f90-49f3-a3ef-82dce63e1b69" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d0adc101-9f90-49f3-a3ef-82dce63e1b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9d97207d-80eb-4146-8794-d77d0fcf550c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityFileNumber_9d97207d-80eb-4146-8794-d77d0fcf550c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_840c7401-a19e-462e-920b-0477e98319ed" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityTaxIdentificationNumber_840c7401-a19e-462e-920b-0477e98319ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_14c09821-42de-4cb1-bb34-6b5c34f1fca5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityAddressAddressLine1_14c09821-42de-4cb1-bb34-6b5c34f1fca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_640663d5-8910-49e8-968b-2e87d6c4e0bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityAddressCityOrTown_640663d5-8910-49e8-968b-2e87d6c4e0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8737d8a0-ac88-4436-86ed-501726e8005d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityAddressStateOrProvince_8737d8a0-ac88-4436-86ed-501726e8005d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_275d2439-3656-4299-8a33-2c3df2d617de" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityAddressPostalZipCode_275d2439-3656-4299-8a33-2c3df2d617de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_60a22e79-ae70-49b8-82f3-af402f3bf452" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_CityAreaCode_60a22e79-ae70-49b8-82f3-af402f3bf452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_88d4c513-5e29-4c59-985e-a4c1f9b7a634" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_LocalPhoneNumber_88d4c513-5e29-4c59-985e-a4c1f9b7a634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f58cd851-3ae7-4576-8f6d-cc2ade22c810" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_Security12bTitle_f58cd851-3ae7-4576-8f6d-cc2ade22c810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5abd545a-6f8b-413a-908d-d7ff8b569071" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_TradingSymbol_5abd545a-6f8b-413a-908d-d7ff8b569071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_42954f5e-ff06-4ed6-8bb6-e73b72b0cc9b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_SecurityExchangeName_42954f5e-ff06-4ed6-8bb6-e73b72b0cc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6fee281f-1789-4665-8114-5b1246fbfbf6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityCurrentReportingStatus_6fee281f-1789-4665-8114-5b1246fbfbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_24169fa3-e762-4384-9cc2-8f0bc80fc115" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityInteractiveDataCurrent_24169fa3-e762-4384-9cc2-8f0bc80fc115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b3c30465-606f-44f3-bbc8-6bdc320c45d3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityFilerCategory_b3c30465-606f-44f3-bbc8-6bdc320c45d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f3273818-43cf-459f-8fa3-07a8fa3b45a2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntitySmallBusiness_f3273818-43cf-459f-8fa3-07a8fa3b45a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2e869389-0f1a-4a79-aca9-3a9e5f24efe8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityEmergingGrowthCompany_2e869389-0f1a-4a79-aca9-3a9e5f24efe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_78598086-4f2f-4d97-8721-141500959659" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityShellCompany_78598086-4f2f-4d97-8721-141500959659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_082e328d-75b5-4ed2-a568-04f5053db9e1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_082e328d-75b5-4ed2-a568-04f5053db9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_74f8e8d6-63fa-4a19-a3ee-db11ad4e63e0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_EntityCentralIndexKey_74f8e8d6-63fa-4a19-a3ee-db11ad4e63e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_297cae75-a24c-4ca8-b27f-b891f878f4dc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_CurrentFiscalYearEndDate_297cae75-a24c-4ca8-b27f-b891f878f4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7155423f-3eb8-4e58-b6ca-21fb037adbe0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_DocumentFiscalYearFocus_7155423f-3eb8-4e58-b6ca-21fb037adbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b0ec6ccb-1dba-4555-8040-28ed47216e28" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b0ec6ccb-1dba-4555-8040-28ed47216e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c52b893e-757c-462f-be4e-86481f6a6fdc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c43ea70-cdd4-4ea4-9537-df36d231fcb2" xlink:to="loc_dei_AmendmentFlag_c52b893e-757c-462f-be4e-86481f6a6fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ccrn-20250331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9ecd992b-5c55-4ce3-9dc6-889f7426e682" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3aba86a0-982b-4f34-ac74-4faa5b6b34c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ecd992b-5c55-4ce3-9dc6-889f7426e682" xlink:to="loc_us-gaap_AssetsAbstract_3aba86a0-982b-4f34-ac74-4faa5b6b34c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_08d99ff0-e386-43ef-b224-b3a55b7823a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aba86a0-982b-4f34-ac74-4faa5b6b34c4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_08d99ff0-e386-43ef-b224-b3a55b7823a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_99271581-0509-42b1-9705-b64d802bdde2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08d99ff0-e386-43ef-b224-b3a55b7823a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_99271581-0509-42b1-9705-b64d802bdde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0c660321-ca7a-48e9-932a-8a98720dc9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08d99ff0-e386-43ef-b224-b3a55b7823a2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0c660321-ca7a-48e9-932a-8a98720dc9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_3ba3e8bc-68c2-4a62-829e-c230bdfe70ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08d99ff0-e386-43ef-b224-b3a55b7823a2" xlink:to="loc_us-gaap_IncomeTaxesReceivable_3ba3e8bc-68c2-4a62-829e-c230bdfe70ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_11709b2c-e6dc-4e89-bf28-f889204035e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08d99ff0-e386-43ef-b224-b3a55b7823a2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_11709b2c-e6dc-4e89-bf28-f889204035e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_fc4337b8-fc21-4a27-b534-e421e217d711" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08d99ff0-e386-43ef-b224-b3a55b7823a2" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableCurrent_fc4337b8-fc21-4a27-b534-e421e217d711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e513ee90-bf91-4a41-bbe8-e9ad14eb0c75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08d99ff0-e386-43ef-b224-b3a55b7823a2" xlink:to="loc_us-gaap_OtherAssetsCurrent_e513ee90-bf91-4a41-bbe8-e9ad14eb0c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e429541c-af08-48cb-8c3d-11d4613fcb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08d99ff0-e386-43ef-b224-b3a55b7823a2" xlink:to="loc_us-gaap_AssetsCurrent_e429541c-af08-48cb-8c3d-11d4613fcb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b5472a21-df0c-404c-9eeb-b9fbe5c5ef92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aba86a0-982b-4f34-ac74-4faa5b6b34c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b5472a21-df0c-404c-9eeb-b9fbe5c5ef92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8298ff32-ca1d-4671-9ca1-945c1801ac12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aba86a0-982b-4f34-ac74-4faa5b6b34c4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8298ff32-ca1d-4671-9ca1-945c1801ac12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_053f0686-29c6-47a8-8ab0-f9e70babcc74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aba86a0-982b-4f34-ac74-4faa5b6b34c4" xlink:to="loc_us-gaap_Goodwill_053f0686-29c6-47a8-8ab0-f9e70babcc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8abb1ac9-dbc4-4671-814a-9cb0d62220f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aba86a0-982b-4f34-ac74-4faa5b6b34c4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8abb1ac9-dbc4-4671-814a-9cb0d62220f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_11f32b59-372d-4c27-ab3b-73a75b058084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aba86a0-982b-4f34-ac74-4faa5b6b34c4" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_11f32b59-372d-4c27-ab3b-73a75b058084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableNoncurrent_0dbf231b-9350-42f1-9ca0-7dcf59fdfafa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aba86a0-982b-4f34-ac74-4faa5b6b34c4" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableNoncurrent_0dbf231b-9350-42f1-9ca0-7dcf59fdfafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_CloudComputingNoncurrent_66b8f33b-6197-453d-9c34-b4de3f560f17" xlink:href="ccrn-20250331.xsd#ccrn_CloudComputingNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aba86a0-982b-4f34-ac74-4faa5b6b34c4" xlink:to="loc_ccrn_CloudComputingNoncurrent_66b8f33b-6197-453d-9c34-b4de3f560f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_98bb6a22-6f3a-43ca-a208-657024107860" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aba86a0-982b-4f34-ac74-4faa5b6b34c4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_98bb6a22-6f3a-43ca-a208-657024107860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_44c28c36-e0eb-4fb4-9972-351a63bd2e63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aba86a0-982b-4f34-ac74-4faa5b6b34c4" xlink:to="loc_us-gaap_Assets_44c28c36-e0eb-4fb4-9972-351a63bd2e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1046c5dc-4b9e-4dc6-9fe2-f0f8013c6b18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ecd992b-5c55-4ce3-9dc6-889f7426e682" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1046c5dc-4b9e-4dc6-9fe2-f0f8013c6b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_35654f7b-53e5-4fa6-bec6-f679a7d36658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1046c5dc-4b9e-4dc6-9fe2-f0f8013c6b18" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_35654f7b-53e5-4fa6-bec6-f679a7d36658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_5ac9f660-091a-4623-b897-148dee88219c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35654f7b-53e5-4fa6-bec6-f679a7d36658" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_5ac9f660-091a-4623-b897-148dee88219c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ceb481e2-8d27-478d-b0fe-4b2c6880fd14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35654f7b-53e5-4fa6-bec6-f679a7d36658" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ceb481e2-8d27-478d-b0fe-4b2c6880fd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_47536e1a-3df2-4cad-965f-4c31dd71aae1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35654f7b-53e5-4fa6-bec6-f679a7d36658" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_47536e1a-3df2-4cad-965f-4c31dd71aae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f7c05b82-ca34-45c8-a488-758a9f216d03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35654f7b-53e5-4fa6-bec6-f679a7d36658" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f7c05b82-ca34-45c8-a488-758a9f216d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8bd017f5-0bf6-400b-a5de-14d7ad6c87fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35654f7b-53e5-4fa6-bec6-f679a7d36658" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8bd017f5-0bf6-400b-a5de-14d7ad6c87fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_aba5f4fc-5599-4772-be9c-cc3714388bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35654f7b-53e5-4fa6-bec6-f679a7d36658" xlink:to="loc_us-gaap_LiabilitiesCurrent_aba5f4fc-5599-4772-be9c-cc3714388bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_66549365-f24b-4ad6-b78c-6c836209e6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1046c5dc-4b9e-4dc6-9fe2-f0f8013c6b18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_66549365-f24b-4ad6-b78c-6c836209e6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_4259c788-fcd9-4703-9122-58659befc55a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1046c5dc-4b9e-4dc6-9fe2-f0f8013c6b18" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_4259c788-fcd9-4703-9122-58659befc55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_27e02424-fee6-4169-a30f-9852f973a237" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1046c5dc-4b9e-4dc6-9fe2-f0f8013c6b18" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_27e02424-fee6-4169-a30f-9852f973a237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_00cc96dd-c5c8-46b3-bb19-71b2246b2e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1046c5dc-4b9e-4dc6-9fe2-f0f8013c6b18" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_00cc96dd-c5c8-46b3-bb19-71b2246b2e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c17f9c24-5db5-4401-ae37-1d0bd8aca990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1046c5dc-4b9e-4dc6-9fe2-f0f8013c6b18" xlink:to="loc_us-gaap_Liabilities_c17f9c24-5db5-4401-ae37-1d0bd8aca990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6eec0833-4b7d-4741-95dd-78c144fa5424" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1046c5dc-4b9e-4dc6-9fe2-f0f8013c6b18" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6eec0833-4b7d-4741-95dd-78c144fa5424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_58038ef7-2f42-46b8-8877-1e83edcf15a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1046c5dc-4b9e-4dc6-9fe2-f0f8013c6b18" xlink:to="loc_us-gaap_StockholdersEquityAbstract_58038ef7-2f42-46b8-8877-1e83edcf15a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f20a1519-8803-494e-918e-5306db0cf9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_58038ef7-2f42-46b8-8877-1e83edcf15a6" xlink:to="loc_us-gaap_CommonStockValue_f20a1519-8803-494e-918e-5306db0cf9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_80b6a509-251a-4cd2-a09a-e4c161d0825c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_58038ef7-2f42-46b8-8877-1e83edcf15a6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_80b6a509-251a-4cd2-a09a-e4c161d0825c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6856e372-a0d5-43b7-83d4-674867da667d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_58038ef7-2f42-46b8-8877-1e83edcf15a6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6856e372-a0d5-43b7-83d4-674867da667d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5f30a55e-31e8-423e-9da9-2ebdaa06ee12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_58038ef7-2f42-46b8-8877-1e83edcf15a6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5f30a55e-31e8-423e-9da9-2ebdaa06ee12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_961d7d33-6d4e-4835-8f3e-693e25091aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_58038ef7-2f42-46b8-8877-1e83edcf15a6" xlink:to="loc_us-gaap_StockholdersEquity_961d7d33-6d4e-4835-8f3e-693e25091aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_acf7703b-1e9d-4f1a-89e3-f6348015ea41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1046c5dc-4b9e-4dc6-9fe2-f0f8013c6b18" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_acf7703b-1e9d-4f1a-89e3-f6348015ea41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ccrn-20250331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0845337b-2962-40f5-820f-e163a2c7a2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_e9209bc0-829e-47f5-af7d-2796ea18bf59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0845337b-2962-40f5-820f-e163a2c7a2b8" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_e9209bc0-829e-47f5-af7d-2796ea18bf59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_21247be0-ea00-4c4e-a773-d21a165a21f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0845337b-2962-40f5-820f-e163a2c7a2b8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_21247be0-ea00-4c4e-a773-d21a165a21f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="ccrn-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c2126533-1c1b-407b-a0a2-69afcb5df5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_0f650c27-3892-46d1-b699-9e24556bc54a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c2126533-1c1b-407b-a0a2-69afcb5df5a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_0f650c27-3892-46d1-b699-9e24556bc54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_008592bd-6ac8-41b5-bfd9-ae82ee040d46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c2126533-1c1b-407b-a0a2-69afcb5df5a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_008592bd-6ac8-41b5-bfd9-ae82ee040d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b98d4958-2c46-432e-8b22-bd0c0c241334" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c2126533-1c1b-407b-a0a2-69afcb5df5a4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b98d4958-2c46-432e-8b22-bd0c0c241334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectOperatingCosts_dce5d5ca-3fc0-4cfd-9832-3f53fdff62ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b98d4958-2c46-432e-8b22-bd0c0c241334" xlink:to="loc_us-gaap_DirectOperatingCosts_dce5d5ca-3fc0-4cfd-9832-3f53fdff62ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b7f2e44b-88fd-42f9-b871-782a0f5a65b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b98d4958-2c46-432e-8b22-bd0c0c241334" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b7f2e44b-88fd-42f9-b871-782a0f5a65b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_dfacf1b2-086a-4641-9d89-d46593f6729d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b98d4958-2c46-432e-8b22-bd0c0c241334" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_dfacf1b2-086a-4641-9d89-d46593f6729d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_73c3e348-5818-4c1d-bf8f-f3d2450ff543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b98d4958-2c46-432e-8b22-bd0c0c241334" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_73c3e348-5818-4c1d-bf8f-f3d2450ff543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_d8add97d-143e-4244-95c7-cd25f58e4f20" xlink:href="ccrn-20250331.xsd#ccrn_AcquisitionAndIntegrationRelatedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b98d4958-2c46-432e-8b22-bd0c0c241334" xlink:to="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_d8add97d-143e-4244-95c7-cd25f58e4f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_5b3c3d8b-382d-492f-8f75-5eee333ae780" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b98d4958-2c46-432e-8b22-bd0c0c241334" xlink:to="loc_us-gaap_RestructuringCharges_5b3c3d8b-382d-492f-8f75-5eee333ae780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LegalAndOtherLosses_d00c4a61-397c-4d92-bcad-f28f0b7ee53c" xlink:href="ccrn-20250331.xsd#ccrn_LegalAndOtherLosses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b98d4958-2c46-432e-8b22-bd0c0c241334" xlink:to="loc_ccrn_LegalAndOtherLosses_d00c4a61-397c-4d92-bcad-f28f0b7ee53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_61c60f51-586a-4c6c-93f2-a273e90b6834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b98d4958-2c46-432e-8b22-bd0c0c241334" xlink:to="loc_us-gaap_AssetImpairmentCharges_61c60f51-586a-4c6c-93f2-a273e90b6834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a3ea0e28-a331-4d1a-a7e6-4f172c5f3df7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b98d4958-2c46-432e-8b22-bd0c0c241334" xlink:to="loc_us-gaap_CostsAndExpenses_a3ea0e28-a331-4d1a-a7e6-4f172c5f3df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9d13746c-2c2b-491e-a11f-1ded8d7f1db4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c2126533-1c1b-407b-a0a2-69afcb5df5a4" xlink:to="loc_us-gaap_OperatingIncomeLoss_9d13746c-2c2b-491e-a11f-1ded8d7f1db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00cfd252-65f1-4096-b1d9-6fdebed236ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c2126533-1c1b-407b-a0a2-69afcb5df5a4" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00cfd252-65f1-4096-b1d9-6fdebed236ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_66674fbe-f9fc-44a4-9a5d-ce50464592ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00cfd252-65f1-4096-b1d9-6fdebed236ba" xlink:to="loc_us-gaap_InterestExpenseNonoperating_66674fbe-f9fc-44a4-9a5d-ce50464592ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4c771054-23c8-41f4-bf75-2bf81e80461e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00cfd252-65f1-4096-b1d9-6fdebed236ba" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4c771054-23c8-41f4-bf75-2bf81e80461e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f6ea9bdb-ad91-4a4b-a507-a84169e461fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00cfd252-65f1-4096-b1d9-6fdebed236ba" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f6ea9bdb-ad91-4a4b-a507-a84169e461fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d26c4d0d-1bae-47eb-baff-4b4ab4e1ef2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c2126533-1c1b-407b-a0a2-69afcb5df5a4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d26c4d0d-1bae-47eb-baff-4b4ab4e1ef2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d4808472-8253-41bf-a526-be7227a310d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c2126533-1c1b-407b-a0a2-69afcb5df5a4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d4808472-8253-41bf-a526-be7227a310d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_069b6372-fc7c-4d16-b858-6e453c5f40c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c2126533-1c1b-407b-a0a2-69afcb5df5a4" xlink:to="loc_us-gaap_NetIncomeLoss_069b6372-fc7c-4d16-b858-6e453c5f40c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6ff0f94b-8d13-4d90-b641-5e57b05a9198" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c2126533-1c1b-407b-a0a2-69afcb5df5a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6ff0f94b-8d13-4d90-b641-5e57b05a9198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_908e1702-6479-48df-8b98-ce089987ad2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6ff0f94b-8d13-4d90-b641-5e57b05a9198" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_908e1702-6479-48df-8b98-ce089987ad2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5138dd98-93d9-4f31-b087-9b6c51bf5122" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c2126533-1c1b-407b-a0a2-69afcb5df5a4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5138dd98-93d9-4f31-b087-9b6c51bf5122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a2016039-f119-43e6-8ee4-7a1404e70a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c2126533-1c1b-407b-a0a2-69afcb5df5a4" xlink:to="loc_us-gaap_EarningsPerShareBasic_a2016039-f119-43e6-8ee4-7a1404e70a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4a82d800-8e53-408e-80c1-b574ddbef6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c2126533-1c1b-407b-a0a2-69afcb5df5a4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4a82d800-8e53-408e-80c1-b574ddbef6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_736c3baf-9283-4dd8-a95d-5da9fb20c953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c2126533-1c1b-407b-a0a2-69afcb5df5a4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_736c3baf-9283-4dd8-a95d-5da9fb20c953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_171e2331-10a7-4ebb-8de5-a8cda4dc6cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_736c3baf-9283-4dd8-a95d-5da9fb20c953" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_171e2331-10a7-4ebb-8de5-a8cda4dc6cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6d4af551-7219-4ee7-a365-5efe217080d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_736c3baf-9283-4dd8-a95d-5da9fb20c953" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6d4af551-7219-4ee7-a365-5efe217080d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ccrn-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_dd9a6549-112a-4d47-886d-0e2c02b42b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_30499616-2a2d-47c9-9b95-4820452c3943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_dd9a6549-112a-4d47-886d-0e2c02b42b1c" xlink:to="loc_us-gaap_StatementTable_30499616-2a2d-47c9-9b95-4820452c3943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_87566685-47e5-4554-8271-eeb71da7fd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_30499616-2a2d-47c9-9b95-4820452c3943" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_87566685-47e5-4554-8271-eeb71da7fd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_23a871e5-dd37-4239-a885-c9d0fbe48e22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_87566685-47e5-4554-8271-eeb71da7fd8e" xlink:to="loc_us-gaap_EquityComponentDomain_23a871e5-dd37-4239-a885-c9d0fbe48e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9bd89a88-e849-4f9e-a492-85b814152c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_23a871e5-dd37-4239-a885-c9d0fbe48e22" xlink:to="loc_us-gaap_CommonStockMember_9bd89a88-e849-4f9e-a492-85b814152c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_858585ca-0ce1-4f9d-9e00-a9c81681e13b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_23a871e5-dd37-4239-a885-c9d0fbe48e22" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_858585ca-0ce1-4f9d-9e00-a9c81681e13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2878e1e3-be5b-4cc7-b8b6-6362cc3a4fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_23a871e5-dd37-4239-a885-c9d0fbe48e22" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2878e1e3-be5b-4cc7-b8b6-6362cc3a4fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d687318a-6c15-4cae-bec2-241c9aaaf1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_23a871e5-dd37-4239-a885-c9d0fbe48e22" xlink:to="loc_us-gaap_RetainedEarningsMember_d687318a-6c15-4cae-bec2-241c9aaaf1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5475d333-7011-47e2-b5c6-7212d842dcbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_30499616-2a2d-47c9-9b95-4820452c3943" xlink:to="loc_us-gaap_StatementLineItems_5475d333-7011-47e2-b5c6-7212d842dcbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5475d333-7011-47e2-b5c6-7212d842dcbf" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ae73a8f8-1621-4f44-a8df-8ac42ef18670" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ae73a8f8-1621-4f44-a8df-8ac42ef18670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fbc7f7c5-41ce-4776-b059-2eab3a3ea166" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_StockholdersEquity_fbc7f7c5-41ce-4776-b059-2eab3a3ea166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c0a2900f-a423-4142-ae06-a73affd576dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c0a2900f-a423-4142-ae06-a73affd576dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ad7de9d7-b27d-44b9-af35-54c5fa90e30e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ad7de9d7-b27d-44b9-af35-54c5fa90e30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4750a720-4723-4b87-9194-9a3ad3caca12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4750a720-4723-4b87-9194-9a3ad3caca12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5052dbbd-6442-4483-ba0d-0008084ce56a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5052dbbd-6442-4483-ba0d-0008084ce56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_53b589db-5bbc-443d-8202-f8e496fdb213" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_53b589db-5bbc-443d-8202-f8e496fdb213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_StockRepurchasedDuringPeriodExciseTax_a4c667e1-793f-4e76-960a-2f8b10cd0f16" xlink:href="ccrn-20250331.xsd#ccrn_StockRepurchasedDuringPeriodExciseTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_ccrn_StockRepurchasedDuringPeriodExciseTax_a4c667e1-793f-4e76-960a-2f8b10cd0f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f38db7dd-d53f-4e36-a2e4-ebc3a38060f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f38db7dd-d53f-4e36-a2e4-ebc3a38060f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f9427db-e8a2-4fc4-9086-53d310b351e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_NetIncomeLoss_2f9427db-e8a2-4fc4-9086-53d310b351e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_76ef8775-3c04-45a5-ba00-6002ab6f0fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_76ef8775-3c04-45a5-ba00-6002ab6f0fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b853a781-0d61-4fce-9a43-c0253c5204fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_470cac89-d9c9-415e-a6e6-094fb8b9e047" xlink:to="loc_us-gaap_StockholdersEquity_b853a781-0d61-4fce-9a43-c0253c5204fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ccrn-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d937afd0-31f2-4268-9a6e-ef96ae6086ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33b54a10-84a1-469c-b2e8-3664f40e9b70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d937afd0-31f2-4268-9a6e-ef96ae6086ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33b54a10-84a1-469c-b2e8-3664f40e9b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2abf1363-3f08-47e1-b223-026e14c42392" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33b54a10-84a1-469c-b2e8-3664f40e9b70" xlink:to="loc_us-gaap_NetIncomeLoss_2abf1363-3f08-47e1-b223-026e14c42392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d7a023-4973-4e4f-b84f-8d20ec9ca328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33b54a10-84a1-469c-b2e8-3664f40e9b70" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d7a023-4973-4e4f-b84f-8d20ec9ca328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b07b7f8b-ccef-4a7b-8ae3-74a62d056714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d7a023-4973-4e4f-b84f-8d20ec9ca328" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b07b7f8b-ccef-4a7b-8ae3-74a62d056714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances_92b53746-fe24-4986-a861-0d2ed62f70c5" xlink:href="ccrn-20250331.xsd#ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d7a023-4973-4e4f-b84f-8d20ec9ca328" xlink:to="loc_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances_92b53746-fe24-4986-a861-0d2ed62f70c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_55879b0e-5560-44f3-a973-517b260866b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d7a023-4973-4e4f-b84f-8d20ec9ca328" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_55879b0e-5560-44f3-a973-517b260866b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OperatingLeaseExpenseNonCash_92b5454d-620b-4a58-8cac-41135eb0e212" xlink:href="ccrn-20250331.xsd#ccrn_OperatingLeaseExpenseNonCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d7a023-4973-4e4f-b84f-8d20ec9ca328" xlink:to="loc_ccrn_OperatingLeaseExpenseNonCash_92b5454d-620b-4a58-8cac-41135eb0e212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_45f74195-f196-42b5-b499-0d9461bfbfba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d7a023-4973-4e4f-b84f-8d20ec9ca328" xlink:to="loc_us-gaap_AssetImpairmentCharges_45f74195-f196-42b5-b499-0d9461bfbfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_27af5268-c5ba-4f73-bb24-3f78da8a9fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d7a023-4973-4e4f-b84f-8d20ec9ca328" xlink:to="loc_us-gaap_ShareBasedCompensation_27af5268-c5ba-4f73-bb24-3f78da8a9fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_a8c2e895-3280-474f-931c-061815ecc82c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d7a023-4973-4e4f-b84f-8d20ec9ca328" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_a8c2e895-3280-474f-931c-061815ecc82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_012f24f0-a85b-46ea-b79b-a21a9c4f71dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d7a023-4973-4e4f-b84f-8d20ec9ca328" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_012f24f0-a85b-46ea-b79b-a21a9c4f71dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fb24faf8-8f44-414a-b42a-0be05768b709" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_012f24f0-a85b-46ea-b79b-a21a9c4f71dd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fb24faf8-8f44-414a-b42a-0be05768b709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0e8bab56-ba57-431b-b37c-68052d3d428e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_012f24f0-a85b-46ea-b79b-a21a9c4f71dd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0e8bab56-ba57-431b-b37c-68052d3d428e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_699f6a05-9895-4d9b-9d05-639b5cd74181" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_012f24f0-a85b-46ea-b79b-a21a9c4f71dd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_699f6a05-9895-4d9b-9d05-639b5cd74181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7beb63b4-109d-4175-b89b-f78dae2b41fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_012f24f0-a85b-46ea-b79b-a21a9c4f71dd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7beb63b4-109d-4175-b89b-f78dae2b41fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities_cbfcc014-42f5-45a4-869b-4cfa9e969988" xlink:href="ccrn-20250331.xsd#ccrn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_012f24f0-a85b-46ea-b79b-a21a9c4f71dd" xlink:to="loc_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities_cbfcc014-42f5-45a4-869b-4cfa9e969988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3cb3d74d-2149-4932-9145-aa86ba90fbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_012f24f0-a85b-46ea-b79b-a21a9c4f71dd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3cb3d74d-2149-4932-9145-aa86ba90fbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4abd76f-3671-408b-aa15-fb8b91a6a6db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33b54a10-84a1-469c-b2e8-3664f40e9b70" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4abd76f-3671-408b-aa15-fb8b91a6a6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ecdcfb-b1e3-4851-96ae-dbd962b4d23b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d937afd0-31f2-4268-9a6e-ef96ae6086ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ecdcfb-b1e3-4851-96ae-dbd962b4d23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_78eab130-6341-4dd5-924b-c1925440a3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ecdcfb-b1e3-4851-96ae-dbd962b4d23b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_78eab130-6341-4dd5-924b-c1925440a3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0ca72a26-cfa0-455a-a58f-1b7780c131c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ecdcfb-b1e3-4851-96ae-dbd962b4d23b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0ca72a26-cfa0-455a-a58f-1b7780c131c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_957c8340-1830-4958-9b31-a10172cf8822" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d937afd0-31f2-4268-9a6e-ef96ae6086ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_957c8340-1830-4958-9b31-a10172cf8822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_517f21d5-617b-44f7-a155-bc422097ba08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_957c8340-1830-4958-9b31-a10172cf8822" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_517f21d5-617b-44f7-a155-bc422097ba08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_fcecd3a6-ea16-4b27-90a6-5b87503ffca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_957c8340-1830-4958-9b31-a10172cf8822" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_fcecd3a6-ea16-4b27-90a6-5b87503ffca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f070167b-9934-41ff-aa93-f221bb33c8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_957c8340-1830-4958-9b31-a10172cf8822" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f070167b-9934-41ff-aa93-f221bb33c8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_79b742ab-21cb-499a-8b6e-af0534bd5b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_957c8340-1830-4958-9b31-a10172cf8822" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_79b742ab-21cb-499a-8b6e-af0534bd5b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_43b05c61-a56e-4ea6-957d-f0b213ecfc65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_957c8340-1830-4958-9b31-a10172cf8822" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_43b05c61-a56e-4ea6-957d-f0b213ecfc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_14f9f9d7-2641-4b41-9029-ba3842ca4291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_957c8340-1830-4958-9b31-a10172cf8822" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_14f9f9d7-2641-4b41-9029-ba3842ca4291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2702bf00-b4fd-43f5-a679-534153727252" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d937afd0-31f2-4268-9a6e-ef96ae6086ef" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2702bf00-b4fd-43f5-a679-534153727252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e64f044-5d17-4d84-9980-e9ffc525f51d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d937afd0-31f2-4268-9a6e-ef96ae6086ef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e64f044-5d17-4d84-9980-e9ffc525f51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54879a6c-3315-4f4f-89f0-743a21985aed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d937afd0-31f2-4268-9a6e-ef96ae6086ef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54879a6c-3315-4f4f-89f0-743a21985aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16b95594-694c-47d6-9139-d4bccca90c63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d937afd0-31f2-4268-9a6e-ef96ae6086ef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16b95594-694c-47d6-9139-d4bccca90c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATION" xlink:type="simple" xlink:href="ccrn-20250331.xsd#ORGANIZATIONANDBASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b67ac1ec-1987-4d67-8a0c-39330d5ccc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1f2a8c34-0abc-4c1d-8f71-4ad45350b45c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b67ac1ec-1987-4d67-8a0c-39330d5ccc6a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1f2a8c34-0abc-4c1d-8f71-4ad45350b45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5b27786f-da11-4e50-9aa2-7a780a3a6c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e1ee9ba0-9922-4385-a757-3f9de2c62c08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b27786f-da11-4e50-9aa2-7a780a3a6c2e" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e1ee9ba0-9922-4385-a757-3f9de2c62c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="ccrn-20250331.xsd#REVENUERECOGNITION"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_21daff7e-106b-4abf-b871-2e2c81d6833f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_56f6bc30-58dd-42af-a6f6-07a26f5bcf77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_21daff7e-106b-4abf-b871-2e2c81d6833f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_56f6bc30-58dd-42af-a6f6-07a26f5bcf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="ccrn-20250331.xsd#ACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/ACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1a637414-1f47-48ba-9bb7-c42acb30ac49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8e2a31bc-ef29-4abf-ba3a-67b9be98357b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1a637414-1f47-48ba-9bb7-c42acb30ac49" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8e2a31bc-ef29-4abf-ba3a-67b9be98357b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/COMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="ccrn-20250331.xsd#COMPREHENSIVELOSSINCOME"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/COMPREHENSIVELOSSINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_45909ce8-4f84-48ae-9791-222ae80bf4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_179b19c7-4024-48c0-a539-c9c5102bc5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_45909ce8-4f84-48ae-9791-222ae80bf4a3" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_179b19c7-4024-48c0-a539-c9c5102bc5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARE" xlink:type="simple" xlink:href="ccrn-20250331.xsd#EARNINGSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_272870e8-b5f1-496e-a160-4b05a240b78a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_487b92c5-360e-4efe-86a3-4dbea0cf984c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_272870e8-b5f1-496e-a160-4b05a240b78a" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_487b92c5-360e-4efe-86a3-4dbea0cf984c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS" xlink:type="simple" xlink:href="ccrn-20250331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ad1ab6bd-b617-4b3c-9769-4bd0190b23fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5aa7c231-28c3-49ac-a7ec-80c95a7ac644" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ad1ab6bd-b617-4b3c-9769-4bd0190b23fc" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5aa7c231-28c3-49ac-a7ec-80c95a7ac644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBT" xlink:type="simple" xlink:href="ccrn-20250331.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b65155a8-6472-49c5-bf3b-f6e0e13fd9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_eb8e70eb-e078-49f8-873b-8d612b8504b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b65155a8-6472-49c5-bf3b-f6e0e13fd9ed" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_eb8e70eb-e078-49f8-873b-8d612b8504b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASES" xlink:type="simple" xlink:href="ccrn-20250331.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7b2c14a8-40d0-4365-a200-5030ee3ff002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_c5fe62d2-2cf6-4019-9545-8cfd8e93794d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7b2c14a8-40d0-4365-a200-5030ee3ff002" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_c5fe62d2-2cf6-4019-9545-8cfd8e93794d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="ccrn-20250331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_debbbddd-0596-4877-8ffd-32ca80ea743f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_98ee19bf-2c1e-4824-b510-38dfec558890" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_debbbddd-0596-4877-8ffd-32ca80ea743f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_98ee19bf-2c1e-4824-b510-38dfec558890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ccrn-20250331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_43acbe2b-4794-4a98-a55b-e84e9f9d8b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_427e8828-853b-43c1-803c-af618ae6507b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_43acbe2b-4794-4a98-a55b-e84e9f9d8b9e" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_427e8828-853b-43c1-803c-af618ae6507b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATA" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SEGMENTDATA"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SEGMENTDATA" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_20abdabe-24f9-4d36-b90e-804912bf014f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_d479a3c5-da84-4b4a-8315-687af9c1fdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_20abdabe-24f9-4d36-b90e-804912bf014f" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_d479a3c5-da84-4b4a-8315-687af9c1fdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONTINGENCIES" xlink:type="simple" xlink:href="ccrn-20250331.xsd#CONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_27c9c25f-2130-4a66-aeff-62c0d6a4116a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_88b040de-b4df-4f54-9ed5-74649862aa47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_27c9c25f-2130-4a66-aeff-62c0d6a4116a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_88b040de-b4df-4f54-9ed5-74649862aa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/INCOMETAXES" xlink:type="simple" xlink:href="ccrn-20250331.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_144b1e61-391d-45bc-afa2-6caa80af2951" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_59e4c976-bf3b-4f8c-8564-086406237e80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_144b1e61-391d-45bc-afa2-6caa80af2951" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_59e4c976-bf3b-4f8c-8564-086406237e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="ccrn-20250331.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6e900321-f81a-45c6-b0d8-8364cfee611f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6e51e9c5-418c-40aa-a95d-23ee90c9d50b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6e900321-f81a-45c6-b0d8-8364cfee611f" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6e51e9c5-418c-40aa-a95d-23ee90c9d50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c515724c-f4c6-438d-8ec9-13fa04a7bd41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d768fedd-2e8e-49fc-88db-6c0894993e22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c515724c-f4c6-438d-8ec9-13fa04a7bd41" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d768fedd-2e8e-49fc-88db-6c0894993e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4a0542ef-4c78-4ab7-bda6-acad383b4d59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c515724c-f4c6-438d-8ec9-13fa04a7bd41" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4a0542ef-4c78-4ab7-bda6-acad383b4d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_bd320046-c1ed-4d4a-88bf-5668cf1f08c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c515724c-f4c6-438d-8ec9-13fa04a7bd41" xlink:to="loc_us-gaap_UseOfEstimates_bd320046-c1ed-4d4a-88bf-5668cf1f08c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_RisksAndUncertaintiesPolicyTextBlock_b7d1b391-9204-4b5d-b460-baed9a4cef55" xlink:href="ccrn-20250331.xsd#ccrn_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c515724c-f4c6-438d-8ec9-13fa04a7bd41" xlink:to="loc_ccrn_RisksAndUncertaintiesPolicyTextBlock_b7d1b391-9204-4b5d-b460-baed9a4cef55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_f9116ac9-21ff-4002-8f8a-d3649c45512d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c515724c-f4c6-438d-8ec9-13fa04a7bd41" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_f9116ac9-21ff-4002-8f8a-d3649c45512d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_43a955f9-a347-4976-9529-bf7132e8d240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c515724c-f4c6-438d-8ec9-13fa04a7bd41" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_43a955f9-a347-4976-9529-bf7132e8d240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7af20a59-3a63-40b9-bde9-1e5791a0d895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c515724c-f4c6-438d-8ec9-13fa04a7bd41" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7af20a59-3a63-40b9-bde9-1e5791a0d895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cd020a65-146b-4b88-b14b-8a0b564e0578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_2a676eb8-7891-4ad0-8108-4692999235b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cd020a65-146b-4b88-b14b-8a0b564e0578" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_2a676eb8-7891-4ad0-8108-4692999235b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_fc5a6e5a-a4a4-43cd-9fc8-eba74ef15c09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cd020a65-146b-4b88-b14b-8a0b564e0578" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_fc5a6e5a-a4a4-43cd-9fc8-eba74ef15c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONTables" xlink:type="simple" xlink:href="ccrn-20250331.xsd#REVENUERECOGNITIONTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_495d8167-efb7-4bee-94a8-b26cabd12b88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d7dade4b-fc26-4462-b05a-131d96ed19f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_495d8167-efb7-4bee-94a8-b26cabd12b88" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d7dade4b-fc26-4462-b05a-131d96ed19f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARETables" xlink:type="simple" xlink:href="ccrn-20250331.xsd#EARNINGSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_41e37875-99cf-49bc-b88a-de8b4bfbe562" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3d2777b9-93c8-4ca9-b30e-72cec928bd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_41e37875-99cf-49bc-b88a-de8b4bfbe562" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3d2777b9-93c8-4ca9-b30e-72cec928bd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_821fce39-0c9f-42d4-96b1-44f66f7b20df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_41e37875-99cf-49bc-b88a-de8b4bfbe562" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_821fce39-0c9f-42d4-96b1-44f66f7b20df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="ccrn-20250331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_58fac176-7cc4-43f4-ba10-165a336ac0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_923ddeb0-8bc5-45c0-943c-3a6d1a5ce8be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_58fac176-7cc4-43f4-ba10-165a336ac0d9" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_923ddeb0-8bc5-45c0-943c-3a6d1a5ce8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_29b7cef6-442b-4de5-8222-8d8c6d9757b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_58fac176-7cc4-43f4-ba10-165a336ac0d9" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_29b7cef6-442b-4de5-8222-8d8c6d9757b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBTTables" xlink:type="simple" xlink:href="ccrn-20250331.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_85e7f939-93a0-4b17-b99e-119465d3bfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_b514cfce-ab10-400b-a9ab-cd98a473b003" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_85e7f939-93a0-4b17-b99e-119465d3bfa1" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_b514cfce-ab10-400b-a9ab-cd98a473b003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASESTables" xlink:type="simple" xlink:href="ccrn-20250331.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b168abc6-f2a0-4be7-b97f-5afedf0a3057" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock_1ed37d7c-424e-4130-83d9-c6975bcfec8a" xlink:href="ccrn-20250331.xsd#ccrn_AssetsAndLiabilitiesLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b168abc6-f2a0-4be7-b97f-5afedf0a3057" xlink:to="loc_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock_1ed37d7c-424e-4130-83d9-c6975bcfec8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1cc79ad8-d9d7-48ae-85e9-7c8152614cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b168abc6-f2a0-4be7-b97f-5afedf0a3057" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1cc79ad8-d9d7-48ae-85e9-7c8152614cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_f98a6eb0-c925-4225-91c8-be91eae38c14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b168abc6-f2a0-4be7-b97f-5afedf0a3057" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_f98a6eb0-c925-4225-91c8-be91eae38c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="ccrn-20250331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_351dc016-3903-49bc-9ee0-50082f6f0484" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ef3187a0-2d0f-47e5-916b-34d136531cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_351dc016-3903-49bc-9ee0-50082f6f0484" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ef3187a0-2d0f-47e5-916b-34d136531cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="ccrn-20250331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_50bb5174-e4e5-49e7-8f23-af899324051a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1a6c72c4-8afd-4b5b-ab2f-e992ed2330d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_50bb5174-e4e5-49e7-8f23-af899324051a" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1a6c72c4-8afd-4b5b-ab2f-e992ed2330d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATATables" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SEGMENTDATATables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SEGMENTDATATables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f9ff5351-06f5-4d0d-b91d-798f9f1623b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_b4562fbf-952b-4a95-92a7-aea66b4f2361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f9ff5351-06f5-4d0d-b91d-798f9f1623b3" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_b4562fbf-952b-4a95-92a7-aea66b4f2361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98cddeff-6a2d-4164-b8aa-7f75e31d97c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_87bcc945-e7a5-4106-8acf-6a3db064405e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98cddeff-6a2d-4164-b8aa-7f75e31d97c8" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_87bcc945-e7a5-4106-8acf-6a3db064405e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_48ec80c3-9881-4c7c-acbb-c93fe3622f92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_87bcc945-e7a5-4106-8acf-6a3db064405e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_48ec80c3-9881-4c7c-acbb-c93fe3622f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3576a10-50cb-4cf9-a2f4-262079bf49cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_48ec80c3-9881-4c7c-acbb-c93fe3622f92" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3576a10-50cb-4cf9-a2f4-262079bf49cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AyaHoldingsIIInc.Member_9bc85817-91bf-4711-b988-9fcc5d46e0c4" xlink:href="ccrn-20250331.xsd#ccrn_AyaHoldingsIIInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3576a10-50cb-4cf9-a2f4-262079bf49cb" xlink:to="loc_ccrn_AyaHoldingsIIInc.Member_9bc85817-91bf-4711-b988-9fcc5d46e0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_35b5619f-aa96-47a5-8575-ddff4dbd6fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_87bcc945-e7a5-4106-8acf-6a3db064405e" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_35b5619f-aa96-47a5-8575-ddff4dbd6fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_93d417c7-33cb-46ea-8e9f-1186bc29b9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_35b5619f-aa96-47a5-8575-ddff4dbd6fa9" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_93d417c7-33cb-46ea-8e9f-1186bc29b9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_baaf86f2-f329-420d-939d-3b439ba8dc74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d111facf-b463-4e27-bbd7-ab4054b3f140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_baaf86f2-f329-420d-939d-3b439ba8dc74" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d111facf-b463-4e27-bbd7-ab4054b3f140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3cc6aa36-0f79-4177-8baf-5aadc37f9fd2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d111facf-b463-4e27-bbd7-ab4054b3f140" xlink:to="loc_srt_RangeAxis_3cc6aa36-0f79-4177-8baf-5aadc37f9fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5281f673-27ac-4d28-8fe8-fcd61b8fc604" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3cc6aa36-0f79-4177-8baf-5aadc37f9fd2" xlink:to="loc_srt_RangeMember_5281f673-27ac-4d28-8fe8-fcd61b8fc604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0e7a3d07-db63-46fe-8adf-8afd4b77fd33" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5281f673-27ac-4d28-8fe8-fcd61b8fc604" xlink:to="loc_srt_MinimumMember_0e7a3d07-db63-46fe-8adf-8afd4b77fd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6f41dbbf-3b17-4271-a046-0873f9bdede2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5281f673-27ac-4d28-8fe8-fcd61b8fc604" xlink:to="loc_srt_MaximumMember_6f41dbbf-3b17-4271-a046-0873f9bdede2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e1318bbb-d299-400a-a240-ddd5a2cac3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d111facf-b463-4e27-bbd7-ab4054b3f140" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e1318bbb-d299-400a-a240-ddd5a2cac3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_1e2039c6-df0a-47f4-88a7-e15846986136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e1318bbb-d299-400a-a240-ddd5a2cac3f2" xlink:to="loc_us-gaap_UnbilledContractsReceivable_1e2039c6-df0a-47f4-88a7-e15846986136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SalesAllowanceBillingRelatedAdjustments_85f26afe-1094-424d-b9a6-8ba68d7233af" xlink:href="ccrn-20250331.xsd#ccrn_SalesAllowanceBillingRelatedAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e1318bbb-d299-400a-a240-ddd5a2cac3f2" xlink:to="loc_ccrn_SalesAllowanceBillingRelatedAdjustments_85f26afe-1094-424d-b9a6-8ba68d7233af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided_1406fd48-5cbd-4764-aa03-9ff5cd3f3296" xlink:href="ccrn-20250331.xsd#ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e1318bbb-d299-400a-a240-ddd5a2cac3f2" xlink:to="loc_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided_1406fd48-5cbd-4764-aa03-9ff5cd3f3296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_55a0c455-25ff-4449-9ccc-78b199eb6cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_ce529bad-20b9-45a4-a10b-ab8632573e96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55a0c455-25ff-4449-9ccc-78b199eb6cf6" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_ce529bad-20b9-45a4-a10b-ab8632573e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_246fcbf6-ba95-424e-9999-03336eb083a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_ce529bad-20b9-45a4-a10b-ab8632573e96" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_246fcbf6-ba95-424e-9999-03336eb083a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_29569019-ea5f-46ca-9ee4-173ed881e2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_ce529bad-20b9-45a4-a10b-ab8632573e96" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_29569019-ea5f-46ca-9ee4-173ed881e2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery_c62aa412-da2b-40ab-a656-917411320b17" xlink:href="ccrn-20250331.xsd#ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_ce529bad-20b9-45a4-a10b-ab8632573e96" xlink:to="loc_ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery_c62aa412-da2b-40ab-a656-917411320b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_c2fe1281-e1ec-4a13-b732-c36a5843bde0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_ce529bad-20b9-45a4-a10b-ab8632573e96" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_c2fe1281-e1ec-4a13-b732-c36a5843bde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c6847244-9adf-4d22-9160-22b224423416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8b4d40ac-dab8-434b-9e42-8461823e0aca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c6847244-9adf-4d22-9160-22b224423416" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8b4d40ac-dab8-434b-9e42-8461823e0aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2f5a160d-394c-4a68-a6c5-635b50bb8b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8b4d40ac-dab8-434b-9e42-8461823e0aca" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2f5a160d-394c-4a68-a6c5-635b50bb8b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_da8cf77b-fdf5-4c95-82be-a8a6c348045d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2f5a160d-394c-4a68-a6c5-635b50bb8b3c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_da8cf77b-fdf5-4c95-82be-a8a6c348045d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_4b977b2a-5af8-42ac-82d8-60755ee8006d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_da8cf77b-fdf5-4c95-82be-a8a6c348045d" xlink:to="loc_us-gaap_EmployeeSeveranceMember_4b977b2a-5af8-42ac-82d8-60755ee8006d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ExitCostsMember_467771b8-ac15-4c8e-a12d-ee05b90ac5cf" xlink:href="ccrn-20250331.xsd#ccrn_ExitCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_da8cf77b-fdf5-4c95-82be-a8a6c348045d" xlink:to="loc_ccrn_ExitCostsMember_467771b8-ac15-4c8e-a12d-ee05b90ac5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_01a2bdcd-fad5-4187-81e4-39eb7161ca15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8b4d40ac-dab8-434b-9e42-8461823e0aca" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_01a2bdcd-fad5-4187-81e4-39eb7161ca15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_d9bc0f3e-81d2-424c-8a0f-543547c1f425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_01a2bdcd-fad5-4187-81e4-39eb7161ca15" xlink:to="loc_us-gaap_RestructuringReserveRollForward_d9bc0f3e-81d2-424c-8a0f-543547c1f425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_efc5c9d3-cc58-45dd-98c5-62a184387e95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d9bc0f3e-81d2-424c-8a0f-543547c1f425" xlink:to="loc_us-gaap_RestructuringReserve_efc5c9d3-cc58-45dd-98c5-62a184387e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_751ad015-193d-4f27-aa59-328fd2a60997" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d9bc0f3e-81d2-424c-8a0f-543547c1f425" xlink:to="loc_us-gaap_RestructuringCharges_751ad015-193d-4f27-aa59-328fd2a60997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_352a47cc-06a9-4ccb-837b-8b4ce80171ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d9bc0f3e-81d2-424c-8a0f-543547c1f425" xlink:to="loc_us-gaap_PaymentsForRestructuring_352a47cc-06a9-4ccb-837b-8b4ce80171ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_7db180aa-e8d1-4ce0-b499-7f7ac9cbcece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d9bc0f3e-81d2-424c-8a0f-543547c1f425" xlink:to="loc_us-gaap_RestructuringReserve_7db180aa-e8d1-4ce0-b499-7f7ac9cbcece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#REVENUERECOGNITIONDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7a095210-f749-43ef-ab49-bf693620fe0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_27a7bdec-99d1-446e-ae6c-899d4c20b704" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7a095210-f749-43ef-ab49-bf693620fe0d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_27a7bdec-99d1-446e-ae6c-899d4c20b704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ee38076b-0000-46e8-81c6-e9a362efafa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_27a7bdec-99d1-446e-ae6c-899d4c20b704" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ee38076b-0000-46e8-81c6-e9a362efafa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fd8a417c-f2e1-476c-be2d-4dbb8d36848d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ee38076b-0000-46e8-81c6-e9a362efafa3" xlink:to="loc_us-gaap_SegmentDomain_fd8a417c-f2e1-476c-be2d-4dbb8d36848d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NurseAndAlliedStaffingMember_65ffa1de-6099-450a-b47e-b4679cd9223a" xlink:href="ccrn-20250331.xsd#ccrn_NurseAndAlliedStaffingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fd8a417c-f2e1-476c-be2d-4dbb8d36848d" xlink:to="loc_ccrn_NurseAndAlliedStaffingMember_65ffa1de-6099-450a-b47e-b4679cd9223a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PhysicianStaffingMember_c66fd75f-f6da-4fe7-8586-65aeaeb0f06a" xlink:href="ccrn-20250331.xsd#ccrn_PhysicianStaffingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fd8a417c-f2e1-476c-be2d-4dbb8d36848d" xlink:to="loc_ccrn_PhysicianStaffingMember_c66fd75f-f6da-4fe7-8586-65aeaeb0f06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ebadce31-c1cd-431e-89f8-3132cecbc224" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_27a7bdec-99d1-446e-ae6c-899d4c20b704" xlink:to="loc_srt_ProductOrServiceAxis_ebadce31-c1cd-431e-89f8-3132cecbc224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_415369d5-7d95-4764-ad87-a0a88afb9ea2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ebadce31-c1cd-431e-89f8-3132cecbc224" xlink:to="loc_srt_ProductsAndServicesDomain_415369d5-7d95-4764-ad87-a0a88afb9ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_TemporaryStaffingServicesMember_85ca2194-037d-49b6-b4bd-60c452adc141" xlink:href="ccrn-20250331.xsd#ccrn_TemporaryStaffingServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_415369d5-7d95-4764-ad87-a0a88afb9ea2" xlink:to="loc_ccrn_TemporaryStaffingServicesMember_85ca2194-037d-49b6-b4bd-60c452adc141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OtherServicesMember_42cb2b84-250b-4b7a-9cf2-365004567ee1" xlink:href="ccrn-20250331.xsd#ccrn_OtherServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_415369d5-7d95-4764-ad87-a0a88afb9ea2" xlink:to="loc_ccrn_OtherServicesMember_42cb2b84-250b-4b7a-9cf2-365004567ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e82b5596-62c5-45cb-b3c6-69ecf1a8f315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_27a7bdec-99d1-446e-ae6c-899d4c20b704" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e82b5596-62c5-45cb-b3c6-69ecf1a8f315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_649318a8-f2e7-4b60-a477-6e9d607c6138" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e82b5596-62c5-45cb-b3c6-69ecf1a8f315" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_649318a8-f2e7-4b60-a477-6e9d607c6138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#ACQUISITIONSDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7be8bb54-147c-4f4a-b086-7e04ff56f2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960c55f3-f73a-4b65-a227-eca0dd1fbd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7be8bb54-147c-4f4a-b086-7e04ff56f2a2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960c55f3-f73a-4b65-a227-eca0dd1fbd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_40e98ac2-67fd-4d3e-b994-83a1b0fe421b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960c55f3-f73a-4b65-a227-eca0dd1fbd7c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_40e98ac2-67fd-4d3e-b994-83a1b0fe421b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5a7c4e-9590-44f3-b97f-2d404e8da0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_40e98ac2-67fd-4d3e-b994-83a1b0fe421b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5a7c4e-9590-44f3-b97f-2d404e8da0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_HireUpLeadershipIncMember_d276201d-d860-4f68-888d-3cf58a14e43c" xlink:href="ccrn-20250331.xsd#ccrn_HireUpLeadershipIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5a7c4e-9590-44f3-b97f-2d404e8da0a3" xlink:to="loc_ccrn_HireUpLeadershipIncMember_d276201d-d860-4f68-888d-3cf58a14e43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember_bd1a0dc2-b54b-46f8-80f4-df6899f73d69" xlink:href="ccrn-20250331.xsd#ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5a7c4e-9590-44f3-b97f-2d404e8da0a3" xlink:to="loc_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember_bd1a0dc2-b54b-46f8-80f4-df6899f73d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_df3e1376-7ca4-4955-81bc-e490392c88d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960c55f3-f73a-4b65-a227-eca0dd1fbd7c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_df3e1376-7ca4-4955-81bc-e490392c88d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b64c2ac5-2b44-4ee3-8a67-895f9287cad5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_df3e1376-7ca4-4955-81bc-e490392c88d3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b64c2ac5-2b44-4ee3-8a67-895f9287cad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e6b73006-2a09-45f6-ae9d-0922541d6971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_df3e1376-7ca4-4955-81bc-e490392c88d3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e6b73006-2a09-45f6-ae9d-0922541d6971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_ba056c9f-9a02-45f5-ac63-289095583585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_df3e1376-7ca4-4955-81bc-e490392c88d3" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_ba056c9f-9a02-45f5-ac63-289095583585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8c3dd8e8-e974-44d8-8c84-da0ee0e7c36c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_df3e1376-7ca4-4955-81bc-e490392c88d3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8c3dd8e8-e974-44d8-8c84-da0ee0e7c36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a828a2c0-95e1-417b-a751-df542299c272" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_df3e1376-7ca4-4955-81bc-e490392c88d3" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a828a2c0-95e1-417b-a751-df542299c272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/COMPREHENSIVELOSSINCOMEDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#COMPREHENSIVELOSSINCOMEDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/COMPREHENSIVELOSSINCOMEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8410ccf9-11e4-42b5-9ccc-d91420332a38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax_8014f042-cd19-4c8d-96e8-4ee1f99882c6" xlink:href="ccrn-20250331.xsd#ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8410ccf9-11e4-42b5-9ccc-d91420332a38" xlink:to="loc_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax_8014f042-cd19-4c8d-96e8-4ee1f99882c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_38ef9c74-9b63-4974-b487-a62d1a52ee28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_58d4115f-e63e-4adf-a125-cfceaf858aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_38ef9c74-9b63-4974-b487-a62d1a52ee28" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_58d4115f-e63e-4adf-a125-cfceaf858aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_17c57ce1-aa0a-40a7-8419-762b35f23d91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_58d4115f-e63e-4adf-a125-cfceaf858aa8" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_17c57ce1-aa0a-40a7-8419-762b35f23d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_0b6deefe-7b63-484a-9b8f-faa486baacd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_58d4115f-e63e-4adf-a125-cfceaf858aa8" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_0b6deefe-7b63-484a-9b8f-faa486baacd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8338d638-cda2-4015-9d92-e881b799059c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_38ef9c74-9b63-4974-b487-a62d1a52ee28" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8338d638-cda2-4015-9d92-e881b799059c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0955ba7c-f0ab-4898-b2e0-af41beaf6d95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8338d638-cda2-4015-9d92-e881b799059c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0955ba7c-f0ab-4898-b2e0-af41beaf6d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_884a0542-2d2c-42e4-a813-95f2a9e4834f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8338d638-cda2-4015-9d92-e881b799059c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_884a0542-2d2c-42e4-a813-95f2a9e4834f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7123aa5b-2f1e-4393-af3c-fda542f1e989" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_884a0542-2d2c-42e4-a813-95f2a9e4834f" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7123aa5b-2f1e-4393-af3c-fda542f1e989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_44d30923-00b6-465b-8f7d-d3996903f91d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8338d638-cda2-4015-9d92-e881b799059c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_44d30923-00b6-465b-8f7d-d3996903f91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6ec85ebf-c749-4e54-988a-49869ef21f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_38ef9c74-9b63-4974-b487-a62d1a52ee28" xlink:to="loc_us-gaap_EarningsPerShareBasic_6ec85ebf-c749-4e54-988a-49869ef21f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_05a86c99-0b04-4013-96de-9e177d320d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_38ef9c74-9b63-4974-b487-a62d1a52ee28" xlink:to="loc_us-gaap_EarningsPerShareDiluted_05a86c99-0b04-4013-96de-9e177d320d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#EARNINGSPERSHAREAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9efbc871-4127-426d-b681-bc47202e78ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e7a40f70-bd4f-49dc-a6fa-c3518d408b70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9efbc871-4127-426d-b681-bc47202e78ca" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e7a40f70-bd4f-49dc-a6fa-c3518d408b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1b8c8b6c-221b-4756-af16-a4057587f9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e7a40f70-bd4f-49dc-a6fa-c3518d408b70" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1b8c8b6c-221b-4756-af16-a4057587f9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_99513b0d-d2eb-4435-9843-436bc414ec84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1b8c8b6c-221b-4756-af16-a4057587f9b2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_99513b0d-d2eb-4435-9843-436bc414ec84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_f93b9cbc-eaf0-44ca-831e-bcfa0719e2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_99513b0d-d2eb-4435-9843-436bc414ec84" xlink:to="loc_us-gaap_StockCompensationPlanMember_f93b9cbc-eaf0-44ca-831e-bcfa0719e2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5c38763c-1289-41c6-b8a6-27e846de7a83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e7a40f70-bd4f-49dc-a6fa-c3518d408b70" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5c38763c-1289-41c6-b8a6-27e846de7a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5287f786-770d-46f2-9b3b-0a74d15de27f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5c38763c-1289-41c6-b8a6-27e846de7a83" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5287f786-770d-46f2-9b3b-0a74d15de27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c59d25aa-34f0-425a-a497-184cc4e61e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_52fcf4d4-90b5-43db-aa1c-7d345b2c78fe" xlink:href="ccrn-20250331.xsd#ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c59d25aa-34f0-425a-a497-184cc4e61e7f" xlink:to="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_52fcf4d4-90b5-43db-aa1c-7d345b2c78fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07d1008e-56be-48b5-bc9e-674be178a34b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_52fcf4d4-90b5-43db-aa1c-7d345b2c78fe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07d1008e-56be-48b5-bc9e-674be178a34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e62d040-2c4f-483c-8ca4-ccbcf4d4ea6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07d1008e-56be-48b5-bc9e-674be178a34b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e62d040-2c4f-483c-8ca4-ccbcf4d4ea6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DatabasesMember_19072a49-034b-4916-90c9-691bae3e0448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DatabasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e62d040-2c4f-483c-8ca4-ccbcf4d4ea6b" xlink:to="loc_us-gaap_DatabasesMember_19072a49-034b-4916-90c9-691bae3e0448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_f611d7e7-1d17-45ee-9002-a79b72091861" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e62d040-2c4f-483c-8ca4-ccbcf4d4ea6b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_f611d7e7-1d17-45ee-9002-a79b72091861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_244863d9-820b-4d91-bb48-1331d2a64f4e" xlink:href="ccrn-20250331.xsd#ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_52fcf4d4-90b5-43db-aa1c-7d345b2c78fe" xlink:to="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_244863d9-820b-4d91-bb48-1331d2a64f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a64b4d0c-5b93-4920-ad78-e59fac0b7412" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_244863d9-820b-4d91-bb48-1331d2a64f4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a64b4d0c-5b93-4920-ad78-e59fac0b7412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7422f26c-ece3-4f1a-87ac-bb6619b6af32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a64b4d0c-5b93-4920-ad78-e59fac0b7412" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7422f26c-ece3-4f1a-87ac-bb6619b6af32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c07e9004-0035-454c-bac0-801657671de3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a64b4d0c-5b93-4920-ad78-e59fac0b7412" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c07e9004-0035-454c-bac0-801657671de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b556f163-98d2-4295-a33f-ff07a92b1033" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a64b4d0c-5b93-4920-ad78-e59fac0b7412" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b556f163-98d2-4295-a33f-ff07a92b1033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_37399942-0643-4254-acaf-eec35fa51f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_244863d9-820b-4d91-bb48-1331d2a64f4e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_37399942-0643-4254-acaf-eec35fa51f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedTradeNames_c91734a6-d96b-448e-834c-327dd86579c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedTradeNames"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_37399942-0643-4254-acaf-eec35fa51f6c" xlink:to="loc_us-gaap_IndefiniteLivedTradeNames_c91734a6-d96b-448e-834c-327dd86579c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e82d25d3-6e4c-4708-8205-80aec4af8844" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1bf23546-321e-45f0-b125-2bdfd19dc9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e82d25d3-6e4c-4708-8205-80aec4af8844" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1bf23546-321e-45f0-b125-2bdfd19dc9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e1ad390b-ce48-4b3d-b782-b607c3dc1f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e82d25d3-6e4c-4708-8205-80aec4af8844" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e1ad390b-ce48-4b3d-b782-b607c3dc1f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d72fbf21-17cd-441e-b0ee-b8392e1ef99d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e82d25d3-6e4c-4708-8205-80aec4af8844" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d72fbf21-17cd-441e-b0ee-b8392e1ef99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3bfb9fb6-8901-4677-9251-30db0d3e2248" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e82d25d3-6e4c-4708-8205-80aec4af8844" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3bfb9fb6-8901-4677-9251-30db0d3e2248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6163c069-8caa-4e79-9477-66a6a3578e57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e82d25d3-6e4c-4708-8205-80aec4af8844" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6163c069-8caa-4e79-9477-66a6a3578e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_f64cb530-901e-4d3e-9507-8a1ef56838b3" xlink:href="ccrn-20250331.xsd#ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e82d25d3-6e4c-4708-8205-80aec4af8844" xlink:to="loc_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_f64cb530-901e-4d3e-9507-8a1ef56838b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3bd9c05e-dfc2-4973-b7d0-67af8ac5e5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e82d25d3-6e4c-4708-8205-80aec4af8844" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3bd9c05e-dfc2-4973-b7d0-67af8ac5e5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_21ca5ac5-0e14-47ee-9d64-d65df86f67df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_7e0bc485-d3a9-4d4e-a4c8-1ba4499dc0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_21ca5ac5-0e14-47ee-9d64-d65df86f67df" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_7e0bc485-d3a9-4d4e-a4c8-1ba4499dc0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5a55b2cc-169e-4fd3-a3a8-21c7c52d6813" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7e0bc485-d3a9-4d4e-a4c8-1ba4499dc0eb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5a55b2cc-169e-4fd3-a3a8-21c7c52d6813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8158487a-be0f-48b6-b8a8-feb21d688c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5a55b2cc-169e-4fd3-a3a8-21c7c52d6813" xlink:to="loc_us-gaap_SegmentDomain_8158487a-be0f-48b6-b8a8-feb21d688c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NurseAndAlliedStaffingMember_696fff47-6da1-494b-b4f8-a3ff2d85475b" xlink:href="ccrn-20250331.xsd#ccrn_NurseAndAlliedStaffingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8158487a-be0f-48b6-b8a8-feb21d688c1e" xlink:to="loc_ccrn_NurseAndAlliedStaffingMember_696fff47-6da1-494b-b4f8-a3ff2d85475b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PhysicianStaffingMember_fd3cfe28-bbdf-4649-9079-615affbf6140" xlink:href="ccrn-20250331.xsd#ccrn_PhysicianStaffingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8158487a-be0f-48b6-b8a8-feb21d688c1e" xlink:to="loc_ccrn_PhysicianStaffingMember_fd3cfe28-bbdf-4649-9079-615affbf6140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_cd34134a-2f4d-4a56-9e87-45bd256bd706" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7e0bc485-d3a9-4d4e-a4c8-1ba4499dc0eb" xlink:to="loc_us-gaap_GoodwillLineItems_cd34134a-2f4d-4a56-9e87-45bd256bd706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_48fe2f89-2391-4b9e-9821-8aedcbcd44c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_cd34134a-2f4d-4a56-9e87-45bd256bd706" xlink:to="loc_us-gaap_Goodwill_48fe2f89-2391-4b9e-9821-8aedcbcd44c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#DEBTLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e8f6fdaf-cd2a-4385-8c50-897d774123bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c0cb3650-114b-45f5-ad8b-558b60bcaa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e8f6fdaf-cd2a-4385-8c50-897d774123bc" xlink:to="loc_us-gaap_DebtInstrumentTable_c0cb3650-114b-45f5-ad8b-558b60bcaa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_06c1632f-c935-4f99-b6c1-d20cf6933a12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c0cb3650-114b-45f5-ad8b-558b60bcaa0a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_06c1632f-c935-4f99-b6c1-d20cf6933a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c47a1cd3-e5d3-41a0-8430-e14db4de0078" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_06c1632f-c935-4f99-b6c1-d20cf6933a12" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c47a1cd3-e5d3-41a0-8430-e14db4de0078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2304523f-b37d-40b0-a599-d70525ee2e15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c47a1cd3-e5d3-41a0-8430-e14db4de0078" xlink:to="loc_us-gaap_LineOfCreditMember_2304523f-b37d-40b0-a599-d70525ee2e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ddb812ae-e378-43eb-a7ea-bc508c629348" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c0cb3650-114b-45f5-ad8b-558b60bcaa0a" xlink:to="loc_us-gaap_CreditFacilityAxis_ddb812ae-e378-43eb-a7ea-bc508c629348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_eb639981-9b7a-4b93-bcbc-a24c51bc3f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_ddb812ae-e378-43eb-a7ea-bc508c629348" xlink:to="loc_us-gaap_CreditFacilityDomain_eb639981-9b7a-4b93-bcbc-a24c51bc3f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SeniorSecuredAssetBasedLoanMember_e2fe5ae8-48c2-4312-8436-cf7b2d41e12d" xlink:href="ccrn-20250331.xsd#ccrn_SeniorSecuredAssetBasedLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_eb639981-9b7a-4b93-bcbc-a24c51bc3f1a" xlink:to="loc_ccrn_SeniorSecuredAssetBasedLoanMember_e2fe5ae8-48c2-4312-8436-cf7b2d41e12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9ee42316-e799-4b83-b0f9-02a7cd912d40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c0cb3650-114b-45f5-ad8b-558b60bcaa0a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9ee42316-e799-4b83-b0f9-02a7cd912d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b0ce1fd0-0227-47d3-9175-96d39efb3f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ee42316-e799-4b83-b0f9-02a7cd912d40" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b0ce1fd0-0227-47d3-9175-96d39efb3f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_70a439f9-78f0-4296-a80e-d133d595c8de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ee42316-e799-4b83-b0f9-02a7cd912d40" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_70a439f9-78f0-4296-a80e-d133d595c8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_41f88b9a-62ae-48f6-86f8-e5d60061bdec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ee42316-e799-4b83-b0f9-02a7cd912d40" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_41f88b9a-62ae-48f6-86f8-e5d60061bdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#DEBTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7aa26b02-b409-4505-89ca-d20c3475d26f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b6eaa907-20fb-451a-bb00-761d078afd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7aa26b02-b409-4505-89ca-d20c3475d26f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b6eaa907-20fb-451a-bb00-761d078afd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#DEBT2019AssetBasedLoanAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ea77e34c-a573-4b22-90ae-f62f3da573fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_d241951c-0711-4b66-879f-76a8d58f6888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ea77e34c-a573-4b22-90ae-f62f3da573fa" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_d241951c-0711-4b66-879f-76a8d58f6888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_866a2367-6b2e-45f4-aa3a-5904702fcbab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d241951c-0711-4b66-879f-76a8d58f6888" xlink:to="loc_us-gaap_CreditFacilityAxis_866a2367-6b2e-45f4-aa3a-5904702fcbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0ef97bdf-2d3c-4ae8-bf22-68c15578f523" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_866a2367-6b2e-45f4-aa3a-5904702fcbab" xlink:to="loc_us-gaap_CreditFacilityDomain_0ef97bdf-2d3c-4ae8-bf22-68c15578f523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SeniorSecuredAssetBasedLoanMember_f67aff30-ec55-44bb-a18d-441ab9b22524" xlink:href="ccrn-20250331.xsd#ccrn_SeniorSecuredAssetBasedLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0ef97bdf-2d3c-4ae8-bf22-68c15578f523" xlink:to="loc_ccrn_SeniorSecuredAssetBasedLoanMember_f67aff30-ec55-44bb-a18d-441ab9b22524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditSublimitAxis_f3abaaff-c783-4f2e-910f-074de2358aac" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditSublimitAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d241951c-0711-4b66-879f-76a8d58f6888" xlink:to="loc_ccrn_LineOfCreditSublimitAxis_f3abaaff-c783-4f2e-910f-074de2358aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditSublimitDomain_7c3c4239-3a06-4686-935c-fd9697a19109" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditSublimitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_LineOfCreditSublimitAxis_f3abaaff-c783-4f2e-910f-074de2358aac" xlink:to="loc_ccrn_LineOfCreditSublimitDomain_7c3c4239-3a06-4686-935c-fd9697a19109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SwingLoansSublimitMember_b9a1081a-42e3-4380-8c47-a0a9de085d65" xlink:href="ccrn-20250331.xsd#ccrn_SwingLoansSublimitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_LineOfCreditSublimitDomain_7c3c4239-3a06-4686-935c-fd9697a19109" xlink:to="loc_ccrn_SwingLoansSublimitMember_b9a1081a-42e3-4380-8c47-a0a9de085d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_StandbyLettersOfCreditSublimitMember_81f05011-ca1d-47a8-a4d7-aee100c81f4e" xlink:href="ccrn-20250331.xsd#ccrn_StandbyLettersOfCreditSublimitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_LineOfCreditSublimitDomain_7c3c4239-3a06-4686-935c-fd9697a19109" xlink:to="loc_ccrn_StandbyLettersOfCreditSublimitMember_81f05011-ca1d-47a8-a4d7-aee100c81f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_af4bdb9b-5425-4cda-9b18-dcbd10e3a46d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d241951c-0711-4b66-879f-76a8d58f6888" xlink:to="loc_us-gaap_VariableRateAxis_af4bdb9b-5425-4cda-9b18-dcbd10e3a46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8969140b-f30c-4853-9dc4-8d67f96a25e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_af4bdb9b-5425-4cda-9b18-dcbd10e3a46d" xlink:to="loc_us-gaap_VariableRateDomain_8969140b-f30c-4853-9dc4-8d67f96a25e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_674a5e48-9f1c-4f5a-ac48-c4a79d556479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_8969140b-f30c-4853-9dc4-8d67f96a25e0" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_674a5e48-9f1c-4f5a-ac48-c4a79d556479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_6b7cf422-9643-4996-92c9-a366d0169d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_8969140b-f30c-4853-9dc4-8d67f96a25e0" xlink:to="loc_us-gaap_BaseRateMember_6b7cf422-9643-4996-92c9-a366d0169d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d241951c-0711-4b66-879f-76a8d58f6888" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_3ff432ee-7265-4d11-b56d-a4e5bb0010c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_3ff432ee-7265-4d11-b56d-a4e5bb0010c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ae284d48-2b57-45d6-9bf9-2bff75643211" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ae284d48-2b57-45d6-9bf9-2bff75643211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources_1857a413-a358-42f9-a867-3e48f7b49843" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources_1857a413-a358-42f9-a867-3e48f7b49843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment_b88c13b9-a5e8-4185-968c-de7bab98295f" xlink:href="ccrn-20250331.xsd#ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment_b88c13b9-a5e8-4185-968c-de7bab98295f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_30b49bc4-9245-4c1e-ad54-ba1abf8fe55a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_LineOfCredit_30b49bc4-9245-4c1e-ad54-ba1abf8fe55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable_e381a6bd-fcc9-4eca-bbfb-f3a767adc4aa" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable_e381a6bd-fcc9-4eca-bbfb-f3a767adc4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditFacilityBorrowingBaseAvailability_abd625db-0f4b-4dcf-93cb-66619632f253" xlink:href="ccrn-20250331.xsd#ccrn_LineOfCreditFacilityBorrowingBaseAvailability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_ccrn_LineOfCreditFacilityBorrowingBaseAvailability_abd625db-0f4b-4dcf-93cb-66619632f253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_0c8d1f20-d516-4451-be99-9565d7183841" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_0c8d1f20-d516-4451-be99-9565d7183841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_76f8814d-ee0f-4b25-9b61-004fb0953b45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_76f8814d-ee0f-4b25-9b61-004fb0953b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_08143988-5cb6-4a82-85c8-e4a44437c738" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_08143988-5cb6-4a82-85c8-e4a44437c738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_24e08aef-c0fc-4d6b-8e05-ce02c4a2d579" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_9884ebdd-b9a4-46e5-adbc-92c8ddb3a357" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_24e08aef-c0fc-4d6b-8e05-ce02c4a2d579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#LEASESSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1ded0f37-c48c-4f79-9534-c853a1c3caa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5da86aec-8f15-4431-9f18-c5f5bd084907" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ded0f37-c48c-4f79-9534-c853a1c3caa3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5da86aec-8f15-4431-9f18-c5f5bd084907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d1b533d5-6525-4786-85c7-756eb842600d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ded0f37-c48c-4f79-9534-c853a1c3caa3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d1b533d5-6525-4786-85c7-756eb842600d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7165456a-f407-4e5a-89ff-58ffc9ad2ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ded0f37-c48c-4f79-9534-c853a1c3caa3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7165456a-f407-4e5a-89ff-58ffc9ad2ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9052987d-34a7-439e-8c47-670eed9947fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ded0f37-c48c-4f79-9534-c853a1c3caa3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9052987d-34a7-439e-8c47-670eed9947fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_270919b9-1815-4e72-bffd-1510e3105d72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ded0f37-c48c-4f79-9534-c853a1c3caa3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_270919b9-1815-4e72-bffd-1510e3105d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#LEASESOperatingLeaseMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fe70a11a-a3ef-4f02-9fc6-d1bd6e735f24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b82f948d-2548-4431-b62b-38be88b8b15e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fe70a11a-a3ef-4f02-9fc6-d1bd6e735f24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b82f948d-2548-4431-b62b-38be88b8b15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9dd863c9-4b20-4143-8090-273cd01f12d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fe70a11a-a3ef-4f02-9fc6-d1bd6e735f24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9dd863c9-4b20-4143-8090-273cd01f12d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_de4744af-340b-4e54-8985-70dc9730d548" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fe70a11a-a3ef-4f02-9fc6-d1bd6e735f24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_de4744af-340b-4e54-8985-70dc9730d548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fed1d7c5-98b6-4756-8e73-c25ffeaea008" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fe70a11a-a3ef-4f02-9fc6-d1bd6e735f24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fed1d7c5-98b6-4756-8e73-c25ffeaea008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d4787f39-3982-4f52-b5d6-aee24ff2aba2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fe70a11a-a3ef-4f02-9fc6-d1bd6e735f24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d4787f39-3982-4f52-b5d6-aee24ff2aba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_f805e813-819e-46fe-9944-8b2328f60dfb" xlink:href="ccrn-20250331.xsd#ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fe70a11a-a3ef-4f02-9fc6-d1bd6e735f24" xlink:to="loc_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_f805e813-819e-46fe-9944-8b2328f60dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_60f8465e-db07-42d0-8a79-7c847b2d07d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fe70a11a-a3ef-4f02-9fc6-d1bd6e735f24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_60f8465e-db07-42d0-8a79-7c847b2d07d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_22e5183d-84e7-458a-aa10-2eac5b6eee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fe70a11a-a3ef-4f02-9fc6-d1bd6e735f24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_22e5183d-84e7-458a-aa10-2eac5b6eee5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c20af35f-219c-46a5-97f6-fea1da24e254" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fe70a11a-a3ef-4f02-9fc6-d1bd6e735f24" xlink:to="loc_us-gaap_OperatingLeaseLiability_c20af35f-219c-46a5-97f6-fea1da24e254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_afc9d09e-086a-48ec-921f-982a9f911772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fe70a11a-a3ef-4f02-9fc6-d1bd6e735f24" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_afc9d09e-086a-48ec-921f-982a9f911772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a459d6db-b375-43eb-9987-720e99c746dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fe70a11a-a3ef-4f02-9fc6-d1bd6e735f24" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a459d6db-b375-43eb-9987-720e99c746dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#LEASESLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9381a504-0477-4eed-9d06-1e00b2957fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_bcbbde65-3e87-40cc-ad58-7982b82e35a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9381a504-0477-4eed-9d06-1e00b2957fb6" xlink:to="loc_us-gaap_OperatingLeasePayments_bcbbde65-3e87-40cc-ad58-7982b82e35a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5b9eee9f-9c36-4333-8615-9af9a8fcb143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9381a504-0477-4eed-9d06-1e00b2957fb6" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5b9eee9f-9c36-4333-8615-9af9a8fcb143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3f394a60-97f0-4507-b13c-cfc7cf9f7e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9381a504-0477-4eed-9d06-1e00b2957fb6" xlink:to="loc_us-gaap_OperatingLeaseCost_3f394a60-97f0-4507-b13c-cfc7cf9f7e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_a1bf9bac-5755-4dff-b47e-bc980716fc64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9381a504-0477-4eed-9d06-1e00b2957fb6" xlink:to="loc_us-gaap_ShortTermLeaseCost_a1bf9bac-5755-4dff-b47e-bc980716fc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_342da78e-c948-4cfa-b485-d582bcc26e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9381a504-0477-4eed-9d06-1e00b2957fb6" xlink:to="loc_us-gaap_VariableLeaseCost_342da78e-c948-4cfa-b485-d582bcc26e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_802cb87b-5275-4c05-b9f0-6fb31bb5b2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e8228dd-0b38-4097-8ff7-4690895dfb26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_802cb87b-5275-4c05-b9f0-6fb31bb5b2a4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e8228dd-0b38-4097-8ff7-4690895dfb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b2971630-1ed3-4e52-8a43-2f48e8c1f7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e8228dd-0b38-4097-8ff7-4690895dfb26" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b2971630-1ed3-4e52-8a43-2f48e8c1f7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b94d0099-20d1-4143-a09e-d467e8655b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b2971630-1ed3-4e52-8a43-2f48e8c1f7b9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b94d0099-20d1-4143-a09e-d467e8655b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DeferredCompensationMember_f697662c-453f-4d83-8e06-d7c96a5f95e7" xlink:href="ccrn-20250331.xsd#ccrn_DeferredCompensationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b94d0099-20d1-4143-a09e-d467e8655b5b" xlink:to="loc_ccrn_DeferredCompensationMember_f697662c-453f-4d83-8e06-d7c96a5f95e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_28dad11c-53de-4d75-9e03-033c09cc29ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e8228dd-0b38-4097-8ff7-4690895dfb26" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_28dad11c-53de-4d75-9e03-033c09cc29ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8df1603b-86b9-4735-bc82-66ea98a66df6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_28dad11c-53de-4d75-9e03-033c09cc29ef" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8df1603b-86b9-4735-bc82-66ea98a66df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DeferredCompensationMember_d9736bd4-93d1-475b-9bbc-e43cec477b6e" xlink:href="ccrn-20250331.xsd#ccrn_DeferredCompensationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8df1603b-86b9-4735-bc82-66ea98a66df6" xlink:to="loc_ccrn_DeferredCompensationMember_d9736bd4-93d1-475b-9bbc-e43cec477b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_25292f99-39fa-4ada-b686-fac1efd573f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e8228dd-0b38-4097-8ff7-4690895dfb26" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_25292f99-39fa-4ada-b686-fac1efd573f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bb69ccf4-04a3-470b-987d-8998bfaecc92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_25292f99-39fa-4ada-b686-fac1efd573f8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bb69ccf4-04a3-470b-987d-8998bfaecc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3ed8ec8e-d62f-4a58-b905-d5b6855745e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bb69ccf4-04a3-470b-987d-8998bfaecc92" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3ed8ec8e-d62f-4a58-b905-d5b6855745e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41050186-10a6-488a-9a79-547268c6da06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e8228dd-0b38-4097-8ff7-4690895dfb26" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41050186-10a6-488a-9a79-547268c6da06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1d407393-b67c-461d-b5ae-219dda283a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41050186-10a6-488a-9a79-547268c6da06" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1d407393-b67c-461d-b5ae-219dda283a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_1b2bd66c-3265-4cad-90e7-93517e960f83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41050186-10a6-488a-9a79-547268c6da06" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_1b2bd66c-3265-4cad-90e7-93517e960f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#FAIRVALUEMEASUREMENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dc33a497-4ef5-4e93-90ef-2e470ff51b97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FairValueMeasurementTable_7f334793-82d3-41c8-a44e-a7d2b33e81e3" xlink:href="ccrn-20250331.xsd#ccrn_FairValueMeasurementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dc33a497-4ef5-4e93-90ef-2e470ff51b97" xlink:to="loc_ccrn_FairValueMeasurementTable_7f334793-82d3-41c8-a44e-a7d2b33e81e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d68cfdd3-b123-4eb5-97e3-1bd76dd4ef34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_FairValueMeasurementTable_7f334793-82d3-41c8-a44e-a7d2b33e81e3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d68cfdd3-b123-4eb5-97e3-1bd76dd4ef34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_801cf86f-1134-4fd3-89f9-51a44ef860e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d68cfdd3-b123-4eb5-97e3-1bd76dd4ef34" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_801cf86f-1134-4fd3-89f9-51a44ef860e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember_e98bf187-d82d-469c-84bb-063b09e049bb" xlink:href="ccrn-20250331.xsd#ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_801cf86f-1134-4fd3-89f9-51a44ef860e9" xlink:to="loc_ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember_e98bf187-d82d-469c-84bb-063b09e049bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_HireUpLeadershipIncMember_9a7fc134-ccfc-48fb-94fc-6198198283fb" xlink:href="ccrn-20250331.xsd#ccrn_HireUpLeadershipIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_801cf86f-1134-4fd3-89f9-51a44ef860e9" xlink:to="loc_ccrn_HireUpLeadershipIncMember_9a7fc134-ccfc-48fb-94fc-6198198283fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FairValueMeasurementLineItems_13e483f8-66c9-4a4f-ba2c-c8b94bb99870" xlink:href="ccrn-20250331.xsd#ccrn_FairValueMeasurementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_FairValueMeasurementTable_7f334793-82d3-41c8-a44e-a7d2b33e81e3" xlink:to="loc_ccrn_FairValueMeasurementLineItems_13e483f8-66c9-4a4f-ba2c-c8b94bb99870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_69ff1c48-5f1e-426e-8a5c-812c2b733679" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_FairValueMeasurementLineItems_13e483f8-66c9-4a4f-ba2c-c8b94bb99870" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_69ff1c48-5f1e-426e-8a5c-812c2b733679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_766a2161-42d0-4b09-96b3-8e283d12722f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c68bd9e-1bd7-44da-88cf-4697c3caa584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_766a2161-42d0-4b09-96b3-8e283d12722f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c68bd9e-1bd7-44da-88cf-4697c3caa584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_1866a7ce-d696-4c29-a09b-142a2b54bb4d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c68bd9e-1bd7-44da-88cf-4697c3caa584" xlink:to="loc_srt_ShareRepurchaseProgramAxis_1866a7ce-d696-4c29-a09b-142a2b54bb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_6cc89c96-576c-44b7-b556-87a833e30961" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramAxis_1866a7ce-d696-4c29-a09b-142a2b54bb4d" xlink:to="loc_srt_ShareRepurchaseProgramDomain_6cc89c96-576c-44b7-b556-87a833e30961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_RepurchaseProgramMember_62c257fc-5c50-4fa7-8854-53b12e3bd662" xlink:href="ccrn-20250331.xsd#ccrn_RepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_6cc89c96-576c-44b7-b556-87a833e30961" xlink:to="loc_ccrn_RepurchaseProgramMember_62c257fc-5c50-4fa7-8854-53b12e3bd662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fd84908b-63d5-42cc-b1a0-71f2afa5126e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c68bd9e-1bd7-44da-88cf-4697c3caa584" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fd84908b-63d5-42cc-b1a0-71f2afa5126e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2c8203b4-899b-4b99-9e0e-5a0493b7f91f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fd84908b-63d5-42cc-b1a0-71f2afa5126e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2c8203b4-899b-4b99-9e0e-5a0493b7f91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9f67cf89-5fa9-49ff-ac6e-ec57c0d69db4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2c8203b4-899b-4b99-9e0e-5a0493b7f91f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9f67cf89-5fa9-49ff-ac6e-ec57c0d69db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9b234eb6-d696-4f52-9fb9-c7fee6038df5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c68bd9e-1bd7-44da-88cf-4697c3caa584" xlink:to="loc_us-gaap_AwardTypeAxis_9b234eb6-d696-4f52-9fb9-c7fee6038df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a738dee0-88c9-44f2-b8a4-eb468c65f222" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9b234eb6-d696-4f52-9fb9-c7fee6038df5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a738dee0-88c9-44f2-b8a4-eb468c65f222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_RestrictedStockAndPerformanceSharesMember_2466d8b4-16d1-49e0-a955-1eaab368d1ad" xlink:href="ccrn-20250331.xsd#ccrn_RestrictedStockAndPerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a738dee0-88c9-44f2-b8a4-eb468c65f222" xlink:to="loc_ccrn_RestrictedStockAndPerformanceSharesMember_2466d8b4-16d1-49e0-a955-1eaab368d1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4a700c70-5685-4d48-bb61-27d5df189c12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_RestrictedStockAndPerformanceSharesMember_2466d8b4-16d1-49e0-a955-1eaab368d1ad" xlink:to="loc_us-gaap_PerformanceSharesMember_4a700c70-5685-4d48-bb61-27d5df189c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f289fd7e-b2f6-48be-88a7-6a106aff878f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c68bd9e-1bd7-44da-88cf-4697c3caa584" xlink:to="loc_us-gaap_PlanNameAxis_f289fd7e-b2f6-48be-88a7-6a106aff878f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_39225b34-b5d1-4710-8090-90eea3ebe074" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f289fd7e-b2f6-48be-88a7-6a106aff878f" xlink:to="loc_us-gaap_PlanNameDomain_39225b34-b5d1-4710-8090-90eea3ebe074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OmnibusPlanMember_c8c7c0bd-8da9-48a5-a17c-15747341bfca" xlink:href="ccrn-20250331.xsd#ccrn_OmnibusPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_39225b34-b5d1-4710-8090-90eea3ebe074" xlink:to="loc_ccrn_OmnibusPlanMember_c8c7c0bd-8da9-48a5-a17c-15747341bfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c68bd9e-1bd7-44da-88cf-4697c3caa584" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount_a132e8f9-0582-4050-b0e8-68ff461532d6" xlink:href="ccrn-20250331.xsd#ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount_a132e8f9-0582-4050-b0e8-68ff461532d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_32867c2f-53b9-4562-a281-85c8ea40e87e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_32867c2f-53b9-4562-a281-85c8ea40e87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_3a867e7b-2ff7-43a7-83b0-01a857fc6b50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_3a867e7b-2ff7-43a7-83b0-01a857fc6b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_ca68e81c-d6a2-46dd-a836-850054fff94d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_ca68e81c-d6a2-46dd-a836-850054fff94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_ed2b43e7-9a13-4531-8684-4888de91a717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_ed2b43e7-9a13-4531-8684-4888de91a717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_StockRepurchasedDuringPeriodExciseTax_a76846d4-dd9a-4260-ba7f-ba19418eebe8" xlink:href="ccrn-20250331.xsd#ccrn_StockRepurchasedDuringPeriodExciseTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_ccrn_StockRepurchasedDuringPeriodExciseTax_a76846d4-dd9a-4260-ba7f-ba19418eebe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8022b0d7-6fb5-48e7-8064-676496dba298" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8022b0d7-6fb5-48e7-8064-676496dba298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3a7e8fe9-9000-42f4-b7b9-82c9e839e08c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3a7e8fe9-9000-42f4-b7b9-82c9e839e08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage_16c0e0bc-22dc-4d91-a146-d2f1d795208b" xlink:href="ccrn-20250331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage_16c0e0bc-22dc-4d91-a146-d2f1d795208b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_150d9eff-0db6-42ee-84c7-9ea456cb0c82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_150d9eff-0db6-42ee-84c7-9ea456cb0c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_61ec624f-c1b9-4d54-9d88-e0b7d3bb7852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_61ec624f-c1b9-4d54-9d88-e0b7d3bb7852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet_a0ebb90b-0ae8-445e-b0ec-0040c6e622a6" xlink:href="ccrn-20250331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b939c3cc-8c0a-4884-81d4-90fb8acc1c69" xlink:to="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet_a0ebb90b-0ae8-445e-b0ec-0040c6e622a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#STOCKHOLDERSEQUITYRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3104388d-3ea1-48fc-89b1-426aa4bfbef4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88566985-58d2-4ca5-8716-67673d39a109" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3104388d-3ea1-48fc-89b1-426aa4bfbef4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88566985-58d2-4ca5-8716-67673d39a109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_de5e4ea7-3628-4e26-9423-6320a1c76c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88566985-58d2-4ca5-8716-67673d39a109" xlink:to="loc_us-gaap_AwardTypeAxis_de5e4ea7-3628-4e26-9423-6320a1c76c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6eb776ec-3ebd-46b7-b59e-564ff58ee0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_de5e4ea7-3628-4e26-9423-6320a1c76c1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6eb776ec-3ebd-46b7-b59e-564ff58ee0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_82bbaf1f-48e5-4b2a-8ab5-e0e6f8c9b4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6eb776ec-3ebd-46b7-b59e-564ff58ee0c1" xlink:to="loc_us-gaap_RestrictedStockMember_82bbaf1f-48e5-4b2a-8ab5-e0e6f8c9b4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_cfb9f40c-159b-4cac-a5e8-0f767569a1db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6eb776ec-3ebd-46b7-b59e-564ff58ee0c1" xlink:to="loc_us-gaap_PerformanceSharesMember_cfb9f40c-159b-4cac-a5e8-0f767569a1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47b179bf-3886-40ca-b908-e6c205b5aed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88566985-58d2-4ca5-8716-67673d39a109" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47b179bf-3886-40ca-b908-e6c205b5aed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97728236-c97a-4ea6-ac91-8c314bd6e286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47b179bf-3886-40ca-b908-e6c205b5aed3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97728236-c97a-4ea6-ac91-8c314bd6e286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ca8317f4-2e45-42c7-adf4-a3ba74aa696c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97728236-c97a-4ea6-ac91-8c314bd6e286" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ca8317f4-2e45-42c7-adf4-a3ba74aa696c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d7a33d2-0a72-4270-b624-6f4fba7ca94e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97728236-c97a-4ea6-ac91-8c314bd6e286" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d7a33d2-0a72-4270-b624-6f4fba7ca94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a2b2ab9f-8c1b-4ccc-8cdb-d693768a7827" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97728236-c97a-4ea6-ac91-8c314bd6e286" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a2b2ab9f-8c1b-4ccc-8cdb-d693768a7827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9896eaaf-f717-42f9-bfc8-cb81c50b9ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97728236-c97a-4ea6-ac91-8c314bd6e286" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9896eaaf-f717-42f9-bfc8-cb81c50b9ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2c038d93-70cf-4b70-bad2-298df0350904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97728236-c97a-4ea6-ac91-8c314bd6e286" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2c038d93-70cf-4b70-bad2-298df0350904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0af8afd9-b88c-49cf-b531-93e4cc25c5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47b179bf-3886-40ca-b908-e6c205b5aed3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0af8afd9-b88c-49cf-b531-93e4cc25c5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_727f683b-c04d-472e-b1f8-31c4b22da0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0af8afd9-b88c-49cf-b531-93e4cc25c5cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_727f683b-c04d-472e-b1f8-31c4b22da0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4792c9b1-17bb-4efc-a4e8-01efbdb6fa86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0af8afd9-b88c-49cf-b531-93e4cc25c5cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4792c9b1-17bb-4efc-a4e8-01efbdb6fa86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f4643c76-2d62-4bac-a04e-a936f582307a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0af8afd9-b88c-49cf-b531-93e4cc25c5cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f4643c76-2d62-4bac-a04e-a936f582307a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_04edd97e-4f2b-4a58-b068-46c6cf69323d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0af8afd9-b88c-49cf-b531-93e4cc25c5cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_04edd97e-4f2b-4a58-b068-46c6cf69323d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_748b03ac-b6af-4cff-b4fe-e2e70ef77403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0af8afd9-b88c-49cf-b531-93e4cc25c5cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_748b03ac-b6af-4cff-b4fe-e2e70ef77403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SEGMENTDATAAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5de12486-fcc6-4fc9-8435-41f0855a00e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_eedbfe22-f482-4ccf-98e2-79b4ea89d63d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5de12486-fcc6-4fc9-8435-41f0855a00e4" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_eedbfe22-f482-4ccf-98e2-79b4ea89d63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_eb77d046-4697-4e33-9ef9-61aed018972a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_eedbfe22-f482-4ccf-98e2-79b4ea89d63d" xlink:to="loc_srt_StatementGeographicalAxis_eb77d046-4697-4e33-9ef9-61aed018972a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4da75908-8315-42cf-aee2-af8dac27d682" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_eb77d046-4697-4e33-9ef9-61aed018972a" xlink:to="loc_srt_SegmentGeographicalDomain_4da75908-8315-42cf-aee2-af8dac27d682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_a7814192-6c8e-43ff-969e-686dec2dc494" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4da75908-8315-42cf-aee2-af8dac27d682" xlink:to="loc_country_IN_a7814192-6c8e-43ff-969e-686dec2dc494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_784b659f-8e0e-4680-b17c-90839faa9606" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_eedbfe22-f482-4ccf-98e2-79b4ea89d63d" xlink:to="loc_srt_ConsolidationItemsAxis_784b659f-8e0e-4680-b17c-90839faa9606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_5e78fce1-fb1f-480c-a151-f3fb01684034" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_784b659f-8e0e-4680-b17c-90839faa9606" xlink:to="loc_srt_ConsolidationItemsDomain_5e78fce1-fb1f-480c-a151-f3fb01684034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_385edf4e-17e6-410c-8ee5-21fca4f52718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_5e78fce1-fb1f-480c-a151-f3fb01684034" xlink:to="loc_us-gaap_IntersegmentEliminationMember_385edf4e-17e6-410c-8ee5-21fca4f52718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_c24b5480-9427-419a-b798-adcb2b756da0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_eedbfe22-f482-4ccf-98e2-79b4ea89d63d" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_c24b5480-9427-419a-b798-adcb2b756da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f5d980c1-354c-4c5a-a883-b0c3a1242aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_c24b5480-9427-419a-b798-adcb2b756da0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f5d980c1-354c-4c5a-a883-b0c3a1242aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_2fcede98-2509-4ab5-87da-310dc4941b68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_c24b5480-9427-419a-b798-adcb2b756da0" xlink:to="loc_us-gaap_NumberOfReportableSegments_2fcede98-2509-4ab5-87da-310dc4941b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_534af47a-33e7-40ca-b8a7-dd44f6f401d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_c24b5480-9427-419a-b798-adcb2b756da0" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_534af47a-33e7-40ca-b8a7-dd44f6f401d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6ad041d3-ddf1-4cf2-af45-a08dca79eef5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_c24b5480-9427-419a-b798-adcb2b756da0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6ad041d3-ddf1-4cf2-af45-a08dca79eef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#SEGMENTDATAOperatingSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_47f54f72-fd7a-48f8-a2e2-b84e9bb3a6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_06fe532f-fe99-4204-9008-b4a0d09d43c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_47f54f72-fd7a-48f8-a2e2-b84e9bb3a6b1" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_06fe532f-fe99-4204-9008-b4a0d09d43c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a4d51b10-f698-4eab-a455-d06d452ec33f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_06fe532f-fe99-4204-9008-b4a0d09d43c5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a4d51b10-f698-4eab-a455-d06d452ec33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5e1691e3-63e6-4edc-b7ef-3b1ca05669a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a4d51b10-f698-4eab-a455-d06d452ec33f" xlink:to="loc_us-gaap_SegmentDomain_5e1691e3-63e6-4edc-b7ef-3b1ca05669a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NurseAndAlliedStaffingMember_40f93de8-f847-44ae-9382-2606ad057e63" xlink:href="ccrn-20250331.xsd#ccrn_NurseAndAlliedStaffingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5e1691e3-63e6-4edc-b7ef-3b1ca05669a2" xlink:to="loc_ccrn_NurseAndAlliedStaffingMember_40f93de8-f847-44ae-9382-2606ad057e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PhysicianStaffingMember_2e01c101-2d87-4d06-973e-7ebe38fb62c4" xlink:href="ccrn-20250331.xsd#ccrn_PhysicianStaffingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5e1691e3-63e6-4edc-b7ef-3b1ca05669a2" xlink:to="loc_ccrn_PhysicianStaffingMember_2e01c101-2d87-4d06-973e-7ebe38fb62c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_cb40c9d4-85ff-4850-914d-20d2742e9248" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_06fe532f-fe99-4204-9008-b4a0d09d43c5" xlink:to="loc_srt_ConsolidationItemsAxis_cb40c9d4-85ff-4850-914d-20d2742e9248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a70ca814-1601-4ed1-9757-c8c55c8f96cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_cb40c9d4-85ff-4850-914d-20d2742e9248" xlink:to="loc_srt_ConsolidationItemsDomain_a70ca814-1601-4ed1-9757-c8c55c8f96cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_a9575aae-9ab2-416e-9bf5-d63d03260c05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a70ca814-1601-4ed1-9757-c8c55c8f96cd" xlink:to="loc_us-gaap_OperatingSegmentsMember_a9575aae-9ab2-416e-9bf5-d63d03260c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_3dc6598b-8366-466d-b7ea-69b8f5eaf96a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a70ca814-1601-4ed1-9757-c8c55c8f96cd" xlink:to="loc_us-gaap_CorporateNonSegmentMember_3dc6598b-8366-466d-b7ea-69b8f5eaf96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_06fe532f-fe99-4204-9008-b4a0d09d43c5" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0c8f15bc-5535-42d3-96a2-3a531fed5678" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0c8f15bc-5535-42d3-96a2-3a531fed5678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectOperatingCosts_59d11bff-1b09-49fc-87ee-5b7ca59a4853" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_DirectOperatingCosts_59d11bff-1b09-49fc-87ee-5b7ca59a4853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense_036a9f32-866f-456b-b3fd-239414a33539" xlink:href="ccrn-20250331.xsd#ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense_036a9f32-866f-456b-b3fd-239414a33539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BenefitsExpense_c501a2c0-a371-401d-bfab-3d17cb911c7c" xlink:href="ccrn-20250331.xsd#ccrn_BenefitsExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_ccrn_BenefitsExpense_c501a2c0-a371-401d-bfab-3d17cb911c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingExpense_f2332958-1b70-4e6b-b3fe-60f3979f4cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_MarketingExpense_f2332958-1b70-4e6b-b3fe-60f3979f4cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_1ca55e1f-721c-41e1-a59c-991aabd1c988" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_1ca55e1f-721c-41e1-a59c-991aabd1c988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_715fe3f9-f298-4741-94dd-9381ce0be82c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_715fe3f9-f298-4741-94dd-9381ce0be82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_d0bd244e-ad74-40fd-b84c-41a0dd5379d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_d0bd244e-ad74-40fd-b84c-41a0dd5379d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_7a8d68ee-3ade-4366-9d4d-8ce52c0cd1fb" xlink:href="ccrn-20250331.xsd#ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard_7a8d68ee-3ade-4366-9d4d-8ce52c0cd1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b446dae3-526b-4f5a-bd4a-fbcf798b18de" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SegmentReportingUnallocatedCorporateExpenses_b62a596e-be26-482c-ab37-d661c7f6a05b" xlink:href="ccrn-20250331.xsd#ccrn_SegmentReportingUnallocatedCorporateExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_ccrn_SegmentReportingUnallocatedCorporateExpenses_b62a596e-be26-482c-ab37-d661c7f6a05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_60b058e2-e6fe-4e16-b45f-9602890417ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_60b058e2-e6fe-4e16-b45f-9602890417ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_934dd11f-b4a6-4731-b474-d9f4e5529d3b" xlink:href="ccrn-20250331.xsd#ccrn_AcquisitionAndIntegrationRelatedCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_934dd11f-b4a6-4731-b474-d9f4e5529d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_438d7e3a-47e8-4323-9e02-f40a0de77b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_us-gaap_RestructuringCharges_438d7e3a-47e8-4323-9e02-f40a0de77b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LegalAndOtherLosses_5cd5b68e-23f1-4b6d-8074-7d52a6fe33c3" xlink:href="ccrn-20250331.xsd#ccrn_LegalAndOtherLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_ccrn_LegalAndOtherLosses_5cd5b68e-23f1-4b6d-8074-7d52a6fe33c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a8b4cc35-81d3-4515-9a55-37849f93c911" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_us-gaap_AssetImpairmentCharges_a8b4cc35-81d3-4515-9a55-37849f93c911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_f25a59f2-8615-40ab-84f9-0f7178c4b6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_us-gaap_InterestExpenseNonoperating_f25a59f2-8615-40ab-84f9-0f7178c4b6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_765c9a5b-f0d9-4d55-bdba-250e567b3030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_us-gaap_InvestmentIncomeInterest_765c9a5b-f0d9-4d55-bdba-250e567b3030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2f2a8a22-c633-47c5-a921-74556f9dbcea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2f2a8a22-c633-47c5-a921-74556f9dbcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6fe78f0-036a-4f85-8155-9e2c22e0c291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_89b8b30b-6136-4722-be46-1c4d50f222de" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6fe78f0-036a-4f85-8155-9e2c22e0c291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#INCOMETAXESDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4c74b9c1-da14-4140-8957-b940fa958647" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a014527c-ba4c-4bc1-9666-c359236e3aac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4c74b9c1-da14-4140-8957-b940fa958647" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a014527c-ba4c-4bc1-9666-c359236e3aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent_d8600586-fac0-4bf9-8fa8-cd3f63c88227" xlink:href="ccrn-20250331.xsd#ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4c74b9c1-da14-4140-8957-b940fa958647" xlink:to="loc_ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent_d8600586-fac0-4bf9-8fa8-cd3f63c88227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_6a2221ce-4670-4aec-9d9c-e78a985dd8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4c74b9c1-da14-4140-8957-b940fa958647" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_6a2221ce-4670-4aec-9d9c-e78a985dd8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_bcdeb4fd-b36d-4bce-ab54-3af6aab7054c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4c74b9c1-da14-4140-8957-b940fa958647" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_bcdeb4fd-b36d-4bce-ab54-3af6aab7054c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3dafd076-481a-4e87-a8d6-7891ee30dff0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4c74b9c1-da14-4140-8957-b940fa958647" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3dafd076-481a-4e87-a8d6-7891ee30dff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="ccrn-20250331.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c8c53561-7dce-4ef5-8b2e-64e3196f465e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_37e12906-4987-43df-afea-6bcff23080fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c8c53561-7dce-4ef5-8b2e-64e3196f465e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_37e12906-4987-43df-afea-6bcff23080fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e0c35f5f-51e3-45f4-8a0b-1ec628680fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_37e12906-4987-43df-afea-6bcff23080fb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e0c35f5f-51e3-45f4-8a0b-1ec628680fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_06cce916-7f27-4d33-9550-0fa234993a84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e0c35f5f-51e3-45f4-8a0b-1ec628680fa9" xlink:to="loc_us-gaap_RelatedPartyDomain_06cce916-7f27-4d33-9550-0fa234993a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_b6943eeb-8896-4245-ae43-cfc3855ba18c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_06cce916-7f27-4d33-9550-0fa234993a84" xlink:to="loc_us-gaap_RelatedPartyMember_b6943eeb-8896-4245-ae43-cfc3855ba18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_712ca2a6-8b8f-43d6-8129-a017456f069c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_37e12906-4987-43df-afea-6bcff23080fb" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_712ca2a6-8b8f-43d6-8129-a017456f069c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e4138970-f334-4533-b5ad-fc631f388da4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_712ca2a6-8b8f-43d6-8129-a017456f069c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e4138970-f334-4533-b5ad-fc631f388da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember_27131005-e1fe-4d42-9da0-57a2d4af675b" xlink:href="ccrn-20250331.xsd#ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e4138970-f334-4533-b5ad-fc631f388da4" xlink:to="loc_ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember_27131005-e1fe-4d42-9da0-57a2d4af675b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_00937b88-b4b7-4877-aa7f-713259a98904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_37e12906-4987-43df-afea-6bcff23080fb" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_00937b88-b4b7-4877-aa7f-713259a98904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_03b595af-91cf-4b78-a93a-4053d6e61424" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00937b88-b4b7-4877-aa7f-713259a98904" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_03b595af-91cf-4b78-a93a-4053d6e61424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ccrn-20250331_g1.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 ccrn-20250331_g1.jpg
M_]C_X1#?17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    D    <@$R  (    4
M    EH=I  0    !    K    -@ +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-#(#(P,3D@*$UA8VEN=&]S:"D ,C Q.3HP-CHQ-R Q-#HT-CHR
M,@     #H $  P    $  0  H ( !     $   Z<H , !     $   7=
M      8! P #     0 &   !&@ %     0   28!&P %     0   2X!*  #
M     0 "   " 0 $     0   38" @ $     0  #Z$         2     $
M  !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ,
M" @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,
M# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,
M#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !
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M4')I;G0 .$))300E       0UPI0%;\,*P7ZOCQ>"-2! 3A"24T$.@
MY0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 2P    !  $!+     $  3A"24T$)@      #@             _@
M.$))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-!         (  #A"24T$ @       @  .$))
M300P       ! 0 X0DE-!"T       8  0    (X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #60    8
M            !=T   Z<    $@!# $, 2 !? $8 :0!N &$ ; !? $P ;P!G
M &\ 7P!2 $( 1P    $                          0             .
MG   !=T                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P  !=T     4F=H=&QO;F<   Z<    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   .G     -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     (_\        #A"24T$%       !     (X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M      $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%1
M81,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"
MHW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W
M1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%
M,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55
M-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=W
MAY>GM\?_V@ , P$  A$#$0 _ /54DDDE*25/*ZQTS$S*,+)R&5Y.3_,UF9.N
MUN[\VO>[V5^I_.V?HZT#*^L72<.]^/DVNKM9])IJL.AX<TMK+7-=^\U-EDA'
MYI"/34TR1P995PXYRL<0J,CQ1^7B']5TTEB_\\/J[N =E[9[NKM:/[3W5[6K
M88]EC&V5N#V/ <Q[3((.K7-<$HSC+Y9"7]TVK)ARXZ]R$H7MQQ,/^DR227.=
M8ZIU?)ZY7]7NB65XMHI^TYF;8SU/3K+O3K932Z&/N?\ RU)&)D:VZDEB)IZ-
M)<_@L^MN!U2K&S;F=8Z=D-=ORPQF/;0YHEOJ5,<*[JK?H?H_TO\ VW^ES.BY
M'UQZWCWY='5:,=E61=0*WXH>?T;H;[VV,_ZE.]O<\4:%:Z]57X%[-)<<SZX=
M4'0GN-%-O61U ](J#"?0?>.+]7;VU;/Y?T_]'O\ T<^H_P#//H6$>KV]2JZI
M7C 69>"['92"S_"_9\BK])NK_-]7_P!0I>T;HD W0O\ 25Q/7)+E>I]>S\[J
MV#TCI.75TQF9BMS?MMS!8][7G;3C8U%A%7J^W>_=_P"B_P!)>Z71]:\3J7H=
M0R:>I]-?67#+V"BYCQMVU>A5NJM;9N_\S_P5H.,@62 :OAZJMW$EQG2\[ZR?
M6;[3EX75ZNEUU6OJJP6T,NL:UA+6/RW7G>Q]G_!KH^B.ZT["V];92S,K>Y@?
M0266,;I7?M/\TZW_ $?_ )[_ )FM2AP[D6-X]5 VZ"2228E22222G__0]56-
M]8OK#5TBGTZ@+<ZULU5GZ+1QZUT?X/\ D_X;_MRRO97'?7'H>6_)_:>*QU['
MM:RZM@+GM+=&V-8WW.J<WZ?^C_\ /</,RR1QDXQ<O^C']YM_#\>')S$8YC4>
M@V$Y_HP)>,S;;<FVR_)>;KKCNML?RX_Z_09^8NRZ)@9_U@Z"/VF-ME.G3LYV
MMCV1_AF_X2G\WU/\/_.?3_3VT_JW]4;,ZT9G5*G58C#+,>P%KK2/](QT.;C_
M /G_ /XK^=[T    0!H %#R^$R@3DVE^B?TO-T?B7/PB8XL-<>,@^X/\E7Z$
M/^[_ $'R?J&-D8>0_&R6&NZOZ3>T'Z+V._/K?^8]7OJQ]:K.BW#$RB7],L=J
M.307'6VK_@/]-3_UZG_"5W=OU[H&+UK'#+#Z617_ #.0!);/+7-]OJ5._.K7
M-X_^+BTY#3FYC'XX(+ZZZW-<X _S>]UGZ/<A'EYXY^C4=#_WR^/Q#E.8Y<QY
MGTFO5"I'U?OXI/<+D<_+HZ%]=SU+J1-.!U'#;CUY1'Z-EU;]_I7._P 'N9^=
M_P"I-G7+GNO]7S']0K^K_2L6G+S+ZO7R#ER<>JD.V-=<QGOM<]_^#6ABW(JP
M01+7A]/F\_)-3];.FYG5Z>E],/[1+VN?DY&.0ZJAH'Z-UUOT'>J[V;:WKGOJ
MAT'$ZKT[+OLR<NHC-R:]N-DVTLT=]+TJ7MKW^[Z2U^D9'7.F=0JZ5U'IV.,;
M*#G4YG3*W-I8]@W.9F5.'Z'?^9=_ZD]*OA=7^L_61;E?5['P<7I;;'-HLRQ9
MOO+26ON:S'V^G6YP_.]ZDH@$1T'I]?%_>1VO['!K?;7T)I8P7L^J_6YOKI8U
MMOV:DG]/;55MW6^[])9L]_\ .V?0ML6Y]9_K7T+-^K]^'TW*9G9G4:S1BXU!
MW6N=9[/=4/?5MW?X78AW?7')HZ-EY8PJL;K.'E58N?COES27D,;<VRO8^RM[
M/YG=_P""?SEF[U9N+T;IF=U7!Q,=F5139:'>F&[BT;XL=7LLV_VD9'U1,HZ\
M7IH]?2@;&CT<7J=GU6IIZ=T#ZT4[7TXM8JS+6N93O:UM5M-.:S:]K_T?J6?X
M+^;]3WH'U?NIQ?K.SIOU?ZA9U+HYH>_,8]_KUX[A_1_L^3^;ZCO;Z.[]_P"G
M_@2Y/UP8W-Z9B=7QZ'=.ZC@X^1D6.!(KMO+P'.%NZO[*UU>SW_S>_P!7U%JY
M^>>C]4Z1TO QZ*L?J5E[;0UNW::Z_4K-;:MK/<_^<W-2U X2#ZA([^CQDK3?
MM]K@WV_XO>L7W962]W1>J5O=ZKGO.%DM<"?TA9N])]C_ *?T;+?](MGZC9F=
MF=(M?E7/RZ69-E>#EVM+7W8[=HJO?N]SMSO4]ZR>J9GUGKS<#'ZETWH]V5G/
M-6,YPLL <P>H[>^QFZMG]3U%>S^M?6GIN)A5Y&/@C/SLT8E+&.M-(K=7-;GN
M]MC7^NWW>S^:2D"8B(UOY>*7%PU^ZH;W^QZI)<O9U[ZS=*R<,=<Q,0X>;>S%
M%V'9875V6?S;K*[V-WL_J?\ F%ESH77LG)R\_I?5V5X_4NGNW.].179CNUIR
MZO4<YVW_ $O^B41QR O0CP-KK#N)+%^KG6<SK3<K/-;*NEFTU].< [U;6,EE
MF39N]GIVV?S+=BVDV43$T=PD/__1]57"?7KZT9]&8>C8#W8HK:VS)R&';8XO
M]S*:G_X*O;[[+&?I+/YO]'^D]7NUS_UK^JE/7*1?013U*ENVFT_1>WZ7V?(C
M_![C^CL^G0__ *[5;)A,1,&6R)76CSOU2^N]N/:WI_6[C9CV&*,VPRZMQ_P>
M58?I4N_,R'_S/^&_1>^GT)>'WT78]UF-DUNIOI.RVI_+3X'\UVYOT'_0L9[V
M+J_J=]<3@>GTKJMGZEHS%RGG^9[-HO<?^TO^BM_[3_S=GZO_ #$^;!?JA]0.
MOC%9&70O<=4ZMB],I%EQW66&*:6_2>1S'\AG^$L_\P6=1]:6/<WU<?963#GA
M^[;/YVW8Q<9U>SJ]76;F]9,Y;M6.;(J=5/Z/[)/T:&_N?SGJ?SWZ3](_9^KW
M3K^INWD%N&PQ9:?SB/I55?O?RW_X/^NF>U&,;)OQ_@GB)+W"Y-]]/3O\85EN
M:\45=1P&UXMK_:QUE;_?3O/M]3;_ -\_TC%UBQ>JY'1LY^=TWJ.&<IG3Z&Y=
M@>QKFD.%FWT"7;VW?HG_ .B_KJ*!HF]B*-+BGR.O=-;U*CH[;/5S,MKR&5#>
M&-:W=OR=G\RQ_P"9N6/]0,_#I^KE?3[[64Y?3GW59=-C@US'"VQ_N:[\S:_Z
M:?IV9T'I!IJZ+T:XVYN)7G%N,RHV>E9]!MUEM['[F._,WOK4_K%C?5-V7@V]
M8Z:+LK/<UC7EC0YO\VS=EO%C/95ZM5?^&3KC1C4J-&_TN*/]7_"1KOH\OU5W
MVW!^L_5\4&W!?G8>RYNH<,<M9?8S]^MN]OO76_6SJ_3'?5//N;E5.KR<=[*"
MUP.]SV[6-8!]+E:--_3JLT_5ZG&%;&8HOV-8P4>DY[J/2V _O?F^EL7/NQ?J
MQTSK(93]6[3FASGX[ZZJBUVPMWWXS;,AK6MJWL_P=;T[W(DBP1PFXUU%1&O^
M(BJ^J##Z75E]=QNE]0J.RSZMTTWU.T((N:W^Q;4_Z'^CL5.C]HXGUDZ%T+J)
M-MG2[[?LN5$>MBV5.&.]W_"T^EZ-G^MEO37=9Z12,_K;L1YOZ;9^SK;@QGJN
M;OJ.RI^_^C^ID,L][V?U%#J77>D5Y_J9&"_(9TJUM=G40QCF8UEX:WV.>_[1
M]&ROU_L]:0RGMH01Y2K?_G*H=T'UJ_\ %%]6?_#5O_GL*/UYK=;;T*IECJ7V
M=2K:VUD%S"6O L9O#V;V?RV+2ZAG]'_;V!T[+Q_5S8=;BWN:TMJ)#_\ ".=O
MKLN]!^W8Q5>K]=Z17EVUYW3[<EO2+*K;,K96]E+[&M?3>W?:V_V[_P#!TIL9
M48:?*#_SDD;^+F]<Z=E],S>C9F9GV]7I/4*:&X^6&-:Q]F[9EU?9&XS/7HV_
MH_79<B?7_I]-G[-R6N?3?DY+.F76U':YV-E;O7J=^]]#]'_UQ:/5>H]/S<F_
MH^1TF_J@QG5.M#65/K:7C?39^FNK>W\[\S]];&5A8>8*VY=++Q38VZH6-#MM
MC/YNUF[Z-C-WTDADHP)W%[=BJKMGCT4XU%>/0P5TTM;76P<-:T;6-']5J(DD
MHES_ /_2]522224Y?5OJUT7K%K+L_']2ZL;6V-<^MVV=VQSZ75[V;OH[_H*C
M_P P/JMP<5__ &_=_P"E5T22<,DP*$B/JBAV<I_U9Z-;T^CIUU+KL;%,XXLL
ML<]@_<9>7^OZ>W]'Z?J?S7Z+^;6E53514VFEC:ZJP&L8T - '#6M"FD@9$[D
ME-*7-=3^K=V?U3J6597N99B,9A%MKJYN:+9%K:G,W5^ZK^=]2M=*DD#2J>/M
MZ!U9E_3[_L->;]EZ=1CNJ=DF@-OJ.\N%E;'^HQO^8C];Z!U?K&1E7;F8S1AM
MHQZY]3>]Q^TWMW^S[/MOJQF>ML_,74I)<113SEN/]8:>K5]5IPJLFU_3Z\>Z
MIUXJ#;@]]UH:_P!*[>S<5=R,#,N^L'3NH;&BG'Q[V7^[5K[/2V-:(]_T'>Y:
MR25JIX[.^J>5D8W5K14#GY&8;<(^LX,-)=2YWJU ^AZFW[1_.5O>KCL'ZQX6
M?GMZ;72:NI9#,AN:]_\ ,B*Z[V68I;NN=LJ=Z7IO_/72I)<153R?4>@=<R<S
M,ZG2ZMMS<JBW$Q70=[,7:*G.R/\  ;_5R_T/II=7^KG4<N_K632T>KD?9G]/
M!M+6.=4UGJ_::/Z/;[F?H_M5=S%UB27$54\OD=*ZHSZPY'5*^GUY;;#0ZAS\
MDTFLUL%=I-=;+6V_V_\ 1KJ$DDB;32DDDD%/_]D .$))300A      !=
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    %P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 0P @ #( ,  Q #D    !
M #A"24T$!@      !P ( 0$  0$ _^$:/&AT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN
M<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XV+6,Q-#4@-SDN
M,38S-#DY+" R,#$X+S X+S$S+3$V.C0P.C(R(" @(" @(" B/B \<F1F.E)$
M1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F
M+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(B!X
M;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM
M;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z
M>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS
M.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V52968C(B!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(B!X;6QN<SII;&QU<W1R871O
M<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(B!X;6QN
M<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(@
M>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]$:6UE;G-I;VYS(R(@>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O(B!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO
M<&1F+S$N,R\B('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P:&]T;W-H;W O,2XP+R(@9&,Z9F]R;6%T/2)I;6%G92]J<&5G(B!X;7 Z
M365T861A=&%$871E/2(R,#$Y+3 V+3$W5#$T.C0V.C(R+3 T.C P(B!X;7 Z
M36]D:69Y1&%T93TB,C Q.2TP-BTQ-U0Q-#HT-CHR,BTP-#HP,"(@>&UP.D-R
M96%T941A=&4](C(P,3DM,#4M,#=4,3$Z,# Z,S4M,#0Z,# B('AM<#I#<F5A
M=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@0T,@,C,N," H36%C:6YT;W-H
M*2(@>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#IF865B93!A,BTR9#4X+30V
M8V$M.6)A8RTP.#(Y,3$S-3 V-V,B('AM<$U-.D1O8W5M96YT240](F%D;V)E
M.F1O8VED.G!H;W1O<VAO<#HS.3<Q8F)F82TY-F,U+64U-# M8C%D,BUA.35D
M-S$Q9&1E-C4B('AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#TB=75I9#HU1#(P
M.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#."(@>&UP34TZ4F5N9&ET:6]N
M0VQA<W,](G!R;V]F.G!D9B(@:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4]
M(E!R:6YT(B!X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#TB1F%L<V4B('AM
M<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/2)4<G5E(B!X;7!44&<Z3E!A
M9V5S/2(Q(B!P9&8Z4')O9'5C97(](D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q
M(B!P:&]T;W-H;W Z0V]L;W)-;V1E/2(S(B!P:&]T;W-H;W Z24-#4')O9FEL
M93TB<U)'0B!)14,V,3DV-BTR+C$B/B \9&,Z=&ET;&4^(#QR9&8Z06QT/B \
M<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/E!R:6YT/"]R9&8Z;&D^(#PO
M<F1F.D%L=#X@/"]D8SIT:71L93X@/'AM<$U-.D1E<FEV961&<F]M('-T4F5F
M.FEN<W1A;F-E240](GAM<"YI:60Z93 R-#8W93<M.69A-BTT.&-A+3DR8V0M
M-V8S,V1A93$U8F0Y(B!S=%)E9CID;V-U;65N=$E$/2)X;7 N9&ED.F4P,C0V
M-V4W+3EF838M-#AC82TY,F-D+3=F,S-D864Q-6)D.2(@<W12968Z;W)I9VEN
M86Q$;V-U;65N=$E$/2)U=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S
M,34P.$,X(B!S=%)E9CIR96YD:71I;VY#;&%S<STB<')O;V8Z<&1F(B\^(#QX
M;7!-33I(:7-T;W)Y/B \<F1F.E-E<3X@/')D9CIL:2!S=$5V=#IA8W1I;VX]
M(G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7 N:6ED.C5E.#@Q83)C+3$X
M,S,M-# X,"TX9C5E+6$U,S(X,F-D,S%D."(@<W1%=G0Z=VAE;CTB,C Q.2TP
M,RTP.%0Q-SHR-CHR,RTP-3HP,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O
M8F4@26QL=7-T<F%T;W(@0T,@,C,N," H36%C:6YT;W-H*2(@<W1%=G0Z8VAA
M;F=E9#TB+R(O/B \<F1F.FQI('-T179T.F%C=&EO;CTB<V%V960B('-T179T
M.FEN<W1A;F-E240](GAM<"YI:60Z8C@P-#4S.&,M,V%F-2TT8S,R+3@T9#(M
M-#$U93<W9&9D,V-F(B!S=$5V=#IW:&5N/2(R,#$Y+3 U+3 W5#$Q.C P.C,U
M+3 T.C P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!);&QU<W1R871O
M<B!#0R R,RXP("A-86-I;G1O<V@I(B!S=$5V=#IC:&%N9V5D/2(O(B\^(#QR
M9&8Z;&D@<W1%=G0Z86-T:6]N/2)C;VYV97)T960B('-T179T.G!A<F%M971E
M<G,](F9R;VT@87!P;&EC871I;VXO<&]S='-C<FEP="!T;R!A<'!L:6-A=&EO
M;B]V;F0N861O8F4N:6QL=7-T<F%T;W(B+SX@/')D9CIL:2!S=$5V=#IA8W1I
M;VX](F-O;G9E<G1E9"(@<W1%=G0Z<&%R86UE=&5R<STB9G)O;2!A<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YI;&QU
M<W1R871O<B(O/B \<F1F.FQI('-T179T.F%C=&EO;CTB8V]N=F5R=&5D(B!S
M=$5V=#IP87)A;65T97)S/2)F<F]M(&%P<&QI8V%T:6]N+W!O<W1S8W)I<'0@
M=&\@:6UA9V4O97!S9B(O/B \<F1F.FQI('-T179T.F%C=&EO;CTB<V%V960B
M('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z93 R-#8W93<M.69A-BTT.&-A
M+3DR8V0M-V8S,V1A93$U8F0Y(B!S=$5V=#IW:&5N/2(R,#$Y+3 V+3$W5#$T
M.C0V.C(R+3 T.C P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T
M;W-H;W @0T,@,C Q.2 H36%C:6YT;W-H*2(@<W1%=G0Z8VAA;F=E9#TB+R(O
M/B \<F1F.FQI('-T179T.F%C=&EO;CTB8V]N=F5R=&5D(B!S=$5V=#IP87)A
M;65T97)S/2)F<F]M(&%P<&QI8V%T:6]N+W!O<W1S8W)I<'0@=&\@:6UA9V4O
M:G!E9R(O/B \<F1F.FQI('-T179T.F%C=&EO;CTB9&5R:79E9"(@<W1%=G0Z
M<&%R86UE=&5R<STB8V]N=F5R=&5D(&9R;VT@:6UA9V4O97!S9B!T;R!I;6%G
M92]J<&5G(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z
M:6YS=&%N8V5)1#TB>&UP+FEI9#IF865B93!A,BTR9#4X+30V8V$M.6)A8RTP
M.#(Y,3$S-3 V-V,B('-T179T.G=H96X](C(P,3DM,#8M,3=4,30Z-#8Z,C(M
M,#0Z,# B('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#
M0R R,#$Y("A-86-I;G1O<V@I(B!S=$5V=#IC:&%N9V5D/2(O(B\^(#PO<F1F
M.E-E<3X@/"]X;7!-33I(:7-T;W)Y/B \>&UP5%!G.DUA>%!A9V53:7IE('-T
M1&EM.G<](C@Y-RXU,# T,#<B('-T1&EM.F@](C,V,"XQ,S T-#0B('-T1&EM
M.G5N:70](E!O:6YT<R(O/B \>&UP5%!G.E!L871E3F%M97,^(#QR9&8Z4V5Q
M/B \<F1F.FQI/D-Y86X\+W)D9CIL:3X@/')D9CIL:3Y-86=E;G1A/"]R9&8Z
M;&D^(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^(#QR9&8Z;&D^0FQA8VL\+W)D
M9CIL:3X@/"]R9&8Z4V5Q/B \+WAM<%109SI0;&%T94YA;65S/B \>&UP5%!G
M.E-W871C:$=R;W5P<SX@/')D9CI397$^(#QR9&8Z;&D^(#QR9&8Z1&5S8W)I
M<'1I;VX@>&UP1SIG<F]U<$YA;64](D1E9F%U;'0@4W=A=&-H($=R;W5P(B!X
M;7!'.F=R;W5P5'EP93TB,"(^(#QX;7!'.D-O;&]R86YT<SX@/')D9CI397$^
M(#QR9&8Z;&D@>&UP1SIS=V%T8VA.86UE/2)7:&ET92(@>&UP1SIM;V1E/2)2
M1T(B('AM<$<Z='EP93TB4%)/0T534R(@>&UP1SIR960](C(U-2(@>&UP1SIG
M<F5E;CTB,C4U(B!X;7!'.F)L=64](C(U-2(O/B \<F1F.FQI('AM<$<Z<W=A
M=&-H3F%M93TB0FQA8VLB('AM<$<Z;6]D93TB4D="(B!X;7!'.G1Y<&4](E!2
M3T-%4U,B('AM<$<Z<F5D/2(P(B!X;7!'.F=R965N/2(P(B!X;7!'.F)L=64]
M(C B+SX@/')D9CIL:2!X;7!'.G-W871C:$YA;64](E!!3E1/3D4@3W)A;F=E
M(# R,2!5(%)'0B(@>&UP1SIT>7!E/2)04D]#15-3(B!X;7!'.G1I;G0](C$P
M,"XP,# P,# B('AM<$<Z;6]D93TB4D="(B!X;7!'.G)E9#TB,C4U(B!X;7!'
M.F=R965N/2(Q,#DB('AM<$<Z8FQU93TB-#4B+SX@/')D9CIL:2!X;7!'.G-W
M871C:$YA;64](E!!3E1/3D4@,3<Y-2!#(%)'0B(@>&UP1SIT>7!E/2)04D]#
M15-3(B!X;7!'.G1I;G0](C$P,"XP,# P,# B('AM<$<Z;6]D93TB4D="(B!X
M;7!'.G)E9#TB,C$T(B!X;7!'.F=R965N/2(T,"(@>&UP1SIB;'5E/2(T-B(O
M/B \<F1F.FQI('AM<$<Z<W=A=&-H3F%M93TB4$%.5$].12 R-S0X(%4@4D="
M(B!X;7!'.G1Y<&4](E!23T-%4U,B('AM<$<Z=&EN=#TB,3 P+C P,# P,"(@
M>&UP1SIM;V1E/2)21T(B('AM<$<Z<F5D/2(V-B(@>&UP1SIG<F5E;CTB.# B
M('AM<$<Z8FQU93TB,30P(B\^(#QR9&8Z;&D@>&UP1SIS=V%T8VA.86UE/2)0
M04Y43TY%(#(S-S8@52!21T(B('AM<$<Z='EP93TB4%)/0T534R(@>&UP1SIT
M:6YT/2(Q,# N,# P,# P(B!X;7!'.FUO9&4](E)'0B(@>&UP1SIR960](CDX
M(B!X;7!'.F=R965N/2(Q,#@B('AM<$<Z8FQU93TB,3(U(B\^(#PO<F1F.E-E
M<3X@/"]X;7!'.D-O;&]R86YT<SX@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F
M.FQI/B \+W)D9CI397$^(#PO>&UP5%!G.E-W871C:$=R;W5P<SX@/"]R9&8Z
M1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TB=R(_/O_B#%A)0T-?4%)/
M1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C
M<W!-4T94     $E%0R!S4D="               !  #VU@ !     -,M2% @
M(
M    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0
M  ($    %')865H   (8    %&=865H   (L    %&)865H   )     %&1M
M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4
M)&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\
M   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT
M("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M
M,BXQ
M          !865H@        \U$  0    $6S%A96B
M    6%E:(        &^B   X]0   Y!865H@        8ID  +>%   8VEA9
M6B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N
M:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                     &1E<V,
M        +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E
M("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@                            !D97-C
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N
M(&EN($E%0S8Q.38V+3(N,0                                  =FEE
M=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6
M %    !7'^=M96%S          $                        "CP    )S
M:6<@     $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R
M #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\
MI "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!$P$9
M 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I ;$!
MN0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"<0)Z
M H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-: V8#
M<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$?@2,
M!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%!=4%
MY07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'3P=A
M!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1 )
M)0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+
M"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-#28-
M0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6
M#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B82
M11)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4\!42
M%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W&!L8
M0!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;8QN*
M&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I'Q,?
M/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\BW2,*
M(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H)Q@G
M22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K:2N=
M*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^,#4P
M;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U$S5-
M-8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV.G0Z
MLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_XD C
M0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&
M(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ
M3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2
MQU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI
M6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %8%=@
MJF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I
M:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAO
MT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S
M>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$?^6
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M 1$  A$! Q$!_\0!00 !  (" P$! 0$           0* PD'" L&!0(! 0$
M  <! 0$              0(#! 4&!P@)"A    ,' 00%"0D! 0$  P$! 0($
M #$#!08'"" P0!$)$#05-0I0(4$3%!8V.!E@<!(R,Q<W&#F &D+0(B0E(Q$
M 00! @(% @\*" P$ @$5 @$#! 4&$0< $B A@1,(,100,$#P05%Q(A75EK9W
MMSA0D;'!M7;6-Y=X8:'A,B,6-IA@<-'Q0M(STR34%X> E"4U4C2G8D-3E;AR
M@I,F9B<8T&-S@T1T158)$@ "  ($!@P)!0T%" (" @,! A$# "$Q!"!!47$2
M!3! 88&1H;'1(C)R$Q#!0E*2LM(S!E!B(W,48/#A@J+"D[,T=)0U!W" 0R05
M\5-CH\/3U-7B@T2T%M E5,3_V@ , P$! A$#$0   +_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                             !^;/#\:K+)EC]%1F
M                     'SM:6--#]6G-^M3B                 (TT/G:
MTH^DH3YX                 !\Q7EQQA^K3F_6IQ
M
M
M            '1/;,?J,Z-A=:N\8OH[M6/ZNY^TXKR%'^0?9VL_:+ WG>S4\
MALYT3*[C>:9SNYJU^                              !^/5EU:[[B=3?
M0\-KJW3&=,-GL>N&;M?E;B0#DVPJ]G\%=]X]4R&RK1\IMZYQF^^&I9
M       =(=JL-1_1<+K7W?%]'MKQ_5S/6G$&2HQ9H"9+'F7&5^U6OW?>+5,A
MLFTC*;:N=YGNMJ]^           !PKE*&H?HV%UB[WB>@VWX[J/L=EP-E[?\
M*K*!R38U>R>$NNZ6KW^Q#3,EM2T#,;.]$RO[%*8
M
M
M     #C:^I5X^RZU7?[-K/2':K      #8/IV2L?\3VC?WQ_8_HJ,P     %
M';U5H/7[,6P       _L^HMYON[2KSOB;CM9KUYWSU+([+M&RG,&-K@
M    =7,_:5J>X:MH"Z_K?"65H      =X-5O[%_%MGL-\:V7[FTJ
M #CV\I5Z>RZW7<[-K/1?;,>      .\.JW]@+CVR6&^-;+S+C*X        '
M\1:<^E8.MSVW5]0O1\+^74@     !S!C:^]3D^P6.N*;/WUU'(@
M
M
M               ?GSPK@=LU>JGZ U#A?*4        .U6OWEN[SEN>\OE.P
M     #S2?<?+.J6P68          GR1V>:)EK!/'=DWU\CV'Z2A.       .
M.KVE5)]!:?6Y[=J_SM:4       #GW#W-M+SQN-@_CFRY8       !BBKS]E
MUJI=Z'TW@K+6X        Y"LJMEWAVTVAN#;;]]9U       !KJW3&4V_2^C
MZU=XQ8        S0;K>79ZV_YUW/NCK%\
M
M                                                        .K&?
MLZ/7JG0=9&]XH         #=_P KS]TOS#O7+..K    #S2?<?+.J6P68
M        ':K7[RXUYJW;<_S'.@     #7-NN,HV>K- ZD;%9          ;B
M.:YN[EY:WWFG%UP     !Q5D*-(3U/H6FSIF#          ':O7[RZ_Y=WO:
MSS[,      ?X5A.[ZG4O]$:=^14E          ^FH3VM//NWV?N#[9+EB
M
M
M                  !K8W?%T-O6W/.#,M;@          =Q]9OK[/D?HG</
M6KT   #S2?<?+.J6P68            _N"TSP/;K8WGG<?\ 0    #2QT_!4
M=O56@_&75,          #N'K5[?L\A]&[::[>     #A;*4//^]@<XZ#;?C@
M          !^E)&WAYQW2S#PW:@    /\*=GI32:V';]6            W+\
MSSEXGRKOW(=E5
M
M                                  UO;MBZ _K_ )SQK?4@
M   .QV$NO0(\?='[FZQ?   #S2?<?+.J6P68             MK>=]RM&\$V
MT    :>^DX2A[ZUY[^%5E            [5:_>>A5XWZ3V/PET    /P:TOG
M[^P><:PM\Q(            %J#@.W6P_/6X@   "KSWG4JD7HK30
M    -F^B96_%Y%Z+R58U0
M
M                                        .L>=M/.P]G\SX'R]N
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M8\=WM/J9L-EKBW7&:>>E83K)G;0    ;<^<YJ^UY&Z)^M3B
M
M
M     !$FAY^GL+G&K+?\0  !+EC8!X_L=HC@NV]S]8O@  !_AJNW_$5./0VG
M:M=^Q    VZ\YS5^?R'T7/   /-)]Q\LZI;!9@ "\3Y5WX     <39&CT9VO
M'Z:NF8/J5L5F   -R_,\Y?,\D=#   _-GAYYGLKFNN'=L6  !*EC8"X_L=IC
M@6W=O];O0  !_$6J3H.'J8>A]-UD[UB@  !:0X)MMM/SON0   ZWYNU\UGW!
MRWY*XD  $N6-A3C>R6@N#;;W"UN]    ^!O*>A;K>NU@>\:GU!V2R   '[-*
M;T&_'72-E^C94  #S^?8/.-470L.  !LFTC*6Q?/6X[<><YK/    ,$6IWH>
M&K$]VU33WTG"    6D.";;;3\[[D
M
M                                              !70[3K%,OTUHX
M '8##W-Y#RIO^U/G^7     &**N%VO5Z@'I'2OG:TH  %S[S'O-B7C&S  #S
M2?<?+.J6P68  ]6/Y^=?      $.:%?SL.N4X?2VD?$W5,  3)8^FIX7ZKV#
MPUR  *YG:M8IG^F='   YBQE>\CY4W_;ASK,@    "--"KUWG4ZF7H;3H\T
M !^]1F]'?Q3T_N=K%\  !4_]":=5<[_J(  ^]LZEZ;RAT'<!S?-      ?@5
MI:S7<]5JF^@M/^2N)  !RC85KW/DSH.UGGV8  &O[<,;YSOM/F0  %G#A6UV
MY/.FYSY(@     :CNBX:F1Z;T;J)L=D  /Z+2_ MNME>>=Q
M
M
M     'PUW3\U'W#RW@/+VP  ['82Z]!WQUTCMQKEZ      !J:Z'AJ'WK3GO
MP5Y3  '.>)N/2N\/=2Y"LZH 'FD^X^6=4M@LP !ZL?S\Z^       -+/3\%1
M$]:<]_D  %WWROON^;DFQ  ?-UY/-.]P\MZXYNU  '*N/K>@=X\Z/L T_)
M     5S^TZQ3.]-:/_(  -]G(]BN[^6-]   \WWVSR_H]M5@  +N7EG?=^/(
MMB       '0G;L=11]8\^Z@;)9 #LY@KN^KY'Z'WRU'(@  5/_0FG57._P"H
M@ #=IRW/7KO)W0?]       ..KVE2L]0:+HTZMKX _4IQN1^:-XL6<7V8
M
M
M               "N!VS5Z;?I?2  !^Q2F]"'QSTC95H^5        TY]*PE
M#CUMSS\^>   N%^;=VLL<.VD #S2?<?+.J6P68  ]6/Y^=?        \^[V)
MS?5;O^(  %IC@6W6R_/.X@ :$NN:[2)]3Z$  !>T\F]!W7\NSP       %,S
MTUH]<_M.L  #]NE-Z8GAKJG83#7( '%60H^7K[RY-CB  [;:[>>E1X?ZGE@
M       X1RMO0C]<\[US;KC!L T_)7TO(_0^R.$N@  !0(]?\YU)]$PP  ]%
M3Q?TS8?IF3        Q15"O1VEUENZ:H.0K*K>4\J;_N-YIFP
M
M           !^/2ONB&F^A>%,7O6W'I?C/\ U    =.>*>ANM?,.R?S&'^31
M_F9_,8_S%_,S^9H_S%_,T?XB_F=_,8_Q%_,T?YG?Q&/\S1_B9_,T?XF?S&/\
M3OYF?Q&/\3OYFC_$8_Q._4N;*55HR:U#Z*^Q7VF1P').7U/FO8-!YCSFBYYJ
M8                              \Z#VES+7WN.-  %F;AFU6_?-^Z@
M      54/0.H52_06G@#]"2.[GEF>M,\"V[8#I^2  \TGW'RSJEL%F  /5C^
M?G7P       *M7?-1J8^A].  %B;C&S7/?,>\@ 4'?7?.]/W2,(  -T?,,[?
M \E]"        '&-_2\U?V_RSA+*T  !<%\W;K9>X;M0 &O;<L;YTOM'F0
MWB<JS]Y_RCT         #B;(T?/N]A\W["8:YO.^4N@<DV-4   #S4O</+.I
M.Q68 'Z]./J@^ NNRY8@       #_"GSZ2TK15UC7KYODCH>P_3,F
M
M               !PEAM^K:^>_J7HLX]] ^)[;;H]Q"QQWCYA6L?0_R$_P!0
M   XYUG;ZJOR2^YO4_DW<OXJ38JK%/-AGFQ5&*M'#4CAGCAJ38J[!4FPSL%6
M?#78*DV&>."O'%5FC5(X:LV&O&/4CAJ38*Z/6FP5)L%:."M-@J31ZS!7FP5)
MHU6.&XC^_D,7VGW/C?>+H?GS8WTWRWM1ZOX^YFS6B@
M         =.=EL?-B]O<N  'U5O/Z8GAKJG.N)N         /Q:LOG3^T>9]
M#MMQWUUM/8"X_LEG#A6U]P]:O0  /-)]Q\LZI;!9@ #U8_GYU\       "O9
MV36J5_I_10 !8%X]LEU[R[O8 ^(NJ?E[>\N3?.5Y0 !Z&/C7I6S+1LJ
M   !5+]!:?50] Z@  -MO.LS?V\@]&  U8[_ (CSZO8G-P !N+YKF[['D;H@
M         X(RUOR_CJW[%*8    >8[[KY3U^S%L !(ECZCW@GK7WMI4
M    C30X%RUOV#P]R
M                                       !IBXY[LJ/^5?M#Q3:;;@N
M(1[F,>XA@N%CONGS"M:^@_D)_J   ''.M;A51^2GW+ZH<G[KBJL4\V&>;%48
MJT<-2.&>.&I-BKL%2;#.P59\-=@J389XX*\<56:-4CAJS8:\8]2.&I-@KH]:
M;!4FP5HX*TV"I-'K,%>;!4FC58X;B,>K/'J,%Q&/5GDW-MM)ZSY"L&>@?FML
M[Z7Y-                           KB]KUBFMZ8T<  ;PN59^]#Y1Z
M       !J/Z+AM4G0</9.XCM'/N'N0   /-)]Q\LZI;!9@ #U8_GYU\
M  "OUV'6Z4/J+1  !8)X[LEUKR]O8 U1]!P_G\>PN<  #M[KE[Z4OA_J7^@
M       '3K9;'S8?;W+@ !]U:5/47\%=:_2DB -=^YXSSK/:',P !]G:S^E1
MX@ZGV(PMR              !YHWN/EG578+,  72_,.]6&.-;*
M
M                      /\1K0>9_JY6=\X?5R+7C@N&"XA'N8Q[B&"X1[E
M8_[A\PK7/?OD)_J   ''&M;A50^2_P!S.IO*>Z8IYL,\V*HQ5HX:D<,\<-2;
M%78*DV&=@JSX:[!4FPSQP5XXJLT:I'#5FPUXQZD<-2;!71ZTV"I-@K1P5IL%
M2:/68*\V"I-&JQPW$8]6>/48+B,>K/'JQP5XQZT^SSI_DJV-ZF^.':[9^.@
M                        4G?4>AU_NP:X  +J?E_>["''-D
M      \TGW'RSJEL%F  /5C^?G7P       *]?9-:I8>G]%  %DGB.T7&O-6
M[@"MAV_5J=?I320 !8FXQLUSWS'O(         'F@>Y.5]6\_:  #TF/$74>
MY>LWP X9R=#S!/>')_Y  !M)T'+WU/(_0^1K*J              //Z]@\XU
M0]"PX  Y6Q];T /'_1MANF9,
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MO[G?F3>=J?/\N             !4[]"Z=5@[]J(  'V]I4MJ^>-RL><3V?\
M;I3
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M(            Z/[58><%[8Y?AB   ';'7KRROP[:=_7(-CYAQM<
M
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M.7,=6
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MWR/Y2XD  ^KMY_4X\"=<                'FD^X^6=4M@LP !ZL?S\Z^
M    !U)V*RH(^O>==0-DL@ !;I\Y[G9ZX1M@ %';U5H.B7K.O  "^_Y%Z+N$
MYMF@         *>_I+2JTG<=5  %U[R[O=@7CVR  #3!T[!41_6?/H<T
M !RYCJVX7FV;W,\RSFXCFN;YAQM<         #@[*V_G6>T.9]8,]:     #
M]FE-M#T/+;FN99S<US+.=T]7OP
M                                                 !$DKU)/%7VQ
MTB\'^@<>NPW"/<,-S"-<1P7$,%PP7$(]S&/<0P7"/<H]RP7$,%P_R(6BNU?*
M*T-VKY2   #BK5=XJ;?*7[J=6N:=JPSQPU)L5=@J389V"K/AKL%2;#/'!7CB
MJS1JD<-6;#7C'J1PU)L%='K38*DV"M'!6FP5)H]9@KS8*DT:K'#<1CU9X]1@
MN(QZL\>K'!7C'K3QZD8]S&/5FP5)HUS&/5CO=[%\^+>_I3XOS)J
M              'EC^^^1_*7$@ 'U=O/ZG'@3K@                \TGW'
MRSJEL%F  /5C^?G7P    !$FATAVJPT2=9UZM3W#5N-KZD  -KW/<Q?N\A=%
M_7IS  4=O56@Z)>LZ\  +[_D7HNX3FV:          I[^DM*K2=QU4  77O+
MN]V!>/;(  !7C[+K5,CTWHWY\\      !^M3CM'T'+[MN6Y[>#RO/]C\)=
M       ='MJQ] _U]SKK;F[4      #NCK%]NSY;GMX_*M@V*Z7D_P"X
M
M                  /SJ5U4@\1_;?2MPCWU@N$>NPW"/<,-S"-<1P7$,%PP
M7$(]S&/<0P7"/<H]RP7$,%P_R("TYVWY,6=.S_*X   <5:MO%3'Y3?=7JSS7
MM6&I-BKL%2;#.P59\-=@J389XX*\<56:-4CAJS8:\8]2.&I-@KH]:;!4FP5H
MX*TV"I-'K,%>;!4FC58X;B,>K/'J,%Q&/5GCU8X*\8]:>/4C'N8QZLV"I-&N
M8QZL8]2?=9UGPE<B]+?$G]JK8@                     #RQ_??(_E+B0
M#ZNWG]3CP)UP                >:3[CY9U2V"S  ':W7[P    #\6I+PME
M*'RMQ(   -T_+\[=Y\L[[R'950 !1V]5:#HEZSKP  OO^1>B[A.;9H
M   "GOZ2TJM)W'50 !=>\N[W8%X]L@   U"]'PM)?U)H?7[,6P       F2Q
MVO<]S%A;C>R[O^5Y[Z2A.       !ULSEK2(]3:%JFZ#AP       .Y.LWU@
M7CVQV$>.;+V$PUR
M                                   /S:-W43\,_<'37PSW?@KL%PCU
MV&X1[AAN81KB."XA@N&"XA'N8Q[B&"X1[E'N6"XA@N'^1 "TYVWY,6=.S_*X
M   <4ZMO%2WY4_=;JQS;M>*NP5)L,[!5GPUV"I-AGC@KQQ59HU2.&K-AKQCU
M(X:DV"NCUIL%2;!6C@K38*DT>LP5YL%2:-5CAN(QZL\>HP7$8]6>/5C@KQCU
MIX]2,>YC'JS8*DT:YC'JQCU)\%Q';STOQ==1]-?#+Z6OBP
M       /+']]\C^4N)  /J[>?U./ G7                !YI/N/EG5+8+,
M           #O9J>0M-<"V[>UR;8?[@   H[>JM!T2]9UX  7W_(O1=PG-LT
M         !3W]):56D[CJH  NO>7=[L"\>V0   #B/(T:J/H'3ZY_:=9^6N)
M        .P6'N;+_  W:K(_$=H^[M*@       CS0K[]AURJ%Z$T[K3G+4
M     #Z&C-OKY'L5IC@6W=O];O0
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MNL"                     /+']]\C^4N)  /J[>?U./ G7
M    !YI/N/EG5+8+,          ?KTYMOO-\U: X/MFT[0,O_H   !1V]5:#
MHEZSKP  OO\ D7HNX3FV:          I[^DM*K2=QU4  77O+N]V!>/;(
M !URS=K6^[9J]?'L>M]>,S;        =CL)=7 /-^Z[U>3[        !\S7D
MT+]<UZN3VK6-<&[8L       #]ZC-96X?M-KGSYN'VUK4
M
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M+NCK%\
M                      /F[/+4^OG]]V=57%?9N"X8+AAN(8*[!<(]=AN$
M>X8;F$:XC@N(8+A@N(1[F,>XA@N$>Y1[E@N(8+A_D0  _P!0MA=T^0EDWL'S
M#   '%&K[Q4@^6GW9ZJ<X[5@JSX:[!4FPSQP5XXJLT:I'#5FPUXQZD<-2;!7
M1ZTV"I-@K1P5IL%2:/68*\V"I-&JQPW$8]6>/48+B,>K/'JQP5XQZT\>I&/<
MQCU9L%2:-<QCU8QZD^"XC'JQC59\%S'OKMWGB];Z;^ O,N0TD
M         >6/[[Y'\I<2  ?5V\_J<>!.N                #S2?<?+.J6P
M68            &ZKE^=NY>6=]Y'LJH  H[>JM!T2]9UX  7W_(O1=PG-LT
M        !3W]):56D[CJH  NO>7=[L"\>V0       1IH:[=SQNH#I&$U$]&
MPNLO>L5^!6E      VM<^S%]GR-T3["VG         '6/.VFGSI.%U$=&PNI
M?HF&X:R=      #FG%U_0!\?]'[\ZAD0
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MR<,O:>F_@#V%RW.                    /+']]\C^4N)  /J[>?U./ G7
M               !YI/N/EG5+8+,  7!_-NZ@    ?/5Y> <O;=#]MQ^K;?L
M1\A<R   ;8>>YB_AY!Z-^E)$ "CMZJT'1+UG7@ !??\ (O1=PG-LT
M  !3W]):56D[CJH  NO>7=[L"\>V0         <?7E/5/T'#Z>^DX33-TW!]
M4M@LP    -^'(MBNY^6=]           @SPUX;GC-/O2,+IMZ9@]:^[XN+-
M    =F\%=^B_XMZ;S3BZX
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MS\_W:/-\G                   'EC^^^1_*7$@ 'U=O/ZG'@3K@
M         \TGW'RSJEL%F  /5C^?G7P     !Q'D:-5KO^H5H.Y:K_$0  N/
M^:=WLB<2V@ "CMZJT'1+UG7@ !?7\C=$W&<US8         %/#TGI-:ON&K
M "Z]Y=WNP+Q[9           /XBUU;IC-"77-=T ]@USA_)4    +Z'DCH>Y
M/F><            '7C,VVBGK&O5XNS:UT6VS'@   6%^-[+=,\P;T
M
M       !\/B]CIT?./[VZY.1^K<%>&"O'#7A@N&"X8;B&"NP7"/78;A'N&&Y
MA&N(X+B&"X8+B$>YC'N(8+A'N4>Y8+B&"X?Y$   !_J%L;NGR"LD]@^8H
MXFUG>*B7R_\ NWU0YWVW#/'!7CBJS1JD<-6;#7C'J1PU)L%='K38*DV"M'!6
MFP5)H]9@KS8*DT:K'#<1CU9X]1@N(QZL\>K'!7C'K3QZD8]S&/5FP5)HUS&/
M5C'J3X+B,>K&-5GP7,8]2/\ D0[)9CF-[KTY^?[N)L'%@
M   /,)]W<HX2RMN  /5 \!]=^CH3                >:3[CY9U2V"S  'J
MQ_/SKX       J0^BM,J]=YU,  =O=<O?2C\0=2_N  4J?4&B5\NQZV  +SG
ME'H&\?E6?          I:>GM%KS]EUH  7D?*>_[TN4;             /@;
MRG6L[?JU6;ONH_#7=,  #9[HF6]";QOTD             8XM,?3<%4']'Z7
MTTV:Q   _6IQ]+;PYU3LO@[H
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MTU\!.]FS\                   'G&^UN8]#MMQP  ])#Q)U#NGJ]^
M          !YI/N/EG5+8+,  >K'\_.O@      #X"\I^8Y[KY1Q]>4P !Z1
M/B7J'=K5K\ 5$/1NEUB^[:H  +AOFS=K*W#]I          H2^N>=Z=NE80
M 7]_('1MMG.\R             .C^U6%![UUSKJ[G[0  ?W!Z9OAGJO9/!W0
M             'Q-U3I$^IM"TD=3P(  %Q3S7NUD_B&T@
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MG@  !=W\L;[OLY'L0               'FD^X^6=4M@LP !ZL?S\Z^
M !06]><ZU"]'PH  O*^4]_WG<HV  5Q.UZQ37],:.  +"?&]DNH>8-[
M     \ROW1RKKAF[4  >E3X?ZEVZUR]              U_;AC?.S]G\S_)J
M0  %[#R=T'=GRW/              #YRO+YVWL[F?0C;L<  -^'(MBNY^6=]
M
M            XOP&YTX/F=]^^BW+O2&&M+AKQPW#!7A@KQPUX8+A@N&&XA@K
ML%PCUV&X1[AAN81KB."XA@N&"XA'N8Q[B&"X1[E'N6"XA@N'^1     #(EMS
M=Z^.-B;K7S7   '"VJ="I_\ S)^\'6'1>Q1JD<-6;#7C'J1PU)L%='K38*DV
M"M'!6FP5)H]9@KS8*DT:K'#<1CU9X]1@N(QZL\>K'!7C'K3QZD8]S&/5FP5)
MHUS&/5C'J3X+B,>K&-5GP7,8]2/^1  <C7>M7A_2GP9VA[KY2
M      %6KOFHU,?0^G  #?-R38;OOE??@         -;.[XNJSW_ %"T9P7;
M=H&AY8   #S2?<?+.J6P68  ]6/Y^=?        ID>FM&KI]IUD  7'?-.[V
M1N);0 -8&^8GSV_8_-@ !VEP%WZ77ASJF2         #HWM>/\X#VQS   <G
M6%7U#/!O69,L0             !0\]:\]TO].P0  N/>:=WLB\2V@
M       "OUV'6Z4/J+1  !MEYYF;_P!X_P"C
M                                               #BS7MUII?,']
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MFQV7\1=OM;O0         -=NYXSSKO:',P !M9Y]F/0*\>]'
M                                                           X
M>UC?J;'R]_0+T[YSWO%7A@KQPUI<->.&X8*\,%>.&O#!<,%PPW$,%=@N$>NP
MW"/<,-S"-<1P7$,%PP7$(]S&/<0P7"/<H]RP7$,%P_R(     ?MU+&[-Z/\
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M\3YZ_LCFP  W7<NSU[7R;T$
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MMEN+SIN8
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M=M?/Z]@\XZ<[+8@ #NSJU_Z.GBGI_P"M3B !YI/N/EG5+8+,  >K'\_.O@
M     56._P"H50_0FG@ "V[YUW*T-P;;0 /RZD/-E]N\MZE;%9@ #D2RJ^@%
MX_Z-L=TG*       5H^Y:K3X](Z4  !8DXQLUS_S'O(  X1RMOYXGLOFO478
M[( 2Y8V7.&[3;#\][C]S:5       !KRW/&>=A[/YG@B  Y.L*OI\^$.L?N4
MI@ /\*57J#1*^78];  VCZ#E[I_F#>NYNLWP       _#JR^<;[6YCTJVBP
M %]3R/T3<?S3-@
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MXFCEZJT#K9G+4  ?T7X/(G1-P/-\V  /-)]Q\LZI;!9@ #U8_GYU\
M"KSWG4JD7HK30 !:T\^[A:O\_;>  -!?7M=I(>I="   Y1L*UWGRQONYGF6<
M     'Y\\*J'H'4*K_?M0QQ  #[*VG](_P 1]1[18&[  ^5N)* OK_G.L#?,
M2  !VCP%W;3\\;EOAY)L,R6(     '!V5M_/J]B<WZ1;58  "P;QS9+JWE_>
MP !5R[WJ52GT1IH  'T]">RWPW:;0'!]LYAQM<     "/-"FGZ8T>NAVG60
M!SABKCTT?"_5?HJ,P
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M^;0               '%M_1\X3VQS#K3G+4  #^C=QRS/6CN";=L;TK)@
M=2=BLJN7>]2KV]CUN#/   "P[QG9;HWF+>@  /-)]Q\LZI;!9@ #U8_GYU\
M      "LWW/5:@'I#2@ !:@X#MUL/SUN(  Q1>?U[!YQJFZ#AP  ,D&^CDFQ
M6HN ;=W5U>_   &*+41T;"U,/0^FZY]UQ@   MK^=MRM&<%VT  5$/1NEUB^
M[:H    .Y6LWUC_B>T;WN2[!SYB+D   #'%I@Z=@J<WI72.K&?M  !.DCZ-'
MBSIW>W4L@ !K&WO$^>[[&YO'F@   !R38U;!G'=DL%<=V38'IV2_T    Z;;
M-8T\O26DZ<NEX0  "V7YYW&TQP+;@
M                                     .N6@==IO?*']"'7W3^HX:K'
M68:[#58:[%7A@KQPUI<->.&X8*\,%>.&O#!<,%PPW$,%=@N$>NPW"/<,-S"-
M<1P7$,%PP7$(]S&/<0P7"/<H]RP7$,%P_P B   _;J6-UKT;\,MS?0_$0
M      X1UCH=-SYR?>?JOI?8\%2;!6C@K38*DT>LP5YL%2:-5CAN(QZL\>HP
M7$8]6>/5C@KQCUIX]2,>YC'JS8*DT:YC'JQCU)\%Q&/5C&JSX+F,>I'_ "(
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MZ=]M:U
M              !PGI_2*8GR/_1%U[TOJN*O##58ZS#78:K#78J\,%>.&M+A
MKQPW#!7A@KQPUX8+A@N&&XA@KL%PCUV&X1[AAN81KB."XA@N&"XA'N8Q[B&"
MX1[E'N6"XA@N'^1  #].>UNF^BOASNPZ/X7          '".L=#II?.?[U=6
MM,[%@K1P5IL%2:/68*\V"I-&JQPW$8]6>/48+B,>K/'JQP5XQZT\>I&/<QCU
M9L%2:-<QCU8QZD^"XC'JQC59\%S&/4C_ )$     +_?J?\[FQ7;?-0
M          KW]CUNEAZ?T3'$           !W.UB^]!CQWTCGW#W(   \TGW
M'RSJEL%F  /5C^?G7P       -1_1<-0,]?<Y  ',^,K^EOX<ZGR+950  -7
M6^XF@EZ]YS\=<R            =V-6O_ $(O'/2>:<77   'YL\*I?H+3ZMW
M?-2AS0             V':9D_0C\<=)^RMIP  !I^Z1A:27J70N"LM;@
M        ?:VM3T%O'?2-C&E9,
M                                 1Z=6G-\F?T(:^^(>J<-6.*O##58
MZS#78:K#78J\,%>.&M+AKQPW#!7A@KQPUX8+A@N&&XA@KL%PCUV&X1[AAN81
MKB."XA@N&"XA'N8Q[B&"X1[E'N6"XA@N'^1  ?ISVMT'T1\0-WG2?"
M      X U/IM,[YU?>OK1JG6,%:;!4FCUF"O-@J31JL<-Q&/5GCU&"XC'JSQ
MZL<%>,>M/'J1CW,8]6;!4FC7,8]6,>I/@N(QZL8U6?!<QCU(_P"1     "UG
MW'Y&67>Q_+H                "O/V76J97IK1OR:D           -BFEY.
M^AY(Z'S_ (>Y    \TGW'RSJEL%F  /5C^?G7P       .*,A1\P?W?R?\NI
M   ;RN4[!=]\K[[^Y2F   U,]#PU$[UES[C.^I           =]=1R-^+R)T
M3L9A;H    #5;O\ B*4OJ+1.I&Q60           '>S4\A?]\?\ 1^>L1<
M  #K_F+:E_Z<T;2YT_!            ?96T]ZCR?T'<3S7-@
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M        HK^L.?:1.IX$  "PQQK9;I?F'>@  !T9VO'T9O5N@=&]KQX
M    &\GE.?NH>8-[Y*L:H     'PUW3JQ=]U&LYW/5?E;B0          ;E^
M9YR[GY9WWEG'5@     -&W5M?J$^CM+ZMY^T          ':; 7=YGRET#9)
MI&4
M            P25:/'QB_2UULT'K^.JPU8XJ\,-5CK,-=AJL-=BKPP5XX:TN
M&O'#<,%>&"O'#7A@N&"X8;B&"NP7"/78;A'N&&YA&N(X+B&"X8+B$>YC'N(8
M+A'N4>Y8+B&"X?Y$!^G/:W0?1'Q W>=)\(             #K]JO3:8GSS^]
MO6;4^M1ZS!7FP5)HU6.&XC'JSQZC!<1CU9X]6."O&/6GCU(Q[F,>K-@J31KF
M,>K&/4GP7$8]6,:K/@N8QZD?\B     &WS?O&=Y3TM\$P
M  .(LC1J9^A]-KN]FUK\>K*       !W4U>^N">;MVW%\US8     \TGW'RS
MJEL%F  /5C^?G7P       !U-V&S\\GV7S3@3+VX  W7\NSU[3R;T$   #Y.
MXDJT=]U&LCW75/C;F0       #L]@;NW=YRW3>OR?8        .JNP6=6/ON
MHZ!>OZY\Y7E        '8/#7-M3SON5@CCVR9(       /D;F2N'VO6*R/==
M3ZZ9JV        '[=*:QGQ79[8GGK<.4;"L
M                                            .@G"O5%-SY(_H7_B
MK#'58:L<5>&&JQUF&NPU6&NQ5X8*\<-:7#7CAN&"O#!7CAKPP7#!<,-Q#!78
M+A'KL-PCW##<PC7$<%Q#!<,%Q"/<QCW$,%PCW*/<L%Q#!</\B'Z<]K=!]$?$
M#=YTGP@              .ONJ]-I??/;[X=9=6ZO@KS8*DT:K'#<1CU9X]1@
MN(QZL\>K'!7C'K3QZD8]S&/5FP5)HUS&/5C'J3X+B,>K&-5GP7,8]2/^1
M  #;_OWC&\CZ6^"H                  '4C8K*MEV_5]!_7==X0RMN
M /[@V7Z-E;(G$]HWK\FV']:G$     "DYZCT/@/+VP  OO\ D7HH
M'6'/6E5[OVHZA^CX7@/+VV*(#=#S'.WE_*6_@    =>,S;5MNW:M7S['K?7C
M,VP     &P;3LE8TXKL]@'C^Q_46\X         Z_9BVKW=DUO0=UW7.C^U6
M       V":=DK$?&=FL#<=V/[:UJ         ?.UI='W5<!7W[#K>I[H>'_(
MJ2@     <\8BXWY<BV.R7Q':.UVO7@
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MO'5[2']P<IV%;M-@+OO=J61V>Z'E=Q/-LYVSUV\
M          _/GAK,WK%:E^AX;7'NV+Z8;-8];<Y:_"7=,9H.5\?6[08"[[T:
MID-E^C97<!S?-]S]8O@           !TVV:QU.="P^M?>,5T;VNPZL9^SX1R
MMO\ DU(#]"2/-.+K]I\!>=Y-4R&RC1\IMUYSFNX6MWH           '$61HZ
MF>B8;61O6)Z#;?CNHFQV77O,VWQUS(/[@Y.L:W9'!W7=/6+[8EI>3VL\_P Q
MLST7*_H21
M                    %47Y=_=/4WY@]V?Q5ACJL-6.*O##58ZS#78:K#78
MJ\,%>.&M+AKQPW#!7A@KQPUX8+A@N&&XA@KL%PCUV&X1[AAN81KB."XA@N&"
MXA'N8Q[B&"X1[E'N6"XA@N$R>A<R]#?$C>CTSP*                .OFK=
M-I9> ?OCUDU7K4:K'#<1CU9X]1@N(QZL\>K'!7C'K3QZD8]S&/5FP5)HUS&/
M5C'J3X+B,>K&-5GP7,8]2/\ D0     MH]V^/EC_ *]\R@
M        /S9X?C59?W*4T^2(
M_(J0_+J2_049I<L0                 /F:\N.,/JK><
M  #\>K+^9/#]^C-,EB
M                                *>OR6_03KKX+ZV_BK#'58:L<5>&&
MJQUF&NPU6&NQ5X8*\<-:7#7CAN&"O#!7CAKPP7#!<,-Q#!78+A'KL-PCW##<
MPC7$<%Q#!<,%Q"/<QCW$,%PCW*/<L%Q#+=4+DGH3XG[W^G_/X
M      =>]7Z=2N\!_?+K!J_6<-Q&/5GCU&"XC'JSQZL<%>,>M/'J1CW,8]6;
M!4FC7,8]6,>I/@N(QZL8U6?!<QCU(_Y$     /09]6?G,[[[1YZ
M
M
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M/\VG]H
M
M
M   "K=\SOMQIR\F_0?\ BK#'58:L<5>&&JQUF&NPU6&NQ5X8*\<-:7#7CAN&
M"O#!7CAKPP7#!<,-Q#!78+A'KL-PCW##<PC7$<%Q#!<,%Q"/<QCW$,%PCW++
M=T+C/I'XG;V^I?/X                   =>=8Z=2C\&_?3J_K/6X]1@N(Q
MZL\>K'!7C'K3QZD8]S&/5FP5)HUS&/5C'J3X+B,>K&-5GP7,8]2/^1     7
M!._?&&P9U;YR@
M
M
M          :.?%GTPK3_ #O^Q_\ %6&.JPU8XJ\,-5CK,-=AJL-=BKPP5XX:
MTN&O'#<,%>&"O'#7A@N&"X8;B&"NP7"/78;A'N&&YA&N(X+B&"X8+B$>YC'N
M(8+AENZ%Q3TO\3M['5?G\                    .O&L].I.^$/OMU>UGK.
M"XC'JSQZL<%>,>M/'J1CW,8]6;!4FC7,8]6,>I/@N(QZL8U6?!<QCU(_Y$
M  .X^P<5]"SU?^<']VKCP
M
M
M                  .M?.^QT=_C#^EO%48ZK#5CBKPPU6.LPUV&JPUV*O#!
M7CAK2X:\<-PP5X8*\<->&"X8+AAN(8*[!<(]=AN$>X8;F$:XC@N(8+A@N(1[
MF,>XAENZ%Q#TW\3MZO6?G\                     .NFL]0I$>#_O_ -<,
M%T^/5GCU8X*\8]:>/4C'N8QZLV"I-&N8QZL8]2?!<1CU8QJL^"YC'J1_R(
M #]>I9WT?4'Y\ME&X>8                      !Q;?T>D6U6'5_/6G#63
MH?+UY/T9)N6L=6[/X&[[U:GD.:,97              AS0Z@[)9=/-ELNO\
MF+;CJ]I18P^RMJG-6+K]K=?O.[FJW_V]K4
M
M                                              IY?)O]!&NO@OK;
M'58:L<5>&&JQUF&NPU6&NQ5X8*\<-:7#7CAN&"O#!7CAKPP7#!<,-Q#!78+A
M'KL-PCW##<PC7$<%Q#!<,%Q"/<Q7-*WYZ>^*V^;L'SS
M     '635>LTDO#7WWZW8#J,>K'!7C'K3QZD8]S&/5FP5)HUS&/5C'J3X+B,
M>K&-5GP7,8]2/^1   #_ %"X-W_XP6">J_.<                    #'%J
MZWW$:.NJX#41T;"])]IL,,0  ']P=T]8O]QG-,WOBY+L.Q_2<H
M!Q'D:.C/J^OZ5^GX+5MOV(XUOJ0   _3IQV"Z=DMQ'-LWO>Y+L/>75,@
M  ./KRGPIE+<  <EV-7F'&UP        ..;VEPSDZ   Y+L:O,.-K@")-#J]
MGK0  =I<!>9X         !UXS-M\U7D  E2Q[18&[ XNOZ/$F1H@
M       <MXZMRC85@/F:\G7G,VP        _4DCRGCZW(ME5     ' >7MOC
M[F0  #L5A;KZ*C,         !QU>TN&,G0   [#8:Y^FH3@
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M$  !:"X-MEN'SKN8         %!SUWSK3_TC"@ #NUJU_P"C/XKZ=]%1F
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MJ,WHR^+.G=X-5OP        -,73L'0Y]:\\  &:#T"O'O2-J?/\ +@
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MG60*O/>=2J1>BM-                MN^==RM#<&VT#6CO.*\\KV5S4
M        ?34)[9?GG<;-W"MKR0 #J7L5GYQ/M;F'PUW3  &VCG>9O]>0.C?Z
M        ?/UI?.(]K\PZ9[-8@ "P;QS9+JWE_>P
M          /G;#+U ?E?]^-=_$?5^&JQUF&NPU6&NQ5X8*\<-:7#7CAN&"O#
M!7CAKPP7#!<,-Q#!78+A'KL-PCW##<PC7$?]NJ5MOU=\7=]/</G6
M                   /@['8M;//O4G1C3^_]>\+TGX6EGL4\<4\V*JQ3QQ3
MQQ58XIXSIZ'*5[J7;7/<>V4;AY@[U;/P'^T                    !CBI^
M^D-*K1=RU4           2)8V^?.&Z68N&[4    !P[DJ% CU_SG7KN6-
M        'WMG4OB>2NA[8N>Y@   5^NPZW2A]1:(  ++?#MJN$>;=U
M   KG]IUFF9Z:T8  66^';5<(\V[J .*,A1\O/WGR8   ;_>/['=F\N;X
M     //*]E<UUH[SB@ .5L?6]0WP9UD"KSWG4JD7HK30               +
M;OG7<K0W!MM UH[SBO/*]E<U             %C+BNSW+O,^\?W  *QG=M4J
M'^C=+   O&^5-_WK<GV        "L=W75*AOH[2P !S?BKCTB_$O4.:<77
M                              'P>$VBFW\I_P!!O2GE7HG'68:[#58:
M[%7A@KQPUI<->.&X8*\,%>.&O#!<,%PPW$,%=@N$>NPW"/<,-S#^;J2VQZS^
M+N^;N?SJ
M     %33T-IU6?ONH@    ??V=3L;A;K[:TJ?*W$G6C.VG'UY3    ']%P_S
M7NUE+B&T@   ?,5Y//\ ?8/.=8N]XD    ?W!SQB;CG/$W$^2/%^0I=;,W:_
MBU90   !R)95?0>\<](V Z?D@  *_78=;I0^HM$  %EOAVU7"/-NZ@
M  5S^TZS3,]-:,  ++?#MJN$>;=U '%&0H^7G[SY,   !=U\L[[ONY%L0
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M]^]?-\
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MI^94@  +./"MKMY><=T       I<>G=%KQ]FUH  ;7>>YCT O'_1\D
M                            '7;1>LTN_E+^A[@S6.CX:K#78J\,%>.&
MM+AKQPW#!7A@KQPUX8+A@N&&XA@KL%PCUV&X8[F6U?ZV^-U@/T%\UP
M                                                  !UWS-MYOOM
MGE_$V1H@  ; =/R5RKS/N^SC1,L    (\T-!O7==J#>C]+X/RMN  !S;BJ_H
M]>*.G\^8BY  &J7H.'\_KV#SC'$  !N YOFKD_F?>.WFN7H    ^-N9*OO>=
M2JT]\U+\:K*  !8[XIL]RCS/O   K]=AUNE#ZBT0  66^';5<(\V[J
M  !7/[3K-,STUHP  LM\.VJX1YMW4 <49"CY>?O/DP    V0:3E/0E\<=)_>
MHS       >>5[*YKK1WG%  <K8^MZAO@SK('%U_1XDR-$     #SD_:O,>-+
MZD !R78U?1L\5=.      Y;QU;E&PK :T=YQ7GE>RN:@ #>UR;8;Q/E7?@
M  !QK?4M;^[8O0?UW7=!/7M<_,J0   M!<&VRW#YUW, "H-Z/TNLKW35  !^
MW2F]&+Q9TWO-JF0      UY[EC/.T]G\TAS0  ^GH3^C3XKZ;W3U>_
M                             Z@\Q[W3'^6'Z$^+\-N&&NQ5X8*\<-:7
M#7CAN&"O#!7CAKPP7#!<,-Q#!78+A'KOXN9;5?KKXWV /0WS6
M                                               I+>I-#T"]?UP
M #?QR#8[HOF+>?IJ$X     '7+-VM$SUCS[6YN^+   W\\@V.[5Y;WP #!%Y
MU'M'F6OK<<:  !:%X-MEM;SON4B6(     &J7H.'H@>M.>\:WU(  ?H21]''
MQ3T[O%JN0  K]=AUNE#ZBT0  66^';5<(\V[J        !7/[3K-,STUHP
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MV6?Q5X8*\<-:7#7CAN&"O#!7CAKPP7#!<,-Q#!78+ACN);5'K_XW[_/1/S6
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M*YKK1WG%  <K8^MZAO@SK(       'EY>\^3<4Y"B !RMCZWJ&^#.L@
M  :T=YQ7GE>RN:@ #>UR;8;Q/E7?@      !7N['K=*WU!H@  'IS^$^K<^8
MBY  T\])PE"3UUSO^0  7?/+&^[Y^1[$    !HLZQK]&_P!5Z   .Z&L7WHU
M^*^G?46\X                                    U]<8]3U#?FQ]X.)
M<+NV"O'#6EPUXX;A@KPP5XX:\,%PP7##<0P5WZ=_C[6OLCXR[T?0/SN
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M7-=:.\XH #E;'UO4-\&=9        \O+WGR;BG(40 .5L?6]0WP9UD
M #6CO.*\\KV5S4  ;VN3;#>)\J[\       /Q*LOF&>[N4<59"B  /0Q\:]*
MV9:-E0 !2!]4:#H:ZWKP  [%X6Z]([Q)U#DJQJ@   ?&75/S=?;7+^K.?M
M/[@O]>0.C;9N>9D                                     <#:ATVKW
MX)^S&J7@?MC!6AAKQPW#!7A@KQPUX8+A@N&&XAWDZ7YTM@>T/BYWNZ)YR
M                                                       'X-:7
MS&O=?*>'\E0  %XSRKO^]?DVP         :P=\Q/GR^Q>;Q)H#^C;?SK,V@.
M#[;MOYUF?[@ XOOZ/F%>[N4?@UI0 !?$\E="W/\ ,<Z        /@KNGYI/N
M/EG!^5MP !=B\N;Y8!X_L8 K]=AUNE#ZBT0  66^';5<(\V[J        !7/
M[3K-,STUHP  LM\.VJX1YMW4 <49"CY>?O/DP     &X?FV;OJ^1NB9X
M !YY7LKFNM'><4 !RMCZWJ&^#.L@       >7E[SY-Q3D*( '*V/K>H;X,ZR
M       !K1WG%>>5[*YJ  -[7)MAO$^5=^        \^+V-S;5SON)  %^;R
M'T7;[SC-  #@C+6_F[^VN7\-Y.@  +,'#=JN!^;MU    JK>@-0JB^@]/  &
M_KD&QW:?+>^                                       =&.4>DM(?E
M[Z*ZN.'^R>O^M]-P5X8*\<->'(^P:?LM[/Y'W7^A_GWM4[/XSSS4P
M                                                   -3O0L/Y_W
ML'G   [38"[]*[P]U.?)$         4L_3^BU^NPZWO%Y3G[/_"-LV&Z9DP
M!I8Z?@J(?K3GH  [8Z]>>E5X?ZE(EB        !4:]%Z96![QJ8  WT\CV*[
MUY8WT 5^NPZW2A]1:(  ++?#MJN$>;=U         KG]IUFF9Z:T8  66^';
M5<(\V[J .*,A1\O/WGR8      6^/.&Z6:^%[6     //*]E<UUH[SB@ .5L
M?6]0WP9UD       #R\O>?)N*<A1  Y6Q];U#?!G60       -:.\XKSRO97
M-0 !O:Y-L-XGRKOP       %"#UUSK3WTG"@ "^_Y%Z+N$YMF@  *^O8M;I3
M>H=$  'Z]./HM>+NF]\M1R(  '6;.VGFW>V^7_#7=, #F3&5_2.\2=0YQQ5P
M                                        .*<#NO!NL]&CPJ\K9W2>
M==GYQEC(
M        *H_H/3ZJGH#4  !9TX3M=N_SEN@         ' F7M_@KREVXUR]
M  %3/T-IU6CONH@ "S+PS:K?WF_=0        !K4WC%>>/[+YJ  .X^M7WI.
M>(>H@"OUV'6Z4/J+1  !9;X=M5PCS;NH        %<_M.LTS/36C  "RWP[:
MKA'FW=0!Q1D*/EY^\^3  #:MS_,=%=LQW">4H  #Z&C-Z%?C;I6Q?2\F
M!YY7LKFNM'><4 !RMCZWJ&^#.L@       >7E[SY-Q3D*( '*V/K>H;X,ZR
M      !K1WG%>>5[*YJ  -[7)MAO$^5=^        H0>NN=:>^DX4  7[O(7
M1=NO.<T  !CBH">O^<:F^AX<  ;4- R_H'>/.D98  !2!]4:#H:ZWKP  NG>
M8-ZL*\;V4
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M/R%S(  +M?EO?-_'(-C  UB;WB?/=]C\VPQ  ;3= R_H(^/.D98
M
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MP$::'G@>S.::Y-UQ@ 'T-&;T8/%G3>\6JY
M
M                   #R^?>/)N(LE1  D2Q]4OP#UW]"2(
M 'G!>V.8=&=KQX  ],CPSU3LW@KL         #SSO9/-=9N]8H  >CQXHZ?W
MKU/( 5^NPZW2A]1:(  ++?#MJN$>;=U         KG]IUFF9Z:T8  66^';5
M<(\V[J .*,A1\O/WGR8  ;VN3;#>)\J[]Q=?T?.4]J\QZL9^T   NY>6=]WX
M\BV(   #SRO97-=:.\XH #E;'UO4-\&=9        \O+WGR;BG(40 .5L?6]
M0WP9UD       #6CO.*\\KV5S4  ;VN3;#>)\J[\       -;^[8OSO/9O-
M !L%T[)>B]XMZ:    /Q*LOG6>T.9]"MNQP  LJ\/VFX=YLW8"OGV+6Z5'J'
M1  !:;X%MULCSSN(                                         'Y\
M\.),C1_2DCRICZV6
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MGVYR[KWF;8 #N#K=[Z.?BGI_U]M.
M        .@^WXZOYV#6]171L-TCVK'_D5(#[6UJ;!M.R6Y+F>;L#\>V3L?A+
MH
M>6/[[Y'\I<2  ?5V\_J<>!.N               #S=/;?+^D^T6   ].+PIU
M;L#A[D         #S]?87.-4W0<.  /1@\6]-V!Z=D@*_78=;I0^HM$  %EO
MAVU7"/-NZ@        5S^TZS3,]-:,  ++?#MJN$>;=U '%&0H^7G[SY,  -
M[7)MAO$^5=^ JG>@=/JF^@M0   V.:5E/0I\;])_>HS   >>5[*YKK1WG%
M<K8^MZAO@SK(       'EY>\^3<4Y"B !RMCZWJ&^#.L@       :T=YQ7GE
M>RN:@ #>UR;8;Q/E7?@     !UPS=K2K]0:)I_Z1A0 !W8U:_P#1A\6]-^JM
MYP    !3J]*:36Q[?JP  V@Z'EO0=\<])J2^B=,J]]YU, #^B_9Y"Z+MUYSF
M@                                       .LN=M*=OI/2=)?4L#_$0
M   ^BHS63.(;3:[\^;A]U:5
M                     !Y8_OOD?REQ( !]7;S^IQX$ZX
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M&I_,UY  -\W)-AN^^5]^
MU+]#PU&3U=H'#^2H     #O)JF0OD>2>A=M]=O0
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M>YBZYY=WOM/@+P      #2YT_!4/_6G/0    !RYCJWI%^).H<^8BY
M                                 &FOIF#HK>L.?_,UY      !V.PE
MUZ _C[H_<[6+X
M          >6/[[Y'\I<2  ?5V\_J<>!.N               #S=/;?+^D^T
M6   ].+PIU;L#A[D         #S]?87.-4W0<.  /1@\6]-V!Z=D@*_78=;I
M0^HM$  %EOAVU7"/-NZ@        5S^TZS3,]-:,  ++?#MJN$>;=U '%&0H
M^7G[SY,  -[7)MAO$^5=^  U3=!P] ?U_P Y_-G@  .?\/<^C3XKZ=SWB+@
M#SRO97-=:.\XH #E;'UO4-\&=9        \O+WGR;BG(40 .5L?6]0WP9UD
M      #6CO.*\\KV5S4           ?76T^X'F^;L7<6V;<+S;-_Z
M 49?5O/]&W5L     !<[\R;S8HXOLP
M         U%]&PM#[UISWY&YD       '8["77H#^/NC]SM8O@
M                                              /+']]\C^4N)  /
MJ[>?U./ G7               !YNGMOE_2?:+   >G%X4ZMV!P]R
M !Y^OL+G&J;H.'  'HP>+>F[ ].R0%?KL.MTH?46B  "RWP[:KA'FW=0
M    *Y_:=9IF>FM&  %EOAVU7"/-NZ@#BC(4?+S]Y\F  &]KDVPWB?*N_  "
MK'WW4:G'H;3@  -P?-LW?9\C=$SP #SRO97-=:.\XH #E;'UO4-\&=9
M   \O+WGR;BG(40 .5L?6]0WP9UD       #6CO.*\\KV5S4          #F
M+&5]YO*<_MMYUFMPO-LUR%9U0       !UZS-MYN_MKE_%.0H@   ;/=#RWH
M.^.ND298@                                      :B^C86B#ZTY[\
M=<R        #L=A+KT!_'W1^YVL7P
M                         \L?WWR/Y2XD  ^KMY_4X\"=<
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M       !78[/K-,/TYHP   _;I3>BQXNZ9WPU+(@
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M8;Q/E7?@  .#LK;^=#[2YEUKSEJ  /H:,WH5^-NE;%]+R8'GE>RN:ZT=YQ0
M'*V/K>H;X,ZR       !Y>7O/DW%.0H@ <K8^MZAO@SK(       &M'><5YY
M7LKFH             V-Z5D[]'D/HO,&-K@      #!%Y]OL3F^K7?L0  !:
M'X-MMMSSKN0                                      &HOHV%H@^M.
M>_'7,@          ['82Z] ?Q]T?N=K%\
M                            /+']]\C^4N)  /J[>?U./ G7
M       !YNGMOE_2?:+   >G%X4ZMV!P]R         !Y^OL+G&J;H.'  'H
MP>+>F[ ].R0%?KL.MTH?46B  "RWP[:KA'FW=0        *Y_:=9IF>FM&
M%EOAVU7"/-NZ@#BC(4?+S]Y\F  &]KDVPWB?*N_   #5UON)\_CV%SC\BI*
M .XVM7WHM^+>F<A6=4>>5[*YKK1WG%  <K8^MZAO@SK(       'EY>\^3<4
MY"B !RMCZWJ&^#.L@       :T=YQ7GE>RN:@ #>7RG8+MOEK?    !@BXXO
MJ76#/6FMG=\5H,Z[KNLW>L4  !N+YKF[Z_D;HG^@       Z#[?CO.4]J<Q
M '8'#W/I6^'NI?:VM0                                      :JN@
M8>A%ZZYW\=<R           #L'AKF_UY Z-WFU3(
M        <4Y"CUBSUIQ%DJ/RU>3^X1RP?Z#\FI*!+EC]-0GY.L*O/>(N.P6'
MN94L0                 !Y:WOCDGPMW3  _:I3>J3X!ZZ
M  /-]]L\OZ/;58  #TSO#'5>RN#N@         //5]D<VUC;WB0 !Z.?BGI_
M?#4L@!7Z[#K=*'U%H@  LM\.VJX1YMW4        "N?VG6:9GIK1@ !9;X=M
M5PCS;NH XHR%'R\_>?)@ !O:Y-L-XGRKOP   %7[O&IU'?1>F   6).,;-<_
M\Q[R//*]E<UUH[SB@ .5L?6]0WP9UD       #R\O>?)N*<A1  Y6Q];U#?!
MG60       -:.\XKSRO97-0 !O:Y-L-XGRKOP      _PK<]MU>G/Z5TC'$
M +[WD7HFX7FV;       '%&0H^7G[SY,  -@6G9+T8?%O30
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M$NZ?G(>U>8]1MCL@            !SWB+CT O'W1^\VJ9
M          8(M4?0L/IHZ9@_EKB2=)-.EA,DC.DC.A&;)&;)-,E9)0    ER
MQV=:+EMLG/,Q,EB                //5]D<UUC;WB@ !Z%GC;I6S?1<J
M            !1(]9\]TI]0P0  O?^2^A;I.89T         0YH>7%[VY+\+
M=TP ,\'J7>!NN?76TX%?KL.MTH?46B  "ROP[:;AGFW=@        *Y_:=9I
MF>FM&  %GSA&V6Y_.>Y@#BC(4?+S]Y\F  &]KDVPWB?*N_    #AK)T/.D]H
M\RZN9^T  '83#7/HZ^*>GT-/6W/-:.\XH #E;'UO4-\&=9        \O+WGR
M;BG(40 .5L?6]0WP9UD       #6CO.*\\KV5S4  ;VN3;#>)\J[\
M-<.[8OSNO9O-  !V'PUSZ;GA7JP       XHR%'R\_>?)@ !L"T[)>C#XMZ:
M                                     !5+]!:?50] Z@
M    .>\1<>@%X^Z/WFU3(                       #CN]I5S>TZQTMVBP
MG233)(S81GR33983:<9TL9LL9LD9TDTJ5_<     '<'6[[>YR?8/V*4P
M           %+ST[HM=_LVM  "W-YTW.S[P?;          /E;B3K_F+;M5K
M]X   *BWHS3*PO=]3  %I7@>W6SO/&X@        #H+M^.\Y;VIS$  =J=?O
M/2Z\.=3 &BSK&OT;_5>@  "P#Q_8[L7ES?         *Q?=M4J(>C=+  %K#
MS]M]K/S[N  XHR%'R\_>?)@ !O:Y-L-XGRKOP    &LS>L5Y]GL3F_X564
M;QN59_K/G+76CO.*  Y6Q];U#?!G60       /+R]Y\FXIR%$ #E;'UO4-\&
M=9        UH[SBO/*]E<U  &]KDVPWB?*N_       #\FI#RR???(OR*D
M!ZEO@;K?VUK4       XHR%'R\_>?)@ !L"T[)>C#XMZ:
M                      /D[B3S*O='*N'<G0               Y[Q%QZ
M7C[H_>;5,@                      .),C1JY=ZU+@?+VTZ6,V6,VG&;+-
M-E3I9ITD)LD9TL9LLTV1.DFD2OZ@     [R:KD-Y_*-@_H
M %>KLFM4L?3^B@ #8_I.4]$3QETL         "N?VG6*<_I72=\/)=AM!\&V
MSO)JF0  &C3JVOT9_5N@  #OIJ.1]&_Q5TX         57^_:C4\]"Z<  -X
MO*L_>>\H]  &JKH&'\_'V'S@  ;/]#RWH2>..D@        4W_2VD5O.VZN
M +FOF7>;%W%MF '%&0H^7G[SY,  -[7)MAO$^5=^     %9GN>JU O2&E
M?4V\_P M<2  <K8^MZAO@SK(       'EY>\^3<4Y"B !RMCZWJ&^#.L@
M    :T=YQ7GE>RN:@ #>UR;8;Q/E7?@       /,3]V\HX(RUN  /3B\*=6[
M X>Y       XHR%'R\_>?)@ !L"T[)>C#XMZ:
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MX7ZKV-PET      !Q1D*/EY^\^3  #8%IV2]&'Q;TT
M                   5$?1NEUBN[:H                .=\3<7[/(71=@
M&GY(                    </Y*A5+]!:AP%E[:;",V2,^G&=*FRQFRS3:<
M9TL9LL9LL9TD)U.:;",V6,VG&;+'-*     ^TMJEEOAVT_34)P
M    !YZOLCFNL;>\4  -E>CY7T*/&_2?T)(@       "F%Z<T:NSV?60 !;;
M\[;E:(X+MH H!>P.<ZF>AX8  ;2M!R_H)>.^D9X        *VG;M7IS^E=(
M 'ZE./IF>&.J]@\/<@ >99[HY5UOS=J  +LWES?-_O']C        ZJ;!9^:
MC[AY;%F@ !^I3CZ@O@[K/)5C5 '%&0H^7G[SY,  -[7)MAO$^5=^      XE
MR-'SI_:/,NIVPV8    '*V/K>H;X,ZR       !Y>7O/DW%.0H@ <K8^MZAO
M@SK(       &M'><5YY7LKFH  WM<FV&\3Y5WX       #S5?<'+>HVQV0
M]+?PYU/M9K]X      !Q1D*/EY^\^3  #8%IV2]&'Q;TT
M                      43/67/M)_4<"                !S3BZ]_KR!
MT;8!I^2                   '%.0HU+?1&F]?LQ;S9$V6,Z6,V2,^G&;+&
M=!-DFF21G2QG233I83)(SY(S81FR1FR33)624    !MUYUFMH&AY8
M        : NP:Y29]1Z&  !:0X)MMM/SON0       %=CL^LTP_3FC  "1+'
MT:O%?3>^.I9$ :(.M:]1[]4Z"  !;Q\X[I9RX5M8       Z/[58>=][,YIQ
M[>T@ !NVY;GKUOD[H(  I2>H=$K[]BUL  =Q=:O?1O\ %73_ *^VG
M%,OTUH]=#M.L  #:5H.7]!GQUT@ #BC(4?+S]Y\F  &]KDVPWB?*N_
M#7!NV+\][V-S;YRO*    .5L?6]0WP9UD       #R\O>?)N*<A1  Y6Q];U
M#?!G60       -:.\XKSRO97-0 !O:Y-L-XGRKOP       'FZ>V^7])]HL
M !Z6_ASJ?:S7[P      #BC(4?+S]Y\F  &P+3LEZ,/BWIH
M                        \_SV#SC4_P!"PX                 YIQ=>
M_P!>0.C; -/R0                  XGR-&I7Z'T[K7G+.;+--DC-E398SI
M9IM-.DC.EC-E3I)IDD9T(SI)ILL)M.,Z6,V6,V2,Z2:5*_N     <P8ZO94X
M?M/^@              'XE67S;/;G+^I6Q60  _HMD>>=QM+<#V[^X
M!74[1K--7TQH\&>   W[<AV.[;Y:WP #\FI#S=?;7+NGFRV0  G21NL>7][W
M^\?V,      =/]DLO/\ O8'..KN?M  !_<'H:>->E;+-'RH  U!=(PM!GUWS
MH  #?UR#8[L/EW>Y$L0     !IFZ;@Z'_K3GL6:   N;^9-YL6<7V8 #BC(4
M?+S]Y\F  &]KDVPWB?*N_       5K^WZM3L]*:2    .5L?6]0WP9UD
M   #R\O>?)N*<A1  Y6Q];U#?!G60       -:.\XKSRO97-0 !O:Y-L-XGR
MKOP       'G,>U.8] ]OQP  ])CQ%U'N7K-\      !Q1D*/EY^\^3  #8%
MIV2]&'Q;TT                                     4.O6O/-,/3L&
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M^).H=V-7OP      .*,A1\O/WGR8  ; M.R7HP^+>F@
M                   "G5Z4TFMCV_5@                 !S3BZ]_KR!T
M;8!I^2                '$>1HU!_1^E=8<]:3I)ILB;+-/D38)M.:;+&;+
M&;)&?33I8S98SI9IDB=)-.EC-EC.DA-DFFRITLTR2,Z2.>#_ &    #<7S;-
M[*M'RH               %%OU?S_ $@=4P    ^QMI]]_(MCW[<@V+9KHV5_
M8I3  #I-M-AH%Z_KE<SM.L<19*B  !F@O7>3N@[K^79X   48?5W/]'75<
M  .QV$NK)?$=HWP<EV'M5K]X  ./;REIKZ9A*V?;]6U?;YB0  !SGB;CT;_%
M73NP.'N0  !I+ZE@:*'K'GP   Y?QM:QSQ3:-\?)-A[RZKD/[@  ''5[2T[]
M)PE;+M^KZMM^Q    N0>:=WLA\2V@  <49"CY>?O/DP  WM<FV&\3Y5WX
M    <77]'SKO:',^GVR60   Y6Q];U#?!G60       /+R]Y\FXIR%$ #E;'
MUO4-\&=9        UH[SBO/*]E<U  &]KDVPWB?*N_        >>W['YMK W
MS$@ #T2/&/2]C>E90      #BC(4?+S]Y\F  &P+3LEZ,/BWIH
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M]I1ZC@0 !<Z\R;S8IXOLP      '%&0H^7G[SY,  -@6G9+T8?%O30
M                              !\!>4_,I]T<IXQOZ0
M     '-.+KWXO(G1=C&EY,              <67]&G3Z5TGJ+LEG/IPFR1FR
MS381FTXSY)ILL)TLTZ2,R1.EC-EC-DC/IQFRQG039)ILD9LL9TDTZ6$R2,^2
M,V$9LD9LDTR5DE   #NIK%_OAY+L(                ZI[!9^?=[$YOU9S
M]H           !9[X1MEN?SGN?\ H    .INPV?GX>P^;]7<_:
M "=)&[!Y=WS?KR'8@    .,KZEY[GL?FW0S;L<           !VZUR]]"SQO
MTGGW#W(  '%&0H^7G[SY,  -[7)MAO$^5=^        %<OM6L4T/3.C@  <K
M8^MZAO@SK(       'EY>\^3<4Y"B !RMCZWJ&^#.L@       :T=YQ7GE>R
MN:@ #>UR;8;Q/E7?@       *D/HK3*O7>=3  '>C4\AZ*/C#IGU5O.
M .*,A1\O/WGR8  ; M.R7HP^+>F@
M     5.?0NG58N_:B                   .6<=6OW^0NB[&]*R@
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MFXIR%$ #E;'UO4-\&=9        UH[SBO/*]E<U  &]KDVPWB?*N_
M :F.AX:@'[ YR  !N%YMF[OWE??>8,;7      XHR%'R\_>?)@ !L"T[)>C#
MXMZ:                                     !\-=T_.B]H\RZ9;/8@
M                 #EG'5K]_D+HNQO2LH            .*<A1IB^F]&Z>;
M+939(SI)IL$V5/IQFR1G2QFRS39$V2;]"1,@G4YILL9D$Z2:=33I8SI8S98S
M:<9TLTV5-EFG20FTXSI8S8339$Z2:1*_J   =Z]4R.\KE.?
M    'R%S)4=]%:96Y[=J\.:         '<G6;ZZWY>WO9_H>6       ^"NZ
M=/[TCI5>#LVLX8@        -@^G9*[AY9WWO9J>0       X^O*=-/TSH^@G
MKVN          ;R^4[!= \Q;SRQCZP   '%&0H^7G[SY,  -[7)MAO$^5=^
M        XYO:7G9^S^9]+MGL0 .5L?6]0WP9UD       #R\O>?)N*<A1  Y
M6Q];U#?!G60       -:.\XKSRO97-0 !O:Y-L-XGRKOP       $>:'G;>S
MN::[=SQ@  %U[R[O=@7CVR      <49"CY>?O/DP  V!:=DO1A\6]-
M                                '1+;<?Y\7L7FW$V1H@
M        #EG'5K]_D+HNQO2LH           .)\C1I:>G=%Z;[-83I9ILD9L
MD9TLTV5.EA-ISSI8S94Z2:;(FRS?H2)D$VG-.EC,EC-DC/IITL9LL9TLTR1.
MDFG2QFPC.IPFR3394Z6:9)&=)'/!_L  &T70\OMPYUF0
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MK.A)ZYYWTKVBP  %U[R[O=@7CVR      <49"CY>?O/DP  V!:=DO1A\6]-
M                                      UR;KBZ"'KWG7$V1H@
M             #EG'5K]_D+HNQO2LH          .,[ZE2E]1:)TAVC'SY(S
M81G21FR33)4Z6:;+&?)";)&=+-,E3J<TZ2,V"?)--E3:<9LL9L(S9(SZ<9TJ
M;+&;+--IQG2QFRQFRQGTX39)IL$V6:;3C-ECFE  ;T^4;!WBU7(
M          #H]M5A7^[#K>D_J.!Z7;/8@   #Z*C-M2Y_F-\W)-AWJ<GV#[6
MUJ          #7-NN,K\]AUO2GU# ]9\[:@   #[JTJ;<>=9G?%R38MV_+<]
M^_1F          _B+5COV(T$]?US33TS!]><S;     =@</<[E^99S?=R+8M
MK7/\Q_<      _$JRZ:^F8,  =E,'=[&]*R8         &NC=,9UGSMH /VJ
M4VY7F><        TU=,P?XM64 #]JE-N5YGG        .(<E0U7;_B  !V4P
M=WL;TK)@        ?.UI=,O3L%KFW3&?&74@ WR\DV'9'I&4      _$JRZ:
M^F8,  <H6%;:_P ]S                                        UT;
MIC*#GKOG7"V4H                   #EG'5K]_D+HNQO2LH         .,
M;ZE29]2:%T7VRPG21G2)TD9LL9LL9U.:9",Z6,V6,^G";)&;+--A&;3C/DFF
MRPG2S3I(S9$V6,V6,V2,^G&;+&=!-DFFR1FRQG2S3I(3)(SY(S81FR1FR33)
M624!^A)-9XX3M?UMO.                    !USS5KKNW3&=,MFL>MN;M>
M+\A2_-GA^K3CS%C:_:7 7?>_4LCL9TK)_=6E0            #_#I]LEEKSW
M/&=.=ELNO^8MN.;VECB^JMYN;<5<=K]?O.^.HY'8/IV2^@HS
M ?Q%T\V2QU_[ACNH>R677O,6W&U]2@3PGR1Y*L:O83#7/;S7+WO_ *?D>X6M
MWV2
M                                                         :_]
MPQM CU_SGA/*4                   !RSCJU]WR-T39;HV5        '&%
M_2I#^I] Z);78381G2QFR1GTTV6,Z6:;*FTYITL9DL9L'Z%*,R5.EFFRQFTX
MSI9I\D)LLTV2,V5-EC.EFFTTZ2,Z6,V5.DFFR338)TDTZ2$V2,V6,V6,Z2,V
M2:5*_N =Y=5R&]#E&P
M
M
M                   =&=KQ_G^^P><<"9>W                   ')5C5
MOQ>1>B[-]$RH       XNOZ-'7U5H/0_;L=-D39)ILL9LL9TDT^FFP39)ITL
M9DD9TDTV";*GTXS9(SI8S99ILB;+-^A33()U.:;+&9!.DFG4TZ6,Z6,V6,VG
M&=+--E399ITD)U.,V6,V$TV2,Z2,B5DA&Q+QC9>QV%N@
M
M
M                                            !TCVFPH#>O\ G/7'
M-VH                   Y*L:M^+R+T79OHF5      ''5[2HP^KM U^[AC
MI\B;!-DC-DC.DC-A&;3F_0D394V6:;)&;)&=+--E3I83:<\Z6,V5.DFFR)LL
MWZ$B9!.I3381F2QFR1GTTZ6,V6,Z6:9(G233I8S81G4X3I)IDJ=+--DC-DCL
M%T[);N.6YX
M
M
M            =,=GL: GK_G/67.V@                   Y*L:M^+R+T79
MOHF5     ''-[2HO>K^?ZZ=TQDZ2:;+&?)"9+&=)--D3I9ILL9M-/DC.A&;)
M&;)-,E3I9ILL9\D)LD9TLTR5.IS3I(S8)\DTV5-IQFRQFPC-DC/IQG2ILL9L
MLTVG&=+&;+&;+&?3A-DFFP399N9,77L@<3VC[&VG
M
M
M                                           ZD;%9>?K["YQU=S]H
M                   .2K&K?B\B]%V;Z)E0   !QQ>TJ)WK'GVN/=L7.EFF
MR)LDTV6,^2$V$9M.:;+&=+&=)&;33I8SI9ILJ=3FFRQF0C-EC^A3A,DC.EFF
MRQFR1G233I83I9ILD9LB;+&=+&9)&?3C.EC-E399ILD9TL9LLT^2$R2,Z2/W
MEK4L6<6V?L)AKD
M
M
M                 #JSG[3S^?87..I&Q60                   Y*L:M^
M+R+T79OHF5    I$^I]"TE=2P$ZG--E399ILD9LL9TD9\L)DL9M.:=+&;",Z
MG-.IPG0C-EFFR1FR1G2S394V5/IQFRILLTZ2,R2,Z6:?)";+&;)--EC-E399
MIU-.DC.EC-EC-DC.DFF2ITLT^2')5A5L/\:V;LU@KL
M
M
M                                              #J[GK2@7Z^YSTR
MV>Q                   ')5C5OJ>1^B;1="RP   ZF[#9T&/7O.NN&:M)L
MDTZ6,V6,VG--E3I8SI$V6,V2,Z6,V6,VG-/D394Z6:;+&;3C.EFFP394ZE&;
M+&=+&=+-,IITLT^1,@G4YIDL9L$Z2:=3398SI8SI8S:<9LLTV5S;B[BQSQ39
M^=\1<
M
M
M           =<<U:^?\ >P><]*]HL                   !][9U+Z/DCH>
MU7G^8   '4W8K.@UZ\YWUQS-I-EC-DC-A&=3FFRQG2)LJ=)&;+&=)&;+&;)&
M?)&;+&=+&;)-,D3I9ILJ=+"=3FFRS394Z2:;)&;+&?(FRIM.:;",V6,V2/Z%
M-,EC.EC-EFFR.RF#N[)7$=HY7Q]8
M
M
M                                  #@7+V_G^^P><=&-KQX
M           ^]LZE]'R1T/:KS_,   #J=L5G0<]=\ZZX9FUFRQG2QFRQFR33
M9(SY8398S:<TV5.EFG2QFTTZ2,Z6,V6,Z2:9+&;+&=+&=)";3C.EFFP3:<TZ
M2,V"?)--E3:<9LL9L(S*<?T)(S94V6/<;6;^R;Q':/NK2H
M   !JSS%@ !^K+'9OB;X  #X&I)KQREF !RG1J=^<;=@ :TLK8_@3P
M YRMZO=K'W0    '2+(6O"%Q2  ^EDCLGQ5\    !QO5DU]Y.S  Y>H5.]V.
MNP     -;N5LOE9Y0       !LCQ5[]3),!K2RMC^!/  #:%B+^5   /P)I=
M:66L@ /M*<VQC%WH   '$]:GIISN,U>9:PZ8W]KPO7I0XPY'I5.TEG<;$L9>
M[EL'DN\&/NP      -8^6L?RYH  <_VU;N;87(    'RT\NMS*V0    'TLD
M>P-M6[/6EQ(@    _ FEUI9:R       ';&RN.S=I7
M                                     '!66MZ"/KWG6O\ W#&@
M              #[VSJ7T?)'0]JO/\P   .IVPV=!_UWSKKAFK6;+&=+--DC
M,DC.EC/DA-A&;3FFRQFRQG21G4TZ6,Z6:;*FTYILL9LL9L$^G&;(G2S398S)
M(SI)ITL)TLTV2,V1-EC.EC,DC^A3CL U#)60.)[1])0F
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M;%&L9H
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M-]O5    '6RZH>?OTG3P      /NZ<]Q+1]DVG8C(  #A&XI>>ETO30
M !9SU/.V*-8S0
M         XFR-&@AZ]YUKDW7%@                  #[VSJ7T?)'0]JO/\
MP   .I^PV=!3UYSGK_F+>=+&;+&;3FFRITL9TB;+&;)&=+&;+&;3FGR)LJ=+
M--EC-IQG2S38)LJ=2C-EC.EC-EFF2)TLWZ%-,@G4YYLK<GS3.;_>/['E@
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MGG;%&L9H
M    #C*^I4(/77.M9&]XH                   ?>V=2^5Y)Z'M<Y]F   !
MTYV6QH4>N>=\"9>WFR1FPC.IS398SI(398SI(S98SI(S98S9(SY(S98SI8S9
M)IDB=+--E3I83J<TV6:;*G2339(S98SY$Z5OKY%L>\'E>?
M      'FR=3T@ #DJE/Z*/,=T   Z17]I1!Z)J8 &R?%7UW30=I  \]/I>F\
M(7%(      #<K@\G<&TC9    !2VWO6-5N8QX  '*=&IZ'/,]RGPB   !K]R
M5G1FZ#J@ &TS#W]T_1-H      \_CI&G]:[N@        /0(YMN'9.UK@>>G
MTO3>$+BD !Z.W+]V^EDB  .$;BEYZ72]-  [<V5Q?BYSMX %>39L-5_VW @
M "?",",   +&&KYJS7JF=    ^:GE\[SIFF?&5)0  -Q.#R5Q+2-E    '6R
MZH>?OTG3P       -[&O9:V'INP@ <(W%+STNEZ:       +.>IYVQ1K&:
M                                                       '&M]2
MH:>MN>:L=_Q                    ^QMI[WWDOH6W3G.:   '3K9;&A3ZX
MYYP)E[:=+&;+&;3FG2QG2PFRQFTYILJ=+-.EC-IITD9TL9LL9TDTR6,Z6,V6
M,^2$RG&=+--@FTYITD?UY(V0.);1M\YQF@                    /-DZGI
M  ')5*?T4>8[H  !TBO[2B#T34P -D^*OKNF@[2 !YZ?2]-X0N*0 &TS#WX
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M#*[C<'DP
M     /@KNG0U];\\U1]!PX                   ^QMI[WWDOH6W3G.:
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MV^EDB  .$;BEYZ72]-  [<V5Q?BYSMX U"YO&TWMXUH #G.WJWR^=[=R[0J
M 4_-VUO3/G<8 !?;YUMW<"QN0  !5GV_ 5_-DPX   %WK0-JV0XN]    ZV7
M5#S]^DZ> !W=Q]U>^YYMH '"E>EY_?2=/^3GE  ]&SE^Z_7R3 #A&XI>>ETO
M30 .[N/NKWW/-M
M                  ^/N9*('K3GNHOHV%                   'V-M/>^
M\E]"VZ<YS0   Z=[+94+?6_.^!<O;399ILD9TL9LD9\L)DL9M.:=+&;",ZG-
M.IPG0C-EFFR1G21FRS394V5/IQFRN1+*M:[\^;AL$T[)
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M2J #A&XI>>ETO30 .[N/NKWW/-M
M                               'Q]S)1@]7<_TU],P8
M       ^QMI[WWDOH6W3G.:   '3O9;*A?ZWYWP-E[>;+&;3FFRITL9TJ;)&
M;)&=)&;",VG-/D394Z6:;+&;3C.EFFP397,V*N+=?G/<^Y>LWP
M            \V3J>D  <E4I_11YCN@  '2*_M*(/1-3  V3XJ^NZ:#M( 'G
MI]+TWA"XI  >DWRS=P        !0"Z1I_6&[H #=E@,II-S^+ &0]!_FFX\\
M6]8   :_<E9T9N@ZH !M,P]_=/T3:         --6<QE/G=];  L":UF+2^H
MY\    >>GTO3>$+BD !Z.W+]V^EDB  .$;BEYZ72]-  [<V5Q?BYSMX IG[S
MK.I3-8X "YUHNS;8<-D0 !TBO[2B#T34P +E6C;-MQPN1   ZN7=O0'Z1J
M^RIS;4<1D-/F;QH [HV%U?*YWMH   '6RZH>?OTG3P .[N/NKWW/-M  %&;H
M.J:_<E9@ >BCS'<^2J50 <(W%+STNEZ: !W=Q]U>^YYMH
M                                                 'S->2C-ZMT#
M2WT_!                   #[&VGO?>2^A;=.<YH   =/-ELJ&/K;G? N7M
MYTL9LDTV6,Z2$V6,Z2,V6,Z2:;*FR1GR1FRQG2QFR339$V6;LEA+FX1YMW7L
MU@KL                      #S9.IZ0 !R52G]%'F.Z   =(K^TH@]$U,
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MO?<\VT
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M^ZO?<\VT
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M4@ ._6.O)$   _'FAT5R%H !VYLKB_%SG;P!2PWO5]6>8L  +NF@[3LGQ5\
M       !\E/+YW?3=,^5GE %Z?GNV=\\==^>]TK3N!KFB -MF%R-R_1MF
M'6RZH>?OTG3P .[N/NKWW/-M '\FBC8<34]W+7@ + 6MYBTSJ&?  X1N*7GI
M=+TT #]66/+5&H  !<AT?9MA>,O
M                             !^74A2C]0Z'H,Z]KH
M     ^FH3WJ?)_0-RG,\X   .GNR6-#?UMSW@;+V\Z2,V6,V2,^5,E3J<9LL
MTV$9U.:=3AM4T#,6]_..Z_8VTX                        \V3J>D
M     ;)\5?7=-!VD #ST^EZ;PA<4@    !:7U#/V!-;S     ^+J2^=WTS3/
MG)Y0!>3Y]M>PC&WFD7/XJH]NFN@ 7;]!VG99BKX  #7[DK.C-T'5  -IF'O[
MI^B;0        !IJSF,I\[OK8 %@36LQ:7U'/@   #ST^EZ;PA<4@
M!VYLKB_%SG;P!2PWO5]6>8L  +NF@[3LGQ5\        !JIS&/I=;WK  Y+H
MS^B%S/<YT(U ]VUO3!G<8 /N:<_HA<RW/Z"6(  '6RZH>?OTG3P /L:<W=&Q
MN@/Y. KBCU\NJ( '>3'W=W/0=IY$I3@ <(W%+STNEZ:     !=TT':=D^*O@
M
M  (4\*6'I[1:_'8M;                   'TU">]3Y/Z!N4YGG   !T]V2
MRH<^MN><#Y>WFTYILJ=+&=*FR1FR1G21_5EFL0<7V:R[P[:?T)(@
M                >;)U/2         -D^*OKNF@[2 !YZ?2]-X0N*0
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M:#M.R?%7P
M            CS0J?^A-/JW=[U*+-                   #Z:A/>I\G] W
M*<SS@   Z>[)94//6O/>!\O;39)ILL9TD)LL9TD>[>K7]K_SWN.R#2<H
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M!VG9/BKX
M            :P=\Q-2[T/INJ[?\1_$0                  ^FH3WJ?)_0
M-RG,\X   .GVR65#WUKSW@?+VTVG-^I)-LITC)6"..[)N;YEG9TD0
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MFZ/HFS@  <W4*OTLDP
M                       ZF[#9ZK>@8?IQLME\%>4P
M /IJ$UIC@6W<E6-4   =/MDLM%76=>[NZKD-G&B97L#A[D
M             #S9.IZ0 !]]2GO2\^VP  #J)>VU-?>=9  V3XJ^NZ:#M( '
MGI]+TWA"XI  >DWRS=P       .GE];4)^BZB !=UT#:>[EA= :8<[C*IFXZ
M^ !:VT[8-\NNY<  :_<E9T9N@ZH !M,P]_=/T3:         --6<QE/G=];
M L":UF+2^HY\    >>GTO3>$+BD !?#YYMOT$DP  XBKTJ/._P"J@ =N;*XO
MQ<YV\ 4L-[U?5GF+  "[IH.T[)\5?        "OMLN'JV[=@ !RU0J7\N<;?
ME *E6YZ]J#S>-  O]\WV_M!:7   ZV75#S]^DZ> !W/L+F\%H&U #B2M3KX;
M-A]#&Q8@ #8OB[V\)H&U  <(W%+STNEZ: !W=Q]U>^YYMH
M
M                                                  'FR=3T@ #D
MJE/Z*/,=T   Z17]I1!Z)J8 &R?%7UW30=I  \]/I>F\(7%( #TF^6;N
M   !7IV;#5>MMP(      &V+#9"YSHNS@ #7[DK.C-T'5  -IF'O[I^B;0
M      !IJSF,I\[OK8 %@36LQ:7U'/@   #ST^EZ;PA<4@ /1VY?NWTLD0 !
MPC<4O/2Z7IH ';FRN+\7.=O %+#>]7U9YBP  NZ:#M.R?%7P  UUY.RIA;WK
M  %U_0MH[Y8Z\  I2[YJ^K[+V       %J;3]@WZZYEP !ULNJ'G[])T\ #N
M[C[J]]SS;0 ,10DZ-J/42]M@!G@]%+F6Z<A4IP!PC<4O/2Z7IH '=W'W5[[G
MFV@
M
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MA&XI>>ETO30 .[N/NKWW/-M
M
M                            \V3J>D  <E4I_11YCN@  '2*_M*(/1-3
M  V3XJ^NZ:#M( 'GI]+TWA"XI  >DWRS=P      !\'4D\[SINF?AS0
M  %U30]HVCXB_  U^Y*SHS=!U0 #:9A[^Z?HFT         ::LYC*?.[ZV !
M8$UK,6E]1SX    \]/I>F\(7%( #T=N7[M]+)$  <(W%+STNEZ: !VYLKB_%
MSG;P!5,W'7]"^Q8@ "SSJ6=L1:SF@ !I]S>-IS;QK0 %Z'GNU]^L=> #4SF<
M=3*WK60      !]1)-Z(W,MS^MDF  ZV75#S]^DZ> !W=Q]U>^YYMH  J/;I
MKND7/XH "_'SG;^W%E< #A&XI>>ETO30 .[N/NKWW/-M
M
M                                                 \V3J>D  <E4
MI_11YCN@  '2*_M*(/1-3  V3XJ^NZ:#M( 'GI]+TWA"XI  >DWRS=P
M !J)S6.IM;SK(       &_[6\Q:=U#/@ :_<E9T9N@ZH !M,P]_=/T3:
M     --6<QE/G=];  L":UF+2^HY\    >>GTO3>$+BD !Z.W+]V^EDB  .$
M;BEYZ72]-  [<V5Q?BYSMX TG9[%U%=UUP #L=:U[Y/.]MY$I3@ 4^-VUO37
MG<8 !Z"?-MQ[$6M8 52-QU[0WL6)        NAZ)L^UC#Y  #K9=4//WZ3IX
M '=W'W5[[GFV@ "H]NFNZ1<_B@ +\?.=O[<65P .$;BEYZ72]-  [NX^ZO?<
M\VT
M
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MN+*X '"-Q2\]+I>F@ ?523=L[*X    &_P!UO,;P<!E0
M
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MW<"QN0!PC<4O/2Z7IH       LYZGG;%&L9H
M
M                                   >;)U/2  .2J4_HH\QW0  #I%?
MVE$'HFI@ ;)\5?7=-!VD #ST^EZ;PA<4@      -RN#R=P;2-D '2R_M:&_1
M-2  N/:/LNWW"9(  "J%N.O:(=BQ( %IS4,_O_UO, #7[DK.C-T'5
M!<&TC9-RN#R8   TU9S&4^=WUL "P)K68M+ZCGP   !YZ?2]-X0N*0 'H[<O
MW;Z62(  X1N*7GI=+TT #MS97%^+G.W@ ? 5)*)?0]3ZKWEN      .QMK7O
MG<ZVWD"G. *\^S8:KYMN! 'Z,(^A_P RW/DNE.  !Y_G2-/ZSW=  "^]SG;N
MWME<@#K9=4//WZ3IX '=W'W5[[GFV@ "K-M^ K^[)AP +F>B[-MHPV1 '"-Q
M2\]+I>F@      "SGJ>=L4:QF@
M
M                        !YLG4](  Y*I3^BCS'=   .D5_:40>B:F !L
MGQ5]=TT':0 //3Z7IO"%Q2       W*X/)W!M(V0 5VMGPM8G;,$ /TY8^B#
MS/<^1Z4X  &H#-XVG'O&M  ;1L1?W5=#V@ :_<E9T9N@ZH       +@VD;)N
M5P>3   &FK.8RGSN^M@ 6!-:S%I?4<^    //3Z7IO"%Q2  ]';E^[?2R1
M'"-Q2\]+I>F@ =N;*XOQ<YV\  =5[RWI.;[J_6^ZH     #EBC4NRZ%M/=['
MW0 %)7?=6UG9:Q &Q#&7MXOG^U   "IYN6O:)]AQ( %HO4<]80UK,@#K9=4/
M/WZ3IX '=W'W5[[GFV@ #2WGL74(W77  -G^(O[J^A[1E .$;BEYZ72]-
M    %G/4\[8HUC-
M
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M.G@ =W<?=7ON>;:  /F)Y:)W0M3Z>7UL !=GT+:=FF)O@.$;BEYZ72]-
M   %G/4\[8HUC-
M
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MS.8SBVM3 &XW!Y/LW:5P/EIY=-V<Q@       [UXZ[[GV-T
M
M
M                                                           (
M<7&-6G#C#DBE4_>EB
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                   /_]H " $"  $% /\ \GVDA1(H
M^R*F,F4$+]BBIE!R^R*FB08L+R*4ICF]D5-[(J8Q3%'R("54(>R*FB08L+_C
M&4T-5<Z:6V0F<4$-FJ23 EH&C480)3*DS.Z8Z)&I9715)+67V>H]4$SLA,80
M3BBJHD0>7X,&,HB2JUU931I=8Z$#(K344D!-2%+)&@I$J?1'E<L4@JH2CU@+
MK.4BJ:960F$,)M0M5R7>Y31-4SMI;9&;1@168I5.R6WM%HV@222I6*4I"]!R
M$B%CR*1JF5VZHI8"ZR],* F-D9S!":T55,EWJ6R2;S@\LLW5*QD%D)-"9);"
MB4;)Z8IQ(T*! @!TQI9+5 *J(I!8RVT%&JFF%CC@TTMA64L"-!C)XG_$\OEL
MPFJBG[*KE 22BJ9I\-K/*"I:H&J&S<X0 H3*$D;:T[;:BUU/_M90;?M90;?M
M90;?M90;?M90;?M90;?M90;?M90;?M90;?M90;?M90;?M90;?M90;?M90;?M
M90;?M90;#:R@Q#]IJ(:)9VCC@HLA(3 KL:L*R^TM:(@F$FFTI-NLBIB>5'&D
M%E4,$)7))1)86UG=%4S4 5#9>8)F6H5LM4;H@ERZ:*:?LM,%(26B*8D ;:<T
M32\^"?644P@FDFFLD4;F "(T[:RI9Z$CM32DH"%"A0(>UF4GE4XA3RR\G5M4
M%#5+37_$D.'$C1*3L\L6A*9+*Y&EW&?4O(ZE@5;:F<2(-I27PKNT2'#BDG-L
MZ0G 3^S<\EX*4RE'&W"7RY=-55*6<2I@3IDZ2#N,YD$HJ!-5MHIE*@$!*.X
M F&D;13&:!)Y%*9 EW)?+D,T3539DA@7R];+%6X4I0D\JR)3%OZ>I@NY" &"
MIK44_.PJ.D)[2T;_ (@IVF9M5"ZD* DU)PMUK2V$LJ()I*9A)5NRI+X5WF?4
MO(ZE3UE;*;4UMZ/H>;5<IIREI/2R/=:TMM*ZH+.)-,I"NVTKE:^<K:)MM+:8
M)NU0TQ)JG25E;R;4H?:O:A+4&4A!@PD\+=5*5,M@5I:(\ #D/#/_ ,.T70\Q
MJ]7)9)+:?0;O4]*2JJT-44K-*4F&QI+X5WH0 0N%:XABNVE 6[4U1%1(DDN2
M[O4]*RNJY?4U,S.E9CM)/)YA/IA1]'2VD$&\184.-#K^UID ;-[6WML67EWF
MN;<(*HAS"7+94L_X;H>C%=7S*6RU%*$6\S^02VI);55*S&DYEL*2^%=\NM09
M8 [*WE"1:K6P($%+!WFI:;EU42NH)!,*:FFR3P(RJ/0=%IZ1E>]W+ML!@V5I
MZ$*H'>ZXH=%5Z*92U;*%O_#--T^NJ:;2.2H*>EFP$0 )O<2D),,POBD**J\]
M61AC72KF*W[E5NT*Z%<P127GJN ,MOA+X@R:M*8GX[&IJ;E]4RJ>25=3\SUT
ME\*[Y%A0X\*NZ7/2L_V%)4PKJN<2R6HY0@V!CE(6;W+H^4#,+XAQ57CK".,2
MY]<Q1_<JMV@W3KF$R2]-3P1EM[Y5%&3UC34^'8UU1Z>KI2I31T:C8V>I  +L
M!$ ";7#I"3BOOC+R,JO54\5HMUZYB#^Y5;L6YE<$,FN[6L 4%\5Y1E=W:1F
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M?[NG-<Z[X\0$1$C$<1Q'E>5BOM[<$4NQJZD9#7,ANW:*?6GGP= ,5@8' X'
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MBL1B.(XCRO*Q7E>&B'#B1HE#T/#D4/?JPH^35M)JTHJ<T+.2L5@># X'@Q7
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M5RM9-UDBD*.0HQ#CT.86$&<P@P@Q@XL(<>AS"#"#<&%A!A 6'S[2M9?^"+Y
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M\JSJ)ZR::I3"]5+?(,P[PW>JHG FJE8?"'HJH_&/JI:'P3;K44/\$SU4^?\
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M;'7PI6]]*BP.Z >Q6%@<#"P/;T WI!P.%X/!PL#RL+F*P]!>DK>GT@X'^GT
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M>C_Y8&!@<#P8' P,#@=M#D)$)F'AX>CC["V-SJLM)5EE[TTG>ZDP<#"P/;T
MWI!P.%X/!PL#RL+F*P]!>DK>GT@X'^GT \&%X.!VFL*/INO:;R=Q?J&PL_\
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MO!P.VG,MJHBNL?)XE S>KAL  7[%B4IF]7#8   \B_@(+>KA^1A*4S>KAL
M ?<M@RGA0<8!<#S/%P.%O0#>EO0# YA<+N@'@]A86%[>C_Y8&!@<#P8' P,#
ME*E,B39>Y>J;HJ?(EI;M5=9JKK-WCI&]E)%87,5AZ"])6]/I!P/]/H!X,+P<
M#MIE371;A7[_ .9,$5H*L91<#S/%P.%O0#>EO0# YA<+N@'@]A86%[>C_P"6
M!@8' \&!P,#*%*9$FR\R]4W04>1K2W:JZS57V:O'2-[*1%S%8>@O25O3Z0<#
M_3Z >#"\' [9Y$W+AVFLZ8QCF_YDY<$]"865%P/,\7 X6] -Z6] ,#F%PNZ
M>#V%A87MZ/\ Y8&!@<#P8' RA2F1)\O,O5-T%'DBTMVJNLU5UG+R4A>RD&*P
M]!>DK>GT@X'^GT \&%X.!VSYAMX2U/6__,O+3K B"N1<#S/%P.%O0#>EO0#
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M8L># +VA+V[0E[=H2]NT)>W:$O;M"7MVA+V)$)%)Y=Q,OB-D+J08L*/#,\7
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M,Q@^68BB!"8\T2E89L1NUC"/:IF[5,W:IF[5,W:L1NU8C=JQ&":G8)J#%FD
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M;%A$CPY@AB2]3Y(3J(J6++)G"F,+>E"B$FA+UT5?$ >@!8!X,(<&>P"SNE[
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M6]=TJ/U]I)_T]E,XGJTNB&08D0  H,HA^M@:9/%X'US#J>F6=<W.;=5TR?\
M5V2C]?<DG6M$SZYIEO4MSF\7\471*X?XU71-X?XH&F6Q?6)=:KJVV@IXT<8$
MI !(0L,NI1^AM9;U+[@! !";4^("(" ^1R'/"/)YP1>38+D,%?!5I(R*,SV
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M=_K5Y,6Q\E5Y\<::#^./(6=_SP[WRXN<G>/#]?:.[MM[[V\U>(?^?G5R(_\
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MM7AIOYQT7X_@[5RAL;+>Y;9#9%6!N'C!>752=5U)0E3\LW/.FL\L?MGSA_\
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MS&'8W.#$C)&'JN-=NUEGY+D?X@##2T4/,#FZ9B9@0]AC=CU<;*:\^+>-]O\
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M\<KG\N?F,6PS[MAOEZ;TVZQ_MUF=FG</,:XI#\6(=B'X,4S$/Q8AVAQ&(?\
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M#,;#FT>:]HLL,3KNX:W=AG:$?@Q#\&AGXM#B-"B,0[0SM#/Q:'$XM#/P$A^
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M-&?!^K)GY;]. _SJZ/$ UY'6W9T\@2RR,R75SD[=(JZP2T\FF;#,L MAG)>
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M :Q.(^BBJ3FU>5EDE8&55CA7IY$-XAJ_&W8<T[Y ]/)H^?S<^>A\E6GP_O\
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MA1E'V^IW[A+Z8*8@Y*#<SPY^&U4Q:J\,U44$_P#YIKXM_P"::^+?^::^+?\
MFFOBW_FFOBW_ )IKXM_YIKXM_P"::^+?^::^+?\ FFOBW_FFOBW_ )IKXM_Y
MIKXM_P"::^+?^::^+?\ FFOBW_FFOBW_ )IKXM_YIKXM_P"::^+?^::^+?\
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M_-I^PZS_ $-T_P#-I^PZS_0W7_S:?L.L_P!#=?\ S:?L.L_T-U_\VG[#K/\
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MFD^5B5R>E4&Z5;?*=PN_^[N\E>"6HQ8<Z]$Q[V8[QRZ3$XZ\>/Y"U9^Z7?\
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M-;]9JH*,$88PDU%KJ9D63-8[PEN?48]DGJ[#.^'/B.3WLB;6"(!Y3B.C-E-
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M)8^:H7D V%KCJXK>;]9H@Q25NS"#ULDL'2\[1!$7O^L9AFSIABS-:<@R  5
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MY5)4U$TG:JOZZ,R2T#D(M5ERJP@1N'+_ &+SM;ZWG+(NTA2SNQ@ !QDDP"J
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MM<:X;0E)%;O=U),N1+)ZHLTG: ,R80"Y J5%1%VH,,;,LB0I=W("J!$DFH
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MG .C,EM Z++'=# E6!4D%M5:U73E/%I$]00DY ;1;HNL0)DLDE"165*LU!M
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M(8T9[S=S-DC_ !949B0RF TD_'5=B"ZINS3%QS"-&6,L9C06(R EL@-%O?Q
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M)D6/1E2ECW4B5&*RY:FP"UF/2=HLQ).V!AC8UD2%+NY 50(DDU  "TF@O]_
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MK59&!J&U7U?JDK>;[88&,N4?GD'I,/,4U>45J!>_ZRFM.FS#$LQX@+ !B4
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ME!WLV9=R?]Y*;EE]X!G)A0=QK&[UXFFJAX'*GBH/L\^7,CYKJUMEA-OA+,8
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M]R#BR:9'6/DCH@UL3\A/JC7"1!KES!#3E/"IT.(C&+&$58$&C:JUJL08F5-
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M2F'3@=U00N]_=EUI-K^FEW1Z[*KI)E]'*/H^&(Q;<&&/ )<L%F8@  1))J
M%9)-@HNM=;*&O;"*J:Q)!Y9AQGR;!C)^1GU1K=(@UHXAIRGA4Z'$1C%C"*L"
M#1M5:U6(,3*F@'0FI&IE.(BQE-:&HQ!!.$/"-K7>X$10MI/V$Z31S@:(W2*0
M']V6YZS4=&]W&7$Y7E39R-O:!EX\NYMP88H)<L%F8@  1)),  !6238*+K;6
MRAKVPBJFL20>(S"+3Y-@QD_)#ZHUND0:T<0TY3PJ=#B(QBQA%6!!HVJ]:+$&
M)E30#H34C4RY"+&4UJ:C$$$X(\(VL^NYXA,O/13<E*;?QV$<RJ1;_=FU1\3R
MEB;G>)DAR,27E P)W \@*(V%X8]N##67+!9F(  $223   5DDV"BZWUNH:^,
M(JIK$D'B,PBT^38N,GY*?5.MDB#6CB&G*>%3H<1&,6,(@@@T;5>M%B#$RIH!
MT)J><N0BQE-:FHQ!!. /"-JR]7I$)UIC#R98ZQSGJK\XC%1+O(4*DL!5 L"@
M0 &8?W9M:_#:+I3ITAFDC'W\HB;) .+2F(JDCR6(K!()5A C;8PEERP69C
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M<918^4J]V_I2]%CODT,S4E[>2V))H$Q<P9=%E&Z0YH9EYNQFRE_Q)/TB0RF
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M4_EE[_AYWL4_EE[_ (>=[%/Y9>_X>=[%/Y9>_P"'G>Q3^67O^'G>Q3^67O\
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M5 4#,!5\EIK?XG4I),"DBM7<8C,QHAQ*(,UI*CK+=[LBRY: !54!54"P "H
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MF[38)/48T)J8#SI9Z0RC26(TC19TE@R. RD&(((B"#C!%8.&OQ3<4Z<H!)X
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MNG\SO?\ $3O;I_,[W_$3O;I_,[W_ !$[VZ?S.]_Q$[VZ7>9,)9FE2R23$DE
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MBH/]0OLF4/\ AJ\P_E"4([]!,OQF7QQB=M%/02!WF9A1;M<I2R9:V*BA5&8
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M)E@U&'G-UFW3"P#[D/M5ZC*N,H]-["Y'^'+W?.:Q1E) I+N5REB5*E *JJ(
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M1JBZV2EZ30@7<UNYW6:)W!!; /"4< @B!!K!!M!&2C3[@/L,\UQEB,LG=E1
M'XA3=C1IMYD]]=U_QI722&5AUDW2RA8U!C@W76B?X$U'.ZH8:0_&6(WZ+-E$
M,K $$6$$1!&X1ASI<M82+P>^E9(.3I*.P\0!;HZ)-NTTNUW4O,F,%51:68P
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M\Y6'19?G*2-_94UCK]6NUTM"'HS9HQ5&N6AQL>D1U0 0X2YW.6LJ5+$%51
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M>JT2%&U6N.J2M[OE8,#&5*-G38=9@?(4XCI,M0+ZPUG-,V:]I.(8@!8JC$H
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M6&(Y#8PK%6''P1\$#L%>!$;!&D:1P(&#SV'12/Y39%XVL&,AKU?'+NV/(,0
MQ 8@/D;J#TASTZ@](<].H/2'/3J#TASTZ@](<]"S(( 1ZPY]@63+$68P%.H/
M2'/3J#TASTZ@](<].H/2'/3J#TAST,^<H"K"-8-I Y3A!U408 CI"P[].H/2
M'/3J#TASTZ@](<].H/2'/3J#TASTZ@](<].H/2'/3J#TASTZ@](<].H/2'/3
MJ#TASTZ@](<].H/2'/3J#TASTZ@](<].]GJ L86@U[VR=[)6*QA60+,].H/2
M'/3J#TASTZ@](<].H/2'/3J#TAST,QD$%!)K%@KR[(),H19K,5.H/2'/3J#T
MASTZ@](<].H/2'/3J#TAST,Z<H"B&,&W9EFHH@P!'2%A$1CIU!Z0YZ=0>D.>
MG4'I#GIU!Z0YZ=0>D.>G4'I#GIU!Z0YZ=0>D.>G4'I#GIU!Z0YZ=0>D.>G4'
MI#GIU!Z0YZ=0>D.>G4'I#GIU!Z0YZ=0>D.>G4'I#GHTI[5)!S@P. '51!@".
MD+#OTZ@](<].H/2'/3J#TASTZ@](<].H/2'/2!Q881;6( SFG4'I#GIU!Z0Y
MZ=0>D.>G4'I#GIU!Z0YZ--F* JB)Z0LX=BT)"ECN#E-@WZ1O#A-P=(^(<M.D
M"YW3S0IT)2>B.4TJ4#>%.J. 4@\M3G4<U*Y>B=PD>.'%0F[S"-QA'C$.0T)F
M)%1Y2UC\&^!M ,$$#7UASTZ@](<].H/2'/3J#TASTZ@](<].H/2'/03)ZP!,
M+0:][-LBRDM8@#.3 4Z@](<].H/2'/3J#TASTZ@](<].H/2'/3J#TASTZ@](
M<].H/2'/3J#TASTZ@](<].H/2'/3W<<S+SQI%Y3 9B1PBD#L01;6( SFG4'I
M#GIU!Z0YZ=0>D.>G4'I#GIU!Z0YZ=0>D.>G4'I#GIU!Z0YZ=0>D.>G4'I#GI
MU!Z0YZ=0>D.>G4'I#GIU!Z0YZ=0>D.>G4'I#GHHO AI1A6#9F^[%-9:KF=W,
M6K*K*;586,IR98$0(!'?R(2[Q+ $V436ARCSD;R6WC @CY)F7"_RQ-DS1!E-
MA'*"#6"($$ @@BG>RHS;E-/T<S&IM[N9"H,!8:@X$1 AE78%UA<&B# 3)9ZL
MQ?-;=\UK5-8JB"NL=7-$&ID/6EMC5AE&(V,*Q5@1\$<'=\$:1\$#2'AJ\$1@
M0.P0-#=Y$'O+"H8DC8S\H6TXX"NC7F\L7F.8DFT\PR 5 5"KY,?LGDV"5VL*
M;^+ZZX4OL+R#: [8Y#LDN4;0(G.:SQG"@;#1Y)\DD;V+A&QRLYY#A/G7E&S2
M>PGJC:<[MOZQP)?87D&$V<\N'+[:\HPIW8/)L 1!$FP"V@FWX_B#QGQ#AH)<
MI0JC$!#8B\L=V^46'./&('/3NYXAD.(YC]YR[++DV@L(YA6>('#F(+0-(9UK
MY(C?V23VT]8;-"<@;./'32NK%#D-:\XX3FIH3UAD.(YC]YV"7VUY1M&5F;E'
MW92]9ZLF&7-EG>88U8>4K8QOB! ([R1]'>98'>RB:U/G+YR$V-BL8 PC\D3+
MA?Y8FR9H@RFPCE!!K!$"" 0013O949MRFGZ.9C4V]W,A4& L-0<"(@0RKL"Z
MPU>T0:IDLGHS%\UMWS6M4UBJ(*ZQU<T18Z'KRVQJPRY#8PK%6#'P0\$*1I$>
M".! ^"(P*\"(\$1X(&D*-<-7D/>3::BLO/E?(M@M;(6FS6+,Q)))B23:2?DU
M^R>38)7:PIOXOKKA2^PO(-H#MCD.QRY.(FO,*SQ#8!.%DP<8J/%#8Y6<\APG
MSKRC9I/83U1M.=VW]8X$OL+R#";.>7#E]M>484[L'DPQ)DB+'[^"D>M,-K>(
M9!QG'N;(9,X1!X1NC(::#UJ>JV4<XQC9'GFQ! 9V_ #PX<#1Y/FL0,V+BV.3
MVT]8;0,J<H93B-.\E]*634<8.0^(X<OMKRC:,K,W*/NSEZRU;,,N;+,01CRJ
MPL*D5$&HBG>2X2[U+ [V5&SYZ8S+)L-JGHM7 GY(F7"_RQ-DS1!E-A'*"#6"
M($$ @@BG>RHS;E-/T<S&IM[N9"H,!8:@X$1 AE78%UAJ]H@P$R63T9B^:V[Y
MK6J:Q5$%-9ZN:*M4R^5+> BC#$1P$081!!\$1L$<*(INX,#X(C#;5FJ&C-%3
MS!8F55ROE-BV#I=4LQB3:?DY^R>38)7:PIOXOKKA2^PO(-H#MCD.QO>#Y @,
MY_ ./8!-%LL@[QJ/'#@V.5G/(<)\Z\HV:3V$]4;3G=M_6.!+["\@PFSGEPY?
M;7E&%.[!Y,(*HB34!2+5S&ZQR;@W!QG>V<R)F.PY#B(^^L54:3,$&4P/WY#:
M-C#&V82V]8.(1W]@6<+)@XUJY(;')[:>L-HF5,$580(HTAL58.4&P\^['"E]
MM>4;1E9FY1]VDO6&KIAE3I9B&'&"+"IL*F((J(I PE7R4!WLJ.]II&LH3G*$
MZ+>2S?)$RX7^6)LF:(,IL(Y00:P1 @@$$$4,Z2&FW&8>A,A6I/\ AS(5!AB-
M0<5B!BHV 7VY'21H"9+)Z,Q<AR,/):$5.4$J4UEJU])&J93UD;&CC$PX"($$
M@@X$#2'ACX(8O##PQ%(CP0/@KP(CP0-*Z/JO4SU5AYHQXBLLY,KX_)JK/R>_
M9/)L$KM84W\7UUPI?87D&T!VQR'8U8VN2WB'$([^P/)/E CA%"K5$;%*SGD.
M$^=>4;-)[">J-ISNV_K' E]A>0839SRX<OMKRC"G=@\F$;[,%2U+GQG>L&['
M)L-1CL"WQ!6.BV;$?%OC8EEK:Q &<U464MB@ ;PAL'>"V60=XU'E!WMCD]M/
M6&TEO*BM# ]D\QAPG"E]M>4;1E9FY1]VLO6.KIAE3I1BK#C!%A!%1!B""01"
MG=N!)ODL?22HU$6=Y+C64.,5E#48@JS?)$RY7V6)LJ:"K*PB"#]\016# @@B
MGVJZQFW&:>@]I0G_  YF[YK6,,A!&PB^W(Z2- 3)9/1F+D.1A7HM"*G*"RE-
M9:M?21JF4]9&QHXQ,. B!!((.%'P1\$#@PP:O!$8!>80 !$DU  6DDV 8Z-J
MW53%9%8=[#,W!C"<;8X"H_*#]D\FP2NUA3?Q?77"E]A>0877/HGFIUSZ)YJ=
M<^B>:G7/HGFIUSZ)YJ=<^B>:G7/HGFIUSZ)YJ=<^B>:G7/HGFIW4AB6T@;"*
MJ\NQ++6UB ,YJHLM;%  S 0V%P+&Z0W[>..Q2LYY#A/G7E&S2I;S "J*"(&T
M  XJ>]' >:GO1P'FI[T<!YJ>]' >:GO1P'FIW<APS0C"NS?&$&O#:(-EOBI[
MT<!YJ>]' >:GO1P'FI[T<!YJ>]' >:GO1P'FI-F(8AG8@[A)(P)?87D&$V<\
MN'+[:\HPIW8/)@K+2LL0!G-%D)8HASG?->%I33$FQ1:?P;M")9[M<BV[YMX(
M4C,8MG)/+2(I&5,8;D8C@,102;V C&QAU3GR<F;">0?*!&_B.\:Z0.PJ38@+
M<%0XR-A>2UC CA%"K5$5'8I/;3UAA//41*B-=/=IQ\]/=IQ\]/=IQ\]/=IQ\
M](3I5653XCSTTI#1A:#41G'CLW<*9*\Y3PPJX\*7VUY1A-.F&"K6:=<^B>:G
M7/HGFIUSZ)YJ=<^B>:G7/HGFIUSZ)YJ=<^B>:G7/HGFIUSZ)YJ=<^B>:DLW<
MQT08U$6PR_=M+O\ <)AE3I1BK"T'D((J(,002""#029Q65?I8Z<N-3 ?XDN-
M94XQ64-1B(,?DB9<K[+$V5-!5E81!!^^((K!@0013[5=8S;C-/0>TH3_ (<S
M=\UK&&0@C81?;D=)&@)DLGHS%R'(P\EH14Y064IK+5KZ2-4RGK(V-'&)AP$0
M()!!\,?!'!W?!&D?! TAX:O!$>%I]X8(B EB:@ ,9H;C<24N@.9IA&-LBY%W
MVK@%^47[)Y-@E=K"F_B^NN%+["\@VTK&Q 6\0XS'>V*7>1BBIY1X]BE9SR'"
M?.O*-J'L'E&%*[1Y-CE]A>0839SRX<OMKRC"G=@\F#WALE@G?L'+'>PFGS+%
M%F4XAOFAG3C$GBW!N#",B88M+A7E7%P6<&%-0><3PU^/87O!\HP&8?A/%L3P
ML?I#?MXX[%)[:>L,*;V<)9\HUCC&,'<-%FI8P!&8UX3*,1(X\&7VUY1A3>S_
M &!2[[<IAE391#*RF!!'WP(-1$000:?9;U"5?I0Z:6!P/\27N><MJG*"#\DS
M+E?98FRIH*LK"((/WQ!%8,"""*?:KK&;<9IZ#VE"?\.9N^:UC#(01L(OMR.D
MC0$R63T9BY#D85Z+0BIR@LI366K7TE:HJ>LC8T<8F' 1 @D$'"AX(4C2(\$<
M"!\$1@/?+ZX26@B2>092; !634*=S*C+NJ'HIC;(SY3D%B[IB3\I/V3R;!*[
M6%-_%]=<*7V%Y!MI[P?+,!F'X3Q8.CC'C_V'!F)C TAG6OCLW]BE9SR'"?.O
M*-J'L'E&%*[1Y-CE]A>0839SRX<OMKRC"G=@\F#,G96 X!'\["EW8=H\@\>&
MJXG!!X(CC PG.4*?R0/%L,N4;0(G.:SQG!B*[>*H\>#+O Q$J=^L<AX=BD]M
M/6&%-[.'*)R<A(PG[1Y<&7VUY1A3>S_8'+OMRF&5-E$,K*8$$?? @U$1!!!H
M+C?B)=_ECI+8)H%KH,OGIBM'1ZOR1,N5]EB;*F@JRL(@@_?$$5@P(((I]JNL
M9MQFGH/:4)_PYF[YK6,,A!&PB^W(Z2- 3)9/1F+D.1A7HM"*G*"RE-9:M?21
MJF4]9&QHXQ,. B!!((-(CPPV.(IN^&NC7V_OH(N^6.)5&,G)OF !--.;T)*$
MZ$L&H;K><Y%IL%@ KC\IOV3R;!*[6%-_%]=<*7V%Y!MJ7)Q@".<UGC)P9LF-
M171&=:_&V%,D^:Q S8N*&PRLYY#A/G7E&U#V#RC"E=H\FQR^PO(,)LYY<.7V
MUY1A3NP>3!!RLQXX>+"89 HXH^/#E=K"/978)<G$37F%9XA@M-:Q02=X1HRO
M:K'\KI<I.#,EBV$1G%?'"&Q2>VGK#"F]G#E9CRG"?M'EP9?;7E&%-[/]@B7N
MZ.9<V60RLI@5(L(-%U=K B5?T6L5!9P%K)\Z%;IBZRQ6.C\D3+E?98FRIH*L
MK"((/WQ!%8,"""*?:KK&;<9IZ#VE"?\ #F;OFM8PR$$;"+[<CI(T!,ED]&8N
M0Y&%>BT(J<H+*4UEJUM)&J93UD;&CC$PX"($$@@^&!I#PQ\$/##PQ%(CP&]W
M]K8A%'6=H1@HY2:AC-E#>KX8**D0=5!N92<;&L[@  ^5'[)Y-@E=K"F_B^NN
M%+["\@VS+E&PF)S"L\0P6F-8H).85T2\MY\3OFOB)PEGBQQQK5R0V&5G/(<)
M\Z\HVH>P>484KM'DV.7V%Y!A-G/+AR^VO*,*=V#R8*9VY3A3?Q?47#E$^=3K
M#A%.L.$4ZPX13K#A%.L.$4)!CT5V![P?)$!G/X!QX+ 6N0OC/$#1Y)\M8[Z_
M@)PIDGS289K1Q0V&3VT]884WLX<K,>4X3,,9/+@R^VO*,*;V?[!4O-V<I,0A
ME93 J16""*P0:#5FLR$OZ#,)P%K*+ X%;H.TO1B%^2)EROLL394T%65A$$'[
MX@BL&!!!%/M5UC-N,P]![3+)_P .9N^:UC#(8C81?;D=)&@)DLGHS%R'(PKT
M6A%3E!92FL=7/I(U1!ZR-C1QB8<!$""00<&/@CX('!AX.^O!TIK@]W+!Z3D9
M?-48V.81, 6OU_?28V =5!B51B X2:R28GY6?LGDV"5VL*;^+ZZX4OL+R#;+
MW@^2-$9S6> #CP7RO!1OV\0/@ES<941SBH\8.#W@MED'>-1Y0=[896<\APGS
MKRC:A[!Y1A2NT>38Y?87D&$V<\N'+[:\HPIW8/)@IG;E.%-_%]1=JJQM<EO$
M.(1W\&7=QB!8[]0Y#PTE3<08 YC4>(X23Q8X@<Z_@(X-AD]M/6&%-[.'+E-:
M%$<YK/'@O./DJ3OPJX\*7VUY1A3>S_8,L^0Q1T(*LI(((K!!%8(Q$475.MF"
M7Y!4:@)X M&(3 *V46]9:HA?DA[I>T$R5,!5E81# V@BAOUQ!F7"8>BUIE$V
M(YR>8^.P]+K; +[<CI(T!,ED]&8N0Y&%>BT(J<H+*4UCJU])6J(/61L:.,3#
M@(@02"#@1P=WP1I'P:%4V]..A+_/?(HX6-0QD/?K^YF3'M)Q#$ + HQ 5#Y7
M*M8:>Z'">>GNAPGGI[H<)YZ>Z'">>GNAPGGI[H<)YZ>Z'">>@FRY8#+88GGP
MIOXOKKA2^PO(,+W:>B.:GNT]$<U/=IZ(YJ>[3T1S4]VGHCFI[M/1'-3W:>B.
M:DL2U"Q4V #'N;(I-KQ;ALX@,&7=QBBQWZAR'P-*-J-Q&OEC@M):Q@1PBA1J
MB# [VP2LYY#A/G7E&U#V#RC"E=H\FQR^PO(,*)E#A//3W0X3ST]T.$\]/=#A
M//3W0X3ST]T.$\]/=#A//0.LH @Q%9M&_A3NP>3!3.W*<*;^+ZB[466MK$ ;
MYA19:V* !F A@S&%@.B/Q:N6)\$N=YR@G/CX\$N+99!WK#RQWMAD]M/6&%-[
M.$MYO*Z*"L VL<563/;FPA<T-;5MF%G">3"E]M>486BPB#B-/=IZ(YJ>[3T1
MS4]VGHCFI[M/1'-3W:>B.:GNT]$<U/=IZ(YJ3%0  :-0J'57[OUGR&*.A#*R
MD@@@Q!!%8(-8(HNI]=$)?0((UBSP!P"9C*BIK5 K ^2'NE[03)4P%65A$,#:
M"*&_7$&9<)AZ+6F438CG)YCX[#TNML OMR.DC0$R63T9BY#D85Z+0BIR@LI3
M66K6TE:IE/61L:.,3#@(@02"#L$12(\$:&Z70B;?&%2VK+C8TSE"6G' 0)>^
M7QS,FS#%F-I/B L %0$   /N&F_B^NN%+["\@V67V3R[&LI;6( WS"@EK8H
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M !634*77^J']59"S-<D+,N=Q< K<":UG3P:FO@$"B=6ZFLZ5X@9&S7K^K?\
M22Z_2]*;K'5TI?>6L][NB*/>6M/D*/I*YLH=YI+,V"[?%WPC>3=KY=C4;4F(
M8:<F<D0)DJ8!!T.XRE756'^JZLA=M8W4(M]N9,6D3&!@R&K3D3=%C*F0Q%'
M=6& -I'P#PCPC9)_]3OZ.7,";!IE^U9)4*'@"S7FY2U@.\J^ENR#Z0].2O>%
MDF0-1'RDQ.,GEP@#E'R'/^L?UCM<S/+-2C*<N86G@QTTC63A)=TM<@9AC.\(
MF@1:@H &88(["\K8:9V]8[6E=D\N&_UA]5,)I$SJN('GSBT;M&N\VU3PC$1N
M$5['I7=RF8U;XL.^*:-Z0.,HZ)\8/%2!?NSD>KCK7CII(00<8K&V?M,L=";7
MF;&-^T;^38].62I&,&!X12$PB:/G"OA$#PQI">#*/I#A%?%32D.KC<(/#D_L
MO61(4O,<A5502S,3 *H$2228 "LFH4NW]3_ZGW</KZ8 ]TNC@%=7*1$3)@,0
M;Z0:A9=14/IHF7M"]?U;_I)=?I>E-UCJZ4OO+6>]W1%'O+6GR%'TE<V4.\TE
MF;!=_B[X1O!D7J08,IB94Z42-.1/2(TY3P&DL000KHRS%1U776I&$B^R JWR
MYLP,V[32-[O),R!,F<  X!5@LQ71? -I'P#PCPC9;W_5#^DUVT-:@M.OUPEB
M"WP0B\^[(*EO51:9*6J\DED O%4]I,Y2CH2K*P(*D&!!!K!!J(-8/RBV<X2Y
MQ\AS_K']8[6[R>:\0QDY!SV"AG3:A8!B R<YQG#-_FBMJDS8SOV#<CEPAV%Y
M6PTSMZQVM*[)Y<-_K#ZJ8?>R1]*@J^</-YMVK'&FBU1&RZ4AV0[A(X<M(3@L
MP;H@>$5<1I"<&EG=$1PBOBII2'5\Q!X<FUFN\X15N(XB-T4,B<++#B(Q$??4
M:METD)!&,5&D-/3&1Z^.IN.D+U+*[JF(X# CA-(29JDY#4> P/!_97+N=SEM
M.G3F5$1%+.[L0JHBJ"S,S$!5 ))( $:2/ZC?U'D).^(YRAKO=V@Z:M1AOJU]
M8&#S!$203+E&.F[#:5Y_K!_2FYU=*;K2X25KCUGOMVEJ,[7J4@J]^BF,V&P7
M?XO^$+P9%ZD&#*8F5.E$C3D3TB.\E3(#26(((5T99BHZKKK4C"1?9&BM\N;,
M#-NTT@YN\DS($R9P #@%6"S%=%H-I'P#PCPC9KQ_4G^F<I9&OU4O>;H %EZQ
M@(Z:&I9=\@"(GH7@P#E)D9C3+G?);2ITIF1T=2KHZDJR.K ,K*P(92 0001'
MY0;.<)<X^0Y_UC^L=IQ-5/I)JQR Z1X%CQT*7%(?.;Q+SG>H9L]BS'&?OJ&X
M*L/2>J4IZ1R_-&Z<>0;T0B" %0&080["\K8:9V]8[6E=D\N&_P!8?538#>KH
M(3,8\[=[7+GM*L($6@[/I*8$8Q0#3TQD>OCZW'31O4LH<HZ0X*B..D;O,#;D
M:^ UC@VIW4RIAU6Q@^,'&/'0R9X@<1Q$90<8^\[0A)FD 8C6. Q'!2%[E@[J
MU'@-1X12"3 IR-T3QU'>)_LGDZMU;)>\7B\.LN5*EJ7F3)CD*B(B@LS,Q 50
M"22 !&DG^H7]0T2\_$DQ TF20'E:L#"L*T2LR]E3"9.'1E1:7)+#2FS*#:=Z
M_JW_ $DNOT72FZQU=*7W=K/>[HBCW=K3Y"CZ.N;*'=Z2R]@N_P 7?"-X,B]2
M#!E,3*G2B1IR)Z1'>2ID!I+$$$*Z,LQ4=5UUJ1A(OL@*M\N;,#-NTTC>[R3,
M@3)G  . 58+,5T4;2/@'A'A&SS?CC^G\F7=?B:4(S$&C*E:R4>3-:I4O2BJ5
M>&(#@"5/;0[N9)GZHUO(>[7J[.TJ;*FJ4F2YB$JZ.C %64@@@B(/R>V<X2YQ
M\AS_ *Q_6.'[^9Z;<]/?S/3;GI[^9Z;<]/?S/3;GI[^9Z;<]/?S/3;GI[^9Z
M;<]/?S/3;GI[^9Z;<]/?S/3;GI[^9Z;<](M.<_CMSTZ;%LY)V$39T4E9<;=G
M<W;,D:"3)4*HL PQV%Y6PTSMZQVM*[)Y<-_K#ZJ;#WB=";EQ'M<]N>RG=7A=
M$XLAW0<>T8BHT +=XN1J^.WCH%G@RFW:UX1XP!NT#RR&!L(,1P[2[F\+$8CC
M!R@XOOC0N.G+\X8NT,6>SDVE]!,(&0UKP&K@KH%OJ0^<MF^I\1.:FE=G#9K1
MG!K&^/[(Y6K=627O%XGNLN5*EJSS)CN0JHB*"S,Q("J 228 4E?'OQ[*2\?$
M\](RY9@\O5LMQ RY9$5:],IT9TY8A 3)DG0[R9.\ VI>OZM_TDNOT72FZQU=
M*7W=K/>[HBCW=K3Y"CZ.N;*'=Z2R]@N_Q?\ "%X,B]2#!E,3*G2B1IR)Z1'>
M2ID!I+$$$*Z,LQ4=5UUJ1A(OL@*M\N;,#-NTTC>[R3,@3)G  . 58+,5T7:)
M\ \(\(VA-^+/A54N?Q3(3HO4DJ_H@Z,B\XA,AT9-X-:P67-)E!3*O&H=?W:9
M<[[=',N=)FJ4F2W6U64UC*,1!!!((/R<V<X2YQ\AS_K']8[:C)0Z/G&I>''O
M1H)EX^E?=ZHWL>_P#81V%Y6PTSMZQVM*[)Y<-_K#ZJ;$95X4,IR^+&#NBAF7
M$Z8\T]89C8>(YZ&7,4JPM!$#M+3N[E>0YQ8=\4"7Y='YRV;XM&]'-03)+!E.
M,&.T8&AF70]V^3R3[.]5N4T+PA7(<1S&P[2#RR5(L(,"-\4"7L=ZN6QAXCOU
M[M(W=XG&IJ8;WC$1N_V02-4:HD/>;U>765*E2E+S)DQR%1$102S,2  !$FDO
MXR^,D2\_%-Y3<>7JZ6XZ4B0U8:>P.C>+PM4(R9)[K3>>?"-JWK^K?])+K]%T
MINL=72E]W:SWNZ(H]W:T^0H^CKFRAW>DLO8+O\7_  A>#(O4@P93$RITHD:<
MB>D1WDJ9 :2Q!!"NC+,5'5==:D82+[("K?+FS S;M-(WN\DS($R9P #@%6"S
M%=%V@? /"/"-HC6^JC+N'Q)=$(D7HKT+PBQ(NU[T:S+C[N: SR"20'0M+:]?
M"_Q1=7N5_N3F7.DS!!E85@@B(96!#(ZDI,0JZ,RL"?DQLYPESCY#G_6/ZQVO
M D#=,?$">*@[^]@;@4K^4PAQ4T[LJS#YQ(?G W@-C'87E;#3.WK':TKLGEPW
M^L/JILFC>4#;N,9C:*%[D\?FM;O,/&!GIHWA"NZ14<QL.\=I=Y=W*Y1B.<6'
M[X4$J\0ES/R3F.([AWB=I%)@# XB(C@-"]U)E-DM7G'##<H2Z:2CREK'.-\#
M:0="01814102K^-(>>+1G&/.*]PF@F2F#*;"/[';OJ+45WF7N^7N8LJ3)E*7
MF3)CF"JJBLDG> K, ":2_B[XK"7WXHO$N#-4TK5ZN.G)NQ\J:0="?>/*$9<J
M$HNTZA\(VM>OZP?TJNL+O%INLM7R5JE1BSWV[(MDJ/2O,E1"5$SD E"8)>P7
M?XO^$+P9%ZD&#*8F5.E$C3D3TB.\E3(#26(((5T99BHZKKO4C"1?9 5;Y<V8
M&;=II!S=Y)F0)DS@ ' *L$F*Z+LY\ \(\(VB*-.EB7<OB&Z(?L=^T8:0$2+M
M>BHTIEV8DP/2>[NQF2@09DJ;>?A#XQNCW*_W1H/+:!!!K69+<169*<09)B$J
MZF(/R8V<X2YQ\AS_ *Q_6.V=)"0<H,#2#-WBY&K/#;PDT"3/HG.)K#F;GAL(
M["\K8:9V]8[6E=D\N&_UA]5-FT6$0<1H2J]VV5:N*L< %(W9A,&0]$\=7&*0
MO$MDSBKAL.T1(O<7EXC:R\XW+1BR4$R40RFL$6':9,Z6(G&*CPBW?C2-TF;S
M^T/9H3,E$@8UZ0XHPWX;1TI)BIM4V'F.Z.2JG>23 CK*;0>;(<>>K^QN[Z@^
M'KK-OM]O3A),B2A>9,<UP55!)@ 238J@LQ"@D+\3_$ZR[W\4WN7"9,$'EW&6
MXKNUV-A<BJ?/%<PQERR)0)F> ^$;6@:P:7K^K/\ 2:ZQN!TINL-7RE_9?*>]
M75%__&M:=)4?Y>N9+'V?26[[!=_B_P"$+P9%ZD&#*8F5.E$C3D3TB.\E3(#2
M6(((5T99BHZKKO4C"1?9 5;Y<V8&;=II&]WDF9 F3.  < JP68CHNS'P#PCP
MC:(\'V368%TUO=4;[%?U6+RF-?=30(=]=G:MY9,5)+RF1R2UY^#OC2ZM=;Y=
MCCB9<U"3H3I#P FR9@$4<;JL%=65?DILYPESCY#G_6/ZQVX)4Z+RLF->R<FY
M9DA03I+:2M81]_%ACL+RMAIG;UCM:5V3RX;_ %A]5-HP-8I%Y04Y5Z/)4=\&
MD;K-AN,(\8YJ1[O3&5:^+K<5-&8"I&(B!V;1:+2FM&3=&[N8^ @391TE:L$;
M5^GEJQRPKX17QTC(=I9R'I#Q'CI&5HS!N&!X##B)I">C)G!&S"?(,&''N'*#
M3O$J8=9<A\8.(^/^QF[?#GPY=IE\OU\F"5)DRAI/,=K !8 !%F9B%1068A02
M!KK70EWSXGODL"\7@#22[(T";K=21$(##O9L T]ABEA$'A/A&UX&L&EZ_JS_
M $FNL;@=*;K#5\I?V7RGO5U1?_QK6G25'^7KF2Q]GTEN^P7?XO\ A"\&1>I!
M@RF)E3I1(TY$](CO)4R TEB""%=&68J.HUWJ0B1?9 5;Y<V8&;=II&]WDF9
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M4Y0?&+#PX\-DQ,AX00>2/]B5W^#_ (*N;7R_7F,%$ J(O7FS7:"2I2 Q9W(
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M%2C(.<XSXH4$Z0VBPX]PC&*"6W0FXUR[JY<UHW;=JS3E '"P&&&\U6/B\?\
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MP[#]NG#HIU=ULN9>7-AP-#>+@-TI[/L\&2D#41LD)$UE&2,1P&(XJ0FJKC-
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MFT&L4,W5YC\PGU2>0\-#+FJ586@B!VEH7="V4XAG-GCR4$V\?23/R1F&/.>
M;2T;P@.0V$9C;O6;E"]T/>+D-3#Q'B.Y0I,!4BT$0.T^[NR%CQ#.;!03;W"8
MXQ>2/:WZMRD!M RYJAE-H(B*&9<6T#YK5C>-HWX[U-"\(5W<1S&P[3"("2;
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M+Q>5CO74PW*[10;,,$^$;1G:RUE.2[W>[HTR;-F,$ERY: L[N[$*J*H+,S$
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M=$1PB/&!33DL'&4$'DVFUWFV,+<AQ$9J-(FB#*8'GS&T;$%8?1I6WB&_R1I
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M'U:>J-H/V6Y#AR>U]QI'FJH\?C^1!/D&##CW#E!III4XZRY.<'$?'\DF;-,
M./<&[3O'J L&(#[[3CX*0\$<&K K\,*5TCLQD'%6/']^[\@B\H.E*M[)MX#
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MW<V"M3E4V<QW0<,,I@107:]&$T5 XG_^6YCQ9-G[V<:\2XV.YXSBH9\\YAB
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MHZ++6"*:+=&:MHR[HW.3@)V R9PS'&#E'C&.ADSA7B.(C*/OJI X-?@B*0I
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MJ;41U6Q@\V48\\#3Z2=P+XR1R4C,+/G,!Q0/'3Z"6J[H%?#;Q_+Z@Y13W:\
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MHD&*WH#$=IMEM$ !1/2(U?71),^?-?;C0X4)AV5+ER7C1MF/&C,(1N&9*@B
MBJJO4B<0K&NV6D[88U.1DV\HWJL V[B@T_HK3ZXW,![('&B!>\1UBF<!1ZT)
M5(4*-+WM\4+;;RHWYW0;5X&3S8EY74C9?ELMM23V!4J-/;5/8X93(4WIW'?$
M![\\JW%C5;+KO=F)JVS@==3D <QH0BKA*G("*1?TG>.!&\,59+)X&!==M]R=
MY+IPU80D1QM+7(G1:4N95/N!!"ZM4T$43[+&*?*S<OX[X>-OP\/T,I]P7"ET
M&ZV\4/D06^[[MF!)OWH;8KU$J!&155-=>LM3>PG<#?C;V<JIW;0Y'BF548!R
M*A<\"YIQF$2EH2*EDB?SDY5U11ES=D?$!MUN*VTAO,4V>X_>;:VSP"/,,2+,
MJG+^(Z\J^]$WSC-EY25M%T29/WEV$S?'\;A..@[F]1$CYA@@MAS$V_(S#$7)
ML",CH"KC;<Q]EWE1>9L5$D'TF)D;SEA;[+9X]74.\V%QC-U9E*T\0P,OI(A$
MC?PO3$ZZ_%YM._9.1$4FTD(ZUCF<X7>5^2XCE])69'C.05+Z2:VYH[B($^LL
MH3X_SFWF3$QU1%Z]%1%U3TJ+X&MK;U6XS+=5DWB#L:R2G_$ON\EKB.U\@P35
M!;%(]U9@)>^4H+7,G));7TAIAAIQ]]]P&6660)QUYUPD!MIIL$52(E5$$435
M5ZDXB66*>'_)L5QN7RF&4[J.1=LZE8Y\JMS8L/+"CV4Q@D)%!V! ?$DU5%5$
M7B/(WF\2^!8BFC3DBKVVPZ_SYT]4U<C);Y*_CH-$GD[Q(CR:Z^]5.OAE[,MQ
M-_<[F H=\S_63#L7HWA% 4D2#54AS!4B0T54LE]Z2(B(0\ZJS8;%WF4.*VP'
MG=[O!N_'D(32$CCR#C5W7-<SNJ*:*URIRIR""<VOV6,4^5FY?QWP[$?\+>.@
MT\B"9P\YW8KI*()(:=U-K[]IYM=4ZU!Q%5-47J54X=&FP/<7;\G%-0<Q'=7*
MIIL(1@0BTF>.78J@H!"G.)+H9:JJH"@\[LWXF\\QEX$=./7[FX;CV<-R2\K#
M#UOBKN/*PGL&\,%WVT;]CB;88928)OK1Q@.0+VV^5M0L@2**JG]/B^<-U3QO
M]6OF]>Y+5=4Y5)=41W%-U=OLTVWR5E",Z'.<8N<6M5:$^3OVH5VRRX;2K_-=
M 5 DZQ)45%]+J/!_X@\C63NMCE<;.SF<7,MUV;N1B]3"5YS#;R7)4E=O*N.T
MX['DFYS388JAIYS&-V7Z1D.X,!Z!)W7R]QW"MFJ*8C,@)693XI..9%.@&JJ[
M I8Z'/E(H\CCB1XADV4L"2YR;([.;=Y#D5M8WM[<V<AR78V]S;S#L+2SL);R
MJ;K\A]PW77"55(B5575?26_^ANQ.X>X$ W187(X%(=;AK#Y.=TC,S.+XHE.P
M>J%[UZ<*Z"2^025(T[=?<7:/9V&^ *[6,SK;<7+(9J6AA(KZ%J/5+HG6BLWA
MZKU=7EX:7<_Q#[R9F^ ,JXN$4N%[<Q7G@3^F56+MC)W$;-=- %_F%-4[Q55"
M1D;7;[<'-E;-DC/)]ULOB%(1I54VWDPQZH%$<U1#[M!5-$Y%'KU2+&\+E"XT
MAF:%89]N[;2=375469:Y \\J>T*GHGL(G'V6,4^5FY?QWPYYEL9=8G(=609R
ML;W:W84^\D&)H;<7(+FPC C>A(V#; @B$J**H@\K[VVN\F]VW\YWF5MJ^=P_
M/J*,O+H",P!KZB:J:]9(Y9DJ^PJ<2YNSN[&U6\4*.CI,UMNW;[7Y9/Y=59&)
M76'PI5(1(GON_O&T%51.8DU)#3?+8G<+ ( .=RF1SJ8K3#'WN9 [B'G./E+I
MGSU4=09G$2<P]7ODU]*:Q+.+"QM_#/N-;QV]P,?'SB<6$6\E&X3.Y^+P6^8D
M?C@#86L9@569$#EY')#$10J,EQNUK[W'L@K(-U1W=3+8GU=O46<89E=95TZ,
M1-O,/M&#C3@$HD*HJ*J+_P"!B;:6DV)6UM;$DS[&QGR68<&!!ALK(ES9LN0H
MMM---B1N.&2"(HI$J(BKQ-+&+"8UL)M9)LL:VCJ")UEFX;1T6+S<:?$/3_B;
MEQD7(Z. )LPAC,D(NH\I].%65D*78V5C+CP*^O@1WIDZ?.F/)'B0H42.A..N
MNN$(-M@*D1*@BBJJ)Q4YWXG;B9X>]O9B1YL?#F(<:PWDOX#B(:B]63.:'CJ&
M*^].S"1* D47:T45#XB'LQL[CE?E,=I6W=Q\C8'*]R)1&)#(-,ONT=DQ =0M
M'8U=YM'+1/Z'WJ:>D$)"A"2*)"2(HD*IHHDB^5%]E.+2Y+ V-F-S9ROR6]Q]
MHHD'&WY5B\JO')RC$6P^"+1'G50Y3SL5N:YUH,UI24N++*I]0F[>RT5QPV]V
M\!KICL2IA@*$+V?8QJ_+HE]@GW3>A<RB S3<) ]):QC.K22?ASW=L:^IW&A.
M$X_'PJ[-1A4NZ5;&1=1*%J+%N+2*3\!27NWGXL01CS(<AB7#EL-28LJ,ZV_&
MDQGVT=8D1WVE43 Q5" Q545%1473I^,O]ZSQ#_6[<=/_ -X\0/[1,:_1_C_W
MCQ _M$QK]'^/_>/$#^T3&OT?X_\ >/$#^T3&OT?X_P#>/$#^T3&OT?X_]X\0
M/[1,:_1_C_WCQ _M$QK]'^/_ 'CQ _M$QK]'^/\ WCQ _M$QK]'^/_>/$#^T
M3&OT?X_]X\0/[1,:_1_C_P!X\0/[1,:_1_AQ,&WWW\QN232HTYE*[>YG&;D+
MWFAK&JJ>C,FT56OZ/OD+02_I-310D2]E]_=LMS&V45T*S-J&_P!KKA\>77S:
M&M>YD4-QU%]ZA/RHX$B<RJ"KR(ZYOGL?F>(4C;H,AF<:+'R; 'S><5N*V&=8
MLY,J@==TY@C/2@?T7WS0KJB>D8[@-U9'&VW\2'F&UV11G#1(D?,WY)EM?>\A
M$ ]Z%F\55SDN@LV#Y<I*(Z=.UO[VQAU%)1ULZXN+:QD-Q*^KJJR,4VPL9TIY
M4!IEAD#==<-401%5541.+O+(4V<QLW@;MAB.RF./]ZPU'QAJ4B3,NG02T0;&
M]=;&9*)1YVV4BPR(QB 2].)75T23/L)\EB% @0F'94R;,E.HQ%B1(K"$;CKA
MD(-M@*D1*B(BJO%-GWB@MK+P^[<349FL86Q#8?WIOX#B<W*]660'$QQ#1443
MM&I$H%11<K111/B-'V1VAQRCOVHB19NX-PPF2;CVW,G_ !)SLSN$=EM@\2J9
MQ89,147J;8 4$4](-IT <:< FW&W!0VW&S3E,# M45%1=%1?+Q9W,7"6MC]S
M);4ER/G^T4*OQ]B39.!S,RLIP=L!J;(%=T.28LQYCR<R)-;4N=)N1Y#1AN;L
MVTZB1]X, A3I=)7LNN=W'#.*8T.51.JJ@"G)YX9.&+3,QYQ>7TD_ UNK>J=-
M<K:7WA]M+.2O)5W2<]KD^V+;[RZ"S.3O[6K;7E1)(RV44W)4=M/2-U]_<C!B
M4U@.,2)=)4/NJT.19?9.A3X;CG,*H:#-LY$5AXV]2;:)QW14;7C+-Q<XN).0
M9CG&16^59/=3%19%G>7DX[&QEF@H@BA.N$HM@B" Z"*(*(B=*%65D*78V5C+
MCP*^O@1WIDZ?.F/)'B0H42.A..NNN$(-M@*D1*@BBJJ)Q3Y]XJKNQV#P68C$
MUC;Z#$C2MX[J"Y[_ )+*//0X>.*8*BHDYJ5+!44'H#*]?$1O939O%J3((\?N
M']P+F*.3[CV"G[Z0<G-;SOIK0.E[\XT1QF,BZ(#("(BGI,G#=UL P_<?%9?.
MKU!FN.U625B.FT3*2F(MJTZ+3XB1=V^URN O6!"NB\6&2>%W+K38?+7%>D!A
MN0/6.:[66#Q:FD>.<QP[JH4S)5)YN7.9 $$&H(IU\#6[Z;:V5+22YAPJ+<"E
M+^L&W62."BFV-3E<$>Y!XP%7$@S1CS!!.8XX)Z3293C%O84&28W;5][07E3*
M>@VE/<U,L)U99UTV.HFT^P\V#K3@*BB0HJ+JG$.^N7X$+>_;M(&-;S8[$;"*
MT5NXT:4^;5,0-$&!=M,N/@V H+$D)45-09!QSIY6Q06;DO:G9%RPVLVX9;=(
MH$YVIG*&;9@PWKR*5K9MFC3XHBN0H\)"ZP](B7N'T#6W^T'G:L6.\>>L2X&-
M.@RZK<QC#ZUL?.[V2'*X'+"!(P.CW4F7&547B!<W^'KX@=Q8RQI+F8;OQ8%Q
M30IS HI'CFWC8_!,9KO$1UE9K4V4T2)RR^KB/#AQV(D.(PU&BQ8S3;$:-&8;
M1IB/'8:1!  %$$ %$1$1$1-/29$.9'8EPY;#L:5%DM-OQI,9]M6GX\AAU%$P
M,543 D5%1514TXL[:LP$-B=P9@.N,YILTS#QJ"[-+5P'KO 4!:.6!NJKDHV8
M<:6]JNLL25"2UR?%J3_]8/:B#WTC^N6V=9,?R6IKV]2[_+=N>9^PB\H"3CST
M YT5H$YG9+>O*GI-=X&MY;XBI[A^6]X><AM)'O*RY>)RPL]JY,M\M$9FDKDJ
MD$E322KL,5(I$1H?_ O6>$3;JY6-GV]M0Y:;H2H+I#*Q_9Y9#D%*,W045!W)
M)33T9P4(O^!C2VG00);1+TZG:39'%'\ER:P09=C,=(XF.XG1#);C3<GRVYY#
M&' CDX'>.*).&2BTPV\^XVT==E$B'"W4\0+\1/AG=F_K6U&A>?:Y)-5MK2R5
M="IC"BFV4P56=)$C[Y\63&,UZ8]%E,M28TEIQB1'?;!YA]AX%;>9>9<11("%
M5$A)%1471>KB_P!Y?!G6TVWVYY)*M;W9@3BTNW>>/H*O.KAAGR1L?M'511",
MJA6/&H(7F']*^Y>89F^.W6)9;C-E)J,AQK(JV747=+:0S[N3 LJV<(.LN@OE
M$Q1?(OD5/2)OA'W'N#D[C;(4C=AMO.GO..2\GV?;E! "I[YTBYW\:?>8A /O
M?^ >A@T!)&?-.EXR_P!ZSQ#_ %NW'J6956T&':5EC&?A6%;8Q6)L"?#DMJS)
MB3(<D2;=:<!5$VS%1)%5%147BYW#\)L.FV0W<;;?GG@C//#VASE]%5TX;58T
M)ICLL^H6'JX$@ZH@.PP5PI3>1;;[FXG=X1G6)V#E7D.,9#"<@6=;+ 4<!3:<
MZG&GFR!^-(:(FGV3!YDS:,#+I0;6LE/P;*LF1;"OG1G":DPYT)\9,25'='K$
MVW!$P).M%1%XV2WQC=P+NY.W6.9!<1XR<L>!DY0AAY=5LIU^]B6C4R,B^SW?
M3H_"/@-R<7.-[82WFYK\"0(2Z7:&%+*,Q1OD"HXVN13VC9+D+0X<.8PZ*MRD
MYNGC^T.R^(S\RSC(G#6/!B\C,*MKHZCY_?7]H^HL0:^*)"4B7(,0'4012<,
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MR226O6I6-7(DUXII[ U">[['$6'NKB6X>S5@[R>=3RA-[A8C$YB02_\ 5,9
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M.ZH4;;[*G$8B7B*J+W;  Q.444BA *<R^K?#GXDJ^)S1IM??[)97-1M11B5
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M5.;S.:YRZHA:+U>HFLWV&W(O,*G&_'.ZI&WO/\/RR-'542ORW$YO/!GM*!&
M&ZUWS/,IQW674%P:?;7?EJGV$WME]Q"@R)ED0;5Y[8$(@(8[D%F2%53'SYD;
MJ[1TD)>1N/-DO&C2>H;+$,]Q7',UQ2X:1BVQK+*2MR&ALV1)#%N?46S;T=U$
M)$(4-M=%1%3K3BQR;PX9/;^'K+Y"O24QF0$K-=JYT@E-Y6FJJ>^%I5*ZX2"K
MD6P>CL@B(U ZM%GV.8;0V.=81!5\BW'VB\ZW Q,8C"_TEA9LUS 6M6PB<O\
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M=OH+V\+PG;Z"\)Q][A>$X7L_!PO9^'A."[>$]WCL]$NWH=G"^[Z-=NML[>I
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MT\ID ++;9Z2=TKBJ@..NMF7>JY$AQW$->54$A;4=0U7U86+[H4P5.:5$20.
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M[>.:$A1KV^QF/D-]'7F55_HYLM\$7JUTUT'R)ZMO\"D0ZZ'NIB[$W)MF,RD
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MBFW$@0F$2?EV"B\O,A"J*[/J54G(R+WC9O1T,VON'OU50HA2K_;VFA[Q8[R
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M,)EP8K^[F,QF9"BJ-.R(F&B[)9 _(I-B\T1)["&/MIZ3<;P;DN+932<6GP+
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MISNIZ1CF[&S^7VV$9WBTM)-7=5+W*IM%[V766<1Q"9F0I0:LRX4ELV7FU4'
M(5TXI=M=RW*?:+Q)I'CQ#Q67.2/B.Y<T 1MZ?MG9V!\RR'2172H)+A2VD548
M<G-M.OAZ98WE[9U]+2T\*59VUQ;38U=5U=;!9*3-L+&PF$#3##+8DXZZZ8B
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MV2T<CR6E%UEQ!<:,'!$DM]Q/ [;.7]4BOSI6P^:W+87T%O4G"C;>YO:$+<T
MU$6H-V\V^@"J^?RG2%M;?"MPL4R+",OH9)0[K&<JIY]#>U<D>ONIM99-MO-J
MJ:$*D&A"J$*JBHOJ>HW(W'2XV>\-ZNLR?ZW2X'=9;N/$$D-R'MG56(<A1W$_
MHROI+91&U5>X;G.-NL!0;3;,8958-@N.-*,*HJP<)V5+< 1EW%S922.3.GR5
M$2DS9;KCSJHG.:Z(B>FW&X&Q_P %^'K>F6LB=).FK--K,UL751TSRC$:]!^#
MY+QHO/9TX@JD;CTF)-=)%1<6WXVYML89E2Y,;'LPB =K@68#'3G)_%\MBCYM
M(7N^5TXIJW*9$A\X8:)>7U.SM[L=A[]N;#D4LIS&T2178'@E=)-4&TR_)!:<
M".*B#A,16@=ER>0QBQWC%117Z$&\\WJOZX(><;PW%<S&LY3!D+[^.XA 4G?@
MFG1P ,HS;QNR# ')3SO=L@S_ (BY$V8^U%B0V'I4J2^8M,1XT=M77WWG#T00
M 44B)5T1$U7C<G=1]]YRIM[Q^NP^,\BA\'X32+\%XM%1CR-F45L)$A!ZE?<=
M/RDJJOH^OVO0[/Q\)Z"=OH]G"]GX/0[>%]Q>%]Q>%X^_QV>@O;Z">[QV?CX7
MLX7T5X7U^SPG;QZ_:X7MX[>.SA?=Z%7CV/5=A>7UY80ZBEI:B'(L;6VM;&0,
M2!6UL"()NO/O.F+;338J1$J"**J\5N^.^-;7WGB0O*]7*NK<6/8U6S-58QU!
MZJJG@4VGKUYHU:LK)I5%H5*)$)6E??E^K+/;3<NL[Z.]SS,=R*&#0Y!AV0"T
MK<2_H);B+R.!KRO,EJV^VI-.B0%Q.V[W$@]]&>1^=B&7P6'1Q_-L?%WNVK:I
M=<UY' U$)D,R5R.XO*7,!-N.=OH+V\+PG;Z"\)Q][A>$X7L_!PO9^'A."[>$
M]WCL]$NWH=G"^[Z;MU&:%HF[?!]TJZ2K@FI@PUADFV$F%$D1#[R*V*J2$G*I
M)IJJ*GW%LMLM[L H-P\+LU%URJO(Y]]!F *@S:T=M#)J97S6T(A:FP9#3P(1
M"+B"1(MOGO@^M9F\V"@KLQW:Z^?@0MV,>C_SW&:6=_00,@9;1"(1!(LW109;
MC3'-72M<9RJCN,9R2BFOUEWC^05DVEO*>RBGW<JOM:FR!M^.^V2*+C3S8D*]
M2HB^H@A[+;?23Q1B9YG>[I94K^/;:8Z8IJ\$S)'6G%E/M^]YX-6Q*EHA"2L(
MVJFE1GF9M1M]M]HB1I;6;954L#BV&6+:B_S;>8=()YJ.\RX(]U;32>FHH\[!
M0Q<-GTWQE_O6>(?ZW;CU3E6R6>IYB[-Y+O",L89%ZQP?.JUAP:+)80%IS@/>
M.1ID?F3OXKKS*$!&+@9%LSO-CKE#E5"XCT26RKLBARFAD.F%7E>*6A@"3*Z8
M@$K3J")@8FP^#4AIYEOI8W]%.Z'Y+9]*N\#W$Q6@S;#,DAE OL8R>KAW-):Q
M")'$;EU\X#;)0,1<;/3F Q$P43$52XW%\#=PD^(2R)TG8/-KD6IT9/YZ1-NL
M\MSY'QU7E;A7S[9BB*2V+I*+26N#;E8=DF!YC1OK'ML9RRGGT5S!<1502=@V
M(-GR&B<S3HHH&.A 1"J*OJ'^JNPNVEUEWFK[35]E#H)4X-BC;BBJO9-E]AR0
MHQ(!=Z$5'"E/")>;L/$G+Q2;C[]OU/B!WH@^;SHD6;7$NTN$VK:B\#V/8W9B
MCEM)CN(7<V5NV@Z\CK,"*^ FGJ%<=WXVSI\FE1XY,4>90A^!=P,7554P+'LQ
MKD"8TVCB]X4-PW(CI(G?QW13EXL<L\+&0!O]A#9N/CA=N=9C>[M-%UU1ML72
M8J;Q&P12-V(Y#D&2H#->:]?%GB6<XQD&&Y332#B6^-Y336%!>U<IM>4X\^IM
M6VGV31?]%QM%]1_U*V$VRR+<"U85A;:; 9:AXWC<>2:@U,RC*;,F:^O:+0N1
M94@"<45%H3/WO%+N3XI9M-OQNG!<CV,#"F(SY[-8G.;3F%'ZZT;;>R1YLNL7
M;..S$Z]%@&8 ]PTPPTVPPPV#+++("VTRTV* VTTV"(@B*(B"*)HB=2>H+?!M
MQ\1QS.L-OX_FMUB^64\"^H[)D31UL9=;9 XT2@8BXV?+S 8B8*)"BI:YMX-,
MS8VVN7U.6>S^X4NSM<"?=5.9QG%LS 95I6(NBJ$:>U/;)P]$?B,B@B6,[];4
M95@$AR2Y%K+F="\]Q'(2;%7%/&<QK%>K)Z<B<Y#&E&8)U."!(HIZBJ\7Q#'[
MO*LFO);<"EQW&ZJ?>7MO.=U5J%5U%8V[(D.EHO*VTV1+["<4^X/C,M9>U.%J
M;$Z/M#C<R%*W,R&/RB^TSDUTUW\*ACNHHHXRWYQ/4>\:,(#R"ZE3MGLQ@>/[
M=X/2@J0J+'HBLMN/F*"_86<U\G),Z8]HBR)TUYV0Z7OG73+K_P 1NYTJ#)2-
M=Y^U#VLI"YB B<S3GCWR-$/6C@TS5FXVJ+JA"B^QZ"^CZ_:]#L_'PGH)V^CV
M<+V?@]#MX7W%X7W%X7C[_'9Z"]OH)[O'9^/A>SA?17A?7[/"=O'K]KA>WCMX
M[.%]WT:O'L>J["\OKRPAU%+2U$.18VMM:V,@8D"MK8$03=>?>=,6VFFQ4B)4
M$455XK=\=\:VOO/$A>5ZN5=6XL>QJMF:JQCJ#U55/ IM/7KS1JU9632J+0J4
M2(2M*^_+]76>V>YE9WL=[GF8[D4,&1R##L@%E6XE_02W$7D<#7E>9+5M]M2:
M=$@+B=MUN+![V.ZK\[#\P@L.CC^;8^+O=M6U2ZYKR.!J(3(9DKD=Q>4N8";<
M<X7MX7A.WT%X3C[W"\)PO9^#A>S\/"<%V\)[O'9Z)=O0[.%]WTW )2.HVE-@
MFZ-D0*"DL@7<1>J.Z$D5.5464CFNB]0Z:=>J?<=ZOWSVGQ_(;KS1(E;G]8P.
M/[D40M"7FJ56;52-S>Z:(N\2%)<>B&2)WL=Q.KBQR'PF[FU>YU**N/QMO-S'
M86(YVPUU]W"KLMCB-+9.JO+_ $DMNJ!$5?*J:DF/[Y[19WMC8..FS"=RF@F0
MZBW(%)".@R$!.OL&_>'_ $L&2Z"\I:%U+IZ8#30&XZX8MMMMBIN..&O*   Z
MJJJJZ(B>7B!8X_M+,VUPF:C;H[@[RK+P&@.,ZJ*U*K:J6P[=6#1CS$V_7U3S
M*Z:$Z.HZU^3[]VEAXD\WC&Q)&KMXKF+[5UTEI>\$6\.@ONR+/E55 _A6<[&>
M%$4H0*JIQ78]C--4X[04\1J!44=%70ZBGJH+ \K$*NK*\&V&&@3J!MH!%$\B
M>G>)+<[#-K,9L</W&W\WASO%+!_=#;VO?G8UE^X=CD%%,>@3; 'F#=BR&C)E
MX!,%7E(4)%3C]4&*?M<VT^,^/U08I^US;3XSX_5!BG[7-M/C/C]4&*?M<VT^
M,^/U08I^US;3XSX_5!BG[7-M/C/U(F ;\81&R.+"62_C.2P7$JLVPJPE  O6
M.)9,R*O12<5MI7XYHY&D=VV,IAX $4GW'AFS/&]]L55Q]V%C&0RZ[;O<J&R3
MO-'@DY</#13U;;ZG)?PC"5PDU&("%RH_%SWPP;XT@1^;GLV]N,FN<>/E<[HO
M-\GH8\JN=T)11>ZE%_.%?(0JKK#^#Y>P^PX;+S+V-73;K+K9*#C3K9L(HD*H
MJ$*IJB]2\?V,ROY.V_\ N>/[&97\G;?_ '/']C,K^3MO_N>,<F6N.7U9$':S
M<ULI5A46$*,AG6,H *_);$=5]A->OTQ<2W[VMQG/X#+3S=59SXQPLIQPWD]^
M_C&6UA,V5>:KH1I%D@+FB(Z)CJ*V63>#_=:->0E<=DM;7;ONA6W##2\SBQ*'
M<*G8\UE%S*+;#-C7Q4$$U=FN'UDM7OQLOG>VZK(\UC6]S3G(Q2SD(/.K5)FM
M2LFGGJB?SO,ISNGLZ>G5T[;[96^Q[#;'N'0W'W.!W;["$@2$16[2OFWC8S+6
M/[Y-2I(4TO+[WWI:5F4>*#,K'??*8ZLRCPF@\_PW:V%)!4<6/+=CN#<7 @8H
MHN'(@LN"J@]#,55%JL,V_P 3QS",1HHZ1*;&,3I:['Z&KC(O-W,"IJFVF&D5
M54BY 35555U557U*N-[][1X?N/#".<6#87%>L;)Z5IQ2(OZNYA5%'M:Y54B5
M2@S6E557775>)]_X3-Z'\>?-77V-N=Z&7K2FYW#0TCUNX>,QUF1F6TY@::ET
M\QPM1[R4FBD4^7NKL)F;&,U_>..YWB40,[P08@DHMS9>38D4MB"#B)J#=DL9
MW3^<V*]7I\&3@.QV28_BDU6S_P"H&YS+NW6&!#<(1^$84W(@;E63(J2:_ T.
M8?46@+R%I6Y/XI\]LM[,ACJQ)/ L06?ANV<=\=#<BV-F)#=VP"::@X#M:)"J
MB['-%X@81M?@^*;>8?5\ZP,9PR@K,<I(SCJ)W\@*ZI:::5UU40GGB%3<+WQD
M1*J^I+'%,XQ?'<RQ>X8*-;8WE=)6Y%06D8OYT>QI[=IZ.^"^R#K9)_!Q89!L
MG9Y%X;<PDH\\$/'T+,-LY,QT^])V5A5X^$J*BJG(#=7;18[0JJI&+1$XGV=-
MM_#WXQ&(KSC=_LK*DY+;>:@/>-+*P*8S&O.^4->\;A0938DBBCQIRD4RBR:D
MM\=O*]SN9]->ULRHM8+O*A=U,KK &WFBT5%Y3!%T].6FV+V=SW<R2V^$>9,Q
MNAE/4%4ZXJ('P[E$E&JVO%=4]_-EM#U^7BNR'Q;;I5VW=,2MOR-NMJGHF3YN
M\RNG>0[+,[%HZ:N>1>;WT./:MJFFAHJJ@E6;#;44&)V,J,,6YS.6+U_G^0 F
MA.C<9G=$].)DW$[U(33K<1LE7N8[:=7^(_83:J-)3NR7+=P;J)S=:F'F^.8Q
M)4$7J1$6W%%5.O7J\B^@OH^OVO0[/Q\)Z"=OH]G"]GX/0[>%]Q>%]Q>%X^_Q
MV>@O;Z">[QV?CX7LX7T5X7U^SPG;QZ_:X7MX[>.SA?=]"KQ['JNPO+Z\L(=1
M2TM1#D6-K;6MC(&) K:V!$$W7GWG3%MIIL5(B5!%%5>*W?'?&MK[SQ(7E>KE
M75N+'L:K9FJL8Z@]553P*;3UZ\T:M65DTJBT*E$B$K2OOR_N!9[9[F5G?1WN
M>9CN10P9'(,-R 65;B7]!+<1>1P->5YDM6WVU)IT2 N)NW6XL'OHSW?SL/S"
M"P\./YOCXO=VU;5+KFO(X&HA,AF2N1G%Y2Y@)MQQ>WA>$[?07A./O<+PG"]G
MX.%[/P\)P7;PGN\=GHEV]#LX7W?3=T\P,"6%B6PUO7\XKRH%ME&<4@04/KZT
M6-"G>]T\NBZIIU_<F91Y)35.0TEBT3%A3WE=#MJN<P7\YF97SP<9=!?9$P5.
M)TYS9A-J;^<KA%?[*W,G ECDZ:N$43$P&3C@+S*NBK2KHG5_-1$25,V-\3ZH
M.I^98]NO@Z$2#JG=I*S+$)*:KY4)0H4]M$]CA\J'#=MMUV6 )Q7MO-S:6-W@
M!UFK$;<D,=?-4354 6N8M-!%25$61_6/PD[\*U%5Q),S'=O+[-*Y@65-''G+
M/#&K".C2<A+WO>\FG*O-H0JI,Y5M=N+C+P+)$VL@PG):9P"A:>>"06,9M45K
MF'O45/>ZIS::^B#30&XZX8MMMMBIN..&O*   ZJJJJZ(B>7@6\2V:W6RDS-Q
ML QS;O+[LR-I$5T!&LANJJBA"I(GDU37R\,A0>$K=VO)]>4%SFFB[8 *\_=_
MTSFY3]2+::^RXHII[[R=?#,C<'(=F]HJ]3TE1[?*[#,,C;'35#BUN%PY5>[U
M]2H=LW_!KQ&G[W[V;E;KRF59=*GQ&LI]KL:?-.M^+/1P[NR>:\HH<:PB&O\
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M414YFWLB>;)0E2@51B"I1XY*2O/.?<RXVNW)K@('VWIF+9/'8;.]PC)ACDU
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MG#N+!62[OF+E 74YD0>;1>9/LS[K?*[$?]3@QN/#IO-!C(T2@]6W>$6KY/\
M.*"V<>5)A"(*/,JFCJJBHB<BHJJ++5WA?B+Q%TDCI(?L\'PFRKFG'55'NY?Q
M_)94AP&M-5(H@$J*G*"KJB,1V_$*QB=@^@EYAG6"[AXR+**T#A=_=2:LJL5$
MB5M4\_55(25-0Y2)H-IM\-I=R7W6T=&'A&X>)Y-8 *BI*C];42W7VB1!+F!Q
ML231=431?5TBRM9T.LKH;:O2Y]A*8A0HK2+HKLB5)(0 =51.8B1.)#.9^*O9
M&'-B<R2JNGSNFRZZC$**JMOT>(.3Y@'U+H!,(2]6B=::NC4[GYKGQLHYJ&(;
M59PPCCC8JO=-/9I%IVR553E$D/D5=%YN7WW!M46U7B4O76Y"-]\_C&VM/7O1
MN[52D1WG,I>?5>;E%&W(H:HJJJIHB$Z%?X;MWY4-%3N'YF1X7 DN#RHI*[$8
M<D@"H6J(B/%JFBZIKHGV9]UOE=B/^IQ&2]V.\1%:!L(4PJF%MK=$Q)[K4FHP
M3,@KT>!#]ZCAJVJC[[D1?>\,_"TO>C!^\1M3_K1MHW+\W4VR,A>_J58W&J@J
M(!=WS)JJ<JD.I(TS0^*W;FL<>-MM$SQO)=L&@-UQ6D1V3N3 J6A1%%>8U<Y4
M30E+E425;7;?<'"-P*M$YELL(RNARN @\W)S+,H9$AO37JUYO+_X"LGFU4#S
M7 ]VG)>XN(&RWR0XTFTE*674+*"B "P[$G3;8!-&XS\9$1$5$X7T?7[7H=GX
M^$]!.WT>SA>S\'H=O"^XO"^XO"\??X[/07M]!/=X[/Q\+V<+Z*\+Z_9XBPH4
M9^9-F/M18D2*RY(E2I4AQ&8\:-'913-PS5! !15)51$157BN\17B%H(<G?*Y
MALR<%PZQ8226SU5+8)')LX#56_ZPS&S07= 4H#6K(FCSL@0^YT[;?<B#W,EG
MOYV&YE!89+(L&R(F>[:MZAUS3G:/00FPC)&I+2<A\IBTZW:;7[H5?<R6>>;C
M>20@>+'<TQTGE:AY#CTQQ$YVSTY7F2T=8=0FG1$QX7A.%[/P<+V?AX3@NWA/
M=X[/1+MZ'9PON^DH(HI$2H(B**I$2KHB(B>55XK/%%X@:)H-X[^K[W;/";!I
MI]S:['K>*B.7]PRX*]UD,Y@U;%H2YH,5PVG-)+[S<;[ENOONML,,-F\\\\8M
MM,M-BIN.NN&J((BB*I$JZ(G6O$ZJL-V W7S"#W@'AVR<6/GDP7VUY#CRLF;?
MCT$=P#]ZZR_;B\.B_P!$JHJ<3:SP\;(X1MK7&XXS'R?<6PL-PLI.,BZM38E1
M6_!=;"?71.9J0E@VB:HBDJH8R_Z_^)W=4Z^:KGG&/XCD#FW>,.LF7,,9_',
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M26;953QNY;/']U3A[J5TB(PNK< 9><MS;"*TG4*>838YB*( D@)R\0ZOQ/\
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MPI_WA]HOCCC[9?A3_O#[1?'''VR_"G_>'VB^../ME^%/^\/M%\<<?;+\*?\
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M=9B^FY)NON_F%1@^"8K#.7:75O(1L3<Y5\UJZR*.KTR=*-$9AP8P&^^ZHMM
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M8&"HHJB*BHJ<8QX7/%OD3#.XQMPZ+:O>:YE*V.XLA%\W@XCN!.DERC?&G(W
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M+1YP>5U;B[PV'.N0=3R<X2C> ^551515%5315Z+V88%3>>;^;'Q+3)<%"#&
M[/-<;)I)&5[<DK8JX\Y(;:274M=:I-:%D.09;Q*0D*B0JHD)(J$)(NBB2+Y%
M3V4Z;GATW N/.-WO#W55\"F>FR!.;F&SPJ-=C5FWSJAN/TA\E/-]ZNC/P>Z1
MF[(<Y?2QV(P.Z2'O!XBH%C2ON0GQ&RQ/:1O_ (+,KY>15)AVU4O@2"9B/.!S
MG6#%Z&BITL+V8I?/H&,*ZF2;H93$:4OZH[<U$EK^L%F#Q-N-C+D=XW K4=!0
M*8^PAIW?.0XO@&$4L'',/PRAJ\9QFAK6D9@U-)30P@5T&.'ET;: 44B52)=2
M)5)55?\  IJRC/0L.WGQJ ^QB&=^;DL>PCH)O,XKF8QA)U^M-XN9MX!-^&9$
MXP)B;S#]EMUNOBEABF35JJX+,H$<@6T S4(UQ0VC.K$V&]RDC<B.9#S(39<K
M@& ^AV<+V?@]#MX7W%X7W%X7C[_'9Z%3BV*4MID>27\]BKI**EA2+*UM;&6X
MC4:% @Q1)QUPR71!$57BAWU\1L&OR#>=GS>TP_!N9BQQ[:V0HJ;%C8.@ILV%
MZWJ)-N!S1X+B<S!//BW(;_PVV]\+E!9<^/;,4+.9YO$9<:4'MQ\[A#(J8LUL
M5)>>NH5C/,*O*O\ ZD\BBJ<I=/ ]B<0)V S>RRM<TR8&/.&<,V_IW =RG*'V
MRT$C::(6(;1D(O2WH\=3'O4),+VDVSHH^-X+@-##Q['*B/J7<0H@J1R)3Y>^
M?DR72<DRY+BJX^^XX\XI&9*OJ',MD]VZ1+O"\TK5B2D:(6+.GL6"2149'032
M$O-["!(%N3%>Y2'G'E<!QHG&SRG9/<!LYK4 TML*R]J(Y%J\[PF>Z:4F35H$
MIH"F@&Q,CHX:QY3;S"D?(AETMW6KO:W-H/AIW,QFJR>DW NX!T^-+N%C<X:^
M$6*I;FP=BU95\N2W,E5K3X"<.,#IAR]70R7":FP\ZPWP[T\7:BJ;9,EB.9:T
MXMSN-/[H^L9 63_P.^J=1)7-JB>R72P[:*.LN#@U=_\ EENWD4;WAT.W-)+9
M&W"(^J*@S;%UUBKKUY#Y'Y /&!,LNJ..8-A='7XUB.(4E9CF,X_4L)&K::CI
MX@0*RMA,#_-;99 0'557JU5575?447QR[7TJ,PK:958QX@*RNCH#$>UD\E7B
M.YC@![T4EGW-19DB)J^L)W0G'Y#G3Q'<#$IQUF4X/DU%EV-V(:J<&]QRS:N*
MF6B(J:]V^RV6FO7IIQM7O5C/(%-N?@F-9G&BB\+YUCUW5MR["ED.!U*_!DJ[
M#D)[#C1I['1VK_>LP?ZHLYZ?B7^BC$OG>7J38G]X%KZN;OI^)?Z*,2^=Y='>
M;Z*-Q/FA,]-PC?/;*;W.08C8(4VK>=<;J\JQR6J,Y!B5V (O-$GQ^9HUY5)H
M^1]O1UILAP??/:ZP\[QG,ZP7WJ]]QDK;&+Z,OF][B>0,LJJ-3:^0AL/#_--$
M%YI39=;,O3?%/^=>)_5I2=+9KZ5MO/G=#]1;R_2MN'\[IG2V:^E;;SYW0_47
MBG_-3$_K+I.G<?N_;B?.7'_4.08EDM?'M\<RFDM<<OZJ6".1;.ENX#E9:U\E
MM?YS;S#KC9I[*$J<;M;/6CCC\[:[<?-,!?E.B(E-_JID,BE:L$0/>J,@&1?!
M1ZE$D5.I4Z?A9LB[S6-C&98\G>M--%RXENC>XH&@LJJ*.D).0E7F(=")$)51
M.D'B*VWI A[*[]W$E^TAU[ ,UV"[O/-.6-]2-L-IHU$NFVWKB B+HCJ3V !I
MEAA"Z6W6_.!NN'985=-N6]+YP4>%EF)ST\RRG$K-40A5F?"-UH3("5EWNI#:
M(ZRV0X'O%MQ;-W6$[B8W79/C\X%%'4BSVM7H$]D5569<1Y'(DV,:\[,AMQHT
M0P)$])S#<O/+>/0X;@F.6^59+;RB$6X512PCG3'!$E3G<404&6A]\XXH@"*1
M(B[C;\95YS$:R:T6'A^/2'Q>##\!J%6'B.+LJUHWS1XJ"<MQH1%Z6Y(D*G.\
M2KT0:: W'7#%MMML5-QQPUY0  '555571$3R\0[#-*@(N_.\S57F&Z)R&42P
MQ>&D97,5VU4U34?@EEYQR<*:ZSWY2(;C3;"I_@8>$[OXG&OH;/?NTEU&)(.3
MXM/?:[LK+&KQL5<CN=0*;:H;#W*(OLN@G+Q995MW%F[U[5,D](2VQNN<<S7'
M(:+SH.4XC%YW7 ;'FYY]<CS*"!./C$11#A1)%$A54(5145%1=%147V>.SA>S
M\'H=O"^XO"^XO"\??X[.(,_#<7<Q3;5U]1G;KYE'E5F) RP_W,L:!%'O[>0"
MH8(S  P%P>1]YA/?($G$:TLPW/F1%CY!NSD\6.61S!>#23 Q^&"FS40"551(
MT55<,>49,B2H"2?X;9'F.2SFJO',3H;?);^R?5!8KJ6BKW+2UG/$OD!EAIQP
ME]I.-U]Z\C)]+;<[/<ES%V,^^L@JR)<6;DBJHV75_P#K,"(K$*.*=0M- *=2
M)TQWYRJM[G<WQ*M0LB8\[B=U-Q_:FO>=3!JMDW.942U0COG3;(1=9D0@,>>,
MB^I+"OQ^O@M[Z[8M6.4[.7;O<QWILY6!.[V_FS7=$&'>-,MM#SF(-3&XCYDC
M;3@G-K+.%+KK*NER(%A7SX[T.= G0WECRX4V)(07&G6G!('&S%"$D421%14]
M$1$5(B5!$115(B5=$$43RJOL)Q79#;8L&PNV,T&)29ONS$G5=I9P'M"1[%<
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MQYLES3ZC.QK)&(_,7(S:5KT2Q8%254;?#7KZ>9[+V<Y9-OL!N+(:K(ZKJL+
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M($E7:_*]X'6UA93:$H:"XW2 I4D75%Y7DL' ,FI Z=)_Q7[D4W<;H[Y4C+&
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MX=G D"B*3$V!(&5%>%%ZM1,!)-?:XQG+((\D+)\?I<AAAJX7+%NJUNRCCS/
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M"@ #=;7(0CK'8%P@%UUU5_QI[VY(CK#Z9!N[N3>(]&$AC/);9E-G]['$E54
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M9[JNR)+Y(B"*>06VFQ%ML$%ML ;$13U!0[R;-WRUEY6*D.ZI9BO/8UFN-//
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M,@%5>9V91-LDV(Z#7/D2F-%GVW654.;87DT$+&AR?&K*+;4UI$-5!7(LV(1
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ML:V?$?1#:>8> VW )$42147IXOO)B!2K*C14HMR,*"3YO#SK Y[PE;4KZEJ
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M9)N]-OPB[LWC<;:?=J\[[;.YLWR2/@^ZUF01F:-7C71JNR(D!C1?>-6",&B
M,J4ZGH>*?\Z\3^K2DZ6S7TK;>?.Z'ZBWE^E;</YW3.ELU]*VWGSNA^HO%/\
MFIB?UETG3N/W?MQ/G+C_ *>0D*$)(HD)(BB0JFBB2+Y47V4XR+Q!^#S$8>,[
MM04E7>;[/8^RU!QO<V. J_/M,*J&D%F!D"(BN%#CH$>P77E;"<2G+=8?:<8?
M8<-EYEX";=9=;)0<:=;-$42%45"%4U1>I>G1X[E=NY:[F^'^9'VMRN1,>[ZR
MM,<CQ/.=N<CED9FX:O5@_!SDAXN=^3 DNEJI:KZ@WF^BC<3YH3.GX3/I7KOR
M9*_P/>RR2W R+=S,TG4VS^ 27#[NYO&&167D-^W','@IJM'&W9IMD).F3,5L
MP-]'&\HW0W0RBTS//,SM'KC(LBN'D=F3ICJ(    @MLL,MB#$6*P ,L,@#+(
M T  GJK'=YMF<B<H<JH7%9EQ'D=D4.4T,AT#M,4RNK P2973$ 4=:4A,#$'V
M#:D-,O-L9U@K[=#G%"W"@[H;7SIK4B^P6^D-*HD)(@+,JIB@X=99@V(/ ) 8
MM26GV&ONJ[D>>Y32XI3-*H^>W,UJ*C[J)S>;0F%579#RI_-98 S7V!7B55;*
M8>]DDELG&F\KS,)-71$HZH#\#'HAA.D-EU*BR7H9IHJ*VNNO#S>4[D7C56\I
M_P#H..NIC-&+1+JD=Z!2(SYR(_Z*RR=+_P"J5>/PI^#KXU_C_DXT^\G\O"Z_
M?_DXT_B_EX_@7V?<]*2?A66Y!C$E3%QPJ:TEPF9*CIH,V*T2-/CU)J#P$*^R
MG$>!N;1U^=5HZ Y;UH,8_DH"J_[5P(P>8R.5.I&TCL*OE5W@3PG)F';46>^E
MXO:(-9DT$135Q7:MXE5T U1#?BF\RBJB=YKU?<7Q4XMW0,M47B)WGKX@MQFX
M3)5[.XEBE<\Q#:(A:;<8[MQML25!$D37JZ>R6>,."\QFVT6VV7,NCRH+K628
M;"N6W!0#<30D>14T<)/:(O*OJ_Q55[@OB4C-:&]1)')WBAE. 5&3-D/(B)R*
M,M%:]GDY==5UZ?A&M0>-](FR>(XPIF\KZB6$QBPPV4-431&R@*V(:>\1$#5>
M75?4OB[M <5U(N^>;XTI$ZZ\J%AEDN'FWSO(*H@%!4$%$Y11.454415Z7A%I
M'&3CR(?AKV3*<P;S;ZM64O;FNFVC:/-*0$B2''4'D)1TT1%5-%Z&U?[UF#_5
M%G/3\2_T48E\[R]2;$_O M?5S=]/Q+_11B7SO+H[S?11N)\T)G3N/W?MQ/G+
MC_I4B',CL2X<MAV-*BR6FWXTF,^VK3\>0PZBB8&*J)@2*BHJHJ:<?]1=MJA_
M_P#5NW?MYTK$/-VW'8VW&6N(5A:[9S7DUY&!#GE41NJA.Q!<8U=<A/NGT@=:
M,VW6S%QMQLE!QMP%Y@,#'145%35%3R<?]/MQKEN1XB-EJZ#6Y@<EP FY]AR$
MD''MQV&ET4WE]Y!NE#F09: ^7=C.9:'CQ3_G7B?U:4G2V:^E;;SYW0_46\OT
MK;A_.Z9TMFOI6V\^=T/U%XI_S4Q/ZRZ3IW'[OVXGSEQ_U#0^)_;^J"OP/Q!V
M%C&SB#"B*U H]Y(+'PE8V'>-HC8?UDB=Y8(UISG+C6+Y*J.(@])W:R=8.1\<
M\06!WF++")P@A.9GAL=S-\4GO]:#WH18UQ!CJ2+J4Q0'WQIZAWF^BC<3YH3.
MGX3/I7KOR9*_P.S3=3<*W:HL*P#'+3*<EM7DYO-JNIBE)?%AE/?.ON:(U'8#
M4W72!L$4R1%R_>O-#?@UTQ\Z;;_$5?[^)@V 5\EQ<?QR.0Z";R"92)\@1'OY
M;KSJ" D+8>K,=WFV9R)RARJA<5F7$>1V10Y30R'0.TQ3*ZL#!)E=,0!1UI2$
MP,0?8-J0TR\VQG6"OMT.<4+<*#NAM?.FM2+[!;Z0TJB0DB LRJF*#AUEF#8@
M\ D!BU):?8:^Z4B9,D,1(D1AV3*E276V(T:,PVKK\B0^ZJ"  **1F2HB(BJJ
MZ<3\1V#CP<SOF2.-*SRP!US#Z]T25MY**("MN6;@JB\LA2"+KRF"RFU5.'\I
MW!RFVRN\D:HLVTD<X1FE75(U?":0&(K*+_-8C--MI[ IQK[?L?R\:Z]O'X$^
M_P"SQK[?L_R<?B_EXU]KV?Y./Q?R\+K]_P#DXT^]^/TN+95<Z76V,)X)$.?
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M^5B$M<>?$$\I-3DCNBGMBG3PG<7&GO-LCP'+L;S6@D:JG<76+7+-Y5/:I_\
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M1T<EPS?41(U@O30; G3;TCS(<AB7#EL-28LJ,ZV_&DQGVT=8D1WVE43 Q5"
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MP_-_.-;+#<T@PXDC)-O\LCAI R.@=DI__)FQN<!E1C<8(@YT,+7:C>"B<CN
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M$-\T0VZ^ !H[+>3D#E;%YYK$MD-I*E:[&,7C<TJPE(RY>95D,H!6ZR[)IC
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M +(<A)_']O<??EQ]NMN8\LG:['*YXN0K&Q,$$9=K+$1*9,4?:::0&0$..O\
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M4U3O$70D>/ _%EE]"WJ91X^7;54V6GR\[A T],IKJD3515H5<%CJ43+D5"0
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M\7\?K1R7]F.X'Q?Q^M')?V8[@?%_'ZT<E_9CN!\7\/;;;.9K<9!EK%!89,Y
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M4T8:<ZHD;E9$1=.2X]Z=BV\.!/FX_4O>89-CIRG(U;FF'S7@6]Q6V44-.[D
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MKQEMJ[%*;#D11DM(B*KD=7Q'G'WP]8ZIUI[?I&<>%#)[#6!>,3MR=K_.7?\
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M_:=M_P#&''ZKL:_:=M_\8<?JNQK]IVW_ ,8<?JNQK]IVW_QAQ^J[&OVG;?\
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MMM]YD2<E370$UC0(PDX:IS&K3*&\$";FV.2-]\U:9:6==;BZ'BZ2Q)#>^"<
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M^$JVI:05ZM7-=>K1>@#C9DVXV0FVX!*!@8+S"8$/6BHO6BIQLINYYP$F=F6
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MDQ#0X,94T)*EHTDGKI**-R''=KJ2CK:^FI:B%%K*FHJH<>NJZNM@LC&A5]=
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MJ/DEE_\ K<?:7VH^267_ .MQ]I?:CY)9?_K<?:7VH^267_ZW'VE]J/DEE_\
MK<?:7VH^267_ .MQ]I?:CY)9?_K<?:7VH^267_ZW'VE]J/DEE_\ K<?:7VH^
M267_ .MQ]I?:CY)9?_K<?:7VH^267_ZW'VE]J/DEE_\ K<?:7VH^267_ .MQ
M]I?:CY)9?_K<?:7VH^267_ZW'VE]J/DEE_\ K<?:7VH^267_ .MQ]I?:CY)9
M?_K<?:7VH^267_ZW'VE]J/DEE_\ K<?:7VH^267_ .MQ]I?:CY)9?_K<?:7V
MH^267_ZW'VE]J/DEE_\ K<?:7VH^267_ .MQ]I?:CY)9?_K<?:7VH^267_ZW
M'VE]J/DEE_\ K<8]G6"^+C;[%,PQ2VAWF.9'1X]FD"VIK: ZC\2=!EL&A"8D
MGN*FHDBBJHN*UF]UUB&2[GUU<$'*LFP6!/J<;R2;&)6F[R+2V*(<-V2V@N28
MP$30NJ?<\K2@V'I$K;K<6*E;?UJ2[#;O<2OBLO9'@.1/,H"382FH+(A2.1MN
MRK7'!;DMB/OFGVH\AEI[/_%35PV )5?K\/VLEV3L@/?B(M6]U=Q$95/>%JL)
MW_2'1.HEC2\YL]VMW)(=TLJ#D.71\7QZ00#_ $@M1,$BUU@V!JJJJ+:F2)HB
M$FBJK7_1W9+;G IK39-)>4^-0#REUH@[LFY>6SQ>M'QTZM'I9)UK[:Z_=[;:
MKLHK$ZNLL^PZ!80I38O1ID*9D4:/*BR&CU0@<;(@,5314547C[+FR/[/Z#_<
M\?9<V1_9_0?[GC[+FR/[/Z#_ '/'V7-D?V?T'^YX^RYLC^S^@_W/'V7-D?V?
MT'^YX^RYLC^S^@_W/'B!S'"O#WM+B^58_@,N?1Y!2872U]M530G,-C*@S8[2
M&V:"1(A"J+UKTO#U_P!V?J.R;I>(+Z;MU_GY/]3[\Y^S*6);A@\[%L:>;)4D
M-Y/G3@8;128J J$IQGYPRUT\@M$2^]%>EL/AT[<G;NOO+#$&\YR2/+S3&8\]
MJ\W!E.9C)AV+)R1('H;<QJ"0$*$*,():J*JOZU]M?EUB_P#S7'ZU]M?EUB__
M #7'ZU]M?EUB_P#S7&'YGBV<81D&3;6[E5\@HE/E-#:V*XMF,!VAN@CPX+YN
MKK.&H<-1%400)53V4Z.Z6S$Z6CECM?G<;)JEAPT$PQ;<2"1#'C-*B<X,V=;8
M/.D*KRE)!"Y>8.;I>(_\VL:^L"HZ6UWYM;G?5_8>I*OZ;L%_(%WTO$#]&N,_
M.@O2_$%]-VZ_S\G]+&I4GPP[*/R9-!32)#[N T)NO/O5S;CKKAJSJI$2JJJO
ME7C[+FR/[/Z#_<\?9<V1_9_0?[GC[+FR/[/Z#_<\?9<V1_9_0?[GC[+FR/[/
MZ#_<\?9<V1_9_0?[GC>V^H_#7LW575)M%N3;U%I!P6CCSJVTK<-FS:^?#D-M
M(3;K+H XV8KJ)(BIUITO"Y]-VW_Y?9Z.Z/YM;8_5_7]+P]?]V?KQR;U'LOL=
M EHDO-<MM=P;^.T:(Z%+A<#X'IF98?\ V*5,LW76]/*<-=?YJ:]#:;;ZWFPZ
MVES#</$J&^L["8S7PJW'Y]VRS?6,J9(( ;"/#5]XB4DZAZNO3AJ/'W1VPCQX
M[3;+##.;8JTRRRT" TTTT$I!$1%$011$1$31./UK[:_+K%_^:X_6OMK\NL7_
M .:X_6OMK\NL7_YKB+N/A608YD=7NGMUC5K;S<=N:RW:9RG%U=PZ;%DG6NNH
M!)7PZIQ%-44N=>KWNJ]'8W=-R4LRTR# JF'DSY'SFYF.,H6+9@9*I$2(=G"E
M&"&2ERD*EUKT_%;^[9OI]5]ITO#A5W%?!M:R;N+"9FUUE$8G0);*P)"JS*B2
MA-MP55$7E,53C]5&VOR%Q?\ Y7C]5&VOR%Q?_E>/U4;:_(7%_P#E>/U4;:_(
M7%_^5XD1<V\.NTU@<E'$>LZO$*S%<A5'557.[R?$P@V(*JDI:A*30EYDZ^OB
M_P![O#99764;=X]'?M<TVZO32QRK#Z=E.]F9!C]NR(+95L8>8I3#[:2HS0]\
MKLIOO28Z.WCTJ>['PG=.=%VISB,3QA"6)EDYJ)CUS( B1H5K[7S.03YBJA'\
MY$=$=+7H^(+Z$=U_F'/Z7AF^DJ#^3Y/_ ( =J?I)P7YT1?2/$S]&TW\HQNEX
M>O\ NS]1V3=+Q!?3=NO\_)_J?9/8B!(TD9;DMON5D;39\IM56(PO@''F) Z>
M^:E2;*8Z*(O4<-%5/YOJ#&L9F2UCT>\N,Y!MS-1QQ!BC;]P.4XN^8%Y73F5P
MP&%3K192IY"+I^(_\VL:^L"HZ6UWYM;G?5_8>I*OZ;L%_(%WTO$#]&N,_.@O
M2_$%]-VZ_P _)_2Q/\VJ+\EM=/Q!?0CNO\PY_2\+GTW;?_E]GH[H_FUMC]7]
M?TO#U_W9^O')NGOY<4%M94=M$_Z6>:6E/.E5MC%\XWJQR*_YO-A&#H<[1FV?
M*2:B1"NJ*J<?K6W)^764?\UQ^M;<GY=91_S7'ZUMR?EUE'_-<?K6W)^764?\
MUQ^M;<GY=91_S7'AYMKNSL+BUF8YD9S+*UFR;"PE&&>6S(')F2R-QQ4 1%%(
MET1$3R(G2W!KX<I9-'M+5T>U%3H2\@RJ%D[7*A[K540V[F?81R).LA:'7R(B
M>G[M[(SY:'.VZS2%F=$RZXO>IC>>P5C2XL1I>KNHUA6OON*/D.8G-_.'I^*W
M]VS?3ZK[3I>&;Z2H/Y/D])V/(::D1Y#3C+[#S8.LO,N@H.M.M&BB0D*JA"J*
MBHNB\;S;54['F^,U>2A>8>R*?T4?$\PKV<KH:YDO])(3$P8!%[),ET8\R(\[
M&EQ'VI,60R9-O1Y##B.LO-.#UB0$B$*IUHJ:\;9;A(39)G>WN%YFA-*RK1)E
M&-QKM";6.1-J*]_U<A*.GD54T7H^(+Z$=U_F'/Z7AF^DJ#^3Y/\ X =J?I)P
M7YT1?2/$S]&TW\HQNEX>O^[/U'9-TO$%]-VZ_P _)_J?<YF-*252;5QZC:*E
M5"$NY+$VCE92P2 JHA-WTRV#RZZ"G-HJ*B>GX/N-CY<EY@678YF-0O>&T*V6
M-6[-Q# W ZT$G&1$M/85>I>,4SC'G_.:#,\:HLKHY.H+YQ3Y%5M6]:_JVI"O
M.R\!>])4Z^I53I>(_P#-K&OK J.EM=^;6YWU?V'J2K^F[!?R!=]+Q _1KC/S
MH+TOQ!?3=NO\_)_2Q/\ -JB_);73\07T([K_ ##G]+PN?3=M_P#E]GHYM+>U
M[N]P?;:UBZMF"=PSC#=(7*1=1IWL-SWP]6OO?**]+;&"DCOOZMY/N=2JWW8A
MYHK^>S\B\WYA%%/5)_>\RJJ^_P"77041.EXA?^TWUXXSTO#A^;62_6!;]'.]
MR;]=*3 ,/R7,[9.\1HCKL9IWKF6V!Z%H1@R0CH*KJJ:(J]7&4YK?O^=7V89'
M=Y3=R>O_ (BWR"S=MK)_K_\ C>>,NWU!AE)*EK&H]X*#(=K[-#-?-_/IT<,C
MQ<U95%173M*V+#:--"%)!HB\I&A=+Q6_NV;Z?5?:=+PS?25!_)\GIXY.:Y.?
M(]AL(NI'("B7?,9;D./#WI*J\Q=W #WR(G5HFG5JO1\+$B0@(XWL)M; 'NQ4
M1[BKP^)61E5%5??=VR',OLEJNB>3H^(+Z$=U_F'/Z7AF^DJ#^3Y/_@!VI^DG
M!?G1%](\3/T;3?RC&Z7AZ_[L_4=DW2\07TW;K_/R?ZFW W-OB%*;;[#,ES*R
M$G$:[Z)CE.];.QFST5>=U&NZ;$152(D04551%R#+;^44Z^RB\MLBNYIZ\\RW
MNY[EG92CUUZW'G3->OV?4.!U<R9YW>[16]]M7;<[FKPPZ=\+K%$[HNL6FZ>?
M!B-EUBJL%HNJ$(]'Q'_FUC7U@5'2VN_-K<[ZO[#U)5_3=@OY N^EX@?HUQGY
MT%Z7X@OINW7^?D_I8G^;5%^2VNGX@OH1W7^8<_I>%SZ;MO\ \OL]'9?<,6":
MC9CM++Q=74%L69-C@F62K"4>HIS*Z+%[$ U)53D1M$TT77H[V[ 3I(C94.15
M^[&.QW7T-^74Y% CXIDXQ62ZQ9A2(%81Z>]YYNNB$2JO2EXRX\"3-R=S<&QF
M-'YC[UQFG??SF4^( 2>\;6J:$R)%%%,$T0B!4Z/AN9DMJTX>)74H15155CSL
MVM)T1S455-#:< T3RIKHNBZIT<AQ>%*2/=[S97CFW<1&R'SH*=M\LMR:0 *O
M^R.+6K ?+E71):(FA$)#Z@Q#/<>?6-D&$91C^74<D245CW&-6S-S6/H0]:*#
M[(%JGM<89N#CSJ/T.<XICV7TKR&AHY59)4LW%>?..B*JM/!KU>7I>*W]VS?3
MZK[3I>&;Z2H/Y/D]/;?]VS#_ *T,QZ7A<^A';_\ (#/1\07T([K_ ##G]+PS
M?25!_)\G_P  .U/TDX+\Z(OI'B9^C:;^48W2\/7_ '9^H[)NEX@OINW7^?D_
MU-9X;#EHS=;T9CCN#LM-F@RDH*QY<PR.6"+Y6E&O8@O_ ,$M$]E=/4.\6R,^
M6C<7/\.K<XH67C1 *_P2>L"QB0P\O>R8-H3[GMA#_P#J4UZ/B/\ S:QKZP*C
MI;7?FUN=]7]AZDJ_INP7\@7?2\0/T:XS\Z"]+\07TW;K_/R?TL3_ #:HOR6U
MT_$%]".Z_P PY_2\+GTW;?\ Y?9Z.,;G08Y/3=F]PZ^58NB',D?%,[:3%[(E
M5.M-;/X%37R::Z^PJ='!-Z<<:.>..3SBY+0(^K#63X=;-K!R6@<-=10W8Y$Y
M%<<$A9D@P_R$K2)QBVZ.VM]%R3#<PJV+2HL8Q#S@CB<LFOL8VJE'F174./,B
MNHCC+P&V:(0JG2J]IL*M&;+ MA6;6EE3X3Z/0KK<BV>;3+Y##K2\CC5>$:-6
M-JJ+RO-RU$B!P>EX>L&E1BB6&.[.;>0[B,;;31LWQXQ&E7PFVR(HB^>N/JNN
MI>R1$6I+T-KMEX$SO:_:W!9.27,=IS0&LJW$F@XL66T.G,;-775S[1$J\HRB
M0>7G/F]0XGC\N4K][LWD-_ME8HZ:+(*MC/!DN+/(VI*J,A76+$%HM$15C&*?
MS%Z7BM_=LWT^J^TZ7AF^DJ#^3Y/3VW_=LP_ZT,QZ7A<^A';_ /(#/1\07T([
MK_,.?TO#-])4'\GR?_ #M3])."_.B+Z1XF?HVF_E&-TO#U_W9^H[)NEX@OIN
MW7^?D_I?:9W*_P#/5_\ RW'VF=RO_/5__+<?:9W*_P#/5_\ RW'VF=RO_/5_
M_+<?:9W*_P#/5_\ RW'VF=RO_/5__+<?:9W*_P#/5_\ RW'VF=RO_/5__+<?
M:9W*_P#/5_\ RW'VF=RO_/5__+<6.%[M[R9AGF*M;2Y?=MT=[)B.P@MH-U4Q
MXDY!99!>=L'W1%>;R$O5TMNMG8,I7:[:7 BM[5@2418RW<64%A)8=;1="4*J
M%4N@2IJG?&B=6JKT-E-HI$9V75YGGU+%R-AE7A=+$*QU;S,C;..0F*A519AH
M8D*CIS:IIJGV<,:^4NX'QOQ]G#&OE+N!\;\?9PQKY2[@?&_'V<,:^4NX'QOQ
M]G#&OE+N!\;\?9PQKY2[@?&_&[R;5;&TV-[EQMO,JL<#N(-]FLF3'RRJJ';.
MB9%B=9/M$,B2RW'<YV3]XX2H*KHG2V*W.>E+#J*?/:JKR=_O!;!O#\K4L4RU
MYQ#]X2-5\V0\(FJ(I /O@5$(>CXC_P VL:^L"HZ5;N/M1E$K#LVJ(]C%KK^%
M%K9LB+'MH)UMBV$>V9D,*CK#IMJI-*J(NJ:+HO'VC\E^36W_ ,4<?:/R7Y-;
M?_%''VC\E^36W_Q1Q]H_)?DUM_\ %''VC\E^36W_ ,4<?:/R7Y-;?_%''VC\
ME^36W_Q1Q]H_)?DUM_\ %''VC\E^36W_ ,4<?:/R7Y-;?_%'%AGF\>8S<XRU
MG=;+:!NZGPJF ^-/7TU5)APD8IH\9GE;.0\2$K?,O,NJJB)IZ15_3=@OY N^
MEX@?HUQGYT%Z7X@OINW7^?D_I8G^;5%^2VNGX@OH1W7^8<_I>%SZ;MO_ ,OL
M]'<?:/(T%*C</#[S%WY!-HZ5<_9P39K[=@%ZE>A2>ZEL+[#C8K['&68!EL$J
MW*,*R.YQ7((!:KYK<4-@Y66#(F2)S"CK1<AHFA#H2=2ITI#V'NLY7MO?3696
M8[6WLE]NCMW1$6#MZ68TAG66B,BC0S60,#% &2Q(!ML0@QUW#@;39I(0&I.$
M[L2X.*2!EDB!W53DLISX)GBX:J,<69B2#33GCMD2#Q'G5\N-.A2FA>BS(;[4
MJ+)9--0=CR&%(#%?8(55%] [K=C<O"=O:\8[LEH\LR.KIY$UMK5"&K@2W!D2
MW%5.4&8K3CA%[T14NKB\VC\(A7576V\=^KR+>VPCR:*Y>@/*K4J)MS4O<LJ&
MC[7O%M9HLR00C1B.RXC<I%(E4B)5(B)54B)5U555?*J]'9C:)J.4B'E^=5#6
M0"+9/*SB-2:WV92N['37N:J+,<1%5$511%)$75$$401%$$1%$01%$T1$1/(B
M=!2)4$112(B5$$11-5557R(G&]^[#4GSRNRW<"[<QZ1S<_/B5.ZF/X<G-HFO
M+51(8^3V.CNI<;R8>QFNW&W6$5T9*67,MJZ*[FN87*? ,IR53R(SQHS!K;75
MI#Y>8VR+3E%"^SAC7REW ^-^/LX8U\I=P/C?C[.&-?*7<#XWX^SAC7REW ^-
M^/LX8U\I=P/C?C[.&-?*7<#XWXPO=K8+;*#@KU)N'&Q[.$J[7([ )E#E%4^E
M;/EA>S)0BD:?$CQP5I!+65UZIY.CNOLG82T;@[F83"RVD:><)1/)]O9I-O0X
M37D1R16V<N0Z2)[X(8ZK[T>EXK?W;-]/JOM.EX9OI*@_D^3T]M_W;,/^M#,>
MEX7/H1V__(#/1\07T([K_,.?TJ+.<&O9V,Y=C,X+*AOJTP"?5SP FPE13<$A
M0D$B3K%?+Q]IG<K_ ,]7_P#+<?:9W*_\]7_\MQ]IG<K_ ,]7_P#+<?:9W*_\
M]7_\MQ]IG<K_ ,]7_P#+<?:9W*_\]7_\MQ]IG<K_ ,]7_P#+<?:9W*_\]7_\
MMQ]IG<K_ ,]7_P#+<?:9W*_\]7_\MQX@9F\^Y&1[B2L8OMO8U ]D+\=XZIBT
MK[9VP:BJPVWHCI,-*>NO\U/\>VU/TDX+\Z(OI'B9^C:;^48W2\/7_=GZCLFZ
M7B"^F[=?Y^3_ %!:?0CG7Y?I.B;CABVVV)&XX9(   )S$9D74B(G6JKQO3NZ
MKROPLUS^^G4)%S<S>)PI/P1AT8U-$529JH\-DBY1U457E'7E3H;D;OS8R.P-
MIL ;J*QT@36/E>XTPX$20T9(O6-7 MV3051?Z8=5T71>GOOM<W&6'78YN)=O
MX_&(1%6L2R,QRK#D5!T35:J=#75$1%UU1$3JZ6Q>YS\GSNWN,#JZK)WU=[QQ
MW+\34L2RQ]S55(>^L(4A\!-5) ,=5+7F7H>(_P#-K&OK J/4-I]-V=?D"D])
MJ_INP7\@7?2\0/T:XS\Z"]+\07TW;K_/R?TL3_-JB_);73\07T([K_,.?TO"
MY]-VW_Y?9Z5/XL<+K"_JYN ["Q?=1N*V/<U.;P8(Q<=R%QII$Y&K6$QYN\>G
M*DF.A&2NRTUZ:GA><YAB!JZCZEB^375 2O"F@O*52^TO,B=2%Y>'(D[?C>:9
M%>1!>C2MT,WD1W4$D,4<9>G*)(BHBIJGE37AZ;82Y,Z9(+GD2YC[LF2^>B#S
MO/OJ1DNB(FI*O3S[Q79/6*$<69.V>UKDII4[]TS"7GN1PT<1/>MH,6KCR&]4
M)2GLJJ*!)T=^<_9E+$MPP>=BV-/-DJ2&\GSIP,-HI,5 5"4XS\X9:Z>06B)?
M>BO2C9U,C*U<[U9MD68$Z\TC4D<=HG_ZEX_$+5$56E.!,G,*7E&4I)[TAZ>_
M.VC$5)EK<;>W%GC<;NT<)[+<3$<MQ1@%7K%7;&#&:4TU44)5T+^:O1V-W4<E
MK"K<:S^F9R.0AJV@8AD!EC.8\R]?5\%S)?4J::_?Z7BM_=LWT^J^TZ7AF^DJ
M#^3Y/3VW_=LP_P"M#,>EX7GHSB.MALSA44B1"1$D0*H(,MO0D1=0=;,%7R+I
MJFJ:+T?$%]".Z_S#G^H?$]^<NUOY+O/\>VU/TDX+\Z(OI'B9^C:;^48W2\/7
M_=GZCLFZ7B"^F[=?Y^3_ %!:?0CG7Y?I.COSFL:4D2ZEX7*PG&G!(4DAD.X#
MP8;7RX0DJ<SL/STYZ)UH@L$2B0BHKT8>;2XJLW.]&;9'F9O.HB2/ZOT[PX9C
M\11331K6OE36=4U5)2EJHJ*)T]K]X(<96X&Z6 2*"R>$147LGVZL!9?>=(>L
M2.MLJQH$+RHR7*J\I(/1WAV/L)G/,P',*[.J".\YJY_5_.8"U]E%AM__ &&-
M/K%?<]IR;_\ 5)IT/$?^;6-?6!4>H;3Z;LZ_(%)Z35_3=@OY N^EX@?HUQGY
MT%Z7X@OINW7^?D_I8G^;5%^2VNGX@OH1W7^8<_I>%SZ;MO\ \OL]+,-K-PJD
M+O#<XI)5%>UY%W;A1Y&ALRX4A$56949X6Y,20'OF7FVW0T($7B\VNS%MV?4&
M3MM@.9-QR9KLVPY]\@KK>.G6C<EO3S>QB<RJQ($Q0G&E:>=].Q?9_!&2:<LW
M?A'*,A<8-ZOPW#8#S8WN46?+HG*R+@-1VB,>_DN,1Q)"=%>,,VKP&M&IQ#!:
M&%C])#1>=U8\0-7IDQ[J5V3)>)R3*?+WSKSAN%J1*O1V1V)@2='LKR6XW+R-
MEHR!QNMQ*#_5_'&)*)HALRI-E-=0>M.\AB2HBH*]&KHJF,<RUNK&#4UD-KK<
MEV%C)&'"C-HO^DXX8BG\*\;9[55:LG!V[P3%L-:?8;[L)AX_2LULBQ(51%4Y
M+K9ON$7OB,R(NM5](WUVL:B^95V,[AW;F/Q>Z[A&<3R!P<GP]!:\B(M7-AJG
M+U*BZCU*G2V'W#?F>?7$C!8&-Y.^;G/)=RK"'#PW(94L%T(#DRH+DM!).L'0
M(=0(27H>*W]VS?3ZK[3I>&;Z2H/Y/D]/P_YLK6C&0[9Y)BK;W<\O>.X=E*6[
MS7?\J<W(EZVO)SKR\VN@\^I='&\4.0CMUL[EN68'8@9?\24"=9EFM!)(-?\
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MMIKN8[8*Y+L[:8<^?*<5<.55)QUPS7^%>/UD>)/Y8;7_ *'<?K(\2?RPVO\
MT.X_61XD_EAM?^AW'ZR/$G\L-K_T.XRS-=KKS<O(\@R_'H^+S)6X5UBUJE;3
MM606TB/4#C=+4J"R'V8Y/J\KNO<M\J!H7-Z3G>YUOF.^M#<;@Y9>YE<5.+Y1
MM_#QZ%;Y'8N6UH%1$M,7F/M,$^ZX8-.27.77E1>5$1/UD>)/Y8;7_H=Q^LCQ
M)_+#:_\ 0[C]9'B3^6&U_P"AW'ZR/$G\L-K_ -#N/UD>)/Y8;7_H=QA&S6+7
MF4Y'CF ULBGI;;-9M78Y([6N63]A%BSYE-#KXQC%%Y(L9&HC?*PVV)<Q(1EZ
M.;;*YO89!5XMGD&#7V\_%95=!R",S7W$:[9*ME6\2=& E=BMB2NQ7$4%)$1%
M5"3]9'B3^6&U_P"AW'ZR/$G\L-K_ -#N/UD>)/Y8;7_H=Q^LCQ)_+#:_]#N/
MUD>)/Y8;7_H=Q^LCQ)_+#:_]#N/UD>)/Y8;7_H=Q^LCQ)_+#:_\ 0[C]9'B3
M^6&U_P"AW'ZR/$G\L-K_ -#N/UD>)/Y8;7_H=Q^LCQ)_+#:_]#N/UD>)/Y8;
M7_H=Q^LCQ)_+#:_]#N/UD>)/Y8;7_H=Q^LCQ)_+#:_\ 0[B1M-MG<YG>8Y)R
MFVRXYN=6%)9W:65Q#BPI+ 2:"NK&.X$(C:MBL9215+4R140?2(^TVYESF='C
MD;*:G+@FX+84E9=K94\.5"C,')OZZS8[@@EN*X*1D)50=#%$5"_61XD_EAM?
M^AW'ZR/$G\L-K_T.X_61XD_EAM?^AW'ZR/$G\L-K_P!#N/UD>)/Y8;7_ *'<
M9CE&U>4;IW]AFU'!H+5G<"[Q*UAQX=?/6Q9<KV\<HZHP=4UT(G''!4>I!1>O
MTO,<\N=P?$-&N,VRG(<NM8U9E>V[-;'LLDMGKF<Q7LRL3>=!@'7B%H7'G"04
M1",EU)?UD>)/Y8;7_H=Q^LCQ)_+#:_\ 0[C]9'B3^6&U_P"AW'ZR/$G\L-K_
M -#N/UD>)/Y8;7_H=Q7U<<G3CUL&)7L&\0$\;,..,=HG2 1%241125!1-?(B
M>3IYC@=R_.C4^;8MD.(VLFL<89LH];DE2]33GZ]Z4T\T#X-/$31.,N"A(BD!
M)J*_K(\2?RPVO_0[C]9'B3^6&U_Z'<?K(\2?RPVO_0[C]9'B3^6&U_Z'<?K(
M\2?RPVO_ $.XP+=G%\]W\GY'MWE-/EU)"O\ *-O)5)*LJ28,V(Q:1J[%HKYL
M$8HC@LR6B5/(8KU^E3;'<7;:'59G,YS+<? S9Q+.5D'U+*GV,1HXUD:)J@_"
M\26(_P"B**B*DVQV$W?Q?-:Q%[V+C>XL.7B&1MM::+$9O*@)T"8[KH2..M00
M5%5%1%%%-T,F\-^Y4UAKO"*PPFH#<BM%EO55DNSMOW+-MH%1.;5]05$_G(B]
M7'F&1T=Q03M.;S*[K)M5+Y=$77S:<#9Z:*GL>RGHM1HK#TF2^8M,1X[1O/O.
MFN@-M--HI$2KU(B)JO$=<$\/.[=W$EKRL7#F%75/CIESH"HN37K4:O%45>M"
MDIHFJKU(J\1)F\&68+LM3N<JS(+<L=Q<R8]E6PK,<=;J2\FBFEXNBKJ@EQ"O
M)V)O[RYQ%Y' R?=5(=W7PI"#[\Z;"V6VZEE$)$-ER3&DR6E1%"2G7J#;8"VV
MV(@VV H   )RB "/4B(G4B)T\RV6RZ^RS&\9SF-70KNSPF;45V1I!@7$>Y*'
M#F7D&QC@$@HPL2.:(2DR9B*BI(2?K(\2?RPVO_0[C]9'B3^6&U_Z'<?K(\2?
MRPVO_0[C]9'B3^6&U_Z'<?K(\2?RPVO_ $.XK-G-LI&0S\=KK:[NW;;+9=5/
MR2VL[V<LN3*M9E+"KXQDV'=16>[B!HRTV)<Q(IEZ1GFU67C+7&-P\3O</NSK
MG([%G&@7U<Y7O3:M^6T^TW*8YT>BN.,N"#H 2@2)RK^LCQ)_+#:_]#N/UD>)
M/Y8;7_H=Q^LCQ)_+#:_]#N/UD>)/Y8;7_H=Q^LCQ)_+#:_\ 0[C'<NH-T/$K
M#O<6O:C(Z66.8;8\T6VH[!NSKI*<F'BNH/- 742+U=2IT=P=KLADV4.@W)PC
M*\!O)E*]%CW$2GS"AD8]9R:F1.9D,-R6V))DP;T=T!-!4VS%%%?UD>)/Y8;7
M_H=Q^LCQ)_+#:_\ 0[C]9'B3^6&U_P"AW'ZR/$G\L-K_ -#N/UD>)/Y8;7_H
M=Q@V\.(9UOQ99-M_>-7]-!R3)]OIE%)F,LFP+=G&J\7AR#:T<746I39:Z>^]
M(L,"W6PNASO$;/E*52W\,93(/MZ]Q-@OBHO19+6JJS*C.-O-KU@8KP_/VUW0
MW,VU:D.DY\"V+=/GE+"%3148K?/1@SQ!!U1/.K"0>O6IJB<O'VGLE_9;5_'G
M'VGLE_9;5_'G'VGLE_9;5_'G'VGLE_9;5_'G&,['UV6RLWBXW8Y+8!D4VH9H
MY$LLCOG[TVCK6)$D01I7U;14>7F1-=$UT3T<QP.Y?G1J?-L6R'$;636.,,V4
M>MR2I>IIS]>]*:>:!\&GB)HG&7!0D12 DU%?UD>)/Y8;7_H=Q^LCQ)_+#:_]
M#N/UD>)/Y8;7_H=Q^LCQ)_+#:_\ 0[C]9'B3^6&U_P"AW'ZR/$G\L-K_ -#N
M/UD>)/Y8;7_H=Q^LCQ)_+#:_]#N/UD>)/Y8;7_H=Q^LCQ)_+#:_]#N/UD>)/
MY8;7_H=Q^LCQ)_+#:_\ 0[C]9'B3^6&U_P"AW'ZR/$G\L-K_ -#N/UD>)/Y8
M;7_H=Q^LCQ)_+#:_]#N,[J]J<BW%R"/N%.H+"Z/<&VQJU>BO8['E1X0U98Y4
M5(@)#,<5U'1<550>51T5"_\ $$L6R@P["*I":QIT9F6PI@NH&K+XD.J>PNG5
MPW\+[*[2VO=$9M?"6W&'3N[-W3O#;\ZAEHI:)S*GETZ^&Y<'8?9F'*9529DQ
M=K\(CR&E(5 E;>9@H0JJ*J+HOD73CS?&L<H<>8Y2#N:.GKZEGD)U7R#NX#;:
1:*9$:II_.55\J_\ [5E__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Apr. 18, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CROSS COUNTRY HEALTHCARE, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-33169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-4066229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6551 Park of Commerce Boulevard, N.W.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">998-2232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CCRN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,783,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001141103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 80,697<span></span>
</td>
<td class="nump">$ 81,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $9,792 in 2025 and $9,301 in 2024</a></td>
<td class="nump">219,789<span></span>
</td>
<td class="nump">223,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="nump">5,893<span></span>
</td>
<td class="nump">10,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">8,295<span></span>
</td>
<td class="nump">7,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableCurrent', window );">Insurance recovery receivable</a></td>
<td class="nump">9,343<span></span>
</td>
<td class="nump">9,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">325,199<span></span>
</td>
<td class="nump">335,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $21,837 in 2025 and $19,285 in 2024</a></td>
<td class="nump">28,117<span></span>
</td>
<td class="nump">28,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,219<span></span>
</td>
<td class="nump">2,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">135,060<span></span>
</td>
<td class="nump">135,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, net</a></td>
<td class="nump">39,965<span></span>
</td>
<td class="nump">42,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">8,804<span></span>
</td>
<td class="nump">8,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableNoncurrent', window );">Insurance recovery receivable</a></td>
<td class="nump">20,193<span></span>
</td>
<td class="nump">20,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_CloudComputingNoncurrent', window );">Cloud computing</a></td>
<td class="nump">11,358<span></span>
</td>
<td class="nump">10,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">5,320<span></span>
</td>
<td class="nump">5,809<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">576,235<span></span>
</td>
<td class="nump">589,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">56,325<span></span>
</td>
<td class="nump">64,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">50,056<span></span>
</td>
<td class="nump">47,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="nump">2,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Earnout liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">980<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">109,048<span></span>
</td>
<td class="nump">120,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,623<span></span>
</td>
<td class="nump">1,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Accrued claims</a></td>
<td class="nump">33,982<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Uncertain tax positions</a></td>
<td class="nump">10,168<span></span>
</td>
<td class="nump">10,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">3,204<span></span>
</td>
<td class="nump">3,566<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">158,025<span></span>
</td>
<td class="nump">170,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">202,074<span></span>
</td>
<td class="nump">202,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,436)<span></span>
</td>
<td class="num">(1,441)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">217,569<span></span>
</td>
<td class="nump">218,059<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">418,210<span></span>
</td>
<td class="nump">418,959<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 576,235<span></span>
</td>
<td class="nump">$ 589,251<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_CloudComputingNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cloud Computing, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_CloudComputingNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) of amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-9E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for credit losses</a></td>
<td class="nump">$ 9,792<span></span>
</td>
<td class="nump">$ 9,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 21,837<span></span>
</td>
<td class="nump">$ 19,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible List]</a></td>
<td class="text">Service [Member]<span></span>
</td>
<td class="text">Service [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">$ 293,408<span></span>
</td>
<td class="nump">$ 379,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct operating expenses</a></td>
<td class="nump">234,750<span></span>
</td>
<td class="nump">301,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">52,486<span></span>
</td>
<td class="nump">63,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit loss expense</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,772<span></span>
</td>
<td class="nump">4,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_AcquisitionAndIntegrationRelatedCosts', window );">Acquisition and integration-related costs</a></td>
<td class="nump">2,041<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_LegalAndOtherLosses', window );">Legal and other losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">294,385<span></span>
</td>
<td class="nump">376,253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(977)<span></span>
</td>
<td class="nump">2,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expenses (income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(681)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income), net</a></td>
<td class="nump">60<span></span>
</td>
<td class="num">(1,057)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income taxes</a></td>
<td class="num">(899)<span></span>
</td>
<td class="nump">3,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(409)<span></span>
</td>
<td class="nump">997<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to common stockholders</a></td>
<td class="num">(490)<span></span>
</td>
<td class="nump">2,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized foreign currency translation gain (loss), net of tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (485)<span></span>
</td>
<td class="nump">$ 2,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share attributable to common stockholders - Basic (in dollars per share)</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share attributable to common stockholders - Diluted (in dollars per share)</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">32,282<span></span>
</td>
<td class="nump">34,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">32,282<span></span>
</td>
<td class="nump">34,597<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_AcquisitionAndIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition and integration-related costs include costs for prior acquisitions, costs incurred for potential transactions, and accretion and valuation adjustments on contingent consideration liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_AcquisitionAndIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LegalAndOtherLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal And Other Losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LegalAndOtherLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate direct operating costs incurred during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectOperatingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss, net</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 467,651<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 236,417<span></span>
</td>
<td class="num">$ (1,385)<span></span>
</td>
<td class="nump">$ 232,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Vesting of restricted stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Vesting of restricted stock</a></td>
<td class="num">(2,706)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,706)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity compensation</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock repurchase and retirement (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock repurchase and retirement</a></td>
<td class="num">(6,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_StockRepurchasedDuringPeriodExciseTax', window );">Stock repurchase excise tax</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment, net of taxes</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">2,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,692<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">462,448<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">228,525<span></span>
</td>
<td class="num">(1,388)<span></span>
</td>
<td class="nump">235,307<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">418,959<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">202,338<span></span>
</td>
<td class="num">(1,441)<span></span>
</td>
<td class="nump">218,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Vesting of restricted stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Vesting of restricted stock</a></td>
<td class="num">(1,582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity compensation</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment, net of taxes</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(490)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2025</a></td>
<td class="nump">32,476,983<span></span>
</td>
<td class="nump">32,477,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 418,210<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 202,074<span></span>
</td>
<td class="num">$ (1,436)<span></span>
</td>
<td class="nump">$ 217,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_StockRepurchasedDuringPeriodExciseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchased During Period, Excise Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_StockRepurchasedDuringPeriodExciseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net (loss) income</a></td>
<td class="num">$ (490)<span></span>
</td>
<td class="nump">$ 2,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,772<span></span>
</td>
<td class="nump">4,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances', window );">Provision for allowances</a></td>
<td class="num">(135)<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="num">(680)<span></span>
</td>
<td class="num">(809)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_OperatingLeaseExpenseNonCash', window );">Non-cash lease expense</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity compensation</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash costs</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">3,584<span></span>
</td>
<td class="nump">13,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">57<span></span>
</td>
<td class="num">(1,227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes</a></td>
<td class="nump">4,549<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(9,173)<span></span>
</td>
<td class="num">(15,492)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(562)<span></span>
</td>
<td class="num">(785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other</a></td>
<td class="nump">1,989<span></span>
</td>
<td class="num">(1,443)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">5,681<span></span>
</td>
<td class="nump">6,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,886)<span></span>
</td>
<td class="num">(2,210)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,886)<span></span>
</td>
<td class="num">(2,210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowings under Senior Secured Asset-Based revolving credit facility</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">14,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments on Senior Secured Asset-Based revolving credit facility</a></td>
<td class="num">(373)<span></span>
</td>
<td class="num">(14,166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Cash paid for shares withheld for taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,706)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Stock repurchase and retirement</a></td>
<td class="num">(314)<span></span>
</td>
<td class="num">(6,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="num">(4,411)<span></span>
</td>
<td class="num">(6,579)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(4,725)<span></span>
</td>
<td class="num">(15,653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents</a></td>
<td class="num">(936)<span></span>
</td>
<td class="num">(11,852)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">81,633<span></span>
</td>
<td class="nump">17,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 80,697<span></span>
</td>
<td class="nump">$ 5,242<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_OperatingLeaseExpenseNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Expense, Non-Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_OperatingLeaseExpenseNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision For Doubtful Accounts And Other Allowances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. All such adjustments consisted of all normal recurring items, including the elimination of all intercompany transactions and balances.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form&#160;10-Q and Article 10 of Regulation&#160;S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2024 included in the 2024 Form 10-K. The December&#160;31, 2024 condensed consolidated balance sheet included herein was derived from the December&#160;31, 2024 audited consolidated balance sheet included in the 2024 Form&#160;10-K.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the current year presentation. See the condensed consolidated statements of operations and comprehensive (loss) income.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aya Healthcare</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2024, the Company entered into an Agreement and Plan of Merger (Merger Agreement) with Aya Holdings II Inc., a Delaware corporation (Parent), Spark Merger Sub One Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), and, solely for purposes of Section 11.14 thereto, Aya Healthcare, Inc. (Aya Healthcare), pursuant to which Merger Sub will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (Aya Merger). On February 20, 2025, the Company and Aya Healthcare each received a request for additional information (Second Request) from the U.S. Federal Trade Commission (FTC) in connection with the FTC&#8217;s review of the transactions contemplated by the Merger Agreement. Issuance of the Second Request extends the waiting period under the Hart-Scott- Rodino Antitrust Improvements Act of 1976 until 30 days after both the Company and Aya Healthcare substantially comply with the Second Request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. The Company expects that the Aya Merger will close in the second half of 2025, subject to the satisfaction or waiver of the other customary closing conditions specified in the Merger Agreement. The Aya Merger was approved by the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s stockholders at a special meeting held on February 28, 2025. Upon completion of the transaction, it is expected that the Company will become a private company and its common stock will no longer trade on Nasdaq. During the first quarter of 2025, the Company incurred $2.0&#160;million in fees associated with the pending Aya Merger, which is included in acquisition and integration-related costs in the condensed consolidated statement of operations and comprehensive (loss) income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, using information that is reasonably available to the Company at the time. Significant estimates and assumptions are used for, but not limited to: (i) the valuation of accounts receivable; (ii) goodwill, trade names, and other intangible assets; (iii) other long-lived assets; (iv) revenue recognition; (v) accruals for health, workers&#8217; compensation, and professional liability claims; (vi) valuation of deferred tax assets; (vii) legal contingencies; and (viii) income taxes. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. As additional information becomes available to the Company, its future assessment of these estimates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">could materially and adversely impact the Company&#8217;s consolidated financial statements in future reporting periods. Actual results could differ from those estimates.  </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments from customers and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers. See associated risk factors in Item 1A. Risk Factors in the 2024 Form 10-K.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Accounts Receivable, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers, which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for credit losses and sales allowances. Estimated revenue for the Company employees&#8217;, subcontracted employees&#8217;, and independent contractors&#8217; time worked but not yet billed at March 31, 2025 and December 31, 2024 totaled $61.9&#160;million and $60.4&#160;million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for credit losses is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for credit losses when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of its accounts receivable based on a combination of factors. The Company bases its allowance for credit loss estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered expectations of future economic condition</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when estimating its allowance for credit losses.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening balance of the allowance for credit losses is reconciled to the closing balance for expected credit losses as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Loss Expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-Offs, net of Recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,349&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the allowance for credit losses, the Company maintains a sales allowance for billing-related adjustments that may arise in the ordinary course of business and adjustments to the reserve are recorded as contra-revenue. The sales allowance balance as of March 31, 2025 and December 31, 2024 was $0.4&#160;million and $0.5&#160;million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s contract terms typically require payment between 30 to 60 days from the date of invoice and are considered past due based on the particular negotiated contract terms. The majority of the Company&#8217;s customers are healthcare systems with a significant percentage in acute-care facilities. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No single customer accounted for more than 10% of the Company&#8217;s revenue for the three months ended March 31, 2025 and 2024, or the Company&#8217;s accounts receivable balance as of March 31, 2025 and December 31, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions, and are primarily included in the accounts payable and accrued expenses on the condensed consolidated balance sheets. Restructuring costs on the condensed consolidated statements of operations and comprehensive (loss) income primarily include employee termination costs and lease-related exit costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliations of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Termination Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease-Related Exit Costs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to restructuring</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2025</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 27, 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses, enhances interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and requires certain disclosures related to the chief operating decision maker. The Company adopted this standard for its fiscal year ended December 31, 2024, and its interim periods beginning in the first quarter of 2025, and applied the guidance retrospectively to all prior periods presented in the financial statements. This standard only expanded the Company&#8217;s disclosures with no impact to results of operations, cash flows, and financial condition. See Note 12 - Segment Data.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve decision usefulness of business entities&#8217; income statements through the disaggregation of certain expense captions, such as employee compensation, depreciation, and intangible asset amortization, with required disclosure in a single note to the financial statements. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments in this update should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this update, or (2) retrospectively to any or all prior periods presented in the financial statements. The Company expects to adopt this standard for its annual report for the fiscal year ending December 31, 2027. The Company expects this ASU to only impact its disclosures with no impacts to results of operations, cash flows, and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that public business entities, on an annual basis, (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The amendments also require that all entities disclose, on an annual basis, disaggregated information regarding income taxes paid and income tax expense. This guidance is effective for annual periods beginning after December 15, 2024. The amendments should be applied prospectively, but retrospective application is permitted. The Company plans to adopt this standard for its annual report for the fiscal year ended December 31, 2025. The Company expects this ASU to only impact its disclosures with no impacts to results of operations, cash flows, and financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text">REVENUE RECOGNITION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s revenues from customer contracts are generated from temporary staffing services and other services. Revenue is disaggregated by segment in the following table. Sales and usage-based taxes are excluded from revenue.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse<br/>And Allied<br/>Staffing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician<br/>Staffing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary Staffing Services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,417&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,551&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse<br/>And Allied<br/>Staffing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician<br/>Staffing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary Staffing Services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div>See Note 12 - Segment Data.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text">ACQUISITIONS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HireUp</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 13, 2022, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of HireUp Leadership Inc. (HireUp) for a purchase price of $6.0&#160;million in cash, subject to adjustment, and $0.8&#160;million in shares (or 29,811 shares) of the Company&#8217;s common stock. The transaction was treated as a purchase of assets for income tax purposes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The sellers were eligible to receive up to an additional $8.0&#160;million in earnout cash consideration based on HireUp&#8217;s revenues and Adjusted EBITDA for each of the twelve-month periods ending on the first and second anniversaries of the first day after the closing date. Quarterly throughout 2023, and during the first quarter of 2024, the Company performed analyses using multiple updated forecasted scenarios and determined that the earnout would only be partially achieved. As a result, the Company recognized a decrease in the fair value of the related liabilities in the second and third quarters of 2023 and the first quarter of 2024. The Company paid the remaining earnout liability of $1.7&#160;million in the first quarter of 2024. See Note 10 - Fair Value Measurements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mint</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 3, 2022, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of Mint Medical Physician Staffing, LP and Lotus Medical Staffing LLC (collectively, Mint) for a purchase price of $27.0&#160;million in cash, subject to adjustment, and $3.6&#160;million in shares (or 114,278 shares) of the Company&#8217;s common stock. The transaction was treated as a purchase of assets for income tax purposes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The sellers were eligible to receive up to an additional $10.0&#160;million in earnout cash consideration based on Mint&#8217;s revenues and gross profit for each of the twelve-month periods ending on the first and second anniversaries of the first day of the calendar month following the closing date. In the fourth quarter of 2023, the Company performed a calculation for the first measurement period, resulting in the achievement of a $4.9&#160;million earnout, which was paid in the first quarter of 2024. During </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the fourth quarter of 2024, the Company performed a calculation for the second measurement period, resulting in the achievement of a $4.4&#160;million earnout, which was paid in the first quarter of 2025. See Note 10 - Fair Value Measurements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other than the fees associated with the pending Aya Merger as discussed on Note 1 - Organization and Basis of Presentation, the Company did not record any acquisition-related costs associated with the Company&#8217;s acquisitions for the three months ended March 31, 2025, and recorded an immaterial credit for the three months ended March 31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMPREHENSIVE (LOSS) INCOME<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">COMPREHENSIVE (LOSS) INCOME</a></td>
<td class="text">COMPREHENSIVE (LOSS) INCOME<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total comprehensive (loss) income includes net income or loss and foreign currency translation adjustments, net of any related deferred taxes, and is included within the accompanying condensed consolidated statements of operations and comprehensive (loss) income. Certain of the Company&#8217;s foreign subsidiaries use their respective local currency as their functional currency. Assets and liabilities of these operations are translated at the exchange rates in effect on the balance sheet date. Income statement items are translated at the average exchange rates for the period. The cumulative impact of currency fluctuations related to the balance sheet translation is included in accumulated other comprehensive loss in the accompanying condensed consolidated balance sheets and was an unrealized loss of $1.5&#160;million as of March 31, 2025 and December&#160;31, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax impact related to components of other comprehensive income (loss) for the three months ended March 31, 2025 and 2024 is included in unrealized foreign currency translation gain (loss), net of tax in the condensed consolidated statements of operations and comprehensive (loss) income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/220/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER SHARE</a></td>
<td class="text">EARNINGS PER SHARE<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(amounts in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common stockholders - Basic and Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(490)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,692&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares - Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of diluted shares:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Share-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares - Diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">a</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,282&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,597&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share attributable to common stockholders - Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share attributable to common stockholders - Diluted</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)  For the three months ended March 31, 2025, the effect of diluted shares was not included in the weighted average share calculation due to the Company&#8217;s net operating loss position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the share-based awards that could potentially dilute net (loss) income per share attributable to common stockholders in the future that were not included in the computation of diluted net (loss) income per share attributable to common stockholders because to do so would have been anti-dilutive for the periods presented.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based awards</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS</a></td>
<td class="text">GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following acquired intangible assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Databases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,068&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,003&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,065&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,068&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,782&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets not subject to amortization:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names, indefinite-lived</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, estimated future annual amortization expense was as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:80.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,065&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Goodwill, Trade Names, and Other Intangible Assets Impairment </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests reporting units&#8217; goodwill and intangible assets with indefinite lives for impairment annually during the fourth quarter and more frequently if impairment indicators exist. The Company performs quarterly qualitative assessments of significant events and circumstances, such as reporting units&#8217; historical and current results, assumptions regarding future performance, strategic initiatives and overall economic factors,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and macro-economic developments, to determine the existence of potential indicators of impairment and assess if it is more likely than not that the fair value of reporting units or intangible assets is less than their carrying value. If indicators of impairments are identified a quantitative impairment test is performed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company performed a qualitative assessment of each of its reporting units and determined that it was not more likely than not that the fair value of its reporting units dropped below their carrying value. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lthough management believes that the Company&#8217;s current estimates and assumptions utilized in its qualitative testing are reasonable and supportable, there can be no assurance that the estimates and assumptions management used for purposes of its assessment as of March 31, 2025 will prove to be accurate predictions of future performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, goodwill by reporting segment was: $112.2&#160;million for Nurse and Allied Staffing and $22.9&#160;million for Physician Staffing, for a total of $135.1&#160;million.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-lived assets and definite-lived intangible assets, the Company reviews for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of March 31, 2025 and 2024, the Company performed a qualitative assessment of its trade names and other intangible assets and determined it was not more likely than not that their carrying value may not be recoverable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s debt consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Secured Asset-Based Loan, interest of 6.21% and 6.31% at March 31, 2025 and December 31, 2024, respectively</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,807)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025 and December 31, 2024, there was no debt outstanding on the condensed consolidated balance sheets. The Company has elected to present the debt issuance costs associated with its senior secured asset-based credit facility as an asset, included in other assets on the condensed consolidated balance sheets.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Asset-Based Loan Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October 25, 2019, the Company terminated its prior senior credit facility and entered into an asset-based loan agreement, by and among the Company and certain of its domestic subsidiaries, as borrowers or guarantors, Wells Fargo Bank, N.A., and PNC Bank N.A., as well as other Lenders (as defined therein) from time to time parties thereto (Loan Agreement). The Loan Agreement provided for a five-year revolving senior secured asset-based credit facility (ABL) in the aggregate principal amount of up to $120.0&#160;million, including a sublimit for swing loans up to $15.0&#160;million and a $35.0&#160;million sublimit for standby letters of credit.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2020, the Company amended the Loan Agreement (First Amendment), which increased the current aggregate committed size of the ABL from $120.0&#160;million to $130.0&#160;million. All other terms, conditions, covenants, and pricing of the Loan Agreement remained the same. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2021, the Company amended the Loan Agreement (Second Amendment), which increased the current aggregate committed size of the ABL from $130.0&#160;million to $150.0&#160;million, increased certain borrowing base sub-limits, and decreased both the cash dominion event and financial reporting triggers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company amended the Loan Agreement (Third Amendment), which permitted the incurrence of indebtedness and grant of security as set forth in the Loan Agreement and in accordance with the Intercreditor Agreement (as defined in the Loan Agreement), and provides mechanics relating to a transition away from the London Interbank Offered Rate (LIBOR) as a benchmark interest rate to a replacement alternative benchmark rate or mechanism for loans made in U.S. dollars.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2021, the Company amended the Loan Agreement (Fourth Amendment), whereby the permitted indebtedness (as defined in the Loan Agreement), was increased to $175.0 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2022, the Company amended the Loan Agreement (Fifth Amendment), which increased the current aggregate committed size of the ABL from $150.0 million to $300.0 million, extended the term of the credit facility for an additional five years, through March 21, 2027, and increased certain borrowing base sub-limits. In addition, the agreement provides the option for all or a portion of the borrowings to bear interest at a rate based on the Secured Overnight Financing Rate (SOFR) or the Base Rate (as defined in the Loan Agreement), at the election of the borrowers, plus an applicable margin. The applicable margin increased 10 basis points due to the credit spread associated with the transition to SOFR.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 29, 2023, the Company amended the Loan Agreement (Sixth Amendment), which changed the minimum fixed charge coverage ratio from a maintenance covenant to a springing covenant based on excess availability, which provides for compliance with the covenant only during a compliance period (any time that excess availability falls below a certain threshold), and in such case, the financial covenant shall be tested during this period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2024, the Company amended the Loan Agreement (Seventh Amendment), which allows for all share repurchases paid in cash prior to June 30, 2024 and thereafter to be excluded as restricted payments in the fixed charge coverage ratio calculation, if as of the date of the share repurchase, there is no revolving ABL balance (except for interest and fees payable in accordance with the terms of the Loan Agreement).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amendments were treated as modifications of debt and, as a result, the associated fees and costs were included in debt issuance costs and are amortized ratably over the remaining term of the Loan Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ABL availability is subject to a borrowing base of up to 85% of secured eligible accounts receivable, subject to adjustment at certain quality levels, minus customary reserves and subject to customary adjustments. Revolving loans and letters of credit </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued under the Loan Agreement reduce availability under the ABL on a dollar-for-dollar basis. At March 31, 2025, there were no borrowings drawn under the ABL, and borrowing base availability under the ABL was $148.4&#160;million, with $133.5&#160;million of availability net of $14.9&#160;million of letters of credit outstanding related to workers&#8217; compensation and professional liability policies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the interest rate spreads and fees under the ABL were based on SOFR plus 1.85% for the revolving portion of the borrowing base. The Base Rate margin would have been 0.75% for the revolving portion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The SOFR and Base Rate margins are subject to monthly adjustments, pursuant to a pricing matrix based on the Company&#8217;s excess availability under the revolving credit facility. In addition, the facility is subject to an unused line fee, letter of credit fees, and an administrative fee. The unused line fee is 0.375% of the average daily unused portion of the revolving credit facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains various restrictions applicable to the Company and its subsidiaries. For the three months ended March 31, 2025, the excess availability did not fall below the stated threshold and, as a result, there was no covenant compliance period. Obligations under the ABL are secured by substantially all of the assets of the borrowers and guarantors, subject to customary exceptions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease population of its right-of-use assets and lease liabilities is substantially related to the rental of office space. The Company enters into lease agreements as a lessee that may include options to extend or terminate early. Some of these real estate leases require variable payments of property taxes, insurance, and common area maintenance, in addition to base rent. Certain of the leases have provisions for free rent during the lease term and/or escalating rent payments and, particularly for the Company&#8217;s longer-term leases for its corporate offices, it has received incentives to enter into the leases, such as receiving up to a specified dollar amount to construct tenant improvements. These leases do not include residual value guarantees, covenants, or other restrictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification on Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the undiscounted cash flows for each of, and total of, the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of March 31, 2025:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:75.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: operating lease liabilities - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding supplemental cash flows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets acquired under operating lease</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Included in Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable and other lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense, short-term lease expense, and variable and other lease costs are included in selling, general and administrative expenses, direct operating expenses, and restructuring costs in the condensed consolidated statements of operations and comprehensive (loss) income, depending on the nature of the leased asset. Operating lease expense is reported net of sublease income, which is not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company did not have any material operating leases that had not yet commenced, and does not have any finance lease contracts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy was established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Measured at Fair Value on a Recurring Basis:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial assets/liabilities required to be measured on a recurring basis were primarily its: (i) deferred compensation asset included in other assets; and (ii) deferred compensation liability included in other liabilities on its condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company utilizes Level 1 inputs to value its deferred compensation assets and liabilities. The Company&#8217;s deferred compensation assets and liabilities are measured using publicly available indices, as per the plan documents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s financial assets and liabilities measured on a recurring basis is as follows:&#160;</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,889&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Measured at Fair Value on a Non-Recurring Basis:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s non-financial assets, such as goodwill, trade names, other intangible assets, right-of-use assets, and property and equipment, are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record any material impairment charges during the three months ended March 31, 2025 and 2024.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments not measured or recorded at fair value in the condensed consolidated balance sheets consist of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses. The estimated fair value of accounts receivable and accounts payable and&#160;accrued expenses approximate their carrying amount due to the short-term nature of these instruments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial instruments not measured or recorded at fair value include earnout liabilities related to the (i) Mint and (ii) HireUp acquisitions, as discussed below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i) Potential earnout payments related to the Mint acquisition were contingent upon meeting certain performance requirements based on 2022 through 2024 performance. On a quarterly basis, the Company performed an analysis using multiple forecasted scenarios to determine the fair value of the earnout liability. In the fourth quarter of 2023, the Company performed the earnout calculation for the first measurement period, resulting in an earnout of $4.9&#160;million, which was paid in the first quarter of 2024. During the fourth quarter of 2024, the Company performed a calculation for the second measurement period, resulting in the achievement of a $4.4&#160;million earnout, which was paid in the first quarter of 2025. See Note 4 - Acquisitions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii) Potential earnout payments related to the HireUp acquisition were contingent upon meeting certain performance requirements based on 2022 through 2024 performance. Quarterly throughout 2023 and in the first quarter of 2024, the Company performed analyses using multiple updated forecasted scenarios and determined that the earnout would only be partially achieved. As a result, the Company recognized a decrease in the fair value of the related liabilities in the second and third quarters of 2023 and the first quarter of 2024. The remaining liability of $1.7&#160;million was paid in the first quarter of 2024. See Note 4 - Acquisitions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk:</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See discussion of credit losses and allowance for credit losses in Note 2 - Summary of Significant Accounting Policies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, based on the large number of customers in differing geographic areas, primarily throughout the United States and its territories, the Company believes that the concentration of credit risk is limited.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STOCKHOLDERS&#8217; EQUITY</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 1, 2023, the Company&#8217;s Board of Directors authorized approximately $59.0&#160;million in additional share repurchases, such that, effective for trades made after May 3, 2023, the aggregate amount available for stock repurchases was set at $100.0&#160;million (the Repurchase Program). The shares can be repurchased from time-to-time in the open market or in privately negotiated transactions. The Repurchase Program does not obligate the Company to repurchase any particular number of shares of common stock and may be discontinued by the Board of Directors at any time. Decisions regarding the amount and the timing of repurchases under the Repurchase Program will be subject to the Company&#8217;s available liquidity and cash on hand, applicable legal requirements, the terms of the Company&#8217;s Loan Agreement, general market conditions, and other factors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the third quarter of 2023, the Company entered into a Rule 10b5-1 Repurchase Plan to allow for share repurchases during the Company&#8217;s blackout periods, beginning on January 2, 2024 and effective through November 7, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, the Company repurchased a total of 310,235 shares of common stock for $6.4&#160;million, at an average price of $20.51 per share. During the three months ended March 31, 2025, the Company did not repurchase any shares of its common stock, but did pay $0.3&#160;million in excise tax related to previous share repurchases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2025, the Company had $40.5&#160;million remaining for share repurchase under the Repurchase Program, subject to certain conditions in the Company&#8217;s Loan Agreement. As of March 31, 2025, the Company had 32,476,983 unrestricted shares of common stock outstanding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 14, 2024, the Company&#8217;s stockholders approved the Cross Country Healthcare, Inc. 2024 Omnibus Incentive Plan (2024 Plan). Pursuant to the 2024 Plan, awards may be granted to employees, non-employee directors, consultants, and key advisors of the Company and its subsidiaries, including stock options (including incentive stock options and nonqualified stock options), stock appreciation rights, stock awards, stock units, other stock-based awards, and cash awards. The 2024 Plan was adopted principally to serve as a successor plan to the Cross Country Healthcare, Inc. 2020 Omnibus Incentive Plan (2020 Plan) and to increase the number of shares of Company common stock reserved for equity-based awards to 2,400,000 shares (in addition to the share reserve amount that remained available under the 2020 Plan immediately prior to the adoption of the 2024 Plan and other eligible returning shares). No awards may be granted under the 2024 Plan after May 13, 2034.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock awards and performance stock awards activity issued under the 2020 Plan and the 2024 Plan (Plans) for the three months ended March&#160;31, 2025:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Stock Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Target <br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock awards, January&#160;1, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220,873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock awards, March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards granted under the Company&#8217;s Plans entitle the holder to receive, at the end of a vesting period, a specified number of shares of the Company&#8217;s common stock. Share-based compensation expense is measured by the market value of the Company&#8217;s stock on the date of grant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards granted to non-employee directors under the Plans will vest on the first anniversary of such grant date, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or earlier subject to retirement eligibility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, effective for the three months ended June 30, 2020, the Company implemented modified guidelines that provide for accelerated vesting of restricted stock grants on the last date of service when a retirement-eligible director retires.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Plans, the number of target shares that are issued for performance-based stock awards are determined based on the level of attainment of the targets. During the first quarter of 2025, the Company&#8217;s Compensation Committee of the Board of Directors approved a 75.5% level of attainment for the 2022 performance-based share awards, resulting in the issuance of 85,001 performance shares that vested on March 31, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March 31, 2025, $1.3 million was included in selling, general and administrative expenses related to share-based payments, and a net of 199,588 shares of common stock were issued upon the vesting of restricted and performance stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, $1.2 million was included in selling, general and administrative expenses related to share-based payments, and a net of 251,024 shares of common stock were issued upon the vesting of restricted and performance stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT DATA<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT DATA</a></td>
<td class="text">SEGMENT DATA<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two operating and reportable segments, Nurse and Allied Staffing and Physician Staffing, which align with its management structure and reflect how the operating results are regularly reviewed by the Chief Executive Officer, who the Company has determined to be its Chief Operating Decision Maker (CODM). The Company&#8217;s segments offer services to its customers as described below:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9679;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Nurse and Allied Staffing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211; Nurse and Allied Staffing provides traditional staffing, recruiting, and value-added total talent solutions including: temporary and permanent placement of travel nurse and allied professionals, per diem, and healthcare leaders within nursing, allied, human resources, and finance, managed service programs services, education healthcare services, in-home care services, and outsourcing services. In addition, Nurse and Allied Staffing provides executive search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services, and offers the Company&#8217;s SaaS-based, proprietary, vendor management technology, Intellify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to facilities to manage all or a portion of their agency services. Its customers include: public and private acute care hospitals, non-acute care hospitals, government facilities, local healthcare plans, national healthcare plans, managed care providers, public schools, charter schools, academic medical centers, Programs of All-Inclusive Care for the Elderly (PACE) programs, outpatient clinics, ambulatory care facilities, physician practice groups, and many other healthcare providers throughout the United States.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9679;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Physician Staffing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Physician Staffing provides physicians in many specialties, as well as certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments throughout the United States at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, and the profit and loss measure of contribution income, are reported to the CODM by each of the operating segments to assess performance. Contribution income is the profit and loss measure used by the CODM to allocate operating and capital resources to each segment. The Company defines contribution income as income (loss) from operations before depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, impairment charges, and corporate overhead. Management believes that its measure of contribution income is most consistent with that used to measure the corresponding amounts on its consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in the following tables is derived from the segments&#8217; internal financial information as used for corporate management purposes. Certain corporate expenses are not allocated to and/or among the operating segments. Those include corporate overhead and the remaining line items below contribution income in the consolidated column in the tables below, and are presented to the CODM on a consolidated basis only.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on reportable segments and a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reconciliation to loss before income taxes for the period indicated are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:40.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse and Allied Staffing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician Staffing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,717&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss (income) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divisional corporate G&amp;A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,244&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,029&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,273&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of profit or loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate overhead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration-related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(899)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) For each reportable segment, the other segment items category includes the following expenses: rent, insurance, maintenance, utilities, professional services, office, software and hardware, taxes, and miscellaneous employee expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on reportable segments and a reconciliation to income before income taxes for the period indicated are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:40.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse and Allied Staffing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician Staffing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,880&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,430&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divisional corporate G&amp;A</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,337&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution Income</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,183&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,138&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,321&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of profit or loss:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate overhead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,642&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and other losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) For each reportable segment, the other segment items category includes the following expenses: rent, insurance, maintenance, utilities, professional services, office, software and hardware, taxes, and miscellaneous employee expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is based on services provided. During the three months ended March 31, 2025 and 2024, all revenue was generated in the U.S., and all of the Company&#8217;s long-lived assets were located in the U.S. and India. The Company provides its staffing services and workforce solutions in all 50 states. The India location is a cost center with no revenues and an immaterial amount of long-lived assets. The Company had no intersegment revenues between reportable segments for the three months ended March 31, 2025 and 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not evaluate, manage, or measure performance of segments using asset information; accordingly, total asset information by segment is not prepared or disclosed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the segments are the same as those described in Note 2 &#8211; Summary of Significant Accounting Policies, which also provides information about major customers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the tables in Note 3 - Revenue Recognition, which present segment revenues by services.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CONTINGENCIES</a></td>
<td class="text"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTINGENCIES</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various litigation, claims, investigations, and other proceedings that arise in the ordinary course of its business. These proceedings primarily relate to employee-related matters that include individual and collective claims, professional liability, tax, and payroll practices. The Company establishes reserves when available information indicates that a loss is probable and an amount or range of loss can be reasonably estimated. These assessments are performed at least quarterly and are based on the information available to management at the time and involve significant management judgment to determine the probability and estimated amount of potential losses, if any. Based on the available information considered in its reviews, the Company adjusts its loss contingency accruals and its disclosures as may be required. Actual outcomes or losses may differ materially from those estimated by the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s current assessments, including available insurance recoveries, which would impact the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s profitability. Adverse developments in existing litigation claims or legal proceedings involving the Company or new claims could require management to establish or increase litigation reserves or enter into unfavorable settlements or satisfy judgments for monetary damages for amounts in excess of current reserves, which could adversely affect the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s financial results. The Company believes that the outcome of any outstanding loss contingencies as of March 31, 2025 will not have a material adverse effect on its business, financial condition, results of operations, or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Other State Non-Income Tax Liabilities </span></div>The Company&#8217;s sales and other state non-income tax filings are subject to routine audits by authorities in the jurisdictions where it conducts business in the United States which may result in assessments of additional taxes. The Company accrues sales and other non-income tax liabilities based on the Company&#8217;s best estimate of its probable liability utilizing currently available information and interpretation of relevant tax regulations. Given the nature of the Company&#8217;s business, significant subjectivity exists as to both whether sales and other state non-income taxes can be assessed on its activity and how the sales tax will ultimately be measured by the relevant jurisdictions. The Company makes a determination for each reporting period whether the estimates for sales and other non-income taxes in certain states should be revised. The expense is included in selling, general and administrative expenses in the Company&#8217;s condensed consolidated statements of operations and comprehensive (loss) income and the liability is reflected in sales tax payable within other current liabilities in its condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three-month periods ended March 31, 2025 and 2024, the Company calculated its effective tax rate estimating its annual effective tax rate. The Company&#8217;s effective tax rate for the three months ended March 31, 2025 and 2024 was 45.5% and 27.0%, respectively, including the impact of discrete items. Excluding discrete items, the Company&#8217;s effective tax rate for the three months ended March 31, 2025 and 2024 was 56.1% and 37.0%, respectively. The effective tax rates for the first quarters of 2025 and 2024 were primarily impacted by federal and state taxes. The increase in the effective tax rate was primarily related to a decrease in book income relative to nondeductible items.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company had approximately $10.2&#160;million of unrecognized tax benefits included in other non-current liabilities, $11.1&#160;million, net of deferred taxes, which would impact the effective tax rate if recognized. During the three months ended March 31, 2025, the Company had net increases of $0.3&#160;million to its current year unrecognized tax benefits related to federal and state tax provisions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2024, many international jurisdictions implemented the Pillar Two rules issued by the Organization for Economic Co-operation and Development. In general, large multinational entity groups with consolidated revenue in excess of 750 million Euros in at least two of the preceding four years could be subject to the new rules in jurisdictions with an effective tax rate below fifteen percent. The Company currently operates in one country that has adopted the Pillar Two rules, but should meet the safe harbor rules. The Company does not expect the adoption of the Pillar Two rules by any jurisdiction in which it currently operates to have a material impact on its financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax years 2012 through 2024 remain open to examination by certain taxing jurisdictions to which the Company is subject to tax, other than certain states in which the statute of limitations has been extended.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an arrangement for digital marketing services provided by a firm that is related to a certain member of the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Board of Directors, who is a minority shareholder in the firm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s parent company and is a member of the parent company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Board of Directors. Management believes that the terms of the arrangement are equivalent to those prevailing in an arm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s-length transaction and have been approved by the Audit Committee of the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Board of Directors through the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s related party transaction approval process. The digital marketing firm manages a limited number of digital publishers covering various Company brands for a monthly management fee. During the three months ended March 31, 2025 and 2024, the Company incurred an immaterial amount in expenses and had an immaterial payable balance at March 31, 2025 and December 31, 2024.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides services to entities that are affiliated with certain members of the Company&#8217;s Board of Directors. Management believes that the services were conducted on terms equivalent to those prevailing in an arm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s-length transaction. Revenue related to these transactions was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2025 and an immaterial amount for the three months ended March 31, 2024. Accounts receivable due from these entities was an immaterial amount at March 31, 2025 and December 31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (490)<span></span>
</td>
<td class="nump">$ 2,692<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. All such adjustments consisted of all normal recurring items, including the elimination of all intercompany transactions and balances.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form&#160;10-Q and Article 10 of Regulation&#160;S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2024 included in the 2024 Form 10-K. The December&#160;31, 2024 condensed consolidated balance sheet included herein was derived from the December&#160;31, 2024 audited consolidated balance sheet included in the 2024 Form&#160;10-K.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the current year presentation. See the condensed consolidated statements of operations and comprehensive (loss) income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, using information that is reasonably available to the Company at the time. Significant estimates and assumptions are used for, but not limited to: (i) the valuation of accounts receivable; (ii) goodwill, trade names, and other intangible assets; (iii) other long-lived assets; (iv) revenue recognition; (v) accruals for health, workers&#8217; compensation, and professional liability claims; (vi) valuation of deferred tax assets; (vii) legal contingencies; and (viii) income taxes. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. As additional information becomes available to the Company, its future assessment of these estimates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span>could materially and adversely impact the Company&#8217;s consolidated financial statements in future reporting periods. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments from customers and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers. See associated risk factors in Item 1A. Risk Factors in the 2024 Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, net</a></td>
<td class="text"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Accounts Receivable, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers, which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for credit losses and sales allowances. Estimated revenue for the Company employees&#8217;, subcontracted employees&#8217;, and independent contractors&#8217; time worked but not yet billed at March 31, 2025 and December 31, 2024 totaled $61.9&#160;million and $60.4&#160;million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for credit losses is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for credit losses when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of its accounts receivable based on a combination of factors. The Company bases its allowance for credit loss estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered expectations of future economic condition</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when estimating its allowance for credit losses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the allowance for credit losses, the Company maintains a sales allowance for billing-related adjustments that may arise in the ordinary course of business and adjustments to the reserve are recorded as contra-revenue. The sales allowance balance as of March 31, 2025 and December 31, 2024 was $0.4&#160;million and $0.5&#160;million, respectively.</span></div>The Company&#8217;s contract terms typically require payment between 30 to 60 days from the date of invoice and are considered past due based on the particular negotiated contract terms. The majority of the Company&#8217;s customers are healthcare systems with a significant percentage in acute-care facilities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Restructuring Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions, and are primarily included in the accounts payable and accrued expenses on the condensed consolidated balance sheets. Restructuring costs on the condensed consolidated statements of operations and comprehensive (loss) income primarily include employee termination costs and lease-related exit costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 27, 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses, enhances interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and requires certain disclosures related to the chief operating decision maker. The Company adopted this standard for its fiscal year ended December 31, 2024, and its interim periods beginning in the first quarter of 2025, and applied the guidance retrospectively to all prior periods presented in the financial statements. This standard only expanded the Company&#8217;s disclosures with no impact to results of operations, cash flows, and financial condition. See Note 12 - Segment Data.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve decision usefulness of business entities&#8217; income statements through the disaggregation of certain expense captions, such as employee compensation, depreciation, and intangible asset amortization, with required disclosure in a single note to the financial statements. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments in this update should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this update, or (2) retrospectively to any or all prior periods presented in the financial statements. The Company expects to adopt this standard for its annual report for the fiscal year ending December 31, 2027. The Company expects this ASU to only impact its disclosures with no impacts to results of operations, cash flows, and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that public business entities, on an annual basis, (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The amendments also require that all entities disclose, on an annual basis, disaggregated information regarding income taxes paid and income tax expense. This guidance is effective for annual periods beginning after December 15, 2024. The amendments should be applied prospectively, but retrospective application is permitted. The Company plans to adopt this standard for its annual report for the fiscal year ended December 31, 2025. The Company expects this ASU to only impact its disclosures with no impacts to results of operations, cash flows, and financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks And Uncertainties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 420<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of Allowance for Doubtful Accounts</a></td>
<td class="text"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening balance of the allowance for credit losses is reconciled to the closing balance for expected credit losses as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Loss Expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-Offs, net of Recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,349&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Employee Termination Costs and Lease-Related Exit Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliations of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Termination Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease-Related Exit Costs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to restructuring</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2025</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s revenues from customer contracts are generated from temporary staffing services and other services. Revenue is disaggregated by segment in the following table. Sales and usage-based taxes are excluded from revenue.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse<br/>And Allied<br/>Staffing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician<br/>Staffing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary Staffing Services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,417&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,551&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse<br/>And Allied<br/>Staffing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician<br/>Staffing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary Staffing Services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(amounts in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common stockholders - Basic and Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(490)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,692&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares - Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of diluted shares:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Share-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares - Diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">a</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,282&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,597&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share attributable to common stockholders - Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share attributable to common stockholders - Diluted</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)  For the three months ended March 31, 2025, the effect of diluted shares was not included in the weighted average share calculation due to the Company&#8217;s net operating loss position.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the share-based awards that could potentially dilute net (loss) income per share attributable to common stockholders in the future that were not included in the computation of diluted net (loss) income per share attributable to common stockholders because to do so would have been anti-dilutive for the periods presented.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based awards</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Acquired Intangible Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following acquired intangible assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Databases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,068&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,003&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,065&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,068&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,782&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets not subject to amortization:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names, indefinite-lived</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Annual Amortization Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, estimated future annual amortization expense was as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:80.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,065&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s debt consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Secured Asset-Based Loan, interest of 6.21% and 6.31% at March 31, 2025 and December 31, 2024, respectively</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,807)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification on Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the undiscounted cash flows for each of, and total of, the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of March 31, 2025:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:75.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: operating lease liabilities - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding supplemental cash flows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets acquired under operating lease</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Included in Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable and other lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_AssetsAndLiabilitiesLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s financial assets and liabilities measured on a recurring basis is as follows:&#160;</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,889&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock awards and performance stock awards activity issued under the 2020 Plan and the 2024 Plan (Plans) for the three months ended March&#160;31, 2025:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Stock Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Target <br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock awards, January&#160;1, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220,873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock awards, March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT DATA (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Information on Operating Segments and Reconciliation to (Loss) Income from Operations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on reportable segments and a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reconciliation to loss before income taxes for the period indicated are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:40.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse and Allied Staffing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician Staffing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,717&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss (income) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divisional corporate G&amp;A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,244&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,029&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,273&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of profit or loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate overhead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration-related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(899)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) For each reportable segment, the other segment items category includes the following expenses: rent, insurance, maintenance, utilities, professional services, office, software and hardware, taxes, and miscellaneous employee expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on reportable segments and a reconciliation to income before income taxes for the period indicated are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:40.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse and Allied Staffing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician Staffing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,880&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,430&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divisional corporate G&amp;A</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,337&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution Income</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,183&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,138&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,321&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of profit or loss:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate overhead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,642&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and other losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) For each reportable segment, the other segment items category includes the following expenses: rent, insurance, maintenance, utilities, professional services, office, software and hardware, taxes, and miscellaneous employee expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND BASIS OF PRESENTATION - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ccrn_AyaHoldingsIIInc.Member', window );">Aya Holdings II Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ccrn_AyaHoldingsIIInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ccrn_AyaHoldingsIIInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled contracts receivable</a></td>
<td class="nump">$ 61.9<span></span>
</td>
<td class="nump">$ 60.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_SalesAllowanceBillingRelatedAdjustments', window );">Sales allowance, billing-related adjustments</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided', window );">Threshold period, past due for payment of services provided</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided', window );">Threshold period, past due for payment of services provided</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_SalesAllowanceBillingRelatedAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Allowance, Billing-Related Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_SalesAllowanceBillingRelatedAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold Period, Past Due For Payment Of Services Provided</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 8,841<span></span>
</td>
<td class="nump">$ 19,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit loss expense</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery', window );">Write-Offs, net of Recoveries</a></td>
<td class="nump">473<span></span>
</td>
<td class="num">(1,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 9,349<span></span>
</td>
<td class="nump">$ 19,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance For Credit Loss, Writeoff, After Recovery</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring (Benefits) Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charged to restructuring</a></td>
<td class="nump">$ 301<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Termination Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at beginning of period</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charged to restructuring</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at end of period</a></td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ccrn_ExitCostsMember', window );">Lease-Related Exit Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at beginning of period</a></td>
<td class="nump">788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charged to restructuring</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at end of period</a></td>
<td class="nump">$ 604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ccrn_ExitCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ccrn_ExitCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">$ 293,408<span></span>
</td>
<td class="nump">$ 379,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ccrn_TemporaryStaffingServicesMember', window );">Temporary Staffing Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">284,857<span></span>
</td>
<td class="nump">369,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ccrn_OtherServicesMember', window );">Other Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">8,551<span></span>
</td>
<td class="nump">9,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember', window );">Nurse And Allied Staffing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">242,291<span></span>
</td>
<td class="nump">332,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember', window );">Nurse And Allied Staffing | Temporary Staffing Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">236,157<span></span>
</td>
<td class="nump">324,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember', window );">Nurse And Allied Staffing | Other Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">6,134<span></span>
</td>
<td class="nump">7,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember', window );">Physician Staffing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">51,117<span></span>
</td>
<td class="nump">46,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember', window );">Physician Staffing | Temporary Staffing Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">48,700<span></span>
</td>
<td class="nump">44,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember', window );">Physician Staffing | Other Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">$ 2,417<span></span>
</td>
<td class="nump">$ 2,499<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ccrn_TemporaryStaffingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ccrn_TemporaryStaffingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ccrn_OtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ccrn_OtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 13, 2022</div></th>
<th class="th"><div>Oct. 03, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,411<span></span>
</td>
<td class="nump">$ 6,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ccrn_HireUpLeadershipIncMember', window );">HireUp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration, gross</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity consideration for acquisition, value</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity consideration for acquisition (shares)</a></td>
<td class="nump">29,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earnout liabilities</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember', window );">Mint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity consideration for acquisition, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity consideration for acquisition (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earnout liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ccrn_HireUpLeadershipIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ccrn_HireUpLeadershipIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMPREHENSIVE (LOSS) INCOME (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax', window );">Loss on currency fluctuations</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income attributable to common stockholders - Basic</a></td>
<td class="num">$ (490)<span></span>
</td>
<td class="nump">$ 2,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net (loss) income attributable to common stockholders - Diluted</a></td>
<td class="num">$ (490)<span></span>
</td>
<td class="nump">$ 2,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares - Basic (shares)</a></td>
<td class="nump">32,282<span></span>
</td>
<td class="nump">34,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of diluted shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Share-based awards (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares - Diluted (shares)</a></td>
<td class="nump">32,282<span></span>
</td>
<td class="nump">34,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share attributable to common stockholders - Basic (in dollars per share)</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share attributable to common stockholders - Diluted (in dollars per share)</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE - Anti-dilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Share-based awards (shares)</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets subject to amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 89,068<span></span>
</td>
<td class="nump">$ 89,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">55,003<span></span>
</td>
<td class="nump">52,782<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">34,065<span></span>
</td>
<td class="nump">36,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets not subject to amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedTradeNames', window );">Trade names, indefinite-lived</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DatabasesMember', window );">Databases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets subject to amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">36,530<span></span>
</td>
<td class="nump">36,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">23,029<span></span>
</td>
<td class="nump">21,945<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">13,501<span></span>
</td>
<td class="nump">14,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets subject to amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">52,538<span></span>
</td>
<td class="nump">52,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">31,974<span></span>
</td>
<td class="nump">30,837<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 20,564<span></span>
</td>
<td class="nump">$ 21,701<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedTradeNames">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trade name to gain or protect exclusive use thereof for a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedTradeNames</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DatabasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DatabasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Estimated Annual Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2025</a></td>
<td class="nump">$ 6,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">7,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">6,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">4,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">4,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">5,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 34,065<span></span>
</td>
<td class="nump">$ 36,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 135,060<span></span>
</td>
<td class="nump">$ 135,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember', window );">Nurse And Allied Staffing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">112,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember', window );">Physician Staffing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 22,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Long-term Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs</a></td>
<td class="num">$ (1,606,000)<span></span>
</td>
<td class="num">$ (1,807,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Senior Secured Asset-Based Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate percentage</a></td>
<td class="nump">6.21%<span></span>
</td>
<td class="nump">6.31%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs</a></td>
<td class="num">$ (1,606,000)<span></span>
</td>
<td class="num">$ (1,807,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - 2019 Asset-Based Loan Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 21, 2022</div></th>
<th class="th"><div>Oct. 25, 2019</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jul. 29, 2024</div></th>
<th class="th"><div>Nov. 18, 2021</div></th>
<th class="th"><div>Mar. 08, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources', window );">Amount of indebtedness permitted from other sources</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember', window );">Senior Secured Asset-Based Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Line of credit term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="nump">$ 130,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable', window );">Borrowing base, percentage of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_LineOfCreditFacilityBorrowingBaseAvailability', window );">Borrowing base availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Borrowing availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Quarterly commitment fee on the average daily unused portion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember', window );">Senior Secured Asset-Based Loan | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment', window );">Basis spread on variable rate, additional credit spread associated with SOFR</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest margin percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember', window );">Senior Secured Asset-Based Loan | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest margin percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember', window );">Senior Secured Asset-Based Loan | Swingline Sublimit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember', window );">Senior Secured Asset-Based Loan | Standby Letters Of Credit Sublimit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Basis Spread On Variable Rate, Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit, Amount Of Indebtedness Permitted By Senior Secured Asset Based Loan To Be Borrowed From Other Sources</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit, Borrowing Base, Percentage Of Accounts Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LineOfCreditFacilityBorrowingBaseAvailability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Borrowing Base Availability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LineOfCreditFacilityBorrowingBaseAvailability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LineOfCreditSublimitAxis=ccrn_SwingLoansSublimitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LineOfCreditSublimitAxis=ccrn_SwingLoansSublimitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LineOfCreditSublimitAxis=ccrn_StandbyLettersOfCreditSublimitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LineOfCreditSublimitAxis=ccrn_StandbyLettersOfCreditSublimitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,219<span></span>
</td>
<td class="nump">$ 2,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="nump">2,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - non-current</a></td>
<td class="nump">$ 1,623<span></span>
</td>
<td class="nump">$ 1,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">7.12%<span></span>
</td>
<td class="nump">7.05%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Operating Lease Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025</a></td>
<td class="nump">$ 1,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">3,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount of lease payments representing interest</a></td>
<td class="num">(342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">3,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: operating lease liabilities - current</a></td>
<td class="num">(1,687)<span></span>
</td>
<td class="num">$ (2,089)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - non-current</a></td>
<td class="nump">$ 1,623<span></span>
</td>
<td class="nump">$ 1,782<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 625<span></span>
</td>
<td class="nump">$ 863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets acquired under operating lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable and other lease costs</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis (Details) - Level 1 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ccrn_DeferredCompensationMember', window );">Deferred Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations', window );">Deferred compensation liability</a></td>
<td class="nump">$ 2,556<span></span>
</td>
<td class="nump">$ 2,926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=ccrn_DeferredCompensationMember', window );">Deferred Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Deferred compensation asset</a></td>
<td class="nump">$ 2,534<span></span>
</td>
<td class="nump">$ 2,889<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of obligations measured on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ccrn_DeferredCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ccrn_DeferredCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ccrn_DeferredCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ccrn_DeferredCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_FairValueMeasurementLineItems', window );"><strong>Fair Value Measurement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="nump">$ 4,411<span></span>
</td>
<td class="nump">$ 6,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember', window );">Mint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_FairValueMeasurementLineItems', window );"><strong>Fair Value Measurement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ccrn_HireUpLeadershipIncMember', window );">HireUp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_FairValueMeasurementLineItems', window );"><strong>Fair Value Measurement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_FairValueMeasurementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_FairValueMeasurementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ccrn_HireUpLeadershipIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ccrn_HireUpLeadershipIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 14, 2024</div></th>
<th class="th"><div>May 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock repurchase and retirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_StockRepurchasedDuringPeriodExciseTax', window );">Stock repurchase excise tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Unrestricted shares of common stock outstanding (shares)</a></td>
<td class="nump">32,476,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage', window );">Performance attainment percentage</a></td>
<td class="nump">75.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ccrn_OmnibusPlanMember', window );">Omnibus Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for share-based payments (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ccrn_RestrictedStockAndPerformanceSharesMember', window );">Restricted Stock And Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet', window );">Vested in period, net (shares)</a></td>
<td class="nump">199,588<span></span>
</td>
<td class="nump">251,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="nump">85,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=ccrn_RepurchaseProgramMember', window );">Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount', window );">Additional authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Common shares amount left remaining to repurchase under the plan (up to)</a></td>
<td class="nump">$ 40,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased and retired (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">310,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock repurchase and retirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average market price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_StockRepurchasedDuringPeriodExciseTax', window );">Stock repurchase excise tax</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Target Attainment Level, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other than Options, Vested In Period, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchase Program, Additional Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_StockRepurchasedDuringPeriodExciseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchased During Period, Excise Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_StockRepurchasedDuringPeriodExciseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ccrn_OmnibusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ccrn_OmnibusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ccrn_RestrictedStockAndPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ccrn_RestrictedStockAndPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=ccrn_RepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=ccrn_RepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards, beginning balance (shares) | shares</a></td>
<td class="nump">538,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares) | shares</a></td>
<td class="num">(220,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares) | shares</a></td>
<td class="num">(9,101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards, ending balance (shares) | shares</a></td>
<td class="nump">308,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted stock awards, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 19.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">20.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">20.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted stock awards, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards, beginning balance (shares) | shares</a></td>
<td class="nump">409,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares) | shares</a></td>
<td class="num">(85,001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares) | shares</a></td>
<td class="num">(27,586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards, ending balance (shares) | shares</a></td>
<td class="nump">297,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted stock awards, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">21.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">21.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted stock awards, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT DATA - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>segment </div>
<div>state</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">$ 293,408,000<span></span>
</td>
<td class="nump">$ 379,174,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IN', window );">INDIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT DATA - Operating Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">$ 293,408<span></span>
</td>
<td class="nump">$ 379,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct operating expenses</a></td>
<td class="nump">234,750<span></span>
</td>
<td class="nump">301,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit loss (income) expense</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Reconciliation of profit or loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,772<span></span>
</td>
<td class="nump">4,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_AcquisitionAndIntegrationRelatedCosts', window );">Acquisition and integration-related costs</a></td>
<td class="nump">2,041<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_LegalAndOtherLosses', window );">Legal and other losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(681)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income), net</a></td>
<td class="nump">60<span></span>
</td>
<td class="num">(1,057)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income taxes</a></td>
<td class="num">(899)<span></span>
</td>
<td class="nump">3,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">293,408<span></span>
</td>
<td class="nump">379,174<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard', window );">Contribution Income</a></td>
<td class="nump">21,273<span></span>
</td>
<td class="nump">30,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Segment Reporting, Reconciling Item, Corporate Nonsegment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Reconciliation of profit or loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_SegmentReportingUnallocatedCorporateExpenses', window );">Corporate overhead</a></td>
<td class="nump">15,136<span></span>
</td>
<td class="nump">17,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember', window );">Nurse And Allied Staffing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">242,291<span></span>
</td>
<td class="nump">332,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember', window );">Nurse And Allied Staffing | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">242,291<span></span>
</td>
<td class="nump">332,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct operating expenses</a></td>
<td class="nump">194,033<span></span>
</td>
<td class="nump">264,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense', window );">Employee compensation</a></td>
<td class="nump">21,369<span></span>
</td>
<td class="nump">28,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_BenefitsExpense', window );">Benefits</a></td>
<td class="nump">2,549<span></span>
</td>
<td class="nump">2,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">Marketing</a></td>
<td class="nump">1,670<span></span>
</td>
<td class="nump">2,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit loss (income) expense</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Divisional corporate G&amp;A</a></td>
<td class="nump">3,718<span></span>
</td>
<td class="nump">4,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">1,718<span></span>
</td>
<td class="nump">1,896<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard', window );">Contribution Income</a></td>
<td class="nump">17,244<span></span>
</td>
<td class="nump">27,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember', window );">Physician Staffing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">51,117<span></span>
</td>
<td class="nump">46,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember', window );">Physician Staffing | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">51,117<span></span>
</td>
<td class="nump">46,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct operating expenses</a></td>
<td class="nump">40,717<span></span>
</td>
<td class="nump">36,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense', window );">Employee compensation</a></td>
<td class="nump">5,366<span></span>
</td>
<td class="nump">5,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_BenefitsExpense', window );">Benefits</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">Marketing</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit loss (income) expense</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Divisional corporate G&amp;A</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard', window );">Contribution Income</a></td>
<td class="nump">$ 4,029<span></span>
</td>
<td class="nump">$ 3,138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_AcquisitionAndIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition and integration-related costs include costs for prior acquisitions, costs incurred for potential transactions, and accretion and valuation adjustments on contingent consideration liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_AcquisitionAndIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_BenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Benefits Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_BenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Labor and Related Expense, Excluding Benefits Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LegalAndOtherLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal And Other Losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LegalAndOtherLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Income Loss Before D And A Acquisition And Integration Restructuring Legal Impairment And Corporate Overheard</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_SegmentReportingUnallocatedCorporateExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment Reporting Unallocated Corporate Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_SegmentReportingUnallocatedCorporateExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate direct operating costs incurred during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectOperatingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">45.50%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent', window );">Effective tax rate, excluding discrete items</a></td>
<td class="nump">56.10%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Uncertain tax positions</a></td>
<td class="nump">$ 10,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increase to current year unrecognized tax benefits related to federal and state tax issues</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Excluding Discrete Items, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">$ 293,408<span></span>
</td>
<td class="nump">$ 379,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Services Provided Entities Affiliated With Board Members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>72
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *V%IUI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( *V%IUI\)3)<\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( *V%IUJ@4D6MY04  -X>   8
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M\SI3W^7#1[%SR-?])3*KFK_.P\[6G3E)72F9[QJ#@CPMVO_\<3<0@P;$FVA
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M+%-T)0JL74$3X)D%BKE49C)V]1AV?/<0N2[5YF3<P,:_J'\0IE#LMR)/LW:
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MO)G]AL(_/US<_HU.T8?9%#U_=H*>H21'MXMB5=%\7IT-N1B71!_&S1C>;,9
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M>ZJ.9>N8TP:8F2=@-]CB,_H.+,!R2&'R)+F=*29Z29B\=K?57K>C_6-M37L
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M$>_WNVI52>7+'Y>]-TC5X4@<MRDF:]D/B/*5.#*.#F 8 4 D?+B]BP@P/AX
M9ZY\6;F-]@C8UP+"Y48Q\L/#H-A0  /D?&[5W -W%Q(.;YMI[1%E-#@>$ZAL
MC8:=MG6(G4H'47P(>9>8"#!M]#9.S9J"N7V7Y\=$BJ=1H89VBF_$&J; .XK%
MA K0 B<NM^A.*I:;]Q6Y@LTRW;F]V+Y#H>,2&/@_80C'43H2Z8 #L=H( '03
M%A/YD5!.24*'27Q"39ZCO.WD[$:]GE'2I?0=GG'T/$F*;Z0N:4IG]]\BZKPO
MWDA;!$@AXQ(+H%I?\V4&GXIA"WFZ&F#,:7S=<HMX"!^A0&F^>#H<'A&X;L+
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M^=F!L/ZG:/X+" ___&MJZMJ4_)'..92E 7@_,RCDX0LMD'X/^.J_4$L#!!0
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;+5976_;N!+]*X2WNT@
MUY])D[9)@*1ML+UHFZ+I[CY<W =:HBQN)5%+4G:\O_Z>&>K+CI--@'M?$IDB
MAS-G9LX,J;.UL3]<JI07=WE6N/-!ZGWY9CQV4:IRZ4:F5 7>),;FTN.G78Y=
M:96,>5&>C6>3R:MQ+G4QN#CCL:_VXLQ4/M.%^FJ%J_)<VLV5RLSZ?# =- /?
M]#+U-#"^."OE4MTJ_UOYU>+7N)42ZUP53IM"6)6<#RZG;ZZ.:#Y/^%VKM>L]
M"[)D8<P/^O$Q/A],2"&5J<B3!(E_*_5.91D)@AI_U3('[9:TL/_<2+]FVV'+
M0CKUSF1_Z-BGYX/3@8A5(JO,?S/K7U5MSS')BTSF^*]8A[FSDX&(*N=-7B^&
M!KDNPG]Y5^/06W Z>6#!K%XP8[W#1JSE>^GEQ9DU:V%I-J31 YO*JZ&<+L@I
MM][BK<8Z?_'^P]7WL[&')/H]CNI55V'5[(%5<_'9%#YUXD,1JWA[_1@:M&K,
M&C6N9H\*_"SM2,RG0S&;S(X?D3=OS9JSO/E#9JF%%^^UBS+C*JO$OR\7SEN$
MP'_V&1MD'>V716GQQI4R4N<#Q+U3=J4&%[_\-'TU>?N(ID>MID>/27_0 ?^\
M2GQ/E7AG\E(6FU]^.IU-3]XZ!"0,CPR2QGDG3"(\)B4F0_+I8OE& .@H;9$6
M[U6D\H6RS<B1^&IU$>E29H(Q_.A<)8N(-B*!C[\]D+FI"CSH ON:RLDB=H?B
M5A7:6/R+X(I87#JG_,LKI%(L/AE9##'=*R#K2=]7H]GT9X&%>)K3D]_5F=[=
MTWL(AG"EXAS/-N*%8$1F;_%T,!V^FKPZW!T[G9P<!BN>.OF2 7V:-H =8;>6
M3A0F. 6,Z#QFPPW"%.P7^"D&OP$'\IC)="P]?BQDQJ!R5KM1W\\BA42F-,SS
M1G! %IZE\2ZZ\4C$'I'.F4BSU+7VJ= 8<\$=KG:'9'<LV!T1!K07B8QTIOT&
M[V!?F$%>BK(*Z4[>-61?>.&>:<UL,GU]+P;$Y=(JE9,I'Y(DN%'<1-X0JK/C
M(:]B5%LD$#+@0]Z"K"IM,(IMNV<'G*0XR$A[X-985=N=D0JR46$H%F$)PAG.
MZF]*HY&R7A(&"6\<FQRAJR/4M873L996*S<DZ!;&@@R4!4)6+"MI);:V>/<'
MBI 3U](NC;B2Q8^A^#*Z' U9^M<O[WBL&7)BC=GT/V#^20%E2[E&R9Z %^(0
M;+HX%(DUN? HFA0;_+^4UD.?, 6#!]MH'X;HVG%!:<U*DZ=1](44"9SQ<J.D
M18ZM3+:B"'Y&$!U<7GTZ#)2@ #)V6<)KY+":2@)K$)Y528J_F,XFHPFJ79:A
M<#>!1[M* CG3.8FGW8G3V'FN77K<K0P^%"_F_;%M 920<':FO&<_);7V(W%3
MB']5A1+S":?T9#OX9$YN8.1WP3NXUA94=DDS&.*A6*<:E $ST#:Y>A5PLS2]
M R0R.?2B>';Z;]5P-\ +;MU&)1@[[XV,Q"7B) 0)Y0;BC#)24_/#SRM5( !=
M"#.@'S$3)?MLL(KZN5I3!V,9C\!\IXS'].EX@/>AQ_\#D/D]0(YW Z?>H,G9
MD))D.,4J!<-+CH8:E5@U"Q8 ,J@E74HYK@O:1*U814Q%YH'6-,+7JM(@R8@I
MK%XN$4==]#P;K.^IMONP*HGM& M:!<,8K8A1T051OXH+Y1SKMB2FH3><GC61
M(T$IYJD(%/NVIH6:VN3(V)@9FRL&S?Q(U!D2 TG3T[;'07N%'C;!QGSB1*ZB
M5!8Z<@ MDP$SD#& 0PKKT*:OY:;F,197Q!AD!1;$BC>H#D0XWRA #CY]O+KY
M=LAE2BP 1XJ#Q8^NG; TB3> CS)T<,'0#*]1.*C$=(MX+JRK570Y$T3@EES&
MA+GX;70[0BQDF:Q]_ 5)Q85_^FQ'7YN*?+'M::@--J+IG;^WO/L4Q*GIZ*46
MI<7)<9\GVE2>A79E]AQN2^XI_3])Y>/=5)Y/ME)9W?E.*Z*W1L9NM>&2A3"*
M _,A/ZE\"2I?CNRTIEJFV_:?#.O@?S);C!"1[1;#NK#M5$^NN<*4'-6L%=$S
MU5.F"U,T%K2[.#)\076VC6!TOS*$9JBM=:O5M-(W*T0RG3O%=: CJ!HRX_;F
M&HF![6@Z]5GU^%,R-K23[<%Y2TU%*)99%1K#LLQT)!>90HK8I2Y"-W%ON ?M
M=$*6:/1K1M-)(:Y"K])Y,EPNW.M<V>\=36 -F<C!?*M*'])P]IH=.G]&<=)W
M>P.:2&!9KR'NSRL0@KZCX$AAD^)Z:B4>X!UM0AA+06734YV-5%MQ P,YZG>6
MY*!VO'6INHN8NE=29W+!<=SR?A-,%$'((B"[S<VM-%/@W!-7-O1)O:F@$FUB
MN)Z:9NX-4[AXSYY((NI+%W130R+J+$#.*)>:+#YL\@290!!!_0!T5PM;;5Q*
MX;Z@7'7DPUHQGY+K6:&Z2$+IVFM'SVDIJ [O\YNDDZYK\PUJX!@&]J^0[] 7
MFTO-)G!=#X<&^*??ZAVQE=PPR\0K&[*2  O''TG5RZ'6\R&LE!M2P#7I]%B0
M1#*+*JI[W)PDW-2'Y(JY^H3G79V;PZ3FLV37@A-[-H>K W)G&9K:CCRH35%L
M\X:S\8'RSMWB_DXPG _ 'K)!FLXCEE)1<6["A-S$.D&^<Z-)8O@@BLV'H3!#
MERKS-4MV6<V:\7F*3ZHLM7_$W'N<I8;>DC9$H7]C(H"%:1M!0/,.H77E6.M5
MB6VK DT1?EOA#X!!\7^"]D+*[M!_>SXY/?ZY;:Z@@LKT4A.\A"U??U@5*;TB
MR(=;$N,_*^=##^+;]/JKDKQ[AIC.0*Y@&[!KN/J3=B/J*Z=@?$]:-Z.3B\+T
MK8V/T+O0JGO'&\85JE=TEMQ_ (@KH+X%3S>9D*-6K>Z%7B+J7H;'0.XXBNS>
MVK0W(O0'8=PK>K&5ZV);>B":'?P?489:GA?3H]/14=<Q<'CCC# ?';>-!0#8
MDE(H;I.Q=/2Z/^D^8/W;&^Y=0VM%5\Z86%^_,>NJPDG?G#Y!WPEH-C0BX.-Z
MW]*@0.)8/MI[IS2L>_Q^%UM?N7<YO0, P=K6$ZJ,H4A/1Q2LB6ERHXF-AUH0
MEA'2HVL:ZB*^-E46BU1RVZP*,1F=/"H[B&%=2.M=>8XSN1?0.5TI9UOAC%:C
MLL0 =48VI]9<@G[OMGNBW9O0?06N ZU3=Z>!W-/:M;WE#D%0T%9\?81^BKPR
MK .G%S?DJQ#-W)12*T$7T7SXP+N T8X8VF<RFI\$FF':K,M(#%LVS?0='SYB
MT9XK'AS)B7V<6$G4P*HK:4SBO0ZN;L[Z%V!\B=B[[!J)ZSH(J%50P9%P )?O
M?:&]SS4QRG)A//<@=0O"Q="'5&MZD/UUI;MJ;1N0>PT0^HT%F+HN4]OIPY%8
MTSD.8&0<DMVCHZ%XI+X]:<J7ZJ[5N_L]/G3W+OCVTG0HT;3[:-]W@W'O(TZN
MT#V\XUM"+BGA>TX[VGX-NPP?@;KIX5/:YSK!,I5@*>7I0-CP>2K\\*;D3T(+
MXZ$</Z:@%V5I MXGQOCF!VW0?B.\^"]02P,$%     @ K86G6A8Z'L'$!@
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M<*T*JBPB24YZS,CG./1(M:>)@W^22DJ.X12<Z=#X<MD70'5J >TP@E@EJIC
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M:6B!.^)]:?NVO6T>QTO6Y?)X58U);(8^+G(UQ=:=_MO]7AQ<FX=@2[YRG=@
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M&T,ON5A0?B)1HU"A*;M]86600=6D&JTD-/,)/ZCM?>'$;IB1H MK/$\ U\\
M4<_8"&T/"M?:05- S(ET0?GMU)-&)Y.,"KNJ0GM9T"#7HVI/#3U:!KM/=Q\K
M_'1,TIR(56/*CAW5TZ6"5@HTT!TBT/S8066R)##T/B!H^+5%T]&O:@##VI,X
M;132&+H=+U4%21R89(;#&O*'7HHT>[Y>J#6T9/3G9"8)N>9!+]UPG!!(K;L@
MR4Q#H4WV0B A5/,S-$$]^*-OT0@5<@,BFKNZ@X%!'BLA":U1<A$-;@CY//N+
MBD2@07Z# -"I-E7.KBI-R\U5Y;LI4#&%SMD8O@/0OMMQ+)_U7M.5'TN]'$QV
M91 '6R+)W:TEP0!DP-?<^XLV=2$9RB*[H*$*L&,U) W'LP:$S3N[#4IEW>*E
M)4"\!DQA%!YL4]\ +E;YWK8RK@]4M@A<<4[ULC0D\=Z\(55!O*N0>SS7)W.C
M: ZGPS0>P)*JM+X%W>^S*GAB8&P,E&W96S/8D$GXN/'5 <-/]10 R%"/::'/
MT.32XH%:J9T]>9Y_-G]X\M3JF(H S>\%!T[]D%M!<B>_A::*80+^-91(A)7$
MF(24-L2"O8 !&Z4>S:J(=>JMNE'S0'.WIWY=#Y4\[D*730;<!Q&D90!:'W-]
M&_B]2,9)E"QB/$WB*(YG]&J11N/17+S7#4U'NPCH0R=>C*-1FHKQ*)KAR(>R
M+LR#(L^5M,-;*HFC=+H0$_P[%>\"/H@DFHP78KQ(2>.OBNG&T70V@MX+<8TJ
M"H!E"Q][VYYT;,5Q/#H1XPGDNM>^51W$WH^O9%F_OA(I))J+^4A\8M@)S@RA
M=RQ/P(PVQ+/Y8Z"_\8[\'BM1,A[C 2HF"S)''"6S% 9\% > G5 -C >W"]![
ME@C'2S"<1'$ZQ6AW (7!;#9+Q-4?@&+&5YAQ-(XATQ"$_4HZBKD])H#N33<9
MI[N77=&8SN.38*:P#]V*<F(Z$C^]%.+?B^/Y8G$B_OGX/[;L#[ $5[+GR11Y
M+-GC$DJ0-36* 4[L$]3L8NX"5(F.KH#8W0!&]@G3&+S8=YB#868PB1B>SM'O
MF)7;RG %@!*4TX_(ZQ<:%FTSM'GHXZAM4EUT]^%/7MWC[%Z#MMIAZFX$"]/F
M1M>#LDAM>",+_9L:EL!56V7=0-W69,S@W*Y7ZX?0FR^AU+XPK99=DCUJ7L.X
MD(4F8U<2AH7X=(N>F(SY+Z  IR/L*TD5>_*G\#,$U'\40<?_/01-TR2*YU-"
MC&FTF,_IU6P182P]@*#)=!S-@5(ICBQ>1- YL',"!!VGHR&"ILE43$:S 8("
MPX&>29H\0M N^Q<+,!J-#@/G.$K3F8B3^ !RSA=32)Z^@)S)#'9(27T 'IMA
M!%'C/X&<LV@R_7WDG(Z3O4BX@! _[6U#(>%T,A(WSWI18-_X.7J.I\ES](QG
M:8>>W2Q"X'D<1Z/)[*2SRGX,!?OYXG\:0\_^#Z(G_?1+,P'?@1&2]L@2;B4P
M![WW4<T-,.->Z7%/[>L<B3T!(%]CTI4U<]A"X#40I&%[AF[ZE[.[LZB[..T&
MY:<W= 4F@=."YQ6:EAT9@.Y.@VL&I)C2#2!;/IYA^^L50J_N@GBG)YVB3V5(
ME$P]N@UFL9"G-MSN$%&F[[GSY&"YR:=!CR^T_)!7F4[Q4(6PL42Q0E4A-&!X
M)WV?Z7;VY%,%W87X::S+N)[N4KFM4OLK7U?&_KBWGDS]!@QH-E-T:PZYNYN_
MB#"SFUH'MQ:D3,^]M3S!DD+#L?$U)GW$)8VWQ4,4[N"?[:)KC!Y=O!! WUK2
M]9:A>W2; 4,I*DE@HMCR!;&H43\SNGP-<;1K \* ;:6_LW \/>X^2<#//QOD
M:])?T=WY+[)$Z4ZO*PW,D1#G:L?L-C#;??&Q9A!GPUEY2?=BI?P7S<K=[>Z9
MN%-J.%!V,J3BM$]**EOK*ERV>S9AT!3/@V%PD;SOT]OYX(LH!%CS=U^Z5H ^
M_N-H_[;_M'SEOZCNMOOOT@B@-0 <@+7"T='9;'(D&O^MU_]PIN;OJTOCH"T_
M;A@U:0/65P::AA_$H/_@?OEO4$L#!!0    ( *V%IUH8^K?;'04  (@+   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;(5676_;-A3]*X0+]"F-'2=9
MBS8QD*3M%J!-@Z;;'H8]T-25Q98B59*2XW^_<TE)D8LD>[%%\GZ<>^X'>;9U
M_D>HB**XKXT-Y[,JQN;M?!Y41;4,AZXABY/2^5I&+/UF'AI/LDA*M9DO%XO?
MYK74=K8Z2WNW?G7FVFBTI5LO0EO7TN\NR;CM^>QH-FQ\U9LJ\L9\==;(#=U1
M_+.Y]5C-1RN%KLD&[:SP5)[/+H[>7IZP?!+X2],V3+X%1[)V[@<OKHOSV8(!
MD2$5V8+$7T=79 P; HR?O<W9Z)(5I]^#]8\I=L2REH&NG/E;%[$ZG[V9B8)*
MV9KXU6W_H#Z>4[:GG GI5VRS[.ER)E0;HJM[92"HM<W_\K[G8:+P9O&$PK)7
M6";<V5%"^5Y&N3KS;BL\2\,:?Z10DS; :<M)N8L>IQIZ<77UY>;;]<WO'VZN
MKC_<G<TC3/+!7/7JEUE]^83ZL?CL;*R"^& +*O;UYX RXED.>"Z7SQK\+/VA
M.#XZ$,O%\O09>\=C?,?)WO%3\;FZUA%5%(.0MA!7@*OMAJS2%,1['91QH?4D
M_KE8A^A1)/\^QD)V<O*X$VZ<MZ&1BLYGZ(Q OJ/9ZN6+H]\6[YX)X60,X>0Y
MZ_^?HF?5'P>W9U-\HHTTXM8[152 G2 ^>E>+B.X3T:7_ Q$K GMU(^U.Z""T
M[9SIJ,"'Z*37K@W"Z*@WDKOM0"@C=1T.6(["L(TU)\'!EA?-Q%^L9!2P$HCM
ML2OG<8(Q(91K/;9=*31RN&X#X@OA4'RK$,R>D<9K#!9M=I@61L:$G>K&N!W1
MJ[Q5H'=B)-][U%:9MF"?A>YTT8(%QH>F2E.CHS$,^"GA%C% QFBYU@AV!U;D
M?8ZID3L/-0CRH%&4$8Z,@0.Y-AJ-&D2?A2"V%6$N=5(;G#&*/&1Y6C$B!< #
M-0)E&IAW %DG:78JH5Z[UD;0);Q$73-/253A;$WP)0,PKTV" '[ P<"=# $A
M];V!%FC(,P"0!(\&BE'\;*4'7=!.[B#$(Q 9S$F:(GZ( [37TF*DLVFVQ:*I
MF-A(7S@BZ(W5)8*$S$3\>UMLT@>L% 3?&'J4+.3($^_)T!C/R$$I&A>AJSE'
MCJ-#_940WAV*RRGNQSE7*%!=D,]%S=7FJ>-K8+_X9?$=<SDD@4SU.%-PJ)1'
M&>5APQ+%.&*P%Q#I+J?E9ZL]I^)"12X[W)?*U9!!(C/T)%KHLD2K<)@>42$/
M9>K,RB%_#P2L=WL(7[YXLSQZ_4X 6NM]2L)#J@_ZJ@?B/1X 45K%T)3KX(W)
MVU9:5;A76X-@8%O%)_QP>^C89P=!%;  A 5UN/:;7&+@E.YU8*HFDZ+OL!1W
M&D/3CLZUP@I3MQ"UN.Y[1970]81.*XF[?^@ZUD'8W TT=3ZV(LZA0RP%O=:6
MLG,^,1,H1D,Y!$@%*(9R-]9I$"@@43M+D:=5(6OXSYNY+/O ,1$"5^B0D<'S
M0'(.0V;BN-^0^"?I+C$:<8.!+9C!^^.78;,FHZD;9D>:IKF\&$!BL(U@QJ8:
M^*6$=:Y3".(J!J[A+L:[!-/-NB@JB>Z58TT.F 5EQ,[N#>J#"5AX*72^'GK<
M[ </3#_<#F!-2:2KQ&,10=U)0[F5OJ0KXR[R6+]Q]M6U3?%\D_?B4S^-&?EC
MU^U\\CJJR6_2&S#5C8WYH33NCL_,B_RZ>A#/;U10LD&GH%)+J"X.7Y_.A,_O
MOKR(KDEOK;6+>+FESPI/9?(L@//284#U"W8P/KY7_P%02P,$%     @ K86G
M6HB)-.<Y!0  A@P  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&ULM5?;
M<MLV$/T5C')Y4JB;%6<26S.^=9K.I/$D[F6FTP>07(I(0( !P$CJU_<L(-%2
M(CM]Z8-M7G;/GCU[(7RVLNZSKXF"6#?:^/-!'4+[>C3R14V-])EMR>!-95TC
M V[=<N1;1[*,3HT>3<?CEZ-&*C-8G,5GMVYQ9KN@E:%;)WS7--)M+DG;U?E@
M,M@]^*"6=> 'H\59*Y?TD<)O[:W#W:A'*55#QBMKA*/J?' Q>7UYPO;1X'=%
M*[]W+3B3W-K/?/.V/!^,F1!I*@(C2/SY2E>D-0.!QI<MYJ /R8[[USOTGV+N
MR"67GJZL_D.5H3X?O!J(DBK9Z?#!KGZF;3YSQBNL]O&W6"7;V6P@BLX'VVR=
MP:!1)OV5ZZT.>PZOQ@\X3+<.T\@[!8HLKV60BS-G5\*Q-=#X(J8:O4%.&2[*
MQ^#P5L$O+-[^>O7^W8VXN_CSYN/9* "1GX^*K?=E\IX^X#T3[ZP)M1<WIJ3R
MT'\$)CV=Z8[.Y?11P'?296(V&8KI>#I_!&_6IS>+>+.'TC.%;4C<R;6X5K[0
MUG>.Q%\7N0\.#?'WL903XLEQ1!Z2U[Z5!9T/, 6>W%<:+)X_F;P<OWF$[TG/
M]^0Q]!^6X[]["S2M"#7AQQ&]:+A.HB6G;.D%<;D$Q"[J7FTA3<D7)\/H=F6;
M5IJ-**0N.BT#[%6 9U51'"01H*G#<T$^*(R',LMH(8WII#YBF(F[>]SG3UY-
M)Z=OC@)6^\Q%DSKL4<IB);TXF6?S9^G1:39^-L3.\&W"UINA4*;07<DL&5N!
M11&$K42)OG"$L"I0XS-QL][9';XYD.5_H#]_F4T2_=GW])-VWP?S?;1*.1_$
METZZ0,YS8M^$(#1^ZU II_1FFS\HY1M144D.)6-;'S@%P)-/,2$;EKWGBQCG
M2,+,_A[94>J68(7$?KSWYM7,<#R0T2B"6&$L:],!--=]%2YB"H=Z'39F+4LA
MV];9-7<?-!)/)^-LBB6I->][N'?&46&71OW#?$ W)T,5-VEJ!NYI& +5,8L7
M1><<F2"TDKG2*BA"U9].)MEDASH4AE+74$4P+I-40[&J%9BN;*?+76\]H):J
MQ#VK3%QW;M>3/VR8[P5@-KL*1<6>CK-9+P'$Y61W:6U(ND<TV2O<T8Y C>U7
MQ5]CGI(^L5\DYMUM1.*([=$P.670AD;REQ<XGY"D+U7\$'O61Q,^[#$8$KH%
M73"[6UGA.HT\E/==:DU^_=XM)>A&K-CN-X4UME$%E'B!TXE+;YCK-6%8;,O8
MF7AKQ!*Y(8^A /X2TN)3K7I2,%)A(Y;.=JW'9Q?[$<#>:E5&'1S 3!=;E]8%
M^:COZ7S<RWO3.<NM)"1:!A5 R9$"C)@U/@X%Q352V<Y%[5&)V!\YX0R4?R+N
M$1N-#4XOV]3--V)%7M(<ZZ2<CU08_"H0&=[M1<S[;G][I])C.))0*8(UQ%1,
M<*PPV->88%G:]J&*#$7>!>'K2+_ALR);>5D17%V.FD2SP]BE131C ]1K:3L/
M,<AV.H^6'C5GWWT-F'$:+Q6.)00-:PE=I. ]X!1*N]ON)O9_A9J;@I_'7N;N
MV%)E*5-EIN/)E ?0=LLZ+4Q'?*;E,'&0:"V;;>\PR8)<X-= X!H?U@SFB?#^
MN"I_4'6Y'FXW#RI@>KS(T-^G''7&LP[UAF9:-2K(%(6+EG/E:1WBMLB.'4!&
M>V?#AC %? +VJ?SIF-@_[0_9%^EL>6^>3NA81DN%P)HJN(ZST_E N'3J33?!
MMO&DF=N <VN\K/&/ CDVP/O*VK"[X0#]OQZ+?P%02P,$%     @ K86G6H!F
M&C8F!   =0H  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULK5;O;]LV
M$/U7"'7HI\QV;*<-4MN \V-8@:8+'&_#,.P#+9TM(A2IDI0=__=[1\F*G3E!
M6NR++5)W[][=O:,XVECWX'.B(!X+;?PXR4,H+[I=G^942-^Q)1F\65I7R("E
M6W5]Z4AFT:G0W7ZO]Z%;2&62R2CNW;G)R%9!*T-W3OBJ**3;7I*VFW%RFNPV
M9FJ5!][H3D:E7-$]A=_+.X=5MT7)5$'&*VN$H^4XF9Y>7 [9/AK\H6CC]YX%
M9[*P]H$7G[-QTF-"I"D-C"#QMZ8KTIJ!0.-;@YFT(=EQ_WF'_DO,';DLI*<K
MJ_]46<C'R7DB,EK*2H>9W?Q*33YGC)=:[>.OV-2V QBGE0^V:)S!H%"F_I>/
M31WV',Y[+SCT&X=^Y%T'BBRO99"3D;,;X=@::/P04XW>(*<,-^4^.+Q5\ N3
MV<V7Z?SF6MQ-9_._Q'PV_7H_O9I__NWK_:@;@,]6W;3!NJRQ^B]@#<2M-2'W
MXL9DE!WZ=\&K)=??D;OLOPIX*UU'#$Y/1+_7/WL%;] F.XAX@Y>2)2T#9>).
MNK 5<R>-EU$<7OP]7?C@L/KG6-XU[/ X+,_-A2]E2N,$@^')K2F9O']W^J'W
MZ172PY;T\#7T[^S0CV*)>4[BRA:E-%N12R_(!'*HE3+!"HGQ<2C7BC"/0> L
M$)E:J2 UM.@>*"BS$IRX2LF+TMFU@@+$8BND6"I7B)#+()3'&-<=8$R1D@LX
M-D1!Q8*<L$N8/9%X_^Z\?_KQD_#BTDJ7\>MKY3#,UOD3L<DMXTF>">L4VNES
MZ2BW.@,40!DJAG["*6$ ]FD30)JL@3B(_\SJ-1H=<2N-;(JR(*UHC?1CKHR$
M A9^![M?/T00]*U2:ZEYB6*$W'J$=K262G,QD4$L^A[_GV&\"KD(3[J-.>1R
M38A.6)5<^KKP''-:92IP00L5 M'W5!B&SE:K_ 6'71_+.$D'C"('" -_$ -J
MQ,KZKUIB;XI8/NZ!5N (0%/M>K%S*:N%5CC@P"E%<HZ=U](I6_F6V ($,A]U
MB7;R(:2W#7@M6**.N*ZB;^Q,[E".HCZMB$\K=-*E>7O8Q,+B87AR4 !ETLKQ
M5* W"E\Q=%B!HBQLA2CH&3WB:^DYH]B8YX:EW,J%1K>DEB:%*,*QN->4UHIL
M=H>=@^ELQLL_#1P$A"Q54#OUL<#D<@DIQ2YM%&1S.&W^F1B:UOZ REL6&YP7
M:)')JI2#0@OU /PO2N^(&<*:BO:/$(0'5M@_QS<XNG[J=WHX%[1F/;(FWM[R
MHWU]*P3Z-$U3=N$!20E9<[,SD%XZ6S1TVTXQU:/QWJJ*8Q^7[MY5H""WBA<>
MGAP U[>"=K>]4TWKJ\23>7TA X>50DDU+>':ZWP\2X2K+SGU(M@R7BP6-N":
M$A]SW O)L0'>+ZT-NP4':&^:DW\!4$L#!!0    ( *V%IUJ$>^"Z2@(  )\%
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;*U4;6_:,!#^*U963:VT
MXI $MK(D4H%5J[1.J*S;9Y,<Q&IB9[9#VG\_OX2,=H"F:5^([WS/<_<<OHM;
M+AYE :#04U4RF7B%4O4$8YD54!$YX#4P?;/FHB)*FV*#92V Y!94E3CP_3&N
M"&5>&EO?0J0Q;U1)&2P$DDU5$?$\A9*WB3?T=HY[NBF4<> TKLD&EJ >ZH70
M%NY9<EH!DY0S)&"=>-?#R2PR\3;@.X56[IV14;+B_-$8MWGB^:8@*"%3AH'H
MSQ9F4):&2)?QL^/T^I0&N'_>L=]8[5K+BDB8\?('S561>!\\E,.:-*6ZY^UG
MZ/2,#%_&2VE_4>MB1R,/98U4O.K NH**,O<E3UT?]@##8X"@ P2O =$10-@!
M0BO4569ES8DB:2QXBX2)UFSF8'MCT5H-9>9?7"JA;ZG&J71!GM%6H@4(^R)8
M!FA.959RV0A E^AA.4?G9Q?H#%&&OA6\D83E,L9*YS8,..OR3%V>X$B>$-UQ
MI@J)/K$<\I=XK&ON"P]VA4^#DX1W1 Q0.'R' C\8':AG]O?PZ$0Y8=_'T/*%
M_]+'0^UR=-%A.C.[$UF3#!)/#Z<$L04O??MF./8_'M+ZG\A>*(]ZY=$I]O2K
M7C6W+.,5H/,O7,J+0VH=Q=A2F,6R32^C*S_&VWT5?P8%XZN@#W+5X;VW7H'8
MV!4@4<8;IMSKZ;UNRTSUEK'3^,JOM\^U'3K\F\:M+OTV-I1)5,):4_J#]WIV
MA5L'SE"\MA.UXDK/IST6>H.", 'Z?LVYVADF0;^3TU]02P,$%     @ K86G
M6A.MA^M$ @  B@8  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULG95=
M;YLP%$#_BL6D/;6%0#ZV#)"2;M/RT"E*N^W9P1>P:FQFF]#^^]F&L&Q*J)27
M8)M[C\]UY$O<"OFL2@"-7BK&5>*56M=+WU=9"156=Z(&;M[D0E98FZDL?%5+
MP,0E5<P/@V#N5YAR+XW=VE:FL6@THQRV$JFFJK!\70,3;>)-O./"CA:EM@M^
M&M>X@$?0/^JM-#-_H!!: 5=4<"0A3[S59+E>V'@7\)-"JT[&R%:R%^+93C8D
M\0(K! PR;0G8/ YP#XQ9D-'XW3.]84N;>#H^TK^ZVDTM>ZS@7K!?E.@R\3YX
MB$".&Z9WHOT&?3TSR\L$4^X7M5UL]-%#6:.TJ/ID8U!1WCWQ2W\.)PF&<SXA
M[!-"Y]UMY"P_8XW36(H621MM:';@2G791HYR^Z<\:FG>4I.GTXTY7@(2/4E,
M*"_02DK,"S#'KE7L:[.#C?.SGK;N:.$%6H0>!->E0E\X ?)OOF_,!KWPJ+<.
M1X$/6-ZA:'*#PB"<C?"BH=S(\:(+O'-EWJ#]*]IP0@^4-)B=J[J#3L]#[;U9
MJAIGD'CF8BB0!_#2]^\F\^#3B/)T4)Z.T=-=PP!-@OWL=G*JC59$U/K_0^YT
MQX$Y9@I&Q&:#V&R4\UWPVRODQJ%OR<T'N?E5I_8$TMPB?,%MG/F6VV)P6UQ]
M<.-^X]R+?OY)?ZA %JX+*I2)ANNN50RK0Z-==?WE;WC7I<V%+"A7B$%N4H.[
MA?D[9=?YNHD6M>LV>Z%-[W+#TGPL0-H \SX70A\G=H/A\Y/^ 5!+ P04
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M=T/%'Y7=0.LK*<UA8 GJWXGAOU!+ P04    " "MA:=:O';O@%D#  !G!P
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M=MI75%BJF)B*C9&9FU+6TM#,XY8Q#9FHK #=;R151;FQ!JJQ=?H/4$L#!!0
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MN(*PZ\:A3T(0NGXP(*$3NK'?>;/5<0=1;+<B-^['<%.W*O%76-20.N=;#7%
MY_LVJ$$OHKC<N!NU2M_MASV+U"/L)TJ=^CE1+@B*[PKZ ]?O]DF(8]?W0TLE
M(DW\9BMP>_V@81GTNR?"%]*<3\%2L0Q!L!+)*Z<.77/!#7XHZ-G,++P[\/WV
M>Z%2X[92X_]=J7-M>%G?9R)$Q0I(CKC!_)6&D,9317O1Q>FB3;3U^+8 7<"6
MP;HRML590^0X28 -$=@Q33G=ESI5\YD"_!.9JE\[VPU')3YLBOX*NFY$Y42+
M+O3<B"Z/Q!YI.X..%?L0N;U&')#8\7M '4?#=VT(ARJ!JJFMA%,WXAU-!JK.
M33W_-*26;#,D6FT[8I-FLOPXWLQGRM>&"PT%KLG4O^Y1YE4S\YJ%D=MZSJRD
MH5:HQ9S^)J"R!VA_+:4Y+*R#]H_'Y#]02P,$%     @ K86G6ART*QNS @
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M4J=@<'[9N.H,KT->[Q=\E[BV.VW@2&9:_^3.;7S9:+-#J#!RC"#HL\()*L5
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M"*-]O$\A%G$VGN.\;%02CIFN0;-^ HV@T2[1,ZR&7V%8P%L5<II%VILI7_,
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M@WN!Y+(HL/@U!,K7?<=S7A?&9#979L&->PL\@PFHQ\6]T#.W9LE( 4P2SI"
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MBW3L#$%?EN/<%N.@"^.8X($F8L/!+ E(T,S7TYJKPM&Q\%LD!7S [ :8\!>
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M^BHI4 36H  :]1^PH4:5)<ZIWCS;AF>B[(CR70B[-0E/; *45OFX8YR 21*
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MO<QQ3(\3"UJO!9_)-A*JP)Z.=VB+5U@\[1Z9O+-+RIHD..6$IH#AS<2:P?L
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M,+7X'*:>!^'8/IP[7J_4[PU&9:6*D[W2R9[6R8^$X:==DUE:75NS3,)\D[#
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M0,AB2-OTL+#@FZVQ"UX89&P#$9CG;*[0\VJ6%4\@U5RF1,%Z2&_;@U''QKN
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M^3[L &J-=P!N#G#_%U#/ ?74:*8LM35 "GE=P;<@3+1F,XUT;U*T=D.8.<5
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MF&!P.Z9$MR/4&JAJWX4KA;:G_;:PKPYH%V#/-TKAP7"-W;]CZ5]02P,$%
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M_]W0RZLMM=],U?/^^WQ%(W;141-[SL2&=28__6 /K9^;W(*$N4B8AX3Y2%B
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MBSC0N@B4YD)I'I3F0VD!E!:B:'4K5G41QUP7:;DD(]/PUR6M=HGZ@2496NB
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M7C?"HJOJCJHF1N;E,;^0!B^-<KC&:QV4#<#W2RG-T\3>',T?A?@W4$L#!!0
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M(O;W(O9-Z-.E9-&]RM2;+8_62B*D?F?J5B8\UZ]-%2-@5U4*L$$.I@>CA^G
M&PS'UD.=;<@:0R"P!MO^GFV_&]OD,4K4A\2/;4P;P;HR[1\Q[0P.>(:L+P0"
M:_ \V/,\,/)\0Q6FY$DD5<XI!Q5VAR*692H_B5P%-=L14KWM"5VADZ+,^S81
MBIK\&F^>VS\?C(9>D[VYL4E=$PPD6 @$UI#B?"_%N5&*!>'YN$\CE5ND&O5I
M/@!L"(_4IYI#MG%>0(YJG-MGY[Y_0+BQXJZ$0X*%0& -PH=[PH=&PK]D-+G=
M"K1(,6WCUAC=-:E @@608"$06$."T5Z"T1O/C$:0(D*"!9!@(1!80T3'KBR-
M;1ZMBX&CA(Z1RF/%8%)*MBDD$\;APUQ'5ZE T8(2K3ZVN7U;_S4S;0A5;5.(
MFK=TC$)<5X-Y,8.:J4EJ?6 IE&JEWXC<F7Y(M  4+81":VKD5AJY;YSSR@9
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M$2UN)-OD9R!OF90LRR_7!*LQ5A=0W]\Q)I]O= 7[@[K3_P%02P,$%     @
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MZ4-A#/3W.>=J.S$!JC8R^@E02P,$%     @ K86G6I:<ND*1!P  DRH  !D
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M4K"\;2P1Y&G1_$^^M8'8:R#]F!N@M@$:-B"6!KAM@.N.-LCJ;ETE(IF=<?8
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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MD56CR*I19-4HLFH46?5_ROID[?JO?[+H[WEKZNX]GPU_LER] E!+ 0(4 Q0
M   ( *V%IUI&QTU(E0   ,T    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ K86G6GPE,ESR    *P(  !$
M     ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ K86G6IE<
MG",0!@  G"<  !,              ( !Y $  'AL+W1H96UE+W1H96UE,2YX
M;6Q02P$"% ,4    " "MA:=:H%)%K>4%  #>'@  &               @($E
M"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ K86G6B09
MXF>]!@  @AT  !@              ("!0 X  'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;%!+ 0(4 Q0    ( *V%IUJ!6'?/G0(  /X%   8
M  " @3,5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "M
MA:=:+ 2%+',&  !)&@  &               @($&&   >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ K86G6NB*$8U/!@  S"D  !@
M         ("!KQX  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( *V%IUJ*>932MP8  ! <   8              " @30E  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "MA:=:F"W)>(,'  "<$@
M&               @($A+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ K86G6AGC 32)#@  &R@  !@              ("!VC,  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( *V%IUIBL:U710,
M & '   8              " @9E"  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " "MA:=:0CJ\W[L%  !U#P  &0              @($4
M1@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( *V%IUJ:
M" K:O ,  #\)   9              " @09,  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ K86G6I*E*W#6 P  W D  !D
M     ("!^4\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *V%IUJQ^IZ1#0D  #88   9              "
M@?MT  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ K86G
M6C?8T5AL"P  ?!\  !D              ("!/WX  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " "MA:=:&/JWVQT%  "("P  &0
M        @('BB0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( *V%IUJ(B33G.04  (8,   9              " @3:/  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ K86G6H!F&C8F!   =0H
M !D              ("!II0  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " "MA:=:A'O@NDH"  "?!0  &0              @($#F0
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( *V%IUH3K8?K
M1 (  (H&   9              " @82;  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ K86G6GC=/I\*#P  82P  !D
M ("!_YT  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "M
MA:=:SUGQYI\#  !:"   &0              @(% K0  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *V%IUJ\=N^ 60,  &<'   9
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M970S,"YX;6Q02P$"% ,4    " "MA:=:O2Q<J> "  !N!@  &0
M    @('HQ   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M *V%IUI91 JN)@,  /4&   9              " @?_'  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ K86G6BQY6QB>!0  9 \  !D
M             ("!7,L  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " "MA:=:?15^>'0"   J!0  &0              @($QT0  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( *V%IUIW\).L= ,
M *,,   9              " @=S3  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ K86G6BTMN=D) P  W0<  !D              ("!
MA]<  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "MA:=:
M&ZA,C[P#   Z$   &0              @(''V@  >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( *V%IUI&?^AW? 0  "4;   9
M      " @;K>  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ K86G6@[)+\-A!   81P  !D              ("!;>,  'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "MA:=:9P/B!S "    !0
M&0              @($%Z   >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( *V%IUJKKC$;L ,  /<,   9              " @6SJ  !X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ K86G6A(_L@.J
M @  ] 8  !D              ("!4^X  'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " "MA:=: ;E\L-4#   J$   &0
M@($T\0  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( *V%
MIUHV!2DB"@,  +D)   9              " @4#U  !X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ K86G6N3>5,[2 @  ; H  !D
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M 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "MA:=:4\Y
MU.@"   T"   &0              @($+" $ >&PO=V]R:W-H965T<R]S:&5E
M=#0Y+GAM;%!+ 0(4 Q0    ( *V%IUI$':3O6@,  -(,   9
M  " @2H+ 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
MK86G6KW/0;T0 P  > @  !D              ("!NPX! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    " "MA:=:8H$W1-,"  !U"0  &0
M            @($"$@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( *V%IUJ59E C_0(  "4+   9              " @0P5 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ K86G6B<$G*Q?!@
MM"L  !D              ("!0!@! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    " "MA:=:@>)?;3D$  #Y$P  &0              @('6
M'@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( *V%IUJ7
MWL[2B@,  %(.   9              " @48C 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ K86G6I:<ND*1!P  DRH  !D
M     ("!!R<! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M" "MA:=:+G5(16(#  !2"P  &0              @('/+@$ >&PO=V]R:W-H
M965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( *V%IUIG/=L"UP(  'X(   9
M              " @6@R 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L!
M A0#%     @ K86G6D>UR:XT P  SA,   T              ( !=C4! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " "MA:=:EXJ[',     3 @  "P
M        @ '5. $ 7W)E;',O+G)E;'-02P$"% ,4    " "MA:=:GKC!41<%
M  #@)@  #P              @ &^.0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ K86G6EEV ?CU 0  .",  !H              ( ! C\! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ K86G6A?(S!O; 0
MT2(  !,              ( !+T$! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $, 0P!,$@  .T,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>121</ContextCount>
  <ElementCount>247</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>39</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATION</Role>
      <ShortName>ORGANIZATION AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/REVENUERECOGNITION</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - COMPREHENSIVE (LOSS) INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/COMPREHENSIVELOSSINCOME</Role>
      <ShortName>COMPREHENSIVE (LOSS) INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - EARNINGS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARE</Role>
      <ShortName>EARNINGS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS</Role>
      <ShortName>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - SEGMENT DATA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SEGMENTDATA</Role>
      <ShortName>SEGMENT DATA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/CONTINGENCIES</Role>
      <ShortName>CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - REVENUE RECOGNITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONTables</Role>
      <ShortName>REVENUE RECOGNITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/REVENUERECOGNITION</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - EARNINGS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARETables</Role>
      <ShortName>EARNINGS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARE</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables</Role>
      <ShortName>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/DEBT</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/LEASES</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - SEGMENT DATA (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SEGMENTDATATables</Role>
      <ShortName>SEGMENT DATA (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/SEGMENTDATA</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails</Role>
      <ShortName>ORGANIZATION AND BASIS OF PRESENTATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring (Benefits) Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring (Benefits) Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - REVENUE RECOGNITION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails</Role>
      <ShortName>REVENUE RECOGNITION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - ACQUISITIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails</Role>
      <ShortName>ACQUISITIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/ACQUISITIONS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - COMPREHENSIVE (LOSS) INCOME (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/COMPREHENSIVELOSSINCOMEDetails</Role>
      <ShortName>COMPREHENSIVE (LOSS) INCOME (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/COMPREHENSIVELOSSINCOME</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails</Role>
      <ShortName>EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - EARNINGS PER SHARE - Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesDetails</Role>
      <ShortName>EARNINGS PER SHARE - Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails</Role>
      <ShortName>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Estimated Annual Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails</Role>
      <ShortName>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Estimated Annual Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails</Role>
      <ShortName>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - DEBT - Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails</Role>
      <ShortName>DEBT - Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - DEBT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/DEBTNarrativeDetails</Role>
      <ShortName>DEBT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - DEBT - 2019 Asset-Based Loan Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails</Role>
      <ShortName>DEBT - 2019 Asset-Based Loan Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>LEASES - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - LEASES - Operating Lease Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails</Role>
      <ShortName>LEASES - Operating Lease Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - LEASES - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails</Role>
      <ShortName>LEASES - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - FAIR VALUE MEASUREMENTS - Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - SEGMENT DATA - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails</Role>
      <ShortName>SEGMENT DATA - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - SEGMENT DATA - Operating Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails</Role>
      <ShortName>SEGMENT DATA - Operating Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/INCOMETAXES</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ccrn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ccrn-20250331.htm">ccrn-20250331.htm</File>
    <File>ccrn-20250331.xsd</File>
    <File>ccrn-20250331_cal.xml</File>
    <File>ccrn-20250331_def.xml</File>
    <File>ccrn-20250331_lab.xml</File>
    <File>ccrn-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ccrn-20250331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="483">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>78
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ccrn-20250331.htm": {
   "nsprefix": "ccrn",
   "nsuri": "http://www.crosscountryhealthcare.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "ccrn-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "ccrn-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ccrn-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ccrn-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ccrn-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ccrn-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 220,
   "keyCustom": 27,
   "axisStandard": 22,
   "axisCustom": 1,
   "memberStandard": 22,
   "memberCustom": 16,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 2
   },
   "contextCount": 121,
   "entityCount": 1,
   "segmentCount": 39,
   "elementCount": 509,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 483,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.crosscountryhealthcare.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
     "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ccrn:ProvisionForDoubtfulAccountsAndOtherAllowances",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATION",
     "longName": "9952156 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION",
     "shortName": "ORGANIZATION AND BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952157 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITION",
     "longName": "9952158 - Disclosure - REVENUE RECOGNITION",
     "shortName": "REVENUE RECOGNITION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.crosscountryhealthcare.com/role/ACQUISITIONS",
     "longName": "9952159 - Disclosure - ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.crosscountryhealthcare.com/role/COMPREHENSIVELOSSINCOME",
     "longName": "9952160 - Disclosure - COMPREHENSIVE (LOSS) INCOME",
     "shortName": "COMPREHENSIVE (LOSS) INCOME",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARE",
     "longName": "9952161 - Disclosure - EARNINGS PER SHARE",
     "shortName": "EARNINGS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS",
     "longName": "9952162 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS",
     "shortName": "GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.crosscountryhealthcare.com/role/DEBT",
     "longName": "9952163 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.crosscountryhealthcare.com/role/LEASES",
     "longName": "9952164 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTS",
     "longName": "9952165 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITY",
     "longName": "9952166 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.crosscountryhealthcare.com/role/SEGMENTDATA",
     "longName": "9952167 - Disclosure - SEGMENT DATA",
     "shortName": "SEGMENT DATA",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.crosscountryhealthcare.com/role/CONTINGENCIES",
     "longName": "9952168 - Disclosure - CONTINGENCIES",
     "shortName": "CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.crosscountryhealthcare.com/role/INCOMETAXES",
     "longName": "9952169 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONS",
     "longName": "9952170 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONTables",
     "longName": "9955513 - Disclosure - REVENUE RECOGNITION (Tables)",
     "shortName": "REVENUE RECOGNITION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARETables",
     "longName": "9955514 - Disclosure - EARNINGS PER SHARE (Tables)",
     "shortName": "EARNINGS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables",
     "longName": "9955515 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)",
     "shortName": "GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.crosscountryhealthcare.com/role/DEBTTables",
     "longName": "9955516 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.crosscountryhealthcare.com/role/LEASESTables",
     "longName": "9955517 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ccrn:AssetsAndLiabilitiesLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ccrn:AssetsAndLiabilitiesLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSTables",
     "longName": "9955518 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9955519 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.crosscountryhealthcare.com/role/SEGMENTDATATables",
     "longName": "9955520 - Disclosure - SEGMENT DATA (Tables)",
     "shortName": "SEGMENT DATA (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails",
     "longName": "9955521 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION - Narrative (Details)",
     "shortName": "ORGANIZATION AND BASIS OF PRESENTATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-32",
      "name": "us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-32",
      "name": "us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
     "longName": "9955522 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:UnbilledContractsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:UnbilledContractsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails",
     "longName": "9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails",
     "longName": "9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring (Benefits) Costs (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring (Benefits) Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-35",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails",
     "longName": "9955525 - Disclosure - REVENUE RECOGNITION (Details)",
     "shortName": "REVENUE RECOGNITION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-43",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails",
     "longName": "9955526 - Disclosure - ACQUISITIONS (Details)",
     "shortName": "ACQUISITIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-57",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.crosscountryhealthcare.com/role/COMPREHENSIVELOSSINCOMEDetails",
     "longName": "9955527 - Disclosure - COMPREHENSIVE (LOSS) INCOME (Details)",
     "shortName": "COMPREHENSIVE (LOSS) INCOME (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails",
     "longName": "9955528 - Disclosure - EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details)",
     "shortName": "EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesDetails",
     "longName": "9955529 - Disclosure - EARNINGS PER SHARE - Anti-dilutive Securities (Details)",
     "shortName": "EARNINGS PER SHARE - Anti-dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-64",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-64",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails",
     "longName": "9955530 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details)",
     "shortName": "GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails",
     "longName": "9955531 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Estimated Annual Amortization Expense (Details)",
     "shortName": "GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Estimated Annual Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails",
     "longName": "9955532 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details)",
     "shortName": "GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-70",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
     "longName": "9955533 - Disclosure - DEBT - Long-term Debt (Details)",
     "shortName": "DEBT - Long-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.crosscountryhealthcare.com/role/DEBTNarrativeDetails",
     "longName": "9955534 - Disclosure - DEBT - Narrative (Details)",
     "shortName": "DEBT - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails",
     "longName": "9955535 - Disclosure - DEBT - 2019 Asset-Based Loan Agreement (Details)",
     "shortName": "DEBT - 2019 Asset-Based Loan Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-80",
      "name": "ccrn:LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-80",
      "name": "ccrn:LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails",
     "longName": "9955536 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details)",
     "shortName": "LEASES - Supplemental Balance Sheet Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ccrn:AssetsAndLiabilitiesLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ccrn:AssetsAndLiabilitiesLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails",
     "longName": "9955537 - Disclosure - LEASES - Operating Lease Maturity (Details)",
     "shortName": "LEASES - Operating Lease Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails",
     "longName": "9955538 - Disclosure - LEASES - Lease Costs (Details)",
     "shortName": "LEASES - Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "longName": "9955539 - Disclosure - FAIR VALUE MEASUREMENTS - Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-91",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-91",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
     "longName": "9955540 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
     "longName": "9955541 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails",
     "longName": "9955542 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-98",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-98",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails",
     "longName": "9955543 - Disclosure - SEGMENT DATA - Additional Information (Details)",
     "shortName": "SEGMENT DATA - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails",
     "longName": "9955544 - Disclosure - SEGMENT DATA - Operating Segments (Details)",
     "shortName": "SEGMENT DATA - Operating Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails",
     "longName": "9955545 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "longName": "9955546 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-120",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ccrn-20250331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r862"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Allowance for Doubtful Accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ccrn_AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery",
     "crdr": "debit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Write-Offs, net of Recoveries",
        "label": "Accounts Receivable, Allowance For Credit Loss, Writeoff, After Recovery",
        "documentation": "Accounts Receivable, Allowance For Credit Loss, Writeoff, After Recovery"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net of allowances of $9,792 in 2025 and $9,301 in 2024",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r125",
      "r537"
     ]
    },
    "ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/COMPREHENSIVELOSSINCOMEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on currency fluctuations",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Before Tax",
        "documentation": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r68",
      "r130",
      "r533",
      "r572",
      "r573"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss, net",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r9",
      "r16",
      "r418",
      "r421",
      "r473",
      "r568",
      "r569",
      "r836",
      "r837",
      "r838",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "ccrn_AcquisitionAndIntegrationRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "AcquisitionAndIntegrationRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition and integration-related costs",
        "label": "Acquisition And Integration-Related Costs",
        "documentation": "Acquisition and integration-related costs include costs for prior acquisitions, costs incurred for potential transactions, and accretion and valuation adjustments on contingent consideration liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r846",
      "r847",
      "r848",
      "r849",
      "r924",
      "r979"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r351"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r765",
      "r775",
      "r807"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r768",
      "r778",
      "r810"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r769",
      "r779",
      "r803",
      "r811",
      "r815",
      "r823"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r230",
      "r234",
      "r235",
      "r237",
      "r946"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, allowance for credit losses",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r230",
      "r234"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based awards (shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 10.0
      },
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment charges",
        "terseLabel": "Impairment charges",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r27"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r107",
      "r129",
      "r152",
      "r192",
      "r198",
      "r216",
      "r220",
      "r231",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r413",
      "r415",
      "r448",
      "r529",
      "r610",
      "r681",
      "r682",
      "r720",
      "r746",
      "r891",
      "r892",
      "r936"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_AssetsAndLiabilitiesLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "AssetsAndLiabilitiesLeasesTableTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Balance Sheet Information",
        "label": "Assets And Liabilities, Leases [Table Text Block]",
        "documentation": "Assets And Liabilities, Leases [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r134",
      "r152",
      "r231",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r413",
      "r415",
      "r448",
      "r720",
      "r891",
      "r892",
      "r936"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation asset",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r710"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ccrn_AyaHoldingsIIInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "AyaHoldingsIIInc.Member",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aya Holdings II Inc.",
        "label": "Aya Holdings II Inc. [Member]",
        "documentation": "Aya Holdings II Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BaseRateMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Accounting",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_BenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "BenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefits",
        "label": "Benefits Expense",
        "documentation": "Benefits Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r407",
      "r705",
      "r706"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r407",
      "r705",
      "r706"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Business Acquisition, Transaction Costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity consideration for acquisition (shares)",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity consideration for acquisition, value",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnout liabilities",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r93",
      "r410",
      "r429",
      "r430",
      "r431"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnout liability",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r93"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACQUISITIONS",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r408"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r124",
      "r671"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r78",
      "r149"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r78"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_CloudComputingNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "CloudComputingNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cloud computing",
        "label": "Cloud Computing, Noncurrent",
        "documentation": "Cloud Computing, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r100",
      "r531",
      "r597"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r281",
      "r282",
      "r656",
      "r880",
      "r886"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserved for share-based payments (shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r737",
      "r738",
      "r739",
      "r741",
      "r742",
      "r743",
      "r744",
      "r846",
      "r847",
      "r849",
      "r924",
      "r978",
      "r979"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (shares)",
        "periodEndLabel": "Ending balance (shares)",
        "terseLabel": "Unrestricted shares of common stock outstanding (shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r59",
      "r598",
      "r616",
      "r979",
      "r980"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r532",
      "r720"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive (loss) income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r136",
      "r138",
      "r143",
      "r525",
      "r542",
      "r543"
     ]
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/COMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMPREHENSIVE (LOSS) INCOME",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r142",
      "r524",
      "r541"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r105",
      "r156",
      "r192",
      "r200",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r681",
      "r682",
      "r891",
      "r892"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r105",
      "r156",
      "r192",
      "r200",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r681",
      "r682",
      "r891",
      "r892"
     ]
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]",
        "label": "Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]",
        "documentation": "Disclosure of information about effect of change in parent's ownership interest in subsidiary on equity attributable to parent. Excludes change from deconsolidation of subsidiary."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r43"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r673"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Reconciling Item, Corporate Nonsegment",
        "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r215",
      "r216",
      "r217",
      "r218",
      "r221",
      "r855"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Costs",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r83",
      "r84"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r889"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r889",
      "r890"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r878",
      "r879"
     ]
    },
    "us-gaap_DatabasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DatabasesMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Databases",
        "label": "Database Rights [Member]",
        "documentation": "Exclusive legal rights granted to the owner or licensee of collections of information stored in electronic form (such as on computer disks or files)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r878",
      "r879"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r151",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r287",
      "r288",
      "r300",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r316",
      "r323",
      "r324",
      "r326",
      "r456"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest margin percentage",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_DebtInstrumentBasisSpreadOnVariableRateAdjustment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "DebtInstrumentBasisSpreadOnVariableRateAdjustment",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread on variable rate, additional credit spread associated with SOFR",
        "label": "Debt Instrument, Basis Spread On Variable Rate, Adjustment",
        "documentation": "Debt Instrument, Basis Spread On Variable Rate, Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r99",
      "r327"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate percentage",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r328",
      "r456",
      "r457",
      "r718"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r718",
      "r842",
      "r931",
      "r932"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r31",
      "r32",
      "r46",
      "r88",
      "r89",
      "r156",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r718",
      "r842",
      "r931",
      "r932"
     ]
    },
    "ccrn_DeferredCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "DeferredCompensationMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Compensation",
        "label": "Deferred Compensation [Member]",
        "documentation": "Deferred Compensation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt Issuance Costs",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r930",
      "r931",
      "r932"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r116",
      "r844"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r192",
      "r203",
      "r220",
      "r681",
      "r682"
     ]
    },
    "us-gaap_DirectOperatingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DirectOperatingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct operating expenses",
        "label": "Direct Operating Costs",
        "documentation": "The aggregate direct operating costs incurred during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income per share attributable to common stockholders - Basic (in dollars per share)",
        "verboseLabel": "Net (loss) income per share attributable to common stockholders - Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r172",
      "r175",
      "r185",
      "r186",
      "r187",
      "r191",
      "r405",
      "r412",
      "r424",
      "r425",
      "r526",
      "r544",
      "r674"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income per share attributable to common stockholders - Diluted (in dollars per share)",
        "verboseLabel": "Net (loss) income per share attributable to common stockholders - Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r175",
      "r185",
      "r186",
      "r187",
      "r191",
      "r405",
      "r412",
      "r424",
      "r425",
      "r526",
      "r544",
      "r674"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EARNINGS PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r188",
      "r189",
      "r190"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r709"
     ]
    },
    "ccrn_EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective tax rate, excluding discrete items",
        "label": "Effective Income Tax Rate Reconciliation, Excluding Discrete Items, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Excluding Discrete Items, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Termination Costs",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r119",
      "r139",
      "r140",
      "r141",
      "r157",
      "r158",
      "r159",
      "r161",
      "r166",
      "r168",
      "r170",
      "r193",
      "r232",
      "r233",
      "r264",
      "r329",
      "r395",
      "r396",
      "r402",
      "r403",
      "r404",
      "r406",
      "r411",
      "r412",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r460",
      "r473",
      "r541",
      "r568",
      "r569",
      "r570",
      "r583",
      "r640"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r765",
      "r775",
      "r807"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ccrn_ExitCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "ExitCostsMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease-Related Exit Costs",
        "label": "Exit Costs [Member]",
        "documentation": "Exit Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r441",
      "r710"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r441",
      "r710"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442",
      "r712"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442",
      "r712"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r440",
      "r441",
      "r443",
      "r482",
      "r483",
      "r484",
      "r690",
      "r691",
      "r702",
      "r703",
      "r704",
      "r710",
      "r714"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r522",
      "r710",
      "r715"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r342",
      "r347",
      "r428",
      "r441",
      "r482",
      "r702",
      "r703",
      "r704",
      "r710"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation liability",
        "label": "Obligations, Fair Value Disclosure",
        "documentation": "Fair value of obligations measured on a recurring basis."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r926",
      "r928"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442"
     ]
    },
    "ccrn_FairValueMeasurementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "FairValueMeasurementLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement [Line Items]",
        "label": "Fair Value Measurement [Line Items]",
        "documentation": "Fair Value Measurement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_FairValueMeasurementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "FairValueMeasurementTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement [Table]",
        "label": "Fair Value Measurement [Table]",
        "documentation": "Fair Value Measurement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r440",
      "r441",
      "r443",
      "r482",
      "r483",
      "r484",
      "r690",
      "r691",
      "r702",
      "r703",
      "r704",
      "r710",
      "r714"
     ]
    },
    "ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Finite Lived And Indefinite Lived Intangible Assets [Line Items]",
        "documentation": "Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite Lived Intangible Asset, Expected Amortization, After Year Four",
        "documentation": "Finite Lived Intangible Asset, Expected Amortization, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r240",
      "r259",
      "r688"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r668",
      "r688"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r668",
      "r688"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r668",
      "r688"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r668",
      "r688"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r261",
      "r262",
      "r490",
      "r491",
      "r668"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r259",
      "r491",
      "r688"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r261",
      "r262",
      "r668"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails",
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r875"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets subject to amortization:",
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r769",
      "r779",
      "r811"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r769",
      "r779",
      "r811"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r769",
      "r779",
      "r811"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r769",
      "r779",
      "r811"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r769",
      "r779",
      "r811"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divisional corporate G&amp;A",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r620"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r241",
      "r523",
      "r682",
      "r687",
      "r711",
      "r720",
      "r867",
      "r868"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r869"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r687"
     ]
    },
    "ccrn_HireUpLeadershipIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "HireUpLeadershipIncMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HireUp",
        "label": "HireUp Leadership Inc [Member]",
        "documentation": "HireUp Leadership Inc"
       }
      }
     },
     "auth_ref": []
    },
    "country_IN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "IN",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INDIA",
        "label": "INDIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r102",
      "r106",
      "r527",
      "r539",
      "r676",
      "r681",
      "r852",
      "r854",
      "r856",
      "r857",
      "r858"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r272",
      "r275",
      "r433",
      "r437",
      "r442",
      "r565",
      "r567",
      "r625",
      "r668",
      "r713",
      "r948"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r275",
      "r433",
      "r437",
      "r442",
      "r565",
      "r567",
      "r625",
      "r668",
      "r713",
      "r948"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r383",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r394",
      "r397",
      "r399",
      "r400",
      "r401",
      "r579",
      "r709"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax (benefit) expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r117",
      "r169",
      "r170",
      "r192",
      "r206",
      "r220",
      "r386",
      "r387",
      "r398",
      "r545",
      "r709"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes receivable",
        "label": "Income Taxes Receivable, Current",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r835"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "documentation": "Increase (Decrease) In Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based awards (shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r187",
      "r353"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets not subject to amortization:",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedTradeNames": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedTradeNames",
     "crdr": "debit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade names, indefinite-lived",
        "label": "Indefinite-Lived Trade Names",
        "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trade name to gain or protect exclusive use thereof for a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r877"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r769",
      "r779",
      "r803",
      "r811",
      "r815",
      "r823"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r827"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r827"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r827"
     ]
    },
    "us-gaap_InsuranceSettlementsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InsuranceSettlementsReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance recovery receivable",
        "label": "Insurance Settlements Receivable, Current",
        "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_InsuranceSettlementsReceivableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InsuranceSettlementsReceivableNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance recovery receivable",
        "label": "Insurance Settlements Receivable, Noncurrent",
        "documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) of amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r875",
      "r877"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r840"
     ]
    },
    "us-gaap_IntersegmentEliminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntersegmentEliminationMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intersegment Eliminations",
        "label": "Intersegment Eliminations [Member]",
        "documentation": "Eliminating entries used in operating segment consolidation."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r192",
      "r200",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r681"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r201",
      "r220",
      "r681",
      "r839"
     ]
    },
    "ccrn_LaborAndRelatedExpenseExcludingBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "LaborAndRelatedExpenseExcludingBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation",
        "label": "Labor and Related Expense, Excluding Benefits Expense",
        "documentation": "Labor and Related Expense, Excluding Benefits Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Costs",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_LegalAndOtherLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "LegalAndOtherLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal and other losses",
        "label": "Legal And Other Losses",
        "documentation": "Legal And Other Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Maturity",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ccrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: amount of lease payments representing interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letters of credit outstanding",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r49",
      "r50",
      "r51",
      "r54",
      "r55",
      "r56",
      "r57",
      "r152",
      "r231",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r414",
      "r415",
      "r416",
      "r448",
      "r596",
      "r675",
      "r746",
      "r891",
      "r936",
      "r937"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r101",
      "r535",
      "r720",
      "r843",
      "r864",
      "r929"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r123",
      "r152",
      "r231",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r414",
      "r415",
      "r416",
      "r448",
      "r720",
      "r891",
      "r936",
      "r937"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued claims",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r735",
      "r944",
      "r949"
     ]
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax positions",
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit outstanding",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r99",
      "r945"
     ]
    },
    "ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of indebtedness permitted from other sources",
        "label": "Line Of Credit, Amount Of Indebtedness Permitted By Senior Secured Asset Based Loan To Be Borrowed From Other Sources",
        "documentation": "Line Of Credit, Amount Of Indebtedness Permitted By Senior Secured Asset Based Loan To Be Borrowed From Other Sources"
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_LineOfCreditBorrowingBasePercentageOfAccountsReceivable": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "LineOfCreditBorrowingBasePercentageOfAccountsReceivable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing base, percentage of accounts receivable",
        "label": "Line Of Credit, Borrowing Base, Percentage Of Accounts Receivable",
        "documentation": "Line Of Credit, Borrowing Base, Percentage Of Accounts Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_LineOfCreditFacilityBorrowingBaseAvailability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "LineOfCreditFacilityBorrowingBaseAvailability",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing base availability",
        "label": "Line Of Credit Facility, Borrowing Base Availability",
        "documentation": "Line Of Credit Facility, Borrowing Base Availability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit term",
        "label": "Line of Credit Facility, Expiration Period",
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Line Items]",
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r842",
      "r889"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r53"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing availability",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r53",
      "r288"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Table]",
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r53",
      "r288",
      "r842",
      "r889"
     ]
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quarterly commitment fee on the average daily unused portion percentage",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_LineOfCreditSublimitAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "LineOfCreditSublimitAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line Of Credit Sublimit [Axis]",
        "label": "Line Of Credit Sublimit [Axis]",
        "documentation": "Line Of Credit Sublimit [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_LineOfCreditSublimitDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "LineOfCreditSublimitDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line Of Credit Sublimit [Domain]",
        "label": "Line Of Credit Sublimit [Domain]",
        "documentation": "[Domain] for Line Of Credit Sublimit [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r881",
      "r882",
      "r883"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r30",
      "r881",
      "r882",
      "r883"
     ]
    },
    "us-gaap_MarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketing",
        "label": "Marketing Expense",
        "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r349",
      "r382",
      "r431",
      "r487",
      "r564",
      "r566",
      "r574",
      "r588",
      "r589",
      "r646",
      "r648",
      "r650",
      "r651",
      "r653",
      "r666",
      "r667",
      "r686",
      "r694",
      "r707",
      "r714",
      "r715",
      "r716",
      "r717",
      "r730",
      "r893",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r349",
      "r382",
      "r431",
      "r487",
      "r564",
      "r566",
      "r574",
      "r588",
      "r589",
      "r646",
      "r648",
      "r650",
      "r651",
      "r653",
      "r666",
      "r667",
      "r686",
      "r694",
      "r707",
      "r714",
      "r715",
      "r716",
      "r730",
      "r893",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "ccrn_MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mint",
        "label": "Mint Medical Physician Staffing, LP And Lotus Medical Staffing LLC [Member]",
        "documentation": "Mint Medical Physician Staffing, LP And Lotus Medical Staffing LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income attributable to common stockholders",
        "verboseLabel": "Net income (loss)",
        "netLabel": "Consolidated net (loss) income",
        "terseLabel": "Net Income (Loss)",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r80",
      "r103",
      "r121",
      "r135",
      "r137",
      "r141",
      "r152",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r169",
      "r170",
      "r183",
      "r231",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r405",
      "r412",
      "r425",
      "r448",
      "r540",
      "r618",
      "r638",
      "r639",
      "r745",
      "r891"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income attributable to common stockholders - Basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r162",
      "r163",
      "r164",
      "r165",
      "r172",
      "r173",
      "r184",
      "r187",
      "r412"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income attributable to common stockholders - Diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r174",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r187"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r769",
      "r779",
      "r803",
      "r811"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expenses (income):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r853"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r685",
      "r853"
     ]
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfStatesInWhichEntityOperates",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of states in which entity operates",
        "label": "Number of States in which Entity Operates",
        "documentation": "The number of states the entity operates in as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_NurseAndAlliedStaffingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "NurseAndAlliedStaffingMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Nurse And Allied Staffing",
        "label": "Nurse And Allied Staffing [Member]",
        "documentation": "Nurse and allied staffing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_OmnibusPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "OmnibusPlanMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Omnibus Plan",
        "label": "Omnibus Plan [Member]",
        "documentation": "Omnibus Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r676",
      "r852",
      "r854",
      "r856",
      "r857",
      "r858"
     ]
    },
    "ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Contribution Income",
        "label": "Operating Income Loss Before D And A Acquisition And Integration Restructuring Legal Impairment And Corporate Overheard",
        "documentation": "Operating Income Loss Before D And A Acquisition And Integration Restructuring Legal Impairment And Corporate Overheard"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r719"
     ]
    },
    "ccrn_OperatingLeaseExpenseNonCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "OperatingLeaseExpenseNonCash",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Operating Lease Expense, Non-Cash",
        "documentation": "Operating Lease Expense, Non-Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Present value of future minimum lease payments",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails",
      "http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities - current",
        "negatedLabel": "Less: operating lease liabilities - current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails",
      "http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities - non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r467"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r719"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r719"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r221",
      "r681",
      "r682"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r95",
      "r575",
      "r576"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r720"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized foreign currency translation gain (loss), net of tax",
        "verboseLabel": "Foreign currency translation adjustment, net of taxes",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r9",
      "r96"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r720"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other non-cash costs",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expense (income), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ccrn_OtherServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "OtherServicesMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Services",
        "label": "Other Services [Member]",
        "documentation": "Other Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r767",
      "r777",
      "r809"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r760",
      "r770",
      "r780",
      "r812"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r760",
      "r770",
      "r780",
      "r812"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of contingent consideration",
        "terseLabel": "Payment of contingent consideration",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Stock repurchase and retirement",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r841"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash paid for shares withheld for taxes",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash consideration, gross",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r409"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Stock Awards",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_PhysicianStaffingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "PhysicianStaffingMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Physician Staffing",
        "label": "Physician Staffing [Member]",
        "documentation": "Physician staffing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r238",
      "r239",
      "r672"
     ]
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Borrowings under Senior Secured Asset-Based revolving credit facility",
        "label": "Proceeds from Long-Term Lines of Credit",
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r489",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r669",
      "r695",
      "r729",
      "r730",
      "r732",
      "r735",
      "r736",
      "r887",
      "r888",
      "r896",
      "r947",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r489",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r669",
      "r695",
      "r729",
      "r730",
      "r732",
      "r735",
      "r736",
      "r887",
      "r888",
      "r896",
      "r947",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net of accumulated depreciation of $21,837 in 2025 and $19,285 in 2024",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r472",
      "r528",
      "r538",
      "r720"
     ]
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails",
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit loss expense",
        "verboseLabel": "Credit loss (income) expense",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r236"
     ]
    },
    "ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "ProvisionForDoubtfulAccountsAndOtherAllowances",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Provision for allowances",
        "label": "Provision For Doubtful Accounts And Other Allowances",
        "documentation": "Provision For Doubtful Accounts And Other Allowances"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r341",
      "r349",
      "r376",
      "r377",
      "r378",
      "r382",
      "r431",
      "r485",
      "r486",
      "r487",
      "r564",
      "r566",
      "r574",
      "r588",
      "r589",
      "r646",
      "r648",
      "r650",
      "r651",
      "r653",
      "r666",
      "r667",
      "r686",
      "r694",
      "r707",
      "r714",
      "r715",
      "r716",
      "r717",
      "r730",
      "r739",
      "r884",
      "r893",
      "r927",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r341",
      "r349",
      "r376",
      "r377",
      "r378",
      "r382",
      "r431",
      "r485",
      "r486",
      "r487",
      "r564",
      "r566",
      "r574",
      "r588",
      "r589",
      "r646",
      "r648",
      "r650",
      "r651",
      "r653",
      "r666",
      "r667",
      "r686",
      "r694",
      "r707",
      "r714",
      "r715",
      "r716",
      "r717",
      "r730",
      "r739",
      "r884",
      "r893",
      "r927",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of profit or loss:",
        "label": "Segment Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATATables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Information on Operating Segments and Reconciliation to (Loss) Income from Operations",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r348",
      "r477",
      "r478",
      "r530",
      "r536",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r615",
      "r617",
      "r645"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r477",
      "r478",
      "r479",
      "r480",
      "r530",
      "r536",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r615",
      "r617",
      "r645"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478",
      "r935"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r621",
      "r622",
      "r625"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r348",
      "r477",
      "r478",
      "r530",
      "r536",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r615",
      "r617",
      "r645",
      "r935"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r475",
      "r476",
      "r478",
      "r481",
      "r580",
      "r581",
      "r582",
      "r623",
      "r624",
      "r625",
      "r643",
      "r644"
     ]
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments on Senior Secured Asset-Based revolving credit facility",
        "label": "Repayments of Long-Term Lines of Credit",
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ccrn_RepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "RepurchaseProgramMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase Program",
        "label": "Repurchase Program [Member]",
        "documentation": "Repurchase Program"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r805"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r764",
      "r774",
      "r806"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r771",
      "r781",
      "r813"
     ]
    },
    "ccrn_RestrictedStockAndPerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "RestrictedStockAndPerformanceSharesMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock And Performance Shares",
        "label": "Restricted Stock And Performance Shares [Member]",
        "documentation": "Restricted Stock And Performance Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Awards",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails",
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring costs",
        "verboseLabel": "Charged to restructuring",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r277",
      "r278",
      "r885"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r278",
      "r279"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r279"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Reserve [Roll Forward]",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r90",
      "r534",
      "r571",
      "r573",
      "r578",
      "r599",
      "r720"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r157",
      "r158",
      "r159",
      "r161",
      "r166",
      "r168",
      "r170",
      "r232",
      "r233",
      "r264",
      "r395",
      "r396",
      "r402",
      "r403",
      "r404",
      "r406",
      "r411",
      "r412",
      "r417",
      "r419",
      "r420",
      "r422",
      "r423",
      "r458",
      "r460",
      "r568",
      "r570",
      "r583",
      "r979"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from services",
        "verboseLabel": "Revenue from services",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r192",
      "r199",
      "r200",
      "r214",
      "r220",
      "r223",
      "r225",
      "r227",
      "r338",
      "r339",
      "r489"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE RECOGNITION",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets acquired under operating lease",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r719"
     ]
    },
    "ccrn_RisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties",
        "label": "Risks And Uncertainties [Policy Text Block]",
        "documentation": "Risks And Uncertainties"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ccrn_SalesAllowanceBillingRelatedAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "SalesAllowanceBillingRelatedAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales allowance, billing-related adjustments",
        "label": "Sales Allowance, Billing-Related Adjustments",
        "documentation": "Sales Allowance, Billing-Related Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "label": "Accounts and Financing Receivables [Table]",
        "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r66",
      "r229",
      "r862"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r407"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r31",
      "r32",
      "r46",
      "r88",
      "r89",
      "r690",
      "r692",
      "r845",
      "r931"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r926"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill [Table]",
        "label": "Goodwill [Table]",
        "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r687"
     ]
    },
    "ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Indefinite Lived And Finite Lived Intangible Assets [Table]",
        "label": "Schedule Of Indefinite Lived And Finite Lived Intangible Assets [Table]",
        "documentation": "Schedule Of Indefinite Lived And Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Acquired Intangible Assets",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r869"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r621",
      "r622",
      "r625"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Termination Costs and Lease-Related Exit Costs",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r83",
      "r84"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Annual Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r876"
     ]
    },
    "us-gaap_SecuredOvernightFinancingRateSofrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredOvernightFinancingRateSofrMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SOFR",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r192",
      "r195",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r227",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r263",
      "r276",
      "r280",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r678",
      "r681",
      "r682",
      "r687",
      "r734",
      "r947",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r585",
      "r586",
      "r587",
      "r647",
      "r649",
      "r652",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r670",
      "r696",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r733",
      "r739",
      "r896",
      "r947",
      "r950",
      "r951",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATA"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT DATA",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r210",
      "r212",
      "r213",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r227",
      "r677",
      "r679",
      "r680",
      "r681",
      "r683",
      "r684",
      "r685"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r212",
      "r213",
      "r220",
      "r681"
     ]
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_SegmentReportingUnallocatedCorporateExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "SegmentReportingUnallocatedCorporateExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate overhead",
        "label": "Segment Reporting Unallocated Corporate Expenses",
        "documentation": "Segment Reporting Unallocated Corporate Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, General and Administrative Expenses",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_SeniorSecuredAssetBasedLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "SeniorSecuredAssetBasedLoanMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Secured Asset-Based Loan",
        "label": "Senior Secured Asset-Based Loan [Member]",
        "documentation": "Senior Secured Asset-Based Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_ServicesProvidedEntitiesAffiliatedWithBoardMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "ServicesProvidedEntitiesAffiliatedWithBoardMembersMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services Provided Entities Affiliated With Board Members",
        "label": "Services Provided Entities Affiliated With Board Members [Member]",
        "documentation": "Services Provided Entities Affiliated With Board Members"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested restricted stock awards, beginning balance (shares)",
        "periodEndLabel": "Unvested restricted stock awards, ending balance (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested restricted stock awards, beginning balance (in dollars per share)",
        "periodEndLabel": "Unvested restricted stock awards, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366"
     ]
    },
    "ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance attainment percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Attainment Percentage",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Target Attainment Level, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (shares)",
        "negatedTerseLabel": "Vested (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested in period, net (shares)",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other than Options, Vested In Period, Net",
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other than Options, Vested In Period, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ]
    },
    "srt_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "srt_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r91"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease expense",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r719"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r150"
     ]
    },
    "ccrn_StandbyLettersOfCreditSublimitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "StandbyLettersOfCreditSublimitMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standby Letters Of Credit Sublimit",
        "label": "Standby Letters Of Credit Sublimit [Member]",
        "documentation": "Standby Letters Of Credit Sublimit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAOperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r120",
      "r192",
      "r195",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r227",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r263",
      "r266",
      "r276",
      "r280",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r678",
      "r681",
      "r682",
      "r687",
      "r734",
      "r947",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r59",
      "r63",
      "r64",
      "r119",
      "r139",
      "r140",
      "r141",
      "r157",
      "r158",
      "r159",
      "r161",
      "r166",
      "r168",
      "r170",
      "r193",
      "r232",
      "r233",
      "r264",
      "r329",
      "r395",
      "r396",
      "r402",
      "r403",
      "r404",
      "r406",
      "r411",
      "r412",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r460",
      "r473",
      "r541",
      "r568",
      "r569",
      "r570",
      "r583",
      "r640"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATAAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r585",
      "r586",
      "r587",
      "r647",
      "r649",
      "r652",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r670",
      "r696",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r733",
      "r739",
      "r896",
      "r947",
      "r950",
      "r951",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r193",
      "r460",
      "r489",
      "r577",
      "r584",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r617",
      "r619",
      "r620",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r640",
      "r740"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r193",
      "r228",
      "r460",
      "r489",
      "r577",
      "r584",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r617",
      "r619",
      "r620",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r640",
      "r740"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r766",
      "r776",
      "r808"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock (shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r58",
      "r59",
      "r90"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r58",
      "r59",
      "r90"
     ]
    },
    "ccrn_StockRepurchaseProgramAdditionalAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "StockRepurchaseProgramAdditionalAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional authorized amount",
        "label": "Stock Repurchase Program, Additional Authorized Amount",
        "documentation": "Stock Repurchase Program, Additional Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares amount left remaining to repurchase under the plan (up to)",
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Stock repurchase and retirement (shares)",
        "terseLabel": "Shares repurchased and retired (shares)",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r58",
      "r59",
      "r90"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Stock repurchase and retirement",
        "terseLabel": "Stock repurchase and retirement",
        "label": "Stock Repurchased and Retired During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r58",
      "r59",
      "r90"
     ]
    },
    "ccrn_StockRepurchasedDuringPeriodExciseTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "StockRepurchasedDuringPeriodExciseTax",
     "crdr": "debit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Stock repurchase excise tax",
        "terseLabel": "Stock repurchase excise tax",
        "label": "Stock Repurchased During Period, Excise Tax",
        "documentation": "Stock Repurchased During Period, Excise Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r63",
      "r64",
      "r82",
      "r600",
      "r616",
      "r641",
      "r642",
      "r720",
      "r746",
      "r843",
      "r864",
      "r929",
      "r979"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_SwingLoansSublimitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "SwingLoansSublimitMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swingline Sublimit",
        "label": "Swing Loans Sublimit [Member]",
        "documentation": "Swing Loans Sublimit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ccrn_TemporaryStaffingServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "TemporaryStaffingServicesMember",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Staffing Services",
        "label": "Temporary Staffing Services [Member]",
        "documentation": "Temporary Staffing Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.crosscountryhealthcare.com/20250331",
     "localname": "ThresholdPeriodPastDueForPaymentOfServicesProvided",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold period, past due for payment of services provided",
        "label": "Threshold Period, Past Due For Payment Of Services Provided",
        "documentation": "Threshold Period, Past Due For Payment Of Services Provided"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, net",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r860",
      "r861",
      "r863"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average market price (in dollars per share)",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r278",
      "r279"
     ]
    },
    "us-gaap_UnbilledContractsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnbilledContractsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unbilled contracts receivable",
        "label": "Unbilled Contracts Receivable",
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross increase to current year unrecognized tax benefits related to federal and state tax issues",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r708"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r708"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r112",
      "r113",
      "r114",
      "r115"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable and other lease costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r719"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019AssetBasedLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of diluted shares:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (shares)",
        "totalLabel": "Weighted average common shares - Diluted (shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r187"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Weighted average common shares - Basic (shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r187"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "420",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4M"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/220/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-7"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001628280-25-023234-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-023234-xbrl.zip
M4$L#!!0    ( *V%IUHRC.N2<0,!  TG#0 1    8V-R;BTR,#(U,#,S,2YH
M=&WLO6EWXDBV*/K]_ H]SM"9:P&)Q.RL\ETDQE6^[;3=QMEU^G[I%4B!4:>0
M: VVJ5__]HZ0A !AD!$FA,.KN]+6$(K8L>?8PR__YV5J*4_4]4S'_O4O:K7V
M%X7:NF.8]N.O?^D-^U=7?_D_Y__QR_]7J?SOM_MKY<+1@RFU?:7O4N)30WDV
M_8GB3ZCRA^/^-)^(<F<1?^RXTTJ%O]9W9G/7?)SXBE;3FM%CT5WWS#!:M;HZ
M)I5.5^U4&F.U5>EV=:-2:X_:M5;#&'<-K?QX1NIU;5P;=2M-@QB5AM%I5SJT
MWJTT1F3<TN"M\8B6C3-:ZS;T>DLCVJC3:&MZ9U1KM(QVNZT3HU[OZNR[$Q_6
M#.NVO3/+M'_^6IKX_NSLRY?GY^?JR\BUJH[[^$6KU>I?\/:(>+04/FY0,WZ:
M/>E1O?KH/'V!&_"&UH@>#+S*(R&S^.$Q\49LV/#&TL.>ZZ\_"!>3#RU-\KG.
M'E&[W>Z7%UQ--)+YXJ>OQK1A*12W\(OO$MO#'2(^[#E^HU:I:1556PRR"2)J
M/3%0]#C>-U^!H6E[/K'U&(:Z[MI+C^NNXWFZ$]B^.Y]08OD3G;BTJCM3G%RS
M5J^KB?55 .1+KT=;\-H2U6:EUJDLQL$9&BM;&4ZX]87?C*?+)Y:^[>'-I=U\
M6<.II>W"N]&C5#?2QX4;RV-Z9MJ(,%WUR_]^OQ[J$SHEE55(FY[3T-3V:WO#
MGV OG%D$:+Y$[<J/8>G\%]@)X_R7*?6)@J]7Z+\#\^G74M^Q?:#_RL-\!M_1
M^5^_EGSZXG]AF/CE_#_^XS]^\4W?HN>XU95H#W_YPB_^\H4//7*,^?DOAOFD
M>/[<HK^6#-.;661^9CLVA0F8+V?X('7YKZ9A4)O]"O=O@ FYILZ__^+?T_&O
M);T"VVN3*8Y$S;.!#9^;]V%V+K&N;(.^_)7.2XH)$!]7M&;IO ; 4QNJ6JO_
M\F5IU P?Z0>N"U^X-#V=6/^@Q!W8Q@7PQ9+"L>_7$F#LF0%7*E,895(QR&(.
MK=*YJGU!P+SU\Q$W7GS_$JYX\1?:I7.$?EX?N(/''6/Y$YW2^=_V6$$/1C?8
M%RSRN RUL?E"C<J86,A^PZ]U2^>7O>OA(-,'F]$'0]Y[=D^?J!W02]>9(CJ[
M1/?_ #'6#SS?@0'N7,<(=+]G&T/J/IDZ';P DGOFR*+7IN='DU%K6NG\-?;^
MG^'KW^ET1-VWP2CO*=?WFO*794)TZ9@"^NO42^$?R.?./,:88%$*XWMG/G"-
M7TN>.9U9R*78M8G+UIQD%=47SP!&PKZW^$CX3<\)7/87$SQG@6WZ;'G>!*2&
M5XJN3RGQ I>>\[_XS5^^+-^+_L8QUL8+8 ZK@X7\\NS'\"+K6$ \0YQ$/"9P
M/M.@R4<9G(GON&_\[-K[>/&"VL[4M-.&W14T2T-\69[]:ZNV \2B#3LR@U\S
MP="CC\@HUH9#S#D+;V8;T$=.G3X<WMIEL)!LV7A(MM%URJ1/]!= "OX>F]15
M&$705 6F?_779:FT^G(\@^719XPM1W_!U%T?91!C_96:"O^+WEO<BZ=I)!ZM
M5^KJXA/\3O1W])$O2^M.!X,F !BX+N2'*VM4U$X\4'CG+2NK"[>RY)[ML[*&
M6"N##=-R6EE3@)4M$65C=Z)LY$>4K4.#(5P-9\3\3P,^]C*S3-WTN4:A&.84
M]1+'7J@V0^2U^,X + S0V)WI# P V_=Z+R:(\^@QN XJ]-!W])^1=I+ZB1@:
M\4R.AGGM@H.\9Q@F&M"@^1/3N++[9&;ZQ"H*^#M%![\.QE=@H9OMUI]0%Y]S
MZ01'>Z)7M@Z*?U&VHEOPK;BG/C%M:@R(:YOVHU<4N*NU@@/^H%Q? %59/;C)
M<"HR0H3-.KAA<XH2182-.[C=5GCY(\(N'=P&+;*P.HS9KQ[<.CX5^7,@^!?=
M+#^VD9+G7A3=7G]7*R5/P!?=4G\OQE_/T3(LNDE^#,:?(_RUHEOFQV;\>>Y%
MT8WP=V7\>0)>L)/"/)=6=)/S_3QOQSD/TXIN;1['\W:DS2J\F7ITS]N1-J[H
M]NT[>]Z.M$M%MWS?+S@@-Z-7*[K1>YSH@/S@7W@#^.CA ;GM1;WHQO [QP?D
M!W@1(E8/M#1A#VN_!1[@BN?U=, IC_%0CDTL]+@W)[\[%N;?>5=70,;5HGAQ
MZ\)9O)[KG]T3^Y%R\.*?WTW;G ;3DSP_K0MGT:9M 'DYW0T0UDJ]IY[O!KH?
MN,!7^HZ'F4)PC;I/=%F0#:8SRYE3.J1/U,5<PJ)$NM6%-32WPIZQ_<&+Z>/-
MPH06UH6U&45"=A&XDK"&YM$I0X3=$=8,%8F,#I3S)*S9>73*.!# A3MH194T
M3)Z^=</DYP2$'RC8^RYQYT.?C,>P%^$CVR"^\T;'_H7(*!SRJ7N)2=P$KD<!
M 7J695(CFLE)<L.&<$9[$1#D;C+W8!1BGS9N".E?. !N%'1[A/0^O+(]S&DN
M^?EAD4(XCXBH2/%!>+AP7IH<\:&@6R*L'T?RTN6-$M:/(_E;O$?">7.*8+\<
MA8B/$VG5%,[E5 0$>6_F<23<^"C>L8)N3]%\4Q_+P#T24A3-*?5A#-PCX<,I
M>\$*NB7"^: D+TW?*.&<0Y*_K>V1L-ZBUZ-J?S==^F-VS>K)>Q-S=F7K!]X?
M[*A04>N[[,_*HWOMC[!.(@'V)Q'4L +RO>K+"N?S$0CD K"LEG NE]WVY[MI
MP[N&B8T75F7+]1VH!->.'WCA$_&-Z_[A^5JM4MN5KR4?W6L3A?.-%&T3EYE?
M<E_V87XMX9PB1=L7$3BD<$Z,0F_B<8Z>6L)Y'N)$51C!,*W -Y_HD.J!"_M(
MO<&+;@4&-7A+F^DL\%FSKMMQE$,9-4SY-D\?8#D(F>5^XSCP=3;0G47LT]QH
M8?T9)[O11V++POI#+DW;].DU[))Q98/N\(B-IGJ>1WWOV_P[^9?C]BWBK6P<
MP(%@+\7"1*NWA/5U" S_'#/,6L+Z,MX$_ZA7VSVU&-]"F[LXM""LDZ,@>Y%G
M6QEA'1HB'6@<A@[:POHA!#FC.!#8A74S]%TP+_U+HIL63"L!ZR&U3<=E6BPU
M&#_Z!L(73-*MVNK.W[YV[$>?NM,+.O*Q'^\RC[L&++@=\_D59I^%]43(?<Y5
MA GKK#C /N]I?:I==-=B%^?5>VO6Y^JC^UB?;6'=#&)LT8(P5J&^%V$(9_,S
MR"9YS# 86>;4]). ?T;'*H#9BV[FQ?I.>J^%\R_LM->P7F,TOZ8^B"1O]4&Y
M[SOLN[!^#=&@KM4JM5:E7LL%ZL)Z,(2#NHH*?2V7AMF=@_LJLBY-57/J!=X1
MUA4@'$)IB%!:/DU]/Y(G8-]SJQ6XOQZKL_3H/I9#1QKQ*=_^.W%-,K+H/8!U
MY423?_;VB;JV^3CQ+TV;V#IHU/CHT!F[IXDET@6PN^.EUJYHW5S8I[3JC^#6
M[ AGU4N.*%Y@3T<X?X#86(*?PJNGB0S222#\%@GK4;@DIOMW8@7TVSS^]7<8
MD;CZ9'Y-GZBU3$GQ0U?V+/ ]]H2:%P$G)L.0(A&.P=#F@HZI"QB3C.DKBF#O
M"AN*(5'@=8TZMZ/,KK!N(%%1X!KD.9,=1T>#/#F!L'XIB0;OR0V$\WUA_0<6
M7G]/9P%L.:AD=Z[SZ))I N1K]PX*[WJEUDRH:WO!6S@ODBCP%B"!H2N<LTG(
MS3F.]=(5SB<ERN8<2$$0UKN#"50W9+I4%6AJFZ/ .TQJU;)GNUE1&[G 5UB'
M2>^9N,9ZW";K\6'J/@;!'[YO;7X:CK!>CPUPOJ/NV'&GV)B&<9?"Y'FH-6&]
M"\=":0'DIEH3UN _'@$(L2_"6N ""( <%1D 3L$ _;X2(%=0"V?>1C#E#<;C
MI+-K1R>+ZAR+<US+,NW'WZA-76)ATI\Q-6T3T)Y@BO_@!?T[)\N/A+-^-Y!)
M:%<M,2/8JX\B-H2S@PM(8L?Q+ZDU86UJ,4GL6-LDG&F.KJ:^8WN.91J,J*Z
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M3FE/Z\5.IY,G6^)@4Z-T/@30LNZ=DD><T*[67\TE^\)*[D;77RU&_LXUW-^
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M]E9(OO7];)/+O-]ATVLA]SN=Z?99LW>?M:GUO;,W;7SQ5KVSJ-FZV,R(>!+
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ME5OUO4_JQ5)@1>:>#XY/K#RX9Y:PP-.DCFTG6OL0!N;1:<VRVLW+3;;S/A5
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MIC/+F5-Z3UG1A_T)I0,BI5:N-44)H99G2._'A'-'IF[IO-$NM_;GNN]SH%3
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MN)7!^:QNB_)B"'8)^(49\#CB'Z8_Z0<>+(^Z@Q?="A L/<^C\#\C>V2M6FL
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M.J. XA.P)'8Y)U4JRC?BF?H^24,G*M$*)+1>503OJ#M$='A5(=0VZH,#XMH
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MJ_\3BV"'+TUBY^4,&$EEY%+RLT+&L, S8CV3N8=XFH##U+0K*QBVBAR;L50
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MG/4CCI>R^EJX00V-^T=GCL>JTYRY%(,\GNC79]/P)]$&)EX,EU];O$)&L-C
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MW6SOTU]1:N=%C/;8,6@R4[B'#%([7-!D'L2NHDAI:SF4HY!!DX7'QSV#)O/
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M+G[#\*O3CTGOKWNAU,8CI/?"M3YU?6(BL\,B3VPKR92K 0M.",+,(IYGCDV
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MQ@&>I6I*94'=Q">"-85Z34 55BRQ-23%4B-"8R:50-[$XF;X(Q(HC4JM+I!
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MHO"9.:\K C/L2W6$(RB7J\=SJNPZ9??T.Y].")$8=0N)T6*7Y]??9\G4@B1
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ME&4(' ,6+'AL9'R67#&B&6Q#-#CW$H@T03Y?)6=[*4P<P[/+P2;L0NBNC4/
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MY!!@"$TIJ2YF:/0[]48^L2XYQ]?^>8\-YI)F]P]\R=WT-T^0OEJPY4VGB>/
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MK0Y;'?:X#EMML$Q/54*R.FQUV.JP.P]$/5@J>T[F22TU#C3Z!GV>3RL=H)0
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MJ)/=DK_TL.2,]RJ[;P,WFH@I5I=A-1-2M) U9MH";D,PM3X[@371QCB)VA#
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M>H@;NG^XN_J?O]]]_7S]XUX&!;3K__WMYN%?(2(M]X/;V#&:4[*;5;#)\,B
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MYMUE[/E0ED\X#B.:H>6MX"!\.9NJ_.I..<9R-^5+1<>GO.7DQ#W8OH%D_^R
M"BWL#(H?-E<%F7;;W-T"G1IPX]ON#:[0?TZ/!$RS)D>]B5B,&P)%DR< AGX+
MMJB@KT$DF=3P7Y].U4^^SUX\TS !4=3'->UY9H)@)&>#]FSZ,QK9!)BA,Y?6
MD T;F# E7SJUT,,U<Y[5 &.Y)39<V$YUQ2/.%;9PTNB3*9XCK^C5S!13[?JG
M, (257>P"T.XN(W$Y%Y"IYBY"Q)L+&AKO$((]'"V,$CX/\&:/;^Z^_Q-#F1.
MN5LEF(!?3]%;Q]XD&G-$0Q8#X-1S&LF%[_8,UQSCSH7E/!<<G+(A+V@.WH#O
M9CLM_ON_AKW^,(/K)F,;K[0U6O$C3G\RC0TVFX_5!W*H2A "7C5_64%STOWI
MT=CU<%Q[2'JN,%S0=>AO_#G%"BX 90CA<2@O_'^B0707FCSR4 Y)^ZCY8@X,
M %WE4N&  ^'#"TLW1.@"<G5T2-CA%G7>(NQL*CR/=@1L Z>P3DPQYWW,PFED
MFB5T&E*'G &T3UR'MTO+U+19 &]%VG<"UQ!2HX33H>)3DVQD$OIM%SS7T0M)
MKZ:)26"PI(N]-?H:G89 D]K2QS0V*_#IK30I2WZSY./>X&9$R(H\029"R!70
M;1/;TQ+$@$4\@RJ._V6I_$@7Q6LPIZ3+I8N W^((N,PMR\,@1_(R77#WNG[/
MBGL-%UJXIO#AUFN@?=H3V&.,5_O"F-F _8\O.$;.1U-A^CHQAUZ]NP&-9'C)
M,0WAHEW/& >%1\0%:&!)O_/:+&@E::-(F.H&QFQ,%A ,9<1[#6,9&FF9X40W
M$SX"!#!>XIB8$"G2AONH+8(Q,#VF6==\PLB&#A@H47SF>#043\Y@S/[FT0'0
M2=]BN,F:AB:HE4!9=D3;NN0\Z:\4@2H,1YK .8]RDYXQ<QQ\HS%C7W'X@0[V
MAIC#(SCQ#E_+<0KXYKNB<8 ,4-W%#1[<0P*[PI<H9^@UAG%!03C_/KJZ_A!R
MAAK2R (VC(<SX&), ]\V'X,^X3O ZVBG\5,O0IUF08J2@=/QG& A"6N.R@1/
MV$L2,Q]538#' ?*X+1Q(QWS"SYHQ7%RN'Z."T&H<D8) FTTKMH>,M&I*,TAO
M*Q(\(=[2'&-"4TI3 !PEO(X+&&24%%\%Q=KT@,XHDX%EF_  ;WWX%"F=/F,Z
M0)HG@B1.$VY$!Q'FT0!7C3Q+$[$0A&PDQO"7-,G5CJL7\)-'FS7G5>2"B1A/
MNDOSNF.T%B=6BNCC5%3B:W*>:YS+Q1]6K(7(.:3N?/XGR3UB:([[J-OF?XC]
ME7Y@N,R4 :$>B%HX\!&U#M.G?UHX,%9FF;!["N[+' ?L)K -D#,U:7VA<&*C
MB10*L(C0_A(Z %]&[B*[+32*X&FX:5138LZK.J@CJ==@NLNJS05>S.##E^/2
MTD.Z9,0:/ ,VTB!I$+%.>M@CC^^..QDF8DK)!1EG9W2FO\YQ-Q^TJ>O,U>M0
M=QX+.!4&46/C@4DEGJ,L9S1!R?;OP&2MA2<8@UQ[Y"4NE#_U?"QLV(D/+S$<
MHCQR_Y&=C"=+?V^)1^FK95F$.R3]%LYENH3**&,?%1X;CHO4A_ "7 =JFM3!
MP T5/;!)34 5&?DBBWTE8E""$NR$!C@C!X$UR-BGW]-]H8XCU\![@PW F18.
M30R7PW")+Y"E#*M@&BD!@[5]DRT;G_9W',2&B&7:[*MA4'%T/#G?U4/8@:I@
MTJ!D1"F:%2RI1FKIA"4NZE@1-.)+ VX2D%'[B:XVIKDO OC00[7Q*IQSKQX+
MW?E(W+;CA[1$EP;8\C?42.>.#'ZD21MIR,$L-=9!,Y KY#<\Z1A_C/""RQ9S
MCST@V6AE2V2)X0-<7S /H2EA2$O(> /I7\(3]C*/0D EUP*;P$2LLUYV]I^?
MT)?O.B5I4+:4I,U#%#\$/(#Z"J%LS'/\G03I5Y )7X#!*#_R@W,5HX6,*$8[
M(R+03D<Q5L046IDQA?8A8PHW,;;IV%E>;N8BY3) WL0H6KD#-X%<R%=))Y-*
MC^37OOY3>K9(?Z, *AH!)HL32D3RI 3TRCXLO%?O#]J%AX4WZMWAGH:%]^N-
M5F\O([";]7YO3R.PR[JI]NJ7[S*7N]D]TDG4#Y2G\HWS5*XS4KVV&4F][238
M(QL#F^O;WV6B;L%QNI)=+:UQ*A#.=ZI5H-T1M''%;F\T'F.#QP>GG#9.RO%
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M15LPT1B;*-CI9#U$6I;46=$J\]&#!?;UOP/=!7#!K^EU\%#H2\%+2FA*X3D
M[*P1DP8!:Y$:@LB$BTC$T;R8:A9[_(]@PIH'K#(1\&X0+*S(\,D)[K10>)Z8
M9;D %0<X!=X1I2T#_DWAX9>Z]BF^[VR8 Y/Q0 %T&:D1VT#[,<6SET1^??)'
M@/XY?(!!'3+X%]1H74 CMG_QB4G(\#W47N?Z"U_+OP/3Q:L8&3ZB'6B9&$7P
M5(VZX$<GYG0*I*)L:+@'&E_..G $ %#.8CM\E9KH#1F'=&UE;>'@3 UN*G!=
MPLD(\VN2"9!9%D,+Z0"'FS+0Z1LS%IZ=P(*[!5 ;?@7V3<#.[1<D[0+*3Y[0
MK0#D_20L9\$,""A._#0],L\B.2+Y+U$%"=@XOV=.HKRWBCSA41LV+G]HT&5)
M<HOS&90-BB?C;P +D%>*^,M#1HTQ%W(TFC;\+K"G^I/C2L^'[UN"CP!/X: ]
M;_H2<C'VB,P=6_@HRR;Z'-[/'S+3D@<'>4&6KT)0]6:%<WP,G0&'W!C80H5]
MFV$?QT]0)@!4 VO9VS@6EBF>E* EU8-Y,=X'(53@ Z+8Q"&6^+W)3!T>7/)N
M/9N@"J!_9J:#J-.UR DJ<5_P!3IV0JNIQ38+;YE(TUSN&]_CA,%G<C<9.F#O
MU'*>2^.3**@VW^N6=!9S*AS%#K1;Q[Z0&3$/^D_MJ]2W$-S'&8Q:8=VT$N[%
M,#3DA8"1 5T"#-A4%U%R$&"+19P0%3,O&/]!/,'1@-Y\U)IT$&L^N6[T %0&
MER$H%>P_ E"W0<GD@!"HHIAWY!/:!48,)\,HE&VBJL'!'<F64$5AY*2(4DR?
M1-J9,/X"+E/8-TEVI"B)]#F73FC%KCZA>B[#:TP5$5(C4M9"J"R'&CN'L/]#
MI=#,:Y&;9JJ#K*P"W2Y<X-ZJE1#8$>()=5;<G2L> XO)L:[]"O8"[\W6??0!
MYP3](F*/J\#R^L ,\5]8$A)K@=L< V#P?A@--D +$6K_NHP/*#ZCJQ=05-YY
MEHY57!*/0UP++I-@:)&B*OW9H8H9'C^!/LFKG>M_XAY#]9UA-TTF+I#/%XC)
MF81GP_75#;*,7(T<C,N&<'W=M&6\4/-F)"I)QWXR/6GMJ+ W6ZYD])&2#\+4
MHH YQV_9_-,3#>RCB+F9C7E(,?C A P(3)8AG9SV$Q)#Q+>EA3D'K +SS\,W
MG*-8^:"R_O![?$^$LR9:(E,T2>6NPQL#JY/P%@.@\(7,,Y!*1)QVI$&3L]>Q
M;I&R"^8I1N/2;%4KZ(G=T-W8.\MPW\HDHPO,M_O8[JDD/!-W[G^\P$]>W<F:
MXR?LY/L)"SD(PY2QE>[ ?H;?JY]V!][<7MU]N]8>1O\_^M^6'6\Y/O*8WQJM
M67/Z<E;<-8>;.:!0_1(/-EY0L%&RE+7I&W&#P= M(V#G$)((:V9(EL3AD;U*
MIH0LB[BH;:/)GGXPP09#_I"Q8/$P*269Y :9;<J\2,69XU'F5'KCM=I6B(P_
M8&M9:8YA"!ETE?#N!V>7G6X]/<OZK[3E@COMON9.J45S/9UA\E=2K!>\-$9=
M(T< ^;;8P ?>C2X<4 $$)]/5M3#\OO1-+5,\E.SZJ< _&Z+)OHGA*3_+0U(^
MZW?A8IPK"] ]G,3:JZ?;C>X1)5YQ]]@N=0,TD>I$ZE*CW(>IZ4:>4Q+^2U>)
MFG;DJV8\8PUK*B:A%L*:74QS#CT44@_)0"S$DF4O^ 1U2%3&HE^/'>=/I6VH
MH"@^9:-V@-J_2;HP87M)S,J5@F"488(G>3RF%.D+, =^*MWV+T4R=I+-M+O+
M#$K9IR\@D7ZSI4(*:/E=AI$I"YR5LLTROWL16F(_OD8]K^H6@&E)PR2P70[G
M8WHI8L18SDY.*+R1'IVA)=;V"I7?8AL"8*A1S@\SW?\==?0;0OR0F"49%P90
M&P#4S. Z"0!1;1WQ<C$5KLL06N'2S: M<ZI%YRF6-YK&19L2>Y@B"7D+ ;ZY
M%>!OU/M^D,4.NZ?\,D:#[Z0WQ7&V\$5TSBX;];PY" I1@<N0'2*1[T7H[@K,
MC7&P3-;(.3L>F:#'P*A"9-?^H8,.Z;YHC"$=RB%[87<#V\MPU*2'!K"3'<V"
MS</O %$ WL.SH[D!9?AX7A 9ZG?NHV[+UH,DFJX!AYPYV"97SD5HC1(X/T=^
M^+IV8RM;N*99V/1#FQ.RJ$T)RN?5T*>[\#CQ-F%*JJ3HA%N[WVUH"@.N ]?A
M!&059/3A"-)7@FT4R;L/6PY<0@_EPQ\G7%SD9H%+D4>WE]U9N"^XWPPZ'L-9
MGT%(3WU,8ERP1I!T8$2>(4?F+1/KM(5&&63N"_N*9R!M]8FSR+N1FC8.?.60
MF(-E+=TM4X$5$6,,V>)CR7='Z84_%\K%3R^1;#[SZM'#9[\D8( [9N:&3KWT
M@0"&R[YII?&RJR#R1$>>C*,@LH<9WS8C3ZO1;"&'=H+'&>M?KL":%H0$L2/Q
M4P]]5 !'Y4Z"%1 -DV@%CS-,EY(AXHB)"0&.]&?I*?=4>"N$"O!9P-Y*RYR;
MOG00(5Z-$3F!XY,XV3GA[EUGQC7WDADW?)^9<=T]>;Q^L"3_#D;1RX,+.V+M
M8&4^7*^;=H#UNFD'V(_KKZ.'Z\_:]]&/AW]I#S]&M_>CJX>;N]OU[K#"/B]Z
M?QDSMI(%%!['JTGG1_,/I*U+^4$4^YY2LO@C!NFBHK%T<12)%31GYS);RDN:
ME(JUS04:\$OACBH>G1>/_N3H[@2A]=D$;<=W7#)#'*YJ F:!<;H74!MT5\P<
M:T)9!\JQ,*_ FIMDHI-%H>H<*7I'$$U@9_*I"IJ;(VD=C-HP>R:=-(&AOK!X
M(\YL,#:-Z3=/8"_:4G=W*'-38-B5G.HV<Z@*N_/NXP)@]P@FC1^)3EE9_218
M5R3OUE-D_XTP]J]Q)CI8.A5WWAKQ0^NA@M\&\%,:P@(UO22^$H:J'#Z9PIVA
MAY#"P9EZR+_),H(%.4S \1C^"56V>S-!+@+,T80?JU3T,+L+-C"1"7?LHK->
MXFF 4R&VK@%/&('LX,VI>25G2*SNGMS1B0=5(%]%XH&K9KSWLS!8FLE/=ZN>
M/#BV9!:RAVHHVN;H;#+#)'AL)S&=4H@'(,V^IX0.ZN7EW!069^$N*%HCDZ)D
M]A%)NDJD[5^DU</*Q)B=X5.M0NPICX.A!X1K,6=]J[':7;]SL?<&OOG>V64K
M([:9\,V7$DT*QLIAY\7N9DTHY74+\7O]L\M(!J3K[Z7TV!0$G;JJ<48Q; C@
M3RA2)D!/LFH$*2GDJ4A%F=)J.]FSA5=R,]?;8+ V2ZS;6<X2PT\.E"5V\W#]
M36OE^LV^C6Y'OUY_N[Y]D.SY7OM\<W_UV_W]S=VM-KK]#/]_]/5?]S?WVMT7
M[<O-[>CVZF;T5;NZN_U\\Z">^7%]_]O7!WKD[OOUCY%T=Q7-]GI[B91H5W;X
M0,$B<!>.%YI'44NL2#L(E0CT5094 T@$,;)UZ\4S/>W\V^?_UN>+7T8?T..
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M9#J8$(.A9GV!]2(U,%89;IS@I99/;ER]QL=B#('!!R\8 ^Y1)#KZ,"JZP(Q
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MGK5M7CF(53#SORC@7XJ9V7.T=]<_=9'Z0]?@S*(;A (6D:-DBCD"X>(/,,9
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MAFN_:?/7@.\7,]NOGV9>]]O\WPJ UJ) )\5]-@;#G3]RPS67UVEL"H5";]&
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M'Y2#U57%X$[3L2T<4L:JB.(@8-(?^0P.P>-&ZDG"+[/]89@#/=D</W>)!X.
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M%.!$K1(B\%(2FS6Z-49%;R7P()8[1&D-0\[^_\RVL4YJMKF;2^>:P?WAM+C
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MH,4EL^WGWY<_@A_#SW_Y/U!+ P04    " "MA:=:O@]3=1DZ   '<P( %0
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MHJO< ''?;@%16=#HT5WGGI8[IYJ"(P*):33/UJ.YG&ILE'=>^ATJ[\4R:R'
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M0J(EVRL*!C8Z E([%H7+2J^<M/DR!-NU/#;4XK!K%;1BI[R@J@/WTDJ7P=*
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MI<3D92 +ET$@,7)R]@[VTFB'[[7IN^[L?],F-!Y'.4OZVB[(@FVA& 9#@$:
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M-A+]6&^)R;W_0('Q75*'<GS!H-P-AV=_J]]@7\93<K;<G^8^@_"K;O2UOK
MH. 95A&]JQOW9(SU[>QK@<\?YQT"$6%CW&/24S=42ZQ+/LX+S3M"F!'N,9G
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M'+VF[-&8R'GUA:*HR[OWIW"350?&?9+ DAP*WB@7&8GY].VG.5'[Q^]+!/T
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MZ1Z#P"W;(*[EF20HWI<X^NP8O#,K0&;Z11_"S(3HP5N<_-W4(N.-3\=19N\
MI#Y52:5\;9[V[ODN&#O?L:*J'6UAWUIKBGJ97#)Z^3$$KD1ZZVD;:5K0/8?"
M0N[3$T;FKSCCDG-95(HB& "05S,C93!#.RB ^44Z,U]I?JUC*V NI4BE/-GN
M(3%?^G9="R7YOE9)0R06I,4\MO/GL#1]]+&Y _A<5<.TWJ05E)L/X:)ZF7-
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M;2B<6Z&(/E+R%T2 >,6]IR&9VVU8L!*"^%_FO/]09]!]7-MADZ5T2+]I^/^
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MV0TIII=P)!RV<[ *#S H$JD[V^"6&E>ZKFZJ9<U_6&W[_[3Q6!9K3LT!!U0
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M6Q2UIRS25IKETB#^!GP_S@VU<>L5&VV&P<9@RK;N#%_QAJHE_(59.=A3:BG
M=Z'>=O,F@/S+;">FQWH^176#524Y>4>UL.R_9B/R=KS(I5_[FFVB%6LV+.UB
MSTJ(<.+;8BW]@CR3"X$=7&Q=F4I- #%FR@U#5ZZ068'<S(IM=!Q'3S;V<[P=
M#R-_QN1S[;;"P&/"])01V#V ' =%R#H3_?FO.!+VP\4>NY8-'%Z30.4C$'0*
ME7GJN:<)8LI]W?J3J*>7]1#QCF?&FD1XGH&_B0R?SUK8.FK'7"$&?2XBV-US
MS9FLU[H B(O^6="(.EH'G<"<<T75VH D$0Q,A=E=K&EKZ:.=7<;C?OA8]$+.
M.>7'[@;7"P/&U_X>&[P>C3FV5(W?%E%7TNJBI;.@50H6U9VW[F%+DJE%UV[Z
M];;;JI/(^YN;WE7"^'W=F^8D=^5NRU; E"*2Y68WN1K6"7T7J]AEG!^$TR]
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M7*V*^"_IV5Y]'X?&<)D4P'=M:'UEW=W])Z9;>>[,O0VW690!T-/H_PB-BVP
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M+.2(S L.\E(,K+EX]#W@)*^GPZ!VCL_AI1VN%I!WJGR_)>! _+UG96)DM],
M=/#QZ^5Z0[$ CG>>66%6R]O?[2S^-E!ATJ\U"3:H_V0.<+B1N_:YKO*[+>)=
M5$-EKQ<[7^K,_ L@L*ESXYS _]N?)OA>OK'3$Z#T+XEJ#VC.4-6]C-(YE$"(
M8*:U-^,TNI[\6\'<$65P=/?, 8-)P.'NYT/#U>LM,T, 7\297ML#)A.G 6R
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M))W69Q<\I_5]#X-I_47S0-#ZW*1=Q+]Z";K9F7#JR_K%*0!]V?0E^KN-DD*
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M)-P+L-]]L"8OV\DWXOLA%8 I]ZW:6J+BM;^[W_WSHG"UH .P:ZU7Z?F&S3$
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MK(ZG4X1@VZR B4G%IHZ:*_.RCI"B+28G9=I!;)!PXX[M DN"/,]XZ$L"F<K
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M;W)(;)2O';4KLFZPJV'O9B9.V7$3JW23+-XGHUN .FG>8\,XGE$K$K%X?/S
M AC1ORR1OJ O2UAHB %HX3*"%'X!A.O4N]3#6^KNH*,\FX?O1"IMIY82@>I
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MU;U"6,1)L\C]UEE:\+41R4E:TZKG8R*W)M58B,7="W>PFV2$#UZ@:=N_]FT
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M,9YYN9^:J[^_GV:#C&ZEY0;Z0/E.NKB1-8/P4']S.T-W^KG6IQM%B)8<@XV
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M2%Y]3#\1<1,W#=V7_\FA/R^,9@A!SI[GR^K*.2M567LJPD'R+P Q0K:P6KL
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M"+)'5235/_GTP]D2<>/6;Z +II)68E9:CVMP,Z7ZEJEB=\4C-'!5L^>%PRJ
M0?P[((!>V=??#_JA&-2!%@[HULL[ T"T]WX(+AI..?"DU\*HW/:2V5^PO*%'
M_%AR;B9=*<_E>R4^W?QZ!U/UA2;3OA8CB >JJG6\.RZ1^H1U#Q3-IU^BE8"K
MV,R0D,D^=#?] O\2JTS\^N[< \>PQ+C!$_;3\KM?A+/O&;"R:PW&8X2O4AM1
MA#TJN'GI2U^E)<X>%WDS<S;Q<GH3JU64]6$DR@ W!]\'"B1_N+H9GV9[Y@K
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M)T[!#I].4HB5)J.\BF"W^?VJQ:O)T ^<XRUPSEZ,.P^2\[9JV(>=K><=-].
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ME"+6@)91",&!-!KDV=<WD;B!L6C+OQ2W3<0/GAY)<M>#HU/N*?.<]"/\+DD
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MG)^\T;DO<7VS^::W ZY0<XO')PC<8@ 5  >^G16+0Z8YX( D]J*HOH&F41)
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M#;K;&U5PX0D3Q4%VL^RY>4/BN]MB8I*^>M] 8H0<1!,3:F='"\2=WQDH<XS
M "AK/.Z^ Z7Y!WCO_X(F3FK)XZX2RE,G#XLZS7?KV]HL,BNN8/*O8M>$@7'3
MOVLM4)O09-N0B\]QI;N]C[!;K-@KKPBP@13:HBNG!IFO\Q1HN*2_GFC+,:H8
MJSCZZZA3*F"O0G6I]!W.HGPMCY%L00Z<FW2F;NZX$\PQ8APQL[=;6[+Z0,Q
M3.UZ&><OH.5-=XQZ<* \G;9_\2D4]VC6_,R'J8[^',=_TD"DFZ)A$5S+5ZLG
M3Y"=C(Y\C.^'G]S-[&['-;:TQ6<Z_^Z/UWLKU?"ZDMY'QDM;@KY!61W=(T\6
M77=VFX-_7QA".U%QYJ31L&K*1CWDAL1<\ \M1[])<L[O]O)Y,VMRR7X+N9^*
MO'-I-\/Q;@H*O-<M*X2>H<\V?(1>T'>/RI78Y2(C9?#TBC,S9,HV<#?(!R2_
M?JZ.5KE,@M=RQ!A\KU?3>H9E,&EO,38KN?O8\@$S\\F.RF^@7 (>[T82.#VX
M3X-$]B1MG(8J%4"#M38HRZWGT&>LR'^1*$LW])5.;^X1WXU=7@ZP3Q;4><8*
M?6-5^&AXME3_#T[OUC,Y9B 0N%E^TD[NEG/_$9.':+B%U\.Y=PA)70*/K.,+
M4-(LJ1QR@??GAO.29HJF8CQ11#AGBGG;>B_Q'*5;CC6?<JJPK)G=-=+1+,*?
M2$V28Q=!K\.IJ*B>//P&&B-PVW+?,I!)56<NHE,9\>AJ8B>?AJ/R8KOL:;-B
M*/W?V<$I1(GC87 ]T\DP8='GSEMLC!:A'%97B>HABL\%T]TY5GJ0\.8LVR[]
M2AM,S8EOH#LH!1^9Q4<U4I0[R$ERPXZ:1B<]GD./BH=.D&L1_J@K(U+/.,>J
MR&>;Y_VKCC\"YFVM*F:^3UF5-?C,VUCI&ZS"/<>,&COM)G_%$.UZW#R,4J]?
M[UT\8-Y8G55HKFU^C\GJ;2WXW[R8]M]!\P9CV2/OXV[WS7+J%C'.CK=!5\/F
MKQ[YH1NC_[I22XY\ 7VQ]_(=':0Q?1O\H5+UHA?+C31/G(;)@,BSDV-9X]SU
M.AS4$1XNGZ#J!V)"%\L?\ UIJ&R&? ,EGGV:0Z.-.LE9<Y_:LZJ.5(W6R:_G
MEP5U_H$61,!I9>7E\VWQU >UXN)6;KXZ@N&>TO\+HH*3=J/1$BC9C,Y9<TO6
MZ.$V/LF[,K-&>OL):D?"LBP6OQ&&K?PJ[).$.0WNQB8\B_3!MRNVBLU*Q./3
M?5L,0@4H4A!T"]CA&VDV=]AC$@PJ& UG\1CG*Z3?0/YR-'=J?8+,TEB>&S[_
M(D;]CRY<H/VK"_Q6;J^,!,.Q4O^+!X7]US%;"[Z"%Z^4-[9\ _&@3$.R4 K5
M,PV+YZC4$RF%#]?JD@)C?0@/!GM-[:GDX0/ [/"R5'-_:D(?'"YR?S=+Y\QH
M-))<FU,)!/*=I?2+E)XU9 .DRS.\ZPH],Q:48'1[37RGMU8BU>JZY3NH):7)
MY+^X<BXK5"W.).R<PMNRKG JEP#<F*&YE<VTP=*"_K])M<-CR_VO_511FB8C
M(ET"\-68MX/CE^-53788%H]&-APY]LRFNL,.[I#>^#&O*V)-I)V1,/+=>#QK
M&!1!3V[9N#H@Q])=Y?6EGNP%HG8U OGYA)W,G'@)'Z0JGD_+I\U*^XT7^EK$
M#<?>P%-A@:+3-V.['VC0B,URO_+M_'3N/'ZKS<)2+*)2C$-JZ9IC -4_E;ZG
M;,%85?-V^VA;1[MO<[NB2EUKCEM.KUS);M7@?VU&Q&T3ZPS8SRVB;Y@OG#L9
M2JY!3<68A++&HE>H/Q4?NFU[[E44B6M-=8T+)[8>36!W$"@18*ZZ;Z15- .3
MUW\<Q5^4F4,WU6?&CG?!8QC#6A=>,&J-+1=O)'BZ+JAU;J+Z;*@"<6G$;"@I
MD_YHZUBZS+OY-Y.E3 M@@1EN ?F,1+M9 U\I['%^49XWG@8UM 65K-2*T417
MG>?@W?35D%*.[=^]%J+^"^W:4C"^/F45;+5>/+0'"\X=>H'*S:QK?HS+ZIW)
M_Z\(O>L/1LA9121);\^,#:-43 88S6#.K @9L<$SJ[V!?!0S-4FX,[B+IVL,
M"(_0>LV/W4>)'H9Y\95.QMO&N5,N[\J3C#/IS-*>6KUG!,)FX?-OQDH:ET-0
M9MT,8J9)8NW^I8YLQ6\TA N\,OOW928(SXM]Y=3Z%35ASH469J!&<A9%D7(-
M9C*<^4F6&Q?;<;/F)],:F]H5KC>!_131O:"^C9-4_]"O1L_)YAFXS9_+#6![
M*/W$AJW$W!K:/&J/,WX/O_#?DMTN.P^NJ,YR[8TIM#2,7&,:@;8)#WN<F\E!
MNEY<?T?.2*X:E,S%'=5[V3,F CZC:U^'%J;Z'@#B 4( 8/#B%I(XR$TDRT/&
MP9SQ%9CCSHNL]!C6S2K[-F,TU(DOJC<0A9<#)5"W5ZHIQ#*S^_LPNJUKI$,@
M@7U1;O3#\/3"ZI:K7F<* E>0M\Q@\)L"RP&YI]P-2<-ZD8=7S20^I;0R1S7U
M!J7F-B-1*55 %G/WB(GS;25>'H^>^YNL?W*J^($=?YY;J=6X+^2^7_O),W6M
M00#RD26OJK[\%P",<9\?;_YH8]"*<^$M#"6KTL2O;AEC9/2;1Q:"[K;E/V T
M'*UW#7K8-KR^U)^'!&;,L-J]?7@AGH]SJLB6_ U")^?!L@1->0HI19OFO=,-
M8-FAA%AN>OYI!FYN!L*; 876Y.QR%<I$D;ACQ&2ST!JAY7&+P7RA62.^?=R^
MR<8W4(S\0$*(GB8\O_X8C!2RD'"-Y*T?91#:V VJKS4@^-2NH'D?_::VKBVO
MLBZ(71Q(;$<9"WO_RB4--<[^OTVD<[ -_TVQ'K&W#US"!%1S&KOVW:IJQ=#X
MJIL1//^BJNV!5O4Q?KZQ&O>*ZWXD#8P)R\-MUJAM*@H=$21G/I\#HZ\@W6</
M6>81X C\W++ LP7H[5<H4%@JLBR>P\1SO--4^-&&IBD61B&@GQMW=[SY<BRO
M9)&HO2JEOS4_#4H$;=_BFNG<1%Z%72[)JH76*$BX3>]Y'G->IUK%@QBIZ^FX
M]##^:"A2BX>W*9I3)J *^YP^RV@=?^ M(#29ZZ9JVN,$*U\^?3'8>LQ<<;2I
M52$JK3G;0\D&F!3^E1H:_EPBB^*QO]5> /J7)(H_?//LOW+]N2OB=51MGJO]
MB62"Z><8^L<9\S'<[<(;WE.MK.4&UARF">/644AWBK4:C>EY,VM^ W%>75QD
MMHD E 4""6;H.F^0$F(Z0L;9%1_BLZ\94CX+&R*2?-3%SC\R@TG*/'-WO#1(
M&C;I52FGDFL;+':(=-_ILF$MRP'S(%\F/<3'"KK)DN(.X*%.&/I14R$OTT+*
M3H2!7&AHNR./6:1R@: '"AK5JE+.U>0E[)0OV%SN\R2GJ?IMF4>."E%K&$:Y
M #;B-9&J*L[2)*^.F?D&8J:CXR@FW4+(L1:$LG*@2"QS^%K'&3^:=EP8G3O7
M7-&$-_!DE4=28\)E3/MY>!OLDWCVI<H9J,]VUIIY>Q4-VBQ0G=6W4I&SI64&
M)@";?^FP7K9=X"9F^_6HY/O2B_6$<'/8N$GJB(9OTOU;#4Y+O-0R/75L37BM
M:"'RR10)/88^$QV51ML/,,ZMKZ?K<O!&["-(S50:B'B IY6 E+-V(IG .\F\
MH7P]6"&#OBHQ&",V54KG=$SHE?_WT">2<?9[\E^[!4:GI4F\IP3K/^2'3QEF
M?1D4-.% 7H;=OY<K\JQ@==F/\%CC7WLJ='T8G=#\7()Y<;UG$-,C'U1<6[>^
M6N6+XOD7_=FZX6+(3/UI.*" 1<0%?$_AE7C._?Q[T$PB)=53 "#P7%$)9$+I
M"U4MD5K.[$U4#1>$8J7Y0N@1@XOK4W-'[SATCI^3R1+()[I'F7XZ-,^P<MR%
MWY"4G2.S*O&1=H%^-L]2N58B*U^IJ4'HF=6/5ZQ =;770DLECE.%'>L%*.*X
MU#_HZE8)VR3+9 F9E0M+-KW6WBT65MW=#Y9$=/?A//_2*XKONY'8N'Y.E,W2
MR"=J]:+7673+_HRBH00K21T@:%\OB8"U"GRZ+\#\+!KS#1'CW#=SL7DW@G*&
M*\4\I+@%X]N2*=G]8<*53,"02OZIM<& PZ_:A%1,O&Y(H\!&5 M+\=[5 ]F0
M+)XCF,>X*T%"/NIBZ>U<.+G@^+]XU&TAH2.FDW?*K_V5^#-Q^?G:ND6[<S>9
M>,,VN?[9H8+M_(PW/<,XQCX4380B*R,+AKL##)_UGI#(0.L07HN_[@7+;^;P
MIZ0IX )N'4AS#R09Q,IQ 7-I5,0@#Y.AB43U=-73G#)H9[)GFY3EFIJLCT$&
MUC(T2/68JJI?(BV[LP3&J22[$IGR)$/?I=#!:#!ADDO3Z,2N++40@\5',HGC
M_Q/VROW7X/>L+N91^;Q=/)RV*^R>F'WD\P:NV)#YCX5TAHF$VO>M2E>8#MH"
MILNK!T4+MV/Y6DC/IQ4;'$N"I_>@,H6SW:Z\,F);W*P,[Y7SO81)W=U[V+M4
MZ)-,+V!'8R>#8QG,:X@ZT\"E6)NPU, ;UIEJG'Y79AZK6^#$-$U&9IH*UUQ
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MWWX4\K<G:D_$KMV2 13JQK15REO/;R"9YU\&V*Q"^@:5C_U[U<CD"&?P'WF
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MY^TS6+&>)[.JV_+YMX(NI-=?,)JINLG!_!-PMPG>#XQK/Q+XY-&$E#.8T4O
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M\B/B0_.%JM!F8WD$,KZU-VW@ <Z1C8S'!IH,GKAD+IRGC=''$#^X1<\*S?P
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M&U&8K"09%6BBG\ZG;$K$+< 6-6C=PT880,UQ/+3E?&%7F**)EI>GD68-0UQ
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M\GK(JJ8;"./%N^J5+^$90^H?Q,_Y;*&2&*X7-<=A3Y*3MK+&X$L,="0&Y(A
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M^+?,9WO#2U]<?;#A+%^Z(DF]2VY#DLQ3KI=P+9#F+_QC %HZU-4Q.--]4.-
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M<_V'E8E?T3FWXPDGXD67KV+?#7@N!J2^+F@T]*P@II8Q'_AT[,.#AY8R3F9
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M[\Y)Z,O7Q3NI ^NTKT4HFN@R<"R +?O9)1JMI%LHYF*8;D&E6G.E^23<SJM
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M9KQ\/U_Z79"7QUI3_NUS_6<)U\[OB8MMV=O9VYVWMUM\']O!DG[Z,?[NM,]
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MKI2P201S6#6 K80GR.3SO!(2FO8!K:?5BX^S>_*=1,P%.D4K>K>Y8W_ 'EK
MY+^1#<^<F2?+29_$4\VR!53&V:3E\$X]K6^HC7D)W?I.POVZM+K"S\,.U>:V
MA2>P[2"W)N".P<YCHMG&8VQ'7)3B04\'RDL[ ^'\Z32P@3-,%AGTV@Z>H4/+
MF\(SS=>;W/Z]2_[1)XF>(M/X@M91Y4.4%HG=-//*3:*]_?W*#T+''> >L8.G
M,SQ9>A0 4W@BGV,;G"J!X\33#??1?3M'I )3D,IW$MDF0??=AV/J4A+C:ZFM
MB%D9W2%SN:1U2%' HY7E01R^%C&0R0(_>Z#=Z&&'5M9DV HJ3<.[#C\$?K(1
MLFA[.=(R9QR4I,E=,-83QKN8F^/D* O5OCJXR]B0"9YZ5!ZOL 1J0H"2;0-R
M7.0C1<](, 2)+P/L6UC [2EM%,S5T"Y^,XFU9:Z "AX=G;U9OWNTME:OG#_(
MX8*^]QV3LV/OHM0S)5-XW2,W++FGB%>'0;]=N0*:\Z&1(:H1)0; Y%*V!U!:
M2IEA $;$(1>@2UOT[B2_IT>@S@IZDQ')\S<$'WAGMM[^;XXHJ4837/-5@Z0&
M\Y68/@[FQ'RV'^CZ*FZW%,@HMMT:P[ W]_L!_*QF:9I1>+'*<GX^4&/N6GJK
MNUN)<]AE>(=4RBE)^>'6*Y^Q]GC")(H4U#P#K3)9L0).5@F<S!"S%"C@N=V:
M++,WEG%:-(-UA452B<G56TTS"/C6G#HSP;4@-DAJJ%N)Z?>?Z?RJ_R+7O>B_
MQ"X/5OJ2=C6JU<>[H,T@6(MC0645T=C-"I-99$E343/I._I(D_$LC;!+UP7+
MF$VU3.:4RR7*/,.Q4I# )ZT?D[E3\\<]0YM/UDI?K:A.X;"S@R(B??A?6V<P
M(_"*PY'ZH6K!HOP?*6,V/I-V[7P]MN0?>&2[!<H6MJIK#9$*2_ET?M54NM9]
MR5C@&4 DT%=GY^J23]QO_Q*LOT(3IKQX8J>CV'.C;*#N CGF!20=V](PS@;&
M<\Q-GQD=T6\NP[^\8S2AXB1F?@8DZ&8,SNSBKPU/<2&:9"";+ (6<M&-WL[>
MG9'AAT\#!.0,[_G0H&,_5/6'<UQ7!M0V"D@QE1QN]RVS<D9P! K4!D?W!<4[
M_[W[F,RL>3*3)TVL5WSB)C#^K+]K@TO 9\5;-7O!P:G>1F(X]L+H/25]H"^L
MO G.,F5><Q4WL0MC=*]ZIP>3\!<PC:V77G%Z@$MI7U%YV.+G=K0IRD.XWF(
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M_J$0(=>6AT+N0^F,W/@N#5@Q3#%$"@+R/#KV';_[+,LI:>IV_[<JSKD1&6:
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M0+[C;=+!RB- 8NV:;K;E(;KC1/5_O%5H=(7Y1-#2,X1P>*1R67=6XX6.WLY
M#*<YF -T;4'HS[>/IOI!.G8')Y_#8V^9H=,<$+T2?)J0PG&B#"XFE/I(OS-)
MY#5AAT*MDN)!1HN7(.T',*6<H4WU *Q: G<;QX*E,-(9727(7<$53'XM<0 L
MRAD ?H(3E$33P9,3-RIX[Z$S-IJR(T2VO-68*AP9]PG"3?,9S0(0D6M!GU3<
M"2(8B])_-$$ONH1;H8;=NY4-+3YYD5+:9^,B1JX;YF4SFED7& UYR+_Z$7!7
MI5DL;=3H!P<Q&1UKH+A;P5%2<2=N+XG7])XPW<G9Y_>A#Y!0A8I).-$41Z)7
M"5(G2!8#?.OAH,8LRWD>MX8T=2<;F&MZ_?+%8%[E60)EZ7*PBQ!N6;HH&*>"
MA7G MT<UG]%"/ !DSF97<"1R =D5" \<DJ!W$</"^FS#NU?+=5GS(=4"W$4=
MO=2, 4:4+]PO+K,,>4<^]36?S26W\A6?21/!$9-'5NYDEX8*.:&4/ZPIK)J5
MV1#LBJ5X04UEN95B1E"/FTQ#@7\HXYB6 8M2.@=MV![-!EVYB85W"U2RE\^O
M"^2"87_[40ZSFJ5]+!V(TE BSY&SG$10@BC619';8+"D6%DV=S"H%SS(G5@=
MH@K- *N#AJ\WN&:;(! ^:8J1SE%)7TN5Y%6O_2+TEN3;;"YG-+:/V5#2"?R$
MB9UJ#<^7]S5O9#'J:?$K JP(-7(> =QH6S4/FVC?2:Y,J0^,:8F)7"D*P4ID
ML5E#P(A,_X:8AK1<)AOH.?<@D;P;.6/S@"EAV)"6 (=KUO?L:E>UA.6OBYQZ
M2AJ$)0O<A8>,Q$/"(8+4%IGD.740ZX1;SQW:8;U.@5]^LK.S<V9-?GCF9! 8
M8U@UB4Y!\B9&2@,P#J#&4H1ME!-ZI;KWRJ]G-KM9_Q&@DJXFER)3"PI 123O
M1BPG8AK>P)Z'-&1NUQ6>]-\!DW@4*0BLDMJ7J1D756'5DWJQQM#$B+I@,1$I
M4(=!Y.6(9 O DNA?!@VJOOYL29)$?;0>$X$=(8\ K#5\]LIB"35Q>=ZP?;.W
M2Z ?:5(5[@AS.F-&R71LZ=*]94P6O'Y5GC@2S0/4I\[PI<*76?B$!3I.>^@!
MLW,44D?^$W' ,/(\Q.K L CJTI^EEW$SJ8$V6SBY5E]6=9@\PZK1@S#%@'@!
M:$$O08[NK;1>+K@0NIKD($3^( (5=XA5FM&^C.FVK,W,2;Q.XYAJM4'[ZXR&
MQ&59_@ TUJA[ /HFZF<7ENN; +4T$<:^3CYIZAQ8:4H $J=MYDS:"TR;%%0B
M,S1YSDCG( 1QFT.LPCJFG8-C9A,""!W]D/.3ZAT5_^RMP3F5PX+\1O00TRU$
M UB8K 6:9/&@B^16#8/0H18X8/7'S;Q;T[*E>WJ'"54L)O147V<>)=@O)Y'I
M R0CA5J'P!H'FG-Y?HH,1/N&'O6-!..[RD;"R$(ZW=:T1!%#J<#/_>)"Q'@M
ML*.B9YL?V2\MQDF!U04=68R6-;8H4Q5RB^7:H 1IR@3Y@D1M&D)^]I6BQJ7*
M@,KCP8C8GX[:!H-3<A%(T8+3945?4JN8RD"9A8/Q06H;;#%=/.N/@% M/B,5
MUU\1?B:$5!LFXA+F 5_"]UFN\9/?-3,G+8Z5Y+M%P3JC%F-6)G")ST.HA*DQ
MIVRUQP[9&%UZT"WJYYA@=9*]BUU(<)6C0!;0C$90G/;&Y430@\Y=>[)Z,ODL
M&7,UY;, ;B?W;,+&%V_YW).BJYBYN=G;-*L[NX):[KN-TJFM(JJK8Y2 )8'0
MB&1^$B_O5;U)D(;$G" ZY3SJ?L;-#&6)#6['KA:#[A+$9<982<3 /D1>G=_+
MMVVT_D?'<YX4J'RS8E9HHP%&=('5Y#*H'MF-1:^$J ]2<G4W]""5DU3SJ32N
M9%Q4NUX SV#AFIJ4_XD2/,60BV[C)AO-.V&3GO3RJ\AK9W/$FBV J8D1 #]1
MX<';?&4[@4H&OH!0,>-XF_O,#V"/Y(MQV!@]&Q-5&O5QD)OAU;78C-!*XHZD
M)*IM9'.?6V_O-KL.5/\&Z*T[K:=NM9Z#4J"'\5HCQSX17Z0H*_0(]PP/S2.
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M#;X%*XP+W9.H"*<&0,NC]6T3\L!Q445S!JK*A2+GL.)G4@-BCW+&6IN'Q1M
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M'C$?,8#,A4CQLWQI@9R7Y1LVU<$&F%RR0$QQ,2QC!"Q<V;[&K.DT7/H^  "
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MASS.FOS3U)1OP8\/K@ 7#RXQ^5_D?#$/@&_V2U0JL$S&/1GI=-)85:SE"K4
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M[')XR;K0^)'98MI6\&>H 43P"N##I_5\J\1!7I/,O*"C&;+V)KF?.D7\W U
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MHKV;0\04R'0I,GSR+D5+OK8YO8#OCFJ<A,W\ XIXG$!N)F;$O"_M5#9["-=
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M=]E,<]63HLW=@5!TI<W0]]50:1R9*X#]N6H\]].#!RRW! Y9.V22>O1I +@
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M=KX$AZ58YL_/:,7XO\,E/-E?;D9,_\Z3?'$)WY&4 :V95'P$XW3Z?$-8-#$
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M\P^ /73>C/T2.99VS?4.LR^YK@#IR[N_2\ZZC1'(0SM"(<%("<)!PF;!FQO
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M'\\W]M<E]97#CQ)K=#&*:H15^:IT+PT?*(D3QT^XFX>@PLO0E8)@%['X54A
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M?':NP0D.H.E^*>?(!\YG_^KX-!_=+4Z!?!YR8?ZION,A$<PHN<9[A7SAX1!
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M.^T<2F1CS)"8QZXQQ8>2*U\IVEM"!=M_ L@DW_W_>F^^J<Z:4:@&3B:'R<#
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M^0*Q#9>L-.<-;7+GZPK/'TV3.8EMC':?CQ]X&\S[:-Q8_LBCI@TG](?5YTS
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MRE_%?]E\M)+OHY\Y9[*QMDS?B S6X\G6F5F_M)JPD/K&3TVQV=5PZWCBJ)^
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M*'.A4J#Z/]2]=51<2;<'VGCC=) @#<'=M='@[@X!0N/N&DAP:*!QUR2X!K=
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MLKGNMN[E+O#6&!%)(<-T"[Q!6'T:4Z]?IIG(&5TZ' 53$ 9_DS\35%F_]BI
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M12>C>WP;Z$GITZS?*)<?VC;.]8W!1W:GW*%?AC@N@ 7WLW\ O,DU<AF2?9(
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M(YL3>?-D/U!5HF"Z(]UJPC*-5KX0P)^6=DHZ@SWCO>!B[V%#E<_W?12K[P<
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M'D\8JI9>FKV)RA(7=IJP @]OW;UA+<]_4KM"&92.>JV;Y'91[@> Z$%M] ^
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M&PYJ>7=TS.Y26:5KTP%3?2[&BV&B3!M.3SARG+_![7D!_@&H"3'>^')=>//
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MV'_Y0PKKWK9%KZ],-^-8%?>#24->8W/^QOI#%^T]PVE!"YZN\+?+M6M".>R
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MVV!K(7U"FZO[4VC[1+ @H;[ S_@T^.&;7V7TP!M<X!E-_&O)2WC;(2]TTX3
MX=0A]D=YKW2Z?ERD,/$HZAH1W\QZ8]/WPBD;B-8]>CG8_[>7B\"L/\>NDQ[[
M]/W- A?+W$+>+P %:FC(=\G] &E:A2[EU%Q-6  CU@_TE>.N?83\T>?CF[6T
M%)YS'HRY B/AF'Y!SVT@*#CP@'4Z8L&BD[(_C:O5;%&:)9N ,]S0M.!Z9/[S
MW_U1^?BFV-?;0] J+<V>;SDC@F'A<\FXC#83EL5!GX-+/.@/>"CX1RGCN&QJ
M:,(9S[;IW ]I=25)Q:K&QV8VRFT/+YS-\";LPK]"8 M>UUH0(^[W=$5&,:H&
M%ON39J! _F,QR8<D+R/<;FE5EY@OM/(DBKT #?$YN_GC+=*@T\V'SLD##^ET
M'G-X25&]++!_:2G,TQH#@!P-@%I28%*_H9MD1MWCP:9\J#A=A\N)XYCD&1Q*
MTG!?A/(A2_^3.M-;'-)35FA9.8[A<%B(_DN=H1:7HG&R/P[#5K#JWPH+N7X?
MRG*"D@2O;E4##J6R:#<9\M F4:?A0HNG4R9YN]0H:*;2TX:B/.$1.!;??<U;
MPHY0,*IJKV%7M3_D)8#5F?C <*-O%56.<^'I*GA0L"<Y!$8HM>?X&/"!^R66
MR5[='YC[!4"[MV>@<B+TG>DU-X,]8:?KUUB\TUJ+':@IO@]UXA6%'[8W<;3:
M[C-R9]R U\?(=Q 3H'^TF"-ZD5MHH&0 @$]N\)&B+/RK%.:--*3.)TFO54J5
M'W;E_7W0?"^SL2;FK(D<F6(6N>J0Q'X"DI>?YM+ 06:HR6'-$L6<?](#_<SU
MU$TU'\;?+Z2)0X,,8]NKK &]CDE2*>$<);J3>,%RS&CSF@ .&[]DV$^Z9:3^
M TLA^=,99%O/&?^X#,.@RJIVW_)K0EFS04Q5%Q+BFG>)K]5L1H7,RJN^BFOF
MZD%R$0076A@J;+OS*<YR"*^(>6\K/A7L?SL)6V*>9D.P.@"J]L\$(C<.F0IB
MZTVQC!;E=5D]%<\*CBS+BVA73D"/UG;H16$QK$/(6IX/T=1"2 ?[ VC ZD[M
MQC!*OFU=A*#@@4 &3CU%"6P.$S;+IC(,!AP2A'[<(@R18\.L>KJ-U> BFZ8.
MNGXSWXSI1#%;SF22Z<5R =<5S&"V@K;(=P3I>0?PS<N9L;?[ M@<.S!VD.&2
M7!LE^6XB ?K3..1%:NN9Q1D9Y>V* AWD3L.O]4=$,GC&3>S<F@@%?E$KK.*.
MP*$O"VZ+?"7+KPF0L+M!8GW7??8HU_T%S1*#CJ9]0V*,ZB%J)J3_HJ=)PC+B
M;][';#][_K#3<65$O1ROR"YI3LQKZMB5SR46\M0!Z!8_IT3<R>A@:KHC&!:M
M4Q]\T*VNL\WC$.1^(AVHF(*:CW5WM+P073)(K)0[)\&K XYC@US'"O4%CP]!
M"G7UD0,6-QSF"\J_?*T=L_)!X2"4DF8E'@0I#UL9/41:[6KN$M7&G-I^\/IS
M.DUFOOVUCD>L1KCU*V^^$ %AAM!9H2"*[;Z?H;2+QX4[BB:EI53#PR:E@/)$
M60":$C=O^WDRRK4WE>51R-OM<]#D:P/Y65A[O%2EQ$3]^?S?ELO\W[%<XQ_+
MU718_[8<.'#2FIZ[I%[7?;N9'-E4SACOGIE3:A;%&\I/_GW2G<IR&':&.UU#
M=!R2$L[F;@QXPOVWEMP#B$K?U@[0+5;4C3ST\MD@'W3Q.RGN(_]]C13U"BO$
MIXN'NAN$@<I'$256'%.(@J;-PTV_>H8,08F[3.)(4#V,(_Y$PZ/W!Z6!)YQ\
M_)C48XT25%X!9/"6Q&)W!UWDJ?/1C;D<&6+EJB,S.Z_8<C2S);HD6.Q23&VH
MD&QMC,8_/[YC'J]S5:7FMS1C \2A0KO^;YA).^'BYZ7-';]G)+.Z"V]L<;.=
M/:=N%$^"46>&%ST2.3X,B<,:=<##=7(&;Q(F"E?<-C# U*$WECZ:/OSQU@G&
M1>RU>6/RWPE.CS=3&BW)L%<=L86C -M?TOD$OKG98X4(]/%7N61.XQ30:Q&%
MK>HM<_\"F#:E*FUS'2\6M]9FQ<+NYDU284@I'54.MB\61&* '\7 HD9]:DUF
MFF_+,HG%0BW17V( 7TV3P,H, $@TE6N#\4/@/OX%0#=:P04B%XQ8LJ-+#OAW
MI'XKYRJ0M2&D4,[DNFMT];S,B7J'DY5W@)!#&7'LI&Z&)I>9._MQQO11%[A3
MAM#>:YS6C1#JTNX<;H'FY,8CTMC0-&<ME>#$[;0I.B9LGBI8.;J#5,(_C]<2
M!M ZAV-/H*'W+GX):)VPKO-=[Y8/>.GU=V[-1^SB,,+>X4TT4THT,?+'A/E:
M(6B(J20_;4IRFNO;<6+@6;C6UVK:*%I,@>"OR6-;:YG+.-KMGMK9'>W^[9F<
M]_[T\\2+J6)AVJ?3L12>3N-*>SHUBU5D^O@$C2R,:/C=J4LD01,;F.-YE,NT
M6[=5 5#.Y:8@%EN+0O.4Q$,%0: H,$NC0U26.N\K,&0;#I,=O$C_>NOL1X7C
MQ3,BXGVT[AIH@5:SE(S78?M0JG@.0Q-U;&TS!MS*UV9^!(51KUI5A=0/FKH
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MD\JD#[@L)@0EY8,0Q.#I<K&@/(Q'00XZBQ0)V:<A)I1?Z[WVNB5&<*"#6IV
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M+(!9Q(YD>;PS(F4:7A/4KO0_'#_7VX(C YD=B9W40-ZW%$Y3UY^Z[7]X/WM
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MJ(QZ5 ^,?*Y)34K6QYB[9^\[0:E-QL><\ -N>)G#L51P@^!JN9JO>7O#Y<C
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M[S#G\S\>6*.27:W>V\T7=PV*D>QH46<M4=)S>T*[1$!$H-A!@','*[XSFJM
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MNA$.D.#/ FV7SMK2 !Z7K4FTIA!C*# K4\O! ,K>S"N!!0B;.]!7(,A/(DK
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MDC8B%A11/X6JVF^H BPZ,O?NX!O3&'<)$"=?!VU,LUIWJG]#T5U!0&56_;%
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MP0*.B:L/F*&M T.E$:AXSW'Q2CEY2R9VKK]0]2D>S1=:.V*16A: $0C@K8V
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MVN+>XA*D>'%KT4*_/L\XYWW'N?[&61?K8H]UL=?8:_[^_SG7W#Y=>ND4^/
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M.&:_5=!EFM59?&EIS,I(=W?.SM3Y\L8-O;+5UF+*-(E8_8X,JO!I,W$]4^6
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M3>+2A_N^EEOIZ!\UF<\F"E7E*F:"\",()HM+N5.E,)BY.>I 7)=T^@ML4*<
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MKG-]#WWCW_6\,K^A6M7H<KN7>7W95>+NWS?*5K(QA<@5B.WB5)01+NUFZNI
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MSQ)E6II\*MS/7K$K=)@ZHXHGS,O2=VR"B)9'9TC4K.X*<PWJQD>-@()-3GA
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ML1)K.\% Y'6[1W-2MS-<"6_&=>.41SN@39?9*GR];'">$4RM,$V/31^$^2T
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M07*WJ!&C8)*6TCL*H=U-<;7<O(4&"70O/.6^G;*VW]T7J#I[CGYE7BS_9\(
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MSS)Y\AN/\;]SM"<UPR#*T+O*4,W0! 08K $LHID+JZ1LYK[OS$4>9^=I?VK
MO(U&)NQ7^:WWRG\U*FJS;QB8_(T7]V?>WG^Y67J2WV/.M21X,7Q>>OZ4;M-Z
M,7PAGB4H4$[F+RX4J+PI&"U?.)7WQX5J0VVI,3;P.6J_>]4\K=<[H@[5'B@2
M>K3W5Q=J7'DZDYWBIDL$':+G?QPW +7Z_"4\(;?D7]& V!O@[X[)AEU]3U2@
M6.*^S<#.W=H?8\_*\M9ELK(*3Q<M\5QN> $[52TN;GL(75FSD!MVOF2'19?>
MZC>)3F0HZ'^%JM2^W(H23'ET^DPYW3G9B/0RX1^(Q)0K'E^QL0=+6-BQNV%0
MB@ZXRJ=Y+J15,MG#/H2__3GG&?L'_[2(G]1D7NTK @1Q*];?8B!V8LU,?<;*
M/(Y[B??<]<FW#K8&T9+N76IG A]<D];P27\%[=\Q4GS]?Q,4V3+YG?>];3>7
MBJR9^77KISA4E*ST8&IA2(6Z/AWLK_C$\$$%XP]DJ0DV@HS5M]_&MOTM\%1J
M%1'4]\K:MY;\%5%%]6;.Q]$LWN8K[J$1R4-RG\PN1T'OFN3>"<L:D]A0U+[6
MEC5HVB9:IICC10NP?3#(5_7?XY-MFC IO WU&V(;<")ZN)C=X*M7!F@T>J>X
MW813?>B<YV&W4,GR95@6[.DU%CLF<"C_QG.P$"QSEV_HE*\T]78PY:DLUXGB
M^8U'A*O4: '$>-8 #WYM11L)BQ]J:;0$&:9T@]]5Q9<LHYL%6PI;!A!,$'FW
M>RL_JX8;AH  SY%U*\CD*\4ZN\1-5RN2&A:%ZFA4"ULQ.9.5;@F)/U<6CV23
MZY"/QPWNJN%.H[D9'$,1>?Q0_NOMN*:3S#B9S[:'<_,REH6NZ*P(D;-X#6@6
MXY<%M?8E-[U=0&9F"\V!%>)DJG]&T49_R;!3XS=>7<8J%74.U<4U #C"C'0+
ME#YX"A8).[(M"9ELM[=R!D<OS3V^6_*3MZH!X6X<F%T\G-V:J00_! "ZR)8^
M<V8*X8H,% YQ"0+,& +N:826;V$%3?@)IX'HKHX?E_4<$3VL0X?(FE38="LR
MQHGAT:,ES:BQO->;FO-TGW3*C5)[G&\^$$:9KK^\<+Y@92_K=OX,YU9MQ-8C
M#&/?9R*'[@GA;-5E+D=)ZYFDF>$M:\2P(%H@]S2D/)RONJD\I,),3R<VWQ7.
M+A;Z?EL_O@]XQY'Q)EL<X]V,T D>-:XFI_9KN, *-/UE/?SOS>I=Y?\B^$P[
MBR*O0I?&5$<>>40@RC>Y4EW0;#Z?Z46S3O>/1[/*7\XW=9S\^AHQ--;:R.D#
M'ET\A#XVU#2\X]4=WDS;\+;!KH9&_ M%OXK%<&S!<QR2FXT;)G5?:",FLZD"
M,H$SG^WC>$F<#8YVG-Z"\C9E=2K\O<?T@K"7P6[N7Q-ZE^TQ'ON.!WO/:F!U
M00D6L\#/9::B?2/3'B]EDZ$-9JN/[9$P"?P'C]>)RR1PP6'=?!]PS2.SEL[T
M<0^</58Z'1Y8SC-^%T-]UH<%WQQX?7K&B,B$16G3SP#HKO7YPF7<^BV&A,I
MN;;6<N4+80+*UL6R0S]JR?R'A@ZEU[_9)^!3]Q/'"G'.S,UO6TP*#UNI@]K7
M]ZI+.9IORQ,CLRH*D>9A!VC^D@OBOT4I3V6</K<1(^K%+V(43N[$0/L./W;W
M'VU[(@Q+R(59!R?U55U8EG?087S]DYHJ"T)+NY_#O[+EQX!CMYUYW(( [(3T
MOLD.,9](DI2+.6"S@PE B8S3_(.Z "WP,T3^'3IG@MXEQWB<2ZWZJ\>",P
M-01R^L4C8VKD0U,J$XV@Q%MF:+(^16FCSF-)\X]$9WLD3VDEA]TA$#+H%H0I
MOM/J!D.?9X>KW=8C['U,^Q5WV6OH>Z:&N9:L15=J@\*(3;:O8F,3=:_5I[W@
M;[/9Q[T>I S%# ]\:(JMD7WUB@R\ZM=FOE.!S.#^4CC@(2%$37_6-"N8!;!Z
M:<BGK0VAC""KAX*5@$VSL4"JUQF< MR5F,*/E]5!YM(Q2#W?7;U#&SG]!"A%
M)S[)"VN^3#BQ-MTVU%K5J*+.Y'LM.0C2,G9%NJFDXC#Z>7(^ZW1^4^LY8'J4
MBC!W@589:8<F%A0@.1^.A'RV>)UWXMF8F1]A2</D%-M/,Z<WJF$(Q,P2-BW*
M=(4QR7-*:XC)[S]H*,"5QS<MQ),F?CFOF>P=>?7*L%2P+7/I,6)V\;4H+7;6
M?-Q(37R&WI8''MSB,$DM?W>-64O32,3TI537@=CE@P9'[-![?I$S=:*0&*D%
M]+6PP9!B;$NFL09;TDX&?1&,N-2*P1=Q>"5FSH8#?25I7XM@F:XR?$;L0%>H
M5J=?%COB-*D(&';[JQEFY:D5^[F@\6"O.GATV6I],'%7)Z!<Y,7 )M-QZ:=:
M)KW;X2]8+3F,I1PSF:K3- )C<;HF$[CW[F^RH2Y:CWEY>,V>R+[:?R!VO\%N
M-O01UG'TY[,SQ4WX;=J;<# 1467&C'6*M;M^FXP+$*BXC@._Z3+:'\X#JF[]
MQB-/O[\)5U2X0]U5[<7Y9&7%&W.7B%NL6SE:#+49*<2@92UB#<KVGJ3"D0N!
M((XRE]0+929N6Z\_<O]@H=W1^HU7GFZ3F=@(G%6P+P:&JBG8IH13)N<&R)\'
M/%!H_&-#_7-.E#]?X[Q+KXG5>T1:AM"? UNOW]_&&UJ@,*T_[Z])W0;C<=>Z
M+Q"6/6O5-'UIVD)-#FYH%"WLH0U#6;F90.3ZP\AN,G09\TXI+IF&BNBO)'@V
M9":I+Y<#6OTW[9A?+Y<3M*K%SVU2"D,!%L/1!9C;2+1YX5_WV?H[W6SWI7)<
ME-/#K*LVFF8XS)2GD%S<W(EI;EPYKPC'7TS/BZHWTKJD9?]+,-5V+]!++)#9
M->Y1OHM^"F#3Y8=,3LP%WN<3Q\*J>^3&?G4WE RT*6Z1>B?9*ZA)W4DR)Z+I
M7;,P8WJR<8 (/7]G;%YK.LTZW^E/4)^MPP=*93BVU8(2%H$;W^,TFE;XN93)
MZC/;:!7-!A^A4=+A'VW6?;B:9U6L0TN',S#[@P^'F=)"K^J,E7)DXSZX#!S=
MK;G[M9=$FT84U[84Z,6MPY/+3@8"0:>2W;<TFI[\_=[<V'FN6'C2B6Q?M] ]
M >:8O-+<VY;0V)<J 5R) AZ7CS[Y,ZZ-9[K+O8>P@-5Z%QT+Y(1D:T>%RNZ?
M&))3,=9V'Z[FIP/%Q0WJ=JLJ1 PPI*2)W-?BZDH SM#,Y&TE;F][4IJ.\E\;
MZ<#-,>*PP0X]O_$6F#*A+'T4\T(0]8*=;Y 1WRJY_L>,@ST)FU;5SD,/^DOY
M(FO\293C QC I)H@)BL(4(>-*2U2ME&I.:M'W(EF9/2ID( [?4CX.V(G5P>,
M9U1T_%[)W,!T*7IWSWB\U.KP9S:VZ[SKKN-X*([Z:4E"+6UT';KTURBX:R0#
MP2T1GH%P/^=0+0_1=FV5G1JTQ*O!V11D3S9A7F]4-%BME":P]+F0>$/QP^H9
M%:!?S<POW[X 2+X#J=QZ#1]A4![(,*-@V'8VM)8[]?YJ$2L@TA*IM"2-><,C
M!"XA,8+=/]*Y()\_XEQ/-[J]*F/ZI&?DU/Z^1K2ZNTYV_E3"^0,E"ZG0H4Y^
M(O27H-EH'**6FMZE1O.Z$+Q?O^\#@\%J6CH#O>^/%";IDVQR#^#L+HD2<P+N
MM%%0,^.,7H>TTI1,:XX:'C1WWM>\2FV?AM]X\$9ILK>CSGYHLKE5"TEV7RJH
M!]F YON8B D(H^VX<1S+.VI]=[G9:(8;;"E8W!,/[\!P:5PX2V5VT]=8:-W+
M6<MV.Z74)SCE1&XFSQ]$K8DF<,1=-_=$K=7LJ55_9'5R15L#[4\FSV>X0W2F
M.WTFY#-M%8OHUJ&%1KZ/*BIC9W.E_J(S=UV#96EYI-_<0B]<E,QR-)O=>R7^
MY+(?@7#N^J$BS-:<KY4O@H+3H8'>4.HQ]9<"=7H'R1''C"UV:X<;1,$]]R(>
M>4B=#M=[5\#4()G1'(Z]XRIS3)__5-E;7.=EU)]U<O'M\Y=KN?%'3O1UGCNW
MHX[;.VQ"#S;F#IS;L'_DR&7[&]QGB0T!H8]20R.T8OOJ#<JP)MSKXK]-@\9^
M,SN131 ;W1=:LO>O7":.!.(,,Z;,HSM[A)HKN9DWY9%!]\TJ4NWRX0*==+Q'
MR@TXX\$2E1F=!,M9_5[%C-9>_D7;X/MR<:."_-NJ,H/9MGD[7#7'$D/A!*R$
M(_EE>]Y#'-: C*[8?4AZ#*MZ7D$QYKGQ<*'W:TXY89U7,U)+5KTFGO^*?IK(
M6X;E#?%678TQQM]A<J=6'7',*WW_99!G[ZO)'L*OXK,BA.NF6A,RH^@Q*J_L
M5B3RR%I ATIQ$^8[26*,?+ZNX,;1;9*(/2O)]4Q3 '":T\=4\\AS& <>\A7J
M;F^373C8-6R($CZZ&=W!D<H04Q<_YW,362%&R5L21$83*5::1\JI?NE@.<S)
MY_$4X2K5-*[\_6J*?.R9,"J297.+NIS-)([3U-#2X/+@/PR]BUO[*1K&W'(]
M66Y?0D:+! /Y%\S++-(TN!_\T%B CL3;M]FK<U\:B^\NB3*_]YQS.>$@ (71
MVUM!Q3SRN)\7EXRY6V%L,S!%*0#=MU6MB5.RNVN&4^*47CV,K''$3SNWYB5.
M7"N!8I7C2H[()!-S?("Z%7@7;C*CGK $7EY^F\9=W1[XRXD;UUK(_ZKW,$W-
M'9/F<2'$77SA8UO\/'_/E+2U];Y2-N13:UOVRL:86W['K^>M\4]Z.>9\LL'+
MLZ$OOR>04:=!0. )*1. <_.]+.^93(J&R8.-#')*!]QGZR<*_HS>*;H_)&M6
M\4W*W>?D3CE+G8ZY2/??'A;R=R]E6@MSX>&$;-TX6.V3)\O(*'LQ'Y^]6A#"
MOD>6/S\<^!9-:K0A2>+>XGOEL=B+.D7[@KKW2E&1$:8VQJ+!^W?TO&OMWIO4
ML4!V)\:E?F S#5L-TX/JV,+*/(J>1S4K][[;4G-E%YDJ(:T[ES5-^+CPCC%
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M9#;6Q^UC6$;FZ%1;9W#I@<>&FZLCZ,RLMNJZ+(*'MX&M/1*T4&A+W<>ARP.
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MI82ODRUI3[RL1GWU%7=I]<@EJO..8@GTU=<M; PQ1A<;C4"=B!-A(  '50C
MS[ZRRYRVN2'QD,.1J#A7 @%#:!*XPVWS#B(!>0/S<HA;XBGU3: CIFDD7W-[
MUX!NED]Y>E)G9?/6-IT/*,9'P]+ 6YW/S-4B0:&^,OSN%1LVR7VJ[!LHUC3V
M!TQ:Z>Y5CJ-;UP&K>&&259D%#\$8%^S01RQ-MS-7[@]W9I!S&>Q,!\$>" U7
M;8N'M.0P0YJ,S-[Y[&?_ Y_7M WFI0OOV26[<,;=76C/,3))*YA+;#E$-YG8
M6>@4M<6>>_MV<7F<K0WXL&$_9@U@9(N83AN[%C][JN(B+F@9=E"N:'N]7]UD
MZK_%054* )0J5@( L:6*U<6XQ?[0X(C-FI)G%=>\=QN4B*ONFZK&Z:YGSQEQ
MC\Z8VY2GHF$2A!6)IG#':%71.QI1P?BQBG].9R3O)>_"KY2>SUXVS>14RX;0
MT^/,91@_HM>X,!%\ N!BPB>MR%)<',D7#V$5D/3*ZF1DJ*ZQL=:4CUI?MD:!
MKN,L4I3<A]+R%MZ<7>V^8=-QD5CFK)"J.J3>.W'^]0H68>?7TI)FX*U[!X2#
MSVT6C ;<\7*2RW!JQB/9FFWVYN4^,)N*EZ%,QSW>V7>KEOI=/J'(DF#9DLH2
M0:<+"%E>7GHJ-.*58@K$XR-'ID"I/3QADO<!-@F[I_G!O+S/N/1]%BEGK0R@
M\PL?K4LG_\#\;-G9QT)+:8F=A]&AQ2E  / R^83_S<,AH?+KWJJ)(/ 'L2T5
M[PP*1V^M:68FR87J:N44QL@*R<4PQXE?#,%W)L%WJV(%_MM_[Q?>7YOD>4AT
M!E0EPQMZ;%; C&RG$,D+%YYJ N89TY1'2_;(;.V9RT>,I=Z@,=.2U>46@G"U
M:*/Q@+"Z?BL"4N/L,O'WF7]H,:OE>'.7S?5)&T<PGM2@*NG($.<S1>=!')9K
MSB9)+P_3#Y\\\%<-'O=75>Q(@, NO]'@BQ"]!64C85M5=Q+H"T6#=#25B18T
M4B$2W9<5/(T_0U&'UT6G2L37Y=.:>[_1(C/:)33<=\E:&]'GRV/PF(988V=2
M:K)VOOY&JWUXTNYC.*8>'"5$KV49Q!^V][@I+X:.<Y =.)3<LY(&&\-RT>-4
M:]P1"B"%;(8 EF(VQSTW<+9K=]/[4IJ-L&;<Z2C",T;9 M(G1=UR.DGB/U<
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M]O3B@=+E9_K68OB?W#:JB:[4$T%A*26JE$'K=(FL'7QA(BCML7<RD)CF\I$
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MMK?X&ZW*C>1U>*@1(X>3#3RA<UMS#E9^;4I2K?)N.F=^NR[<6JTR-(D:\!
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M*#D5P^O%%;?K2,0WR=XJ]CS_IR7!1$J?J]^A^244AS,IB?G5*O:BXE/4=,;
M\PW*Q0(S2<"BM#<+L9R1,V.W9WT*SJU=#Z*I\[,M:A@[-26$K5$Y8(=6OE8Y
M1(+')N[-P]PKIOI2FP>Z]EK_EL#RM^/D8]3QJW -.E"=_2+C.")TA#Q1(D>,
M+<*-5-'@:;P2TR6I+9RM2Z1",VLSTT71ZR.]9-=1!=2T?$SPT 7WVV!PA#>>
MH.FN_"Z?,GK;FZ'^&=K_,XAATM]^./7.W[J@:*%7]V,1[(#6"2P^<&JN;ER;
M#IJ3K8<+P+))&+!)B,&D(IJG%SWJ]E<E(;[),#-?R9@&UB-O*TL:9W4*5EYO
M<NZ/N[-@W;TY(_K4^F#0Z14(GMS!B*GIBE<L"J/WSZ$V[8%/B=#O=*:[N;\@
M4&I](9^XXI>"7Z6+WF_8%FC00['NNG:$$.(HD&R8AI+I**9V'D47/*Q?WE8,
MRJB>O1K(8YE_./1/%Z_M#7$ -S^\9Y0G4P&B@$:\;)XF4T>5^(E7%<#K9 Z^
MIIP/H+;@-HS! J_XKT=Y4@3#996=A?B9NJ?EVC \LG>Z5?,D8 J)CF3KC\N:
M"2A>A,U7]K<H_K:N-9XP@>(C(>[YY*)ZV/RT*(T :Q@ 85]=5#)Q_O:'G7^&
M\!Z[89S>\I";(F@\)^MY93O<S9'BPQ7!,*')[)C3H9Q3EGQ#_<4A$D1<(R;S
ML_<7P/KZC;PU84-1WLR;;VNA]GKKULG%"KJ^>4]] %)&8&53_(+,S%X*36E-
M:WWSA?GY125J[YOYBQ)<Y/AC$;1931 G$R",,SHZ7VJM=+U&LDVX[QP.]F#]
MJ%\QM]3"*E#?B++U2L'H$TJM)MVFS@4D ]-LS?6N36"\8MK]7M\.1+I22/$9
MAFC3&'<BY3JA%^@8+%MJ/,+.GQ_31-16?JN)ZAY]K_ZO&($SA(AN/><?/=B,
M@Q%2'K0:=0KB<ZO%SE&>>/JP&PY;DQ"C,4_9)9.@D8-)2(6EVC913L*?[2G:
M=KXL,^H@TZR]BS'W+S[L3'@6.TV%CN#Q7^NT'&V&KC+$;FC(W6G2N5V&?Q3.
M)DF?;*0R2Y&92KAQUC'EH&@OM0][5NCH&,9A5>#"QZJ8DF$T JH&IG[A_GY7
MK![;9DO;7.S;25I\E+_2L5@2/W@I]W(:N1&@;H.D0ZG-) GA)+QW3Q# >5E_
MC97>,N\U3>'WH+?UCO6.?TN+PLHOK*''SQ24*"KSV579[UDTHH[E=NF'/BZ%
M7KH*(Z\W6#NPBJ5V,YOQQQG6U[TSS1HK\B$N;:7/:;WO?#WW+:J ^!Z+3Y,S
M@L(_L5,.W?M]<",7<,^L%Z-B[UQU(B>=TW5V1( :[R<D.2L+GTAPM;#.I7R\
MZU:/Z7XXS#;;]GR<?N%H1'+Q X_V2F1\*81S55PHL%&1V,=)6WI7URTZ.FL&
M<RCQ0#<7=KNT/!+53,S1$#UEW)&"9YB3+4+T&ZTE*O%A,W'K$=<R,9D+2\8Y
MQM=\BUMX<!0*9&;SA8K6OP);;BC?>?I%1 H4%RH".3(3(GRXD).=<QC<]Z6I
MB JX@$6GCLNG",W:TVGIV P> X8-UDD19?X8)2]B839Y7-X+T)D=V8;Z=PP'
MGH5:;Z^&L_"=57'Y1(ZU\# 3LHOP_F-!AK5*E\06G9=;9[3T1J[5XYV9,X&A
MP%(Y5PT6P/58Y&>=1QORKP+R>K7J /VK0=JV=R$$LES H!\>LWAC9=2(P,O&
M 5M1_0TAIXD8E9X SJMB(!EZ)R.5\ 3LHU*81A[!\^%F-Z]DBJ?!T4:/>8+E
MR),A-%R/BH'%[0C)-'7'O=M-Z:V&MSDR*,7,&I8!E4VIGQHM;?.TNV#/M!PH
MG@3Q8@X.E\26Z/<J4I.S[JE/]F(?VZQ2NVO"QC+(Z (X\=BC/NWC X"QCL"(
MF/^,+DPJEQ(8>J4?998@IV^_KL;\^3:1)F[!-B-,J":QB9M!+847Q6(44:[+
MM=T.?5ZMI92]0,*Z-9COU',<7^ZN$\$OR)'B-2\"#6$?\S-MR&#Z\&/EP:MY
MZ;-1O$,%Q^L82[>=M(-.1#TOZJ5#1>_>G,U"W8EH<_M<@X OX]+*HAMX%_"*
MW6S[6HCUKGI$E@JPS)$N"MTRS<A;]@$)[TCS>7V[,LL!.7?@U+T'FE3A:XEO
MIE;1Y #_PO3Z4HL'[ABL=L@5 ]W:T'B.54]"^.FI\]NAWVA,0=$J4E?*=%$F
MTP^+Y<_ZK8NQ;,5=ELS)+P\$N@GHJP;=$=%]T<1'#D7QXL7;N8#VP\*[I-X
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MT/K>;03O)-H<N%+,%?0=#?'M1X6*L7$0MUNC1ASN^(%UNE2-';#BG4*@ 6O
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M6L=.J"ARB7 ''U9QPA1?3](NX'190=P"O\/^G@//TRZIN^ZBJ')RP'D@)77
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M.D"B'#Y;Z4T]H9FOP9HW:6N_4M%94Q?HL2U0X\@$'8'1HB B20L(MBFOI0Y
M<T_KCLV>.L!I1_VI^RZYT!0SM^G1NBS%,34T8/IYS%S((+JN5VO\$ET%[$/@
M&?&ROJ!'R"FCH&'2UE6@#(5\_=+L/L$B$=#*0"YA,,G\S54]3=,;O@](TM=9
M/:Y7(Y^NA1S18_5W=-G;(7B.1#)L=-G<7?B:>R[2A*0V?E>Q;P-H$V@YMISZ
M@7O<;X8JB2FIXN1]C;#>(98"P\&;Q^5Z@F.4+.@C+OEXG_43Z5G<VA4[<&WS
M!"F<^V!P!\UEEQZCCPB(LT"@MK3TY05.#U\I6MM5^QAPEPSB2BI=T[=1:.E&
M! ?R ^364XQ<AKHSCL3OY<.V #5ESR\I"=KNLNSW'6Y/IPQEZ8.3-J?7[-M8
MV>PN:K7I6F8P0%"R5Z[@SI&\K'9=2WTO8L>?)QKTUR&P_J,L-_X!&LA5WHY0
MM)&7P<N!S!P_5[%A-(*X:&DU'$(%0GG@Q]!_%/QK:AI;Q_Y;V=0X]42/BQ<W
MH-'C)RF\.ETN63?B!=N[Y9$WR&IG)]M(^4&\"%@H7=M^NP1KU J]]DI<R_<)
MQ!*2;<)B.CL)HR3!"ES<=R;%8])(0$WY2: !]PXI#WTI.M,=*&%7F&T7>C&J
M$K;&\*W.[Z-.51&DVG5JSJVW\[UE6)9SZI**H/'G2QX_]B91\2$W$G.)AT&6
MP51B1WEH@>7L;X0C+EI6W()(#TP 0HDZD[+7'DOEJ9=@;_G'.D:Q4R8/0:JE
MC-MLY3>526[I:NP?8^^G'4(,K:2IN?>BHPZ5,)Z^=&+Z','8=79$A3W/W"@.
MZI,#13N^9?*OX)JN\HV 7@F#^;F;X]+I0$), G7CA*U'+ >N_Q#]KH5_,'WP
M-A\)%: /(7GC48(<V#_Z,23A#U4D$L?#(Z)ED,0C!-(R&.+*$ R7'S,1+6+#
MV,@P8;R2$0J9IZ,*LYXISI0_$HZU$1S4Y\R2[#CJCO/"L7\82IE5:Q.E$W6R
M[?YR=$=]G2+<>2P3:@W4%T\X]"*!WR380=!R62N$N5OJEOBD'/5LP '3[[$;
M%C!!L(4\ ;C)7Q?4_<'SC."([7W'E/-MM'  [/5+_>P)4]7X8MZHR6^.R<=0
M.^AQHHV.C1J1_*@,'E!-:/"*/,7M3V;4]7-*7%OLA*HNK!@M"-O:"V\:,[<_
M5@DIG52K%+C4B7R/:S6B1ZIW.5OUBU68U6'N8X"+F2HGH"-2M^^TY4F%<$ZX
M%,R2HJBJ6<&!S?R E0V?P)BES18&^RR(ZIQ^W]MJ<FL%S%:_(OK/O)M98R+4
MZS924?V'#K(F'.RKBSLW.K\1<H0&,AG&) I$WPR]CALUB%[2ZL#O"U0'RJYA
M?W[PSAE9'-<5>$1LKGM3$5L.[?[>)$0Y;/,^XO.LXD9T'.!S/*Z,6 ;3A[\E
MC(L^)#4+C)>$ S;J XVS^>Z3$FH,TN)-U$\M&&?]"U[*I? /HS[J?!:";"70
M1<JEXWS WQ@Q+>.VE/5HVE*(?K0YPJ?KG"I->PW%?0V%_'D.#CK_S2KT!;)J
M7 3JN5_A_9>[LK1=X]G.S%_7/5LT;N711<)UZQERP4DLRCBCY"/^;9@N'0-)
MWHUQ*8,U4S!3&C@K]G-1$GJO"?SLPS8](73D7 =8C<'%^AHFYKJBY!TR\O;;
M&)''O(&FZC4X=;A#O&LA>R!F=<M[AZ[F95>Q_N<OPE[D4U;B7V?HH.#$HV*!
M49@:$'F&J'ZVGMNP:^'74."NL.?J-GZ9-2Z-=W:%.#Y0X(.FY9SS<7YS[WY(
M*W[#OAMU+E>)XD27T=;R6[.V! E'0%T]DYAB'^-Z--"?M@=Q+RJYF*. =^\C
M7 978;09@?%7>)':'05\)$";"B-Z[TNA9$)9PSR7[KJH#[.^49$X64?69&S[
MMY?Q*2'[URL7PLW7G6X-HNA>N+6?ZK>NOH]YQ:1(#4/>1I2P)ESLCHLW%,Z^
MVS2HQB:W*43[C1!X=<JS3,$M=NA:'NO(N"I,13JT+6\(-&ZVT?-$24B$TK29
MHN^UJ"%3(&]J_DH:JZ58+J9TBU-S7C]YMIX3.QEXZ9#UI>B$Y*-V[-0[GLM4
M][>*@?1-@A:W3'BAA%\IVG(CE]Y%)V#09L@.E\,_-YX::F2V?-6SR[C7^)?M
MO=G'O+$ML/F5B-V2OR8WYM&-OIJ$'(XT=([<-@_EV2<V#7ROH"84)>C<0[!P
M[#=K.V X?)(V>)E*VP8IK^%V4!A"7,7X0P?1S\?$HB 7&+><):G?A L=Y20(
METM_Y/1"!O%V:,OA"X,?"4FDZ<D^Y)@8FJS_I)4+QQ']2ZLKK:65L6V^@/3'
M+O'U?CKF U,CO U"> O^2ZCP#R=K7Q96PK_UVE%S2";-+Z7KR938KH Q4Y<F
MT#5O8^;MR%Q"F6F#\#F5+#TI$OQ8ZZ.'J7?4S<NB:KCL&,D'K]+'1%C$JIHT
M\/5JH!_*5Q9H(8DNADJJ&/R6,M)H'AX>->EHYT='Y5O1\EP0KB7J8  ?$MR$
M&8)!RZ3^.:6D3Q91,T'@UM_!HGL<\L&4+#3.B5ZG2,1B8K]7^@5=&#P%B?(N
MTL('53Z!PD$=A0$%F+PS6YB2KZ6I*9ED:6O.?;EM18]Q)^78?E#]$;; S/*3
MUD4W\<PG08SOY"DXAF9P45HUS$M]_$5 ',O[[Y#6A?F,WPAU[\)V^OP2C?SY
MO%$D[1T%CD!+PU[$WQ[>KV2/OO7V_#R3/*W+=TENFL;/",X":YZ;9025IE-Q
MLUS7&1B1]T18=^@'!I\4B'>]'6+I9VC+-=J'E)9.)Y1AT!W-17+>VC]/BOB0
MUE;5/3:TI#BAC/:9)S0<"1$+C:3+NF^I(Y*T>MB9CKS$_MRV"1*#@FM-WD=1
M$KY66XS (9?5C\&GEQ\KX-[LBQU&^Q.:WR(@@(/^FJ6<PD5_HJ\?'TOO*TC)
MWC7CP-;H6!.V*D3CUU,X,FBO!M,-8"X&ZO23T%U<-;_+$L4KAR(EV2.O)CL>
MNT_QX!FQ/=:N+"<1:/R+;1ZK.O8EUX-MYRCCSZ4=V.6_CKC\H6Q[_XQR1H4+
MN:LHU>69G?^$HNY>F?L%+A(VRM=WE.B"&;>Y7+WVE&XFEYA,C6YT/>6O=0D\
MEY13M37257YD_M2#WL8C;Y702ME27D\0_D;(_I0[6\2D9-69#+O:<W^GYL0Y
M!=MX.DW_#X1I]"?T\7._JVA5R1XX_=6<*^SR&T'-\3?";O'D+STM]YO@JVHO
MB;KC7S35A(^V2FNG_?WJ"LJ;Y,0>J>G'V^JN_4-3H%IU3R.1#5&3 9TC[*%N
MQ8T0$Y5D1K68Q=&BP=JVS_ 'LHR]2/Y0P*S8]]KR^F!J\2LGKD=0ZV2)3CRD
M)"E:U$-T7^T6)^L%]BH&6@?\W8M3;#ZM9[Q,2ER6\H^5>HR5U(R%0=,KW>DB
M/:79XH-K%5UO4N9H5 !;[J@T=-]2K>:B=E^GL+^>UE 530,5ANN_T*+#O-0D
M).7@%9]:9DTG?0G*M?!L40$X,;@S>S;A#QO$[GR]K:A9X^&G%+6)J?L1# ##
MD)@GX2=Q<!M*OU1'8DGB%/0W).FS'R8M#;8%BL5-<6!D3N,I"F5T "H6O,O(
MD],^4+O*UNOO;W4J2&,;X!J7F%X*5A:D@ &/,RW+K'FJ3*;4U8CFO"5,,Z1W
MZTF)O)492UFSMU'9\Y<K;;T\@MG\]!)>Y,UA%_A7:%703DV9&R&2[4\V2[!1
M?=EXDX\,&BRTTC9%E#6+#E'JA@ 9!0UIX"0>7@OV)ULX@0MD%R])@]8<H]6V
MH-9*#/3&_R<C1FY7CZJ9!.6-!N77X0CDA\J:[LW%*U01Q!8KW/;U0;4!9/D5
MH#0#X22)RILXBN*TV!Y 70\6C)UGA!WC+V&1%@T<^7][2#;60D\2(QAD4A8F
M!#6H(U;M.)J/$KC9I!0;<F1 2.<?4T?&2S-L6J^;;GLM"U6<NUTRQ,M[<]V]
M,^[T^5):<+19) K.C*/P82_(]^4[EJ<IB-#=?W*8UXI6$_LLA%GT4MYX\-9L
M;O-I>6AAZVFNF=?O<3,T7VYU_BA-YS)[7SP= !(R 4@NC)7D#53-4:4O[LV!
M_'4$WUQCXUD\,:<O%23AE2BM?17J'Y4TOE&#$TJJRI_7-^ M<V$L 7J6,SU;
M$J0D5R:J^[D'A-4\9"Q93S2 *IVW99]32S9?^%>8"8!,7AN]@S7#)^($GZN;
MB1T-5X>#,E@P:TVGZGK"6CGI5]5VI22,U3^%%)MQ9AF9I(WX?(M-"VJ]]FXS
MI7>-\A>P)5%WE?D@X-RK 7S.7(6D@#LX,>Z'_U!JR=71-QFK2G%TV/T#;F3.
M/3RZ+P\\;(AN\!4^)N.Y3P+Q@!KY?^-P(5M\:J%R.&I,)NV3_;)S=;-E6&Y#
MKZM-"\6+YE-3A54HK5)UTO Y1B)F_GA/:]U1D.[JP&F,4]>](Z;SB=L9SZLB
MRQU[<"*SJQU3(0)!#9M9DOIF<UY(G@TC]7K:*R6J,:ZC<BPWUCX.UCHLU^=B
MR;ZZDI:RK[SV%:;R.+4N)>^5M8=F(9#BLKXO1D?)LSX]P8583I^=[ZQB8JQD
M'7*[[L4U/QB=VU7!+8<^)GO(9I-R/0ZHT#0;I?Y;L?@A^\Z#UO*[[.G_AUKW
MSV*4Z>9?:TT$>QSO#MG7GF:6_D"O\9R^(6]]K5-.P:!^)AIF?#E[K]-#!4H9
MZ1]M"U7[X/(S;VU#;>F#UIX3@<=7,(?VD>\<?%<J&,$Q(HN0?'1:*"[4IFRF
M'9 ;KIGE%[8JYW#YJ]([;'[4I<7FKB7YI"L>#&97#@]8#]=C][G0R%I!O?\,
M=-K1<I1=I%C5&R7Q7'!9U=$<S>HF-W8>U1[45#=VWL:WZS1[FD1D0N\@32;:
M+>Q/G'8:B.\)N'I5<TX7W3XR!HU Q,A'QX"R<)3-3IOWS*&X$@@D]72$[!,G
M4BMHVU]VK'LTAGY=P@\+VG(/*%(@T3323NSZSF/W_F#*O^_+MH8764&G9G1M
M0'?6>.(%=H[W>2Z^"9- (!V]!XPI!U+(M106E*<J#_+O3P%)Q;TX/M%:/HE=
MK0&T.@;09Q M>[-!H*Z1(=&A&UPHFE)2,C_N0T5T4*X2NL5SSG>]G_=T7[%X
M'2X:<:#+JS1'EI;N>) K8$,XP!S%I>%CMTA &B$+,K]Z45 $#',T:#XW.\S3
M!@W"/->D!X6D-H[-#HN_74RH"6;UNK5W=L-+K$QK/O&4>/*#15%@I4J]7"M,
M^3 "H2$M23567S.;=YDRY%!2LI5T(FS1M)A=[G)M[1;)AQ2'38>)VY3-ST7U
MZX;J_48X3?L"\(O2]9<%^ ]LW<3.C#Z#?YW_1I ?\ID]4J6]+J]B-=*9X^?=
M6/P>_S92&1!(;2GS2>US(P$B_?S2%ND(=1P]6RY5T:!I6!4)FSYT[K@@CO?[
M9%7 (6/A B>,MD/A[PG4*ENW7Y95LYI_(Z!WD)G*)K9+.B2S+7)!I"RT>EQ@
MJ\(MMMXA^Y2_#FK N;6%(&%P-C.W/HIPJ>1TWVT2+K.6IDV93,OKCPI7G[SG
M4,4W6.VT9QH1$R?1E*OBRWYA%6?0[MH:.IR/+</)]A<%T'/5^@:Y1\#ED'?X
MLI4=;S0PS]*2B=8]V0:K:(5Z3II'@C@0,3YK_UL]5VE3ZH&^\[.7\G]L*<Y_
M%2O\QP>4MDL'J_!=V\G"BB.%&^ !K3V+[7X')QVK_D+PE..P^P0\/L)IS=N1
MJ?,2=8<"3$ZDAN%X/&S<8)$Q$*_5ZG."@H>S U[?T;3ZH30 3YQ.8%$Y?"S/
M6-[\H0?6HK0NJ_-E2Z/?ZZ'%O6.)F<V::(!Z0> MU(7*]T-RWPNL-M!5JZW0
MC76PA=9"E:H"-^JWRK;"#&<V.F88% =#"*.R=1%7B(41^;U\^91_C\3ZLO?X
M\:<O)6%S_(P.P9Y?C.O-SK75AG==@(!EOVFS'-D,6EF1R]M3LMYLLJ.*SX-T
M3HP'WL^(]1=PKJM!XLM\>[\L.KO66TTU<@6D/>97.<+H!2K:R6H'ZCF>RND<
MS4\1KYK_U2-ALPPO@24!CP4*/>SP8UE8!)J?.3A.LSO:M[E&-*E33".R:U/
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MRZ#Y0U\>!W;[\?JQ%:%CBG)HY%:,&X23I90EMC2J)%D<L)E>4M#R>H*II[#
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M$[4_(!2*9=<0>&0<YF!U>?J<V)B89.[DX<+%>GA$/8!3[W&;]1).>)D(<8D
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M+*'"=""3@@(K,4!RQDH^_HJ6!4*<45Q^<O$KND]"9<:_9>N1--(WN_0W@MO
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M73N>0E_C M)_&5.T[1;/I$?RXR/NB@#820Z0V%L1'5UH!:OHM-O'_>=.!K%
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MH].\ -.>.V/FAIU[B3=5#W \,"6JJUJZ:KTW7<.HZ S\BGD8*"7XZX7#NW_
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MZ\?>(3Z C*0VW$SFY9BXP66_( 0<@7<LX7E+U=S9[(%1.#GY$0A(XI.)HH?
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MTOC*!/AR%DB-'SJ.1T+WSFA+?1!1PFZL9<?WE%6N78%G!H$(A)%6'AX$4WH
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M-^3)6&^0H&H%:)EI:IK]U2-2&4$@AA+^ZA'=](>:F:&QY/SI$7$V35N46%4
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MX ]:U54"W$[1+Q$T8&M]WA'^[+[PS5HZ\MP$<J/364@%WCW-[M-@)KDW\/Y
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M@$S$Z=ES7WV?^MFDHYZ9'>>ZY54F,KR'.(DVS)+RIIW/K7*C2>YA"?Q"N</
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MNCF[5@F[K@%^Q:=/[@ZC("#JZTS8::H5SAQB%D3H#]3H3&F;C)I3EC 7>JO
M?4-UX,O'O=[;J!HS'RLD$]/I9CS\YIX2^?Q(U8I\A5D8L6OO;5PX1,FIMI\C
MFPV1XG[@,PN?Z_Q,#0C(QWW@R4/O<KI'8_$HJZ&;G<R\W*(_!$4=RX"DEG$U
MC^/3-J5.;F%N_:6)DFU-E[W;B@QXQ+2$O5]Z09J;H)W;UA>G=\&6"9#'P>@B
M]W'JA!6D?FA@UE*W]Z"<"^N(7R2V1';/]SMGW^<TJ<#7VUQ*Q[F?8LF:_:*K
M6=8Z),5+&PP:7#PYX0RH_)$_!?%>V0OE#(=L%;'IF(<*A&218:6[5.B.\)LR
M;LEC<J',*KVKF;4+?6!7@]&+@B(    LH1DJ2MWL>N]=MYRM%?1]AXG!VM[;
M)6_Y#;ATO,&JW%9M8ES*7[97KOB1-EW]1/2,W,^"%W3ZV>)V)6IG??MVG/D7
MRIS33=J\WTQ@YE6D:&5JZ95J)5)3(DY=D%31FM!OCR^F(?6E6EIKO^GR*=RK
MU%0GI^_R)+<NF=!UF)BUZGXD4_3TFHN!&H[&] F7S^3"4YYKSJ_9@5':AD9U
M0OW OG." +DW>Z\[7O.LR85/0QK4P]46EO3>AJ>8O7?X-[\5^W5N-N4\=DU7
MR5;%X\J8.C>5,AZNL=GR !4.Q2QBZN+0:-A)GE9^Q=/<1<IYO)H>^UWG)Q)1
M=6Z*;&]X.>?*4Q0KF&$H3"6XT*P3>JWGTP.3-_DZOU#@_^Y-^3<_OE(I=F[J
MU+E,__(IZ75@J T1(_-<%,B)\HA#LMQ2-D73ETD>!JV/+-@Y_->W^W;0OF57
M?.@&\4^_J>S\0'S^X-MU#B<O?>')"N91LQO/,?W^, '+IT0S]V0(NFV/ZDKR
MH04[E[%C.(/L*4\1!(WAJB7E15D9S9=!,U0E7TB[<D=JM3T(U(@2NB:X)4&,
M3B+'J!&9MK3C8[S?6.86I3.#F6LQY! J>/W$97MZ!CX[UM/1,Y@X*(^XI3A:
MO757/I:'=XJ%5UH5;3XWJN!<MUW36-!YT@N(V+3L\^[]LB_VB+]Y]$KM2('U
M%XI>5%7SN'=LWR^4;RN[K-7/:2I^H9S KQ1V97J86V[L.6[2^X[3O$0K>MR#
M7\S5L#C5;S-VLW^:,]*^99XP*=)EA)=\B!^LE\XXD6J5W);ZN?.! $ZDG$>7
M4XW8O1<,#!ZL7W^0,":5B  ^>)-&@R>Y9=C\OW%+_S;YX<\A/$=13MGF#5YN
MW\0B16W@G+M,*>5F<6\?&W@50>O)2X@:@2H'4O4-V1%!^UBTI&)V'[<1I20:
MUICM6@M=SK*[#.1;.C*P.@HE+,&P#9R)9TUVUZGFM8DD?]2ADMM!?M>AABWU
M)Y)6KOVN0]6/H*U2<J6;(URPZVK?D_[O"OG'T<PKC?=0+9^;LV*:3FG+&[JO
M-OL>$0 U7]S&:DXK6_9K%X6F!N5#,X J <Q"Q\0S^L:FGV9]:DGT^R?9+!59
M9&*9GLSWPN,7K[0\V_A84Q%GZ2M1@*P3KS1?%H')6A56#"3]\.4^A2LWMQCY
M_,E.3D[^D;20YNFR_BT_L'7D2\FM<NPT<>O+!40RCI/2W[T&T#-4$ C=/X-C
MV[NG\,G94]'$  ._L/_E+MO--^I !+^;.R$VK#"K]G94\0J#&I?&\1;/L4-C
M?@6O;2D_S19$69"-%H MM+K]^:%%+G'>I0IQ7&YS#V[I7,^SO?W@^>PA6S,2
M^,GN'N;K/:4%@10!.S-F#L)7!6 7)N<X QPMH.3(&4-9>N=,\"I3KOWNMW5#
MH1?;O3G*['A.P521,X"23[.VV2;C#.@O^]H7?UYU4JZLW)=O:C/71F5/CS/)
MWXPBH)ES2?>,*E(5*IC8UTI>W,H+I:BNE[2=B-K&PH@W$5[)7_[TH$"/93%:
MDXN69EW30"9!C3^A*F^!]6E<TIL3<!]S%)C1  V2P$]FSD++C>XZ DEH-0 K
M&Q9KG11\5UGKVKO]X'C6+MCS/0,E%"VUV%RL_LWJ#\92CZBG1>I$ 'HMQM",
M^I+\%+"_.26S8PK=Y,UG$R\=KX2D7RBOO^R35=7EBM\FOMZF.8/EK2E+V0T@
M#A\TD40!:N0'J74"W^(LJ'( T&*_L8AO4-&_@#W(,I#,M\Q)*\]!;:O.F.GB
M$@UTYWW5Q_'3+_ZBPW1EO\\Z:01IIJC@/#7K-&^,&D%W_]T!EHBH5F)*6C$H
M\*A"*#RJ]?S:8]?RY?C+GO%TN:TV7'PJ&C4J&BE< B5\.:+>L)T\7!I[4)#P
MY_J*C^;.1X_[E0FI$A3H\:1T=.Q)#GQ24\#YQWV&0*#:"% K.*/SF2?/ES9U
MOL.RF]8(L/8( _8'!T[XQ)FSOA6!:KSZ6]*C+'=HRM8Q'"W,:^N3,CCJ =L,
MX_6[M(E'9';;GGI;'9A$R9I=.#;C4(PL&,S$E[K&;3KCIA6O\=. TQDAAU\%
M6/?=0 I5Z:72,8R^S*P]OVO[7,LIP'$DD;+_S"Y8WPI#K1(<W:;_FE8)/Y"<
M1FI+',1X6RWT\AH^OSAL#_B%HET[V;ZFF]*P42!_N[*8XR3.LF9<M"6P<"&'
MC1\]4@)4EU1?DZ*;'V@$:7Y=VP-N:M?T]]?N@S?V9^U'9VD^S!]MD@>5#:6J
MCZ,EX*?XB<Q'G [1U,X72)=4M+/URCVFR]D2Q156_)&"ZPS-=GN1O9\(5%>6
M'1KW,&MW3D4E2N^YRN1\,7_OXWKAYY[<0;/!(DG)80BI_[T)6&AL ;.MU],N
MIVMI?\IF*YEPC3?#&IWCJEH#A8RI5N\F'N$M^(,!7H9%/.DH3GDHJ4ZUCS!K
MR;C6V-A>J:FIN6J"6'$IYQR>"HK:&;V2_6*HN>Q8MI,B1PJ+[>YE:_E0I 0&
M:*['US-NI?MXRWF16$#<BM*UE+EL69W\9QZJL]2D[IT!'OW\8$G42TN?KJ&Y
MC^-*XW$@2JCC\\0S628JT0[(H^O=N(?-];/7!B8Y(:5+X*B]I<:QJDF#XG)9
MNFQA74* 4[+]_5J"I6NX1T%FI+-$T% 3?T),(S79,P&MKPU3^<##.)6H@4"K
MR-EGHC Z$E;*1V,Y%="Z)CDFO@\VT%K(32G=UFC+[(N8OT']+CWK(<0N'C8?
MFSTQ+;(U(ZNEIA%-R)4F3GP$LREPK\\-V=<R4,O<%@TI+LP'H'T45_U^82\=
MP4>7_[6B!@OH\ADKU%26' :#!H7T%Q."EX?8NDDVQ"%I*M8O'<\(F@^KZ6;B
MG-P]H(W0S<^%C"G1B73OLIS2>U;VZ;;(S-MCB0=XB:VIY.A&O-;5FFH_B)]S
M+9?&T##Y0Z&1V_U?*';K#MHK3WAP\.5?K=70/V'OR<9F9"CRSN8ZE^X@4B,P
MU)&#Y19.3K8KLHW9LK6_[6.NN#^K6#7UB6=,R1^ '@IX$4H'39>[Y5<AZKTO
MPEY/W &I<"L%4XL3[;+KR2#2MG91^)7MF,>P20[0Q[JC.(J[;3$YA#,6;'4-
M7R6MQ&)PL3O-A&W5/@UJH>W<U92JFQCMT%SIL1,]3W74@]22/OM/1+90#%G(
MA_V/5""" <3,Y#IU[JO8AR[];+4@PR,[ZOU8U,+"X3DJ8ZWCE1;Z<1VZK;T2
MN6>$;8>6-HQM;>K'+;3'9]$P:R.TG[&YO2[2QIUF^'/<DI)',&]JHXVDFI'E
M8UK4F=VRG@WCN@]2;RL48[0-]X#]N;]09AJ^X;2^$0*O[I-[(55U5NG10<90
MXH%C:-AL'JD?434B\<)C^\@7ZVZS'?=I4^0_YK/_9VGN_R2U?0X?\0[9^</%
M1?A%(;W8R^M&Z\R_NLN[C"@V>_L>A=D!'DW'U [VU='L>22MF@&/\*Q9!^XK
MN3(LIWCM^AU,W3Y)9_O=+7MZ%E2/;<3]1[=L*HS'^7?=LC$#TXW@+P[0D_#4
M=8U.*UXE+]B">\EA@1V>-#7 :7Q^I:?!BHQ'C>K#7W'-7#ONOTD7PWN 9W1@
M+:'"L3@7KN7FELI8WNXRQ]/!G+_/I*@ZRT5@K?BR/%W<6E'N%0XB&>LU&6N%
M^=BGU_)A\W4';F0M27:NQG,#E20T[Y:HGH*V:_ V))5[OL3^>(Q=0#9LR!Y!
M$_*8*]GP4X\["'RD[5%"$-JN\X80-S']@C6S,5!# UTT)X%'(ZVH,[2[X(](
MR;ET^Q"[W>=.<WG,ZMG7"8.=-J@!;:MU+]F:Y@J3[9#$#<R-OM3L0 $11%!*
M2>VN@&RFOA,9+CI$"%O=\0=6C+M],]Y6V\I<H..#C":^HQ-6"D-0Z]_#)\6B
M87],)/*"/^,G8;?VO\/8H(N_]SXZ%V[Y<]O\7?_O-I:6SK8[DW'Z8Q].A%!H
MFF7AZBV+*%'MG[LO\6\-N55,IF]57I-:8B+TV>UJ9@EXR1TGXU%0P$ @< 1'
MJ%%U1"D\?(W(,IG%4)(AZM% ZHO/VC9KDOY?JPFD"&0:T9[ZS;#>DBF@SN7;
MJ'U4XS5BM:OER>64B5U*C*-VMU[Q[J6$Z%Z$*9AH;OO/O4>AHC/EZ0@JK7&
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M>OY<Z?N6H=S<S'5U.VF!-(M2RJ[,SFE$)7*6;Y\AO8@4<OD?I%OE'2#Q88+
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MM(Q]*L&8KY]0 JBJ\G(CJ&'I[=-\/>&*@<YIK;1NW0G&E[D GBS%>YD27$4
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M^N>=DA'W?=;TF\;N89(R=8I;$1-CFL 9&1L@$EN0\:7_((2%*0M1E">7!XM
MX6[QP!SL?<% I=-8UMY3.5HGR6Q$\0@[35IFV*,.#)F#J:P&.*[*A$A@)M,U
M4'O6FDZIL+%0PI' J2IZ']^-[(LM1_QKB<]*(S]&@8I.EQ9"FJRE]/G/<Z:@
MI(FS:;,7; 6UA3H\/[EQR KG'3=VF)1Y:;CV!S=&^7S&>BG#SLUX\+,;F;C>
M^>#XE^->N]@IWP_7\NUJ_MZ["$L-ZQC5"+.WS_N6^S8TWJA'&B\'QXS*20(,
M%(@!2BHB\..W>DLA8M)]<ZR&[IMV!X$3V]4*ZV6SXB9(:8H>,+\ [$$M,>T8
M?=!#Z@0E2Z\OT#\IX1PMN$,R3(>:]8P6COJH%;:U%GL27&QE3Q/\D16K(M\'
M\L:$8R5-%A06NZ13:,M'F/+6M?<.-.\:BHEML ?A=E4R-!$!=AYK8#S$;&^N
M4QJNM_XZQ0KWQ@7O/(J4O[]FLS)52="SN7_=U6$HU[:TM .Q#!0[SL!$T\Z\
M19BF;-D$@71H@< <,7V6<TSWJ<2+32RLSB0.MZJFX%7+% ([!G7:='20N6TO
MB"&3_75D@>)_]*X?S;)GD4_U! E4!H5T8F+BOKTR$P,T2V,#Q,#Y'S"DHL%L
MX$&5KOJG:W,NX2,4JRZMRD\5%M.3YN]_ PN@=$>BE]\BF "-FDI7==1:08-<
M\BH#^XB5A:*'M4_HJVJKTH.]^V27)MZ&&@6_(NYZ&0/8]XWG'M:RUZ&2<F7G
M=J\0CR^B %>Q8LRRB?IL/DG=X^MF0KQ%*.WZ:#Q<9+'\R"SG4$4[-7!^MLR#
M/W^;CY\^B^_]1CZG3,; EH51([*[6#@ 8Z)T(8QSTA26]$6\3C# +)FO'L\
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MG+TM2OFA_&F32K+PO4"@+(MA$/BJSYVT "F7KD(<!B&-O3",J-;!G3'EB4W
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MX9!(5NO=R0%G6]*&Q.FO6H//F>E15=:[DI!_Y<5#B9^D:X^736&9)&1,X(Q
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M3)JU ,40HQ!#GV:>%\4!#XA1^(8)\:E#T"@M50U;VE W,TM&&.K9HJF0,3-
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M$KDJWV++EEHX#QFS+C&LB>6P=LX"HYD.&R,(_G":L7<Q)"YJ#&M2?*TBPV:
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M&-@#=.@!7#"2G;G:M'6_7DDRM?SVY=)]:$O"[.H";G4(8<RB%%$8>FF3K9O
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M0_-N.XSYZ>&OJZ=<I5O?YX^<O2]*517J=[PT"9X8&&)BD_SKI]L/_1( #0=
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MOH_"L,6QELW,;EB*991Y<R3&!5DWN[%FR[@Y8K^?;7/\1XO:@;SXA!^Y=JW
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M^ZMMB%0)=>I>YK2).6U65<M6)18X:YX=38N>H1_7QI&V[%QU8:57I_N%[$X
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M4F%3#T-,XP"RA./03RG!OE8&@0ZQB95V2QULR(,-?8.8T3' AI76-0QFBCN
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MTC!61:**@MXGGJLN5^I'DQ,R1@X;[19Z>S)19_W+;5B&A8M3 .G%A8%FPP+
M_5')9PV!/2?OL<:2-Y^2,*G;]IAXZ)]]CYHYXN^DS.OZ"9E,M#R($?%X1K!
MG 2AVAZ*$<G2  GU;S^-N.\SR"KA6,3(JX&-P";9-:.)/(&+GOL-LQ;F?4!#
MP<YWWA9+OG="P*2N=][ 0\_K>=+,\3ZNJ[P0535C_U[GS0W'K_(7JD)6)M;$
M%R(-,L0"=2"6,28G19*@@%+IG'X61[!"Z3YA(SOC1K33D>W\J:37U<#0CD^]
ML.EYJ"TP8+YJC@/8;74,M.3 O:(F=64=HP^=6NN=812.32&\BAQ;7L(P\.,H
M3#C*_!#+^95DB/+00W%&1$QH1#,/='/QO*BQBW&V/(;E5O1 %L<3<&FNAJV
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M9&@\J(9'QS*CBIW>@2>KS]$QKUN-H_4\W L?2SXKRQE?OD!][_C-L4MD6E%
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MM<YD+DH:V?&E%,2DF*;SS.:6%F!?L1<EC6U56[;#?/NP(TPKMZY70DJT+00
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M5"2,$)0%;HHP90E*$\*1FS'"$LRX()G>O58#Z9#OM=$UUZTZ=6-,LA4,R/V
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MFIC3Z<" 8TJGPP<,.]NJL[^[9;'<\)LT3M9N1<R)BS/*L(^\6#5)(X0CRH(
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M\9*KA*5N;0.^CJHQU,CS?J.!4ZN@.*X?\^>ZK\&O=P^WG>H^F7G7:@&[55]
MJ3^PC  0+)+H8M,VP'*L7UX%6&_>$_O"^-,VRM8S]JA[MN9KPV;+3A2Y7E:K
M^ZS^A9R\;XJ5G*H?2U)4,K*T?Z[F0< ]Z@8,$9YD"/N9CPA./)1&-(I#+CP"
MJWHVU&/D -(1)Y<.4AYL"6 *+BPG&1$RP^1D+Q/I8GC=BZ%QTF&(@.7L ZK%
MNZ0AAE"=RT=,AS-A*A9%OBR_JR;=HLE\ZK.OKTM2M/??DB".HL@GB+'019AD
M&:*I&Z&$\(B$3,1Q&.LS"E\2-W;I6BW?:15H4OSVM$_I &%TO0B<QOZW53B
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M(?9B%_F8NPC3B*#$$RG"<4P%#J@7)L >S5IRQ][NN?_\#=JP60\OO= Q @K
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MTQ1E,D67N3K+$.%!BN(,4]_SHHA%L%S]C*"Q<_)&K+.5:US&>18IS?3:@OW
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M]=2HX+0Z./>9T[8*VJ@!J!;60K _:HR""RQ<7(;$I(&;%C: @FK;&)G55=O
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M)00G'D84!ZJS9$(0$8% /.$930DGJ1> \H=A]&<VT/)3CH')Q$#\]$SEC*C
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M@RG9:0_H*^FY92K<=$?6SJC,E_1Y/A'+1C?G_91OU;/Y1*21SLRG(V=L,?#
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M^I435?XLNY=*SG9EJ<[[B^QN4Y3[O[XC55[5#:=7L=1-$<2I7# Q1I@E%)%
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MR1-9]9.D/"5+2D^2PH$H]X5+>ROK(A7)DZ!?*W_<!4_/J6BGJ4=SX-E3SAU
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MAI')B=JU6F_1U.X%G4.GIO972S68M=SO^_-</U_2;!#<\"ESM9I_/WU%*YW
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MSLN2TH=^%=Z:**PTP((HS699 N,9 Q])P/4F*.>UMXBUQ+1[6-($M.K(O0,
M^CA YWAVS\[Q>#J;]F-(,LK@@.=0G-X<P1K.\*^2YYBS8BE7QLY+=+2[5U92
M\6K3NGWEW0',7*;AL#1J3"/D8EA"J7@S& V*=&:#;^FNNMWKS)(0'HQ!A@3+
M%KS1%+1A#H,YIZ2O?9:V&67M[G3-X*H!G70 :>@\?AM,43$OI*'Z,;N0J6=
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MV0MRN>^"(RDW,2+MEI<NSIE3\,1HP$TP2/2,)&6UZUQ?(:?EJ9E-F/5:PN^
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M5HDDRG.TU4L"7Z9D__E-CY_ZZ-3'FX2N@H=$- 8CMC1%ULB@B8HR;R01OOZ
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M+=KQJ.Q&^-F/CG:/3QH$V0'5T\W=[R'FCIDGRC7ZGL$)$%9*,-0'2,(2;EG
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M/!!E2_&" Y&T!2N05:6<<EQJDV3MY,-NE+8[/J?+<-U:CQTJ&UEAL7 55LY
MCC*^]I[/K$3PDA/ 19D6 \ZM)!J,PRU$*L.-7SE >+MV9%LB-H*B>K]0/*B2
MNFTZRQ$)]]$&(A/$'%CI3,31R8X$E$;QN2"3# >L\=WTS$J_7_PUH)=J1U<=
M2<\>Q3B?X>:&)Z,\GMS,"3G,3;/7WMSN-;.-9=)*WI71X&29[$P2%;@22F%G
M5 *BDC$;E96.[_*.V?-;W'>O790MZD1\$$9"Y,Y"J8P%)X(!ZIT0&/0%DJKW
M9'B9E/>4']T&+>O[/NVNB0YLRY>HFWF[V[O9E9?I>M[]=GY;1#I9BEX#4&71
MQ\BXQ3CN#*#@=) L*D-K5Y*\2E!7FBCMH?)G/3YJR;\+8%K0OBS>-U0:8;0#
MGT@IWO?SF_(&<O*,(NDFT%0;/(\):!DL]12["IF=I=QV3'IVBX]!TWPT' Y2
M1 GE/!A=+^]D**MRS@*CZ>@H>IK"@Q?9H%QR9M%(H:5_R\-Z\RTM8V)WS8V;
M$&.KQ8QS5CY_^3$=A($;K7"!"R+DQ QX'U$V2E@,<[4%125^SV=%!=D(#&M>
MT'(OGCHXJ"&\#NP:=YOIZ7VI6XA<4"X<L"PB""<5V&3*12V/<:[R49/:)ZG/
MB.A*MZ9ZKL9^<NX04/K"(+RSL<"X11OG<0NUAE$P+L7@0Q0B-%5=TXWP9D<5
MK@'$5O)\'S5X'WL?KD['HVM\Z<W'Y&=[9&W6/:J!-,Q&5%?*J\R?_U(J,:L<
M7880F0/!T=28( D8JZ,N)?#<UR[A?IF2O6_SXU-/1OBLV[+5+JQG(,%SA=Q0
M6FZ5RRS!1>-!2MQTT;"6>9X-,+="1KLFI(+>GUW>WU/4'=A:'J^Z*_R91:\,
M%:CB#&5BR[V@;"UX_ @B(R$KR[FK?HOU)3K:Q\M>RAU7EG0'T;)TY(/0CN*&
M#*F<Q0CJ</D(3B!1$;V(B1!=NRSE94K:1<S^&GX#,CN(NPN@09_M/!_CBP>S
M9:#&.!&2\0R>:W3>B"?@)$H&G3;)9$HLT=IS/Y]3T2VP[*+;5;CL)^@.0&5!
M^R<7!L/![,=\_<3H#64N0>+:X/Z</#B=''C<I$U0S/+J)6_/J6@W)JZ]$^TI
MY<[A9+ETDE?<6D/!>NU*,,>1?!_ ,1$D]8%G6MO)?8F.=LW*OKI]%2H["+KM
MS/ME&@W&DWG/X13GYZ'SJ9>GX_N&\HGE)%U"R9A2Z,$I*Q970<C:LRAHHFRE
M 'Q=#]*W7M4E9.RBRG%C<NV 27EJ9!_R3#8EP3A5D#3NF\(;E!#)%@AS.D2+
M3*PFY"N'SMLE9AN[ 5![$ZHA[\[!YF2$3T[3V86;I5[.*92&YY_3)!1-7:>^
M)R'1' ER4^9M:73Q+-6RS WD9187S[9VE<Y6!'8IXMX1$J_"K*9^.@>^8S>9
M_"CSI!?=\C5Q@EL4DS;S5M%6@3,D0:2<1VEE,+%V%<)K]'3)A6X"6GM(OQ.M
M=3XN7_QI,'*CD(['TT4=K*#9&&\=J.)""I,5&)5+=YBH"%'4QU0_+_XB*5W:
M_VHA:'^9;P\>NP#/*%V7G@)7ASZ=.L.%XHK=W?-HZMES&CJ7>IW>9@^EM'-,
M><+ "X+@DJ6TW08W3QYRH65DJ@E_H>E#J15;Z55RSA*-Q.3B1E*,33TAH!6-
M1!N7XVH$UOY.=>ACJFV0L-5&M8WPW\L4Z[)L&:'V:5QZ=#U)\\+$/0W/!D]N
MR!1MRU/#)^9.ZU0Z%CFI.>Y\C($EN%]EQ3*/Y</<Q*%R?>/T.&]^EQ]9!+B1
M"6HE#4 T+?4A"C=B;3,N#F>BQ'W9F.H'6^N(Z:19V@8#KQU7["[V#H1A+^1<
MC5*.<:5!>39O "/ .>Y 6B(T83EX5_M:RHZG%LT=<-51[]MG%]O(NG-H6>9A
M2<I6EZ)5%GD 4=*F/N-B4B90*3&&E*SV?9-W<7:QE6XW.;O81M#=/[O(Y39J
M+L?#04H0PGMPU,P;H#AOT1I+)MYR:=[MV<56JMSN[&(;N;:-DL=V]O+6#P<W
M@]E\[63NO$,V(&A3&H_C K*49+2Z(B;&I7$N; 2.=6]H-Z57=W^I)\HNXF&Y
M8G3@03!N@3NB0"BCP'(9($>KK'84>;([(Z+-':2B]M["PPZB;!L1EW]BN%^L
MV_2.B:69\]918C#B%ZR,)N"&@ E"@R/.QD2,C$INMGVL>4/'T+"+[L:U!=DZ
M&F9N%/V/TS0K#UP5T9(A0S.1!*UG<!2W/>T,.!&1H90H(0'_><,A2IN\K<66
MY(V@I+: .Q"T_,U-!F5O+0>G<YOJLO 172&0@J&'%*(#ZZF!&/[_]KZMN8T<
M6?-]_PO. 5"XOFR$+,L]CG5;6DGNV7Y2X"KQ#,72%$FW-;]^@2)%210O11)%
M0&Y'3)QCMV14(K\/B4QD(J$M@JY2A*4^LUV6(6\^J)_P]B ]%\:3IUN>8;D@
M C4(_G1PTP6M@+2& &$9]S*$=]2E+J!Y*T7>\.4P5#=09 \5%T"2>>1U_MTU
MH\'MW626_@Q;:YS25>V;IQO=G"@:6\]*'U83\?&Q:Q/^:HCBTE+*")>)F=-1
MM'+HM \#WK152 ]' 2R+,7V<P9/TFAM/XOET^XB#E&$[QT8"53%F(6+2\M0G
M;*\ER!LM)^;, <HM@!JK]NXOSQ4=0A"GK07!JR?!\7.QJE&;."-AK:YBP\LC
M)'V^[%3WV5LKW7[\G'0(%$JGLQ\/@Z8%Z<(U@]K>5-Z3"CL'.&9AR[=!99HR
M&[Q^1V/"'<'D[_!TD:N\'-&>-.A L(,P*91GOZL?@_OI_8>Z:>IX.G&J'L)/
M)H\WRF%!;-B>L::Q*X(-)EE[&?[J/0][=851ZM>W=Y&OO+/C_GB7!*/<QT8O
M)S8K'9H],ZTGSL8N7V%)W0\FX2\?'C?D5Z[K#VZF!V<_!5C.)W>NN:JGC7'C
M&R0H5P3%CF!4 (*#)I1@'%3!Z?1<$RE(M^[+_<M:WMG#8?0M$>+<C']=-A?F
M-QA?!4&4/1^]"NCM_TS'D_@K-SJVK*ITF!.-]Y["9(-#+ RPCFNEI<"2^DX$
MWOG3Y?F("?C8+P"%;>@W%0STUR'^DIC$,R'D@IHH 5HAI;WPCM+4Y70OOY_W
M!83C;,@[Z3BW^7DI^,)UB%;V^;[2N3\Q;<GH^-(9-_C>AF6N$D@Q;8$W(0(G
MSL2"7A^C?,495R'"5VKG770' ?*^7W"$K;$O,$HBW)/J7LWUY+L:A'_4_N!&
M:<LPM1I '^]^6N.!K(P&++YJ'QN>8+J[L[;ULWD?)S@"N=(JOK ][FERLT<3
MX^3>A$0PZ IY#(&EB %": C)G91 4D8M1Z(2Y!AAZWH).S%0O!\&'@&G$ECX
M.AE_/IV,8Y;^Q7U-YH5 Q +7]J+5.'B.FB$ (?$:2EIIDKPCT1:9.C%-OD.F
MI<2B &YU#%/0#0R3JH+F #4ZK!DE,!#4"."((H14W/ J]6V2KK)U.P:&[X]L
MO8!3 .E6:>S;:#IV]LE$G];W]X,V+/[D7O8XP,1!H9P'!GH3_ >F@7"0 N,@
M#NXHMC1Y5GUO8;O1\B=)3Z2'[WVT+(XO+)U=74T?'H;M548U_*"&\3[\U9US
MDS0O4.W\C1YN<!XVST1W.;^X$$^,%_?W4!@1^HH#0T2LZ8@/.]** "-HI9"I
MC%*IJR)>2W"H'3Q_<#&E-[IMA[V,]2OG_MMX]O31#;5*,.4,$![%>QP5BL4K
M ACJJ;90$ E3)UTW"I0YV[H_]LOV*YW:BVA^\GHZ7P;S6/MTVD2]WEBD:6S;
M AB-Y7I<L.@;<, I<UH0S"!,7>RZ6:+,V=.^>'20XDLFTM=Z9.93XHA10ID"
MGD .B*,*".D]H,)[(Y7%QJ4.-+<*E3F;V3N=]E1_@8SZIXNFUMF3\(G@#2X.
M:-H?7KOF'MU(2+$4W(**J###2KK9713&H7-62L*3MV785<;,V<J^^)88G *B
MS(WSB^T@HK<;X^=Y@'*#.91(:@F0B#N_XQAH[RU -):U(T@M3_URP*XR9DYT
M'HE\AX+SGD+'UXKX74VF3;PE?FBTN'G8W@+$'6;33TSH'8<*(054Y7S@),3!
M>S<,!&?,,L<KZI>;"A06$WYQ(0IQ:WR!"_78OD8YL\YAL9_[3V&MJ&%\7_Y&
M"^PE$19@2L0L<M$,:U )[8300B.:NFGF_M(6%4WNPIJW&8&C %; AMIIIA^G
M[FM8VM=_N>%W]WL]FMR-;Z2U@E6QAD!C" @B%1!00H!Y92Q$'F&;_J!F/UF+
M"DY[I^6A8+TC4L8%=_U7?6,=X80H'YQ8J&,,14(,)2C@T!K)*VAI\B<Y=A2Q
MJ(#V&!3<!YKWQKQ )1>4:9'EA@(9GXLEG#(@@@Z!P=1[IYR","OWHI!%A;='
M8]_.\+PS_GVJI\V-)5QP'YM"2('C'=@00L5K&\HY3+S'2JOD+^/M*&-1\>VQ
MV+<S.-F++3=-+EZAN% #>^+#UQ;3\P)2)U#P)9!T@##O@)0D&'B-*RP\@]9W
M>R=^]V]GKND]G%/'T/D[LF<W#'I!&'7 ZG@,CBT$0G$)N!$D/L\#N<UEQS*7
M^![??NT$QOXDJR=JV#_)OHWL_.31V;,?)OSJO*@/8T>1J"P0Q,6[CB+H5*$0
M$SEEJ&;.N>.>K*P3-'-][Y'HEP2FU$]/)$^[WA@,E0]: AA)$\RW"HXI]PP$
M5Q19A8G#-/51YAI1,A?SIJ-5"E478,2V%!XH;Z2%8<N'@BE A(ME?<B'L 8K
MZ25"O.<\UEX5'ST6Z/9.H'TT?Z@!.E+)AR)46F9U?(27SA[@E%)PP#%T4AI.
MF$W]A%*:DH\>*VM[Y].>^G\O3YS,<H7ME-MGHP[.=KX=JK<,YQ:I^\EJRG@3
MDT("(.&Q\,=9$.P, \A!J+&DW&N6W/_LK]+U*7ZXT49KZQ@%E0N4)M"8>*59
M !X,IA;8552EGM=J28K*1NZ"]F:#LI>B"S@*6*K)/==AI8V<_3P*[OZ=&MVZ
M3W6SSI>C6@9'7X9-UU0L&,RJ H*AX- I+Y7P1J/E1BP'<^H <8O*-QY"O&-!
M5@ [7T\C[@4WE:\D40S&L '&%\XXT*@RP'C#C9>>.YCZ@."M%$4E#M,9L9T5
M7 !%KN[J9A*K)I]GH)#V4BL#*(_/<ECO@2;< 6VD@!RQX#*F#N??2E%4=N\0
MBARHX (H\G2#\P7'";:*"P>,C.5 QJLP 4%!V*BQ-@8S!U._N_5&B*(2<(<0
MY##UOH\*TD\GGR__./GR[>SW$)I\NPS_[^OUU=EX,KB/!P2?U*#Y0PVG;ES[
M>5MD-6PWY[$:V:?==^#&OP<5Q59H]4A=QJ9HS:QSQ^"0N.Q8HO40YV71:J*X
M<2'=\W.'S\M)0&RTX!I0'(\2#*1 R[";,J\KI#756*7>@3;)<Z@!78P]T_[)
M2NV?CQ;*#[_PM1XUK["8-0.F3F LK 505\$R0,F!\#Y8'":AD-1ZC5.'H<F$
MSQNY)N/;LOG. VX!;L%BXA\>VZF?#M5XW+Z[$':\X,54,&Q_MHKE<1@(12J
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MS8&FL;L\5R)XU!64#/7&L9QG9BGQW4J9/92=.PA],X=Y(,V"CTE#+ VHH<'
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M2L4=PA*&52-C;\/*>J!\[/BCC?>X@@(N%^8??N-D'T%SUWPFY-.;"R6] U?
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M\6+!*%*5P R0BWU:1A0YRW%G)%<LY3$>&:9SZ9C306Y'H!"QL)8CY!#)^8/
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M9?RX3E)B)S(%BMBD\)JH)/>)NE';+6+M6['.G2U+5I7YF)BQ#>\9YXP4\$L
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MM_KV-XP'[F;S+U!+ 0(4 Q0    ( *V%IUHRC.N2<0,!  TG#0 1
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M &-C<FXM,C R-3 S,S%?9S$N:G!G4$L! A0#%     @ K86G6FIRU)0XW
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M<65X,S)X,2YH=&U02P$"% ,4    " "MA:=:6*ZF[$$%  #@%   &@
M        @ %:*0@ 8V-R;C(P,C4P,S,Q+3$P<65X,S)X,BYH=&U02P4&
/  L "P#L @  TRX(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>ccrn-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ccrn="http://www.crosscountryhealthcare.com/20250331"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ccrn-20250331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <instant>2025-04-18</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:AyaHoldingsIIInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ccrn:ExitCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ccrn:ExitCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ccrn:ExitCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:HireUpLeadershipIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-13</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:HireUpLeadershipIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-13</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:HireUpLeadershipIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-03</startDate>
            <endDate>2022-10-03</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-03</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MintMedicalPhysicianStaffingLPAndLotusMedicalStaffingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DatabasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DatabasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-25</startDate>
            <endDate>2019-10-25</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-25</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ccrn:LineOfCreditSublimitAxis">ccrn:SwingLoansSublimitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-25</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ccrn:LineOfCreditSublimitAxis">ccrn:StandbyLettersOfCreditSublimitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-25</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-08</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-21</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-21</startDate>
            <endDate>2022-03-21</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-21</startDate>
            <endDate>2022-03-21</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-29</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ccrn:RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ccrn:RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ccrn:RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ccrn:RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ccrn:OmnibusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-14</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ccrn:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ccrn:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ccrn:ServicesProvidedEntitiesAffiliatedWithBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ccrn:ServicesProvidedEntitiesAffiliatedWithBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>ccrn:segment</measure>
    </unit>
    <unit id="state">
        <measure>ccrn:state</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001141103</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-5" id="f-102">http://fasb.org/us-gaap/2024#ServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-1" id="f-103">http://fasb.org/us-gaap/2024#ServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityRegistrantName contextRef="c-1" id="f-5">CROSS COUNTRY HEALTHCARE, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-7">0-33169</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">13-4066229</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">6551 Park of Commerce Boulevard, N.W.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">33487</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">998-2232</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">CCRN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">32783168</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">80697000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">81633000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">9792000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">9301000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">219789000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">223238000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">5893000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">10389000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">8295000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">7848000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InsuranceSettlementsReceivableCurrent contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">9343000</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:InsuranceSettlementsReceivableCurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">9255000</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">1182000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">2637000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">325199000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">335000000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">21837000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">19285000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">28117000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">28850000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">2219000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">2468000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">135060000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">135060000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">39965000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">42186000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">8804000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">8104000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:InsuranceSettlementsReceivableNoncurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">20193000</us-gaap:InsuranceSettlementsReceivableNoncurrent>
    <us-gaap:InsuranceSettlementsReceivableNoncurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">20928000</us-gaap:InsuranceSettlementsReceivableNoncurrent>
    <ccrn:CloudComputingNoncurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">11358000</ccrn:CloudComputingNoncurrent>
    <ccrn:CloudComputingNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">10846000</ccrn:CloudComputingNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">5320000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">5809000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">576235000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">589251000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-66" unitRef="usd">56325000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">64946000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">50056000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">47646000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-70" unitRef="usd">1687000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">2089000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">4411000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">980000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">1310000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">109048000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">120402000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">1623000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">1782000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-3" decimals="-3" id="f-80" unitRef="usd">33982000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">34425000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent contextRef="c-3" decimals="-3" id="f-82" unitRef="usd">10168000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent contextRef="c-4" decimals="-3" id="f-83" unitRef="usd">10117000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-84" unitRef="usd">3204000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">3566000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-86" unitRef="usd">158025000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-87" unitRef="usd">170292000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-88" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-89" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-90" unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-92" unitRef="usd">202074000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">202338000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-94" unitRef="usd">-1436000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">-1441000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-96" unitRef="usd">217569000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-97" unitRef="usd">218059000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-98" unitRef="usd">418210000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-99" unitRef="usd">418959000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-100" unitRef="usd">576235000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-101" unitRef="usd">589251000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">293408000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">379174000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DirectOperatingCosts contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">234750000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts contextRef="c-5" decimals="-3" id="f-107" unitRef="usd">301877000</us-gaap:DirectOperatingCosts>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">52486000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">63252000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">35000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-5" decimals="-3" id="f-111" unitRef="usd">1290000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">4772000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">4642000</us-gaap:DepreciationDepletionAndAmortization>
    <ccrn:AcquisitionAndIntegrationRelatedCosts contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">2041000</ccrn:AcquisitionAndIntegrationRelatedCosts>
    <ccrn:AcquisitionAndIntegrationRelatedCosts contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">0</ccrn:AcquisitionAndIntegrationRelatedCosts>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">301000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">938000</us-gaap:RestructuringCharges>
    <ccrn:LegalAndOtherLosses contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">0</ccrn:LegalAndOtherLosses>
    <ccrn:LegalAndOtherLosses contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">3650000</ccrn:LegalAndOtherLosses>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">604000</us-gaap:AssetImpairmentCharges>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">294385000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">376253000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">-977000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-125" unitRef="usd">2921000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">543000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-5" decimals="-3" id="f-127" unitRef="usd">462000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">681000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-5" decimals="-3" id="f-129" unitRef="usd">173000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">-60000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-131" unitRef="usd">1057000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">-899000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-133" unitRef="usd">3689000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">-409000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-135" unitRef="usd">997000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">-490000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-137" unitRef="usd">2692000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-139" unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">-485000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-141" unitRef="usd">2689000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-142"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-143"
      unitRef="usdPerShare">0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-144"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-145"
      unitRef="usdPerShare">0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-146" unitRef="shares">32282000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-147" unitRef="shares">34216000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-148" unitRef="shares">32282000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-149" unitRef="shares">34597000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="-3" id="f-150" unitRef="shares">32277000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-151" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-152" unitRef="usd">202338000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-153" unitRef="usd">-1441000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-154" unitRef="usd">218059000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-155" unitRef="usd">418959000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-10" decimals="-3" id="f-156" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-11" decimals="-3" id="f-157" unitRef="usd">-1582000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">-1582000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-11" decimals="-3" id="f-159" unitRef="usd">1318000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">1318000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-3" id="f-161" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-163" unitRef="usd">-490000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-164" unitRef="usd">-490000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-14" decimals="-3" id="f-165" unitRef="shares">32477000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-166" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-167" unitRef="usd">202074000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-168" unitRef="usd">-1436000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-169" unitRef="usd">217569000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-170" unitRef="usd">418210000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-18" decimals="-3" id="f-171" unitRef="shares">34385000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-172" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-173" unitRef="usd">236417000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-174" unitRef="usd">-1385000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-175" unitRef="usd">232615000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-176" unitRef="usd">467651000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-23" decimals="-3" id="f-177" unitRef="shares">251000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-24" decimals="-3" id="f-178" unitRef="usd">-2706000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-5" decimals="-3" id="f-179" unitRef="usd">-2706000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-24" decimals="-3" id="f-180" unitRef="usd">1198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-181" unitRef="usd">1198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="c-23" decimals="-3" id="f-182" unitRef="shares">310000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-24" decimals="-3" id="f-183" unitRef="usd">6368000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-5" decimals="-3" id="f-184" unitRef="usd">6368000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <ccrn:StockRepurchasedDuringPeriodExciseTax contextRef="c-24" decimals="-3" id="f-185" unitRef="usd">16000</ccrn:StockRepurchasedDuringPeriodExciseTax>
    <ccrn:StockRepurchasedDuringPeriodExciseTax contextRef="c-5" decimals="-3" id="f-186" unitRef="usd">16000</ccrn:StockRepurchasedDuringPeriodExciseTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-25" decimals="-3" id="f-187" unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-188" unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-3" id="f-189" unitRef="usd">2692000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-190" unitRef="usd">2692000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="-3" id="f-191" unitRef="shares">34326000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-192" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-193" unitRef="usd">228525000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-194" unitRef="usd">-1388000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-195" unitRef="usd">235307000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-196" unitRef="usd">462448000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-490000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-198" unitRef="usd">2692000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">4772000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-3" id="f-200" unitRef="usd">4642000</us-gaap:DepreciationDepletionAndAmortization>
    <ccrn:ProvisionForDoubtfulAccountsAndOtherAllowances contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">-135000</ccrn:ProvisionForDoubtfulAccountsAndOtherAllowances>
    <ccrn:ProvisionForDoubtfulAccountsAndOtherAllowances contextRef="c-5" decimals="-3" id="f-202" unitRef="usd">1170000</ccrn:ProvisionForDoubtfulAccountsAndOtherAllowances>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">-680000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-204" unitRef="usd">-809000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <ccrn:OperatingLeaseExpenseNonCash contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">250000</ccrn:OperatingLeaseExpenseNonCash>
    <ccrn:OperatingLeaseExpenseNonCash contextRef="c-5" decimals="-3" id="f-206" unitRef="usd">241000</ccrn:OperatingLeaseExpenseNonCash>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-5" decimals="-3" id="f-208" unitRef="usd">604000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">1318000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-210" unitRef="usd">1198000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">-202000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-5" decimals="-3" id="f-212" unitRef="usd">-203000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">-3584000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-5" decimals="-3" id="f-214" unitRef="usd">-13724000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">-57000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-5" decimals="-3" id="f-216" unitRef="usd">1227000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">4549000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-5" decimals="-3" id="f-218" unitRef="usd">1293000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">-9173000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-5" decimals="-3" id="f-220" unitRef="usd">-15492000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ccrn:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">-562000</ccrn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <ccrn:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-5" decimals="-3" id="f-222" unitRef="usd">-785000</ccrn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">1989000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-5" decimals="-3" id="f-224" unitRef="usd">-1443000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">5681000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-226" unitRef="usd">6011000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">1886000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-228" unitRef="usd">2210000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">-1886000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-230" unitRef="usd">-2210000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">373000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-5" decimals="-3" id="f-232" unitRef="usd">14166000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">373000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit contextRef="c-5" decimals="-3" id="f-234" unitRef="usd">14166000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-5" decimals="-3" id="f-236" unitRef="usd">2706000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">314000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-5" decimals="-3" id="f-238" unitRef="usd">6368000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">4411000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-5" decimals="-3" id="f-240" unitRef="usd">6579000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">-4725000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-242" unitRef="usd">-15653000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">-6000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-244" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-245" unitRef="usd">-936000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-246" unitRef="usd">-11852000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-247" unitRef="usd">81633000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-3" id="f-248" unitRef="usd">17094000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-249" unitRef="usd">80697000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-31" decimals="-3" id="f-250" unitRef="usd">5242000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-251">ORGANIZATION AND BASIS OF PRESENTATION&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nature of Business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. All such adjustments consisted of all normal recurring items, including the elimination of all intercompany transactions and balances.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form&#160;10-Q and Article 10 of Regulation&#160;S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2024 included in the 2024 Form 10-K. The December&#160;31, 2024 condensed consolidated balance sheet included herein was derived from the December&#160;31, 2024 audited consolidated balance sheet included in the 2024 Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified to conform to the current year presentation. See the condensed consolidated statements of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Aya Healthcare&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2024, the Company entered into an Agreement and Plan of Merger (Merger Agreement) with Aya Holdings II Inc., a Delaware corporation (Parent), Spark Merger Sub One Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), and, solely for purposes of Section 11.14 thereto, Aya Healthcare, Inc. (Aya Healthcare), pursuant to which Merger Sub will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (Aya Merger). On February 20, 2025, the Company and Aya Healthcare each received a request for additional information (Second Request) from the U.S. Federal Trade Commission (FTC) in connection with the FTC&#x2019;s review of the transactions contemplated by the Merger Agreement. Issuance of the Second Request extends the waiting period under the Hart-Scott- Rodino Antitrust Improvements Act of 1976 until 30 days after both the Company and Aya Healthcare substantially comply with the Second Request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. The Company expects that the Aya Merger will close in the second half of 2025, subject to the satisfaction or waiver of the other customary closing conditions specified in the Merger Agreement. The Aya Merger was approved by the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s stockholders at a special meeting held on February 28, 2025. Upon completion of the transaction, it is expected that the Company will become a private company and its common stock will no longer trade on Nasdaq. During the first quarter of 2025, the Company incurred $2.0&#160;million in fees associated with the pending Aya Merger, which is included in acquisition and integration-related costs in the condensed consolidated statement of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-252">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nature of Business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. All such adjustments consisted of all normal recurring items, including the elimination of all intercompany transactions and balances.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-253">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form&#160;10-Q and Article 10 of Regulation&#160;S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2024 included in the 2024 Form 10-K. The December&#160;31, 2024 condensed consolidated balance sheet included herein was derived from the December&#160;31, 2024 audited consolidated balance sheet included in the 2024 Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified to conform to the current year presentation. See the condensed consolidated statements of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c-32" decimals="-5" id="f-254" unitRef="usd">2000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-255">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, using information that is reasonably available to the Company at the time. Significant estimates and assumptions are used for, but not limited to: (i) the valuation of accounts receivable; (ii) goodwill, trade names, and other intangible assets; (iii) other long-lived assets; (iv) revenue recognition; (v) accruals for health, workers&#x2019; compensation, and professional liability claims; (vi) valuation of deferred tax assets; (vii) legal contingencies; and (viii) income taxes. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. As additional information becomes available to the Company, its future assessment of these estimates&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;could materially and adversely impact the Company&#x2019;s consolidated financial statements in future reporting periods. Actual results could differ from those estimates.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments from customers and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers. See associated risk factors in Item 1A. Risk Factors in the 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Accounts Receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers, which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for credit losses and sales allowances. Estimated revenue for the Company employees&#x2019;, subcontracted employees&#x2019;, and independent contractors&#x2019; time worked but not yet billed at March 31, 2025 and December 31, 2024 totaled $61.9&#160;million and $60.4&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for credit losses is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for credit losses when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of its accounts receivable based on a combination of factors. The Company bases its allowance for credit loss estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered expectations of future economic condition&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;when estimating its allowance for credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The opening balance of the allowance for credit losses is reconciled to the closing balance for expected credit losses as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Loss Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-Offs, net of Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the allowance for credit losses, the Company maintains a sales allowance for billing-related adjustments that may arise in the ordinary course of business and adjustments to the reserve are recorded as contra-revenue. The sales allowance balance as of March 31, 2025 and December 31, 2024 was $0.4&#160;million and $0.5&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s contract terms typically require payment between 30 to 60 days from the date of invoice and are considered past due based on the particular negotiated contract terms. The majority of the Company&#x2019;s customers are healthcare systems with a significant percentage in acute-care facilities. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;No single customer accounted for more than 10% of the Company&#x2019;s revenue for the three months ended March 31, 2025 and 2024, or the Company&#x2019;s accounts receivable balance as of March 31, 2025 and December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions, and are primarily included in the accounts payable and accrued expenses on the condensed consolidated balance sheets. Restructuring costs on the condensed consolidated statements of operations and comprehensive (loss) income primarily include employee termination costs and lease-related exit costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reconciliations of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.593%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.728%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee Termination Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease-Related Exit Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On November 27, 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses, enhances interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and requires certain disclosures related to the chief operating decision maker. The Company adopted this standard for its fiscal year ended December 31, 2024, and its interim periods beginning in the first quarter of 2025, and applied the guidance retrospectively to all prior periods presented in the financial statements. This standard only expanded the Company&#x2019;s disclosures with no impact to results of operations, cash flows, and financial condition. See Note 12 - Segment Data.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 4, 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is intended to improve decision usefulness of business entities&#x2019; income statements through the disaggregation of certain expense captions, such as employee compensation, depreciation, and intangible asset amortization, with required disclosure in a single note to the financial statements. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments in this update should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this update, or (2) retrospectively to any or all prior periods presented in the financial statements. The Company expects to adopt this standard for its annual report for the fiscal year ending December 31, 2027. The Company expects this ASU to only impact its disclosures with no impacts to results of operations, cash flows, and financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 14, 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires that public business entities, on an annual basis, (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The amendments also require that all entities disclose, on an annual basis, disaggregated information regarding income taxes paid and income tax expense. This guidance is effective for annual periods beginning after December 15, 2024. The amendments should be applied prospectively, but retrospective application is permitted. The Company plans to adopt this standard for its annual report for the fiscal year ended December 31, 2025. The Company expects this ASU to only impact its disclosures with no impacts to results of operations, cash flows, and financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-256">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, using information that is reasonably available to the Company at the time. Significant estimates and assumptions are used for, but not limited to: (i) the valuation of accounts receivable; (ii) goodwill, trade names, and other intangible assets; (iii) other long-lived assets; (iv) revenue recognition; (v) accruals for health, workers&#x2019; compensation, and professional liability claims; (vi) valuation of deferred tax assets; (vii) legal contingencies; and (viii) income taxes. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. As additional information becomes available to the Company, its future assessment of these estimates&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;could materially and adversely impact the Company&#x2019;s consolidated financial statements in future reporting periods. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <ccrn:RisksAndUncertaintiesPolicyTextBlock contextRef="c-1" id="f-257">&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments from customers and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers. See associated risk factors in Item 1A. Risk Factors in the 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;</ccrn:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-258">&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Accounts Receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers, which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for credit losses and sales allowances. Estimated revenue for the Company employees&#x2019;, subcontracted employees&#x2019;, and independent contractors&#x2019; time worked but not yet billed at March 31, 2025 and December 31, 2024 totaled $61.9&#160;million and $60.4&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for credit losses is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for credit losses when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of its accounts receivable based on a combination of factors. The Company bases its allowance for credit loss estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered expectations of future economic condition&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;when estimating its allowance for credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the allowance for credit losses, the Company maintains a sales allowance for billing-related adjustments that may arise in the ordinary course of business and adjustments to the reserve are recorded as contra-revenue. The sales allowance balance as of March 31, 2025 and December 31, 2024 was $0.4&#160;million and $0.5&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s contract terms typically require payment between 30 to 60 days from the date of invoice and are considered past due based on the particular negotiated contract terms. The majority of the Company&#x2019;s customers are healthcare systems with a significant percentage in acute-care facilities.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:UnbilledContractsReceivable contextRef="c-3" decimals="-5" id="f-259" unitRef="usd">61900000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable contextRef="c-4" decimals="-5" id="f-260" unitRef="usd">60400000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="c-1" id="f-261">&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The opening balance of the allowance for credit losses is reconciled to the closing balance for expected credit losses as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Loss Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-Offs, net of Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-4" decimals="-3" id="f-262" unitRef="usd">8841000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-22" decimals="-3" id="f-263" unitRef="usd">19640000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">35000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-5" decimals="-3" id="f-265" unitRef="usd">1290000</us-gaap:ProvisionForDoubtfulAccounts>
    <ccrn:AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">-473000</ccrn:AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery>
    <ccrn:AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery contextRef="c-5" decimals="-3" id="f-267" unitRef="usd">1555000</ccrn:AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-3" decimals="-3" id="f-268" unitRef="usd">9349000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-31" decimals="-3" id="f-269" unitRef="usd">19375000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <ccrn:SalesAllowanceBillingRelatedAdjustments contextRef="c-3" decimals="-5" id="f-270" unitRef="usd">400000</ccrn:SalesAllowanceBillingRelatedAdjustments>
    <ccrn:SalesAllowanceBillingRelatedAdjustments contextRef="c-4" decimals="-5" id="f-271" unitRef="usd">500000</ccrn:SalesAllowanceBillingRelatedAdjustments>
    <ccrn:ThresholdPeriodPastDueForPaymentOfServicesProvided contextRef="c-33" id="f-272">P30D</ccrn:ThresholdPeriodPastDueForPaymentOfServicesProvided>
    <ccrn:ThresholdPeriodPastDueForPaymentOfServicesProvided contextRef="c-34" id="f-273">P60D</ccrn:ThresholdPeriodPastDueForPaymentOfServicesProvided>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock contextRef="c-1" id="f-274">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions, and are primarily included in the accounts payable and accrued expenses on the condensed consolidated balance sheets. Restructuring costs on the condensed consolidated statements of operations and comprehensive (loss) income primarily include employee termination costs and lease-related exit costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-275">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reconciliations of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.593%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.728%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee Termination Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease-Related Exit Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-35" decimals="-3" id="f-276" unitRef="usd">100000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-36" decimals="-3" id="f-277" unitRef="usd">788000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-37" decimals="-3" id="f-278" unitRef="usd">152000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-38" decimals="-3" id="f-279" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-37" decimals="-3" id="f-280" unitRef="usd">137000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-38" decimals="-3" id="f-281" unitRef="usd">184000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-39" decimals="-3" id="f-282" unitRef="usd">115000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-40" decimals="-3" id="f-283" unitRef="usd">604000</us-gaap:RestructuringReserve>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-284">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On November 27, 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses, enhances interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and requires certain disclosures related to the chief operating decision maker. The Company adopted this standard for its fiscal year ended December 31, 2024, and its interim periods beginning in the first quarter of 2025, and applied the guidance retrospectively to all prior periods presented in the financial statements. This standard only expanded the Company&#x2019;s disclosures with no impact to results of operations, cash flows, and financial condition. See Note 12 - Segment Data.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 4, 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is intended to improve decision usefulness of business entities&#x2019; income statements through the disaggregation of certain expense captions, such as employee compensation, depreciation, and intangible asset amortization, with required disclosure in a single note to the financial statements. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments in this update should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this update, or (2) retrospectively to any or all prior periods presented in the financial statements. The Company expects to adopt this standard for its annual report for the fiscal year ending December 31, 2027. The Company expects this ASU to only impact its disclosures with no impacts to results of operations, cash flows, and financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 14, 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires that public business entities, on an annual basis, (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The amendments also require that all entities disclose, on an annual basis, disaggregated information regarding income taxes paid and income tax expense. This guidance is effective for annual periods beginning after December 15, 2024. The amendments should be applied prospectively, but retrospective application is permitted. The Company plans to adopt this standard for its annual report for the fiscal year ended December 31, 2025. The Company expects this ASU to only impact its disclosures with no impacts to results of operations, cash flows, and financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-285">REVENUE RECOGNITION&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s revenues from customer contracts are generated from temporary staffing services and other services. Revenue is disaggregated by segment in the following table. Sales and usage-based taxes are excluded from revenue.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nurse&lt;br/&gt;And Allied&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Physician&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Segments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary Staffing Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nurse&lt;br/&gt;And Allied&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Physician&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Segments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary Staffing Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;See Note 12 - Segment Data.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-286">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s revenues from customer contracts are generated from temporary staffing services and other services. Revenue is disaggregated by segment in the following table. Sales and usage-based taxes are excluded from revenue.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nurse&lt;br/&gt;And Allied&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Physician&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Segments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary Staffing Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nurse&lt;br/&gt;And Allied&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Physician&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Segments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary Staffing Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-41" decimals="-3" id="f-287" unitRef="usd">236157000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-42" decimals="-3" id="f-288" unitRef="usd">48700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-43" decimals="-3" id="f-289" unitRef="usd">284857000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-44" decimals="-3" id="f-290" unitRef="usd">6134000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-45" decimals="-3" id="f-291" unitRef="usd">2417000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-46" decimals="-3" id="f-292" unitRef="usd">8551000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-47" decimals="-3" id="f-293" unitRef="usd">242291000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-48" decimals="-3" id="f-294" unitRef="usd">51117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">293408000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-49" decimals="-3" id="f-296" unitRef="usd">324974000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-50" decimals="-3" id="f-297" unitRef="usd">44489000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-51" decimals="-3" id="f-298" unitRef="usd">369463000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-52" decimals="-3" id="f-299" unitRef="usd">7212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-53" decimals="-3" id="f-300" unitRef="usd">2499000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-54" decimals="-3" id="f-301" unitRef="usd">9711000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-55" decimals="-3" id="f-302" unitRef="usd">332186000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-56" decimals="-3" id="f-303" unitRef="usd">46988000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-304" unitRef="usd">379174000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-305">ACQUISITIONS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;HireUp&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On December 13, 2022, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of HireUp Leadership Inc. (HireUp) for a purchase price of $6.0&#160;million in cash, subject to adjustment, and $0.8&#160;million in shares (or 29,811 shares) of the Company&#x2019;s common stock. The transaction was treated as a purchase of assets for income tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The sellers were eligible to receive up to an additional $8.0&#160;million in earnout cash consideration based on HireUp&#x2019;s revenues and Adjusted EBITDA for each of the twelve-month periods ending on the first and second anniversaries of the first day after the closing date. Quarterly throughout 2023, and during the first quarter of 2024, the Company performed analyses using multiple updated forecasted scenarios and determined that the earnout would only be partially achieved. As a result, the Company recognized a decrease in the fair value of the related liabilities in the second and third quarters of 2023 and the first quarter of 2024. The Company paid the remaining earnout liability of $1.7&#160;million in the first quarter of 2024. See Note 10 - Fair Value Measurements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mint&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 3, 2022, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of Mint Medical Physician Staffing, LP and Lotus Medical Staffing LLC (collectively, Mint) for a purchase price of $27.0&#160;million in cash, subject to adjustment, and $3.6&#160;million in shares (or 114,278 shares) of the Company&#x2019;s common stock. The transaction was treated as a purchase of assets for income tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The sellers were eligible to receive up to an additional $10.0&#160;million in earnout cash consideration based on Mint&#x2019;s revenues and gross profit for each of the twelve-month periods ending on the first and second anniversaries of the first day of the calendar month following the closing date. In the fourth quarter of 2023, the Company performed a calculation for the first measurement period, resulting in the achievement of a $4.9&#160;million earnout, which was paid in the first quarter of 2024. During &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;the fourth quarter of 2024, the Company performed a calculation for the second measurement period, resulting in the achievement of a $4.4&#160;million earnout, which was paid in the first quarter of 2025. See Note 10 - Fair Value Measurements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other than the fees associated with the pending Aya Merger as discussed on Note 1 - Organization and Basis of Presentation, the Company did not record any acquisition-related costs associated with the Company&#x2019;s acquisitions for the three months ended March 31, 2025, and recorded an immaterial credit for the three months ended March 31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-57" decimals="-5" id="f-306" unitRef="usd">6000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-57" decimals="-5" id="f-307" unitRef="usd">800000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-57"
      decimals="INF"
      id="f-308"
      unitRef="shares">29811</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-58" decimals="-5" id="f-309" unitRef="usd">8000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-59" decimals="-5" id="f-310" unitRef="usd">1700000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-60" decimals="-5" id="f-311" unitRef="usd">27000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-60" decimals="-5" id="f-312" unitRef="usd">3600000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-60"
      decimals="INF"
      id="f-313"
      unitRef="shares">114278</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-61" decimals="-5" id="f-314" unitRef="usd">10000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-62" decimals="-5" id="f-315" unitRef="usd">4900000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-63" decimals="-5" id="f-316" unitRef="usd">4400000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="c-1" id="f-317">COMPREHENSIVE (LOSS) INCOME&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total comprehensive (loss) income includes net income or loss and foreign currency translation adjustments, net of any related deferred taxes, and is included within the accompanying condensed consolidated statements of operations and comprehensive (loss) income. Certain of the Company&#x2019;s foreign subsidiaries use their respective local currency as their functional currency. Assets and liabilities of these operations are translated at the exchange rates in effect on the balance sheet date. Income statement items are translated at the average exchange rates for the period. The cumulative impact of currency fluctuations related to the balance sheet translation is included in accumulated other comprehensive loss in the accompanying condensed consolidated balance sheets and was an unrealized loss of $1.5&#160;million as of March 31, 2025 and December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax impact related to components of other comprehensive income (loss) for the three months ended March 31, 2025 and 2024 is included in unrealized foreign currency translation gain (loss), net of tax in the condensed consolidated statements of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax contextRef="c-4" decimals="-5" id="f-318" unitRef="usd">-1500000</ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax>
    <ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax contextRef="c-3" decimals="-5" id="f-319" unitRef="usd">-1500000</ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-320">EARNINGS PER SHARE&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(amounts in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common stockholders - Basic and Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(490)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares - Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of diluted shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Share-based awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares - Diluted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share attributable to common stockholders - Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share attributable to common stockholders - Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(a)  For the three months ended March 31, 2025, the effect of diluted shares was not included in the weighted average share calculation due to the Company&#x2019;s net operating loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the share-based awards that could potentially dilute net (loss) income per share attributable to common stockholders in the future that were not included in the computation of diluted net (loss) income per share attributable to common stockholders because to do so would have been anti-dilutive for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-321">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(amounts in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common stockholders - Basic and Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(490)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares - Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of diluted shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Share-based awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares - Diluted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share attributable to common stockholders - Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share attributable to common stockholders - Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(a)  For the three months ended March 31, 2025, the effect of diluted shares was not included in the weighted average share calculation due to the Company&#x2019;s net operating loss position.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">-490000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">-490000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-5" decimals="-3" id="f-324" unitRef="usd">2692000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-5" decimals="-3" id="f-325" unitRef="usd">2692000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-326" unitRef="shares">32282000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-327" unitRef="shares">34216000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-3" id="f-328" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-5" decimals="-3" id="f-329" unitRef="shares">381000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-330" unitRef="shares">32282000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-331" unitRef="shares">34597000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-332"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-333"
      unitRef="usdPerShare">0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-334"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-335"
      unitRef="usdPerShare">0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-336">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the share-based awards that could potentially dilute net (loss) income per share attributable to common stockholders in the future that were not included in the computation of diluted net (loss) income per share attributable to common stockholders because to do so would have been anti-dilutive for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-64" decimals="-3" id="f-337" unitRef="shares">3000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-65" decimals="-3" id="f-338" unitRef="shares">5000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-339">GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had the following acquired intangible assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Databases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names, indefinite-lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, estimated future annual amortization expense was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.811%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Goodwill, Trade Names, and Other Intangible Assets Impairment &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company tests reporting units&#x2019; goodwill and intangible assets with indefinite lives for impairment annually during the fourth quarter and more frequently if impairment indicators exist. The Company performs quarterly qualitative assessments of significant events and circumstances, such as reporting units&#x2019; historical and current results, assumptions regarding future performance, strategic initiatives and overall economic factors,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and macro-economic developments, to determine the existence of potential indicators of impairment and assess if it is more likely than not that the fair value of reporting units or intangible assets is less than their carrying value. If indicators of impairments are identified a quantitative impairment test is performed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2025, the Company performed a qualitative assessment of each of its reporting units and determined that it was not more likely than not that the fair value of its reporting units dropped below their carrying value. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lthough management believes that the Company&#x2019;s current estimates and assumptions utilized in its qualitative testing are reasonable and supportable, there can be no assurance that the estimates and assumptions management used for purposes of its assessment as of March 31, 2025 will prove to be accurate predictions of future performance.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2025, goodwill by reporting segment was: $112.2&#160;million for Nurse and Allied Staffing and $22.9&#160;million for Physician Staffing, for a total of $135.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-lived assets and definite-lived intangible assets, the Company reviews for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of March 31, 2025 and 2024, the Company performed a qualitative assessment of its trade names and other intangible assets and determined it was not more likely than not that their carrying value may not be recoverable.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c-1" id="f-340">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had the following acquired intangible assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Databases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names, indefinite-lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-66" decimals="-3" id="f-341" unitRef="usd">36530000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-66" decimals="-3" id="f-342" unitRef="usd">23029000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-66" decimals="-3" id="f-343" unitRef="usd">13501000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-67" decimals="-3" id="f-344" unitRef="usd">36530000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-67" decimals="-3" id="f-345" unitRef="usd">21945000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-67" decimals="-3" id="f-346" unitRef="usd">14585000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-68" decimals="-3" id="f-347" unitRef="usd">52538000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-68" decimals="-3" id="f-348" unitRef="usd">31974000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-68" decimals="-3" id="f-349" unitRef="usd">20564000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-69" decimals="-3" id="f-350" unitRef="usd">52538000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-69" decimals="-3" id="f-351" unitRef="usd">30837000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-69" decimals="-3" id="f-352" unitRef="usd">21701000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-3" decimals="-3" id="f-353" unitRef="usd">89068000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-3" decimals="-3" id="f-354" unitRef="usd">55003000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-355" unitRef="usd">34065000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-3" id="f-356" unitRef="usd">89068000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-357" unitRef="usd">52782000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-358" unitRef="usd">36286000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTradeNames contextRef="c-3" decimals="-3" id="f-359" unitRef="usd">5900000</us-gaap:IndefiniteLivedTradeNames>
    <us-gaap:IndefiniteLivedTradeNames contextRef="c-4" decimals="-3" id="f-360" unitRef="usd">5900000</us-gaap:IndefiniteLivedTradeNames>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-361">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, estimated future annual amortization expense was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.811%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-362" unitRef="usd">6430000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-3" decimals="-3" id="f-363" unitRef="usd">7482000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-3" decimals="-3" id="f-364" unitRef="usd">6191000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-3" decimals="-3" id="f-365" unitRef="usd">4791000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-3" decimals="-3" id="f-366" unitRef="usd">4107000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ccrn:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour contextRef="c-3" decimals="-3" id="f-367" unitRef="usd">5064000</ccrn:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-368" unitRef="usd">34065000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill contextRef="c-70" decimals="-5" id="f-369" unitRef="usd">112200000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-71" decimals="-5" id="f-370" unitRef="usd">22900000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-3" decimals="-5" id="f-371" unitRef="usd">135100000</us-gaap:Goodwill>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-372">DEBT&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s debt consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.699%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Secured Asset-Based Loan, interest of 6.21% and 6.31% at March 31, 2025 and December 31, 2024, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2025 and December 31, 2024, there was no debt outstanding on the condensed consolidated balance sheets. The Company has elected to present the debt issuance costs associated with its senior secured asset-based credit facility as an asset, included in other assets on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Asset-Based Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective October 25, 2019, the Company terminated its prior senior credit facility and entered into an asset-based loan agreement, by and among the Company and certain of its domestic subsidiaries, as borrowers or guarantors, Wells Fargo Bank, N.A., and PNC Bank N.A., as well as other Lenders (as defined therein) from time to time parties thereto (Loan Agreement). The Loan Agreement provided for a five-year revolving senior secured asset-based credit facility (ABL) in the aggregate principal amount of up to $120.0&#160;million, including a sublimit for swing loans up to $15.0&#160;million and a $35.0&#160;million sublimit for standby letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 30, 2020, the Company amended the Loan Agreement (First Amendment), which increased the current aggregate committed size of the ABL from $120.0&#160;million to $130.0&#160;million. All other terms, conditions, covenants, and pricing of the Loan Agreement remained the same. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 8, 2021, the Company amended the Loan Agreement (Second Amendment), which increased the current aggregate committed size of the ABL from $130.0&#160;million to $150.0&#160;million, increased certain borrowing base sub-limits, and decreased both the cash dominion event and financial reporting triggers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, the Company amended the Loan Agreement (Third Amendment), which permitted the incurrence of indebtedness and grant of security as set forth in the Loan Agreement and in accordance with the Intercreditor Agreement (as defined in the Loan Agreement), and provides mechanics relating to a transition away from the London Interbank Offered Rate (LIBOR) as a benchmark interest rate to a replacement alternative benchmark rate or mechanism for loans made in U.S. dollars.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 18, 2021, the Company amended the Loan Agreement (Fourth Amendment), whereby the permitted indebtedness (as defined in the Loan Agreement), was increased to $175.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 21, 2022, the Company amended the Loan Agreement (Fifth Amendment), which increased the current aggregate committed size of the ABL from $150.0 million to $300.0 million, extended the term of the credit facility for an additional five years, through March 21, 2027, and increased certain borrowing base sub-limits. In addition, the agreement provides the option for all or a portion of the borrowings to bear interest at a rate based on the Secured Overnight Financing Rate (SOFR) or the Base Rate (as defined in the Loan Agreement), at the election of the borrowers, plus an applicable margin. The applicable margin increased 10 basis points due to the credit spread associated with the transition to SOFR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 29, 2023, the Company amended the Loan Agreement (Sixth Amendment), which changed the minimum fixed charge coverage ratio from a maintenance covenant to a springing covenant based on excess availability, which provides for compliance with the covenant only during a compliance period (any time that excess availability falls below a certain threshold), and in such case, the financial covenant shall be tested during this period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 29, 2024, the Company amended the Loan Agreement (Seventh Amendment), which allows for all share repurchases paid in cash prior to June 30, 2024 and thereafter to be excluded as restricted payments in the fixed charge coverage ratio calculation, if as of the date of the share repurchase, there is no revolving ABL balance (except for interest and fees payable in accordance with the terms of the Loan Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These amendments were treated as modifications of debt and, as a result, the associated fees and costs were included in debt issuance costs and are amortized ratably over the remaining term of the Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ABL availability is subject to a borrowing base of up to 85% of secured eligible accounts receivable, subject to adjustment at certain quality levels, minus customary reserves and subject to customary adjustments. Revolving loans and letters of credit &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issued under the Loan Agreement reduce availability under the ABL on a dollar-for-dollar basis. At March 31, 2025, there were no borrowings drawn under the ABL, and borrowing base availability under the ABL was $148.4&#160;million, with $133.5&#160;million of availability net of $14.9&#160;million of letters of credit outstanding related to workers&#x2019; compensation and professional liability policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2025, the interest rate spreads and fees under the ABL were based on SOFR plus 1.85% for the revolving portion of the borrowing base. The Base Rate margin would have been 0.75% for the revolving portion&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The SOFR and Base Rate margins are subject to monthly adjustments, pursuant to a pricing matrix based on the Company&#x2019;s excess availability under the revolving credit facility. In addition, the facility is subject to an unused line fee, letter of credit fees, and an administrative fee. The unused line fee is 0.375% of the average daily unused portion of the revolving credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Agreement contains various restrictions applicable to the Company and its subsidiaries. For the three months ended March 31, 2025, the excess availability did not fall below the stated threshold and, as a result, there was no covenant compliance period. Obligations under the ABL are secured by substantially all of the assets of the borrowers and guarantors, subject to customary exceptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-373">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s debt consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.699%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Secured Asset-Based Loan, interest of 6.21% and 6.31% at March 31, 2025 and December 31, 2024, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-72" decimals="4" id="f-374" unitRef="number">0.0621</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-73" decimals="4" id="f-375" unitRef="number">0.0631</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-72" decimals="-3" id="f-376" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-72" decimals="-3" id="f-377" unitRef="usd">1606000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-73" decimals="-3" id="f-378" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-73" decimals="-3" id="f-379" unitRef="usd">1807000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-3" decimals="-3" id="f-380" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-3" decimals="-3" id="f-381" unitRef="usd">1606000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-4" decimals="-3" id="f-382" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-4" decimals="-3" id="f-383" unitRef="usd">1807000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-3" decimals="INF" id="f-384" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-4" decimals="INF" id="f-385" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="c-74" id="f-386">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-75" decimals="INF" id="f-387" unitRef="usd">120000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-76" decimals="INF" id="f-388" unitRef="usd">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-77" decimals="INF" id="f-389" unitRef="usd">35000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-75" decimals="INF" id="f-390" unitRef="usd">120000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-78" decimals="INF" id="f-391" unitRef="usd">130000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-78" decimals="INF" id="f-392" unitRef="usd">130000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-79" decimals="INF" id="f-393" unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <ccrn:LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources contextRef="c-80" decimals="INF" id="f-394" unitRef="usd">175000000.0</ccrn:LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-79" decimals="INF" id="f-395" unitRef="usd">150000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-81" decimals="INF" id="f-396" unitRef="usd">300000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="c-82" id="f-397">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <ccrn:DebtInstrumentBasisSpreadOnVariableRateAdjustment
      contextRef="c-83"
      decimals="INF"
      id="f-398"
      unitRef="number">0.0010</ccrn:DebtInstrumentBasisSpreadOnVariableRateAdjustment>
    <us-gaap:LineOfCredit contextRef="c-84" decimals="INF" id="f-399" unitRef="usd">0</us-gaap:LineOfCredit>
    <ccrn:LineOfCreditBorrowingBasePercentageOfAccountsReceivable
      contextRef="c-75"
      decimals="INF"
      id="f-400"
      unitRef="number">0.85</ccrn:LineOfCreditBorrowingBasePercentageOfAccountsReceivable>
    <us-gaap:LineOfCredit contextRef="c-85" decimals="INF" id="f-401" unitRef="usd">0</us-gaap:LineOfCredit>
    <ccrn:LineOfCreditFacilityBorrowingBaseAvailability contextRef="c-85" decimals="-5" id="f-402" unitRef="usd">148400000</ccrn:LineOfCreditFacilityBorrowingBaseAvailability>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-85" decimals="-5" id="f-403" unitRef="usd">133500000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-85" decimals="-5" id="f-404" unitRef="usd">14900000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-86"
      decimals="INF"
      id="f-405"
      unitRef="number">0.0185</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-87"
      decimals="INF"
      id="f-406"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="c-88"
      decimals="INF"
      id="f-407"
      unitRef="number">0.00375</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-408">LEASES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease population of its right-of-use assets and lease liabilities is substantially related to the rental of office space. The Company enters into lease agreements as a lessee that may include options to extend or terminate early. Some of these real estate leases require variable payments of property taxes, insurance, and common area maintenance, in addition to base rent. Certain of the leases have provisions for free rent during the lease term and/or escalating rent payments and, particularly for the Company&#x2019;s longer-term leases for its corporate offices, it has received incentives to enter into the leases, such as receiving up to a specified dollar amount to construct tenant improvements. These leases do not include residual value guarantees, covenants, or other restrictions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.854%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classification on Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.854%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below reconciles the undiscounted cash flows for each of, and total of, the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of March 31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.811%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding supplemental cash flows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets acquired under operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Included in Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable and other lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense, short-term lease expense, and variable and other lease costs are included in selling, general and administrative expenses, direct operating expenses, and restructuring costs in the condensed consolidated statements of operations and comprehensive (loss) income, depending on the nature of the leased asset. Operating lease expense is reported net of sublease income, which is not material.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2025, the Company did not have any material operating leases that had not yet commenced, and does not have any finance lease contracts.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ccrn:AssetsAndLiabilitiesLeasesTableTextBlock contextRef="c-1" id="f-409">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.854%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classification on Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.854%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ccrn:AssetsAndLiabilitiesLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-410" unitRef="usd">2219000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-411" unitRef="usd">2468000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-412" unitRef="usd">1687000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-413" unitRef="usd">2089000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-414" unitRef="usd">1623000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-415" unitRef="usd">1782000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-416">P2Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-417">P2Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="4" id="f-418" unitRef="number">0.0712</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="4" id="f-419" unitRef="number">0.0705</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-420">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below reconciles the undiscounted cash flows for each of, and total of, the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of March 31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.811%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-421" unitRef="usd">1663000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-422" unitRef="usd">728000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-423" unitRef="usd">602000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-424" unitRef="usd">523000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-425" unitRef="usd">136000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ccrn:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour contextRef="c-3" decimals="-3" id="f-426" unitRef="usd">0</ccrn:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-427" unitRef="usd">3652000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-428" unitRef="usd">342000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-429" unitRef="usd">3310000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-430" unitRef="usd">1687000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-431" unitRef="usd">1623000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-432">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding supplemental cash flows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets acquired under operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Included in Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable and other lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-433" unitRef="usd">625000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-5" decimals="-3" id="f-434" unitRef="usd">863000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-435" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-436" unitRef="usd">11000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-437" unitRef="usd">313000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-5" decimals="-3" id="f-438" unitRef="usd">322000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-3" id="f-439" unitRef="usd">268000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-5" decimals="-3" id="f-440" unitRef="usd">597000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-441" unitRef="usd">60000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-5" decimals="-3" id="f-442" unitRef="usd">628000</us-gaap:VariableLeaseCost>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-443">FAIR VALUE MEASUREMENTS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy was established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Items Measured at Fair Value on a Recurring Basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial assets/liabilities required to be measured on a recurring basis were primarily its: (i) deferred compensation asset included in other assets; and (ii) deferred compensation liability included in other liabilities on its condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company utilizes Level 1 inputs to value its deferred compensation assets and liabilities. The Company&#x2019;s deferred compensation assets and liabilities are measured using publicly available indices, as per the plan documents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the Company&#x2019;s financial assets and liabilities measured on a recurring basis is as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Items Measured at Fair Value on a Non-Recurring Basis:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s non-financial assets, such as goodwill, trade names, other intangible assets, right-of-use assets, and property and equipment, are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not record any material impairment charges during the three months ended March 31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments not measured or recorded at fair value in the condensed consolidated balance sheets consist of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses. The estimated fair value of accounts receivable and accounts payable and&#160;accrued expenses approximate their carrying amount due to the short-term nature of these instruments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial instruments not measured or recorded at fair value include earnout liabilities related to the (i) Mint and (ii) HireUp acquisitions, as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(i) Potential earnout payments related to the Mint acquisition were contingent upon meeting certain performance requirements based on 2022 through 2024 performance. On a quarterly basis, the Company performed an analysis using multiple forecasted scenarios to determine the fair value of the earnout liability. In the fourth quarter of 2023, the Company performed the earnout calculation for the first measurement period, resulting in an earnout of $4.9&#160;million, which was paid in the first quarter of 2024. During the fourth quarter of 2024, the Company performed a calculation for the second measurement period, resulting in the achievement of a $4.4&#160;million earnout, which was paid in the first quarter of 2025. See Note 4 - Acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(ii) Potential earnout payments related to the HireUp acquisition were contingent upon meeting certain performance requirements based on 2022 through 2024 performance. Quarterly throughout 2023 and in the first quarter of 2024, the Company performed analyses using multiple updated forecasted scenarios and determined that the earnout would only be partially achieved. As a result, the Company recognized a decrease in the fair value of the related liabilities in the second and third quarters of 2023 and the first quarter of 2024. The remaining liability of $1.7&#160;million was paid in the first quarter of 2024. See Note 4 - Acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See discussion of credit losses and allowance for credit losses in Note 2 - Summary of Significant Accounting Policies. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Overall, based on the large number of customers in differing geographic areas, primarily throughout the United States and its territories, the Company believes that the concentration of credit risk is limited.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-444">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the Company&#x2019;s financial assets and liabilities measured on a recurring basis is as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-89" decimals="-3" id="f-445" unitRef="usd">2534000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-90" decimals="-3" id="f-446" unitRef="usd">2889000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations contextRef="c-91" decimals="-3" id="f-447" unitRef="usd">2556000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations contextRef="c-92" decimals="-3" id="f-448" unitRef="usd">2926000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-62" decimals="-5" id="f-449" unitRef="usd">4900000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-63" decimals="-5" id="f-450" unitRef="usd">4400000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-59" decimals="-5" id="f-451" unitRef="usd">1700000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c-1" id="f-452">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On May 1, 2023, the Company&#x2019;s Board of Directors authorized approximately $59.0&#160;million in additional share repurchases, such that, effective for trades made after May 3, 2023, the aggregate amount available for stock repurchases was set at $100.0&#160;million (the Repurchase Program). The shares can be repurchased from time-to-time in the open market or in privately negotiated transactions. The Repurchase Program does not obligate the Company to repurchase any particular number of shares of common stock and may be discontinued by the Board of Directors at any time. Decisions regarding the amount and the timing of repurchases under the Repurchase Program will be subject to the Company&#x2019;s available liquidity and cash on hand, applicable legal requirements, the terms of the Company&#x2019;s Loan Agreement, general market conditions, and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the third quarter of 2023, the Company entered into a Rule 10b5-1 Repurchase Plan to allow for share repurchases during the Company&#x2019;s blackout periods, beginning on January 2, 2024 and effective through November 7, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2024, the Company repurchased a total of 310,235 shares of common stock for $6.4&#160;million, at an average price of $20.51 per share. During the three months ended March 31, 2025, the Company did not repurchase any shares of its common stock, but did pay $0.3&#160;million in excise tax related to previous share repurchases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of March 31, 2025, the Company had $40.5&#160;million remaining for share repurchase under the Repurchase Program, subject to certain conditions in the Company&#x2019;s Loan Agreement. As of March 31, 2025, the Company had 32,476,983 unrestricted shares of common stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 14, 2024, the Company&#x2019;s stockholders approved the Cross Country Healthcare, Inc. 2024 Omnibus Incentive Plan (2024 Plan). Pursuant to the 2024 Plan, awards may be granted to employees, non-employee directors, consultants, and key advisors of the Company and its subsidiaries, including stock options (including incentive stock options and nonqualified stock options), stock appreciation rights, stock awards, stock units, other stock-based awards, and cash awards. The 2024 Plan was adopted principally to serve as a successor plan to the Cross Country Healthcare, Inc. 2020 Omnibus Incentive Plan (2020 Plan) and to increase the number of shares of Company common stock reserved for equity-based awards to 2,400,000 shares (in addition to the share reserve amount that remained available under the 2020 Plan immediately prior to the adoption of the 2024 Plan and other eligible returning shares). No awards may be granted under the 2024 Plan after May 13, 2034.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock awards and performance stock awards activity issued under the 2020 Plan and the 2024 Plan (Plans) for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Performance Stock Awards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Target &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock awards, January&#160;1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(220,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock awards, March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards granted under the Company&#x2019;s Plans entitle the holder to receive, at the end of a vesting period, a specified number of shares of the Company&#x2019;s common stock. Share-based compensation expense is measured by the market value of the Company&#x2019;s stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Awards granted to non-employee directors under the Plans will vest on the first anniversary of such grant date, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or earlier subject to retirement eligibility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In addition, effective for the three months ended June 30, 2020, the Company implemented modified guidelines that provide for accelerated vesting of restricted stock grants on the last date of service when a retirement-eligible director retires.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pursuant to the Plans, the number of target shares that are issued for performance-based stock awards are determined based on the level of attainment of the targets. During the first quarter of 2025, the Company&#x2019;s Compensation Committee of the Board of Directors approved a 75.5% level of attainment for the 2022 performance-based share awards, resulting in the issuance of 85,001 performance shares that vested on March 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the three months ended March 31, 2025, $1.3 million was included in selling, general and administrative expenses related to share-based payments, and a net of 199,588 shares of common stock were issued upon the vesting of restricted and performance stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2024, $1.2 million was included in selling, general and administrative expenses related to share-based payments, and a net of 251,024 shares of common stock were issued upon the vesting of restricted and performance stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <ccrn:StockRepurchaseProgramAdditionalAuthorizedAmount contextRef="c-93" decimals="-5" id="f-453" unitRef="usd">59000000</ccrn:StockRepurchaseProgramAdditionalAuthorizedAmount>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-93" decimals="-5" id="f-454" unitRef="usd">100000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="c-94"
      decimals="INF"
      id="f-455"
      unitRef="shares">310235</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-94" decimals="-5" id="f-456" unitRef="usd">6400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-94"
      decimals="2"
      id="f-457"
      unitRef="usdPerShare">20.51</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="c-95"
      decimals="INF"
      id="f-458"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <ccrn:StockRepurchasedDuringPeriodExciseTax contextRef="c-95" decimals="-5" id="f-459" unitRef="usd">300000</ccrn:StockRepurchasedDuringPeriodExciseTax>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-96" decimals="-5" id="f-460" unitRef="usd">40500000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-461" unitRef="shares">32476983</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-97"
      decimals="INF"
      id="f-462"
      unitRef="shares">2400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-463">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock awards and performance stock awards activity issued under the 2020 Plan and the 2024 Plan (Plans) for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Performance Stock Awards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Target &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock awards, January&#160;1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(220,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock awards, March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-98"
      decimals="INF"
      id="f-464"
      unitRef="shares">538589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-98"
      decimals="2"
      id="f-465"
      unitRef="usdPerShare">19.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-99"
      decimals="INF"
      id="f-466"
      unitRef="shares">409698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-99"
      decimals="2"
      id="f-467"
      unitRef="usdPerShare">20.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-100"
      decimals="INF"
      id="f-468"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-100"
      decimals="2"
      id="f-469"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-101"
      decimals="INF"
      id="f-470"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-101"
      decimals="2"
      id="f-471"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-100"
      decimals="INF"
      id="f-472"
      unitRef="shares">220873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-100"
      decimals="2"
      id="f-473"
      unitRef="usdPerShare">20.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-101"
      decimals="INF"
      id="f-474"
      unitRef="shares">85001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-101"
      decimals="2"
      id="f-475"
      unitRef="usdPerShare">21.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-100"
      decimals="INF"
      id="f-476"
      unitRef="shares">9101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-100"
      decimals="2"
      id="f-477"
      unitRef="usdPerShare">20.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-101"
      decimals="INF"
      id="f-478"
      unitRef="shares">27586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-101"
      decimals="2"
      id="f-479"
      unitRef="usdPerShare">21.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-102"
      decimals="INF"
      id="f-480"
      unitRef="shares">308615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-102"
      decimals="2"
      id="f-481"
      unitRef="usdPerShare">18.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-103"
      decimals="INF"
      id="f-482"
      unitRef="shares">297111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-103"
      decimals="2"
      id="f-483"
      unitRef="usdPerShare">20.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage contextRef="c-1" decimals="INF" id="f-484" unitRef="number">0.755</ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-101"
      decimals="INF"
      id="f-485"
      unitRef="shares">85001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-104" decimals="-5" id="f-486" unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet
      contextRef="c-105"
      decimals="INF"
      id="f-487"
      unitRef="shares">199588</ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-106" decimals="-5" id="f-488" unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet
      contextRef="c-107"
      decimals="INF"
      id="f-489"
      unitRef="shares">251024</ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-490">SEGMENT DATA&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two operating and reportable segments, Nurse and Allied Staffing and Physician Staffing, which align with its management structure and reflect how the operating results are regularly reviewed by the Chief Executive Officer, who the Company has determined to be its Chief Operating Decision Maker (CODM). The Company&#x2019;s segments offer services to its customers as described below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x25cf;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Nurse and Allied Staffing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2013; Nurse and Allied Staffing provides traditional staffing, recruiting, and value-added total talent solutions including: temporary and permanent placement of travel nurse and allied professionals, per diem, and healthcare leaders within nursing, allied, human resources, and finance, managed service programs services, education healthcare services, in-home care services, and outsourcing services. In addition, Nurse and Allied Staffing provides executive search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services, and offers the Company&#x2019;s SaaS-based, proprietary, vendor management technology, Intellify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; to facilities to manage all or a portion of their agency services. Its customers include: public and private acute care hospitals, non-acute care hospitals, government facilities, local healthcare plans, national healthcare plans, managed care providers, public schools, charter schools, academic medical centers, Programs of All-Inclusive Care for the Elderly (PACE) programs, outpatient clinics, ambulatory care facilities, physician practice groups, and many other healthcare providers throughout the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25cf;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Physician Staffing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Physician Staffing provides physicians in many specialties, as well as certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments throughout the United States at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue, and the profit and loss measure of contribution income, are reported to the CODM by each of the operating segments to assess performance. Contribution income is the profit and loss measure used by the CODM to allocate operating and capital resources to each segment. The Company defines contribution income as income (loss) from operations before depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, impairment charges, and corporate overhead. Management believes that its measure of contribution income is most consistent with that used to measure the corresponding amounts on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information in the following tables is derived from the segments&#x2019; internal financial information as used for corporate management purposes. Certain corporate expenses are not allocated to and/or among the operating segments. Those include corporate overhead and the remaining line items below contribution income in the consolidated column in the tables below, and are presented to the CODM on a consolidated basis only.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on reportable segments and a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reconciliation to loss before income taxes for the period indicated are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.031%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nurse and Allied Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Physician Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit loss (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divisional corporate G&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contribution Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reconciliation of profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate overhead&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and integration-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) For each reportable segment, the other segment items category includes the following expenses: rent, insurance, maintenance, utilities, professional services, office, software and hardware, taxes, and miscellaneous employee expenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on reportable segments and a reconciliation to income before income taxes for the period indicated are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.031%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nurse and Allied Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Physician Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit loss expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divisional corporate G&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contribution Income&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reconciliation of profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate overhead&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and other losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) For each reportable segment, the other segment items category includes the following expenses: rent, insurance, maintenance, utilities, professional services, office, software and hardware, taxes, and miscellaneous employee expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is based on services provided. During the three months ended March 31, 2025 and 2024, all revenue was generated in the U.S., and all of the Company&#x2019;s long-lived assets were located in the U.S. and India. The Company provides its staffing services and workforce solutions in all 50 states. The India location is a cost center with no revenues and an immaterial amount of long-lived assets. The Company had no intersegment revenues between reportable segments for the three months ended March 31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not evaluate, manage, or measure performance of segments using asset information; accordingly, total asset information by segment is not prepared or disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the segments are the same as those described in Note 2 &#x2013; Summary of Significant Accounting Policies, which also provides information about major customers.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See the tables in Note 3 - Revenue Recognition, which present segment revenues by services.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-491"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-492"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-493">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on reportable segments and a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reconciliation to loss before income taxes for the period indicated are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.031%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nurse and Allied Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Physician Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit loss (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divisional corporate G&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contribution Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reconciliation of profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate overhead&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and integration-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) For each reportable segment, the other segment items category includes the following expenses: rent, insurance, maintenance, utilities, professional services, office, software and hardware, taxes, and miscellaneous employee expenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on reportable segments and a reconciliation to income before income taxes for the period indicated are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.031%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nurse and Allied Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Physician Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit loss expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divisional corporate G&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contribution Income&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reconciliation of profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate overhead&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and other losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) For each reportable segment, the other segment items category includes the following expenses: rent, insurance, maintenance, utilities, professional services, office, software and hardware, taxes, and miscellaneous employee expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-108" decimals="-3" id="f-494" unitRef="usd">242291000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-109" decimals="-3" id="f-495" unitRef="usd">51117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-110" decimals="-3" id="f-496" unitRef="usd">293408000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DirectOperatingCosts contextRef="c-108" decimals="-3" id="f-497" unitRef="usd">194033000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts contextRef="c-109" decimals="-3" id="f-498" unitRef="usd">40717000</us-gaap:DirectOperatingCosts>
    <ccrn:LaborAndRelatedExpenseExcludingBenefitsExpense contextRef="c-108" decimals="-3" id="f-499" unitRef="usd">21369000</ccrn:LaborAndRelatedExpenseExcludingBenefitsExpense>
    <ccrn:LaborAndRelatedExpenseExcludingBenefitsExpense contextRef="c-109" decimals="-3" id="f-500" unitRef="usd">5366000</ccrn:LaborAndRelatedExpenseExcludingBenefitsExpense>
    <ccrn:BenefitsExpense contextRef="c-108" decimals="-3" id="f-501" unitRef="usd">2549000</ccrn:BenefitsExpense>
    <ccrn:BenefitsExpense contextRef="c-109" decimals="-3" id="f-502" unitRef="usd">493000</ccrn:BenefitsExpense>
    <us-gaap:MarketingExpense contextRef="c-108" decimals="-3" id="f-503" unitRef="usd">1670000</us-gaap:MarketingExpense>
    <us-gaap:MarketingExpense contextRef="c-109" decimals="-3" id="f-504" unitRef="usd">209000</us-gaap:MarketingExpense>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-108" decimals="-3" id="f-505" unitRef="usd">-10000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-109" decimals="-3" id="f-506" unitRef="usd">45000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-108" decimals="-3" id="f-507" unitRef="usd">3718000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-109" decimals="-3" id="f-508" unitRef="usd">80000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-108" decimals="-3" id="f-509" unitRef="usd">1718000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-109" decimals="-3" id="f-510" unitRef="usd">178000</us-gaap:SegmentReportingOtherItemAmount>
    <ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard contextRef="c-108" decimals="-3" id="f-511" unitRef="usd">17244000</ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard>
    <ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard contextRef="c-109" decimals="-3" id="f-512" unitRef="usd">4029000</ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard>
    <ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard contextRef="c-110" decimals="-3" id="f-513" unitRef="usd">21273000</ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard>
    <ccrn:SegmentReportingUnallocatedCorporateExpenses contextRef="c-111" decimals="-3" id="f-514" unitRef="usd">15136000</ccrn:SegmentReportingUnallocatedCorporateExpenses>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-515" unitRef="usd">4772000</us-gaap:DepreciationDepletionAndAmortization>
    <ccrn:AcquisitionAndIntegrationRelatedCosts contextRef="c-1" decimals="-3" id="f-516" unitRef="usd">2041000</ccrn:AcquisitionAndIntegrationRelatedCosts>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-3" id="f-517" unitRef="usd">301000</us-gaap:RestructuringCharges>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-518" unitRef="usd">543000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-519" unitRef="usd">681000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-520" unitRef="usd">-60000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-521" unitRef="usd">-899000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-112" decimals="-3" id="f-522" unitRef="usd">332186000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-113" decimals="-3" id="f-523" unitRef="usd">46988000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-114" decimals="-3" id="f-524" unitRef="usd">379174000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DirectOperatingCosts contextRef="c-112" decimals="-3" id="f-525" unitRef="usd">264880000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts contextRef="c-113" decimals="-3" id="f-526" unitRef="usd">36997000</us-gaap:DirectOperatingCosts>
    <ccrn:LaborAndRelatedExpenseExcludingBenefitsExpense contextRef="c-112" decimals="-3" id="f-527" unitRef="usd">28365000</ccrn:LaborAndRelatedExpenseExcludingBenefitsExpense>
    <ccrn:LaborAndRelatedExpenseExcludingBenefitsExpense contextRef="c-113" decimals="-3" id="f-528" unitRef="usd">5430000</ccrn:LaborAndRelatedExpenseExcludingBenefitsExpense>
    <ccrn:BenefitsExpense contextRef="c-112" decimals="-3" id="f-529" unitRef="usd">2326000</ccrn:BenefitsExpense>
    <ccrn:BenefitsExpense contextRef="c-113" decimals="-3" id="f-530" unitRef="usd">507000</ccrn:BenefitsExpense>
    <us-gaap:MarketingExpense contextRef="c-112" decimals="-3" id="f-531" unitRef="usd">2209000</us-gaap:MarketingExpense>
    <us-gaap:MarketingExpense contextRef="c-113" decimals="-3" id="f-532" unitRef="usd">232000</us-gaap:MarketingExpense>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-112" decimals="-3" id="f-533" unitRef="usd">990000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-113" decimals="-3" id="f-534" unitRef="usd">300000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-112" decimals="-3" id="f-535" unitRef="usd">4337000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-113" decimals="-3" id="f-536" unitRef="usd">121000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-112" decimals="-3" id="f-537" unitRef="usd">1896000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-113" decimals="-3" id="f-538" unitRef="usd">263000</us-gaap:SegmentReportingOtherItemAmount>
    <ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard contextRef="c-112" decimals="-3" id="f-539" unitRef="usd">27183000</ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard>
    <ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard contextRef="c-113" decimals="-3" id="f-540" unitRef="usd">3138000</ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard>
    <ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard contextRef="c-114" decimals="-3" id="f-541" unitRef="usd">30321000</ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationRestructuringLegalImpairmentAndCorporateOverheard>
    <ccrn:SegmentReportingUnallocatedCorporateExpenses contextRef="c-115" decimals="-3" id="f-542" unitRef="usd">17566000</ccrn:SegmentReportingUnallocatedCorporateExpenses>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-3" id="f-543" unitRef="usd">4642000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RestructuringCharges contextRef="c-5" decimals="-3" id="f-544" unitRef="usd">938000</us-gaap:RestructuringCharges>
    <ccrn:LegalAndOtherLosses contextRef="c-5" decimals="-3" id="f-545" unitRef="usd">3650000</ccrn:LegalAndOtherLosses>
    <us-gaap:AssetImpairmentCharges contextRef="c-5" decimals="-3" id="f-546" unitRef="usd">604000</us-gaap:AssetImpairmentCharges>
    <us-gaap:InterestExpenseNonoperating contextRef="c-5" decimals="-3" id="f-547" unitRef="usd">462000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest contextRef="c-5" decimals="-3" id="f-548" unitRef="usd">173000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-549" unitRef="usd">1057000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-550" unitRef="usd">3689000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NumberOfStatesInWhichEntityOperates contextRef="c-3" decimals="INF" id="f-551" unitRef="state">50</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-116" decimals="INF" id="f-552" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-117" decimals="INF" id="f-553" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-118" decimals="INF" id="f-554" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-119" decimals="INF" id="f-555" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-556">&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CONTINGENCIES&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in various litigation, claims, investigations, and other proceedings that arise in the ordinary course of its business. These proceedings primarily relate to employee-related matters that include individual and collective claims, professional liability, tax, and payroll practices. The Company establishes reserves when available information indicates that a loss is probable and an amount or range of loss can be reasonably estimated. These assessments are performed at least quarterly and are based on the information available to management at the time and involve significant management judgment to determine the probability and estimated amount of potential losses, if any. Based on the available information considered in its reviews, the Company adjusts its loss contingency accruals and its disclosures as may be required. Actual outcomes or losses may differ materially from those estimated by the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s current assessments, including available insurance recoveries, which would impact the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s profitability. Adverse developments in existing litigation claims or legal proceedings involving the Company or new claims could require management to establish or increase litigation reserves or enter into unfavorable settlements or satisfy judgments for monetary damages for amounts in excess of current reserves, which could adversely affect the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s financial results. The Company believes that the outcome of any outstanding loss contingencies as of March 31, 2025 will not have a material adverse effect on its business, financial condition, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales and Other State Non-Income Tax Liabilities &lt;/span&gt;&lt;/div&gt;The Company&#x2019;s sales and other state non-income tax filings are subject to routine audits by authorities in the jurisdictions where it conducts business in the United States which may result in assessments of additional taxes. The Company accrues sales and other non-income tax liabilities based on the Company&#x2019;s best estimate of its probable liability utilizing currently available information and interpretation of relevant tax regulations. Given the nature of the Company&#x2019;s business, significant subjectivity exists as to both whether sales and other state non-income taxes can be assessed on its activity and how the sales tax will ultimately be measured by the relevant jurisdictions. The Company makes a determination for each reporting period whether the estimates for sales and other non-income taxes in certain states should be revised. The expense is included in selling, general and administrative expenses in the Company&#x2019;s condensed consolidated statements of operations and comprehensive (loss) income and the liability is reflected in sales tax payable within other current liabilities in its condensed consolidated balance sheets.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-557">INCOME TAXES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three-month periods ended March 31, 2025 and 2024, the Company calculated its effective tax rate estimating its annual effective tax rate. The Company&#x2019;s effective tax rate for the three months ended March 31, 2025 and 2024 was 45.5% and 27.0%, respectively, including the impact of discrete items. Excluding discrete items, the Company&#x2019;s effective tax rate for the three months ended March 31, 2025 and 2024 was 56.1% and 37.0%, respectively. The effective tax rates for the first quarters of 2025 and 2024 were primarily impacted by federal and state taxes. The increase in the effective tax rate was primarily related to a decrease in book income relative to nondeductible items.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2025, the Company had approximately $10.2&#160;million of unrecognized tax benefits included in other non-current liabilities, $11.1&#160;million, net of deferred taxes, which would impact the effective tax rate if recognized. During the three months ended March 31, 2025, the Company had net increases of $0.3&#160;million to its current year unrecognized tax benefits related to federal and state tax provisions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2024, many international jurisdictions implemented the Pillar Two rules issued by the Organization for Economic Co-operation and Development. In general, large multinational entity groups with consolidated revenue in excess of 750 million Euros in at least two of the preceding four years could be subject to the new rules in jurisdictions with an effective tax rate below fifteen percent. The Company currently operates in one country that has adopted the Pillar Two rules, but should meet the safe harbor rules. The Company does not expect the adoption of the Pillar Two rules by any jurisdiction in which it currently operates to have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax years 2012 through 2024 remain open to examination by certain taxing jurisdictions to which the Company is subject to tax, other than certain states in which the statute of limitations has been extended.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-558" unitRef="number">0.455</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-5" decimals="3" id="f-559" unitRef="number">0.270</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <ccrn:EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent contextRef="c-1" decimals="3" id="f-560" unitRef="number">0.561</ccrn:EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent>
    <ccrn:EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent contextRef="c-5" decimals="3" id="f-561" unitRef="number">0.370</ccrn:EffectiveIncomeTaxRateReconciliationExcludingDiscreteItemsPercent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent contextRef="c-3" decimals="-5" id="f-562" unitRef="usd">10200000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-3" decimals="-5" id="f-563" unitRef="usd">11100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-5" id="f-564" unitRef="usd">300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-565">RELATED PARTY TRANSACTIONS&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into an arrangement for digital marketing services provided by a firm that is related to a certain member of the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s Board of Directors, who is a minority shareholder in the firm&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s parent company and is a member of the parent company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s Board of Directors. Management believes that the terms of the arrangement are equivalent to those prevailing in an arm&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s-length transaction and have been approved by the Audit Committee of the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s Board of Directors through the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s related party transaction approval process. The digital marketing firm manages a limited number of digital publishers covering various Company brands for a monthly management fee. During the three months ended March 31, 2025 and 2024, the Company incurred an immaterial amount in expenses and had an immaterial payable balance at March 31, 2025 and December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides services to entities that are affiliated with certain members of the Company&#x2019;s Board of Directors. Management believes that the services were conducted on terms equivalent to those prevailing in an arm&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s-length transaction. Revenue related to these transactions was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the three months ended March 31, 2025 and an immaterial amount for the three months ended March 31, 2024. Accounts receivable due from these entities was an immaterial amount at March 31, 2025 and December 31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-120" decimals="-5" id="f-566" unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-121" decimals="-5" id="f-567" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-568">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-569">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-570">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-571">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
